{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Load PubMed"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PUMID</th>\n",
       "      <th>Title</th>\n",
       "      <th>Abstract</th>\n",
       "      <th>CancerType</th>\n",
       "      <th>Description</th>\n",
       "      <th>Clean_Description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>17078348</td>\n",
       "      <td>Understanding the symptoms experienced by indi...</td>\n",
       "      <td>The purpose of this study was to gain a better...</td>\n",
       "      <td>Lung</td>\n",
       "      <td>Understanding the symptoms experienced by indi...</td>\n",
       "      <td>understand symptom experience individual lung ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>30206083</td>\n",
       "      <td>Do statins improve outcomes for patients with ...</td>\n",
       "      <td>INTRODUCTION: Lung cancer is the most common n...</td>\n",
       "      <td>Lung</td>\n",
       "      <td>Do statins improve outcomes for patients with ...</td>\n",
       "      <td>statin improve outcome patient non small cell ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>22974775</td>\n",
       "      <td>Lung cancer epidemiology, risk factors, and pr...</td>\n",
       "      <td>The greatest risk by far for developing lung c...</td>\n",
       "      <td>Lung</td>\n",
       "      <td>Lung cancer epidemiology, risk factors, and pr...</td>\n",
       "      <td>lung cancer epidemiology risk factor preventio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>26299737</td>\n",
       "      <td>[Modern Nanomedicine in Treatment of Lung Carc...</td>\n",
       "      <td>BACKGROUNDS: Despite the fast development of n...</td>\n",
       "      <td>Lung</td>\n",
       "      <td>[Modern Nanomedicine in Treatment of Lung Carc...</td>\n",
       "      <td>modern nanomedicine treatment lung carcinoma b...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>8815254</td>\n",
       "      <td>[Nineteen multiple primary cancer cases of 100...</td>\n",
       "      <td>In our department, half of 100 consecutive lun...</td>\n",
       "      <td>Lung</td>\n",
       "      <td>[Nineteen multiple primary cancer cases of 100...</td>\n",
       "      <td>nineteen multiple primary cancer case patient ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9995</th>\n",
       "      <td>24122724</td>\n",
       "      <td>High morbidity and mortality found for high-ri...</td>\n",
       "      <td>OBJECTIVES: To give an updated review concerni...</td>\n",
       "      <td>Bladder</td>\n",
       "      <td>High morbidity and mortality found for high-ri...</td>\n",
       "      <td>high morbidity mortality find high risk non mu...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9996</th>\n",
       "      <td>10447660</td>\n",
       "      <td>Case-referent study on occupational risk facto...</td>\n",
       "      <td>OBJECTIVE: To evaluate the possible associatio...</td>\n",
       "      <td>Bladder</td>\n",
       "      <td>Case-referent study on occupational risk facto...</td>\n",
       "      <td>case referent study occupational risk factor b...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9997</th>\n",
       "      <td>3582456</td>\n",
       "      <td>Intravesical irrigation with distilled water d...</td>\n",
       "      <td>In a retrospective study, the influence of dis...</td>\n",
       "      <td>Bladder</td>\n",
       "      <td>Intravesical irrigation with distilled water d...</td>\n",
       "      <td>intravesical irrigation distill water immediat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9998</th>\n",
       "      <td>21897260</td>\n",
       "      <td>Ileal neobladder in women with bladder cancer:...</td>\n",
       "      <td>PURPOSE OF REVIEW: Radical cystectomy and urin...</td>\n",
       "      <td>Bladder</td>\n",
       "      <td>Ileal neobladder in women with bladder cancer:...</td>\n",
       "      <td>ileal neobladder woman bladder cancer cancer c...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9999</th>\n",
       "      <td>28889377</td>\n",
       "      <td>Molecular Subtype Profiling of Urothelial Carc...</td>\n",
       "      <td>Molecular subtypes of bladder cancer (BC) can ...</td>\n",
       "      <td>Bladder</td>\n",
       "      <td>Molecular Subtype Profiling of Urothelial Carc...</td>\n",
       "      <td>molecular subtype profile urothelial carcinoma...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>10000 rows Ã— 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "         PUMID                                              Title  \\\n",
       "0     17078348  Understanding the symptoms experienced by indi...   \n",
       "1     30206083  Do statins improve outcomes for patients with ...   \n",
       "2     22974775  Lung cancer epidemiology, risk factors, and pr...   \n",
       "3     26299737  [Modern Nanomedicine in Treatment of Lung Carc...   \n",
       "4      8815254  [Nineteen multiple primary cancer cases of 100...   \n",
       "...        ...                                                ...   \n",
       "9995  24122724  High morbidity and mortality found for high-ri...   \n",
       "9996  10447660  Case-referent study on occupational risk facto...   \n",
       "9997   3582456  Intravesical irrigation with distilled water d...   \n",
       "9998  21897260  Ileal neobladder in women with bladder cancer:...   \n",
       "9999  28889377  Molecular Subtype Profiling of Urothelial Carc...   \n",
       "\n",
       "                                               Abstract CancerType  \\\n",
       "0     The purpose of this study was to gain a better...       Lung   \n",
       "1     INTRODUCTION: Lung cancer is the most common n...       Lung   \n",
       "2     The greatest risk by far for developing lung c...       Lung   \n",
       "3     BACKGROUNDS: Despite the fast development of n...       Lung   \n",
       "4     In our department, half of 100 consecutive lun...       Lung   \n",
       "...                                                 ...        ...   \n",
       "9995  OBJECTIVES: To give an updated review concerni...    Bladder   \n",
       "9996  OBJECTIVE: To evaluate the possible associatio...    Bladder   \n",
       "9997  In a retrospective study, the influence of dis...    Bladder   \n",
       "9998  PURPOSE OF REVIEW: Radical cystectomy and urin...    Bladder   \n",
       "9999  Molecular subtypes of bladder cancer (BC) can ...    Bladder   \n",
       "\n",
       "                                            Description  \\\n",
       "0     Understanding the symptoms experienced by indi...   \n",
       "1     Do statins improve outcomes for patients with ...   \n",
       "2     Lung cancer epidemiology, risk factors, and pr...   \n",
       "3     [Modern Nanomedicine in Treatment of Lung Carc...   \n",
       "4     [Nineteen multiple primary cancer cases of 100...   \n",
       "...                                                 ...   \n",
       "9995  High morbidity and mortality found for high-ri...   \n",
       "9996  Case-referent study on occupational risk facto...   \n",
       "9997  Intravesical irrigation with distilled water d...   \n",
       "9998  Ileal neobladder in women with bladder cancer:...   \n",
       "9999  Molecular Subtype Profiling of Urothelial Carc...   \n",
       "\n",
       "                                      Clean_Description  \n",
       "0     understand symptom experience individual lung ...  \n",
       "1     statin improve outcome patient non small cell ...  \n",
       "2     lung cancer epidemiology risk factor preventio...  \n",
       "3     modern nanomedicine treatment lung carcinoma b...  \n",
       "4     nineteen multiple primary cancer case patient ...  \n",
       "...                                                 ...  \n",
       "9995  high morbidity mortality find high risk non mu...  \n",
       "9996  case referent study occupational risk factor b...  \n",
       "9997  intravesical irrigation distill water immediat...  \n",
       "9998  ileal neobladder woman bladder cancer cancer c...  \n",
       "9999  molecular subtype profile urothelial carcinoma...  \n",
       "\n",
       "[10000 rows x 6 columns]"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "PubMed = pd.read_excel('../Src/(Cleaned)pubmed-CancerType_Top1-10-set_10000-data.xlsx')\n",
    "PubMed"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Extract TF-IDF Feature"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(10000, 15814)"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "\n",
    "tv = TfidfVectorizer(use_idf=True, ngram_range=(1, 2), min_df=10, max_df=0.8)\n",
    "tv_matrix = tv.fit_transform(PubMed['Clean_Description'])\n",
    "tv_matrix.shape"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Cluster Articles Using Ward Clustering Algorithm"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [],
   "source": [
    "from scipy.cluster.hierarchy import ward, fcluster, dendrogram\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "from scipy.spatial.distance import pdist"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [],
   "source": [
    "import matplotlib.pyplot as plt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [],
   "source": [
    "def plot_hierarchical_clusters(linkage_matrix, pubmed_data, p=100, figure_size=(8,12)):\n",
    "    # set size\n",
    "    fig, ax = plt.subplots(figsize=figure_size) \n",
    "    pubmed_titles = pubmed_data['Title'].values.tolist()\n",
    "    # plot dendrogram\n",
    "    R = dendrogram(linkage_matrix, orientation=\"left\", labels=pubmed_titles,\n",
    "                    truncate_mode='lastp', \n",
    "                    p=p,  \n",
    "                    no_plot=True)\n",
    "    temp = {R[\"leaves\"][ii]: pubmed_titles[ii] for ii in range(len(R[\"leaves\"]))}\n",
    "    def llf(xx):\n",
    "        return \"{}\".format(temp[xx])\n",
    "    ax = dendrogram(\n",
    "            linkage_matrix,\n",
    "            truncate_mode='lastp',\n",
    "            orientation=\"left\",\n",
    "            p=p,  \n",
    "            leaf_label_func=llf, \n",
    "            leaf_font_size=10.,\n",
    "            )\n",
    "    plt.tick_params(axis= 'x',   \n",
    "                    which='both',  \n",
    "                    bottom='off',\n",
    "                    top='off',\n",
    "                    labelbottom='off')\n",
    "    plt.tight_layout()\n",
    "    plt.savefig('../Output/pubmed_hierachical_clusters.png', dpi=200)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([[-2.22044605e-16,  9.38485016e-01,  9.11187608e-01, ...,\n",
       "         9.72076223e-01,  9.88409271e-01,  9.79036495e-01],\n",
       "       [ 9.38485016e-01, -2.22044605e-16,  9.25825653e-01, ...,\n",
       "         9.71444573e-01,  9.74196960e-01,  9.71792801e-01],\n",
       "       [ 9.11187608e-01,  9.25825653e-01, -2.22044605e-16, ...,\n",
       "         9.90301729e-01,  9.94984425e-01,  9.92278358e-01],\n",
       "       ...,\n",
       "       [ 9.72076223e-01,  9.71444573e-01,  9.90301729e-01, ...,\n",
       "         1.11022302e-16,  9.40010664e-01,  9.32147187e-01],\n",
       "       [ 9.88409271e-01,  9.74196960e-01,  9.94984425e-01, ...,\n",
       "         9.40010664e-01,  0.00000000e+00,  9.60651066e-01],\n",
       "       [ 9.79036495e-01,  9.71792801e-01,  9.92278358e-01, ...,\n",
       "         9.32147187e-01,  9.60651066e-01, -2.22044605e-16]])"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cosine_distance = 1 - cosine_similarity(tv_matrix)\n",
    "cosine_distance"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([[2.14400000e+03, 5.68700000e+03, 0.00000000e+00, 2.00000000e+00],\n",
       "       [3.34700000e+03, 3.60400000e+03, 0.00000000e+00, 2.00000000e+00],\n",
       "       [3.01700000e+03, 3.08800000e+03, 6.23143598e-02, 2.00000000e+00],\n",
       "       ...,\n",
       "       [1.99850000e+04, 1.99950000e+04, 1.31448000e+02, 7.99000000e+03],\n",
       "       [1.99830000e+04, 1.99960000e+04, 1.44300708e+02, 8.98700000e+03],\n",
       "       [1.99860000e+04, 1.99970000e+04, 1.53321513e+02, 1.00000000e+04]])"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "linkage_matrix = ward(cosine_distance)\n",
    "linkage_matrix"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "9999"
      ]
     },
     "execution_count": 62,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(linkage_matrix)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\asus\\Anaconda3\\lib\\site-packages\\ipykernel_launcher.py:26: UserWarning: Tight layout not applied. The left and right margins cannot be made large enough to accommodate all axes decorations. \n"
     ]
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x1008 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "plot_hierarchical_clusters(linkage_matrix,\n",
    "                           p=100,\n",
    "                           pubmed_data=PubMed,\n",
    "                           figure_size=(12, 14))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [],
   "source": [
    "ward_clustering = fcluster(linkage_matrix, 60, criterion='distance')\n",
    "PubMed['Ward_cluster'] = ward_clustering"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Counter({3: 991,\n",
       "         10: 1707,\n",
       "         5: 1046,\n",
       "         7: 1137,\n",
       "         9: 762,\n",
       "         2: 997,\n",
       "         1: 1013,\n",
       "         6: 911,\n",
       "         4: 935,\n",
       "         8: 501})"
      ]
     },
     "execution_count": 56,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from collections import Counter\n",
    "\n",
    "Counter(ward_clustering)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PUMID</th>\n",
       "      <th>Title</th>\n",
       "      <th>Ward_cluster</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1914</th>\n",
       "      <td>53620</td>\n",
       "      <td>Letter: Prevalence and duration of undetected ...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1668</th>\n",
       "      <td>57477</td>\n",
       "      <td>Letter: Breast cancer and preceding breast dis...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1561</th>\n",
       "      <td>70077</td>\n",
       "      <td>Role of simple mastectomy in treating patients...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1055</th>\n",
       "      <td>169381</td>\n",
       "      <td>Estrogen receptor assay in human breast cancer.</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1460</th>\n",
       "      <td>190078</td>\n",
       "      <td>Estrogen receptor in breast cancer of the Japa...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7009</th>\n",
       "      <td>32495017</td>\n",
       "      <td>Radical hysterectomy for early cervical cancer...</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4255</th>\n",
       "      <td>32608553</td>\n",
       "      <td>Identification of functional long non-coding R...</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6613</th>\n",
       "      <td>32664098</td>\n",
       "      <td>Characteristics and prognosis of primary malig...</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6149</th>\n",
       "      <td>32760099</td>\n",
       "      <td>Radiation dose escalation can improve local di...</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7237</th>\n",
       "      <td>32878770</td>\n",
       "      <td>Neoadjuvant Chemotherapy in Locally Advanced C...</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>10000 rows Ã— 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "         PUMID                                              Title  \\\n",
       "1914     53620  Letter: Prevalence and duration of undetected ...   \n",
       "1668     57477  Letter: Breast cancer and preceding breast dis...   \n",
       "1561     70077  Role of simple mastectomy in treating patients...   \n",
       "1055    169381    Estrogen receptor assay in human breast cancer.   \n",
       "1460    190078  Estrogen receptor in breast cancer of the Japa...   \n",
       "...        ...                                                ...   \n",
       "7009  32495017  Radical hysterectomy for early cervical cancer...   \n",
       "4255  32608553  Identification of functional long non-coding R...   \n",
       "6613  32664098  Characteristics and prognosis of primary malig...   \n",
       "6149  32760099  Radiation dose escalation can improve local di...   \n",
       "7237  32878770  Neoadjuvant Chemotherapy in Locally Advanced C...   \n",
       "\n",
       "      Ward_cluster  \n",
       "1914             1  \n",
       "1668             1  \n",
       "1561             1  \n",
       "1055             1  \n",
       "1460             1  \n",
       "...            ...  \n",
       "7009            10  \n",
       "4255            10  \n",
       "6613            10  \n",
       "6149            10  \n",
       "7237            10  \n",
       "\n",
       "[10000 rows x 3 columns]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pubmed_clusters = (PubMed[['PUMID', 'Title', 'Ward_cluster']]\n",
    "                  .sort_values(by=['Ward_cluster', 'PUMID'], \n",
    "                               ascending=True))\n",
    "pubmed_clusters"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "pubmed_clusters.to_excel('../Output/Ward_Cluster_Output.xlsx', index=False) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PUMID</th>\n",
       "      <th>Title</th>\n",
       "      <th>Ward_cluster</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1914</th>\n",
       "      <td>53620</td>\n",
       "      <td>Letter: Prevalence and duration of undetected ...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1668</th>\n",
       "      <td>57477</td>\n",
       "      <td>Letter: Breast cancer and preceding breast dis...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1561</th>\n",
       "      <td>70077</td>\n",
       "      <td>Role of simple mastectomy in treating patients...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1055</th>\n",
       "      <td>169381</td>\n",
       "      <td>Estrogen receptor assay in human breast cancer.</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1460</th>\n",
       "      <td>190078</td>\n",
       "      <td>Estrogen receptor in breast cancer of the Japa...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6142</th>\n",
       "      <td>398752</td>\n",
       "      <td>[Leiomyoma of the esophagus. (Case report)].</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4257</th>\n",
       "      <td>462227</td>\n",
       "      <td>[Importance of health education work in preven...</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6354</th>\n",
       "      <td>469319</td>\n",
       "      <td>[Evaluation of surgical management and postope...</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6530</th>\n",
       "      <td>469320</td>\n",
       "      <td>[Postoperative long-term chemotherapy combined...</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4604</th>\n",
       "      <td>470251</td>\n",
       "      <td>Clinical value of immunochemotherapy with OK-4...</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>200 rows Ã— 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "       PUMID                                              Title  Ward_cluster\n",
       "1914   53620  Letter: Prevalence and duration of undetected ...             1\n",
       "1668   57477  Letter: Breast cancer and preceding breast dis...             1\n",
       "1561   70077  Role of simple mastectomy in treating patients...             1\n",
       "1055  169381    Estrogen receptor assay in human breast cancer.             1\n",
       "1460  190078  Estrogen receptor in breast cancer of the Japa...             1\n",
       "...      ...                                                ...           ...\n",
       "6142  398752       [Leiomyoma of the esophagus. (Case report)].            10\n",
       "4257  462227  [Importance of health education work in preven...            10\n",
       "6354  469319  [Evaluation of surgical management and postope...            10\n",
       "6530  469320  [Postoperative long-term chemotherapy combined...            10\n",
       "4604  470251  Clinical value of immunochemotherapy with OK-4...            10\n",
       "\n",
       "[200 rows x 3 columns]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pubmed_clusters = (PubMed[['PUMID', 'Title', 'Ward_cluster']]\n",
    "                  .sort_values(by=['Ward_cluster', 'PUMID'], \n",
    "                               ascending=True)\n",
    "                  .groupby('Ward_cluster').head(20))\n",
    "pubmed_clusters"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "CLUSTER #1\n",
      "\n",
      "\n",
      "PubMed Titles: ['Letter: Prevalence and duration of undetected breast cancer.', 'Letter: Breast cancer and preceding breast disease.', 'Role of simple mastectomy in treating patients with breast cancer.', 'Estrogen receptor assay in human breast cancer.', 'Estrogen receptor in breast cancer of the Japanese.', '[Modern possibilities in the comprehensive treatment of breast cancer].', 'Thyroid disease in relation to breast cancer.', 'Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer.', \"[The value of postoperative irradiation in the curative management of breast cancer (author's transl)].\", '[Breast cancer in combination with other malignant tumors].', '[Metastatic pleurisy in breast cancer].', 'Screening is not diagnosis.', 'Problems and prospects of cancer of the breast in India.', 'The role of lymphadenectomy in curative surgery for gastric cancer.', 'The breast cancer controversy.', 'Evaluation of biochemical markers in breast cancer.', '[Mammographic evaluation of women with high-risk breast cancer development].', 'Estimated effect of breast self-examination and routine physician examinations on breast-cancer mortality.', 'Problems with the detection of breast cancer.', 'Rapidly progressing breast cancer (poussÃ©e Ã©volutive) in Tunisia: studies on delayed hypersensitivity.']\n",
      "--------------------------------------------------------------------------------\n",
      "CLUSTER #2\n",
      "\n",
      "\n",
      "PubMed Titles: ['Epidemiology of prostate cancer with special reference to the role of diet.', 'Cryosurgery in prostate carcinoma: clinical evidence of immunostimulation of host versus tumor.', 'Prostate cancer tumor location as predicted by digital rectal examination transferred to ultrasound and ultrasound-guided prostate needle biopsy.', 'Diagnosis of prostate cancer: a personal view.', 'Prostate specific antigen: clinical use in the diagnosis and management of prostate cancer.', 'Prostatic specific antigen in prostate cancer.', 'Prostate cancer in North Carolina.', '[Is the early diagnosis of prostatic cancer possible using transrectal echography?].', '[Hormone therapy in prostate cancer: clinical results].', 'Determination of prostate volume with transrectal US for cancer screening. Part I. Comparison with prostate-specific antigen assays.', 'Prostate cancer incidence in cimetidine users.', \"'Local recurrence' and 'disease-free survival'. Doubtful parameters when comparing non-randomized studies of prostate cancer.\", 'Current status of transrectal ultrasonography in the detection of prostate cancer.', 'Steroid receptor profile in human prostate cancer metastases as compared with primary prostatic carcinoma.', 'Prostate cancer.', 'The role of nuclear DNA ploidy in the prognosis and management of patients with prostate cancer.', 'Transrectal ultrasonography in prostatic carcinoma.', 'History and physical examination in prostate cancer. Which information is essential in diagnosis and follow-up?', 'Screening for prostate cancer. The U.S. Preventive Services Task Force.', 'Clinical evidence for and implications of the multistep development of prostate cancer.']\n",
      "--------------------------------------------------------------------------------\n",
      "CLUSTER #3\n",
      "\n",
      "\n",
      "PubMed Titles: ['Letter: Mortality from lung cancer.', '[Evaluation of the compensatory-adaptive processes in the heart of patients who died of lung cancer].', 'The changing histopathology of lung cancer: a review of 1682 cases.', 'Relationship between survival and histologic type in small cell anaplastic carcinoma of the lung.', '[Various aspects of the diagnosis of lung cancer (review of our experience)].', 'Rising lung cancer mortality among nonsmokers.', '[Lung cancer in patients treated in a respiratory tract disease department of the Cracow Special Hospital in the years 1956-1977].', 'From the NIH: Lung cancer mortality appears unaffected by roentgenographic and sputum screening in asymptomatic persons.', 'Advances in the chemotherapy and immunotherapy of lung cancer.', '[Surgical treatment of lung cancer].', '[Treatment of lung cancer. New treatment possibilities].', 'Lung cancer mortality in aluminum reduction plant workers.', \"[Surgical treatment of lung cancer according to n-factor (author's transl)].\", \"[Tobacco smoking and lung cancer in women: relative risk for Kreyberg groups I and II (author's transl)].\", \"[Current problems of the control of neoplasms in later life (author's transl)].\", 'Comparative epidemiology of tobacco-related cancers.', '[Rehabilitation of patients with lung cancer after surgical treatment].', '[Combination of primary lung cancer with extrapulmonary carcinomas].', 'Surgical treatment of lung cancer in patients over the age of 70 years.', '[Vitamin B12-58Co absorption in stomach cancer patients at different times after gastrectomy].']\n",
      "--------------------------------------------------------------------------------\n",
      "CLUSTER #4\n",
      "\n",
      "\n",
      "PubMed Titles: ['The local, regional and systemic attack on bladder cancer.', '[Carcinoma in situ of the bladder. Apropos of 10 cases].', 'Immune function determination in patients with bladder cancer.', 'Immunoperoxidase staining of carcinoembryonic antigen in urinary bladder cancer.', 'Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder.', 'Bladder Cancer: current status of diagnosis & treatment.', '[Cryosurgical treatment of bladder cancer].', 'Non-papillary carcinoma in situ of the bladder: a clinicopathologic study of 2 cases treated with radical cystoprostatourethrectomy.', 'Familial urinary bladder cancer.', 'Phase II trial of cis-dichlorodiammineplatinum(II) in cancer of the bilharzial bladder.', 'Genetic association with bladder cancer.', '[DNFB reaction in bladder cancer, an immunological study].', 'Experiences in treating cancer of the bladder.', 'Eight years of experience with preoperative angiographic and lymphographic staging of bladder cancer.', 'Neovascularization in benign and malignant urinary bladder epithelial proliferative lesions of the rat observed in situ by scanning electron microscopy and autoradiography.', 'Pre-clinical cytological diagnosis of bladder cancer.', 'Alternative methods of diagnosis and staging of bladder cancer.', 'Recent advances in the immunobiology of human bladder cancer.', 'Two aspects of the epidemiology of bladder cancer in England and Wales.', 'Demonstration of nitrosamines in human urine: preliminary observations on a possible etiology for bladder cancer in association with chronic urinary tract infections.']\n",
      "--------------------------------------------------------------------------------\n",
      "CLUSTER #5\n",
      "\n",
      "\n",
      "PubMed Titles: ['[Association of tuberculosis and thyroid cancer. Value of exploratory cervicotomy].', 'Thyroid cancer. IV. The TSH receptor. ResumÃ© of a round table discussion.', 'Radiation safety precautions with 131iodine therapy.', 'Well-differentiated carcinomas of the thyroid.', 'Indication and clinical evaluation of radical and semiradical neck dissection on the basis of 271 operations.', 'Thyroid carcinoma: a clinical and pathologic study of 125 cases.', 'Serum thyroglobulin concentrations and whole-body radioiodine scan in follow-up of differentiated thyroid cancer after thyroid ablation.', 'Angiographic assessment of lymphatic metastasis from gastric cancer.', 'Thyroid cancer: 30 year review of 201 cases.', 'A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group.', 'Serum thyroglobulin in differentiated thyroid cancer.', 'Radioiodine in treatment of metastatic thyroid cancer.', 'Radiation exposure and thyroid cancer.', '[2 cases of thyroid cancer].', 'Surgical treatment of differentiated thyroid cancer at the Institute Gustave-Roussy.', 'Some problems of management of thyroid cancer.', 'Anaplastic transformation of medullary thyroid cancer.', '[Therapeutic management of thyroid cancer with remote metastases (experience with 34 operated cases)].', '[Generalized xanthomatosis in a female diabetes mellitus patient operated on for thyroid cancer].', 'Detection of metastatic thyroid carcinoma after the administration of a therapeutic dose of 131-iodine.']\n",
      "--------------------------------------------------------------------------------\n",
      "CLUSTER #6\n",
      "\n",
      "\n",
      "PubMed Titles: ['[Combined operations in stomach cancer].', 'Attributable risk for diet, alcohol, and family history in the Melbourne Colorectal Cancer Study.', '[Prevention and surveillance of risk groups for colorectal carcinoma].', 'Colorectal cancer screening.', '[Multivisceral resection of colorectal cancer--experiences of the Colorectal Cancer Study Group].', 'The value of adjuvant therapy after radical surgery for colorectal cancer.', 'Recent advances in the treatment of colorectal cancer.', '[Has the strategy in the early detection of colorectal cancer changed?].', 'Staging of colorectal cancer.', 'Hereditary nonpolyposis colorectal cancer (Lynch syndromes I & II). Genetics, pathology, natural history, and cancer control, Part I.', 'Screening sigmoidoscopy for colorectal cancer.', 'Randomized control trial of faecal occult blood screening for colorectal cancer: results for the first 144,103 patients.', '[The possible approaches to prognosis in colorectal cancer].', 'Colorectal cancer screening.', '[Colorectal cancer--diagnosis, early detection and staging].', '[Chemo', 'Systematic computer-aided search of optimal staging system for colorectal cancer.', 'Advances in colorectal cancer.', '[Value of CEA determination in follow-up of patients with liver metastasis of colorectal cancers with loco-regional chemotherapy].', 'Manifestations of hereditary colorectal cancer.']\n",
      "--------------------------------------------------------------------------------\n",
      "CLUSTER #7\n",
      "\n",
      "\n",
      "PubMed Titles: ['[First results of the work of the urban cytological laboratory].', 'Hepatocellular carcinoma in the Rhodesian African.', 'Cancer of the upper biliary junction.', 'Major hepatic resection for neoplasia: personal experience in 108 patients.', '[Relative value of selective arteriography and laparoscopy in the diagnosis of liver cancer].', 'The value of laparoscopy in the diagnosis of primary cancer of the liver.', '[Intraepithelial spread of the squamous cell carcinoma of the uterine cervix into the endometrium. A contribution to the question of a surface spread of the cervical carcinoma].', 'Hepatitis B antigen in acute viral hepatitis and primary liver cancer in Tanzania.', 'Hepatocellular carcinoma in the Malaysian Orang Asli.', '[Diffuse sclerÃ³sing hepatoma. A liver cancer with difficult diagnosis].', 'Internal radiation therapy of liver cancer (90-Yttrium resin spheres intra-arterially) to supplement external radiation therapy, local and systemic chemotherapy.', '[Polyglobulia as a manifestation of a primary of the liver].', '[Androgenic therapy and hepatocellular carcinoma. Report of a case].', '[Primary cancer of the liver in children].', 'Treatment of hepatocellular carcinoma with associated cirrhosis.', 'Carcinoma of the cervix.', 'Hypercholesterolaemia due to loss of negative feedback control in primary liver cancer in a twelve months old boy from a hyperlipaemic family.', '[Oral 5-fluorouracil therapy in liver metastasis].', 'Increased expression of actin-like contractile protein in preneoplastic and neoplastic lesions in rat liver.', 'Internal radiation therapy of hepatic cancer.']\n",
      "--------------------------------------------------------------------------------\n",
      "CLUSTER #8\n",
      "\n",
      "\n",
      "PubMed Titles: ['Adenocarcinoma of the uterine cervix. An evaluation of the available diagnostic methods.', '[Does cancer preventive care on the cervix need to be reformed? Gynecological preventive care and early diagnosis--current knowledge on cervix neoplasms].', '[Gynecologic health screening in Canada and Sweden].', '[Characteristics of the uterine mucosa in cervix dysplasia].', 'Evaluation of abnormal cervical cytology during pregnancy with colposcopy.', 'Cancer cells located deep in invasive cancer tissue of the uterine cervix.', 'Carcinoma of the cervix uteri in Ibadan: clinico-pathologic features.', '[Mass screening for cancer of the uterine cervix from the age of 35?].', '[Wertheim-Meigs operation in cervico-uterine cancer, clinical stage I, during', 'Colposcopy and the management of cervical intraepithelial neoplasia.', 'Colposcopy and the management of cervical intraepithelial neoplasia.', '[Effect of different regimens of teleradiotherapy on the structure of cervical cancer].', 'Carcinoma of the cervix uteri in Ibadan: coital characteristics.', '[The cancer patient', '[CEA and cancer of the cervix uteri].', \"Prenatal exposure to stilbestrol and adenocarcinoma of the female genital tract: the pediatrician's responsibility.\", 'Management of early cervical neoplasia.', \"[Detection and treatment of cervical cancer in Cracow, 1973 (author's transl)].\", \"[Scintigraphic study of radiation effect on parametrium infiltration of cervical cancer (author's transl)].\", 'Cancer screening in East Sussex.']\n",
      "--------------------------------------------------------------------------------\n",
      "CLUSTER #9\n",
      "\n",
      "\n",
      "PubMed Titles: ['[Cytological diagnosis of stomach cancer].', '[Selection of the method of treatment of stomach cancer].', '[Early postoperative complications of radical and palliative surgery in stomach cancer].', 'Susceptibility of the resected stomach to experimental carcinogenesis.', 'Ossification in cancer of the stomach: an experimental study.', 'Factors related to survival following resection for gastric carcinoma: analysis of 903 cases.', 'Immunotherapy of gastric cancer with levamisole.', \"[Nil nocere: perforation of the gastric wall on occasion of peritoneoscopy (author's transl)].\", 'Brushing cytology for the diagnosis of gastric cancer involving the cardia or the lower esophagus.', 'Gastric cancer in the Hawaii Japanese.', '[Survival of 5-fluorouracil-treated stomach cancer patients in the far-advanced stages].', 'Post-operative long-term adjuvant immunochemotherapy with mitomycin-C, PSK and FT-207 in gastric cancer patients.', '[Complications in the early postoperative period in stomach cancer].', '[Use of large-frame fluorography in the diagnosis of stomach cancer].', 'Endoscopic experience in the diagnosis of gastric stump cancer.', '[Causes for refusing surgical treatment among gastric cancer patients].', \"[Local immune system in gastric cancer. Immunomorphological study (author's transl)].\", '[Gastric cancer. Review of 375 cases].', \"[Surgical treatment of the cancer of the stomach. Case report of 87 gastrectomies (author's transl)].\", 'Gastric carcinoma promoted by alkaline reflux gastritis - bile and other surfactants as promoters of postoperative gastric cancer.']\n",
      "--------------------------------------------------------------------------------\n",
      "CLUSTER #10\n",
      "\n",
      "\n",
      "PubMed Titles: ['[Esophago-intestinal bypass anastomoses for inoperable cancer of the proximal portion of the stomach and abdominal portion of the esophagus].', 'Oesophageal cancer on the Caspian littoral.', '[Surgery and adjuvant therapy of esophageal cancer, with special reference to preoperative administration of BLM].', 'Consequence of splenectomy in oesophageal carcinoma.', '[Radiotherapy, bleomycin and immunotherapy (PSK, BCG-CWS) in esophageal neoplasms].', \"[Clinical and roentgenological findings after radiation therapy of malignant esophageal tumors (author's transl)].\", '[Malignant metastizing neuroma in the wall of an epiphrenic esophageal diverticulum. A case report].', \"[The present status of the theory of induction of carcinoma of the cervix in man by herpes virus (author's transl)].\", '[Pseudosarcomatous polyp-like malpighian epithelioma of the esophagus].', '[Labelling index and prognosis in stomach cancer patients].', \"[Epidemiology of carcinoma of the cervix (author's transl)].\", 'Microhematuria found by mass screening of apparently healthy males.', '[Biochemical test for the presence of pepsinogen-pepsin for the diagnosis of stomach cancer metastases].', 'The surgery of cervical carcinoma.', 'Experimental chemotherapy of bladder cancer--systemic and intravesical.', '[Leiomyoma of the esophagus. (Case report)].', '[Importance of health education work in preventing stomach cancer].', '[Evaluation of surgical management and postoperative therapy of esophageal neoplasms--pre- and postoperative immunotherapy].', '[Postoperative long-term chemotherapy combined with immunotherapy in esophageal neoplasms].', 'Clinical value of immunochemotherapy with OK-432 or PS-K for stomach cancer patients.']\n",
      "--------------------------------------------------------------------------------\n"
     ]
    }
   ],
   "source": [
    "# get key features for each cluster\n",
    "# get movies belonging to each cluster\n",
    "\n",
    "NUM_CLUSTERS = 10\n",
    "\n",
    "for cluster_num in range(1, NUM_CLUSTERS+1):\n",
    "    pubmed_articles = pubmed_clusters[pubmed_clusters['Ward_cluster'] == cluster_num]['Title'].values.tolist()\n",
    "    print('CLUSTER #'+str(cluster_num)+'\\n')\n",
    "    print()\n",
    "    print('PubMed Titles:', pubmed_articles)\n",
    "    print('-'*80)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Calculate Accuracy of Ward"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The silhouette score for Ward Algorithm with 10 cluster is 0.16520114859414972\n"
     ]
    }
   ],
   "source": [
    "from sklearn.metrics import silhouette_score\n",
    "\n",
    "score = silhouette_score(tv_matrix, PubMed['Ward_cluster'])\n",
    "print('The silhouette score for Ward Algorithm with 10 cluster is', score)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PUMID</th>\n",
       "      <th>Title</th>\n",
       "      <th>CancerType</th>\n",
       "      <th>Cluster</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>17078348</td>\n",
       "      <td>Understanding the symptoms experienced by indi...</td>\n",
       "      <td>3</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>30206083</td>\n",
       "      <td>Do statins improve outcomes for patients with ...</td>\n",
       "      <td>3</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>22974775</td>\n",
       "      <td>Lung cancer epidemiology, risk factors, and pr...</td>\n",
       "      <td>3</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>26299737</td>\n",
       "      <td>[Modern Nanomedicine in Treatment of Lung Carc...</td>\n",
       "      <td>3</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>8815254</td>\n",
       "      <td>[Nineteen multiple primary cancer cases of 100...</td>\n",
       "      <td>3</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9995</th>\n",
       "      <td>24122724</td>\n",
       "      <td>High morbidity and mortality found for high-ri...</td>\n",
       "      <td>4</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9996</th>\n",
       "      <td>10447660</td>\n",
       "      <td>Case-referent study on occupational risk facto...</td>\n",
       "      <td>4</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9997</th>\n",
       "      <td>3582456</td>\n",
       "      <td>Intravesical irrigation with distilled water d...</td>\n",
       "      <td>4</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9998</th>\n",
       "      <td>21897260</td>\n",
       "      <td>Ileal neobladder in women with bladder cancer:...</td>\n",
       "      <td>4</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9999</th>\n",
       "      <td>28889377</td>\n",
       "      <td>Molecular Subtype Profiling of Urothelial Carc...</td>\n",
       "      <td>4</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>10000 rows Ã— 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "         PUMID                                              Title  CancerType  \\\n",
       "0     17078348  Understanding the symptoms experienced by indi...           3   \n",
       "1     30206083  Do statins improve outcomes for patients with ...           3   \n",
       "2     22974775  Lung cancer epidemiology, risk factors, and pr...           3   \n",
       "3     26299737  [Modern Nanomedicine in Treatment of Lung Carc...           3   \n",
       "4      8815254  [Nineteen multiple primary cancer cases of 100...           3   \n",
       "...        ...                                                ...         ...   \n",
       "9995  24122724  High morbidity and mortality found for high-ri...           4   \n",
       "9996  10447660  Case-referent study on occupational risk facto...           4   \n",
       "9997   3582456  Intravesical irrigation with distilled water d...           4   \n",
       "9998  21897260  Ileal neobladder in women with bladder cancer:...           4   \n",
       "9999  28889377  Molecular Subtype Profiling of Urothelial Carc...           4   \n",
       "\n",
       "      Cluster  \n",
       "0           3  \n",
       "1           3  \n",
       "2           3  \n",
       "3           3  \n",
       "4           3  \n",
       "...       ...  \n",
       "9995        4  \n",
       "9996        4  \n",
       "9997        4  \n",
       "9998        4  \n",
       "9999        4  \n",
       "\n",
       "[10000 rows x 4 columns]"
      ]
     },
     "execution_count": 65,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import numpy as np\n",
    "\n",
    "mapping = {'Breast': 1, 'Prostate': 2, 'Lung': 3, 'Bladder': 4, 'Thyroid': 5, 'Colorectal': 6, 'Liver': 7, 'Cervix Uteri': 8, 'Stomach': 9, 'Oesophagus': 10}\n",
    "pumid, title, cancertype, cluster = (PubMed['PUMID'], PubMed['Title'], [mapping[label] for label in PubMed['CancerType']], PubMed['Ward_cluster'])\n",
    "\n",
    "data_df = pd.DataFrame({'PUMID': pumid, 'Title': title, 'CancerType': cancertype, 'Cluster': cluster})\n",
    "data_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([[994,   0,   0,   0,   1,   0,   0,   0,   3,   2],\n",
       "       [  2, 985,   0,   0,   6,   0,   4,   0,   0,   3],\n",
       "       [  0,   1, 973,   0,   2,   0,   7,   0,   3,  14],\n",
       "       [  0,   9,   0, 926,  15,   1,  24,   0,   2,  23],\n",
       "       [  2,   0,   0,   0, 976,   0,   4,   0,   1,  17],\n",
       "       [  0,   1,   0,   3,   2, 900,  49,   0,   0,  45],\n",
       "       [  6,   1,   3,   0,   5,   3, 902,   0,  23,  57],\n",
       "       [  1,   0,   1,   2,   5,   0,  40, 495,  10, 446],\n",
       "       [  5,   0,   7,   1,  13,   5,  27,   0, 706, 236],\n",
       "       [  3,   0,   7,   3,  21,   2,  80,   6,  14, 864]], dtype=int64)"
      ]
     },
     "execution_count": 67,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from sklearn.metrics import confusion_matrix\n",
    "\n",
    "cm = confusion_matrix(data_df['CancerType'], data_df['Cluster'])\n",
    "cm"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.axes._subplots.AxesSubplot at 0x2bd0c4130c8>"
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 576x360 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import seaborn as sns;\n",
    "\n",
    "sns.set(rc={'figure.figsize':(8,5)})\n",
    "ax = sns.heatmap(cm, annot=True, fmt=\"d\", cmap=\"Blues\")\n",
    "ax"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\asus\\Anaconda3\\lib\\site-packages\\sklearn\\utils\\linear_assignment_.py:127: DeprecationWarning: The linear_assignment function is deprecated in 0.21 and will be removed from 0.23. Use scipy.optimize.linear_sum_assignment instead.\n",
      "  DeprecationWarning)\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "0.8721"
      ]
     },
     "execution_count": 72,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from coclust.evaluation.external import accuracy\n",
    "\n",
    "accuracy(data_df['CancerType'], data_df['Cluster'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0.8721"
      ]
     },
     "execution_count": 70,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from sklearn.metrics.classification import accuracy_score\n",
    "\n",
    "accuracy_score(data_df['CancerType'], data_df['Cluster'])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Select one article (using \"PUMID\"), from each cluster and extract top 5 similiarest articles (instances)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>7</th>\n",
       "      <th>8</th>\n",
       "      <th>9</th>\n",
       "      <th>...</th>\n",
       "      <th>9990</th>\n",
       "      <th>9991</th>\n",
       "      <th>9992</th>\n",
       "      <th>9993</th>\n",
       "      <th>9994</th>\n",
       "      <th>9995</th>\n",
       "      <th>9996</th>\n",
       "      <th>9997</th>\n",
       "      <th>9998</th>\n",
       "      <th>9999</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.061515</td>\n",
       "      <td>0.088812</td>\n",
       "      <td>0.074249</td>\n",
       "      <td>0.097627</td>\n",
       "      <td>0.030607</td>\n",
       "      <td>0.113703</td>\n",
       "      <td>0.062316</td>\n",
       "      <td>0.054583</td>\n",
       "      <td>0.055684</td>\n",
       "      <td>...</td>\n",
       "      <td>0.007435</td>\n",
       "      <td>0.016421</td>\n",
       "      <td>0.029709</td>\n",
       "      <td>0.041221</td>\n",
       "      <td>0.012108</td>\n",
       "      <td>0.012048</td>\n",
       "      <td>0.041185</td>\n",
       "      <td>0.027924</td>\n",
       "      <td>0.011591</td>\n",
       "      <td>0.020964</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0.061515</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.074174</td>\n",
       "      <td>0.088862</td>\n",
       "      <td>0.068625</td>\n",
       "      <td>0.037924</td>\n",
       "      <td>0.171106</td>\n",
       "      <td>0.115116</td>\n",
       "      <td>0.069546</td>\n",
       "      <td>0.135795</td>\n",
       "      <td>...</td>\n",
       "      <td>0.017958</td>\n",
       "      <td>0.044825</td>\n",
       "      <td>0.028957</td>\n",
       "      <td>0.027395</td>\n",
       "      <td>0.018010</td>\n",
       "      <td>0.155452</td>\n",
       "      <td>0.023099</td>\n",
       "      <td>0.028555</td>\n",
       "      <td>0.025803</td>\n",
       "      <td>0.028207</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>0.088812</td>\n",
       "      <td>0.074174</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.137289</td>\n",
       "      <td>0.110647</td>\n",
       "      <td>0.058015</td>\n",
       "      <td>0.248487</td>\n",
       "      <td>0.111255</td>\n",
       "      <td>0.080277</td>\n",
       "      <td>0.081217</td>\n",
       "      <td>...</td>\n",
       "      <td>0.009129</td>\n",
       "      <td>0.036299</td>\n",
       "      <td>0.009844</td>\n",
       "      <td>0.015768</td>\n",
       "      <td>0.020715</td>\n",
       "      <td>0.012955</td>\n",
       "      <td>0.225336</td>\n",
       "      <td>0.009698</td>\n",
       "      <td>0.005016</td>\n",
       "      <td>0.007722</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>0.074249</td>\n",
       "      <td>0.088862</td>\n",
       "      <td>0.137289</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.109521</td>\n",
       "      <td>0.071664</td>\n",
       "      <td>0.247494</td>\n",
       "      <td>0.093393</td>\n",
       "      <td>0.080238</td>\n",
       "      <td>0.056884</td>\n",
       "      <td>...</td>\n",
       "      <td>0.049775</td>\n",
       "      <td>0.023406</td>\n",
       "      <td>0.009157</td>\n",
       "      <td>0.027696</td>\n",
       "      <td>0.034338</td>\n",
       "      <td>0.012724</td>\n",
       "      <td>0.011421</td>\n",
       "      <td>0.016919</td>\n",
       "      <td>0.010655</td>\n",
       "      <td>0.011032</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>0.097627</td>\n",
       "      <td>0.068625</td>\n",
       "      <td>0.110647</td>\n",
       "      <td>0.109521</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.044762</td>\n",
       "      <td>0.157064</td>\n",
       "      <td>0.069573</td>\n",
       "      <td>0.061845</td>\n",
       "      <td>0.044650</td>\n",
       "      <td>...</td>\n",
       "      <td>0.004479</td>\n",
       "      <td>0.018916</td>\n",
       "      <td>0.030967</td>\n",
       "      <td>0.008876</td>\n",
       "      <td>0.036243</td>\n",
       "      <td>0.021370</td>\n",
       "      <td>0.042591</td>\n",
       "      <td>0.033074</td>\n",
       "      <td>0.008619</td>\n",
       "      <td>0.003658</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9995</th>\n",
       "      <td>0.012048</td>\n",
       "      <td>0.155452</td>\n",
       "      <td>0.012955</td>\n",
       "      <td>0.012724</td>\n",
       "      <td>0.021370</td>\n",
       "      <td>0.012357</td>\n",
       "      <td>0.018038</td>\n",
       "      <td>0.033188</td>\n",
       "      <td>0.015994</td>\n",
       "      <td>0.021941</td>\n",
       "      <td>...</td>\n",
       "      <td>0.054799</td>\n",
       "      <td>0.146896</td>\n",
       "      <td>0.055373</td>\n",
       "      <td>0.103847</td>\n",
       "      <td>0.063855</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.067035</td>\n",
       "      <td>0.083979</td>\n",
       "      <td>0.077338</td>\n",
       "      <td>0.112880</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9996</th>\n",
       "      <td>0.041185</td>\n",
       "      <td>0.023099</td>\n",
       "      <td>0.225336</td>\n",
       "      <td>0.011421</td>\n",
       "      <td>0.042591</td>\n",
       "      <td>0.007293</td>\n",
       "      <td>0.033225</td>\n",
       "      <td>0.008350</td>\n",
       "      <td>0.024374</td>\n",
       "      <td>0.048804</td>\n",
       "      <td>...</td>\n",
       "      <td>0.030455</td>\n",
       "      <td>0.122245</td>\n",
       "      <td>0.045901</td>\n",
       "      <td>0.038382</td>\n",
       "      <td>0.065740</td>\n",
       "      <td>0.067035</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.094757</td>\n",
       "      <td>0.057887</td>\n",
       "      <td>0.060383</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9997</th>\n",
       "      <td>0.027924</td>\n",
       "      <td>0.028555</td>\n",
       "      <td>0.009698</td>\n",
       "      <td>0.016919</td>\n",
       "      <td>0.033074</td>\n",
       "      <td>0.014134</td>\n",
       "      <td>0.010902</td>\n",
       "      <td>0.015690</td>\n",
       "      <td>0.012249</td>\n",
       "      <td>0.041560</td>\n",
       "      <td>...</td>\n",
       "      <td>0.096783</td>\n",
       "      <td>0.156038</td>\n",
       "      <td>0.059505</td>\n",
       "      <td>0.044596</td>\n",
       "      <td>0.101673</td>\n",
       "      <td>0.083979</td>\n",
       "      <td>0.094757</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.059989</td>\n",
       "      <td>0.067853</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9998</th>\n",
       "      <td>0.011591</td>\n",
       "      <td>0.025803</td>\n",
       "      <td>0.005016</td>\n",
       "      <td>0.010655</td>\n",
       "      <td>0.008619</td>\n",
       "      <td>0.010631</td>\n",
       "      <td>0.014759</td>\n",
       "      <td>0.002436</td>\n",
       "      <td>0.007899</td>\n",
       "      <td>0.016626</td>\n",
       "      <td>...</td>\n",
       "      <td>0.030624</td>\n",
       "      <td>0.142499</td>\n",
       "      <td>0.102864</td>\n",
       "      <td>0.058796</td>\n",
       "      <td>0.212628</td>\n",
       "      <td>0.077338</td>\n",
       "      <td>0.057887</td>\n",
       "      <td>0.059989</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.039349</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9999</th>\n",
       "      <td>0.020964</td>\n",
       "      <td>0.028207</td>\n",
       "      <td>0.007722</td>\n",
       "      <td>0.011032</td>\n",
       "      <td>0.003658</td>\n",
       "      <td>0.000735</td>\n",
       "      <td>0.056219</td>\n",
       "      <td>0.044971</td>\n",
       "      <td>0.030372</td>\n",
       "      <td>0.024562</td>\n",
       "      <td>...</td>\n",
       "      <td>0.026395</td>\n",
       "      <td>0.100867</td>\n",
       "      <td>0.052111</td>\n",
       "      <td>0.109364</td>\n",
       "      <td>0.035930</td>\n",
       "      <td>0.112880</td>\n",
       "      <td>0.060383</td>\n",
       "      <td>0.067853</td>\n",
       "      <td>0.039349</td>\n",
       "      <td>1.000000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>10000 rows Ã— 10000 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "          0         1         2         3         4         5         6     \\\n",
       "0     1.000000  0.061515  0.088812  0.074249  0.097627  0.030607  0.113703   \n",
       "1     0.061515  1.000000  0.074174  0.088862  0.068625  0.037924  0.171106   \n",
       "2     0.088812  0.074174  1.000000  0.137289  0.110647  0.058015  0.248487   \n",
       "3     0.074249  0.088862  0.137289  1.000000  0.109521  0.071664  0.247494   \n",
       "4     0.097627  0.068625  0.110647  0.109521  1.000000  0.044762  0.157064   \n",
       "...        ...       ...       ...       ...       ...       ...       ...   \n",
       "9995  0.012048  0.155452  0.012955  0.012724  0.021370  0.012357  0.018038   \n",
       "9996  0.041185  0.023099  0.225336  0.011421  0.042591  0.007293  0.033225   \n",
       "9997  0.027924  0.028555  0.009698  0.016919  0.033074  0.014134  0.010902   \n",
       "9998  0.011591  0.025803  0.005016  0.010655  0.008619  0.010631  0.014759   \n",
       "9999  0.020964  0.028207  0.007722  0.011032  0.003658  0.000735  0.056219   \n",
       "\n",
       "          7         8         9     ...      9990      9991      9992  \\\n",
       "0     0.062316  0.054583  0.055684  ...  0.007435  0.016421  0.029709   \n",
       "1     0.115116  0.069546  0.135795  ...  0.017958  0.044825  0.028957   \n",
       "2     0.111255  0.080277  0.081217  ...  0.009129  0.036299  0.009844   \n",
       "3     0.093393  0.080238  0.056884  ...  0.049775  0.023406  0.009157   \n",
       "4     0.069573  0.061845  0.044650  ...  0.004479  0.018916  0.030967   \n",
       "...        ...       ...       ...  ...       ...       ...       ...   \n",
       "9995  0.033188  0.015994  0.021941  ...  0.054799  0.146896  0.055373   \n",
       "9996  0.008350  0.024374  0.048804  ...  0.030455  0.122245  0.045901   \n",
       "9997  0.015690  0.012249  0.041560  ...  0.096783  0.156038  0.059505   \n",
       "9998  0.002436  0.007899  0.016626  ...  0.030624  0.142499  0.102864   \n",
       "9999  0.044971  0.030372  0.024562  ...  0.026395  0.100867  0.052111   \n",
       "\n",
       "          9993      9994      9995      9996      9997      9998      9999  \n",
       "0     0.041221  0.012108  0.012048  0.041185  0.027924  0.011591  0.020964  \n",
       "1     0.027395  0.018010  0.155452  0.023099  0.028555  0.025803  0.028207  \n",
       "2     0.015768  0.020715  0.012955  0.225336  0.009698  0.005016  0.007722  \n",
       "3     0.027696  0.034338  0.012724  0.011421  0.016919  0.010655  0.011032  \n",
       "4     0.008876  0.036243  0.021370  0.042591  0.033074  0.008619  0.003658  \n",
       "...        ...       ...       ...       ...       ...       ...       ...  \n",
       "9995  0.103847  0.063855  1.000000  0.067035  0.083979  0.077338  0.112880  \n",
       "9996  0.038382  0.065740  0.067035  1.000000  0.094757  0.057887  0.060383  \n",
       "9997  0.044596  0.101673  0.083979  0.094757  1.000000  0.059989  0.067853  \n",
       "9998  0.058796  0.212628  0.077338  0.057887  0.059989  1.000000  0.039349  \n",
       "9999  0.109364  0.035930  0.112880  0.060383  0.067853  0.039349  1.000000  \n",
       "\n",
       "[10000 rows x 10000 columns]"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "\n",
    "doc_sim = cosine_similarity(tv_matrix)\n",
    "doc_sim_df = pd.DataFrame(doc_sim)\n",
    "doc_sim_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(array(['Understanding the symptoms experienced by individuals with lung cancer.',\n",
       "        'Do statins improve outcomes for patients with non-small cell lung cancer? A systematic review and meta-analysis protocol.',\n",
       "        'Lung cancer epidemiology, risk factors, and prevention.', ...,\n",
       "        'Intravesical irrigation with distilled water during and immediately after transurethral resection and later for superficial bladder cancer.',\n",
       "        'Ileal neobladder in women with bladder cancer: cancer control and functional aspects.',\n",
       "        'Molecular Subtype Profiling of Urothelial Carcinoma Using a Subtype-Specific Immunohistochemistry Panel.'],\n",
       "       dtype=object), (10000,))"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pubmed_list = PubMed['Title'].values\n",
    "pubmed_list, pubmed_list.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "import numpy as np\n",
    "\n",
    "def similar_articles(pubmed_title, article=pubmed_list, doc_sims=doc_sim_df):\n",
    "    # find pubmed index\n",
    "    pubmed_idx = np.where(article == pubmed_title)[0][0]\n",
    "    # get article similarities\n",
    "    article_similarities = doc_sims.iloc[pubmed_idx].values\n",
    "    # get top 5 similar pubmed article IDs\n",
    "    similar_pubmed_idxs = np.argsort(-article_similarities)[1:6]\n",
    "    # get top 5 article\n",
    "    similar_article = article[similar_pubmed_idxs]\n",
    "    # return the top 5 similar articles\n",
    "    return similar_article"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Letter: Prevalence and duration of undetected breast cancer.',\n",
       " 'Epidemiology of prostate cancer with special reference to the role of diet.',\n",
       " 'Letter: Mortality from lung cancer.',\n",
       " 'The local, regional and systemic attack on bladder cancer.',\n",
       " '[Association of tuberculosis and thyroid cancer. Value of exploratory cervicotomy].',\n",
       " '[Combined operations in stomach cancer].',\n",
       " '[First results of the work of the urban cytological laboratory].',\n",
       " 'Adenocarcinoma of the uterine cervix. An evaluation of the available diagnostic methods.',\n",
       " '[Cytological diagnosis of stomach cancer].',\n",
       " '[Esophago-intestinal bypass anastomoses for inoperable cancer of the proximal portion of the stomach and abdominal portion of the esophagus].']"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "articles= []\n",
    "articles_cluster = []\n",
    "for i in range(1,NUM_CLUSTERS+1):\n",
    "    pubmed_articles = pubmed_clusters[pubmed_clusters['Ward_cluster'] == i]['Title'].values.tolist()\n",
    "    articles.append(pubmed_articles[0])\n",
    "    articles_cluster.append(i)\n",
    "articles"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Title</th>\n",
       "      <th>Ward_cluster</th>\n",
       "      <th>Similar_Title</th>\n",
       "      <th>Similar_cluster</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "Empty DataFrame\n",
       "Columns: [Title, Ward_cluster, Similar_Title, Similar_cluster]\n",
       "Index: []"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data = {'Title': [], 'Ward_cluster': [], 'Similar_Title': [], 'Similar_cluster': []}\n",
    "df_similar = pd.DataFrame(data)\n",
    "df_similar"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Article Title from Cluster 1 : Letter: Prevalence and duration of undetected breast cancer.\n",
      "\n",
      "Top 5 similar article:\n",
      "From Cluster 1 Title : Expression profiling technology: its contribution to our understanding of breast cancer.\n",
      "From Cluster 1 Title : Prospective Validation of a Genomic Assay in Breast Cancer: The 70-gene MammaPrint Assay and the MINDACT Trial.\n",
      "From Cluster 1 Title : High incidence of breast cancer in thyroid cancer patients.\n",
      "From Cluster 1 Title : Breast cancer screening.\n",
      "From Cluster 1 Title : Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer.\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "Article Title from Cluster 2 : Epidemiology of prostate cancer with special reference to the role of diet.\n",
      "\n",
      "Top 5 similar article:\n",
      "From Cluster 2 Title : Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity.\n",
      "From Cluster 2 Title : [A case-control study of prostate cancer].\n",
      "From Cluster 2 Title : Summaries for patients. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.\n",
      "From Cluster 2 Title : Linking fatherhood to prostate cancer risk.\n",
      "From Cluster 2 Title : What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "Article Title from Cluster 3 : Letter: Mortality from lung cancer.\n",
      "\n",
      "Top 5 similar article:\n",
      "From Cluster 3 Title : The risk of lung cancer in males with bullous disease of the lung.\n",
      "From Cluster 3 Title : [Diagnosis of lung cancer].\n",
      "From Cluster 3 Title : Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer.\n",
      "From Cluster 3 Title : MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance.\n",
      "From Cluster 3 Title : Diagnostic workup of lung cancer.\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "Article Title from Cluster 4 : The local, regional and systemic attack on bladder cancer.\n",
      "\n",
      "Top 5 similar article:\n",
      "From Cluster 4 Title : Current trends in bladder cancer in England and Wales.\n",
      "From Cluster 4 Title : Bladder cancer: diagnosis and management of bladder cancer: Â© NICE (2015) Bladder cancer: diagnosis and management of bladder cancer.\n",
      "From Cluster 4 Title : Significance of age and comorbidity as prognostic indicators for patients with bladder cancer.\n",
      "From Cluster 4 Title : [Epidemiology of bladder cancer].\n",
      "From Cluster 4 Title : XPC epigenetic silence coupled with p53 alteration has a significant impact on bladder cancer outcome.\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "Article Title from Cluster 5 : [Association of tuberculosis and thyroid cancer. Value of exploratory cervicotomy].\n",
      "\n",
      "Top 5 similar article:\n",
      "From Cluster 5 Title : Central lymph node dissection as a secondary procedure for papillary thyroid cancer: Is there added morbidity?\n",
      "From Cluster 5 Title : Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma.\n",
      "From Cluster 5 Title : [Association of cancer and tumor-like diseases of the thyroid gland in inhabitants of Kiev and the Kiev region: clinico-morphological aspects].\n",
      "From Cluster 5 Title : [Value of thyroglobulin determination in the follow up treatment of patients with thyroid cancer].\n",
      "From Cluster 5 Title : Radiation safety precautions with 131iodine therapy.\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "Article Title from Cluster 6 : [Combined operations in stomach cancer].\n",
      "\n",
      "Top 5 similar article:\n",
      "From Cluster 9 Title : [Rational support of combined operations in locally disseminated stomach cancer].\n",
      "From Cluster 9 Title : Surgical treatment of gastric cancer today.\n",
      "From Cluster 9 Title : [Gastric cancer. Review of 375 cases].\n",
      "From Cluster 9 Title : [Clinical aspects and prognosis of stomach cancer].\n",
      "From Cluster 9 Title : [Pathways of lymphogenic metastasis from stomach cancer following Billroth II resection].\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "Article Title from Cluster 7 : [First results of the work of the urban cytological laboratory].\n",
      "\n",
      "Top 5 similar article:\n",
      "From Cluster 7 Title : [For the clinical diagnosis of liver sarcoma].\n",
      "From Cluster 7 Title : Induction of apoptosis of liver cancer cells by nanosecond pulsed electric fields (nsPEFs).\n",
      "From Cluster 7 Title : Cell proliferation and apoptosis in normal liver and preneoplastic foci.\n",
      "From Cluster 7 Title : Bigelovin, a sesquiterpene lactone, suppresses tumor growth through inducing apoptosis and autophagy via the inhibition of mTOR pathway regulated by ROS generation in liver cancer.\n",
      "From Cluster 2 Title : Par-4 inducible apoptosis in prostate cancer cells.\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "Article Title from Cluster 8 : Adenocarcinoma of the uterine cervix. An evaluation of the available diagnostic methods.\n",
      "\n",
      "Top 5 similar article:\n",
      "From Cluster 8 Title : [Pap-smear test today].\n",
      "From Cluster 8 Title : Cervicography: adjunctive cervical cancer screening by primary care clinicians.\n",
      "From Cluster 8 Title : Attitudes, knowledge, and practices in relation to cervical cancer and its screening among women in Saudi Arabia.\n",
      "From Cluster 8 Title : Efficacy of visual inspection of the cervix using acetic acid in cervical cancer screening: a comparison with cervical cytology.\n",
      "From Cluster 8 Title : [Following-up females having an abnormal Pap smear in Colombia].\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "Article Title from Cluster 9 : [Cytological diagnosis of stomach cancer].\n",
      "\n",
      "Top 5 similar article:\n",
      "From Cluster 10 Title : [Transumbilical vein infusion of antineoplastic agents, with special reference to postoperative management of stomach cancer].\n",
      "From Cluster 10 Title : Rising incidence of adenocarcinoma of the esophagus and gastric cardia.\n",
      "From Cluster 5 Title : Body mass index in the evaluation of thyroid cancer risk.\n",
      "From Cluster 10 Title : [Lymphogenous metastasis and lymphadenectomy in stomach cancer].\n",
      "From Cluster 10 Title : Esophageal balloon cytology and subsequent risk of esophageal and gastric-cardia cancer in a high-risk Chinese population.\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "Article Title from Cluster 10 : [Esophago-intestinal bypass anastomoses for inoperable cancer of the proximal portion of the stomach and abdominal portion of the esophagus].\n",
      "\n",
      "Top 5 similar article:\n",
      "From Cluster 10 Title : Carcinoma of the stomach; rate of operability.\n",
      "From Cluster 10 Title : Variations in gastric cancer mortality in South Wales.\n",
      "From Cluster 10 Title : Cervical esophago-gastric anastomosis using linear cutter stapler in esophageal cancer.\n",
      "From Cluster 10 Title : A co-operative international study of gastric cancer (under the auspices of the International Federation of Surgical Colleges).\n",
      "From Cluster 9 Title : [Duodenogastric reflux and gastric carcinogenesis in rats].\n",
      "--------------------------------------------------------------------------------\n",
      "\n"
     ]
    }
   ],
   "source": [
    "cluster = 1\n",
    "for article in articles:\n",
    "    print('Article Title from Cluster', cluster, ':', article)\n",
    "    print()\n",
    "    print('Top 5 similar article:')\n",
    "    five_similar_articles = similar_articles(pubmed_title=article)\n",
    "    for one_article in five_similar_articles:\n",
    "        article_details = PubMed.loc[PubMed['Title'] == one_article]\n",
    "        print('From Cluster', article_details['Ward_cluster'].tolist()[0], 'Title :', one_article)\n",
    "        new_row = {'Title': article, 'Ward_cluster': cluster, 'Similar_Title': one_article, 'Similar_cluster': article_details['Ward_cluster'].tolist()[0]}\n",
    "        df_similar = df_similar.append(new_row, ignore_index=True)\n",
    "    print('-'*80)\n",
    "    print()\n",
    "    cluster+=1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Title</th>\n",
       "      <th>Ward_cluster</th>\n",
       "      <th>Similar_Title</th>\n",
       "      <th>Similar_cluster</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Letter: Prevalence and duration of undetected ...</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Expression profiling technology: its contribut...</td>\n",
       "      <td>1.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Letter: Prevalence and duration of undetected ...</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Prospective Validation of a Genomic Assay in B...</td>\n",
       "      <td>1.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Letter: Prevalence and duration of undetected ...</td>\n",
       "      <td>1.0</td>\n",
       "      <td>High incidence of breast cancer in thyroid can...</td>\n",
       "      <td>1.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Letter: Prevalence and duration of undetected ...</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Breast cancer screening.</td>\n",
       "      <td>1.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Letter: Prevalence and duration of undetected ...</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Translational Genomics: Practical Applications...</td>\n",
       "      <td>1.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Epidemiology of prostate cancer with special r...</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Trends in prostate cancer incidence and mortal...</td>\n",
       "      <td>2.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Epidemiology of prostate cancer with special r...</td>\n",
       "      <td>2.0</td>\n",
       "      <td>[A case-control study of prostate cancer].</td>\n",
       "      <td>2.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Epidemiology of prostate cancer with special r...</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Summaries for patients. Screening for prostate...</td>\n",
       "      <td>2.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Epidemiology of prostate cancer with special r...</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Linking fatherhood to prostate cancer risk.</td>\n",
       "      <td>2.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Epidemiology of prostate cancer with special r...</td>\n",
       "      <td>2.0</td>\n",
       "      <td>What role does stereotactic ablative radiother...</td>\n",
       "      <td>2.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Letter: Mortality from lung cancer.</td>\n",
       "      <td>3.0</td>\n",
       "      <td>The risk of lung cancer in males with bullous ...</td>\n",
       "      <td>3.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Letter: Mortality from lung cancer.</td>\n",
       "      <td>3.0</td>\n",
       "      <td>[Diagnosis of lung cancer].</td>\n",
       "      <td>3.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Letter: Mortality from lung cancer.</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Prognostic, therapeutic and diagnostic potenti...</td>\n",
       "      <td>3.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Letter: Mortality from lung cancer.</td>\n",
       "      <td>3.0</td>\n",
       "      <td>MicroRNA in lung cancer: role, mechanisms, pat...</td>\n",
       "      <td>3.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Letter: Mortality from lung cancer.</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Diagnostic workup of lung cancer.</td>\n",
       "      <td>3.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>The local, regional and systemic attack on bla...</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Current trends in bladder cancer in England an...</td>\n",
       "      <td>4.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>The local, regional and systemic attack on bla...</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Bladder cancer: diagnosis and management of bl...</td>\n",
       "      <td>4.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>The local, regional and systemic attack on bla...</td>\n",
       "      <td>4.0</td>\n",
       "      <td>Significance of age and comorbidity as prognos...</td>\n",
       "      <td>4.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>The local, regional and systemic attack on bla...</td>\n",
       "      <td>4.0</td>\n",
       "      <td>[Epidemiology of bladder cancer].</td>\n",
       "      <td>4.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>The local, regional and systemic attack on bla...</td>\n",
       "      <td>4.0</td>\n",
       "      <td>XPC epigenetic silence coupled with p53 altera...</td>\n",
       "      <td>4.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>[Association of tuberculosis and thyroid cance...</td>\n",
       "      <td>5.0</td>\n",
       "      <td>Central lymph node dissection as a secondary p...</td>\n",
       "      <td>5.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>[Association of tuberculosis and thyroid cance...</td>\n",
       "      <td>5.0</td>\n",
       "      <td>Long-term outcome of comprehensive central com...</td>\n",
       "      <td>5.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>[Association of tuberculosis and thyroid cance...</td>\n",
       "      <td>5.0</td>\n",
       "      <td>[Association of cancer and tumor-like diseases...</td>\n",
       "      <td>5.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>[Association of tuberculosis and thyroid cance...</td>\n",
       "      <td>5.0</td>\n",
       "      <td>[Value of thyroglobulin determination in the f...</td>\n",
       "      <td>5.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>[Association of tuberculosis and thyroid cance...</td>\n",
       "      <td>5.0</td>\n",
       "      <td>Radiation safety precautions with 131iodine th...</td>\n",
       "      <td>5.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>[Combined operations in stomach cancer].</td>\n",
       "      <td>6.0</td>\n",
       "      <td>[Rational support of combined operations in lo...</td>\n",
       "      <td>9.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>[Combined operations in stomach cancer].</td>\n",
       "      <td>6.0</td>\n",
       "      <td>Surgical treatment of gastric cancer today.</td>\n",
       "      <td>9.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>[Combined operations in stomach cancer].</td>\n",
       "      <td>6.0</td>\n",
       "      <td>[Gastric cancer. Review of 375 cases].</td>\n",
       "      <td>9.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>[Combined operations in stomach cancer].</td>\n",
       "      <td>6.0</td>\n",
       "      <td>[Clinical aspects and prognosis of stomach can...</td>\n",
       "      <td>9.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>[Combined operations in stomach cancer].</td>\n",
       "      <td>6.0</td>\n",
       "      <td>[Pathways of lymphogenic metastasis from stoma...</td>\n",
       "      <td>9.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>[First results of the work of the urban cytolo...</td>\n",
       "      <td>7.0</td>\n",
       "      <td>[For the clinical diagnosis of liver sarcoma].</td>\n",
       "      <td>7.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>[First results of the work of the urban cytolo...</td>\n",
       "      <td>7.0</td>\n",
       "      <td>Induction of apoptosis of liver cancer cells b...</td>\n",
       "      <td>7.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>[First results of the work of the urban cytolo...</td>\n",
       "      <td>7.0</td>\n",
       "      <td>Cell proliferation and apoptosis in normal liv...</td>\n",
       "      <td>7.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>[First results of the work of the urban cytolo...</td>\n",
       "      <td>7.0</td>\n",
       "      <td>Bigelovin, a sesquiterpene lactone, suppresses...</td>\n",
       "      <td>7.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>[First results of the work of the urban cytolo...</td>\n",
       "      <td>7.0</td>\n",
       "      <td>Par-4 inducible apoptosis in prostate cancer c...</td>\n",
       "      <td>2.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>Adenocarcinoma of the uterine cervix. An evalu...</td>\n",
       "      <td>8.0</td>\n",
       "      <td>[Pap-smear test today].</td>\n",
       "      <td>8.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>Adenocarcinoma of the uterine cervix. An evalu...</td>\n",
       "      <td>8.0</td>\n",
       "      <td>Cervicography: adjunctive cervical cancer scre...</td>\n",
       "      <td>8.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>Adenocarcinoma of the uterine cervix. An evalu...</td>\n",
       "      <td>8.0</td>\n",
       "      <td>Attitudes, knowledge, and practices in relatio...</td>\n",
       "      <td>8.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>Adenocarcinoma of the uterine cervix. An evalu...</td>\n",
       "      <td>8.0</td>\n",
       "      <td>Efficacy of visual inspection of the cervix us...</td>\n",
       "      <td>8.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>Adenocarcinoma of the uterine cervix. An evalu...</td>\n",
       "      <td>8.0</td>\n",
       "      <td>[Following-up females having an abnormal Pap s...</td>\n",
       "      <td>8.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>[Cytological diagnosis of stomach cancer].</td>\n",
       "      <td>9.0</td>\n",
       "      <td>[Transumbilical vein infusion of antineoplasti...</td>\n",
       "      <td>10.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>[Cytological diagnosis of stomach cancer].</td>\n",
       "      <td>9.0</td>\n",
       "      <td>Rising incidence of adenocarcinoma of the esop...</td>\n",
       "      <td>10.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>[Cytological diagnosis of stomach cancer].</td>\n",
       "      <td>9.0</td>\n",
       "      <td>Body mass index in the evaluation of thyroid c...</td>\n",
       "      <td>5.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>[Cytological diagnosis of stomach cancer].</td>\n",
       "      <td>9.0</td>\n",
       "      <td>[Lymphogenous metastasis and lymphadenectomy i...</td>\n",
       "      <td>10.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>[Cytological diagnosis of stomach cancer].</td>\n",
       "      <td>9.0</td>\n",
       "      <td>Esophageal balloon cytology and subsequent ris...</td>\n",
       "      <td>10.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>[Esophago-intestinal bypass anastomoses for in...</td>\n",
       "      <td>10.0</td>\n",
       "      <td>Carcinoma of the stomach; rate of operability.</td>\n",
       "      <td>10.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>[Esophago-intestinal bypass anastomoses for in...</td>\n",
       "      <td>10.0</td>\n",
       "      <td>Variations in gastric cancer mortality in Sout...</td>\n",
       "      <td>10.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>[Esophago-intestinal bypass anastomoses for in...</td>\n",
       "      <td>10.0</td>\n",
       "      <td>Cervical esophago-gastric anastomosis using li...</td>\n",
       "      <td>10.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>[Esophago-intestinal bypass anastomoses for in...</td>\n",
       "      <td>10.0</td>\n",
       "      <td>A co-operative international study of gastric ...</td>\n",
       "      <td>10.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>[Esophago-intestinal bypass anastomoses for in...</td>\n",
       "      <td>10.0</td>\n",
       "      <td>[Duodenogastric reflux and gastric carcinogene...</td>\n",
       "      <td>9.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                Title  Ward_cluster  \\\n",
       "0   Letter: Prevalence and duration of undetected ...           1.0   \n",
       "1   Letter: Prevalence and duration of undetected ...           1.0   \n",
       "2   Letter: Prevalence and duration of undetected ...           1.0   \n",
       "3   Letter: Prevalence and duration of undetected ...           1.0   \n",
       "4   Letter: Prevalence and duration of undetected ...           1.0   \n",
       "5   Epidemiology of prostate cancer with special r...           2.0   \n",
       "6   Epidemiology of prostate cancer with special r...           2.0   \n",
       "7   Epidemiology of prostate cancer with special r...           2.0   \n",
       "8   Epidemiology of prostate cancer with special r...           2.0   \n",
       "9   Epidemiology of prostate cancer with special r...           2.0   \n",
       "10                Letter: Mortality from lung cancer.           3.0   \n",
       "11                Letter: Mortality from lung cancer.           3.0   \n",
       "12                Letter: Mortality from lung cancer.           3.0   \n",
       "13                Letter: Mortality from lung cancer.           3.0   \n",
       "14                Letter: Mortality from lung cancer.           3.0   \n",
       "15  The local, regional and systemic attack on bla...           4.0   \n",
       "16  The local, regional and systemic attack on bla...           4.0   \n",
       "17  The local, regional and systemic attack on bla...           4.0   \n",
       "18  The local, regional and systemic attack on bla...           4.0   \n",
       "19  The local, regional and systemic attack on bla...           4.0   \n",
       "20  [Association of tuberculosis and thyroid cance...           5.0   \n",
       "21  [Association of tuberculosis and thyroid cance...           5.0   \n",
       "22  [Association of tuberculosis and thyroid cance...           5.0   \n",
       "23  [Association of tuberculosis and thyroid cance...           5.0   \n",
       "24  [Association of tuberculosis and thyroid cance...           5.0   \n",
       "25           [Combined operations in stomach cancer].           6.0   \n",
       "26           [Combined operations in stomach cancer].           6.0   \n",
       "27           [Combined operations in stomach cancer].           6.0   \n",
       "28           [Combined operations in stomach cancer].           6.0   \n",
       "29           [Combined operations in stomach cancer].           6.0   \n",
       "30  [First results of the work of the urban cytolo...           7.0   \n",
       "31  [First results of the work of the urban cytolo...           7.0   \n",
       "32  [First results of the work of the urban cytolo...           7.0   \n",
       "33  [First results of the work of the urban cytolo...           7.0   \n",
       "34  [First results of the work of the urban cytolo...           7.0   \n",
       "35  Adenocarcinoma of the uterine cervix. An evalu...           8.0   \n",
       "36  Adenocarcinoma of the uterine cervix. An evalu...           8.0   \n",
       "37  Adenocarcinoma of the uterine cervix. An evalu...           8.0   \n",
       "38  Adenocarcinoma of the uterine cervix. An evalu...           8.0   \n",
       "39  Adenocarcinoma of the uterine cervix. An evalu...           8.0   \n",
       "40         [Cytological diagnosis of stomach cancer].           9.0   \n",
       "41         [Cytological diagnosis of stomach cancer].           9.0   \n",
       "42         [Cytological diagnosis of stomach cancer].           9.0   \n",
       "43         [Cytological diagnosis of stomach cancer].           9.0   \n",
       "44         [Cytological diagnosis of stomach cancer].           9.0   \n",
       "45  [Esophago-intestinal bypass anastomoses for in...          10.0   \n",
       "46  [Esophago-intestinal bypass anastomoses for in...          10.0   \n",
       "47  [Esophago-intestinal bypass anastomoses for in...          10.0   \n",
       "48  [Esophago-intestinal bypass anastomoses for in...          10.0   \n",
       "49  [Esophago-intestinal bypass anastomoses for in...          10.0   \n",
       "\n",
       "                                        Similar_Title  Similar_cluster  \n",
       "0   Expression profiling technology: its contribut...              1.0  \n",
       "1   Prospective Validation of a Genomic Assay in B...              1.0  \n",
       "2   High incidence of breast cancer in thyroid can...              1.0  \n",
       "3                            Breast cancer screening.              1.0  \n",
       "4   Translational Genomics: Practical Applications...              1.0  \n",
       "5   Trends in prostate cancer incidence and mortal...              2.0  \n",
       "6          [A case-control study of prostate cancer].              2.0  \n",
       "7   Summaries for patients. Screening for prostate...              2.0  \n",
       "8         Linking fatherhood to prostate cancer risk.              2.0  \n",
       "9   What role does stereotactic ablative radiother...              2.0  \n",
       "10  The risk of lung cancer in males with bullous ...              3.0  \n",
       "11                        [Diagnosis of lung cancer].              3.0  \n",
       "12  Prognostic, therapeutic and diagnostic potenti...              3.0  \n",
       "13  MicroRNA in lung cancer: role, mechanisms, pat...              3.0  \n",
       "14                  Diagnostic workup of lung cancer.              3.0  \n",
       "15  Current trends in bladder cancer in England an...              4.0  \n",
       "16  Bladder cancer: diagnosis and management of bl...              4.0  \n",
       "17  Significance of age and comorbidity as prognos...              4.0  \n",
       "18                  [Epidemiology of bladder cancer].              4.0  \n",
       "19  XPC epigenetic silence coupled with p53 altera...              4.0  \n",
       "20  Central lymph node dissection as a secondary p...              5.0  \n",
       "21  Long-term outcome of comprehensive central com...              5.0  \n",
       "22  [Association of cancer and tumor-like diseases...              5.0  \n",
       "23  [Value of thyroglobulin determination in the f...              5.0  \n",
       "24  Radiation safety precautions with 131iodine th...              5.0  \n",
       "25  [Rational support of combined operations in lo...              9.0  \n",
       "26        Surgical treatment of gastric cancer today.              9.0  \n",
       "27             [Gastric cancer. Review of 375 cases].              9.0  \n",
       "28  [Clinical aspects and prognosis of stomach can...              9.0  \n",
       "29  [Pathways of lymphogenic metastasis from stoma...              9.0  \n",
       "30     [For the clinical diagnosis of liver sarcoma].              7.0  \n",
       "31  Induction of apoptosis of liver cancer cells b...              7.0  \n",
       "32  Cell proliferation and apoptosis in normal liv...              7.0  \n",
       "33  Bigelovin, a sesquiterpene lactone, suppresses...              7.0  \n",
       "34  Par-4 inducible apoptosis in prostate cancer c...              2.0  \n",
       "35                            [Pap-smear test today].              8.0  \n",
       "36  Cervicography: adjunctive cervical cancer scre...              8.0  \n",
       "37  Attitudes, knowledge, and practices in relatio...              8.0  \n",
       "38  Efficacy of visual inspection of the cervix us...              8.0  \n",
       "39  [Following-up females having an abnormal Pap s...              8.0  \n",
       "40  [Transumbilical vein infusion of antineoplasti...             10.0  \n",
       "41  Rising incidence of adenocarcinoma of the esop...             10.0  \n",
       "42  Body mass index in the evaluation of thyroid c...              5.0  \n",
       "43  [Lymphogenous metastasis and lymphadenectomy i...             10.0  \n",
       "44  Esophageal balloon cytology and subsequent ris...             10.0  \n",
       "45     Carcinoma of the stomach; rate of operability.             10.0  \n",
       "46  Variations in gastric cancer mortality in Sout...             10.0  \n",
       "47  Cervical esophago-gastric anastomosis using li...             10.0  \n",
       "48  A co-operative international study of gastric ...             10.0  \n",
       "49  [Duodenogastric reflux and gastric carcinogene...              9.0  "
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_similar"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "pubmed_idx = np.where(pubmed_list == '[First results of the work of the urban cytological laboratory].')[0][0]\n",
    "PubMed.loc[[pubmed_idx]]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Misclassified article"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PUMID</th>\n",
       "      <th>Title</th>\n",
       "      <th>CancerType</th>\n",
       "      <th>Cluster</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>24976333</td>\n",
       "      <td>Trimodality therapy for stage IIIA non-small c...</td>\n",
       "      <td>3</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>31072604</td>\n",
       "      <td>Incidental pulmonary nodules: characterization...</td>\n",
       "      <td>3</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>72</th>\n",
       "      <td>26909466</td>\n",
       "      <td>Expression levels of microRNA-145 and microRNA...</td>\n",
       "      <td>3</td>\n",
       "      <td>7</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>79</th>\n",
       "      <td>1203864</td>\n",
       "      <td>Carcinoembryonic antigen in 228 patients with ...</td>\n",
       "      <td>3</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>21055842</td>\n",
       "      <td>Costs of bevacizumab and pemetrexed for advanc...</td>\n",
       "      <td>3</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9930</th>\n",
       "      <td>31364733</td>\n",
       "      <td>Plasma miRâ€‘15bâ€‘5p and miRâ€‘590â€‘5p for distingui...</td>\n",
       "      <td>4</td>\n",
       "      <td>7</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9946</th>\n",
       "      <td>23991964</td>\n",
       "      <td>MicroRNA-16 inhibits bladder cancer proliferat...</td>\n",
       "      <td>4</td>\n",
       "      <td>7</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9967</th>\n",
       "      <td>1831033</td>\n",
       "      <td>Urinary tract reconstruction improves quality ...</td>\n",
       "      <td>4</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9976</th>\n",
       "      <td>12576819</td>\n",
       "      <td>Extent of pelvic lymphadenectomy and its impac...</td>\n",
       "      <td>4</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9978</th>\n",
       "      <td>15076285</td>\n",
       "      <td>Standardization of radical cystectomy and pelv...</td>\n",
       "      <td>4</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1279 rows Ã— 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "         PUMID                                              Title  CancerType  \\\n",
       "17    24976333  Trimodality therapy for stage IIIA non-small c...           3   \n",
       "44    31072604  Incidental pulmonary nodules: characterization...           3   \n",
       "72    26909466  Expression levels of microRNA-145 and microRNA...           3   \n",
       "79     1203864  Carcinoembryonic antigen in 228 patients with ...           3   \n",
       "88    21055842  Costs of bevacizumab and pemetrexed for advanc...           3   \n",
       "...        ...                                                ...         ...   \n",
       "9930  31364733  Plasma miRâ€‘15bâ€‘5p and miRâ€‘590â€‘5p for distingui...           4   \n",
       "9946  23991964  MicroRNA-16 inhibits bladder cancer proliferat...           4   \n",
       "9967   1831033  Urinary tract reconstruction improves quality ...           4   \n",
       "9976  12576819  Extent of pelvic lymphadenectomy and its impac...           4   \n",
       "9978  15076285  Standardization of radical cystectomy and pelv...           4   \n",
       "\n",
       "      Cluster  \n",
       "17         10  \n",
       "44          5  \n",
       "72          7  \n",
       "79         10  \n",
       "88         10  \n",
       "...       ...  \n",
       "9930        7  \n",
       "9946        7  \n",
       "9967        5  \n",
       "9976        5  \n",
       "9978        5  \n",
       "\n",
       "[1279 rows x 4 columns]"
      ]
     },
     "execution_count": 89,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = data_df[(data_df['CancerType'] != data_df['Cluster'])]\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1279"
      ]
     },
     "execution_count": 90,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PUMID</th>\n",
       "      <th>Title</th>\n",
       "      <th>CancerType</th>\n",
       "      <th>Cluster</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>9978</th>\n",
       "      <td>15076285</td>\n",
       "      <td>Standardization of radical cystectomy and pelv...</td>\n",
       "      <td>4</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         PUMID                                              Title  CancerType  \\\n",
       "9978  15076285  Standardization of radical cystectomy and pelv...           4   \n",
       "\n",
       "      Cluster  \n",
       "9978        5  "
      ]
     },
     "execution_count": 80,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = data_df[(data_df['CancerType'] != data_df['Cluster'])].tail(1)\n",
    "df\n",
    "# It is classified as bladder cancer, but clustered as thyroid"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "9000    bibliography current world literature bladder ...\n",
       "9001    current trend bladder cancer treatment prognos...\n",
       "9002    accurate determination pathological stage gros...\n",
       "9003    organ reconstruction conservation bladder canc...\n",
       "9004    apparent diffusion coefficient value reflect i...\n",
       "                              ...                        \n",
       "9995    high morbidity mortality find high risk non mu...\n",
       "9996    case referent study occupational risk factor b...\n",
       "9997    intravesical irrigation distill water immediat...\n",
       "9998    ileal neobladder woman bladder cancer cancer c...\n",
       "9999    molecular subtype profile urothelial carcinoma...\n",
       "Name: Clean_Description, Length: 1000, dtype: object"
      ]
     },
     "execution_count": 81,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_type_4 = PubMed[(PubMed['CancerType'] == 'Bladder')]['Clean_Description']\n",
    "df_type_4"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "' bibliography current world literature bladder cancer rationale locoregional stage lymphadenectomy prostate cancer lie accurate diagnosis occult micrometastases order stratify patient may benefit adjuvant therapeutic measure prostate cancer extend pelvic lymphadenectomy epla include lymphatic tissue along common iliac region ureteral cross cranial margin external internal iliac region obturator fossa show increase yield total lymph node lymph node metastasis significantly total numb lymph node remove fold high frequency micrometastatic lymph node approximately fold high compare standard lymphadenectomy furthermore frequency observe positive lymph node clinically localize locally advance prostate cancer significantly high predict nomograms partin table cart analysis although no prospective randomize trial demonstrate survival benefit associate epla may advantage minimal lymph node involvement progression free survival significantly improve patient undergo epla benefit compare standard lymphadenectomy various study document equal risk cancer associate mortality patient no positive lymph node since surgery associate morbidity epla not increase compare standard lymphadenectomy epla favour little intermediate high risk patient undergo radical prostatectomy low risk patient option epla discuss thoroughly future ongoing prospective trial demonstrate clear benefit term biochemical free cancer specific survival regard muscle invasive bladder cancer show lymph node dissection along external internal common iliac artery obturator fossa achieve accurate datum valid locoregional stage freeze section analysis reveal metastatic deposit along area extension lymphadenectomy include aortic bifurcation inferior mesenteric artery seem additional diagnostic value various study demonstrate extend pelvic lymphadenectomy result improvement progression free survival however no significant benefit regard cancer specific overall survival demonstrate nevertheless pelvic lymphadenectomy remain one significant prognosticators regard relapse rate demonstrate recently therefore perform thoroughly anatomically adequate current trend bladder cancer treatment prognostic information carcinoembryonic antigen evaluate bacterium free urine patient bladder carcinoma patient elevate great equal ng ml u cea poor relative symptom free survival patient initial u cea ng ml patient u cea decrease radiation treatment well survival rate patient increase u cea finding significant case large tumor tumor low differentiation g u cea appear independent variable prognostic evaluation survival since difference also true within subgroup know variable class grade one patient short term local control obtain posttreatment u cea ng ml oncology unit malignant bladder tumor treat u cea determination may indicate patient require intensify monitor treatment accurate determination pathological stage gross dissection protocol radical cystectomy current protocol report urinary bladder cancer radical cystectomy may exhibit limitation diagnostic accuracy risk understaging especially case prostatic involvement difficulty arise verification stage pt assessment surgical margin suboptimal develope daily gross dissection protocol practice radical cystectomy totally embed evaluate histologically whole mount section report \\ufeff1 consecutive specimen \\ufeff1 quarter inclusive incidence cancer stage compare datum radical cystectomy literature difference analyze one sample z test p follow emerge series literature datum pt pta ptis pt pt pt pt respectively finding closely reflect mean publish statistical datum base large numb case difference due detail process case number group ptis pt comparatively low group pt pt high difference group pt significant p method sample regard pt granulomatous area hemosiderin deposition indicative early intervention observable entire preparation tumor free organ reconstruction conservation bladder cancer cisplatin base inductive chemotherapy induce remission locally invasive bladder cancer observe two cycle chemotherapy non transitional cell carcinoma bladder not respond therapy toxicity inductive chemotherapy acceptable clinical stage inductive neo adjuvant chemotherapy not correlate pathological stage cystectomy discrepancy indicate bladder preservation inductive chemotherapy not possible diagnostic method improve enough correlate exactly pathological finding many question remain open respect form treatment locally advance bladder cancer patient treat inductive neo adjuvant chemotherapy within context control prospective clinical trial basis current knowledge inductive chemotherapy not consider definitive form treatment locally invasive bladder tumour apparent diffusion coefficient value reflect invasive proliferative potential bladder cancer purpose elucidate role apparent diffusion coefficient adc value biomarker bladder cancer investigate association ki label index li along classical clinicopathological prognosticators material method diffusion weight mri dw mri tesla use b value mm prospectively take transurethral resection bladder cancer patient adc value index tumor measure compare clinicopathological prognosticators include ki li result adc value significantly low tumor high ki lis sessile tumor versus papillary large tumor high grade disease high stage disease adc value inversely correlate ki li p multiple regression analysis stage ki li significantly correlate adc value akaike information criterion confirm two parameter constitute well model determine adc value similarly stage adc value significantly correlate ki li two parameter compose well model predict ki li conclusion adc value would reflect stage ki li represent invasive proliferative potential respectively adc value likely serve biomarker reflect aggressiveness bladder cancer immunological study induction metallothionein bladder cancer metallothionein mt tumor cell indicate one factor involve mechanism resistance anticancer drug relationship expression mt chemotherapy anticancer drug study bladder cancer culture cell line tissue sample clinical case drug resistance cell line mt expression study immunohistological stain avidin biotin peroxidase complex abc method radioimmunoassay ria method use anti mt antibody tissue sample clinical case paraffin embed sample case chemotherapy subject immunohistological stain mt human bladder cancer cell line resistance anticancer drug c cddp adm show increase expression mt compare parental cell line c suggest relationship resistance anticancer drug mt expression clinical case continuous administration intra vesicle chemotherapy oral administration chemotherapy show great incidence positive stain mt expression comparison case few administration intra arterial infusion therapy intravenous administration chemotherapy result demonstrate repetitive continuous administration anticancer drug cause increase mt bladder cancer cell may possible mechanism acquire resistance anticancer drug perspective remove bias co manage patient risk connotation terminology influence decision make not underestimate example superficial hg bladder cancer poor cancer specific survival confer high risk prostate cancer gleason b co management concomitant prostate cancer non muscle invasive bladder cancer require careful compete risk analysis physician patient herein detail patient physician careful not underestimate risk attribute non muscle invasive bladder cancer g bladder cancer case tur bcg evaluate patient various stage bladder carcinoma determine alteration monocyte function since monocyte play important role effector arm immune system defective function may explain host inability destroy neoplastic cell group patient demonstrate defective monocyte monocyte function no correlation tumor stage degree chemotactic defect patient invasive carcinoma significant return monocyte chemotactic response toward normal postoperatively p little monocyte function improve also patient receive bacillus calmette guerin immunotherapy p little nasopharyngeal carcinoma unusual metastasis urinary bladder nasopharyngeal carcinoma npc metastasize urinary bladder uncommon site report interest case npc follow present unusual urinary symptom mimick primary bladder cancer subsequent bladder cold cup biopsy immunohistochemistry unfold metastasis npc highlight unexpected rare presentation cell cycle regulator prognostic factor bladder cancer mechanism intravesical bcg treatment mediate antitumor activity currently poorly understand initiate study determine sequence factor produce immunological event inflammatory answer lot molecule produce chemokine mcp rantes induce mast cell recruitment begin immunological fall study patient superficial bladder cancer treat bcg present improvement cytokine correlate tumor free status low pressure bladder replacement total cysto prostatectomy apropos series patient result consecutive patient undergo bladder replacement follow cystoprostatectomy invasive bladder cancer report cm detubularized ileal segment use make neobladder mean follow month year patient patient achieve diurnal continence nocturnal continence obtain patient no leakage nocturia little occasional leakage urodynamic evaluation show average peak flow ml average neobladder capacity ml six patient spontaneous contraction enteric bladder great cm h always associate elevate urethral pressure post void residue small cc case procedure simple lead excellent diurnal continence although not assure nocturnal continence every single patient cae double cancer involve bladder prostate treat radical cystectomy year radical prostatectomy year old man diagnose prostate cancer neoadjuvant hormone therapy start february observation superficial bladder cancer incidentally find \\ufeff1 transurethral resection carry june radical prostatectomy perform may thereafter bladder cancer demonstrate repeat recurrence time 3 recurrence malignant trasformation recognize tcc g invasive radical cystectomy ileal conduit perform may patient year old perspective double cancer frequency diagnose localize prostate cancer superficial bladder cancer expect increase psa screen increasingly perform recently possibility malignant transformation patient superficial bladder cancer case coincident cancer remain controversial treatment select previously diagnose prostate cancer report clinical course discuss issue extent comet assay measure dna damage predictive bladder cancer cell treatment sensitivity vitro outcome vivo bladder cancer patient suffer significant treatment failure include high rate recurrence poor outcome advance disease mechanism improve tumour cell treatment sensitivity can identify tumour response can predict possible improve local control survival previously show radiation induce dna damage measure alkaline comet assay aca correlate bladder cancer cell radiosensitivity vitro study \\ufeff1 show modify aca measure cisplatin mitomycin c induce damage also correlate bladder cancer cell chemosensitivity vitro essentially rank order chemosensitivity radiosensitivity furthermore aca study radiation induce damage different cell dna substrate nucleus nucleoids intact parent cell suggest feature retain prepare nucleoids responsible relative damage sensitivity bladder cancer cell suggestive difference organisation dna within resistant vs sensitive cell 2 show aca analysis biopsy bladder tumour reveal reduce dna damage sensitivity associate poor treatment outcome notably tumour reduce damage response show significant association local recurrence non invasive disease reduce damage response well predictor recurrence presence high risk histology cohort conclusion study demonstrate mechanism govern treatment induce dna damage central predictive bladder cancer cell treatment sensitivity exemplify link dna damage resistance treatment response tumour aggression molecular alteration associate bladder cancer initiation progression bladder cancer 5 commonly diagnose non cutaneous solid malignancy 2 commonly diagnose genitourinary malignancy amongst people live unite state estimate new case bladder cancer diagnose year approximately malignant tumor arise urinary bladder epithelial origin majority transitional cell carcinoma early stage bladder tumor classify two group distinct behavior unique molecular profile low grade tumor always papillary usually superficial high grade tumor either papillary non papillary often invasive clinically superficial bladder tumor stage ta this account neoplasm remain invasive metastatic lesion time initial presentation study author group other reveal distinct genotypic phenotypic pattern associate early versus late stage bladder cancer importantly early superficial disease appear segregate two main pathway superficial papillary bladder tumor characterize incidence urethral tumor involvement man bladder cancer urethral tumor involvement examine patient treat bladder cancer single institution period year overall incidence primary recurrent bladder tumor event risk factor urethral tumor occurrence tumor bladder neck recurrent multifocal tumor carcinoma situ cis bladder not involve bladder neck muscle invasive tumor without lymph node involvement not significantly correlate urethral cancer patient risk urethral tumor outline work carefully multiple urethral biopsy urethral brushings freeze section membranous urethra consider orthotopic neobladder altogether patient urethral tumor recurrence majority urethral tumor treat single conservative treatment session not recur thereafter conservative approach toward superficial urethral tumor recurrence patient orthotopic neobladder urethra may therefore feasible improvement determination urinary tissue polypeptide antigen tpa clinical study bladder cancer patient background evaluate risk factor invasive bladder cancer develop predictive model improvement individual comprehensive therapy invasive bladder cancer material method record patient invasive bladder cancer operate three chinese medical institute review cox proportional hazard regression model use assess clinical pathological variable affect disease free survival dfs regression coefficient determine cox regression analysis use construct predictive index pi pi use categorize patient different risk group kaplan meier survival curve follow log rank test plot compare difference result tumor configuration rr p multiplicity rr p histological subtype rr p tumor stage rr p tumor grade rr p node status rr p neoadjuvant chemotherapy rr p independent prognostic significance dfs pi x configuration x multiplicity x tumor histological subtype x stage x grade x node status x neoadjuvant chemotherapy range pi five recent case bladder cancer objective investigate prothymosin alpha ptma expression human bladder cancer use tissue microarray method two tissue microarray slide bladder tumor pair normal adjacent tissue investigate use immunohistochemical stain stain distribution categorize negative nuclear cytoplasmic mix expression quantitative immunoreactivity measure use image analysis represent integrate optical density tissue core result normal adjacent tissue positive ptma immunoreactivity can see nucleus normal urothelial cell not minimally cytoplasm underlie submucosal tissue statistically significant enhancement ptma expression find bladder tumor grade compare normal adjacent tissue p normal adjacent tissue vs grade tumor pair test transitional cell carcinoma specimen grade negative positive ptma expression include nuclear n cytoplasmic n mix expression n pattern statistically significant correlation find high grade mix expression p chi test conclusion increase ptma expression find human bladder cancer compare pair normal adjacent bladder tissue distribution ptma expression change high grade tumor clinical significance aberrant ptma expression bladder cancer worthy additional investigation cobalt therapy prophylaxis recurrence bladder cancer eighteen patient transitional cell carcinoma urinary bladder submit transurethral resection tumor follow cobalt therapy rad pelvis rad bladder six week recurrence rate three year follow recurrence transitional cell carcinoma urinary bladder good know condition stage even low grade present recurrence rate one year high loening et al report current literature recent year many study perform orient use intravesical chemotherapy order reduce recurrence rate adolphs bastian huland loening et al national bladder cancer collaborative group rodriguez caserta zincke et al tumor start protocol treatment transitional cell carcinoma urinary bladder protocol call transurethral resection tumor follow cobalt therapy interim report stage stage treatment microrna bind site polymorphism hoxb lead differential gene expression bladder cancer purpose investigate biological function hoxb human bladder cancer explore whether hoxb utr snp g locate within microrna bind site correlate clinical feature bladder cancer method expression hoxb human bladder cancer tissue cell line examine use real time pcr immunohistochemistry next explore biological function hoxb vitro use cell proliferation migration colony formation assay use bioinformatics snp g find locate within microrna bind site utr hoxb real time pcr use test hoxb expression affect different allele finally multivariate logistic regression analysis use determine relationship snp g frequency clinical feature case result hoxb frequently express bladder cancer tissue cell line inhibition hoxb suppress oncogenic function cancer cell next demonstrate snp g locate within microrna bind site utr hoxb can affect hoxb expression bladder cancer mainly differential bind activity microrna snp relate mrna stability finally also show frequency g genotype high cancer group compare normal control correlate risk high grade high stage conclusion hoxb overexpress bladder cancer mirna bind snp g locate within utr hoxb associate gene expression may promise prognostic factor bladder cancer decrease fas expression advance stage bladder cancer not relate p status objective fas fas ligand system important regulator apoptosis involve tumor development invasive cancer downregulate fas expression evade antitumor immune response fas transcriptional target p often mutate bladder cancer therefore fas expression relation p mutation investigate method expression fas protein p status study immunohistochemistry bladder cancer specimen addition mrna level soluble decoy membrane bind form fas compare bladder cancer cell line primary uroepithelial cell quantitative taqman polymerase chain reaction mutational analysis death domain fas gene perform cell line result organ confine tumor maintain specific fas stain cell membrane often also cytoplasm high stage carcinoma fas expression become restrict small fraction cell lack entirely correlation fas stain tumor stage highly significant no correlation tumor grade survival find furthermore no statistically significant relationship observe either presence lack mutate p accumulation membrane bind fas mrna decrease soluble fas increase transitional cell carcinoma line compare primary uroepithelial cell no mutation death domain detect conclusion fas downregulation occur advance bladder cancer unrelated p mutation result immunohistochemistry mrna study soluble membrane bind fas transitional cell carcinoma line support hypothesis immune evasion advance bladder cancer response patient superficial bladder cancer 2 course intravesical bacillus calmette guerin patient receive initial week course intravesical bacillus calmette guerin superficial transitional cell carcinoma bladder treat another course subsequent progression disease muscle infiltration metastasis local progression occur patient patient without progression complete response new tumor render free disease transurethral resection median duration response course bacillus calmette guerin short patient disease progression course no progression month respectively p equal median followup course month range month median interval course intravesical bacillus calmette guerin month range month interval course bacillus calmette guerin progression correlate duration response course treatment p equal appear subsequent treatment bacillus calmette guerin likely useful patient sustain response initial treatment bladder preserve combine modality therapy invasive bladder cancer purpose paper increase nurse knowledge invasive bladder cancer discussion current protocol treatment use chemo radiation therapy pathophysiology clinical feature current medical management address along appropriate nurse intervention include symptom management patient family education research support observation patient complete protocol regimen complete response rate high need radical surgery low risk factor bladder cancer aim background summarize risk factor bladder cancer emphasize role recently establish association present ongoing debate issue method systematic literature search perform use medline database bladder cancer risk factor january june detail examination reference original article review monograph retrieve result cigarette smoke recognize main cause bladder cancer account case develope country strong link exist amount duration cigarette smoke high risk bladder carcinoma observe worker expose aromatic amine base occupational risk estimate bladder carcinoma industrialize country due exposure occupational origin infectious agent major influence bladder cancer risk area world schistosoma haematobium infestation endemic potential risk factor bladder cancer urinary tract infection drink tap water chlorination product arsenic exposure certain drug like cyclophosphamide use chemotherapy heavy consumption phenacetin contain analgesic show cause bladder cancer human total fluid intake high consumption fruit vegetable probably associate small decrease risk conclusion avoidance tobacco smoke incriminate occupational exposure habitual intake fresh fruit vegetable prevention control urinary tract infection recommend bladder cancer prevention study require assess role genetic polymorphism modify effect lifestyle risk factor bladder cancer occurrence evaluate benefit bladder cancer screen particularly high risk study bladder cancer tissue raman spectroscopy scope research lie diagnosis bladder cancer raman spectrum spectrum bladder cancer normal bladder measure use laser confocal raman micro spectroscopy principal component analysis support vector machine apply spectral dataset construct diagnostic algorithm detect accuracy algorithm determine histological diagnosis leave one cross validation raman spectrum show peak intensity nucleic acid cm bladder cancer protein cm normal bladder increase significantly additionally principal component analysis pca support vector machine svm provide effective tool differentiate bladder cancer normal bladder tissue excellent sensitivity specificity positive predictive value negative predictive value diagnosis bladder cancer obtain leave one cross validation conclude raman spectroscopy use accurately identify bladder cancer vitro suggest promise potential application pca svm base raman spectroscopy diagnosis bladder cancer bladder go quality life follow different type urinary diversion method aim continence radical cystectomy bladder cancer e g continent cutaneous urinary diversion orthotopic bladder substitution become clinically accept alternative ileal conduit diversion past decade priori assumption improvement postoperative quality life would great follow new method ileal conduit diversion study validity assumption hamper lack consensus measure do no two study identical test instrument use frequent inclusion patient nonmalignant disease also impede comparative evaluation report large publish study not seem confirm new type urinary tract reconstruction improve quality life bladder cancer patient common method psychosocial sexual problem current management practice bladder cancer hong kong hospital base cross sectional survey objective examine current practice management bladder cancer hong kong government private hospital design cross sectional survey set government hospital major private institution hong kong provide urological service participant urologist respond anonymous intravesical therapy bladder cancer evaluate patient various stage bladder carcinoma determine alteration monocyte function since monocyte play important role effector arm immune system defective function may explain host inability destroy neoplastic cell group patient demonstrate defective monocyte monocyte function no correlation tumor stage degree chemotactic defect patient invasive carcinoma significant return monocyte chemotactic response toward normal postoperatively p little monocyte function improve also patient receive bacillus calmette guerin immunotherapy p little carboxyamido triazole cai reverse balance proliferation apoptosis rat bladder cancer model carboxyamido triazole cai orally bioavailable calcium influx signal transduction inhibitor show anti invasive anti angiogenic culture milk yogurt dairy intake relation bladder cancer risk prospective study swedish woman man background finding epidemiologic study effect dairy food mainly milk risk bladder cancer inconsistent objective aim examine association intake culture milk dairy food incidence bladder cancer prospective population base cohort design prospectively follow swedish woman man cancer free complete item food frequency questionnaire incident case bladder cancer identify swedish cancer registry result mean follow participant woman man diagnose bladder cancer total dairy intake not significantly associate risk bladder cancer serving compare serving multivariate rate ratio rr ci p trend however statistically significant inverse association observe intake culture milk sour milk yogurt multivariate rrs high category culture milk intake serving compare low category serve ci p trend woman man combine ci p trend woman ci p trend man intake milk cheese not associate bladder cancer risk conclusion finding suggest high intake culture milk may low risk develope bladder cancer incidence clinical characteristic low urinary tract symptom present symptom patient newly diagnose bladder cancer purpose incidence low urinary tract symptom luts sole present symptom bladder cancer traditionally report low objective study evaluate prevalence clinical characteristic newly diagnose bladder cancer patient present luts absence gross microscopic hematuria material method query database bladder cancer patient atlanta veteran affair medical center avamc identify patient present solely luts subsequently diagnose bladder cancer demographic clinical pathologic variable examine result bladder cancer patient series present solely luts mean age charlson co morbidity index patient year range range respectively patient cohort present luts patient present clinical stage ta carcinoma situ cis disease median follow year recurrence occur patient progression occur patient patient alive currently disease free patient die one death attributable bladder cancer conclusion database show incidence luts sole present symptom patient newly diagnose bladder cancer study suggest urologist low threshold evaluate patient unexplained luts underlie bladder cancer treatment time bladder cancer early diagnosis bladder cancer central effective treatment disease presently no method available easily specifically identify presence bladder cancer cell prevail method detection bladder cancer identification bladder cancer cell morphological examination exfoliate cell biopsy material pathologist hallmark malignant transform phenotype abnormal nuclear shape presence multiple nucleolus alter pattern chromatin organization nuclear structural alteration prevalent cancer cell commonly use marker transformation many type cancer nuclear shape determine nuclear matrix dynamic skeleton nucleus nuclear matrix structural component nucleus determine nuclear morphology organize dna three dimensional fashion tissue specific central role regulation numb nuclear process include regulation dna replication gene expression previous investigation prostate breast cancer reveal nuclear matrix protein nmp composition undergo alteration transformation nuclear matrix serve marker malignant phenotype study identify nmps possible differentiate human bladder tumor normal bladder epithelial cell examine nmp composition match tumor normal sample patient undergo surgery bladder cancer identify six protein present tumor sample not present correspond normal sample three protein unique normal bladder tissue comparison tumor sample five six bladder cancer associate protein also identify three human bladder cancer cell line examine j umuc therefore demonstrate nuclear matrix composition able differentiate bladder cancer normal bladder tissue may provide useful tool early detection recurrence disease importantly marker may provide valuable tool cytopathological screen bladder carcinoma review epidemiological study artificial sweetener bladder cancer next tobacco saccharin may substance study epidemiologically patient bladder cancer participate interleukin opportunity treatment bladder cancer despite incomplete understand human immune system rapid progress tumor immunology provide framework effective safe intervention near future early approach patient cancer focus nonspecific broad stimulation immune system interferon il replace highly specific stimulation immune reaction target precisely define tumor antigen il several biologic property seem useful immune therapy bladder cancer strike antitumor response il preclinical animal model bladder cancer provide optimism future clinical trial involve agent may impact risk mortality associate disease heparanase protein gene expression bladder cancer purpose determine association heparanase protein messenger rna expression bladder cancer invasion metastasis material method expression heparanase protein mrna assess immunohistochemical stain situ hybridization respectively bladder cancer specimen resect various stage disease knowledge \\ufeff1 systematic study heparanase protein mrna expression human bladder cancer result expression heparanase protein muscular invasive bladder cancer significantly high superficial cancer versus p high primary tumor patient lymph node metastatic cancer nonmetastatic cancer versus p high grade disease significantly high low grade disease versus p expression heparanase mrna also significantly high stage pt great stage pt little bladder cancer versus p metastatic n case significantly high nonmetastatic bladder cancer versus p heparanase gene protein show similar pattern expression bladder cancer conclusion study imply expression heparanase protein mrna associate bladder cancer invasion metastasis heparanase may role disease progression urologic principle define standard successful bladder preservation muscle invasive bladder cancer background retrospectively evaluate clinical outcome patient histologic variant muscle invasive bladder cancer mibc treat trimodal bladder preserve therapy tmt method among patient clinical n mibc treat tmt tsukuba university hospital patient pathological component variant urothelial carcinoma uc complete response cr overall survival os cause specific survival css progression free survival pf rate analyze patient result among patient variant uc uc squamous glandular differentiation sarcomatoid n plasmacytoid n signet ring cell n clear cell variant n median follow month nine patient achieve cr develope recurrence among seven patient uc squamous glandular differentiation two develope recurrence one die disease contrast four patient variant sarcomatoid variant signet ring cell develope recurrence die disease overall year os css pf rate variant uc respectively conclusion tmt may provide acceptable clinical outcome good select mibc patient histologic variant especially squamous glandular differentiation however need pay special attention variant sarcomatoid variant signet ring cell tmt may alternative treatment option patient histologic variant although experiment need confirm two aspect epidemiology bladder cancer england wale context use neoadjuvant adjuvant chemotherapy treatment muscle invasive bladder cancer still controversial objective determine optimal use chemotherapy neoadjuvant adjuvant setting patient advance urothelial cell carcinoma bladder preservation also discuss evidence acquisition critical review publish literature chemotherapy patient locally advance bladder cancer perform evidence synthesis presence occult micrometastases time radical cystectomy lead distant local failure patient locally advance transitional cell carcinoma bladder neoadjuvant adjuvant therapy evaluate patient locally advance bladder cancer study evaluate adjuvant chemotherapy limit inadequate statistical power detect meaningful clinical answer good experimental arm utilize inadequate chemotherapy conclusion aggregate available evidence suggest neoadjuvant cisplatin base combination chemotherapy consider standard care patient muscle invasive locally advance operable bladder cancer patient either unfit refuse radical cystectomy neoadjuvant chemotherapy without radiation render bladder preservation possible patient attain excellent clinical response introduction new cytotoxic drug need good design study address optimal utility perioperative therapy high risk patient bladder cancer optimization operative treatment patient elderly senile age superficial bladder cancer comparative study radical transurethral resection tur bladder carcinoma bc perform standard condition application fluorescence cystoscopy fcs diagnosis early recurrence bc extent tumor aggressiveness prognosis disease examine elderly senile age patient bc week surgery endoscopic study include standard cystoscopy c fluorescent cystoscopy fcs tur area post biopsy scar fluorescent site \\ufeff1 group consist patient perform traditional tur 2 one patient tur fluorescent control tur fcs perform repeat endoscopic examination detect fluorescence patient st group patient nd group endothelial swell reveal st group among patient nd one residual tumor find significantly little frequently patient group compare patient st group significant difference determine frequency residual tumor pta stage patient st nd group p difference frequency residual papillary tumor stage rt analyze group also significant respectively p difference frequency relapse correlate significantly age patient st group among patient multiple lesion bladder residual tumor detect among patient nd group multiform bc residual tumor find patient p early repeat cystoscopy biopsy use fluorescent monitor recommend patient bc stage ta this early repeat cystoscopy biopsy use fcs enable timely identification removal residual tumor recurrence superficial bc high risk nonmuscle invasive bladder cancer definition epidemiology purpose review nonmuscle invasive bladder cancer represent large majority patient diagnose disease precise definition risk stratification paramount group high risk patient high rate progression mortality may benefit early identification aggressive treatment recent finding mainstay definition high risk nonmuscle invasive bladder cancer base grade stage recently effort make incorporate clinical variable multivariate risk assessment tool nomograms predict disease behavior guide management variant histology molecular biomarker explore tool refine risk stratification however result still preliminary need validation summary future research concentrate way well risk stratify patient identify early likely recur progress quickly topic focus well multivariate risk assessment tool nomograms provide continuous scale incorporate molecular marker validation large multi institutional cohort circular rna circmto suppress bladder cancer metastasis sponge mir inhibit epithelial mesenchymal transition bladder cancer remain lead cause cancer relate death distant metastasis high recurrence rate deregulation circular rnas circrnas act either tumor suppressor oncogene control cell proliferation migration metastasis role circmto bladder cancer remain unknown study investigate whether circmto can use biomarker therapeutic target bladder cancer treatment \\ufeff1 demonstrate circmto important circrna frequently downregulated bladder cancer tissue low circmto level positively correlate bladder cancer patient metastasis poor survival ectopic expression circmto bladder cancer cell inhibit cell epithelial mesenchymal transition emt metastasis addition also reveal circmto able sponge mir overexpression circmto negative regulate e cadherin n cadherin pathway inhibit bladder cancer cell emt compete mir conclusion finding provide comprehensive evidence circmto prognostic biomarker bladder cancer suggest circmto may function novel therapeutic target human bladder cancer sparc score multifactorial outcome prediction model patient undergo radical cystectomy bladder cancer purpose multiple independent clinicopathological variable associate outcome radical cystectomy bladder cancer limit prediction tool exist facilitate individualize risk assessment develope sparc survival prediction radical cystectomy score prediction model bladder cancer specific survival radical cystectomy material method evaluate patient undergo radical cystectomy without neoadjuvant therapy institution pathological review specimen patient nonmetastatic urothelial carcinoma identify analysis multivariate model develope use stepwise selection determine variable associate cancer specific survival create score system base coefficient model result median followup radical cystectomy patient alive last followup year iqr time die bladder cancer addition pathological tumor stage nodal status multifocality lymphovascular invasion patient specific factor charlson comorbidity index eastern cooperative oncology group ecog performance status current smoke preoperative hydronephrosis receipt adjuvant chemotherapy significantly associate risk bladder cancer death use cumulative score variable stratify patient risk group year cancer specific survival low high risk group respectively p concordance index model conclusion present model individualize estimation cancer specific survival radical cystectomy pend external validation datum may use patient counsel specifically regard recommendation adjuvant therapy surveillance frequency good clinical trial development correlation nuclear p expression clinical histopathological feature transitional cell bladder cancer forty four pathologic specimen bladder cancer patient analyze immunohistochemically monoclonal antibody detect expression mutant p gene finding interpret correlate patient age sex cigarette smoke numb macroscopic appearance tumour histological tumour grade muscular invasion vascular invasion necrosis urothelial atypia dysplasia mutant p gene express specimen statistically significant correlation grade vascular invasion necrosis patient sex find p expression available follow datum insufficient draw conclusion prognostic role p expression prospective study large numb patient need define exact place nuclear p value lymphography exploration bladder cancer purpose review goal surveillance curative treatment bladder cancer identify bladder cancer recurrence early stage also close follow metabolic functional consequence urinary diversion review propose follow scheme base available literature recent find follow patient undergo curative treatment invasive bladder cancer cover many aspect recurrence see within year curative treatment therefore awareness specific sign symptom indicate local regional distant upper urinary tract urethral recurrence important apart oncological follow also metabolic functional aspect play vital role surveillance summary time no consensus well follow strategy follow strategy base literature suggest systematic review intravesical bacillus calmette gu rin plus transurethral resection vs transurethral resection alone ta bladder cancer objective assess systematic review effectiveness intravesical bacillus calmette gu rin bcg prevent tumour recurrence patient medium high risk ta bladder cancer patient method electronic database search medline embase dare cochrane library cancerlit healthstar bid undertake plus hand search proceeding asco randomize control trial language compare transurethral resection tur alone tur follow intravesical bcg patient ta bladder cancer result search identify publication compare tur tur bcg six trial consider acceptable represent eligible patient tur alone group tur bcg group major clinical outcome choose tumour recurrence weight mean log hazard ratio \\ufeff1 recurrence take across six trial confidence interval p equivalent reduction hazard attributable bcg peto odd ratio patient recur month confidence interval p significantly favour bcg therapy manageable toxicity associate intravesical bcg cystitis haematuria fever urinary frequency no bcg induce death report conclusion tur intravesical bcg provide significantly well prophylaxis tumour recurrence ta bladder cancer tur alone randomize trial still need address issue bcg strain dose schedule well quantify effect progression invasive disease neoadjuvant definitive alternate chemotherapy radiotherapy infiltrate bladder cancer thirty two patient infiltrate bladder cancer treat transurethral resection follow one course alternate chemoradiotherapy radical cystectomy group patient two course definitive procedure group b patient one course consist cisplatin mg v fluorouracil mg v consecutive day \\ufeff1 4 week radiotherapy gy fraction 2 3 week 7 week integrate therapy restart group b patient evaluable toxicity \\ufeff1 course no grade iv toxicity observe significant increase hematological toxicity observe patient receive 2 course chemoradiotherapy two patient grade iv toxicity five patient grade iii fifteen patient group undergo radical cystectomy pathological p complete response cr partial response five patient group not receive either 2 course therapy cystectomy age three patient vascular obliteration one patient enteritis one patient actuarial disease free survival group month patient group b obtain clinical c cr one no evidence disease median follow month range high pcr ccr obtain patient group group b respectively appear promise long follow large numb patient require determine role integrate treatment clinical result prophylactic intravesical chemotherapy superficial bladder cancer use dye exclusion assay chemosensitivity test carry superficial bladder cancer use dye exclusion assay purpose screen chemosensitive drug prophylactic intravesical chemotherapy bladder cancer cell patient incubate vitro presence adriamycin r tetrahydropyranyladriamycin mitomycin c pepleomycin epi adriamycin microgram ml co degree c hour cytotoxic effect drug evaluate ratio stain cell trypan blue effective drug instill postoperatively bladder time \\ufeff1 week every week follow week patient follow month prophylactic effect evaluate fifteen patient complete protocol remain patient fail complete instillation severe irritability bladder tumor recurrence demonstrate two patient non recurrence rate tumor month respectively result suggest rapid handy assay useful purpose screen chemosensitive drug intravesical chemotherapy supervoltage x ray therapy bladder cancer context bladder cancer cause death per year overall rate survival approximately year recurrence free rate no change last decade objective due lack agreement follow cystectomy uniform treatment face various type recurrence analyse recent literature attempt unify criterium diagnosis treatment bladder cancer acquisition evidence review spanish english publication medical literature last year highlight significant series term numb patient follow time good exist meta analysis synthesis evidence recurrence cystectomy occur urinary apparatus upper urinary tract distal urethra local cystectomy bed distant metastasis despite strict control relapse discover base symptom not routine follow test locoregional distant relapse common advance stage time cystectomy go pt n lymphocytic n involvement recurrence urethra upper urinary track prognostic factor multiplicity presence cis involvement prostatic stroma various treatment tumour relapse increasingly patient comorbidity consider decide therapeutic strategy treatment typically multimodal include surgery radiotherapy chemotherapy conclusion follow patient undergo cystectomy individualise take account prognostic factor recurrence patient comorbidity assume case multimodal treatment indicate diagnosis treatment bladder cancer author present retrospective analysis result transurethral conservative radical operation patient invasive cancer urinary bladder ub treat research institute urology throughout immune checkpoint inhibitor effective urothelial cancer kitenin newly identify bind partner kai cd metastasis suppressor recent study use mouse model colon cancer suggest kitenin may metastasis enhancer whose function modulate interaction kai cd begin exploration possible importance kitenin human cancer examine kitenin mrna rt pcr protein expression western blot large series bladder cancer cell line compare level expression kai cd previously determine vitro invasive behaviour cancer cell line report kitenin uniformly express cancer cell line line kai cd not detect high vitro invasive ability alter actin organisation determine fluorescence microscopy line kai cd present datum suggest relationship kitenin kai cd may important determinant tumour cell behaviour bladder cancer biomarker bladder cancer one prevalent cancer worldwide non muscle invasive bladder cancer rate recurrence biological tendency recur progress mandate close follow early detection recurrent tumor urine cytology widely use noninvasive test detect urothelial tumor however limit low sensitivity hand cystoscopy gold standard procedure follow patient history bladder cancer test invasive expensive therefore real need develop new test use bladder cancer surveillance recent year constant effort find well non invasive marker bladder cancer many marker detection bladder cancer test almost urinary marker report well cytology regard sensitivity score low specificity knowledge molecular pathway bladder cancer grow new method marker development emerge perfect marker still find currently not clinically usable molecular marker guide us diagnosis surveillance guide us lower frequency urethrocystoscopy bladder cancer article report prominent urine marker use today value angiography computerize tomography preoperative evaluation bladder cancer comparative study patient tumour urinary bladder value angiographic computer tomographic investigation proof tumour stage control case angiographic proof not successful concordance histologically recognize degree infiltration can establish mean angiography compute tomography possible apply compute tomography stage regard performance angiography pelvis no indicate renal function cystectomy intestinal plastic surgery cancer urinary bladder study renal function intestinal plastic reconstruction urinary bladder ilial graft patient urinary bladder cancer ubc create artificial urinary bladder patient urinary reservoir one control group consist patient undergo brikker operation n ureterocutaneostomy n information renal function obtain dynamic nephroscintigraphy color duplex scan renal vessel show year postoperative follow late postoperative condition kidney determine method urine derivation ilial plastic reconstruction urinary bladder minimal negative effect renal function quality life improve ureterocutaneostomy deteriorate renal function brikker operation lesser degree thus ilial plastic repair urinary bladder method choice treatment patient invasive cancer urinary bladder budget impact incorporate one instillation hexaminolevulinate hydrochloride objective explore cost impact swedish healthcare incorporate one instillation hexaminolevulinate hydrochloride hal blue light cystoscopy transurethral resection bladder tumour turbt patient suspect new recurrent non muscle invasive bladder cancer nmibc material method decision tree model build base european association urology guideline treatment management nmibc input datum compile two recent study compare recurrence rate bladder cancer patient undergo turbt either current standard care soc white light cystoscopy soc hal blue light cystoscopy use publish datum clinical cost datum surgical outpatient procedure pharmaceutical cost model report clinical economic difference associate two treatment option result model demonstrate significant clinical benefit likely observe incorporation hal blue light cystoscopy turbt term reduction recurrence bladder cancer analysis economic output model find use one instillation hal turbt swedish patient nmibc likely cost neutral cost save year relative current soc white light cystoscopy conclusion result analysis provide additional health economic rationale incorporation single instillation hal blue light cystoscopy turbt treatment patient nmibc sweden induction bladder cancer portally divert rat fhit gene alteration may occur early consequence urinary bladder cancer present study aim identify analyze role homozygous deletion hzd transcriptional alteration fragile histidine triad fhit gene development progression bilharzial bladder cancer egyptian patient possible association fhit abnormality clinical variable prognostic impact bilharzial bladder cancer patient determine addition relation homozygous deletion hzd fhit gene fhit protein p waf expression apoptosis demonstrate investigate human bladder cancer normal adjacent tissue control group hzd fhit gene fhit protein p protein apoptosis assess pcr immunohistochemistry dna ladder method respectively fhit hzd deletion express significant correlation fhit protein p p waf protein expression p apoptosis p side no correlation detect fhit homozygous deletion tumor type tumor grade gender therefore fhit gene deletion can important development progression urinary bladder cancer may use independent prognostic indicator clinical outcome patient tumor stage bladder cancer transabdominal real time ultrasound past six year case prove bladder cancer hospital among case receive transabdominal ultrasonographic examination urinary bladder evaluation bladder tumor two hundred fourteen case newly diagnose bladder cancer adequate pathological specimen stage tumor retrospective comparison preoperative local stage bladder tumor ultrasound final pathological report show total accuracy overstaging understaging accuracy stage tumor stage b stage c stage strong echogenic focus surface tumor detect case may indicate encrust stone surface tumor intratumoral dystrophic calcification no strong correlation tumor grade stage except grade lesion stage preoperative local stage urinary bladder cancer real time ultrasound may great value determine management plan prognosis patient combine cisplatin radiation therapy advance bladder cancer since september patient advance urinary bladder cancer treat combine cisplatin full dose radiotherapy patient male female age range year median year radiotherapy consist tumor dose gy administer cobalt cisplatin infuse day daily dose mg st th week treatment evaluable patient achieve complete response toxicity also evaluate patient mainly gastrointestinal toxicity note loss appetite nausea vomit diarrhea leukocytopenia note mild thrombocytopenia mild dermatitis note neoadjuvant chemotherapy management muscle invasive bladder cancer bridge gap evidence practice although cisplatin base chemotherapy follow radical cystectomy standard treatment muscle invasive bladder cancer population base study reveal small fraction patient actually receive treatment comprehensive understand reason gap efficacy effectiveness necessary increase likelihood cure patient muscle invasive bladder cancer reason include system provider patient level barrier not amenable single solution tackle barrier ultimately necessary bridge disconnect achievable actually achieve compare efficiency safety bipolar monopolar transurethral resection non muscle invasive bladder tumor systematic review meta analysis purpose evaluate efficacy safety bipolar monopolar transurethral resection bladder tumor turbt procedure non muscle invasive bladder cancer nmibc patient material method search study investigate bipolar turbt monopolar turbt nmibc patient pubmed web knowledge cochrane central search library systematic review meta analysis perform efficacy assess catheterization time resection time pathology recurrence rate safety assess obturator nerve reflex bladder perforation hemoglobin decrease transfusion result search identify eight study bipolar turbt associate decrease resection time catheterization time hemoglobin change no statistically significant difference bipolar turbt monopolar turbt rate obturator nerve reflex bladder perforation transfusion grade cautery artifact no different two procedure even low bipolar arm no significant difference recurrence rate compare two procedure conclusion systematic review indicate bipolar technique efficacious safe nmibc patient large scale multicenter randomize control study need final clinical recommendation make analysis correlation e f expression numb tumor infiltrate cd cell invasive bladder cancer tissue objective investigate expression e f transcription factor e f infiltration cd cell bladder cancer tissue correlation malignant biological behavior bladder cancer method expression level e f infiltration characteristic cd cell case bladder cancer tissue different histological stage grade good correspond normal bladder tissue detect immunohistochemistry western blot analysis use detect e f cd protein level case bladder cancer tissue correspond normal bladder tissue correlation e f expression cd cell infiltration analyze statistically linear correlation analysis result expression e f high bladder cancer tissue normal bladder tissue expression level e f increase gradually increase tumor histological stage grade numb tumor infiltrate cd cell decrease gradually correspond tumor numb tumor infiltrate cd cell e f high expression group significantly low e f low expression group rate e f positive expression decrease numb tumor infiltrate cd cell closely relate tumor clinical invasive indicator tumor histological stage grade tumor size lymph node metastasis distant metastasis linear correlation analysis indicate numb tumor infiltrate cd cell negative correlate expression e f survival analysis reveal prognosis patient high e f expression wrong operation within year conclusion expression level e f bladder cancer closely relate tumor invasiveness negative correlate numb tumor infiltrate cd cell familial aggregation bladder cancer except smoke certain occupational exposure etiology bladder cancer largely unknown several case report describe familial aggregation transitional cell carcinoma bladder although majority patient bladder cancer not family history transitional cell carcinoma urinary tract study familial transitional cell carcinoma may lead knowledge pathogenesis disease purpose study describe three case urinary bladder cancer single three member family e two generation mother son family member relate marriage patient wife case report three case urinary bladder cancer occur three member family within interval year follow common characteristic detect patient old age work farmer year negative personal medical history relevant health disorder place birth village place residence village water supply similar nutrition positive family history urinary bladder cancer malignant tumor \\ufeff1 sign illness macroscopic hematuria patient pathohistological type cancer carcinoma papillare transitiocellulare conclusion state common characteristic case indicate impact exposure external surround factor occurrence urinary bladder cancer smooth muscle tumor uncertain malignant potential urinary bladder case report review literature multimodality organ spare treatment last decade become standard care many common malignancy appropriately select patient muscle invade bladder cancer bladder preserve treatment combine surgical transurethral resection tur chemoradiation therapy offer chance abandon superficial bladder cancer accept non muscle invasive bladder cancer occasion th anniversary \\ufeff1 eau guideline bladder cancer muscle invasive bladder cancer typically aggressive solid tumour propensity early systemic dissemination although curative intent local therapy either radical cystectomy radiotherapy remain gold standard intervention high rate systemic failure prompt investigator evaluate various strategy attempt improve survival include early administration systemic chemotherapy recently complete phase iii study neoadjuvant chemotherapy trial demonstrate modest real survival advantage small subset patient strategy include attempt preserve bladder use combination limit surgical resection systemic chemotherapy radiotherapy review focus potential neoadjuvantly administer therapy impact management muscle invasive bladder cancer bladder cancer coffee consumption smoker non smoker spain association coffee consumption bladder cancer investigate multi centre case control study conduct spain total case male female histopathologically confirm bladder cancer use analysis along hospital control population control odd ratio adjust age province residence occupation risk consumption artificial sweetener cigarette smoke not show association coffee consumption bladder cancer either sex however non smoker mainly male current coffee drinker cl drinker cup week respective dose response relationship lifelong consumption year exposure regular coffee consumption male non smoker current coffee drinker cl population control correspond level intensity consumption cup week association observe non smoker suggest existence possible association coffee consumption bladder cancer base small number need confirm large study prognostic factor invasive bladder carcinoma treat combine modality protocol organ spare approach purpose result bladder spare approach treatment muscle invasive bladder cancer use combination transurethral resection tur chemotherapy radiotherapy encourage survival patient treat method similar survival patient treat radical cystectomy aim study find pretreatment characteristic influence survival patient treat organ spare approach would enable us identify patient suitable type treatment method material prognostic value different factor age gender performance status hemoglobin level clinical stage histologic grade presence obstructive uropathy completeness tur study patient invasive bladder cancer receive bladder spare treatment period treat combination tur follow cycle methotrexate cisplatinum vinblastine polychemotherapy complete responder treatment complete radiotherapy gy bladder gy regional lymph node whereas nonresponders undergo cystectomy whenever feasible result study confirm independent prognostic value performance status histologic grade obstructive uropathy disease specific survival dss bladder cancer patient treat conservative approach believe performance status well reflect extent disease exert significant influence extent course treatment obstructive uropathy good indicator local spread disease well clinical stage find histologic grade one strong prognostic factor show tumor biology also important prognostic factor patient treat conservative approach conclusion patient muscle invasive bladder cancer likely benefit conservative treatment approach include good performance status absence hydronephrosis histologic low grade transitional cell carcinoma bladder tumor stage transurethral ultrasonic scan determine tumor stage bladder cancer patient cystoscopic suspicion invasion undergo transurethral ultrasonic scan seventeen patient receive radiotherapy exclude prove impossible differentiate tumor irradiation sequela remain examination inconclusive tumor correctly stage tumor overstaged tumor understaged transurethral ultrasound regard useful supplement cytoscopy biopsy stage bladder tumor suspect invasion surgery versus radiotherapy muscle invasive bladder cancer background muscle invasive bladder cancer serious clinical problem fatal majority patient alternative treatment condition radical cystectomy radical radiotherapy choice treatment vary accord resident country ideal treatment would bladder preserve therapy total eradication tumour without compromise survival objective objective review compare survival radical surgery cystectomy versus radical radiotherapy patient muscle invasive cancer search strategy search cochrane control trial register july medline july embase july cancerlit july healthstar july database abstract review effectiveness july attempt contact author unpublished datum undertake selection criterium randomise trial compare surgery versus radiotherapy eligible assessment datum collection analysis three reviewer assess trial quality base cochrane guideline datum extract text article extrapolate kaplan meier plot peto odd ratio determine compare overall survival disease specific survival analysis perform intention treat basis treatment actually receive main result three randomise trial compare pre operative radiotherapy follow radical cystectomy surgery versus radical radiotherapy salvage cystectomy radical radiotherapy eligible assessment trial represent total patient randomise surgery radical radiotherapy peto odd ratio analysis consistently favour surgery term survival significant ci year ci overall survival year ci disease specific survival patient actually receive protocol treatment intention treat analysis disease specific survival result significantly favour surgery year ci not year reviewer conclusion evidence review suggest no overall statistically significant benefit radiotherapy surgery pre operative radiotherapy muscle invasive bladder cancer term survival trend consistently favour surgery continous improvement tnm stage system bladder cancer massachusetts general hospital radiation therapy oncology group lead charge organ conservation bladder cancer north america two decade series six successive study group refine technique move toward translational future novel biologic agent combine well current strategy north american approach characterize selective nature preselects patient likely good trimodality approach select accord response induction course chemotherapy radiation complete responder move onto full dose check point allow salvage cystectomy perform incomplete responder warfarin therapy influence risk bladder cancer grow interest study biological effect certain drug potential reduce risk various cancer one study report decrease incidence urogenital cancer trial patient receive warfarin treatment venous thromboembolism limitation study urogenital cancer small numb bladder cancer case develope follow warfarin therapy objective present study measure association warfarin use bladder cancer total case bladder cancer identify james haley veteran administration va hospital tampa florida use combination computerize pathology record inpatient outpatient diagnosis control randomly select va computerize administrative database control include analysis unconditional logistic regression analysis perform assess risk bladder cancer adjust age gender cigarette smoke among warfarin user although elevation risk not differ significantly nonusers ci no duration response relationship observe anticoagulant use risk bladder cancer result suggest warfarin not protect bladder cancer little male smoker high risk population bladder cancer combination urinary biomarker surveillance patient incident nonmuscle invasive bladder cancer european fp uromol project purpose determine combination marker optimal sensitivity detect recurrence void urine resection incident low grade nonmuscle invasive bladder tumor material method total patient g g nonmuscle invasive bladder tumor include study transurethral resection incident tumor little followup urine sample require patient selection dna extract incident tumor cell pellet subsequently collect urine sample perform fgfr pik ca ras mutation analysis microsatellite methylation analysis tissue urine dna sample result obtain urine sample patient experience total recurrence median year followup sensitivity detect recurrent tumor vary molecular test patient stratification base tumor dna analysis combination marker increase sensitivity decrease numb patient eligible certain test combination combine urine cytology fgfr analysis without stratify fgfr status incident tumor increase sensitivity conclusion combination marker increase percentage patient eligible urine base followup sensitivity recurrence detection add fgfr analysis urine cytology can valuable noninvasive followup patient nonmuscle invasive bladder cancer superficial bladder cancer purpose long term outcome patient high risk superficial bladder cancer unknown report result year followup high risk patient treat initially aggressive local therapy include transurethral resection alone combine intravesical bacillus calmette guerin material method high risk patient enroll randomize study transurethral resection alone intravesical bacillus calmette guerin superficial bladder cancer patient diffuse carcinoma situ stage tumor entry study patient follow death present time median followup month result disease stage progress patient eventually undergo cystectomy progression refractory carcinoma situ upper tract tumor median year year disease specific survival rate respectively year patient overall dead bladder cancer dead cause alive include intact function bladder conclusion despite aggressive local therapy patient high risk superficial bladder cancer lifelong risk development stage progression upper tract tumor 3 patient risk death bladder cancer justify careful vigilant long term followup result support use initial aggressive local therapy patient high risk superficial bladder cancer histochemical expression proliferate cell nuclear antigen pcna pre post chemotherapeutic bladder cancer examine whether stain proliferate cell nuclear antigen pcna can useful marker chemotherapeutic effectiveness nine patient invasive bladder cancer treat bilateral internal iliac artery infusion cisplatin cddp two type monoclonal antibody pc use immunohistochemical stain formalin fix paraffin embed tissue section no difference positive rate pc mean positive rate pre chemotherapeutic specimen tumor marker early detection bladder cancer several urine marker currently investigate diagnosis prognostication bladder malignancy cystoscopy urine cytology remain gold standard detection bladder cancer cystoscopy invasive cytology yield low sensitivity low grade disease availability non invasive accurate office base test would ideal review discuss marker useful prevention detection transitional cell carcinoma bladder general marker well sensitivity cytology low specificity furthermore marker must still use adjunct cystoscopy compute tomography loopogram novel technique upper tract evaluation radical cystectomy background previous study report low prevalence incidental prostate cancer chinese patient evaluate incidental prostatic adenocarcinoma pca urothelial carcinoma uca involvement prostate cystoprostatectomy specimen method analyze cystoprostatectomy specimen patient undergo radical cystoprostatectomy treatment bladder cancer china none patient know prostate cancer prior cystoprostatectomy result overall patient either pca uca prostate find pca uca involvement prostate rate incidental prostate cancer respectively two study period among patient pca gleason score nine pca tumor volume cc eight extracapsular extension prostatic uca prostatic urethra periurethral prostatic duct involvement prostatic stromal invasion age odd ratio p increase stage bladder tumor p multifocal tumor bladder p carcinoma situ cis bladder p bladder neck involvement p strongly associate prostatic uca conclusion rate incidental pca cystoprostatectomy specimen china increase last decade patient advance age elevate serum psa level advance bladder tumor stage multifocal bladder tumor cis bladder tumor location bladder neck exclude candidate prostate spare cystectomy current status conservative treatment urinary bladder invasive bladder cancer year give hyperthermia patient visit department treatment invasive bladder cancer result prognosis report stage grade cancer treatment case case case case transitional cell carcinoma tcc grade case tcc grade case tcc grade anaplastic carcinoma case complication observe case severe heart disease other pretreatment radiation therapy transurethral resection chemotherapy give case hyperthermia perform combine hydroxypropyl cellulose hpc adriamycin radiation therapy follow result obtain complete response cr case partial response pr case no change nc case progressive disease pd case among case pr total cystectomy perform case case case cr alive patient die enhance effect partial cystectomy rat urinary bladder carcinogenesis effect partial cystectomy bladder tumorigenesis initiate n butyl n hydroxybutyl nitrosamine bbn investigate wistar rat examine histological finding cell proliferative activity incorporation bromodeoxyuridine brdurd dna synthesis phase determine vitro label technique eight week treatment drink water contain bbn partial cystectomy perform end week resect bladder suture dexon silk no difference incidence papillary nodular pn hyperplasia control partial cystectomy group however incidence cancer group give partial cystectomy much high control cancer control group grade superficial tumor whereas grade invasive tumor observe six animal partial cystectomy group label index cancer partial cystectomy group great control group also significant difference numb brdurd label cell pn hyperplasia control partial cystectomy group finding indicate partial cystectomy enhance bbn initiate bladder carcinogenesis increase dna synthesis find pn hyperplasia cancer may associate induction bladder tumor bta test diagnosis follow superficial bladder cancer review literature bladder tumor antigen bta trak stat test evaluate usefulness test diagnosis follow bladder cancer compare test routine diagnostic tool also report experience bta test monitor tumor recurrence superficial bladder cancer patient correlation augment risk tumor recurrence serial measurement bta trak positive bta stat identify accord available datum bta test useful diagnosis follow superficial bladder cancer predictive value p prb expression superficial bladder cancer patient treat bcg interferon alpha background nuclear p retinoblastoma protein prb report poor prognostic indicator transitional cell carcinoma bladder author seek determine prognostic value nuclear p prb superficial bladder transitional cell carcinoma patient treat intravesical bacille calmette guerin bcg bcg interferon alpha ifn alpha method prospective histological review perform superficial bladder transitional cell carcinoma patient undergo postresection intravesical regime bcg mg n mg n bcg mg ifn alpha n follow mean year hematoxylin eosin h e immunoperoxidase stain perform tissue section nuclear p prb immunoreactivity assess semiquantitatively use combination stain extent intensity categorize overexpression underexpression datum analyze use chi square analysis multiple logistic regression kaplan meier curve result prb expression not associate patient outcome bcg alone therapy prb underexpression significantly associate bcg nonresponse tumor recurrence p bcg ifn alpha bcg ifn alpha therapy low grade tumor associate prb overexpression without nuclear p underexpression p p respectively p expression alone combination prb expression no significant relation tumor response bcg alone bcg ifn alpha respect recurrence progression cancer specific death conclusion nuclear prb underexpression may predictive nonresponse cancer recurrence intravesical bcg ifn alpha therapy nuclear p expression combination prb expression not associate post bcg clinical outcome p expression p prb expression not use influence decision concern bcg alone bcg ifn alpha therapy characteristic clinical significance histological variant bladder cancer past year evidence clinical relevance variant histology urinary bladder cancer increase increase result new classification urothelial cancer highlight importance accurate morphological description pathological specimen therapeutic management patient bladder cancer rise awareness importance accurate pathological report manifest increase prevalence report variant histology daily practice histological variant generally divide urothelial nonurothelial urothelial variant often similar feature also specific morphological phenotype whereas nonurothelial variant independent feature overall histological variant follow aggressive clinical course conventional urothelial carcinoma conclusive datum effect survival currently lack clinical relevance variant histology manifest three different level diagnostic identification challenge misinterpretation not uncommon prognostic patient risk stratification outcome estimation therapeutic particular variant can responsive specific treatment strategy accurate morphological description histological variant necessary patient consultation therapy plan moreover association variant histology specific mutation pattern promise helpful discover target therapeutic approach base specific molecular pathway gene signature prediction response bacillus calmette guerin immunotherapy primary pt bladder cancer purpose intravesical bacillus calmette gu rin bcg immunotherapy effective prevention recurrence progression many case nonmuscle invasive bladder cancer many patient fail respond aim study identify gene set marker can predict response bcg immunotherapy primary pt bladder cancer use microarray gene expression profile experimental design use patient primary pt bladder cancer treat bcg immunotherapy train test set microarray gene expression profile do train set identify gene differentially express responder nonresponder bcg immunotherapy accord event recurrence progression use real time reverse transcriptase pcr finding validate test set result train set gene significantly associate recurrence progression free survival respectively functional annotation gene include cell mediate immune response inflammatory response cellular growth proliferation predictive gene signature gene recurrence progression high score expression ratio extract validation test set multivariate regression analysis predictive gene signature independent predictor recurrence hazard ratio p progression hazard ratio p test set conclusion predictive gene signature diagnostic value determine response intravesical bcg immunotherapy primary pt bladder cancer extend vs non extend pelvic lymph node dissection influence recurrence free survival patient undergo radical cystectomy bladder cancer systematic review meta analysis comparative study objective compare extend pelvic lymph node dissection eplnd non extend pelvic lymph node dissection non eplnd assess influence recurrence free survival rfs patient undergo radical cystectomy bladder cancer method comprehensive search pubmed embase cochrane library database september perform systematic review cumulative nomograms well currently available stage grouping bladder cancer purpose indication topic chemotherapy immunotherapy good differentiate noninvasive superficial bladder cancer remain controversial side effect treatment promote use unconventional therapy cytokine immunomodulators mistletoe extract however no control clinical datum available efficacy extract bladder cancer evaluate influence subcutaneously applicated mistletoe lectin bladder tumor recurrence transurethral resection material method study consist patient pta g bladder cancer treat transurethral resection year period median patient age year patient male study cohort randomly divide treatment group receive adjuvant therapy mistletoe lectin control group receive no additional treatment patient treatment group receive mistletoe lectin accord schedule week transurethral resection clinical followup assess month initial resection include uretherocystoscopy result study arm comprise similar patient regard total numb previous tumor mean versus numb primary lesion versus numb recurrent tumor versus followup month recurrence free interval study arm similar p total numb recurrence comparable p conclusion subcutaneous use mistletoe lectin adjuvant treatment transurethral resection not seem affect time \\ufeff1 recurrence total numb recurrence recurrence free outcome paolo gontero richard sylvester francesca pisano et al prognostic factor risk group g non muscle invasive bladder cancer patient initially treat bacillus calmette gu rin result retrospective multicenter study patient eur urol purpose assess pathological mechanism silent prostatic stromal invasion patient bladder cancer early detection treatment material method august january patient clinically organ confine transitional cell carcinoma bladder know prostatic stromal invasion transurethral biopsy high risk prostatic involvement due tumor location near bladder neck study histological pattern prostatic invasion cystectomy specimen distend hour formalin via foley catheter step section longitudinally mm interval bladder neck prostate standard hematoxylin eosin stain method use section analyze pathologist result separate pattern prostatic stromal invasion elucidate include previously describe method extravesical intraurethral invasion prostatic stroma 3 one bladder neck directly prostatic stroma 3 pattern not grossly evident endoscopy urethral biopsy cystectomy conclusion longitudinal section bladder neck prostate cystectomy specimen suggest tumor bladder neck may directly invade prostatic stroma without histological evidence extravesical intraurethral spread direct silent tumor invasion prostate superficial endoscopically inapparent tumor difficult detect clinically current biopsy method new method detection necessary simultaneous determination urinary cea ferritin tpa egyptian bladder cancer patient urinary carcinoembryonic antigen cea ferritin fer tissue polypeptide antigen tpa determine case bladder cancer non malignant urinary tract disease healthy control cea determine kit supply roche diagnostica cea eia doumab ferritin tandem e fer kit supply hybritech tpa prolifigen tpa irma kit supply sangtec medical result work reveal combine determination urine cea fer cea tpa fer tpa show high sensitivity determination individual marker no significant difference combine individual marker determination respect false positivity non malignant urinary tract disease specificity sensitivity urine cea fer tpa respectively combine urine cea fer cea tpa fer tpa show sensitivity respectively specificity relate entire non cancer group patient benign urinary tract disease normal control reduction sensitivity combine marker note compare normal group conclusion combine determination urine marker superior determination individual marker diagnosis bladder cancer role surgery local recurrence radical cystectomy bladder cancer introduction local recurrence lr radical cystectomy rc bladder cancer bad prognosis treatment option include chemotherapy radiation therapy surgical excision datum available advantage surgery patient patient method evaluate series select patient undergo surgery locally recurrent bladder cancer rc result median time recurrence cystectomy month complication rate severity not negligible pathology report confirm urothelial carcinoma negative margin patient lr treatment patient recur locally 2 time develope distant metastasis die median follow month one patient remain disease free month conclusion prognosis patient lr poor regardless surgical treatment reflect aggressive biological nature urothelial tumor clinical experience bcg immune prevention superficial bladder cancer previous randomize study show case superficial urothelial carcinoma carcinoma situ urinary bladder complete long last remission obtain immunotherapy bacillus calmette gu rin bcg study show bcg reduce recurrence rate significantly compare transurethral resection alone year experience bcg pasteur strain connaught strain respectively tumour stage ptis pta pt g ii show last remission patient transurethral resection tumour complete remission find patient carcinoma situ patient local rare systemic side effect limit duration tolerable easily treat fully reversible treatment bladder neoplasm vesical instillation bcg vaccine microdoses administer bcg microdoses mg patient surgical operation bladder cancer recurrency rate observe month follow period not significantly different observe mg dose associate know complication novel set dna methylation marker urine sediment sensitive specific detection bladder cancer purpose study aim provide well set dna methylation marker urine sediment sensitive specific detection bladder cancer experimental design fifty nine tumor associate gene profile three bladder cancer cell line small cohort cancer biopsy urine sediment methylation specific pcr twenty one candidate gene profile urine sediment bladder cancer patient case stage case stage case stage ii case stage iii case stage iv age match patient noncancerous urinary lesion neurologic disease healthy volunteer result despite six incidence four gene report noncancerous urinary lesion patient analyze cancer specific hypermethylation urine sediment report gene p methylation assessment gene set sall cftr abcc hpr rassf mt runx itga bcl alx myod drm cdh bmp b ccna rprm mint brca confirm exist diagnosis among bladder cancer case sensitivity accuracy significantly stage stage disease detect indicate value early diagnosis bladder cancer interestingly cluster report methylation marker use u bladder cancer distinctly different identify study suggest possible epigenetic disparity american chinese case conclusion methylation profile gene set urine sediment provide sensitive specific detection bladder cancer define molecular profile poor outcome patient invasive bladder cancer use oligonucleotide microarray purpose bladder cancer common malignancy characterize poor clinical outcome tumor progress invasive disease seek define genetic signature characteristic aggressive clinical behavior advance bladder tumor method oligonucleotide array utilize analyze transcript profile bladder tumor superficial invasive lesion normal urothelium hierarchical cluster supervise algorithm use classify stratify bladder tumor basis stage node metastasis overall survival immunohistochemical analysis bladder cancer tissue array n case serve validate association marker expression stage outcome result hierarchical cluster classify normal urothelium superficial invasive tumor accuracy stratify bladder tumor basis clinical outcome predictive algorithm render correct rate tumor stage use gene differentially express superficial invasive tumor accuracy obtain predict overall survival consider patient bladder cancer patient invasive disease respectively genetic profile consist probe identify patient positive lymph node poor survival two independent global test run confirm robust association profile lymph node metastasis p overall survival p simultaneously immunohistochemical analysis tissue array sustain significant association synuclein tumor stage clinical outcome p conclusion gene profile provide genomic base classification scheme diagnostic prognostic utility stratify advance bladder cancer identification poor outcome profile can assist select patient may benefit aggressive therapeutic intervention oral piritrexim advance bladder cancer effective drug progression mvac chemotherapy four patient advance metastatic bladder cancer progress mvac chemotherapy treat oral piritrexim three four patient evaluable response three partial response treatment piritrexim may effective drug bladder cancer progression mvac chemotherapy inherit form bladder cancer review lynch syndrome inherit condition environmental factor play role urothelial carcinogenesis good characterize current research continuously explore potential heritable form bladder cancer lynch syndrome good know inheritable disease increase risk variety cancer include urothelial carcinoma screen patient know lynch syndrome important evaluate development new primary tumor study may provide information level follow patient need recent datum suggest mismatch repair mutation confer great risk urothelial cancer additional large patient series good advancement molecular test may provide triage lynch syndrome patient regard frequency type screen well suit individual patient two type micturition ileal neobladder eight patient evaluate clinically radiologically urodynamically determine outcome continent urinary diversion ileal neobladder perform treat recurrent superficial bladder cancer cystectomy subcapsular prostatectomy mean age patient year descend dissection urinary bladder without ligation dissection santorini plexus prostate cut bladder neck distally cm subcapular prostatectomy one patient short cm intestinal segment pouch urethra severely prolong micturition peristalsis short segment require operation micturition good seven patient detubularized neobladder directly prostate capsule anastomosis pressure flow study perform seven patient reveal two type micturition fast bladder intermittent flow latter resemble detrusor sphincter dyssynergia urinary bladder cancer locally advance bladder cancer comprise tumor stage pt pt b pt tnm system involvement regional lymph node cure radical cystectomy however little patient experience systemic progression within year surgery order improve fate patient administration additional therapy study various form neoadjuvant adjuvant systemic chemotherapy good combine radiochemotherapy result dozen randomize phase iii trial adjunctive chemotherapy include cystectomy definite treatment report whether neoadjuvant adjuvant systemic chemotherapy superior form adjunctive therapy locally advance bladder cancer continue matt dispute current topic perspective bladder cancer research background give uncertainty surround optimal management early stage bladder cancer physician vary approach disease author report link cancer registry datum medical claim identify source variation opportunity improve value cancer care method use datum surveillance epidemiology end result medicare database patient early stage bladder cancer abstract n primary outcome intensity initial treatment patient receive measure medicare payment bladder cancer incur year diagnosis multilevel model fit partition variation treatment intensity attributable patient versus provider factor potential saving medicare reduce physician contribution estimate result provider factor account variation treatment intensity increase provider treatment intensity not correlate improve cancer specific survival p associate subsequent receipt major intervention include radical cystectomy p provider level variation reduce clinical practice align physician perform th percentile treatment intensity total payment make average patient can lower save medicare million annually conclusion current result indicate substantial amount variation initial treatment intensity early stage bladder cancer drive physician furthermore intensive practice style not associate improve cancer specific survival avoidance major intervention therefore intervention aim reduce provider difference may improve value cancer care age diagnosis bladder cancer opium addiction play role background bladder cancer major health problem especially among man opium addiction important risk factor one important question whether affect age onset bladder cancer perform study evaluate question material method cross section study record patient diagnose bladder carcinoma shahid labbafinejad medical center within role flow cytometry management bladder cancer substantial amount investigation perform seek exploit considerable technologic sophistication automate flow cytometry management bladder cancer although likely modest value ploidy analysis solid tumor resect patient clearly require radical surgery base criterium clinical stage likely application minimally invasive lesion intermediate grade histology use flow cytometry analyze cytologic specimen remain great measure imperfect time not yet appear appropriate utilize technique screen particularly void specimen use appear role flow cytometry monitor patient cis undergo therapy bcg determine whether aneuploid stem line extricate bladder result treatment failure may indicate need radical surgery improvement cytologic specimen preservation development multiparametric analysis use cellular probe neoplasia can substantially augment utility diagnostic technology retrospective analysis patient radical cystectomy treatment bladder cancer without preoperative radiotherapy micrornas mirnas small non code rnas regulate gene expression target repression transcription translation study show mirna b mir b act tumor suppressor bladder cancer quantitative specific micro rna expression pattern distinguish basal luminal subtype muscle invasive bladder cancer role non code rnas control clinical biological heterogeneity bladder cancer remain unclear use tcga publish dataset n tumor discovery cohort create new validation cohort define mirna expression pattern basal luminal molecular subtype muscle invasive bladder cancer mibc identify mirnas pam optimally identify basal luminal tumor target top luminal mirnas activator emt zeb zeb basal subtype transcription il egfr stat whereas target top basal mirnas involve adipogenesis pathway luminal breast cancer erbb erbb also identify mirna signature identify stromally infiltrate basal luminal mibcs correspond cluster iv immune undifferentiated claudin low cluster ii luminal immune subtype identify previously likely contain sample high infiltration rate use mirna signature accurately assign mibcs basal luminal subtype confirm patient basal tumor short overall survival result strongly suggest mirnas contribute control gene expression pattern observe basal luminal mibcs use biomarker candidate therapeutic target robot assist cystprostatectomy urinary bladder cancer \\ufeff1 experience article report case robot assist cystprostatectomy patient malignant bladder neoplasm highly differentiate infiltrative urothelial bladder cancer gr invade bladder wall mucosa multicentric growth type focal tumor growth urethral mucosa prostate ileal neobladder construct use intracorporeal access operate time hour intraoperative blood loss ml no intra postoperative complication void function restore day postoperatively tumor marker diagnosis primary bladder cancer systematic review tumor deoxyribonucleic acid dna ploidy evaluate objective parameter may correlate well responsiveness bladder cancer chemotherapy plus radiotherapy clinical feature histopathological subtype total patient localize muscle invade bladder cancer clinical stage undergo prospective treatment potential bladder preserve protocol tumor patient analyze dna flow cytometry multiple paraffin embed specimen transurethral resection neoadjuvant chemotherapy gy radiotherapy plus cisplatin follow urological reevaluation tumor complete response require negative biopsy negative urine cytology study total noncomplete response patient undergo immediate radical cystectomy whereas full bladder spare treatment radiotherapy gy plus cisplatin give complete response patient noncomplete response patient unsuited surgery tumor purely aneuploid purely diploid five tumor contain aneuploid diploid pattern different tumor specimen partly diploid current status new world health organization international society urological pathology isup classification ta bladder tumor improvement world health organization international society urological pathology isup consensus classification urothelial neoplasm urinary bladder develope attempt improve upon prior classification system good adopt classification system would widespread acceptance prior classification system numerous diverse grade scheme bladder cancer exist whereby lesion see different pathologist would result different diagnosis solely base definitional difference lesion another strength consensus classification system provide detail histological criterium papillary urothelial lesion contrast prior grade system bladder tumor vague subjective current classification system allow designation lesion papillary urothelial neoplasm low malignant potential biologically low risk progression yet not entirely benign past lesion source controversy expert field require restrictive criterium diagnosis papilloma would label lesion malignant expert field not want label patient low grade papillary lesion carcinoma would diagnose lesion papilloma intermediate category allow school think diagnose lesion not fully malignant yet still document need additional follow since inception several study publish document relationship tumor classify use isup system prognosis article summarize within review elderly patient undergo cystectomy compare preoperative american society anesthesiology eastern cooperative oncology group score operative approach objective evaluate preoperative score system operative management relation complication patient old year undergo cystectomy two academic institution method total patient age year muscle invasive bladder cancer undergo cystectomy university utah central hospital bolzano italy rate grade clavien dindo complication radical cystectomy patient n compare use eastern cooperative oncology group score american society anesthesiologist physical status classification rate grade clavien dindo complication also compare urinary diversion type logistic regression use control source institution result total case include primary analysis neither preoperative score system predictive identification radical cystectomy patient grade clavien dindo complication secondary analysis n include partial cystectomy none urinary diversion type associate radical cystectomy significantly different rate complication however partial cystectomy n significantly low rate complication conclusion complication rate among elderly patient undergo cystectomy muscle invasive bladder cancer high patient approve surgery history physical exam none objective metric adequately predict operative risk unique diversion procedure describe bolzano group uretero ureterocutaneostomy equivalent complication rate common diversion procedure also appear base outcome cohort partial cystectomy particularly favorable option within elderly population term perioperative morbidity attenuate expression xeroderma pigmentosum group c associate critical event human bladder cancer carcinogenesis progression xeroderma pigmentosum group c xpc important dna damage recognition protein bind damage dna early stage dna repair xpc protein also involve dna damage induce cell cycle checkpoint regulation apoptosis xpc defect associate many type solid tumor mechanism xpc protein cancer progression however remain unclear report show strong correlation bladder cancer progression attenuate xpc protein expression use tissue derive patient bladder cancer result obtain immunohistochemical study reveal strong correlation xpc deficiency p mutation degree malignancy bladder tumor addition result obtain study also show ht bladder cancer cell carry low level xpc protein exhibit decrease dna repair capability resistant cisplatin treatment xpc gene cdna expression vector stably transfect ht cell however cisplatin treatment induce apoptotic cell death increase increase p p response follow cisplatin treatment also observe ht cell stably transfect xpc cdna take together result suggest xpc deficiency important contribute factor bladder tumor progression bladder cancer cell drug resistance image bladder cancer update current approach diagnosis image play mainstay role evaluation patient bladder cancer especially diagnosis local distant stage treatment follow article aim review update conventional functional image method use clinical management bladder cancer cavitary pulmonary metastasis bladder cancer case report year old correction man radical cystectomy bladder cancer admit hospital hemosputum right femoral pain chest radiograph compute tomogram show mass shadow cavity leave upper lung field sputum cytology show class v squamous cell carcinoma bone scintigram show right femoral metastasis despite radiotherapy leave upper lung right femur patient condition worsen die respiratory failure hospitalization month autopsy pathologic study lung cancer reveal mix type transitional cell carcinoma squamous cell carcinoma adenocarcinoma diagnosis metastatic lung cancer bladder cancer make cavitating pulmonary metastasis uncommon report rare case pulmonary metastasis bladder cancer mix type histopathology primary metastatic site screen bladder cancer recommendation statement accumulate evidence indicate long non code rnas lncrnas play important role tumorigenesis progression aim identify panel lncrnas diagnosis recurrence prediction bladder cancer bc expression candidate lncrnas investigate bc match adjacent normal tissue via quantitative real time pcr differentially express lncrnas analyze serum sample train set three lncrnas meg snhg malat show differential expression logistic regression model construct use train set validate independent cohort serum sample validation set auc three lncrna panel train validation set diagnostic performance lncrna panel ta significantly high urine cytology respectively moreover determine low expression meg associate poor recurrence free survival kaplan meier analysis p univariate cox analysis p multivariate cox analysis p conclusion result identify three lncrna panel bc diagnosis recurrence independent prognostic factor meg expression profile bladder cancer strategy uncover prognostic factor despite common cancer worldwide management transitional cell carcinoma bladder currently rely primarily clinical stage histopathologic parameter assay alteration molecular pathway contribute valuable information accurately predict outcome chemotherapeutic response individual patient bladder cancer medium high throughput gene expression profile technology allow multiplexed assessment alteration responsible genesis progression bladder tumor investigation employ global pathway base approach define molecular signature predict prognosis independent traditional clinical performance metric prognostic panel generate use strategy also elucidate biology tumor progression identify potential therapeutic target quantification micrornas urine derive specimen micrornas small noncoding rnas regulate expression gene involve multitude cellular process dysregulation micrornas consequence affect pathway frequently observe numerous pathology include cancer therefore tumor relate alteration microrna expression function reflect molecular process tumor onset progression qualify micrornas potential diagnostic prognostic biomarker particular micrornas differential expression bladder cancer bca may represent promise tool noninvasive tumor detection urine would helpful not diagnostic monitor purpose also therapeutic decision detection quantification bca associate micrornas urine perform use cellular sediment also contain bca cell exosomes originate cell method isolation exosomes urine extraction total rna cell exosomes good technique rna quantification reverse transcription qpcr base quantification microrna expression level describe herein datum analytic method match case control study recent introduction complex multivariate statistical model match hydronephrosis prognostic marker bladder cancer cystectomy series objective hydronephrosis patient bladder cancer cause tumour ureteral orifice secondary ureteral tumour intramural extravesical tumour infiltration compression ureter study investigate prognostic impact hydronephrosis bladder cancer method series patient treat radical cystectomy curative intent transitional cell carcinoma bladder without neoadjuvant adjuvant radiotherapy chemotherapy january september patient complete follow death study end date survival rate calculate use kaplan meier method multivariate analysis cox regression model perform respect potential influence factor result total patient unilateral patient bilateral hydronephrosis rate organ confine tumour significantly high patient without hydronephrosis vs p forty three hydronephrotic patient tumour involve ureteral orifice group rate organ confine tumour significantly high patient hydronephrosis vs p multivariate analysis preoperative hydronephrosis determine independent prognostic marker recurrence free survival besides pt classification lymph node status p etiology hydronephrosis not affect tumour specific survival conclusion hydronephrosis time diagnosis bladder cancer associate high probability advance tumour independent prognostic factor recurrence free survival runt relate transcription factor methylation possible prognosticator muscle invasive bladder cancer study seek determine runt relate transcription factor runx methylation can accurately predict overall survival patient muscle invasive bladder cancer mibc forty seven patient long followup period cohort report previously analyze tumor sample cohort newly collect obtain mibc patient prognostic significance runx methylation evaluate kaplan meier analysis multivariate cox regression model runx methylation affect overall survival cohort surgical factor bladder cancer node pathology little mortality patient evaluate compute tomography ct ct differ clinical stage patient patient change stage result extravesical extension involvement prostate seventeen patient undergo pre operative irradiation ct scan do regulation sphk suppress bladder cancer progression bladder cancer 2 common urological malignancy around world far frequent urological malignancy china abnormal expression sphingosine kinase sphk associate tumor progression poor patient survival rate however effect sphk bladder cancer cell remain unclear aim paper study expression sphk bladder cancer role sphk cell proliferation metastasis apoptosis bladder cancer vitro result show sphk regulate bladder cancer tissue compare correspond adjacent non neoplastic tissue expression level sphk significantly high human bladder cancer cell comparison normal bladder epithelial cell silence sphk can inhibit proliferation ability cell vitro addition sphk knockdown can induce significant increase numb apoptotic cell furthermore transwell assay also show significant cell migration inhibition sphk sirna transfectant compare cell line transfect nc thus study suggest sphk inhibition may provide promise treatment bladder cancer patient urothelial malignancy urothelial malignancy fascinate urologist range problem present superficial bladder cancer reduce demand treatment use fibrescopic technology make outpatient treatment comfortable acceptable patient adopt policy radiotherapy salvage cystectomy try preserve bladder sexual function patient invasive bladder cancer result recent histological study may help us predict patient respond radiotherapy offer alternative treatment not present endoscopic management tumour upper urinary tract pose technical difficulty resolve advance technique instrumentation topic bladder cancer treatment new reiwa era introduction objective update guideline french urological association cancer committee non invasive nmibc invasive bladder cancer mibc method medline search perform regard diagnosis option treatment follow bladder cancer evaluate different reference level evidence result diagnosis nmibc ta cis depend cystoscopy complete deep resection tumour use fluorescence 2 look indication essential improve initial diagnosis risk recurrence progression estimate use eortc score stratification patient low intermediate high group pivotal recommend adjuvant treatment instillation chemotherapy immediate superficial bladder cancer study group consist patient solitary stage bladder tumour treat transurethral resection tur subsequent neodymium yag laser irradiation ten patient alive without evidence cancer month mean treatment die cardiovascular disease year treatment autopsy reveal no cancer patient treatment fail cystectomy external beam radiation carry long term result indicate combination tur laser irradiation beneficial management tumour select case treatment muscle invasive bladder cancer old patient treatment muscle invasive bladder cancer old patient challenge definitive therapy localize disease require either surgery radiation therapy ideally combine systemic chemotherapy however current population datum suggest little half patient old age offer treatment review tool available assess fitness old patient surgery alternative tip perioperative patient treatment diagnosis bladder tumor prompt diagnosis bladder cancer essential improve management disease hematuria low urinary tract symptom must draw attention bladder difficulty diagnosis base cystoscopy biopsy lesion diagnosis establish tumour stage use tnm system treatment research effort continue identify biological marker sensitive specific enough predict diagnosis behavior disease accurately survival bladder cancer england wale bladder cancer frequently associate occupational chemical carcinogen increase occupational exposure may part account increase risk bladder cancer consistently observe man age specific bladder cancer mortality rate unite state analyze use strehler mildvan modification gompertz relationship age mortality method analysis distinguish aggregate environmental genetic influence upon mortality also suggest environmental influence upon bladder cancer mortality significantly great u man emerge target therapy bladder cancer disease wait drug urothelial cell carcinoma 5 common cancer costly treat largely new case present superficial disease rarely fatal tend recur require long term follow repeat intervention standard care intravesical chemo immunotherapy effective associate considerable side effect profile approximately patient either fail respond treatment suffer recurrent disease within year muscle invasive bladder cancer life threaten show modest chemosensitivity usually require radical cystectomy although bladder cancer fairly good genetically characterize clinical trial molecularly target agent comparison solid tumor lung breast prostate numb largely unsuccessful no new agent register last year hence bladder cancer represent considerable opportunity challenge molecularly target therapy bladder preserve therapy muscle invasive bladder cancer recommend appropriate patient occupational bladder cancer due aniline dye intermediate matrix metalloproteinase polymorphism bladder cancer risk matrix metalloproteinase mmp contribute tumor microenvironment associate bladder cancer study examine association mmp polymorphism bladder cancer risk never publish analyze association single nucleotide polymorphism snps one microsatellite polymorphism mmp gene mmp mmp mmp mmp mmp mmp bladder cancer risk caucasian patient control match age gender ethnicity individual combination haplotype diplotype analysis do no association individual mmp polymorphism overall bladder cancer risk see mmp microsatellite ca repeat allele mmp gg polymorphism associate invasive bladder cancer risk odd ratio confidence interval ci ci respectively smoke stratify analysis reveal several association mmp polymorphism alone combination bladder cancer risk particularly light smoker linkage disequilibrium see mmp mmp mmp mmp snps four five mmp polymorphism test several mmp haplotype diplotypes associate overall invasive bladder cancer risk study suggest genetic variation mmp family associate bladder cancer risk heavy carcinogen exposure may overwhelm genetic effect mmp polymorphism study confirm importance take multigenic pathway base approach risk assessment clinical use case tool assess risk superficial bladder cancer background among approximately patient newly diagnose early stage superficial bladder cancer year substantial variability progression muscle invasive disease enhance risk stratification preoperative hydronephrosis predict advance bladder cancer not independent factor cancer specific survival radical cystectomy introduction hydronephrosis bmi analyze together establish factor tnm stage surgical margin multivariate modality investigate status independent prognostic factor bladder cancer specific survival patient undergo radical cystectomy patient method study prospective cohort patient undergo radical cystectomy bladder cancer institution statistical analysis perform use kaplan meier method kendall tau rank correlation multivariate cox proportional hazard model result hydronephrosis positively correlate advance tumor stage positive lymph node involvement positive surgical margin adjust investigate parameter bmi hydronephrosis not affect cancer specific survival multivariate analysis non organ confine disease hr ci p positive lymph node stage hr ci p positive surgical margin hr ci p prognostic factor conclusion hydronephrosis time radical cystectomy significantly correlate presence advance bladder cancer positive surgical margin however long establish parameter pt stage pn stage surgical margin predominantly influence cancer specific survival patient undergo radical cystectomy irrespective hydronephrosis bmi status study bladder cancer flow cytometry evaluation malignant potential bladder cancer base flow cytometric dna analysis antibody array represent versatile high throughput technology enable multiple protein detection simultaneously allow quantify protein level multiparametrically analyze post translational modification thus improve funtional characterization molecular process associate neoplasic disease moreover identification protein expression pattern characteristic tumor progression different tumor subtype improve clinical management patient bladder cancer near future may allow establish tailor therapy accord aggresiveness specific tumor health relate quality life patient bladder cancer cross sectional survey validation study hungarian version bladder cancer index health relate quality life hrqol important outcome oncology care although underexplored area bladder cancer bc aim assess hrqol patient bc analyse relationship diverse hrqol measure validate hungarian version bladder cancer index bci questionnaire cross sectional survey perform among patient bc n validate hungarian version fact bl sf eq apply sf derive psychometric analysis hungarian bci perform pearson correlation five measure analyse deterioration sf physical function detect among patient age year eq score not differ significantly age match population norm correlation fact bl eq sf utility measure strong r cronbach alpha coefficient hungarian bci range factor analysis confirm datum fit six predefine subdomain test retest correlation reliability n range interscale correlation urinary bowel sexual bci domain weak moderate r convergent validity reveal strong correlation fact bl r generic health state score r result divergent validity hungarian bci treatment group kruskal wallis test promise although limit low sample size cystectomy subgroup generic health state measure limit capacity capture hrqol impact bc validity test yield favourable result hungarian bci map study estimate utility score fact bl encourage little recommendable bci current status bladder cancer protocol eortc genito urinary group report give update account phase ii iii bladder study conduct genito urinary cooperative group eortc phase ii study screen activity patient measurable advance disease phase iii study randomize study aim control recurrence rate superficial bladder tumor long term plan chemotherapy chemoprevention continue orderly fashion expand evaluation radiotherapy surgery immunology regimen tumor control near future long wait time increase overall mortality patient bladder cancer purpose use population level datum determine impact extend wait time survival patient undergo radical cystectomy bladder cancer material method identify patient undergo cystectomy bladder cancer ontario canada use administrative database cox proportional hazard model account patient pathological health service variable can affect wait time create assess impact wait time survival tumor stage specific impact wait cystectomy also assess cox regression analysis model wait time use cubic spline use determine maximum wait time within optimal care provide result median wait time transurethral bladder resection cystectomy day unadjusted adjust analysis demonstrate prolong wait time significantly associate low overall survival rate relative hazard death increase wait time appear great low stage vs high stage cancer cubic spline regression analysis reveal risk death begin increase day conclusion treatment delay transurethral bladder tumor resection radical cystectomy result wrong overall survival effect wait time great low stage lesion suggest maximum wait time transurethral bladder tumor resection cystectomy day study assess disease free survival require corroborate finding hodgkin disease involve urinary bladder diagnose urinary cytology case report unique case lymphocyte depletion hodgkin disease urinary bladder year old woman diagnose exfoliative cytology single pass urine specimen subsequent bladder biopsy confirm diagnosis retrospectively ascertain patient previous diagnosis hodgkin disease base biopsy cervical lymph node ten year previously \\ufeff1 case report presence reed sternberg cell cytologic preparation urine lead diagnosis hodgkin disease involvement bladder pioglitazone use risk bladder cancer vitro study aim whether pioglitazone pio peroxisome proliferator activate receptor gamma agonist increase risk develope bladder cancer debate several year aim study investigate vitro effect pio normal urothelial transitional epithelium nute cell bladder cancer j cell evaluate risk method nute cell obtain sprague dawley rat nute j cell treat different concentration pio various time period cell proliferation test mtt assay cell apoptosis evaluate flow cytometry expression p cyclin bcl bax determine qrt pcr western blot result hour treatment nute cell mol l pio lead morphological change without change j cell moreover pio inhibit proliferation induce apoptosis nute cell not j cell time dose dependent manner however pio not alter growth cell tissue addition treatment pio hour not result change expression p cyclin bcl bax nute cell j cell interestingly pio significantly downregulated protein level p cyclin j cell not nute cell hour treatment conclusion pio not promote malignant alteration nute cell stimulate proliferation j cell pio decrease expression p cyclin j cell long term culture suggest pio may helpful diabetic patient bladder cancer reduce estimate glomerular filtration rate egfr ml min \\ufeff1 transurethral resection bladder tumour significant predictor subsequent recurrence progression objective evaluate moderate chronic kidney disease ckd estimate glomerular filtration rate egfr ml min associate high rate non muscle invasive bladder cancer nmibc recurrence progression patient method multi institutional database identify patient serum creatinine value prior \\ufeff1 transurethral resection bladder tumour turbt ckd epidemiology collaboration formula calculate patient egfr cox proportional hazard model evaluate association recurrence free rfs progression free survival pf result patient identify median interquartile range iqr patient age year datum egfr available patient median iqr follow chemotherapy invasive bladder cancer neoadjuvant versus adjuvant treatment patient invasive bladder tumor base original urologic assessment global recommendation single treatment plan radical surgery chemotherapy radiation variation thereof patient clearly antiquated approach case selection criterium single multimodality approach need define neoadjuvant therapy advantage vivo response evaluation potential bladder preservation however treatment therapeutic goal bladder preservation treatment micrometastases outline patient tumor consider bladder salvage chemotherapy alone chemotherapy plus radiation therapy chemotherapy follow partial cystectomy high stage tumor therapy direct treatment micrometastases bladder preservation secondary goal case additional therapy direct primary require clinical understaging remain significant patient initial surgery definition prognosis firm pathologic ground may represent well strategy positive node offer chemotherapy postoperative set refinement technique ileo neo bladder importance improve quality life use alone not alter natural history disease drug resistance remain major therapeutic obstacle effective agent prospective identification intrinsic acquire resistance invasion metastatic potential require optimize therapy individual patient ultimately large scale randomize trial require negate heterogeneity patient population individualization treatment possible tea polyphenol inhibit autophagy sensitize epirubicin induce apoptosis human bladder cancer cell resistance anticancer agent epirubicin epi become great challenge treat bladder cancer however mechanism chemoresistance arised still elusive present study show evidence epi induce cytoprotective autophagy bladder cancer cell line biu addition epi robustly activate jnk mediate phosphorylation bcl disruption bcl beclin complex furthermore green tea derivative tea polyphenol tp inhibit epi induce autophagy promote apoptosis induce epi bladder cancer cell result reveal pathway epi induce autophagy involve jnk bcl beclin bladder cancer cell tp synergistically promote epi induce apoptosis little partly autophagy inhibition thus tp can utilize combination epi improve epi base bladder cancer therapy identification nine gene panel prognostic indicator recurrence muscle invasive bladder cancer background objective bladder cancer one common highly recurrent cancer worldwide recurrence associate gene may potentially predict cancer recurrence aim construct recurrence associate gene panel improve prognostic prediction bladder cancer method base dna sequence clinical datum tcga blca project identify potential driver gene significantly associate recurrence bladder cancer perform multivariable logistic regression analysis construct optimize recurrence prediction model nine recurrence associate gene eme akap znf pard stag zfp l mettl polr b muc clinical information independent variable result area receiver operate characteristic roc curve model much high baseline model auc trend also validate subset decision curve analysis also reveal significant net benefit gain add nine gene mutation baseline model furthermore kaplan meier survival analysis show eight nine gene exclude muc good effect overall prognosis patient conclusion nine gene panel likely useful tool prognostic evaluation facilitate personalize management patient bladder cancer bladder cancer genetic variant modify risk recurrence survival result intravesical cddp cddp combine external beam radiation compare group patient low stage bladder cancer six patient low stage bladder cancer receive treatment cddp intravesically initial complete response patient within six month recurrent disease develope patient seven patient receive combination therapy rad weekly six week follow two hour late mg intravesical cddp positive response observe initially patient determine pathology pap cytology fluorescence cytology quantitative nuclear fluorescence determination therapy discontinue patient group irritative symptom result indicate combination therapy tolerable toxicity quantitative fluorescence cytology useful adjuvant guide future treatment patient low high grade bladder tumor use microrna profile urine sample develop non invasive test bladder cancer current standard method use detect monitor bladder urothelial cell carcinoma ucc invasive low sensitivity incorporation clinical practice non invasive tool ucc assessment would enormously improve patient quality life outcome study aim examine microrna mirna expression profile urine ucc patient order develop non invasive accurate reliable tool diagnose provide information aggressiveness tumor perform global mirna expression profile analysis urinary cell ucc patient control use taqman human microrna array follow validation select potentially diagnostic prognostic mirnas separate cohort sample use mircury lna qpcr system mirna base signature develope multivariate logistic regression analysis internally cross validate initial cohort patient identify aberrantly express mirna ucc compare control urine high compare low grade tumor respectively quantification key mirnas independent cohort result identification six mirna diagnostic signature sensitivity specificity auc two mirna prognostic model sensitivity specificity auc internal cross validation analysis confirm accuracy rate model reinforce strength finding although datum need externally validate mirna analysis urine appear valuable tool non invasive assessment ucc partial cystectomy versus tur g tumor author report experience conservative treatment patient bladder cancer compare partial cytectomy turv hold partial cystectomy represent good therapeutical option treatment bladder cancer g invadopodia essential transurothelial invasion muscle invasion bladder cancer cell muscle invasive bladder cancer aggressive type epithelial tumor high rate metastasis bladder cancer cell reach muscle layer cell must invade urothelial cell monolayer transurothelial invasion basement membrane however process transurothelial invasion occur not fully characterize study develope novel method evaluate transurothelial invasion capacity investigate cellular molecular process use primary culture cell bladder cancer patient analysis reveal compare prognosis patient non muscle invasive bladder cancer patient muscle invasive bladder cancer particularly poor due metastatic recurrence cancer cell patient muscle invasive bladder cancer exhibit high invasive capacity urothelial cell monolayer compare non invasive bladder cancer patient furthermore muscle invasive bladder cancer cell demonstrate great ability form invadopodia filamentous actin base membrane protrusion require matrix degradation invasion compare non invasive cell bladder cancer cell line establish reduce invadopodia formation silence expression cortactin essential component invadopodia cortactin knockdown bladder cancer cell reduce invadopodia formation demonstrate markedly reduce ability invade urothelial cell monolayer indicate invadopodia essential transurothelial invasion result indicate invadopodia formation require muscle invasion aggressive bladder cancer cell current status controversy management genito urinary cancer local control transitional cell carcinoma bladder analyse respect total dose normalization variation fraction size overall treatment time tcd gy protraction overall treatment time day average give decrease local control rate decrease local tumour control extension overall treatment time likely reflect accelerate tumour repopulation treatment determine time onset accelerate tumour clonogen repopulation datum take literature analyse result show average tumour clonogen repopulation transitional cell cancer bladder accelerate lag period week start treatment dose increment gy per day require compensate repopulation dose increment consistent day clonogen double time suggest overall treatment time important factor dose fractionation protraction time may significant impact treatment outcome thus radiotherapy bladder cancer complete soon possible total dose high probability local tumour control consequently deliver fraction per week surgery versus radiotherapy muscle invasive bladder cancer evaluate patient various stage bladder carcinoma determine alteration monocyte function since monocyte play important role effector arm immune system defective function may explain host inability destroy neoplastic cell group patient demonstrate defective monocyte monocyte function no correlation tumor stage degree chemotactic defect patient invasive carcinoma significant return monocyte chemotactic response toward normal postoperatively p little monocyte function improve also patient receive bacillus calmette guerin immunotherapy p little aromatic amine bladder cancer conduct meta analysis explore dose response relationship bladder lung cancer people chronically expose low dose arsenic search electronic database article publish ten study bladder cancer ingest arsenic exposure five study lung cancer ingest arsenic exposure fit selection criterium also investigate sensitivity absolute risk lung bladder cancer different underlie prevalence measure male high risk bladder cancer female maximum contamination level absolute risk bladder cancer lung cancer ingest arsenic correlate highly smoke rate maximum contamination level g l estimate additional bladder cancer case per people consider study since estimate additional lung cancer case per people bladder cancer screen unite kingdom attempt control industrial bladder cancer unite kingdom start study among worker dye manufacture industry annual cystoscopy examination attempt work force addition study microscopic hematuria way papanicolaou method publish unite kingdom method test refine become standardize use papanicolaou method spread high risk industry include dye manufacture part organic chemical industry rubber relate industry current mandatory screen program unite kingdom summarize consideration give screen may change future clinical practice associate bladder cancer screen review identification possible new high risk group use highlight future trend management outcome tag tumour urinary bladder nationwide population base bladder cancer database sweden bladderbase purpose investigate management tag tumour urinary bladder use nationwide population base datum relation prevail guideline patient characteristic outcome material method bladder cancer datum base sweden bladderbase include datum swedish national register urinary bladder cancer snrubc use study patient tag bladder cancer diagnose patient divide follow management group transurethral resection tur tur intravesical instillation therapy ivit tur 2 look resection slr tur slr ivit patient tumour characteristic outcome study result patient male median age year slr perform often young patient man little often western uppsala rebro healthcare region ivit perform often young patient man western healthcare region little often uppsala rebro healthcare region death bladder cancer occur case within median month month low tur ivit tur slr ivit group compare two group conclusion present study accord prevail treatment guideline treatment slr old patient woman healthcare region similarly treatment ivit old patient cancer specific survival relative survival low tur group compare tur ivit tur slr ivit group management locally advance bladder cancer early vs defer chemotherapy locally advance bladder cancer associate high risk local recurrence distant metastasis clinical pathologic variable useful predict outcome patient muscle invasive bladder cancer recently numb molecular prognostic marker identify help predict tumor aggressiveness response chemotherapy survival transitional cell carcinoma chemosensitive tumor early use chemotherapy reduce risk recurrence improve survival focus many randomize clinical trial unfortunately majority study fail show survival advantage chemotherapy treat patient good design prospective trial target high risk patient define clinical pathological molecular feature incorporate new tolerable chemotherapeutic agent need clarify benefit early chemotherapy bladder cancer role documentation bladder tumor finding target 2 resection background control resection bladder tumor exact relocalization previously infiltrate tumor spread complicate postreactive alteration multiple scar tissue change surgeon study result control transurethral resection bladder turb high grade bladder tumor focus localization importance standardize exact documentation analyze patient method july february control resection perform patient due high grade bladder cancer rate residual tumor tissue localization investigate standardize tumor documentation result patient bladder cancer undergo control resection tumor tissue find primary site affect primary site additionally location patient residual tumor tissue initial site detect histologically conclusion result indicate high grade bladder cancer show relevant rate residual tumor tissue control resection confirm clinical guideline european association urology eau mandatory resection case primary tumor site affect standardize bladder tumor documetation allow good direct control resection also patient multiple scar post tur alteration even perform different surgeon intrinsic subtype high grade bladder cancer reflect hallmark breast cancer biology seek define whether intrinsic molecular subtype high grade bladder cancer consensus cluster perform gene expression datum interstitial irradiation radon seed bladder cancer special reference follow result epidemiological study investigate functional polymorphism methylene tetrahydrofolate reductase mthfr gene may play essential role bladder carcinogenesis numerous publish study report inconclusive result objective current study conduct update analysis order investigate association polymorphism mthfr gene risk bladder cancer search pubmed database article publish march address bladder cancer polymorphism variant mutation mthfr analysis use statistical software result two polymorphism c c case control study article indicate individual carry allele tc tt tc reduction compare wild genotype cc mix population ci ci respectively show significant positive association c polymorphism bladder cancer africans ci c vs ci ca vs aa ci cc ca vs aa however no significant relationship find two polymorphism stratify analysis smoke status interestingly individual carry allele tt tc demonstrate high percentage invasive superficial case ci result current update analysis suggest c c polymorphism mthfr gene associate bladder cancer risk prognosis evaluation base study large group patient require follow method patient non muscle invasive bladder cancer remain recurrence free long time determine follow schedule patient non muscle invasive bladder cancer remain recurrence free year retrospectively review patient ta bladder cancer free recurrence little year patient subsequent recurrence develope patient spite recommendation cystoscopic follow do month interval patient remain recurrence free year follow interval month range month recurrence find recurrent tumor show bladder muscle invasion muscle invasive cancer identify often patient cytoscopic interval month little month versus therefore recommend cystoscopy perform interval little month patient non muscle invasive bladder cancer recurrence detection tumor become muscle invasive even patient remain free recurrence long period high risk superficial bladder cancer intravesical therapy g transitional cell carcinoma urinary bladder ideal treatment g transitional cell carcinoma tcc urinary bladder remain controversial therapeutic option initial transurethral tur resection observation intravesical therapy repeat resection radiation therapy cystectomy half patient g tcc urinary bladder not progress initial cystectomy represent overtreatment however observation alone follow tur g tcc urinary bladder associate progression rate intravesical immunotherapy show decrease recurrence progression high grade ta carcinoma situ bladder cancer patient g tumor good select intravesical therapy follow initial tur significantly improve survival quality life persistence recurrence high grade tumor mandate consideration cystectomy tumor associate macrophage polarization dictate efficacy bcg instillation non muscle invasive urothelial bladder cancer background evaluate prognostic role tam patient affect non muscle invasive bladder cancer nmibc undergo trans urethral resection bladder turb bacillus calmette guerin bcg therapy method datum patient man woman mean age year year treat nmibc turb bcg instillation collect two different group consider group group without bladder cancer recurrence correlation immunofluorescence measure mtot infiltration clinicopathological parameter evaluate use spearman mann whitney method recurrence free survival rate calculate use kaplan meier method result cd positive cell mtot observe specimen test high mtot infiltration observe patient disease recurrence even endovescical bcg instillation significant value infiltration p find calculate significativity two group median bcg therapy p p observe correlate median mtot two group patient respectively value p p p correlation dfs mtot median patient endovescical bcg instillation calculate respectively compare dfs mtot median patient group endovescical bcg instillation significant value obtain p p p respectively conclusion tumor infiltration can prognostic value recurrence patient nmibc localization avidin superficial bladder cancer potentially new approach radionuclide therapy objective verify whether native avidin make radioactive bind technetium label biotin mtc biotin selectively accumulate superficial tumor tissue follow intravesical administration methodology total fifteen patient transitional cell bladder cancer instill intravesically radiolabeled avidin cold biopsy obtain macroscopically normal tumor tissue transurethral resection tur radioactivity sample measure result increase accumulation radiolabeled avidin observe tumor tissue compare normal bladder tissue case remarkably high quotient uptake q tumor versus normal tissue determine three patient instill deglycosylated avidin neutral pi serve control show no significant uptake either tumor normal urothelium no difference relative uptake q conclusion pilot study indicate intravesical administration radiolabeled avidin result preferential accumulation tumor tissue compare normal urothelium instillation radiolabeled avidin warrant investigation order explore possibility treat superficial bladder neoplasm locally replace mtc high energy beta emit radionuclide associate biotin adjuvant chemotherapy bladder cancer not alter cancer specific survival cystectomy match case control study objective assess effect adjuvant chemotherapy acht methotrexate vinblastine adriamycin cisplatin mvac gemcitabine cisplatin gc rate cancer specific survival overall survival benefit acht radical cystectomy rc bladder cancer controversial patient method within study group patient treat rc identify high risk progression due pt pt pn stage receive acht mvac gc patient match remain patient unexposed acht exact match make pt stage tumour grade pn stage lymphovascular invasion age year year surgery year calliper match match result patient treat rc acht treat rc alone kaplan meier life table cox regression analysis use assess cancer specific overall survival result no statistically significant difference cancer specific survival probability year rc two group relative risk p also no difference overall survival year p multivariable analysis delivery adjuvant chemotherapy not independent predictor survival endpoint p cancer specific overall survival conclusion match gfp image analysis mouse orthotopic bladder cancer model precise objective measurement tumor response yet standardize mouse orthotopic bladder cancer model study use image analysis green fluorescent protein gfp objectively measure tumor size response chemotherapy ku human bladder cancer cell transfect gfp intravesically inoculate week old female nude mouse fourteen day tumor cell inoculation mouse assign control pbs group doxorubicin conc mg ml treatment group receive single instillation treatment fourteen day treatment bladder surgically expose fluorescent image capture late analyze use image analysis bladder process histological examination tumor incidence determine gfp expression histology respectively doxorubicin treatment group fold histology vs fold gfp expression difference tumor regression measure tumor area p fold histology vs fold gfp expression difference tumor regression measure percent tumor area bladder p observe doxorubicin treatment group finding suggest use image analysis provide precise sensitive objective mean measure tumor growth treatment response mouse orthotopic bladder cancer model lieu histological method consequently numb mouse require experiment reduce since tissue sample not need histology thus make tissue sample readily available additional assay labor effective cost effective manner minimally invasive radical cystectomy bladder cancer effectiveness intravesical therapy bacillus calmette guerin treatment superficial bladder cancer good establish however no consensus optimum regimen administer bcg maintenance therapy patient result complication address plasma urine dna level relate microscopic hematuria patient bladder urothelial carcinoma objective increase cell free dna observe plasma many cancer patient major biomarker use differentiate patient malignant neoplasm benign neoplasm healthy patient depend characteristic tumor qualitative variation circulate preemptive neoadjuvant chemotherapy analysis eligibility criterium prognostic factor tumor stage different trial provide valid useful comparison objective evaluate association lymphovascular invasion lvi oncologic outcome squamous cell carcinoma scc urinary bladder follow radical cystectomy rc patient method perform retrospective analysis patient undergo rc invasive bladder cancer mansoura egypt patient pure urothelial carcinoma bladder ucb scc pathology include use multivariate cox regression analysis kaplan meier analysis prognostic significance lvi disease free survival cancer specific survival evaluate patient ucb scc result cohort include patient ucb scc median patient age follow year month respectively median numb lymph node ln retrieve lvi present patient ucb vs scc p lvi independent predictor oncologic outcome ucb scc group however lvi prognostic significance scc ln negative lvi positive lvi ln patient scc high risk recurrence cancer specific mortality compare ln positive lvi negative lvi ln patient scc hazard ratio vs hazard ratio vs respectively conclusion presence lvi independent predictor poor oncologic outcome rc great prognostic significance patient scc compare ucb bcg vaccine superficial bladder cancer objective purpose study prospectively investigate value standardize f fluorodeoxyglucose f fdg pet compute tomography ct protocol image primary bladder cancer use standardize bladder flush fill method include patient ct bladder cancer foley catheter insert f fdg injection pet ct image perform accord four bladder protocol bladder empty bladder empty flush bladder fill ml saline bladder fill ml saline tumour visibility assess compare histopathology ct cystoscopy result procedure successfully complete patient reference standard reveal bladder tumour patient sensitivity protocol confidence interval ci compare ci protocol conclusion flush subsequent retrograde fill bladder result high rate tumour visualization quantification flush alone inferior growth inhibitory effect p adenovirus human bladder cancer cell purpose evaluate whether p waf cip consider potential candidate human bladder cancer gene therapy determine basal level p expression bladder cancer cell line response bladder cancer cell increase p expression follow p adenovirus infection mechanism growth inhibition produce p overexpression material method five establish human bladder cancer cell line one primary culture derive invasive transitional cell carcinoma use study examine effect p protein growth human bladder cancer cell recombinant adenovirus vector system contain p cdna control cytomegalovirus promoter construct control virus contain p antisense orientation use eliminate potential artifact cause viral toxicity result human bladder cancer cell line exhibit variable endogenous p level correlate vitro growth status significant highly variable increase steady state level p detect p adenovirus infect cell human bladder cancer cell line respond heterogeneously p adenovirus infection growth wh cell line substantially inhibit dose time course dependent fashion mechanism p growth inhibition find due g g arrest not induction apoptosis contrast p adenovirus fail inhibit growth bladder cancer cell cell resistant viral infection j bladder cancer cell exhibit mark sensitivity adenovirus substantial growth inhibition see sense antisense p early time course infection conclusion find significant variation basal level p protein expression several human bladder cancer cell line increase p expression result adenoviral infection may potent growth suppressor human bladder cancer elicit cell cycle arrest g g stage not induction apoptosis bladder cancer cell exhibit wide spectrum sensitivity adenoviral infection may cause presence viral receptor heterogeneity wide spectrum sensitivity significant basic scientific clinical implication warrant study evaluation diagnostic strategy bladder cancer use compute tomography ct urography flexible cystoscopy void urine cytology result patient hospital haematuria clinic study type subject study add haematuria clinic day image flexible cystoscopy efficient way investigate patient haematuria principal role haematuria clinic reference bladder cancer determine patient normal may discharge patient abnormal undergo rigid cystoscopy good recognise ct urography offer thorough evaluation upper urinary tract stone renal masse urothelial neoplasm role ct urography diagnose bladder cancer little certain aim present study evaluate diagnostic accuracy ct urography patient visible haematuria age year determine ct urography role diagnose bladder cancer study show optimum diagnostic strategy investigate patient visible haematuria age year infection exclude combine strategy use ct urography flexible cystoscopy patient positive bladder cancer ct urography refer directly rigid cystoscopy avoid flexible cystoscopy numb flexible cystoscopy require therefore may reduce present study also show diagnostic accuracy void urine cytology low justify continue use haematuria clinic use ct urography flexible cystoscopy objective evaluate compare diagnostic accuracy compute tomography ct urography flexible cystoscopy void urine cytology diagnose bladder cancer evaluate diagnostic strategy use ct urography additional test ii replacement test iii triage test diagnose bladder cancer patient refer hospital haematuria rapid diagnosis clinic patient method clinical cohort consist consecutive series patient refer hospital haematuria rapid diagnosis clinic march december criterium referral little one episode macroscopic haematuria age year urinary tract infection exclude patient technically adequate ct urography flexible cystoscopy examination analysis day patient undergo examination clinical nurse specialist follow void urine cytology ct urography flexible cystoscopy void urine cytology score use point system ct urography report immediately uroradiologist flexible cystoscopy perform urologist examination score use point system normal equivocal positive bladder cancer reference standard consist review hospital image histopathology database december patient report medical note refer rigid cystoscopy follow month result prevalence bladder cancer clinical cohort diagnostic strategy use ct urography additional test diagnose bladder cancer score classify negative score positive sensitivity confidence interval ci specificity ci positive predictive value ppv ci negative predictive value npv ci diagnostic strategy use ct urography replacement test flexible cystoscopy diagnose bladder cancer score classify negative score positive sensitivity ci specificity ci ppv ci npv ci similarly use flexible cystoscopy diagnose bladder cancer score classify negative score positive sensitivity ci specificity ci ppv ci npv ci diagnostic strategy use ct urography flexible cystoscopy triage test rigid cystoscopy follow option patient positive ct urography score refer directly rigid cystoscopy patient equivocal normal score refer flexible cystoscopy sensitivity ci specificity ci ppv ci npv ci diagnostic strategy use ct urography flexible cystoscopy triage test rigid cystoscopy follow option patient positive ct urography score refer directly rigid cystoscopy patient equivocal score refer flexible cystoscopy patient normal score undergo clinical follow sensitivity ci case adenocarcinoma occur bladder mucosa surgical operation colovesical fistula report case adenocarcinoma occur bladder mucosa year surgical operation colovesical fistula due colonic diverticulitis sigmoid colon patient year old woman undergo sigmoidectomy ligation colovesical fistula age year present complaint gross hematuria cystoscopy compute tomography reveal bladder cancer site original colovesical fistula surgery undergo transurethral resection bladder tumor histopathological finding reveal intestinal adenocarcinoma urinary bladder radical partial cystectomy subsequently perform positive involve margin tumor may originate bladder mucosa replace intestinal metaplastic cell originate initiate event specific relative detection urinary microrna signature bladder cancer point care diagnostics present dual isothermal cascade strategy assist lateral flow peptide nucleic acid biosensor point care detection urinary micrornas without temperature protocol complex instrument propose assay expect great promise bladder cancer diagnosis point care diagnostics high risk adverse pathologic feature patient clinical high grade bladder cancer undergo radical cystectomy background radical cystectomy rc use treat select patient prolidase activity oxidative stress nitric oxide level bladder tissue without tumor patient bladder cancer study design evaluate malondialdehyde mda glutathione gsh nitric oxide no level also prolidase glutathione peroxidase gsh px superoxide dismutase sod enzyme activity malignant benign cancer bladder tissue total patient admit clinic due microscopic macroscopic haematuria prospectively include study reason no request participate study inability reach malignancy alcohol consumption metabolic disease eight patient exclude study patient bladder tumor patient patient without cancer bladder tissue sample obtain patient anesthesia spinal epidural general measurement mda gsh no level prolidase gsh px sod enzyme activity among patient bladder cancer patient female patient male average age among patient without tumor patient female patient male average age patient bladder tumor oxidant mda no prolidase high antioxidant sod gsh gsh px low patient without tumor conclude oxygen free radical play role etiology bladder cancer similar many tumor inflammatory condition therefore assume antioxidant may provide benefit prevention treatment bladder cancer benchmark achieve delivery radiation therapy muscle invasive bladder cancer radiation therapy multifaceted role treatment muscle invasive bladder cancer component bladder spare regimen adjuvant therapy patient partial cystectomy palliative treatment patient metastatic disease review technique currently use setting technique apply advance image radiation delivery allow definition precise treatment volume permit delivery high tumor dose lesser dose critical target well tumor control few therapeutic complication well quality life outcome anticipate unite state rapidly grow use radiation treatment bladder cancer component selective bladder conservation use trimodality therapy consist maximal transurethral resection follow concurrent chemotherapy radiation careful cystoscopic surveillance experience urologist ensure prompt cystectomy fist sign treatment failure majority patient retain good function bladder no survival decrement radiation therapy also use adjuvant therapy partial cystectomy select patient set decrease risk local incisional recurrence also use patient pelvic recurrence cystectomy often combine concurrent chemotherapy radiation effective palliative agent patient locally advance metastatic disease palliate bleed pain patient local progression alleviate pain bony metastasis prognostic predictive factor patient treat chemotherapy advance urothelial cancer stand standard care patient local advance metastatic urothelial carcinoma chemotherapy however result rather disappoint validate prognostic factor biomarker tumor response useful decision make process still lack pubmed database search article publish november several promise clinical biological candidate prognostic factor marker tumor response \\ufeff1 2 line therapy hemoglobin performance status visceral metastasis ercc hent emt marker identify describe article summary clinical parameter molecular profile can revolutionize management local advance metastatic urothelial cancer improvement individualize therapeutic approach still seem distant treatment bacillus calmette guerin refractory non muscle invasive bladder cancer treatment option patient non muscle invasive bladder cancer nmibc refractory intravesical bacillus calmette guerin bcg therapy review article base recent publish literature although intravesical bcg well bladder spare treatment option nmibc prevent recurrence progression case refractory treatment point radical cystectomy standard treatment choice option not feasible intravesical chemotherapy docetaxel gemcitabine combination bcg interferon inf device assist intravesical strategy mitomycin emda chemohyperthermia candidate treatment editorial comment dr kobayashi renal function bladder preserve therapy patient muscle invasive bladder cancer result selective bladder preserve tetramodality therapy consist maximal transurethral resection induction chemoradiotherapy partial cystectomy objective evaluate possible association occupational exposure risk factor male bladder cancer negev region southern israel enable preventive strategy apply method total male bladder cancer patient diagnose regional medical center study interview compare male without oncological disease match age country origin special questionnaire develope gather information demography life time occupational history smoke habit coffee consumption health status statistical analysis case referent datum do use spss package performance chi square test conditional logistic regression multiple classification analysis result significant association find bladder cancer occurrence three different group occupational exposure solvent p not compute due lack expose person among referent b dust p c exposure multiple chemical p nephrolithiasis p cigarette smoke p conclusion certain type occupational exposure different aromatic amine dye may consider contribute factor epidemiology bladder cancer well identification chemical work process use may help abate exposure thus lead reduction risk relatively common cancer bladder cancer risk personal hair dye use several cohort case control study find increase risk bladder cancer among hairdresser barber occupationally expose hair dye however carcinogenic risk associate personal use hair dye remain uncertain since several large case control cohort study not find association personal hair dye use bladder cancer address question author use datum collect bladder cancer case control interview part case control study conduct new hampshire participant undergo structure personal interview regard history hair dye use bladder cancer risk factor unconditional logistic regression analysis use compute odd ratio associate hair dye use control potential confound factor history hair dye use inversely associate bladder cancer incidence man adjust odd ratio confidence interval ci although risk reduction not statistically significant individual dye type woman use permanent adjust ci rinse type hair dye adjust ci associate modestly elevate risk bladder cancer limit statistical precision no association find use semi permanent dye adjust ci permanent hair dye use odd ratio pronounce young age \\ufeff1 use high frequency prolong time since \\ufeff1 use however no clear trend risk factor light prevalence hair dye use study need address effect specific color type hair dye along possible role individual susceptibility high grade urothelial bladder cancer child case report critical analysis literature background bladder cancer relatively common adult child extremely rare majority case low grade low stage urothelial cancer find case report describe diagnostic therapeutic follow management bladder cancer year old boy examine painless hematuria transurethral resection tumor perform high grade urothelial cancer osseous metaplasia find definitive specimen year follow no recurrence typical characteristic prevalent bladder tumor present conclusion despite low incidence low prevalence bladder cancer child serious condition must not miss differential diagnosis hematuria urinary tract infection vital differentiate urothelial cancer hamartoma nephrogenic adenoma particularly osseous metaplasia sarcomatoid carcinoma especially intravesical bacillus calmette gu rin therapy prevent tumor progression death superficial bladder cancer ten year follow prospective randomize trial purpose superficial bladder tumor stage ta this may progress invade bladder muscle cause death metastatic cancer transurethral tumor resection turb standard therapy tumor surgery alone may not prevent tumor progression intravesical therapy widely use adjunct turb bacillus calmette gu rin bcg active intravesical agent whether bcg prevent tumor progression death bladder cancer unknown patient method high risk patient superficial bladder cancer randomly assign receive either turb n turb plus bcg n adverse tumor feature progression equally distribute two group bcg administer weekly week patient evaluate every month thereafter progression muscle invasion metastasis control turb patient recurrent superficial tumor eligible crossover bcg arm patient monitor event minimum year range result year progression free rate confidence interval ci patient treat bcg ci control patient median progression free interval not reach bcg group month control group p control patient cross bcg median month not show tumor progression turb plus bcg result year disease specific survival rate compare turb alone p conclusion study show intravesical therapy bcg delay tumor progression death tumor patient present superficial bladder cancer epidemiology bladder cancer urinary bladder cancer mortality vary different country high rate note denmark uk belgium italy low rate japan singapore venezuela mortality rate increase male female france high rate observe south france contrary cancer site high incidence rate observe europe usa country africa area rate high male increase time mortality high \\ufeff1 year diagnosis five year relative survival rate male female tobacco especially cigarette good know risk factor dose effect relation appear exist occupational risk factor potentiate tobacco modification note relation new factor grind coffee associate urinary bladder cancer appear co carcinogenic factor tobacco drug antimitotics phenacetin radiation urinary bilharziosis etiological factor cancer role artificial sweetener alcohol nutrition little good document bladder cancer nonagenarians multicentre study patient objective investigate oncological outcome nonagenarians bladder cancer substantial rise bladder cancer old old age group upcoming decade expect due demographic change peak incidence around age year paucity datum nonagenarians prompt us investigate outcome patient patient method retrospective multicentre study design assess patient demographics tumour pattern treatment strategy outcome patient age year treat participate centre patient enter either de novo recurrent cancer study period range result total patient mean range age year recruit american society anesthesiologist physical status classification asa score distribution follow ii iii iv male female ratio median range follow month patient de novo cancer diagnosis histological finding reveal pta n pt n pt n overall patient no recurrence one two pta tumour n recur patient pt tumour n pt tumour n six median overall survival os month patient pta tumour month pt tumour month pt tumour overall mortality rate patient pta tumour pt tumour pt tumour asa score also strong influence median os stratification asa score ii month iii month iv month conclusion nonagenarians bladder tumour pta pt pt stage almost evenly distribute two third patient no recurrence transurethral resection bladder mean os year month pt tumour case series patient specific age group require identify well management increase proportion patient bladder tumour intravesical prevention recurrence superficial urinary bladder cancer bcg klh prospective randomize study prospective randomize trial intravesical prophylaxis recurrence superficial bladder cancer bcg versus klh perform patient evaluable mean observation period month month patient klh patient bcg group develope recurrent bladder tumour recurrence rate accord eortc klh group versus bcg group among bcg treat patient cystitis fever whereas patient treat klh cystitis bcg highly effective prophylactic recurrence superficial bladder cancer intravesical instillation therapy klh slight prophylactic effect treatment start week postoperatively hbo promote cell proliferation bladder cancer via activation wnt catenin signal histone acetyltransferase bind orc hbo histone acetyltransferase recently identify oncoprotein however role bladder cancer remain unknown study show hbo highly express mrna protein level bladder cancer hbo expression associate clinical feature human bladder cancer include tumor size p p classification patient high hbo expression short recurrence free survival time whereas patient low hbo expression well survival time moreover find ectopic overexpression hbo promote whereas hbo silence inhibit tumor growth bladder cancer cell vitro vivo demonstrate upregulation hbo activate wnt catenin signal pathway lead nuclear localization catenin upregulation downstream target wnt catenin signal finding suggest hbo play key role progression bladder cancer via wnt catenin pathway may serve potential therapeutic target treatment bladder cancer primary intestinal derive adenocarcinoma intestine bladder substitute case report intestinal primary intestine derive adenocarcinoma bladder substitute intestine rare long term complication complete urethral reconstruction bladder probability occurrence low however recent year prove objective rare literature diagnosis treatment method article describe case cystectomy studer ileal conduit peking university 3 hospital due bladder cancer year discover primary intestinal derive adenocarcinoma bladder substitute intestine male patient year old persistent abdominal pain low abdomen two week carrion like material urine no gross hematuria no urinary frequency urgency dysuria no abnormality examination urinary ct show intestinal metaplasia bladder cm cm cm irregular tissue shadow ureteroscopy find right side bladder tumor whose diameter cm perform open lumpectomy repair bladder postoperative pathology show middle high differentiate adenocarcinoma patient recover good surgery article review similar intestinal primary intestine derive adenocarcinoma bladder substitute intestine find high incidence elderly male population pathogenetic factor closely relate smoke patient develope hematuria carrion like substance urine bladder irritation possibility tumor development suspect patient promptly take test urine exfoliation cytology urine fish urinary system b ultrasound cystoscopy etc microscope direct observation lesion site examination pathological tumor occur tumor immediately remove new urinary diversion need avoid progress tumor postoperative smoke strictly prohibit also patient strictly control eat habit regularly adhere follow little year lifelong follow review must mechanism intestinal primary intestine derive adenocarcinoma bladder substitute intestine still unclear study suggest may relate n nitroso compound smoke postoperative inflammatory reaction bladder cancer mortality diabetic relation saccharin consumption smoke habit frequency diabetes mellitus mention death certificate patient dye bladder cancer compare patient dye cancer exclude cancer lung pancreas estimate relative risk bladder cancer diabetic confidence limit no increase risk bladder cancer patient diabetes long duration diabetic show questionnaire consume substantially saccharin non diabetic duration regular saccharin use diabetic highly correlate duration diabetes therefore no evidence study consumption average amount saccharin lead bladder cancer diabetic proporation current smoker among diabetic significantly little among non diabetic may account low relative risk lung cancer former impact cyclin overexpression prognosis bladder cancer background evaluate relationship cyclin overexpression bladder cancer prognosis method systematic literature search july carry pubmed wanfang database reference retrieve article screen hazard ratio hr cis use combine datum heterogeneity publication bias also evaluate result total study contain case include find increase cyclin level significantly correlate progression free survival pool hr estimate ci significant degree heterogeneity p moreover subgroup analysis indicate elevate cyclin level significantly associate overall survival muscle invasive bladder patient hr ci without significant heterogeneity datum p conclusion increase cyclin expression level detect immunohistochemistry associate good progression free survival bladder cancer limit numb study good design prospective study warrant confirm finding study recent advance immunobiology human bladder cancer bladder cancer heterogeneous disease pose unique challenge treat clinician limit relatively indolent papillary tumor low potential progression beyond stage muscle invasive disease prone distant metastasis former well treat conservatively possible whereas latter require aggressive surgical intervention adjuvant therapy order provide well clinical outcome risk stratification traditionally use clinicopathologic feature disease provide prognostic information assist choose well therapy individual patient bladder cancer inform decision regard type intravesical therapy appropriate non muscle invasive disease whether not administer neoadjuvant chemotherapy prior radical cystectomy recently tumor genetic sequence datum marry clinical outcome datum add sophistication personalization next generation risk classification likely see inclusion molecular subtyping specific treatment consideration base tumor mutational profile compare safety efficiency conventional monopolar plasmakinetic holmium laser transurethral resection primary non muscle invasive bladder cancer purpose compare safety efficiency conventional monopolar plasmakinetic holmium laser transurethral resection bladder tumor cm turbt pk turbt hol turbt manage primary non muscle invasive bladder cancer patient method patient primary non muscle invasive bladder cancer undergo endoscopic surgery among patient undergo cm turbt patient undergo pk turbt patient undergo hol turbt patient divide three risk group low intermediate high base european association urology guideline prognostic factor recurrence clinical datum include preoperative operative postoperative management follow record result patient demographics tumor characteristic three group compare surgery no significant difference operative duration among three group compare cm turbt group pk turbt hol turbt group little intraoperative postoperative complication include obturator nerve reflex bladder perforation good bleed postoperative bladder irritation no significant difference among three group transfusion rate occurrence urethral stricture patient pk turbt hol turbt group little catheterization hospitalization time cm turbt group no significant difference risk subgroup good overall recurrence rate among cm turbt pk turbt hol turbt group conclusion pk turbt hol turbt may prove preferable alternative cm turbt management non muscle invasive bladder cancer pk turbt hol turbt however not demonstrate obvious advantage cm turbt tumor recurrence rate toward personalize guideline bladder cancer bladder cancer incidence high old man show geographic variation mostly environmental disease cigarette smoke occupational exposure water arsenic schistosoma haematobium infestation medication well establish risk factor low penetrance genetic factor also contribute origin interaction environmental factor bladder cancer high prevalence low mortality largely chronic disease datum environmental genetic factor involve disease outcome inconclusive effect agent inhibit cellular iron incorporation bladder cancer cell proliferation agent interfere cellular iron fe incorporation inhibit tumor cell proliferation include metal bind transferrin tf gallium ga indium fe chelators desferrioxamine dfo ga nitrate effective treatment metastatic bladder cancer patient exhibit evidence interference fe metabolism show bladder cancer cell proliferation vitro dependent tf fe concentration dfo readily achieve vivo inhibit cellular proliferation even presence physiologic concentration tf fe inhibition proliferation tf ga associate decrease cellular fe incorporation however physiologic concentration tf fe add equimolar concentration tf ga significant fe incorporation evident despite inhibition proliferation thus besides interference fe incorporation ga may also interfere intracellular fe distribution directly inhibit fe non fe require process necessary cellular proliferation dfo follow sequentially tf ga result mark potentiation inhibition proliferation effect combination appear relate interference fe metabolism increase ga uptake sequential combination may useful treatment bladder cancer bladder cancer advocate early cystectomy improve oncologic control evaluate patient various stage bladder carcinoma determine alteration monocyte function since monocyte play important role effector arm immune system defective function may explain host inability destroy neoplastic cell group patient demonstrate defective monocyte monocyte function no correlation tumor stage degree chemotactic defect patient invasive carcinoma significant return monocyte chemotactic response toward normal postoperatively p little monocyte function improve also patient receive bacillus calmette guerin immunotherapy p little quality care patient newly diagnose bladder cancer prospective assessment northern germany introduction aim study evaluate current quality care newly diagnose bladder cancer patient regional representative sample german urologist material method use standardize questionnaire clinical pathological datum patient newly diagnose urothelial carcinoma bladder ucb january december collect urology health care practitioner northern germany diagnostic therapeutic decision not influence specific protocol finding represent current regional practice pattern result complete datum patient available analysis median patient age diagnosis year range year male female ratio main reason transurethral resection bladder turb microhematuria conspicuous ultrasound finding gross hematuria use photodynamic diagnosis pdd turb perform patient result histopathology show papillary urothelial neoplasm low malignant potential punlmp patient pta ptis pt pt bladder cancer patient multiple tumor record patient repeat turb perform patient median day residual tumor tissue find patient immediate postoperative instillation chemotherapy perform patient adjuvant intravesical maintenance therapy perform patient mitomycin vs bcg patient treat repeat turb adjuvant instillation therapy likely high tumor stage grade p value overall patient experience disease recurrence within month low tumor stage grade performance repeat turb administration adjuvant intravesical therapy associate reduce early disease recurrence p value conclusion current study present contemporary finding practice pattern patient newly diagnose bladder cancer interestingly rate immediate postoperative instillation chemotherapy maintenance intravesical therapy low expect utilization pdd turb still underrepresent remarkable high numb patient residual tumor repeat turb difference patient counsel hospital practice standard compliance factor likely contribute variation guideline adherence identification urinary gc globulin novel biomarker bladder cancer two dimensional fluorescent differential gel electrophoresis dige improve early detection rate surveillance bladder cancer remain great challenge medicine identify sixteen protein include gc globulin gc urine bladder cancer patient normal control two dimensional fluorescent differential gel electrophoresis dige matrix assist laser desorption time flight mass spectrometry maldi tof tof ms bioinformatics analysis indicate gc play important role regulation growth apoptosis death epidermal growth factor receptor activity gc expression pattern urine tissue case control quantify western blot immunohistochemical stain enzyme link immunosorbent assay elisa elisa quantification correct creatinine expression show gc cr significantly increase bladder cancer patient benign bladder damage case normal control versus ng mg respectively receiver operate characteristic roc analysis suggest ng mg urinary gc bladder cancer can detect sensitivity specificity ng mg sensitivity specificity can use detection infiltrate urothelial carcinoma bladder cancer take together identify gc potential novel urinary biomarker early detection surveillance bladder cancer meta analysis luminal basal subtype bladder cancer identification signature immunohistochemical marker clinical use background suggest bladder cancer divide two molecular subtype refer luminal basal distinct clinical behavior sensitivity chemotherapy aim validate subtype several clinical cohort identify signature immunohistochemical marker would permit simple cost effective classification disease primary care center method analyze genomic expression profile bladder cancer three cohort fresh freeze tumor sample md anderson n lund n cancer genome atla tcga n validate expression signature luminal basal subtype relate clinical follow datum also use md anderson cohort archival bladder tumor sample n parallel tissue microarray identify immunohistochemical marker permit molecular classification bladder cancer finding bladder cancer can assign two candidate intrinsic molecular subtype refer luminal basal dataset analyze luminal tumor characterize expression signature similar intermediate superficial layer normal urothelium show upregulation ppar target gene enrichment fgfr elf cdkn tsc mutation addition luminal tumor characterize overexpression e cadherin rab src basal tumor show expression signature similar basal layer normal urothelium show upregulation p target gene enrichment tp rb mutation overexpression cd cyclin b egfr survival analysis show muscle invasive basal bladder cancer aggressive compare luminal cancer immunohistochemical expression two marker luminal gata basal krt sufficient identify molecular subtype bladder cancer accuracy interpretation molecular subtype bladder cancer distinct clinical behavior sensitivity chemotherapy simple two marker immunohistochemical classifier use prognostic therapeutic stratification fund u national cancer institute national institute health pharmacotherapy bladder cancer practice prospect contrast us incidence mortality rate bladder cancer still increase european country despite fact new case diagnose early superficial tumour standard care superficial tumour consist cytoscopic electroresection tumour follow intravesical immunotherapy chemotherapy immunotherapy bacillus calmette guerin bcg prevent recurrence treat patient positive impact survival however approximately bcg refractory progressive tumour pharmacogenomics enable distinguish high risk patient clinical practice soon new immunotherapy approach bcg combine low dose interferon recombinant bcg strain promise approach need explore prospective trial use neoadjuvant adjuvant chemotherapy still controversial result recent trial neoadjuvant chemotherapy locally advance bladder tumour convince lead centre implement neoadjuvant chemotherapy select group patient far four drug methotrexate vinblastine doxorubicin cisplatin regimen widely use metastatic locally advance disease recently two drug combination gemcitabine cisplatin prove equally effective little toxic new chemotherapy test clinical trial include gemcitabine taxanes new drug interfere signal transduction individualisation establish investigational treatment option base molecular tumour characteristic p status probably future bladder cancer pharmacotherapy neovascularization benign malignant urinary bladder epithelial proliferative lesion rat observe situ scan electron microscopy autoradiography approximately year ago protocol urethra spare cystectomy orthotopic urinary diversion urethra female patient bladder cancer initiate several center long term datum regard oncological functional outcome subject review study regard relationship primary bladder cancer secondary urethral tumor woman reveal study low risk woman man study recent meta analysis incidence urethral tumor male female patient transitional cell cancer bladder anatomical functional study reveal smooth musculature find entire length female urethra rhabdosphincter important structure postoperative continence low pressure intestinal reservoir midportion urethra not touch urethra spare surgery recent study look oncological functional result woman orthotopic urinary diversion follow range one half month mean median month no perioperative mortality early late complication rate require secondary intervention patient patient alive patient disease free disease specific survival disease free survival estimate year no pelvic recurrence see patient tcc daytime continence nocturnal continence twelve patient unable empty bladder completely need form catheterization increase experience recent year confirm initial preliminary result show spare urethra cystectomy not compromise oncological outcome satisfactorily use orthotopic reconstruction low urinary tract diurnal nocturnal continence clean intermittent catheterization rate month justify use orthotopic neobladders procedure choice majority female patient bladder neoplasm study tryptophen metabolism patient bladder cancer bladder cancer highly heterogeneous neoplasm examine gene expression profile bladder cancer stage ta use expression microarray analysis bladder tumor differentially express gene find test significance threshold kegg pathway enrichment analysis use study signal pathway gene find gene can use molecular marker predict transition ta among overlap ta stage six gene regulate ta stage regulate stage anxa atp v b ctgf gem il ra lcp gene regulate ta stage regulate stage acpp gnl ripk rapgef zer another gene change relative expression level stage gene include col col fn itga lgals spp vim postn col may involve bladder cancer progression affect extracellular matrix receptor interaction focal adhesion cytokine cytokine receptor interaction neuroactive ligand receptor interaction calcium signal pathway associate bladder cancer progression ta stage variant histology role management prognosis nonmuscle invasive bladder cancer purpose review true clinical significance variant histology controversial diagnosis challenge especially set nonmuscle invasive nmi disease presence variant architecture nmi identify peroxisome proliferator activate receptor agonist bladder cancer lesson animal study article review available animal study possible link use peroxisome proliferator activate receptor ppar agonist bladder cancer discussion possible implication human carcinogenicity study suggest ppar agonist pioglitazone dual ppar agonist ragaglitazar muraglitazar naveglitazar may increase risk bladder cancer dose responsive pattern rat interest bladder cancer relate ppar agonist show remarkable species sex specificity predilection occur ventral dome bladder rodent male rat treat pioglitazone muraglitazar high propensity develop bladder cancer female rat mouse sex not develop bladder cancer even expose high dose direct genotoxicity cytotoxicity ppar agonist unlikely mode action parent compound metabolite ppar agonist neither mutagenic genotoxic rarely excrete urine receptor mediate ppar effect not exclude suggest urolithiasis hypothesis refer formation urinary solid calculus subsequently cause bladder necrosis regenerative proliferation hypertrophy cancer however whether animal finding can human relevance not yet fully understand argue urolithiasis induce bladder cancer may rat specific would probably not applicable human effect increase urinary growth factor induce ppar agonist also propose require investigation fully clarify balance risk benefit use pioglitazone approve oral antidiabetic agent recently link increase not yet confirm risk bladder cancer human justify individual use diagnostic significance micrornas novel biomarker bladder cancer background previous study reveal importance micrornas mirnas function biomarker diagnose human bladder cancer bc however result discordant consequently possibility mirnas bc biomarker summarize meta analysis method study relevant article systematically search cbm pubmed embase chinese national knowledge infrastructure cnki bivariate model use calculate pool diagnostic parameter summary receiver operator characteristic sroc curve meta analysis thereby estimate whole predictive performance stata software use whole analysis result thirty one study article include case control explore functional replacement bladder urethra cystectomy bladder cancer female patient purpose evaluate long term experience combine modality treatment selective bladder preservation identify factor may predict treatment response risk relapse survival patient method patient bladder cancer high risk n n treat radiotherapy rt n radiochemotherapy rct n transurethral resection tur tumor six week rt rct response evaluate restage tur case complete response cr patient observe regular interval case persistent recurrent invasive tumor salvage cystectomy recommend median follow month range month result cr achieve patient local control cr without muscle invasive relapse maintain patient year distant metastasis diagnose patient actuarial rate year ten year disease specific survival survivor preserve bladder early tumor stage complete tur important factor predict cr survival rct effective rt alone term cr survival salvage cystectomy local failure associate disease specific survival rate year cystectomy contract bladder restrict patient conclusion tur rct reasonable option patient seek alternative radical cystectomy ideal candidate early stage unifocal tumor complete tur accomplish non invasive molecular detection bladder cancer recurrence transitional cell carcinoma tcc common bladder tumor approximately bladder tcc superficial initial diagnosis high recurrence rate possible progression muscle invasive disease eventually indicate radical cystectomy establish feature tumor therefore reliable predictor tumor recurrence critical importance management superficial bladder tcc successful molecular diagnosis bladder cancer detect genetic lesion loss heterozygosity loh microsatellite instability msi cell exfoliate urine report several group include aim study evaluate predictive potential microsatellite analysis cell exfoliate urine detection superficial bladder tcc recurrence study caucasian patient confirm superficial bladder tcc pta pt initial diagnosis blood sample obtain every patient whereas urine sample collect cystoscopy initial follow match dnas blood urine subject microsatellite analysis blind fashion follow period range month tumor resection microsatellite analysis correctly identify primary tumor tumor recurrence interestingly enough tumor recurrence molecularly detect month cystoscopic evidence recurrent disease study demonstrate clearly not urine microsatellite analysis reliably detect superficial bladder tumor also reliable test detect predict tumor recurrence caucasian patient result warrant multicenter randomize trial neo adjuvant preliminary chemotherapy cancer bladder evaluation year survival rate bladder tumour invade muscle hence theoretical value neoadjuvant chemotherapy whose result show objective response various protocol use include cisplatin study report result neoadjuvant chemotherapy patient objective response rate among responder alive month one non responder alive month various study neoadjuvant chemotherapy bladder cancer invade muscle show interest result necessary continue study particularly phase iii trial compare local treatment alone neoadjuvant chemotherapy clinical application radioimmunoimaging mtc bdi diagnosis bladder cancer objective evaluate clinical application radioimmunoimaging rii mtc bdi diagnosis bladder cancer method patient bladder cancer normal bladder study rii perform hour intravesical administration mbq mtc bdi follow wash perfuse bladder ml pbs radioactivity ratio target background ct cb calculate result radiochemical purity mtc bdi great rii show radioactive accumulation area bladder cancer no radio active concentration normal bladder sensitivity specificity respectively assignment positive criterion ct cb no statistical difference sensitivity tumor diameter cm cm cm cm ct cb relate pathological grade g g tumor conclusion rii intravesical administration provide new noninvasive method diagnosis bladder cancer morphology nature tumor high sensitivity specificity may use early diagnosis bladder cancer follow surgery diagnosis situ tumor cigarette smoke bladder cancer epidemiological inquiry west yorkshire result give case control study bladder cancer west yorkshire aim study assess risk exist cigarette smoke unite kingdom also investigate dose response effect present study show \\ufeff1 time unite kingdom positive weak relationship cigarette smoke bladder cancer close examination datum regard effect show complex set relationship result quantity smoke period smoke take account dose response effect weakly demonstrate medium quantity cigarette smoke not present smoke cigarette long period no risk appear exist smoke filter cigarette result contrast similar study significance observation discuss prognostic significance deoxyribonucleic acid flow cytometry muscle invasive bladder carcinoma treat preoperative irradiation cystectomy deoxyribonucleic acid dna flow cytometry measurement perform nuclear suspension obtain paraffin embed biopsy patient stage bladder carcinoma patient treat preoperative radiotherapy cystectomy tumor diploid tetraploid aneuploid total tumor stemlines addition diploid cell post radiotherapy stage reduction absence muscle infiltration cystectomy specimen occur often tumor nondiploid stemline diploid tumor nondiploid tumor multiple stemlines year survival rate significantly poor patient diploid nondiploid tumor p although marginally retain multivariate analysis p clinical significance dna ploidy muscle infiltrate bladder cancer seem not evident show superficial bladder tumor may value select patient preoperative radiotherapy pilot trial vaccine base autologous dendritic cell load vitro tumor antigen treatment cancer urinary bladder dendritic cell dc potent antigen present cell control immune response mean interaction lymphocyte antitumor vaccine base dc produce mean patient dc culture load tumor antigen vitro provide mature antigen load dc able activate immune response pilot result trial efficacy antitumor vaccine treatment bladder cancer demonstrate perspective vaccine adjuvant mono combine treatment bladder cancer neoadjuvant phase ii study modify methotrexate vinblastine doxorubicin cisplatin muscle invasive bladder cancer objective current tumor node metastasis tnm stage system urothelial carcinoma bladder ucb base numb size large positive lymph node ln aggregate ln metastasis diameter alnmd may well reflect burden metastatic disease improve ability predict recurrence free rfs overall survival os method clinical characteristic follow information patient ln positive ucb treat radical cystectomy model use cox proportional hazard regression analysis predict os pathologic specimen retrospectively review single genitourinary pathologist unaware treatment outcome determine great dimension metastasis affect ln median follow survivor month result median os month median ln density median numb ln remove alnmd significant predictor rfs os adjust pathologic stage lymphovascular invasion ln density comorbidity extranodal extension adjust hr p even restrict analysis patient ln remove predictive accuracy model os contain alnmd superior one without parameter tnm stage system c index vs vs conclusion alnmd significant predictor rfs os adjust standard prognostic parameter among patient ln positive ucb may useful parameter include future predictive nomograms tnm stage system muc mucin tumour marker bladder cancer objective evaluate serum muc level high molecular weight glycoprotein upregulated abnormally glycosylated bladder cancer carcinoma patient variety stage grade transitional cell carcinoma tcc bladder assess potential tumour marker patient method blood sample take treatment patient tcc bladder control undergo cystoscopy benign condition serum muc level estimate enzyme link immunosorbent assay use c monoclonal antibody result patient tumour muc level normal range p patient tumour also significantly high muc level control overall sensitivity tumour upper limit normal define u ml specificity conclusion serum muc not useful tumour marker screen low sensitivity however muc level high advance disease serum muc level may useful disease monitor expression function sirt muscle invasive urothelial carcinoma bladder sirt member class iii histone deacetylase show inhibit glycolysis promote dna double strand break repair despite propose tumor suppressor role no significant difference sirt mrna level among normal bladder urothelium non muscle invasive muscle invasive urothelial carcinoma note two large bladder cancer gene expression dataset available oncomine therefore study expression function sirt muscle invasive urothelial carcinoma bladder immunohistochemistry study sirt radical cystectomy sample show dramatic decline sirt expression bladder cancer progress functional study bladder cancer cell line confirm role inhibit glycolysis cell proliferation reduce sirt sirna however not sensitize bladder cancer cell drug induce dna damage differential expression pattern sirt amongst different stage muscle invasive bladder cancer indicate little reliance glycolysis urothelial carcinoma invade deep bladder adjacent tissue association symptomatic versus asymptomatic recurrence survival bladder cancer background benefit surveillance curative cystectomy bladder cancer unproven may justify detection asymptomatic recurrence improve survival previous study show benefit surveillance may affect lead time length time bias material method conduct retrospective cohort study among cystectomy patient university pennsylvania patient follow accord standardize protocol classify accord asymptomatic symptomatic recurrence detection primary outcome cause mortality adjust cox regression model use assess effect mode recurrence survival time cystectomy model time recurrence model account lead length time result one hundred ninety seven patient recur asymptomatic symptomatic unknown relative patient asymptomatic recurrence patient symptomatic recurrence significantly increase risk death model hazard ratio hr confidence interval ci model hr ci low year overall survival time recurrence vs symptomatic patient diagnose recurrence median month asymptomatic patient yet median survival recurrence month little conclusion symptomatic recurrence associate wrong outcome asymptomatic recurrence not explain lead length time bias similar method account bias consider study cancer surveillance shorten surveillance interval may allow detection recurrence asymptomatic phase bladder cancer molecular genetic basis carcinogenesis transformation normal malignant cell multistep mechanism involve various alteration molecular genetic level molecular alteration occur spontaneously induce carcinogen e g naphthylamine component cigarette smoke one important carcinogen lead bladder tumor carcinogenesis report summarize important molecular genetic alteration bladder cancer malignancy generation bladder cancer cause accumulation various molecular change expression oncogene ras erbb egf receptor tumor suppressor gene rb p cell cycle gene p p dna repair gene alter mostly mutation chromosomal aberration loss heterozygosity chromosome p q show crucial event transition normal urothelium papillary transitional cell carcinoma p primarily involve development carcinoma situ consideration use urine marker bladder cancer background aim study present survival outcome identify prognostic factor patient undergo radical cystectomy rc urothelial bladder cancer ubc homogeneous surgery series patient method patient undergo rc ubc intent cure january december without neoadjuvant adjuvant treatment include retrospective study clinical histopathologic datum collect institutional review board approval obtain outcome interest day mortality dm rfs os univariable multivariable analysis perform median follow year result two hundred forty five patient include median age year range year dm rate patient year rfs os rate respectively total patient undergo lymph node ln dissection median numb remove positive lns respectively variable independently associate decrease os rfs tumor stage ln status addition positive soft tissue surgical margin stsm status independently associate decrease os ln positive patient presence extranodal extension ene associate decrease rfs vs p conclusion radical cystectomy ubc associate low perioperative mortality rate provide year disease control approximately two third patient independent prognostic factor include tumor stage ln status rfs os stsm status os presence ene ln positive patient univariably associate decrease rfs os suicide gene therapy chemically induce rat bladder tumor entail instillation adenoviral vector efficacy vivo gene therapy protocol make use adenoviral vector treatment bladder cancer examine bladder tumor induce rat oral administration bbn n butyl n hydroxybutyl nitrosamine histologically tumor resemble see human bladder cancer cell selectively transduce use adenoviral vector therapeutic protocol thus entail instillation adenoviral vector contain hsv tk suicide gene rat bladder follow regimen intraperitoneal ganciclovir gcv injection histological examination short term gcv regimen day reveal mark vacuolization tumor cell moreover tunel assay show cytotoxic reaction mediate apoptosis follow long term gcv regimen day tumor growth significantly inhibit glandular metaplasia observe \\ufeff1 report demonstrate efficacy vivo suicide gene therapy chemically induce transitional cell carcinoma like see human bladder cancer intravesical instillation already good establish clinical technique finding indicate strong potential incorporation new useful gene therapy aim treatment human bladder cancer surgical bladder preserve technique management muscle invasive bladder cancer purpose bladder preservation surgical strategy treatment invasive bladder cancer develope provide option patient medically unfit undergo radical extirpative surgery prefer conservative therapy limit disease purpose manuscript review available bladder preserve surgical technique treatment muscle invasive bladder cancer method perform thorough literature search determine available bladder preserve treatment muscle invasive bladder cancer good correspond outcome result available surgical strategy include radical transurethral resection tur without neoadjuvant chemotherapy partial cystectomy multi modal therapy patient selection critical determine patient safely offer bladder preservation therapy disease characteristic portend favorable outcome set bladder preservation include ct stage unifocal tumor absence carcinoma situ hydronephrosis complete tur several new technology include fluorescence cryoablation treatment incorporate exist treatment modality improve surgical precision margin ongoing study aim improve accuracy clinical stage refine patient selection improve clinical outcome conclusion surgical bladder preservation technique treatment invasive bladder cancer require careful long term follow prospective randomize study compare bladder spare treatment modality radical cystectomy need ultimately difficult accrue due variety factor cross national investigation diet bladder cancer existence large unexplained portion attributable risk mark variation bladder cancer rate globally stimulate interest role nutrition cancer urinary bladder cross national comparison study complete datum available country use stepwise regression follow general linear model age truncate year world standardise sex specific bladder cancer mortality rate regress array nutritional socioeconomic independent variable effort identify important predictor bladder cancer mortality separate principal component analysis use summarise nutritional socioeconomic ses variable stepwise analysis use food score express kcal day per caput oppose nutritional component total fat consistently enter model \\ufeff1 explain great share variability r male female general linear model fit include total fat tobacco alcohol three ses component comprise seven socioeconomic predictor two food category find significant stepwise model root tuber vegetable oil r value male rate female rate mean study factor account bladder cancer mortality man woman substitution nutritional component food result general linear model slightly high r value male female attenuate fat effect result discuss light biological plausibility primitive cancer gallbladder flow cytometric analysis do exfoliate urothelial cell control patient patient transitional cell carcinoma grade grade ii grade iii determination aneuploidy dna analysis not provide identification low grade tumor cell flow cytometric parameter cellular change cell size nuclear size nuclear cytoplasmic ratio cell refractivity may provide well identification low grade lesion controversial role play toll like receptor urinary bladder cancer systematic review introduction urinary bladder cancer ubc prevalent human cancer main mechanism lead eradication progression disease yet clarify toll like receptor tlr membrane receptor express either immune cell tumor cell review article aim clear main mechanism play tlr relate intracellular pathway outcome ubc method pubmed scopus google scholar database use search relate research article evaluate role play tlr relate intracellular pathway outcome ubc result collect information relate article reveal tlr either participate induction immune response ubc development malignancy limit investigation regard genetic variation tlr ubc discussion accord result seem tlr ligand interaction outcome dependent several factor include tlr ligand dose interaction tlr ligand immune cell tumor cell tlrs ligand interaction simultaneously intra cavity thermo chemotherapy bladder cancer clinical use nurse care cancer stem cell cscs associate occurrence metastasis human malignant tumor target cscs important strategy cancer prevention overcome drug resistance epigallocatechin gallate egcg bioactive polyphenol green tea study extensively beneficial effect various tumor include bladder cancer however mechanism underlie effect egcg bladder cscs remain poorly understand author investigate expression bladder cscs marker include cluster differentiation cd cd oct aldh nanog role effect egcg bladder cscs egcg inhibit bladder cancer tumorspheres downregulated stem cell marker suppress expression proliferation associate protein promote apoptosis bladder cscs effect egcg mediate sonic hedgehog signal pathway upregulation sonic hedgehog signal pathway component attenuate suppressive effect egcg take together result indicate egcg can important natural compound bladder cscs provide new insight effective molecular target bladder cscs tree model dependent copy numb change bladder cancer analyze comparative genomic hybridization datum collection bladder cancer tumor aim identify set copy numb aberration cnas tend occur together test base fisher exact test pair take account multiple test show strong dependency amongst several pair aberration include q p q q p p p p p p determine whether co occurrence cnas may characterize tumor subtype use two recently propose method construct tree model tumor progression construct tree model tumor tumor stage pt tumor stage pt tree model confirm non random event association different stage conclude combination large datum set tree model provide useful approach systematically identify tumor subgroup characterize single chromosomal aberration occupation tobacco risk factor urinary bladder cancer case control study among male female invasive bladder cancer patient great equal pt g pt equal numb age sex match superficial bladder cancer patient g g pta hospital control patient conduct order analyze influence occupation tobacco consumption patient admit department urology kyoto university hospital no significant risk factor among occupation bladder cancer except housewife female cigarette smoker sex high relative risk non smoker significant dose response relation observe increase cigarette consumption chemotherapy still use treat muscle invasive bladder cancer era immunotherapy background bladder cancer one common genitourinary cancer patient present invasive disease radical cystectomy standard treatment patient muscle invasive disease although local treatment curative patient develop distant metastasis optimal treatment high risk patient include local perioperative systemic therapy adjuvant neoadjuvant chemotherapy patient method perform review clinical trial metanalysis adjuvant treatment muscle invasive bladder cancer result datum single publish trial adjuvant chemotherapy ct not univocal several methodological problem find recent meta analysis individual patient datum ipd eligible publish unpublished trial find adjuvant chemotherapy administration provide significant survival disease free survival advantage two large multi center randomize trial go clarify role post operative ct conclusion trend favour adjuvant chemotherapy come trial review us metanalysis perform abc collaborative group however not clear yet patient may derive maximum benefit approach one may safety candidate defer treatment relapse incoming result eortc trial italian trial currently compare value early vs defer treatment patient high risk relapse probably provide adequate answer question outside clinical trial potential benefit adjuvant chemotherapy appropriately weight versus putative hazard decision make appropriately tailor individual patient accord aggressiveness disease presence comorbidity survivin role diagnosis prognosis treatment bladder cancer survivin belong family protein serve inhibitor apoptosis survivin inhibit apoptosis block activation effector caspase extrinsic intrinsic pathway apoptosis expression survivin demonstrate several malignant neoplasm generally associate adverse prognosis case bladder cancer survivin express neoplastic epithelium not uninvolved mucosa several study bladder cancer indicate may relationship survivin expression ultimate behavior carcinoma although exact nature relationship still not fully understand result study seem contradictory survivin differentially express bladder cancer not normal urothelium several study demonstrate efficacy urine test survivin diagnostic tool early detection bladder cancer survivin also suggest suitable target develope specific therapy local treatment bladder cancer encourage initial result thus survivin potentially significant protein crucial role diagnosis prognosis treatment bladder cancer report th symposium german association bladder cancer research annual symposium german research association bladder carcinoma dfbk organize february th th sseldorf \\ufeff1 day eight international guest speaker invite dfbk department urology heinrich heine university sseldorf present current state research bladder cancer bc topic genomic change molecular classification non muscle invasive muscle invasive bc prospect limit proteome technology urine diagnostics function chromatin regulator bladder carcinogenesis cellular reaction aneuploidy organoid technology biobanking good novel aspect immunotherapy bc 2 day dedicate new result idea dfbk member bc pathomechanisms diagnostics therapeutic approach importantly discussion development collaborative project additional information available http www forschungsverbund blasenkarzinom de evaluation survivin reverse transcriptase polymerase chain reaction noninvasive detection bladder cancer purpose survivin member inhibitor apoptosis gene family express common cancer investigate expression pattern survivin tumor patient bladder cancer assess diagnostic potential rt pcr detection survivin mrna urine material method rt pcr use analyze mrna expression survivin case bladder cancer include tcc scc adenocarcinoma match nontumor tissue urine specimen ml collect patient bladder cancer document transurethral resection biopsy nonbladder cancer urological disease healthy volunteer total rna extract urine sediment rt pcr perform survivin result survivin expression detect bladder cancer tissue contrast survivin not detectable normal urothelium specimen urinary survivin detect urine sample patient tcc scc adenocarcinoma overall sensitivity survivin mrna not detect healthy volunteer positive result obtain patient renal cell carcinoma hematuria contract bladder none urological disease overall specificity conclusion survivin mrna detection urine sediment use rt pcr show high sensitivity specificity bladder cancer may prove useful routine screen monitor patient clinical epidemiology nonurothelial bladder cancer analysis netherlands cancer registry purpose nonurothelial malignancy represent small fraction bladder malignancy little extensively study result sparse empirical datum tumor seek insight tumor characteristic survival material method datum obtain nationwide netherlands cancer registry patient tumor characteristic followup patient primary invasive great bladder tumor netherlands datum analyze use frequency table relative survival analysis do result identify patient invasive bladder cancer present nonurothelial carcinoma mean patient age range diagnosis adenocarcinoma soft tissue tumor year year diagnosis nonspecified tumor histological subtype common male except squamous cell carcinoma lymphoma muscle invasion see urothelial carcinoma case vs squamous cell carcinoma adenocarcinoma neuroendocrine tumor case respectively urothelial carcinoma squamous cell carcinoma adenocarcinoma woman present advance stage neuroendocrine group stage difference opposite survival analysis show year relative survival rate great urothelial carcinoma squamous cell carcinoma adenocarcinoma neuroendocrine tumor respectively conclusion patient nonurothelial carcinoma present advance stage overall wrong survival relative survival muscle invasive adenocarcinoma equal survival muscle invasive urothelial carcinoma stage ii iii disease case even well muscle invasive squamous cell carcinoma neuroendocrine tumor show wrong survival regardless stage pre treatment lymphocytopaenia adverse prognostic biomarker muscle invasive advance bladder cancer background pre treatment lymphocytopaenia may result cytokine secrete tumour microenvironment association aggressive tumour biology seek establish prognostic significance lymphocytopaenia muscle invasive advance bladder cancer patient method seventy four patient muscle invasive bladder cancer treat radical chemoradiotherapy patient advance bladder cancer treat palliative chemotherapy include study absolute lymphocyte count \\ufeff1 day treatment record invasive local systemic recurrence muscle invasive bladder cancer cohort cause mortality advance bladder cancer cohort define survival end point receiver operate characteristic roc curve analysis utilize determine cut define lymphocytopaenia muscle invasive bladder cancer cohort follow multivariable analysis model evaluate follow variable anaemia neutrophilia tumour stage hydronephrosis neoadjuvant chemotherapy subsequently lymphocytopaenia assess multivariable model advance bladder cancer cohort analyse follow prognostic variable neutrophilia anaemia performance status presence bone visceral metastasis analysis carry evaluate absolute lymphocyte count continuous variable result absolute lymphocyte count l determine cut roc curve analysis muscle invasive bladder cancer cohort multivariate analysis reveal lymphocytopaenia predictive inferior outcome cohort advance bladder cancer cohort lymphocytopaenia hazard ratio hr confidence interval ci p performance status hr ci p adverse prognostic factor binary variable multivariate model absolute lymphocyte count sole significant factor analyse continuous variable hr ci p conclusion pre treatment lymphocytopaenia independent adverse prognostic factor muscle invasive advance bladder cancer may manifestation cancer induce immune suppression drive tumour progression case human chorionic gonadotropin produce bladder cancer year old man consult hospital complain gross hematuria cystoscopy reveal nodular broad base cancer dome bladder patient initially treat transurethral resection bladder tumor since histological examination show grade transitional cell carcinoma contain giant cell positive beta human chorionic gonadotropin beta hcg make diagnosis beta hcg produce bladder cancer advance age poor general condition patient undergo partial cystectomy alone without adjuvant chemotherapy one month late chest x ray film reveal multiple lung metastasis develope paraplegia low extremity suggest spinal metastasis one month late bring hospital cardiopulmonary arrest well knowledge nd case report beta hcg produce bladder cancer japan mortality urologic cancer surgery impact non index case volume objective quantify degree overall urologic oncology volume either reduce enhance effect single procedure volume short term outcome urologic oncology surgery method urologic oncology procedure prostate kidney bladder cancer perform identify nationwide inpatient sample procedure specific volume urologic oncology volume exclude procedure interest determine cancer hospital multivariable logistic regression model construct measure independent effect urologic oncology volume non index procedure operative mortality prostatectomy cystectomy nephrectomy index procedure adjust patient hospital factor result unadjusted operative mortality prostatectomy cystectomy nephrectomy respectively prostatectomy cystectomy magnitude volume mortality association reduce adjust non index urologic oncology case volume example relationship surgical volume mortality reduce radical prostatectomy radical cystectomy conclusion volume outcome effect index urologic oncology procedure modify experience non index specialty relate procedure effort identify transferable effective process care focus subset high volume center importance serum urine cea determination diagnosis bladder cancer aim study evaluate clinical outcome achieve use preoperative intra arterial chemotherapy transurethral resection bladder tumor bladder preservation therapy treatment muscle invasive bladder cancer patient clinical stage muscle invasive bladder cancer treat course preoperative cisplatin base intra arterial chemotherapy lectin diagnosis bladder carcinoma purpose study change expression glycoconjugate structure nonmalignant cancerous lesion urothelium lectin cona tka pna dba sta lfa uea mpa rca lca gsa sba gsa wga pha lot test formalin fix paraffin embed tissue section cold biopsy normal urothelium bladder cancer different grade g g human normal transitional epithelium n butyl n hydroxybutyl nitrosamine bbn induce bladder cancer animal experiment wistar rat human transitional cancer cell line ht human urothelium tka sba positive marker demonstrate positive stain reaction tumor grade without bind normal epithelium stain also human transitional carcinoma cell line ht g wistar rat dba cona lca sba gsa wga specific affinity bbn induce carcinoma finding positive lectin marker transitional cell cancer may offer progress diagnostics therapy annular rectal constriction due infiltration bladder cancer invasive bladder cancer frequently show lymphatic hematogenous metastasis furthermore aggressive local invasion adjacent structure also commonly observe however occurrence rectal stricture due infiltration bladder cancer relatively rare report three patient aggressive bladder cancer cause rectal obstruction criterium response neo adjuvant chemotherapy treatment invasive bladder cancer critical assessment paper address difficulty assessment response clinical trial pre emptive neo adjuvant chemotherapy bladder cancer attempt set guideline apply problem clear order real progress make field considerable attention must pay design appropriate trial innovation must test standard treatment date many phase ii pilot study effect report without clear determination result survival benefit compare standard treatment although discuss assessment response paper not forget no consensus response useful endpoint set randomize assessment role pre emptive intravenous cisplatin plus radiotherapy versus radiotherapy alone invasive bladder cancer carry west midlands australian bladder cancer study group response not regard important endpoint trial assess survival important index documentation toxicity secondary goal raghavan future phase iii trial address survival primary endpoint invasive bladder cancer selection primary treatment background modification resection technique may overcome obvious limitation conventionally perform transurethral resection e g tumor fragmentation bladder tumor provide easy patient treatment algorithm e g tumor vaporization objective present review article summarize current literature term en bloc resection technique histopathological quality complication rate oncological outcome material method separate datum search perform en bloc resection erbt n vaporization n bladder tumor result case erbt perform circumferential fashion alternatively erbt may perform undermine tumor base via antegrade application short energy impulse base high rate detrusor specimen erbt well histopathological quality assume significant difference perioperative complication rate not observe although obturator nerve base bladder perforation not see laser energy use nonstatistically significant trend towards low recurrence rate erbt group tumor vaporization may provide little invasive technique old patient recurrence low risk bladder cancer perform outpatient set conclusion erbt may provide well histopathological quality tumor vaporization perform health care system reimbursement adequate benzalkonium bromide new potential instillation drug bladder cancer hypothesis pilot study non muscle invasive urothelial carcinoma bladder high rate recurrence necessitate use variety adjuvant treatment single immediate post operative administration chemotherapy important measure reduce rate recurrence overall effect not satisfactory treatment burden patient hence need new effective cheap agent adjuvant treatment non muscle invasive bladder carcinoma although cationic surfactant benzalkonium salt use clinically hygienically control bacterial growth report cationic surfactant benzethonium chloride induce apoptosis normal cancerous cell report experience benzalkonium bromide bb accidentally administer patient bladder saline cause severe hematuria pain week persistent administration bladder patient cure support evidence cystoscopy indicate bb destroy bladder mucosa suggest bb maybe novel agent use single immediate post operative administration present preliminary datum support hypothesis provide discussion hope useful foundation experiment prepubic urethrectomy radical cystoprostatectomy objective muscle invasive bladder cancer risk develope urethral recurrence cystectomy vary especially ileal conduit perform reason author advocate urethrectomy indication center develope technique prepubic urethrectomy assess feasibility implication technique yr use patient method retrospectively analyze medical file consecutive male patient undergo urethrectomy simultaneously cystectomy invasive bladder cancer describe technique step step present possible technical difficulty complication urethrectomy result mean increase operative time prepubic urethrectomy cystoprostatectomy alone min range postoperative complication occur patient subcutaneous penile haematoma note four patient two need circumcision late scrotal haematoma see five patient two need surgical drainage three treat conservatively prepubic collection note one patient also treat conservatively no thromboembolic neurologic complication encounter conclusion urethrectomy indicate well perform use prepubic approach easy little identification gene expression pattern superficial invasive human bladder cancer objective study difference gene expression pattern invasive superficial human bladder cancer method cdna microarray use detect rna sample invasive superficial human bladder cancer sample normal bladder tissue control group obtain operation scanogram analyze apply image process software genepix pro obtain relevant datum gene finally analyze datum knowledge type gene characteristic human bladder cancer result gene remarkable difference sample superficial bladder cancer regulate regulate gene remarkable difference sample invasive bladder cancer regulate regulate numb regulate gene sample superficial bladder cancer two time regulate gene regulate gene metabolism cell signal transduction dna combination transcription protein translation synthesis development relate gene serum proteomic profile patient bladder cancer background despite continue research accurate bladder cancer biomarker analyte suffer lack sensitivity specificity objective search discriminate protein pattern serum use magnetic bead base separation follow matrix assist laser desorption ionization maldi time flight tof mass spectrometry ms identify patient bladder cancer design set participant total serum sample patient bladder cancer healthy control prostate cancer patient include study measurement serum sample fractionate mean surface activate magnetic bead subsequently analyze maldi tof ms multidimensional datum analysis do generate algorithm capable distinguish cancer patient healthy individual algorithm train use train set bladder cancer patient healthy control validate independent test set bladder cancer patient healthy control additionally prostate cancer sample use 3 test set result limitation train set patient bladder cancer can identify overall sensitivity specificity similar result can achieve test set show sensitivity specificity even presence low stage tumor can predict sensitivity can distinguish high stage grade tumor sensitivity distinction tumor stage however result low sensitivity value conclusion finding demonstrate screen serum protein pattern use maldi tof ms show high sensitivity specificity identify patient bladder cancer regardless tumor stage due high throughput capability identify differential protein panel may improve detection bladder cancer neoadjuvant chemotherapy management muscle invasive bladder cancer muscle invasive bladder cancer typically aggressive solid tumor propensity early systemic dissemination although radical cystectomy remain gold standard intervention high rate systemic failure prompt investigator evaluate various strategy attempt improve survival include early administration systemic chemotherapy effort provide mix result two recently complete trial provide conflict result strategy include attempt preserve bladder use combination limit surgical resection systemic chemotherapy radiotherapy review focus potential neoadjuvantly administer therapy impact management muscle invasive bladder cancer vitro vivo experimental model tool investigate efficacy antineoplastic drug urinary bladder cancer several drug show vitro vivo pharmacological activity urinary bladder cancer review aim compile different drug evaluate vitro vivo model urinary bladder cancer review advantage limitation type model good different methodology apply evaluate antineoplastic drug activity auxotrophic recombinant mycobacterium bovis bcg overexpress ag b enhance cytotoxicity superficial bladder cancer cell vitro bcg therapy remain forefront immunotherapy treat patient superficial bladder cancer high incidence local side effect presence non responder disease lead effort improve therapy hence propose auxotrophic recombinant bcg strain overexpress ag b bcg leud ag b can enhance cytotoxicity human bladder carcinoma cell line rbcg generate use expression plasmid encode mycobacterial antigen ag b transform bcg leud strain inhibitory effect bcg leud ag b cell determine mtt method morphology observation live dead assay gene expression profile apoptotic cell cycle relate oxidative stress relate gene investigate qrt pcr bax bcl p induction bcg leud ag b treatment evaluate western blot bcg leud ag b reveal superior cytotoxicity effect compare control strain use study result show expression level pro apoptotic cell cycle relate gene increase bcg leud ag b treatment whereas mrna level anti apoptotic gene decrease interestingly bcg leud ag b also increase mrna level antioxidant enzyme bladder cancer cell line bax p protein level increase follow treatment conclusion result suggest treatment bcg leud ag b enhance cytotoxicity superficial bladder cancer cell vitro therefore rbcg therapy may potential benefit treatment bladder cancer nf b inhibitor bay suppress tumor associate macrophage induce emt potential via mir nf b snail signal bladder cancer cell background chronic inflammatory microenvironment show play key role initiate tumorigenesis facilitate malignant progression primary tumor surround infiltrate tumor associate macrophage tam significantly promote epithelial mesenchymal transition emt distant metastasis urothelial bladder cancer method study aim explore potential target tam treatment malignant bladder cancer result \\ufeff1 find high numb tam cd pan macrophage marker clever macrophage marker associate high pt category grade cohort patient vitro assay show co culture tam promote metastatic potential htb regulate emt marker include snail vegf vimentin good oncogenic marker catenin nf b importantly co culture htb show increase level metastatic microrna mir silence mir result reduce metastatic potential migration invasion association decrease expression twist vimentin addition bay tam cancer co culture system significantly reduce phenotype tumorigenic property coincidentally mir level significantly lower presence bay conclusion study demonstrate ams promote metastatic potential bladder cancer cell via promote emt increase mir bay treatment suppress oncogenic metastatic potential bladder cancer cell prevent polarization tam bladder cancer stem like cell origin therapeutic perspective bladder cancer bc common cancer arise human urinary tract consist two major clinicopathological phenotype muscle invasive bladder cancer mibc non muscle invasive bladder cancer nmibc mibc frequently metastasize associate unfavorable prognosis certain proportion patient metastatic bc achieve remission systemic chemotherapy however disease relapse case evidence suggest mibc comprise small population cancer stem cell cscs may resistant treatment may able form new tumor bladder organ therefore unambiguous identification bladder cscs development target therapy urgently need nevertheless remain unclear bladder cscs originate generate review recent study bladder cscs specifically focus propose origin possible therapeutic option base csc theory polymorphism xpc gene affect urinary bladder cancer risk case control study meta analysis trial sequential analysis compromise activity dna repair enzyme may raise risk numb cancer analyze polymorphism xeroderma pigmentosum complementation group c xpc gene correlation urinary bladder cancer ala val ly gln polymorphism genotype urinary bladder cancer case control sample significant association ala val polymorphism bladder cancer observe ci p however ly gln unrelated ci p analysis reveal ala val significant risk factor presence smoke ci p tobacco chew ci p appraise association undertake intravesical instillation cytotoxic lymphocyte induce soluble tumor antigen prophylaxis recurrence bladder cancer objective explore new method prevent recurrence bladder cancer method adjuvant bcg cytotoxic lymphocyte ctls induce human peripheral blood mononuclear cell pbmc bladder tumor soluble antigen extract salt infiltrate biochemical procedure autologous bladder tumor intravesical instillation ctls together supernatants culture day perform patient superficial bladder cancer surgery effect treatment evaluate endocytoscopy pathological examination elisa assay level cytokine il tnf alpha ifn gamma patient serum urine distribution lymphocyte subpopulation also monitor sap immuno histochemical technique result proportion cd cd lymphocyte subpopulation increase significantly cd lymphocyte subpopulation stable ratio cd cd increase level cytokine il tnf alpha ifn gamma serum urine increase significantly especially level tnf alpha urine pathological study reveal non specific inflammation major change bladder mucosa therapy follow month show patient havd moderate heterogeneity bladder mucosa recurrence rate side effect not find except transient low fever hematuria conclusion intravesical insitillation ctls can effectively prevent recurrence superficial bladder cancer improvement immunological reactivity whole body result treatment bladder tumor infiltrate muscle recent study show improvement survival patient invasive bladder cancer perhaps result stage selection reduce perioperative morbidity rather increase effectiveness treatment main ongoing therapeutic trial combine use chemotherapy either surgery radiation therapy aim control occult metastasis may present apparently localize bladder cancer identification risk factor metastatic disease therefore crucial study factor potentially associate response treatment analyze basis review outcome report current treatment histopathological analysis bladder cancer stalk observe mri papillary transitional cell carcinoma bladder loose connective tissue stalk stage bladder cancer magnetic resonance image mri important clearly separate cancer bladder wall possible distinguish stalk cancer difference intensity use mri sixteen stalk polypoid bladder tumor w dynamic image delay enhance image demonstrate stalk show low signal intensity tumor w little enhancement dynamic image strong enhancement delay enhance image stalk consist fibrous connective tissue capillary blood vessel inflammatory cell infiltration edema stalk extend bladder wall center tumor superficial muscular bundle pull stalk histopathological finding compatible pattern signal intensity mri identification stalk polypoid tumor may important observation exclude bladder wall invasion tumor increase risk factor occurrence bladder cancer risk factor bladder cancer development study population base knockdown tyrosine monooxygenase tryptophan monooxygenase activation protein zeta ywhaz enhance tumorigenesis vivo vitro bladder cancer bladder cancer common tumor urinary tract tyrosine monooxygenase tryptophan monooxygenase activation protein zeta ywhaz gene encode protein observe frequently amplify bladder cancer however role various type cancer controversial reproduction cancer genome atla database search correlation ywhaz expression survival outcome multiple cancer silico result reveal bladder cancer positive survival trend ywhaz overexpression study role bladder cancer ywhaz successfully downregulated lentivirus cell mtt colony formation assay show ywhaz downregulation increase cell proliferation wind heal transwell assay show ywhaz downregulation enhance cell migration invasiveness facs analysis show ywhaz induce cell cycle arrest not apoptosis xenograft tumor model reveal ywhaz knockdown enhance tumor growth gene set enrichment analysis confirm cell cycle pathway play vital role function ywhaz gene conclusion knockdown ywhaz promote vitro vivo tumorigenesis bladder cancer may novel biomarker bladder cancer deserve study prognostic value association epithelial mesenchymal transition molecular subtype proteoglycan biglycan advance bladder cancer objective dysregulation extracellular matrix molecule biglycan bgn predict poor survival several cancer entity study investigate prognostic impact bgn bladder cancer bc independent cohort assess role epithelial mesenchymal transition emt association molecular bc subtype method bgn protein expression correlate oncological outcome patient bc undergo radical cystectomy rc single center furthermore gene expression level tcga database cut value bgn protein rna expression test receiver operate characteristic roc curve bgn gene expression correlate establish emt bc gene signature tcga database use gene set enrichment analysis gsea key emt basal luminal molecular bc subtype marker correlate bgn expression datum show heat map result bgn upregulation bc cell protein level predict poor oncological survival institutional cohort univariate p multivariate p analysis bgn expression not associate clinicopathological parameter prognostic value bgn validate mrna level bc tcga database p emt bc core gene signature p correlate bgn expression gsea bgn gene expression associate key indicator emt bgn associate positively molecular basal bc subtype negative bc luminal subtype conclusion bgn independent prognosticator poor survival bc patient bgn associate basal molecular bc subtype emt may key player bgn drive oncogenesis bgn expression correlate emt gene signature current trend bladder cancer england wale purpose examine trend bladder cancer bc incidence mortality survival england wale year period material method age standardize incidence mortality rate bc cohort incidence ratio year relative survival bc calculate current trend assess result total numb case bc increase around almost directly age standardize incidence increase male female directly age standardize mortality decrease male show little change female period five year relative survival improve around point early however little improvement survival thereafter year relative survival patient diagnose man woman conclusion almost increase incidence last decade bc incidence remain much high man increase rapidly woman steady decrease mortality rate mark man woman unusually woman significantly low survival rate man reason pattern trend unclear trend bladder cancer incidence birth cohort suggest relationship smoke may not strong factor may involve research focus reason recent increase bladder cancer incidence young female birth cohort perioperative outcome early survival octogenarian undergo radical cystectomy bladder cancer objective evaluate perioperative outcome early survival series octogenarian undergo radical cystectomy rc urinary diversion bladder cancer patient method retrospectively evaluate clinical record patient age year undergo open rc urinary diversion high volume center july december estimate blood loss ebl transfusion rate length hospital stay los evaluate ninety day postoperative complication stratify accord type urinary diversion univariable analysis perform identify predictor overall major complication overall survival os estimate use kaplan meier method result median age year interquartile range iqr age adjust charlson score patient american society anesthesiologist score patient ileal conduit ic perform case cutaneous ureterostomy cu no urinary diversion require dialytic patient median ebl ml iqr patient require blood transfusion median los day iqr overall complication record patient major complication observe death occur no difference complication observe ic cu year os estimate conclusion open rc octogenarian acceptable rate major complication mortality ic consider good urinary diversion patient review current guideline well practice recommendation management nonmuscle invasive bladder cancer international bladder cancer group purpose although european association urology \\ufeff1 international consultation bladder tumor national comprehensive cancer network american urological association guideline provide excellent evidence base framework management nonmuscle invasive bladder cancer guideline vary respect important issue risk level definition management strategy risk category therefore build exist framework provide current guideline provide consensus definition low intermediate high risk nonmuscle invasive bladder cancer good practical recommendation treatment patient risk category material method international committee expert bladder cancer management identify analyze european association urology \\ufeff1 international consultation bladder tumor national comprehensive cancer network american urological association guideline good publish english language literature relate treatment management nonmuscle invasive bladder cancer available april result base review current guideline literature international bladder cancer group develope practical recommendation management nonmuscle invasive bladder cancer conclusion complete transurethral bladder tumor resection recommend patient nonmuscle invasive bladder cancer low risk disease single immediate chemotherapeutic instillation transurethral bladder tumor resection recommend intermediate high risk disease no significant benefit immediate postoperative chemotherapeutic instillation intermediate risk disease intravesical bacillus calmette gu rin maintenance intravesical chemotherapy recommend high risk disease bacillus calmette gu rin induction plus maintenance recommend appropriate management recurrence depend patient level risk good previous treatment management treatment failure depend type failure good level risk recurrence disease progression management abdominal aortic aneurysm invasive transitional cell carcinoma bladder january june treat patient invasive carcinoma bladder abdominal aortic aneurysm three distinct group patient identify group comprise patient initially diagnose invasive bladder cancer cancer stage concomitant abdominal aortic aneurysm find group consist patient previously treat invasive bladder cancer aneurysmal disease late date group include patient undergo previous aneurysm repair subsequently invasive carcinoma bladder total survival patient mean month followup initial diagnosis find comparable long term great year survival patient invasive carcinoma bladder alone fact none patient study experience rupture aneurysm die aneurysmal disease find patient abdominal aortic aneurysm invasive bladder cancer poor overall prognosis although aneurysm repair present technical challenge mortality dependent upon carcinoma vascular medical disease not bear direct relationship abdominal aortic aneurysm bladder cancer screen lesson biologically base model bladder cancer progression therapeutic intervention screen asymptomatic high risk population evaluate use biologically base model bladder cancer model build upon mathematical representation induction precursor bladder lesion possible progression clinical disease state screen strategy base regimen include void urine cytology diagnostic therapeutic component model provide basis end result evaluation cytology screen project increase average life expectancy year among diagnose reduce death bladder cancer additional contribution realize screen test perfect sensitivity would primarily increase identification dysplasia low grade superficial papillary neoplasm lesion much little life threaten high grade lesion already detectable cytology theoretical potential screen not realizable diagnostic inaccuracy treatment failure limit flow cytometry histogram analysis method assess bladder tumour antigen expression tumour associate antigen detect cell obtain bladder washings tumour useful marker bladder cancer flow cytometry commonly use quantify immuno stain cell straightforward way analyze datum count fluorescent cell threshold empirically determine control histogram representation however specific antigen express highly variable rate give rise wide range distribution flow cytometry illustrate mucin antigen urinary bladder titrate monoclonal antibody urothelial cancer cell evaluate several method background estimation subtraction order determine proportion mab positive cell include threshold set histogram shape dependent hsd threshold develope study preset preset background subtraction blank test histogram kolmogorov smirnov statistical test hsd method appear reliable method background estimation however case low antigen expression specific fluorescence histogram can hardly distinguish background fluorescence microscopy remain valid method since allow distinction specific non specific fluorescence basis structural difference two immunohistochemical study tumor infiltrate lymphocyte intravesical bacillus calmette gu rin treatment superficial bladder cancer background study investigate change phenotypic characteristic tumor infiltrate lymphocyte intravesical bacillus calmette gu rin bcg treatment use immunohistochemical technique method total patient superficial bladder cancer undergo intravesical bcg treatment therapeutic purpose tissue specimen obtain patient bcg treatment cold cup biopsy result number cd cell cd cell cd cell cd cell significantly increase treatment compare number treatment p although gamma delta cell not observe treatment appear treatment patient patient tumor disappear size reduce none tumor recur induction cd cell treatment see patient conclusion gamma delta cell may play important role immune response host tumor intravesical bcg treatment although correlation statistically insignificant taurine pilot study h nmr spectroscopy urinary bladder cancer major epidemiological problem continue grow year open avenue investigative research identification new disease marker diagnostic technique pilot study utility non invasive h nmr spectroscopy evaluate probe metabolic perturbation occur non muscle invasive urinary bladder cancer h nmr spectrum urine bladder cancer patient control healthy urinary tract infection bladder stone n acquire mhz non overlap resonance citrate dimethylamine phenylalanine taurine hippurate \\ufeff1 identify quantitated h nmr spectrum respect external reference sodium trimethylsilylpropionate tsp concentration metabolite statistically analyze cancer patient show significant p variation concentration hippurate citrate compare healthy control benign control significant elevation concentration taurine observe urine bladder cancer patient sensitivity limit mhz control case however stage ta carcinoma situ cis not differentiate basis alter metabolite index composition may reflect biochemical alteration metabolism cancer cell chemoprevention superficial bladder cancer development evaluation approval promise agent bladder cancer prevention chemoprevention depend upon rational integration four key component agent pharmaceutical biologic nutrient b biomakers intermediate endpoint predict clinical response risk reduction c cohort good define high risk target population design efficient trial design link clinical phase development promise overall strategy ability conduct fast small cost effective trial incorporate validate surrogate endpoint rather conventional clinical endpoint cancer incidence recurrence survival current national cancer institute nci phase iii bladder cancer chemopreventive trial progress describe since patient superficial transitional cell bladder cancer present early disease ta this lesion frequently recur easily accessible serial cystoscopy urine cytology bladder cancer serve powerful clinical conduct prevention trial new agent tobacco relate malignancy bladder preservation twice day radiation plus fluorouracil cisplatin daily radiation plus gemcitabine muscle invasive bladder cancer nrg rtog randomize phase ii trial purpose fluorouracil plus cisplatin radiation twice day fct establish chemoradiation crt regimen selective bladder spare treatment muscle invasive bladder cancer gemcitabine daily radiation gd molecular aspect invasion metastasis bladder cancer objective examine effect non muscle invasive bladder cancer nmibc diagnosis treatment survivor quality life qol patient method patient nmibc diagnose north carolina patient randomly select invite enroll cross sectional study datum collect postal mail survey european organisation research treatment cancer quality life questionnaire core qlq c nmibc specific module include survey measure qol descriptive statistic test anova pearson correlation use describe demographics assess qol vary sex cancer stage time since diagnosis treatment result total survivor return questionnaire response rate mean qol score qlq c range high well qol domain symptom global health status function domain score range score top five symptom insomnia fatigue dyspnoea pain financial difficulty range low nmibc specific qol domain sexual issue include sexual function enjoyment problem intimacy woman wrong bowel problem sexual function sexual enjoyment man well sexual intimacy few concern contaminate partner stage ta high global health status follow this qol not vary time since diagnosis except sexual function cystectomy group n wrong qol sexual function discomfort sexual intimacy sexual enjoyment male sexual problem non cystectomy group n conclusion survivor nmibc face unique burden associate diagnosis often lifelong surveillance treatment regimen find important implication design tailor supportive care intervention improve qol nmibc survivor invasive bladder cancer ignore datum aim platinum base neoadjuvant chemotherapy nac improve overall survival muscle invasive bladder cancer mibc pathological complete response pcr radical cystectomy nac associate well overall survival no establish predictive biomarker response nac mibc aim study find laboratory variable associate pcr follow nac material method carry retrospective review mibc patient treat nac follow radical cystectomy sheba medical center overall survival calculate use kaplan meier product limit method compare patient achieve not achieve pcr use log rank test baseline pre surgery laboratory value collect compare patient subsequently achieve pcr not use logistic regression result fifty eight patient undergo radical cystectomy nac median follow range month diagnosis patient document pathological outcome radical cystectomy achieve pcr complete responder complete responder follow datum still alive time last follow study july patient not achieve pcr significantly wrong overall survival complete responder p baseline lymphocyte count neutrophil lymphocyte ratio nlr platelet lymphocyte ratio plr significantly associate response p p p respectively univariate analysis whereas baseline albumin haemoglobin neutrophil platelet total white blood count not significantly associate response lymphocyte count significantly high responder non responder throughout three time point p use generalise linear mix model conclusion high baseline level lymphocyte associate achievement pcr radical cystectomy nac turn associate significantly long overall survival result suggest chemosensitivity mibc associate lymphocyte count impact age clinical factor non muscle invasive bladder cancer treat bacillus calmette guerin therapy background bladder cancer disease old person incidence expect increase population age prognostic factor local recurrence patient non muscle invasive bladder cancer not fully establish aim study determine influence age outcome non muscle invasive bladder nmibc cancer treat intravesical bacillus calmette guerin bcg therapy method retrospectively review clinical pathologic datum primary nmibc patient treat transurethral resection follow bcg immunotherapy time follow month clinicopathologic characteristic response bcg therapy correlate age use univariate multivariate method analysis result univariate analysis show age analyze categorical variable not associate clinicopathological characteristic hand multivariate analysis show multiplicity stage tumor size independent significant prognosticators conclusion result study show age no impact outcome high risk nmibc treat bcg immunotherapy cell origin gene signature indicate human bladder cancer distinct cellular progenitor two distinct form urothelial bladder cancer muscle invasive mi nonmuscle invasive nmi disease since currently believe bladder cancer arise transformation urothelial cell basal layer bladder cancer stem cell cscs isolate base expression marker find cell however cscs identify mi tumor raise intrigue hypothesis nmi tumor progenitor not arise basal compartment test hypothesis carry genome wide expression profile laser capture microdissected basal umbrella cell two histologically distinct cell type normal urothelium develope cell origin coo gene signature distinguish coo signature well predictor stage survival bladder generic breast csc signature bladder cell differentiation marker multiple patient cohort assess whether nmi mi tumor arise distinct progenitor cell dpc common progenitor cell develope novel statistical framework predict coo score function know genetic alteration tp hras kdm fgfr drive either mi nmi bladder cancer compare observe coo score tumor analysis patient five cohort establish dpc model well fit available datum observation support distinct progenitor cell nmi mi tumor provide paradigm shift understand bladder cancer biology significant diagnostic therapeutic implication inductive chemotherapy bladder cancer critical evaluation cisplatin base inductive chemotherapy induce remission locally invasive bladder cancer observe two cycle chemotherapy non transitional cell carcinoma bladder not respond therapy toxicity inductive chemotherapy acceptable clinical stage inductive neo adjuvant chemotherapy not correlate pathological stage cystectomy discrepancy indicate bladder preservation inductive chemotherapy not possible diagnostic method improve enough correlate exactly pathological finding many question remain open respect form treatment locally advance bladder cancer patient treat inductive neo adjuvant chemotherapy within context control prospective clinical trial basis current knowledge inductive chemotherapy not consider definitive form treatment locally invasive bladder tumour guanidino anthrathiophenediones g quadruplex binder uptake intracellular localization anti harvey ras gene activity bladder cancer cell prepare series anthrathiophenediones atpds guanidino alkyl side chain different length compound aim investigate interaction dna rna g quadruplexes uptake malignant nonmalignant cell capacity modulate gene expression inhibit cell growth flow cytometry show atpds enter efficiently malignant bladder cell nonmalignant embryonic kidney fibroblast nih cell malignant cell compound two ethyl side chain take endocytosis respectively propyl butyl side chain transport passive diffusion design atpds localize cytoplasm nucleus tightly bind dna rna g quadruplexes also decrease hras expression increase cell population g g strongly inhibit proliferation malignant bladder cell not nonmalignant nih cell clonal origin multiple focus urinary bladder cancer analyze pattern molecular damage urinary bladder cancer ubc author study allelic imbalance chromosome locus p p patient diagnose multiple primary ubc focus patient state marker no informative value case informative case deletion allele determine little one locus question tumor nodule may point monoclonal origin multiple tumor patient five patient exhibit deletion allele different tumor nodule suggestive active process clonal evolution feasibility tumor subcloning not preclude possibility monoclonal origin five patient imbalance different allele vary nodule may show oligoclonal origin tumor nodule concern concordant discordant pattern molecular damage encounter virtually frequency tumor multiple primary ubc support view synchronous tumor develop monoclonally intraluminal dissemination tumor cell cancerization field determine occurrence oligoclonal tumor coincidence bladder prostate cancer purpose diagnostic bias problem determine coincidence prostate bladder cancer objective study calculate coincidence bladder prostate cancer correct diagnostic bias material method cancer registry medical institution provide numb patient diagnose prostate bladder cancer expect incidence bladder prostate cancer calculate use surveillance epidemiology end result datum diagnostic bias determine review chart patient type cancer result patient diagnosis bladder cancer also prostate cancer prostate cancer also bladder cancer diagnostic bias involve diagnose bladder cancer patient prostate cancer patient eliminate incidence datum rate prostate cancer bladder cancer rate bladder cancer patient prostate cancer age sex race match general population expect rate prostate bladder cancer respectively conclusion rate bladder cancer patient prostate cancer time high p rate prostate cancer bladder cancer time high p expect rate not include case involve diagnostic bias flow cytometry urinary tract malignancy iii quantitative analysis dna histogram application bladder cancer detection evaluation treatment follow examination mitochondrial mt dna mutation describe recently different tumor whereas similar study focus bladder cancer scarce effort understand significance mtdna mutation bladder cancer investigate mtdna alteration clinical human bladder cancer carcinogen induce rat bladder cancer model human bladder cancer tissue obtain radical cystectomy transurethral resection bladder tumor rat bladder tumor induce sd rat treatment n butyl n hydroxybutyl nitrosamine drink water week genomic dna extract tumor specimen microdissected normal bladder mucosa mitochondrial gene loop region amplify pcr amplify pcr fragment either clone plasmid vector use direct dna sequence result dna sequence reveal numerous point mutation non code loop region different mtdna gene human rat bladder cancer addition also detect deletion variable length mononucleotide repeat loop region nd atpase coiii gene human bladder cancer sample result show mtdna exhibit high rate mutation human rat bladder cancer also demonstrate repetitive sequence mononucleotides within mt genome unstable subject deletion high incidence mtdna mutation bladder cancer suggest mtdna mitochondrion can play important role process carcinogenesis also mtdna can valuable marker early bladder cancer diagnosis intraoperative radiation therapy bladder cancer combination intraoperative radiation therapy external beam irradiation new treatment modality add therapeutic armamentarium management patient bladder cancer encourage result see combination utilize patient superficial this bladder cancer experience specific indication combine treatment modality identifiable ileal neobladder local recurrence bladder cancer pattern failure impact function man purpose diagnostic bias problem determine coincidence prostate bladder cancer objective study calculate coincidence bladder prostate cancer correct diagnostic bias material method cancer registry medical institution provide numb patient diagnose prostate bladder cancer expect incidence bladder prostate cancer calculate use surveillance epidemiology end result datum diagnostic bias determine review chart patient type cancer result patient diagnosis bladder cancer also prostate cancer prostate cancer also bladder cancer diagnostic bias involve diagnose bladder cancer patient prostate cancer patient eliminate incidence datum rate prostate cancer bladder cancer rate bladder cancer patient prostate cancer age sex race match general population expect rate prostate bladder cancer respectively conclusion rate bladder cancer patient prostate cancer time high p rate prostate cancer bladder cancer time high p expect rate not include case involve diagnostic bias prospective randomize pilot study evaluate era protocol versus standard protocol patient treat radical cystectomy urinary diversion bladder cancer objective report long term outcome selective organ preservation muscle invasive bladder cancer mibc use bladder spare trimodality approach material method patient bladder cancer prospectively enroll successive bladder spare protocol forty one patient treat neoadjuvant methotrexate cisplatin vinblastine mcv chemotherapy follow radiotherapy gy complete responder protocol p patient treat weekly cisplatin concurrent radiotherapy gy protocol p result median follow month range month five year cumulative overall survival series correspond number cancer specific survival respectively survive patient maintain bladder although no significant difference overall survival p cancer specific survival p distant metastasis p protocol complete response rate p disease free survival p significantly high p treatment conclusion trimodality therapy bladder preservation represent real alternative radical cystectomy rc select patient overall survival cancer specific survival rate encourage survivor retain functional bladder bladder cancer perspective year key event lead well understand natural history urothelial tumor bladder summarize recognition flat carcinoma situ relate lesion intraurothelial neoplasia principal source invasive cancer identification unique structure urothelium analysis dna content recognition two pathway urothelial tumor brief comment current status immunologic molecular genetic marker append impact histological reclassification pathology review evidence rogers effect bladder cancer purpose investigate association histological reclassification pathology review radical cystectomy specimen clinicopathological outcome patient initially classify urothelial carcinoma material method identify patient initially diagnose urothelial carcinoma radical cystectomy pathological specimen review urological pathologist survival estimate use kaplan meier method compare log rank test result case previously record pure urothelial carcinoma reclassify variant histology common variant histology identify squamous patient micropapillary variant histology review associate high rate extravesical disease urothelial carcinoma initial diagnosis pure urothelial carcinoma review p median postoperative followup year patient die include bladder cancer notably reclassification result significant stratification year cancer specific survival patient pure urothelial carcinoma review urothelial carcinoma initial interpretation variant histology review p ten year overall survival patient urothelial carcinoma review urothelial carcinoma initial interpretation variant histology review respectively p conclusion pathological review radical cystectomy specimen identify variant histology 3 patient variant associate high rate locally advance disease may impact note rate cancer specific overall survival thus critical aware review status interpret outcome historical datum set stratify risk analysis japanese patient treat without long term epirubicin plus ara c intravesical instillation therapy low grade superficial bladder cancer high incidence tumor recurrence follow transurethral resection tur represent major problem encounter management bladder cancer study examine efficacy intravesical chemotherapy superficial bladder cancer retrospectively analyze japanese case low grade superficial transitional cell carcinoma stage grade render tumor free turbt tur bladder tumor thereafter treat without intravesical chemotherapy among instillation terminate patient due adverse effect severe reversible chemical cystitis remain patient divide group accord therapy turbt group n define patient treat turbt alone instillation group n define patient treat weekly intravesical instillation therapy use epirubicin plus ara c recurrence free rate significantly high instillation group turbt group p hr year recurrence free rate instillation group turbt group instillation schedule represent intensive regimen among previously report therapy result decrease incidence tumor recurrence believe result study can provide useful information management bladder cancer quality life patient bladder cancer objective review examine publish datum regard quality life qol patient bladder cancer not single randomize control trial exist study retrospective cross sectional serious methodological flaw no single qol tool preferably use bladder cancer no long term datum therapy superficial cancer investigation compare impact different form urinary diversion qol contrast prevail notion patient undergo cystectomy undergo continent urinary reconstruction superior qol receive conduit exist report fail show significant advantage one technique cancer incidence cause specific mortality among worker two norwegian aluminum reduction plant background concern health hazard aluminum industry initiate study investigate association exposure polycyclic aromatic hydrocarbon pah fluoride cancer incidence cause specific mortality among worker two norwegian aluminum plant operation since respectively method study design historical cohort study comprise identify man employ six month cancer incidence investigate start employment cause specific mortality investigate observe case cancer observe death compare expect number calculate national rate internal comparison make use poisson regression age smoke include model historical exposure pah fluoride estimate previously use statistical model industrial hygiene measurement process parameter job exposure matrix use investigate possible association cumulative exposure cancer incidence cause specific mortality smoke habit identify cohort member result study show significant excess risk urinary bladder cancer among worker expose pah no clear efficacy combination therapy intravesical instillation doxorubicin low dose radiation bladder cancer comparison instillation doxorubicin alone background angiogenesis vital importance development progression solid tumor study perform test clinical significance vascular endothelial growth factor vegf expression primary superficial bladder cancer material method cohort case pta pt transitional cell bladder cancer six case normal urothelium study immunohistochemistry expression vegf correlate biological indicator bladder cancer examine prognostic value result variable amount vegf detect case pta pt tumor respectively positive association vegf expression histological grade p otherwise no apparent correlation observe remain biopathological indicator p respectively risk factor predict tumor recurrence multiple tumor diagnosis lamina propria invasion p respectively patient multiple tumor also low survival rate solitary tumor p however expression vegf not correlate risk tumor recurrence patient survival p conclusion expression vegf one characteristic tumor dedifferentiation may play role development subset superficial bladder cancer evaluation vegf expression dose not provide independent prognostic information patient superficial bladder cancer level risk lung bladder cancer heavy smoker analysis base multicentric case control study metabolic interpretation shape dose response relationship carcinogenic exposure cancer risk key issue theoretical model carcinogenesis practical risk assessment point view human population expose polycyclic aromatic hydrocarbon pah via air pollution show non linear relationship level exposure wbc dna adduct among highly expose subject dna adduct level per unit exposure significantly low measure environmental exposure exposure dose non linearity observe lung dna rat expose pah analyze case control study bladder cancer incident case hospital control eight case control study lung cancer incident case population control conduct europe recent year study collect detail information smoke history similar methodology estimate relationship numb cigarette smoke risk cancer without adjustment duration smoke observe level relationship numb cigarette smoke relative risk lung bladder cancer man woman level occur odd ratio bladder cancer occur lung cancer man potential explanation level involve metabolic pathway individual susceptibility suggest metabolic polymorphism exert effect important low level exposure granulocyte colony stimulate factor produce undifferentiated carcinoma urinary bladder case report case bladder cancer produce granulocyte colony stimulate factor g csf report year old woman progressive grade undifferentiated carcinoma show mark leukocytosis maximum mm elevate g csf pg ml immunohistochemical examination monoclonal antibody specific g csf reveal positive stain examination epidermal growth factor receptor egf r p positive ki index datum suggest tumor extremely aggressive grow nature biological character chemoradiotherapy muscle invade bladder carcinoma final report single institutional organ spare program purpose chemoradiotherapy become alternative radical cystectomy among patient muscle invade bladder cancer begin prospective study determine possibility conservative treatment aim improve result obtain cystectomy alone invasive bladder cancer combination methotrexate vinblastine adriamycin cisplatin vac follow radiotherapy concomitant cisplatin use method fifty patient good performance status stage operable untreated invasive bladder cancer enter study treatment protocol follow cytoreductive transurethral resection ii two cycle vac chemotherapy iii radiotherapy gy pelvic volume time mg cisplatin day cystoscopic evaluation complete response radiotherapy complete gy not complete response cystectomy perform median follow series month result tumor response follow complete response partial response nonresponses observe year overall survival local control respectively complete responder patient year survival local control respectively severe toxicity uncommon frequent leucopenia cystitis no treatment relate death occur either treatment protocol conclusion conservative combination treatment may acceptable alternative immediate cystectomy select patient bladder cancer although randomize clinical trial would require produce definitive result host gene affect survival period chemically induce bladder cancer mouse treatment c bl j b non male mouse n butyl n hydroxybutyl nitrosamine bbn result high incidence bladder cancer mean survival period however differ significantly strain day b n day non n p major cause death renal failure due obstruction urinary tract local invasion tumor fact bbn treat non x b reciprocal f mouse survival period short parental non mouse suggest genetically dominant susceptibility non recessive resistance b linkage analysis back cross mouse b suggest little two quantitative trait locus determine length survival period one map close mit logarithm odd lod score microsatellite marker locus cm centromere chromosome another close mit cm centromere chromosome lod score biological property drug sensitivity rat bladder cancer implant subcutis bladder wall rat biological property drug sensitivity rat bladder tumor bc implant either subcutis bladder wall aci n rat compare growth rate tumor implant bladder wall one 3 slow subcutaneous tumor mid log phase tumor bladder wall show invasive growth mucosa muscularis propria formation capsule contrast subcutaneous tumor grow expansively form thick capsule tumor subcutis bladder wall remarkably sensitive adriamycin tumor subcutis sensitive peplomycin bladder wall insensitive sensitivity tumor bladder wall adriamycin peplomycin consistent clinical efficacy drug human bladder cancer result suggest model tumor implant original organ useful predict clinical efficacy experimental cancer chemotherapy new approach bladder cancer individualize patient chemotherapy interphase fish technique use fluorescent molecule detect chromosome specific region dna rapid powerful technique detection cytogenetic abnormality malignant cell independent cell cycle status use variety pericentromeric locus specific probe numerical chromosomal change aneusomy good loss gain amplification specific genetic region detect clinical sample numerous study identify genetic alteration dna level occur pathogenesis variety human neoplasm include bladder cancer use detection prognosis intermediate endpoint evaluate response therapy recently sensitivity specificity multicolor fish assay consist four probe p analyze several prospective retrospective study datum suggest method applicable void urine specimen may allow safe extension interval cystoscopy routine surveillance patient transitional cell carcinoma bladder fish analysis cell isolate bladder washings void urine also hold promise monitor treatment outcome predict recurrence progression disease therefore technique important aid effort reduce mortality transitional cell carcinoma bladder since increase ability prevent progression incurable muscle invasive disease no association toenail selenium level bladder cancer risk matrix metalloproteinase mmp contribute tumor microenvironment associate bladder cancer study examine association mmp polymorphism bladder cancer risk never publish analyze association single nucleotide polymorphism snps one microsatellite polymorphism mmp gene mmp mmp mmp mmp mmp mmp bladder cancer risk caucasian patient control match age gender ethnicity individual combination haplotype diplotype analysis do no association individual mmp polymorphism overall bladder cancer risk see mmp microsatellite ca repeat allele mmp gg polymorphism associate invasive bladder cancer risk odd ratio confidence interval ci ci respectively smoke stratify analysis reveal several association mmp polymorphism alone combination bladder cancer risk particularly light smoker linkage disequilibrium see mmp mmp mmp mmp snps four five mmp polymorphism test several mmp haplotype diplotypes associate overall invasive bladder cancer risk study suggest genetic variation mmp family associate bladder cancer risk heavy carcinogen exposure may overwhelm genetic effect mmp polymorphism study confirm importance take multigenic pathway base approach risk assessment invasive bladder cancer uremia dilemma management invasive bladder cancer present uremia rare phenomenon management sick patient become problematic since one not know aggressive treatment possible outcome expect retrospective review patient invasive bladder cancer describe patient uremia discuss management strategy prognosis lymphovascular invasion associate oncologic outcome follow radical cystectomy squamous cell carcinoma urinary bladder objective evaluate association lymphovascular invasion lvi oncologic outcome squamous cell carcinoma scc urinary bladder follow radical cystectomy rc patient method perform retrospective analysis patient undergo rc invasive bladder cancer mansoura egypt patient pure urothelial carcinoma bladder ucb scc pathology include use multivariate cox regression analysis kaplan meier analysis prognostic significance lvi disease free survival cancer specific survival evaluate patient ucb scc result cohort include patient ucb scc median patient age follow year month respectively median numb lymph node ln retrieve lvi present patient ucb vs scc p lvi independent predictor oncologic outcome ucb scc group however lvi prognostic significance scc ln negative lvi positive lvi ln patient scc high risk recurrence cancer specific mortality compare ln positive lvi negative lvi ln patient scc hazard ratio vs hazard ratio vs respectively conclusion presence lvi independent predictor poor oncologic outcome rc great prognostic significance patient scc compare ucb smoke bladder cancer egypt case control study smoke carry egyptian male bladder cancer divide patient previous urinary bilharziasis without past infestation smoke index significantly high bilharzial non bilharzial patient bladder cancer control significant association find heavy moderate cigarette smoke bladder cancer develope non bilharzial subject local habit meassel smoke not differ significantly bladder cancer patient control current status radiation therapy combine modality treatment bladder cancer background standard treatment muscle invasive bladder cancer radical cystectomy combine modality treatment cmt include transurethral resection turbt radiation therapy rt systemic chemotherapy show produce survival rate comparable radical cystectomy program cystectomy reserve patient incomplete response local relapse trimodality treatment method review summarize series radical rt different fractionation schedule focus cmt muscle invasive bladder cancer current protocol bladder spare approach discuss background future development include incorporation promise new chemotherapeutic agent good role predictive prognostic factor select patient respective treatment alternative give result moderate evidence hyperfractionated accelerate regimen superior conventional rt little situation no concomitant chemotherapy apply several phase ii study one phase iii study indicate concomitant radiochemotherapy superior rt alone modern series cmt year survival rate range publish three quarter survive patient maintain bladder recent datum suggest incorporation new chemotherapeutic agent particularly gemcitabine taxanes cmt protocol feasible promise clinical criterium helpful determine patient bladder preservation include variable early tumor stage unifocal tumor visibly microscopically complete turbt absence ureteral obstruction conclusion cmt bladder cancer reasonable treatment option patient deem medically unfit cystectomy seek alternative radical cystectomy bladder cancer primary pregnancy purpose expression fibulin investigate urothelial carcinoma bladder normal bladder sample effect fibulin cell proliferation motility invasion explore bladder cancer cell line material method expression fibulin bladder carcinoma sample normal bladder sample detect western blot fibuin cdna clone p egfp n vector transfect bladder cancer cell line growth curve estimate dimethylthiazol yl diphenyl tetrazolium bromide assay cell numb count migration invasion transfect cell control cell measure boyden chamber assay result compare normal control mean sd expression fibulin low grade tumor high grade tumor p p respectively expression ta tumor tumor p p respectively difference low grade high grade tumor ta tumor not statistically significant p p respectively growth rate fibulin transfect gfp f cell remarkably reduce untransfected cell empty vector transfect gfp cell besides compare control cell gfp f cell show significant inhibition cell invasion slight inhibition cell migration conclusion fibulin regulate urothelial carcinoma bladder act tumor suppressor gene inhibit proliferation invasion bladder cancer cell tumor target multifunctional micelle image chemotherapy advance bladder cancer aim work aim determine treatment outcome bladder cancer can improve target micelle decorate bladder cancer specific ligand surface load chemotherapeutic drug paclitaxel material method target efficacy specificity determine cell line vivo target anti tumor efficacy study conduct mouse carry patient derive xenograft result discussion target micelle efficient nontargeting micelle deliver drug load bladder cancer cell vitro vivo p micelle formulation paclitaxel little toxic free paclitaxel cremophor sigma mo usa allow administration three time maximum tolerate dose without increase toxicity target micelle effective nontargeting micelle control cancer growth p prolong overall survival p conclusion target micelle load paclitaxel offer strong potential clinical application treat bladder cancer microdissection detect genetic aberration early advance human urinary bladder cancer laser microdissection essential method investigation multistep carcinogenic process urinary bladder reliable detection tumor specific alteration compromise presence normal cell require microdissection pure tumor cell population detect loss heterozygosity loh either fluorescence situ hybridization fish sequence analysis multiple molecular method need perform course study often small lesion chapter describe detail use laser microdissection whole genome amplification improve primer extension preamplification pep polymerase chain reaction subsequent loh fish sequence analysis investigation urothelial tumor precursor lesion combination describe method allow wide spectrum molecular investigation tumor cell help understand fundamental alteration involve urothelial carcinogenesis molecular detection primary bladder cancer microsatellite analysis microsatellite dna marker widely use tool detection loss heterozygosity genomic instability primary tumor blind study urine sample patient suspicious bladder lesion identify cystoscopically analyze molecular method conventional cytology microsatellite change match tumor detect urine sediment patient percent diagnose bladder cancer whereas urine cytology detect cancer cell percent sample result suggest microsatellite analysis principle perform one 3 cost cytology may useful addition current screen method detect bladder cancer intravesical interleukin gene therapy orthotopic bladder cancer model interleukin il know stimulate proliferation cd cell natural killer cell also help maintain memory cd cell suggest may value cytokine treatment bladder cancer experiment test efficiency intravesical liposomal il gene delivery antitumor effect mouse orthotopic bladder cancer model establish orthotopic bladder cancer model implant mbt cell female c h hen mouse urethra mouse receive repeat intravesical gene delivery inject liposome mediate plasmid g transurethrally day bladder weight group receive medium alone beta galactosidase gene delivery control group il gene therapy group mg mg mg respectively p demonstrate antitumor effect intravesical il gene therapy model bladder treat il gene plasmid instillation histological analysis reveal many inflammatory cell induce around tumor immunohistochemical analysis confirm predominant infiltration cd cell around tumor nest intravesical il gene therapy growth rechallenged subcutaneous mbt cell survive mouse inhibit via tumor specific cytotoxic lymphocyte although newly implant fm cell mouse not reject present finding indicate il gene therapy may promise new adjuvant therapy bladder cancer bladder cancer smoke part efficacy health promotion last four part series bladder cancer smoke part present overview bladder cancer role smoke development anderson naish part discuss diagnosis management bladder cancer anderson naish b part examine perception belief relate smoke health anderson naish c part examine evidence efficacy health promotional measure help people stop smoke aim provide insight whether health education health promotion increase awareness impact smoke health wellbeing whether person subsequent behaviour change enough stop smoke finally discuss role healthcare professional help people achieve objective loco regional immunotherapy bladder cancer urothelial cancer subject large numb vary communication international conference innovate study likely modify patient management select regard non muscle invade tumor maintenance treatment use intravesical instillation emphasize laser laparoscopy assess urothelial tumor upper urinary tract finally new radiochemotherapy protocol appear infiltrate bladder tumor extend lymphadenectomy laparoscopy also evaluate detail mirna expression bladder cancer potential role clinical practice background date mirna sequence describe human register mirbase since discovery however function mirnas experimentally determine use deep sequence technology aberrant mirna expression associate differentiation invasion metastasis several cancer context recent report suggest mirnas play important role regulation target gene bind complementary region messenger transcript repress translation regulate degradation addition expression profile certain mirnas function biologically oncogene tumor suppressor gene method review summarize relationship mirnas expression bladder cancer bc comprehensive review literature show differential expression malignant normal tissue mirnas can drive molecule bc progression similarly expression level mirnas urine blood sample bc patient demonstrate different healthy people find may diagnostic value conclusion conclusion understand mirnas mechanism cell distribution provide new opportunity diagnosis prognostic disease monitor personalize therapy bc patient photoinactivation bladder tumor cell methylene blue study variety tumor normal cell human bladder cancer cell line j yen shen zoa murine bladder cancer cell line mbt use target cell dye sensitize photoinactivation study use methylene blue normal fibroblast cell fb fb use control group cytoplasmic activity lactic dehydrogenase soft agar clonogenic assay vivo tumor growth survival rate tumor take rate without photoinactivation monitor compare different cell line efficacy photoinactivation time relate per cent cytotoxicity can obtain within minute illumination plateau cytotoxicity curve can achieve stain minute methylene blue illumination time normal fibroblast feature cancer cell photoinactivation tumor cell show significant inhibition tumor growth tumor take rate experimental animal survival rate also significantly prolong animal tumor cell receive photoinactivation result suggest methylene bladder cancer taiwan relationship trihalomethane concentration present drink water supply objective study evaluate whether exposure disinfection product dbp associate bladder cancer match case control study use investigate relationship risk death bladder cancer exposure total trihalomethanes tthm drink water municipality taiwan bladder cancer death municipality obtain bureau vital statistic taiwan provincial department health control death cause year experience bcg immunoprophylaxis superficial bladder cancer year experience bcg tumor stage ptis pta pt g ii show last remission patient treat bcg preparation pasteur connaught transurethral resection complete remission patient carcinoma situ patient can find local systemic neoadjuvant chemotherapy pt bladder cancer associate survival benefit population base analysis background patient organ confine muscle invasive bladder cancer mibc candidate radical cystectomy rc receive neoadjuvant chemotherapy cht however contemporary cht use rate indicate low adherence guideline test contemporary neoadjuvant cht rate associate cancer specific mortality csm overall mortality om pt n mibc patient treat rc material method within seer database identify patient pt n mibc patient undergo rc cht administration rate evaluate use estimate annual percentage change eapcs analysis inverse probability treatment weight iptw kaplan meier km analysis cox regression model crms use test effect cht vs no cht survival landmark analysis test immortal time bias result rc patient patient receive cht cht rate increase eapc p iptw adjust km show year csm free survival rate cht vs no cht patient p similarly iptw adjust km show year om free survival rate cht vs no cht patient p iptw adjust mcrms cht not significantly associate low csm hr ci p om hr ci p virtually csm om rate record landmark analysis conclusion cht use pt n mibc rc patient sharply increase study spin however neoadjuvant cht not associate well survival patient group coordinate epigenetic repression mir family mir invasive bladder cancer micrornas mirna small noncoding rnas commonly deregulate cancer mir family mir b c mir frequently silence advance cancer implicate epithelial mesenchymal transition emt tumor invasion target transcriptional repressor e cadherin zeb zeb zeb also know repress mir c transcription negative feedback loop otherwise little know transcriptional regulation mir family mir recently mir silence also report cancer stem cell imply mir deregulation key event multiple level tumor biology however prevent mir expression remain largely unanswered report concerted transcriptional regulation mir mir locus bladder tumor bladder cell line use combination mirna expression array qpcr assay mass spectrometry dna methylation analysis show mir mir locus specifically silence gain promoter hypermethylation repressive chromatin mark muscle invasive bladder tumor undifferentiated bladder cell line moreover report mir c expression significantly correlate early stage bladder tumor progression propose mir mir silence dna hypermethylation possible prognostic marker bladder cancer addition observe mesoderm transcription factor twist mir expression inversely correlate bladder tumor sample cell line twist associate directly mir mir promoter may act repressor mir mir expression advance cancer urinary bladder analysis result radiotherapy alone vs radiotherapy concomitant fluorouracil prospective randomize study case employment dna flow image cytometry oncological diagnostic procedure favor high correlation tumor biological behavior prognostic statement therapeutic strategy therefore base high validity dna cytometric measurement use bladder washings patient suspect bladder cancer study examine clinical value various common method dna single cell sci stemline interpretation sli compare specificity sensitivity dna image cytometry detection bladder tumor find respectively sci boecking sli boecking sli fu conventional stemline interpretation improve diagnostic prognostic validity dna image cytometry design method interpretation consequence identify six single dna parameter record measurement correlate histopathological grade g g create reference value random rate point use cytometric grade system rank detection bladder cancer specificity sensitivity ultimately arrive almost application method thus study able show sensitivity dna examination increase combine various dna parameter apart scheme discrepancy interpretation dna image cytometry not allow us recommend procedure diagnostic detection bladder cancer however regard prognostic statement particularly tumor biological behavior dna image cytometry appear useful epidemiology etiology bladder cancer urinary bladder cancer long associate specific etiologic factor knowledge factor increase century important factor even industrialize society cigarette smoke specific chemical also identify cause bladder cancer variety occupational exposure little good define specific agent part world association bladder cancer balkan nephropathy endemic blackfoot disease schistosomiasis provide additional lead investigate potentially prevent process carcinogenesis human many critical observation understand bladder cancer make practice physician likely continue essential physician deal bladder cancer patient attune potential etiologic factor include cigarette smoke various industrial exposure drug exposure understand issue bladder cancer potentially preventable disease important one indicate total numb case extent morbidity death attributable around world utility nuclear matrix protein nmp detection recurrent bladder cancer article examine nuclear matrix protein nmp urine test recurrent bladder cancer detection study nmp compare cytology sensitivity specificity false positive false negative occur consequence discuss speculation make regard possible future use test perioperative therapy muscle invasive bladder cancer muscle invasive bladder cancer mibc aggressive disease associate poor survival rate high rate relapse despite radical cystectomy suggest administration systemic therapy perioperative period may improve clinical outcome neoadjuvant treatment cisplatin base combination regimen establish standard care improve long term survival mibc use neoadjuvant chemotherapy steadily increase clinician still need decide administer adjuvant chemotherapy patient high risk disease review examine detail late evidence available neoadjuvant adjuvant chemotherapy highlight pertinent study dynamic contrast enhance magnetic resonance image bladder cancer implication biological image adapt radiotherapy purpose assess role image parameter derive dynamic contrast enhance magnetic resonance image dcemri bladder cancer stage investigate potential use parameter image biological image adapt radiotherapy rt material method high resolution volumetric interpolate breath hold vibe dcemri patient diagnose bladder cancer perform dcemri parameter derive tumor muscle contrast uptake curve extract subject correlation analysis tumor volume good clinical pathological histological weight mr tumor stage parameter show significant correlation tumor stage malignancy map generate initial step towards delivery biologically adapt intensity modulate radiotherapy imrt hypothesize malignancy map can use rt dose prescription map simulate imrt delivery multi leaf collimator mlcs idealize dose distribution constitute dose cube adapt prescription map size dose cube vary mimic mlcs vary leaf width difference adapt prescribe dose distribution quantify root mean square deviation rmsd result no significant relationship find tumor volume extract dcemri parameter normalize area tumor muscle contrast uptake curve nabc evaluate second nabc nabc correlate significantly tumor stage p p respectively dose prescription map patient generate nabc rmsd prescribe adapt dose distribution decrease decrease size dose cube large interpatient variation rmsd dependence rmsd different dose cube size find conclusion nabc nabc may provide add value stage bladder cancer high resolution imrt require patient optimal adapt rt bladder cancer associate hypercalcaemia case report hypercalcaemia associate bladder cancer rarely encounter case history male patient year old large deeply infiltrate squamous cell bladder carcinoma hypercalcaemia mmol l low parathormone level no sign skeletal metastasis present review early report case bladder cancer associate hypercalcaemia discuss likelihood bladder cancer associate non visible haematuria quantify \\ufeff1 time retrospective study do include patient mean clinical follow year mitotic activity initial bladder tumor biopsy estimate use two different method traditional mitotic activity index mai recently introduce volume correct mitotic index v index grade result obtain use index compare prognostic information obtain subjective histological grade clinical stage uicc progression bladder cancer follow period significantly relate v index p little mai p little histological grade p little order progression ta tumor significantly relate v index univariate multivariate analysis good recurrence free period significantly relate mai p v index p clinical stage p little histological grade p little v index p little mai p little predict bladder cancer relate survival multivariate analysis v index predict progression survival well mai give comparable result obtain subjective histological grade result encourage use v index grade bladder cancer place mai application apparent diffusion coefficient ratio diagnosis bladder cancer grade pre operation objective explore value apparent diffusion coefficient adc ratio diagnosis bladder cancer pre operation analyze difference among different grade bladder cancer method total case bladder cancer definitely diagnose histological result routine examination magnetic resonance image mri diffusion weight image dwi perform preoperatively patient adc map construct work station adc value tumor internal obturator muscle measure b mm ratio adc calculate internal obturator muscle reference site relationship adc ratio bladder cancer grade analyze result mean ratio adc tumor g g sensitivity specificity adc ratio respectively optimal threshold ratio adc low grade group significantly high high grade group value non muscle invasive group significantly high muscle invasive group ratio adc tumor inversely associate malignancy degree bladder cancer r p conclusion ratio adc bladder cancer reflect lesion tissue property measurement play important role diagnosis bladder cancer grade pre operation postoperative radiotherapy management bladder cancer people pt g bladder cancer high risk tumour progression death induction maintenance intravesical bacillus calmette guerin bcg prove reduce tumour progression superficial bladder cancer moderate risk progression extrapolation treatment often give pt g bladder cancer phase ii study publish past year use adjuvant intravesical bcg follow transurethral resection tur tumour suggest important effect numb patient progress datum mix however randomise study use adjuvant radiotherapy pt g bladder cancer show not benefit overall progression rate remain high early cystectomy high risk case not commonly use result often disappoint presumably consequence negative selection identification patient extra high risk progression desirable tumour size co existence carcinoma situ early tumour recurrence may prognostic indicator datum present insufficient role human glutathione transferase individual susceptibility bladder cancer several gene involve metabolism carcinogen find polymorphic human population specific allele associate increase risk cancer various site study focus polymorphic enzyme glutathione transferase gstm gstt involve detoxification many xenobiotics involve etiology bladder cancer investigate role gstm gstt bladder carcinogenesis polymerase chain reaction use determine gstm gstt genotype cancer patient n control n proportion putative risk gstm null genotype case group compare control group gstt frequency bladder cancer group significantly high p comparison control group vs individual lack gstt gene approximately fold high risk c develope bladder cancer comparison individual little one active allele gstt locus significantly high incidence gstm deletion genotype p find smoker bladder cancer compare control vs smoker lack gstm gene approximately fold high risk bladder cancer c effect smoke associate gstt genotype not find affect risk bladder cancer urinary bladder cancer stage ct urography use machine learn purpose evaluate feasibility use objective computer aid system assess bladder cancer stage ct urography ctu material method dataset consist bladder cancer lesion ctu case use develop computerize system bladder cancer stage base machine learn approach case group two class base pathological stage decision threshold neoadjuvant chemotherapy treatment clinically cancer stage cancer stage lesion automatically segment use previously develope pre clinical cytological diagnosis bladder cancer record recent urology service patient bladder neoplasm evaluate correlation cytological finding clinical histological diagnosis time diagnosis patient synchronous positive biopsy cytology negative cytology even though urothelial cancer present remain abnormal cytology clinical examination negative patient invasive cancer identify subsequently not yet return clinical followup analysis patient cancer prove eventually reveal distinct period range month cytology abnormal concurrent clinical examination histological diagnosis negative ten period precede tumor recurrence antedate \\ufeff1 occurrence cancer relationship find cytological diagnosis carcinoma situ severe dysplasia presence future appearance low grade clinical cancer cytology contain overtly malignant cell commonly associate precede appearance high grade cancer patient sensitivity single spontaneously void urine specimen per cent sensitivity per cent specimen submit per patient bladder barbotages per cent sensitive population base study pattern care muscle invasive bladder cancer sweden objective analyse management muscle invasive bladder cancer population base national register specifically investigate role curative therapy e cystectomy radiotherapy relation patient tumour hospital characteristic material method swedish bladder cancer register cover patient country diagnose disease since result analyse regard curative intent treatment give within month diagnosis muscle invasive bladder cancer result total patient clinical bladder cancer include analysis patient receive curative intent treatment form radiotherapy cystectomy male gender age year favourable tnm category registration high volume hospital associate treatment curative intent treatment give significantly patient register high volume hospital low volume hospital chi p cystectomy perform often register behavior lipiodol marker image guide radiotherapy bladder cancer purpose investigate stability novel type marker use partial bladder tumor irradiation tumor deformation indicate marker material method patient solitary bladder cancer lipiodol inject bladder wall flexible cystoscopy identify tumor plan ct scan make follow daily cone beam ct cbct scan treatment study accuracy use marker image guidance uncertainty u u calculate define difference submask registration cover single marker average submask registration difference submask registration general mask registration include marker respectively finally study tumor deformation relative movement marker pair correlate relative bladder volume rbv result analyze patient marker injection average lipiodol spot size cm intensity spot ct cbct significantly high surround bladder tissue uncertainty u u comparable uncertainty diet bladder cancer ethiopathogenesis aim paper show influence different food bladder cancer appearance good possible consequent way prevention consuption food rich animal fat cholesterol fry food especially several time use cookin oil fry process meat additive nitrate nitrite azo colourrs influence bladder cancer occurrence regularly continous consumption ferment milk product contain come type milky acid bacteria consider protective factor develope bladder cancer report fruit vegetable protective food item pretty consistent datum mineral intake bladder cancer obscure omega fatty acid inhibit tumor growth rat model bladder cancer omega fatty acid test prevention treatment several cancer type efficacy vivo bladder cancer not analyze yet study aim evaluate chemopreventive efficacy eicosapentaenoic acid epa docosahexaenoic acid dha mixture animal model bladder cancer forty four male wistar rat divide group week protocol control carcinogen n butyl n hydroxybutyl nitrosamine bbn dha epa bbn bbn give initial week week blood bladder collect check presence urothelium lesion tumor marker inflammation proliferation redox status incidence bladder carcinoma control bbn bbn bbn group no infiltrative tumor carcinoma situ tumor volume significantly reduce compare bbn mm versus mm also show reduce mda tas ratio bbn induce serum crp tgf cd prevent conclusion omega fatty acid inhibit development premalignant malignant lesion rat model bladder cancer may due anti inflammatory antioxidant anti proliferative irradiation bladder cancer surgical open select patient definitive external irradiation fail control bladder cancer potentially salvage cystectomy patient cancer center undergo salvage cystectomy year survival rate per cent postoperative hospital mortality rate per cent infectious complication develope 3 patient ureteroileal urine leak develope per cent incidence complication not dissimilar radical cystectomy without prior large dose irradiation biomarker patient treat bcg update introduction bacillus calmette guerin bcg instillation recommend treatment non muscle invasive bladder cancer high recurrence progression rate remain treatment despite patient risk stratification bcg effectiveness remain unpredictable close invasive expensive follow mandatory improve even replace heavy surveillance high risk population validate biomarker develope material method identify useful tool urologist monitor bladder cancer patient review literature focus plasma urinary biomarker bcg therapy outcome article date include specific keyword urinary bladder neoplasm biological marker intravesical administration recurrence examine relevant paper select result treatment initiation genetic polymorphism multiple agent cytokine matrix metalloproteinase find become useful tailor therapy monitor biomarker belong personalize medicine topic great interest today still need validate cohort different ethnicity instillation cytokine il il il il report reliable determine treatment response efficacy study need confirm result standardize threshold treatment urovysion fda approve fluorescence situ hybridization fish appear robust marker clinical parameter review not yet validate bcg treat patient conclusion no recommendation everyday practice establish today combination several marker clinicopathological characteristic may future bladder cancer diagnosis management evolve practice urologist aware utilize bladder cancer marker clinical practice cytologic detection urothelial cancer abnormality cohort worker expose aromatic amine total member cohort increase risk occupational bladder cancer undergo month program screen urine cytology select worker receive urologic study cystoscopy bladder biopsy eight worker positive suspicious cytologic finding one eight prior history bladder cancer biopsy show invasive carcinoma nonpapillary carcinoma situ five worker group severe atypia one no significant abnormality two worker atypical cytologic finding bladder biopsy show atypia flat urothelium nonpapillary carcinoma situ one noninfiltrating papillary carcinoma one no significant abnormality three cytologic detection urothelial abnormality often require single specimen since cohort study may develop bladder cancer passage time continue follow indicate extravesical cryosurgical approach vx bladder tumor rabbit study characterize vx bladder cancer model rabbit test feasibility treat bladder cancer extravesical cryosurgery growth characteristic vx bladder tumor model determine vx tumor inoculate rabbit dome bladder one week late three freeze thaw cycle follow immediate surgical repair control group undergo sham operation without freeze vx tumor inject bladder wall invasion central necrosis occur within week lymphatic metastasis week lung metastasis week inoculation week control rabbit large vx tumor bladder advance lung metastasis nine ten rabbit cryosurgical group mild moderate degree lung metastasis six relatively small local recurrence one rabbit no tumor bladder microscopic lung metastasis extravesical approach cryosurgery employ bladder inversion good tolerate cryosurgery exhibit modest efficacy treat local tumor delay lung metastasis aggressive tumor model paradox life among survivor bladder cancer treatment objective interpret meaning attribute experience bladder cancer among survivor therapeutic follow method qualitative methodological approach base medical anthropology narrative methodology approval research ethic committee public university hospital datum collect january february mean record semi structure interview direct observation field journal entry daily immersion group six man six woman age year therapeutic follow narrative analyze mean inductive thematic analysis result meaning reveal difficulty process disease treatment breakdown normal life uncertainty future due possible recurrence disease difficulty continuity care emotional control relate conflict way understand present life thus mean narrative synthesis paradox conclusion interpretation mean experience bladder cancer among patient provide nurse comprehensive view care encompass biological psychological social dimension thereby systematize humanize care objetivo interpretar significado atribu experi ncia c ncer de bexiga entre sobreviventes em seguimento terap utico todo empregou se abordagem metodol gica qualitativa embasado pela antropologia dica e todo narrativo ap aprova comit de tica os dado foram coletados de janeiro fevereiro de por meio de entrevistas semiestruturadas gravadas observa direta e registros no di rio de imers com grupo de seis homens e seis mulheres entre e anos em seguimento terap utico em um hospital p blico universit rio narrativas foram analisadas por meio da lise tem tica indutiva resultados os sentidos revelam dificuldades com processo da doen e tratamento como rupturas na vida futuro incerto pela possibilidade de recidiva da doen continuidade tratamento e controle emocional relacionando se com pondera es contradit rias da vida atual assim significado desta ntese narrativa de paradoxo conclus interpreta significado da experi ncia com c ncer de bexiga entre os adoecidos permite ao enfermeiro um olhar integralizado cuidado que perpasse dimens es biopsicossociais dos adoecidos e com isso sistematize assist ncia de maneira humanizada preoperative patient report mental health associate high grade complication radical cystectomy purpose psychological distress associate impair immune response poor wind heal hypothesize preoperative patient report mental health would associate high grade day complication radical cystectomy material method retrospectively identify patient undergo radical cystectomy bladder cancer complete short form sf survey self assessment health status little month surgery median physical mental composite score calculate expert model include know predictor postoperative high grade complication develope sf physical composite score mental composite score add determine association end point result january august patient undergo radical cystectomy bladder cancer complete preoperative sf questionnaire responder likely white p high preoperative albumin p receive neoadjuvant chemotherapy p pt disease p positive soft tissue surgical margin p median sf physical composite score iqr mental composite score iqr responder overall responder experience high grade day complication patient high grade complication low preoperative median sf mental composite score vs p no difference physical composite score vs p sf mental composite score also significant predictive variable add expert model p conclusion preoperative patient report mental health independently associate high grade complication radical cystectomy therefore patient self assessment health status surgery validate questionnaire may provide additional information useful predict short term postoperative outcome transurethral resection bladder tumour turbt non muscle invasive bladder cancer basic skill transurethral resection bladder tumour turbt standard surgical procedure non muscle invasive bladder cancer believe urologist train procedure dvd provide overview turbt particular focus basic skill include basic surgical technique obturator nerve block important basic surgical skill require complete turbt non muscle invasive bladder cancer resection visible tumor ii resection apparently normal mucosa border tumor iii resection muscle layer base tumor normal muscle fiber visible iv applicable case random biopsy apparently normal urothelium bladder wall transurethral resection tur biopsy side prostatic urethra v possible procedure complete different operate surgeon inspect bladder lumen confirm no remain tumor particular sample resection implement apparently normal mucosa approximately cm around tumor base tumor superficial muscle layer resect specimen examine histopathologically order confirm absence malignant finding fundamental procedure turbt include one stage two stage resection one stage resection use relatively small tumor involve single procedure simultaneous resection tumor tissue tumor base superficial muscle layer two stage resection \\ufeff1 resection expose low level mucosa 2 resection remove low mucosal layer order sample superficial muscle layer cancer stage start resection loop electrify make contact mucosa delicate movement sheath use along delicate movement loop adjust depth resection illustration surgical technique show not basic technique also point caution resection actual resection important fully understand property tumor combine technique appropriately individual resection procedure resect multiple tumor basic resection technique use single tumor apply repeat necessary translate section video article originally publish japanese dvd audio visual journal vol no japanese urological association bladder cancer patient derive murine xenograft aim study explore cost consequence introduce hexaminolevulinate hydrochloride guide blue light flexible cystoscopy hal blfc adjunct white light flexible cystoscopy compare white light flexible cystoscopy alone detection management nonmuscle invasive bladder cancer sweden method model evaluate patient outpatient set successful initial transurethral resection bladder tumor result hal blfc introduction across risk group result minimal budget impact total cost year swedish krona sek per patient year translate cost saving intermediate high risk group year conclusion hal blfc allow outpatient treatment improve recurrence detection reduce transurethral resection bladder tumor cystectomy bed day operate room time minimal cost impact across risk group demonstrate economic benefit introduce hal comparison multitarget fluorescence situ hybridization urine noninvasive test detect bladder cancer objective present single centre study investigate aneuploidy chromosome p e g loss p use multitarget fluorescence situ hybridization fish system identify genetic alteration urine specimen promise approach noninvasive detection bladder cancer patient method urine sample patient evaluate include histologically confirm urothelial carcinoma two urological malignancy act control urine sample take manipulation validity fish urovision vysis downer grove ill usa compare noninvasive urine test include bta stat test nuclear matrix protein nmp test immunocytology p lewisx evaluate test unaware clinical histopathological datum fish consider positive five urinary cell gain two chromosome threshold urine test u ml indication lymphography bladder cancer proceed analysis clinical x ray finding bladder cancer patient frequency lymphogenic metastatic spread determine relation degree local extent disease no metastasis metastasis b b case metastasis mainly detect external inguinal lymph node lumbar lymph node involvement always combine tumorous change pelvic lymphatic plexus indication lymphography relation primary tumor spread b define author determine role x ray monitor repeat lymphography detection metastasis study regression cause therapeutic measure leiomyosarcoma bladder year radiation therapy bladder cancer purpose although transitional cell carcinoma bladder tcc metastasize frequently devastate consequence no marker available monitor process uroplakins group specific marker normal urothelium continuously express majority tccs detection uroplakin positive cell circulation would strong indication hematogenous dissemination tumor cell patient tcc material method total rnas extract peripheral blood patient tcc non metastatic metastatic healthy control reverse transcribe subject polymerase chain reaction amplification rt pcr use oligonucleotide primer human uroplakin ii gene uroplakin express human bladder cancer cell line rt use positive control establish sensitivity rt pcr assay result show pcr amplification mrna encode uroplakin ii upii kda urothelium specific marker constitute highly sensitive specific assay detect transitional cell carcinoma tissue assay detect single bladder cancer cell ml blood sample upii mrna detect blood sample patient metastatic bladder cancer without chemotherapy patient chemotherapy not non metastatic patient normal control conclusion uroplakin ii highly specific marker human tcc detection uroplakin ii peripheral blood associate metastatic spread bladder cancer cell specific sensitive detection uroplakin ii provide useful adjunct detect bladder cancer metastasis stage monitor chemotherapeutic response evidence base clinical practice guideline bladder cancer summary edition japan treatment bladder cancer base guideline overseas problem practice option recommend overseas guideline not necessarily suitable japanese clinical practice relatively large numb clinical trial conduct japan field bladder cancer japanese urological association jua consider appropriate formulate guideline guideline present overview bladder cancer clinical stage follow clinical question address problem frequently face everyday clinical practice english translation shorten version original guideline abridge overview summarize clinical question answer include reference consider particular importance human epidermal growth factor receptor non muscle invasive bladder cancer issue assessment method role prognostic predictive marker putative therapeutic target comprehensive review although human epidermal growth factor receptor play prognostic predictive role breast gastric cancer function bladder cancer bc still controversial comprehensive review literature carry electronic search database pubmed scopus google scholar implement search term bc bladder carcinoma bladder neoplasm human epidermal growth factor c erbb c erbb erbb erbb neu marker biomarker prognosis result review consent summarize available datum predictor recurrence progression free survival univariate multivariate analysis b explore relate issue assess status tumor sample since may severely impair predictive function c report state art putative therapeutic target bc especially non muscle invasive bc stand prognostic factor good therapeutic target various cancer datum literature concern use bc provide conflict result probably due inherent complexity bc biology effort make establish suitable tumor specific score system assess single drug efficacy good design clinical trial lymph node assessment lymphadenectomy bladder cancer lymph node status key prognostic indicator patient bladder cancer lymphadenectomy important accurate stage moreover lymphadenectomy curative patient nodal metastasis although evidence quality regional node dissection associate oncologic outcome controversy exist factor may also explain observation consequently no consensus regard optimal extent lymphadenectomy numb node assess treatment infiltrate bladder cancer cobalt radiation recurrence tumor bladder initial disappearance purpose objective explore gender difference bladder cancer treatment decision make research approach secondary qualitative analysis interview transcript set one multidisciplinary genitourinary oncology clinic dana farber cancer institute two urology clinic brigham woman hospital beth israel deaconess medical center boston participant part original study man woman bladder cancer participate individual interview participant primarily caucasian little college education methodologic approach word frequency report use identify thematic difference man woman statement line line code construct prevalent among woman perform participant nvivo code result compare gender use matrix code query finding role family decision make process find dominant theme woman not man woman primarily describe family member facilitator bladder cancer treatment relate decision man likely describe family nonsupportive role conclusion result suggest influence decision make process different man woman bladder cancer family may play particularly important role woman face bladder cancer treatment relate decision interpretation clinical nurse care individual bladder cancer routinely assess patient support system desire level family participation decision make people bladder cancer family may serve stressor nurse support decision make process patient familiar resource provide support patient not receive family noble rat bladder cancer model fanft induce tumor laboratory unit work nb rat prostate adenocarcinoma model last several year recently use model system study efficacy various chemotherapeutic agent fanft induce bladder carcinoma rat strain purpose project identify factor chemotherapeutic agent may useful treatment human bladder carcinoma propose use nb rat utilize develop datum base advance understand management bladder carcinoma induce fanft ingestion nb rat conventional cytotoxic agent new combination chemotherapy utilize intravesically systemically gadolinium enhance mr image weight mr image transurethral ultrasonography purpose assess value problem dynamic gadolinium enhance mr image weight mr image transurethral ultrasonography tuus stage urinary bladder cancer material method dynamic gadolinium enhance mr image fse weight mr image patient urinary bladder cancer subsequently surgery retrospectively review compare tuus finding result specificity muscular invasion tuus significantly well dynamic mr image p rate overestimation superficial cancer pt dynamic mri weight mr image respectively stage accuracy invasive cancer pt dynamic mr image well rate achieve weight mr image conclusion although tuus well modality diagnose superficial cancer pt dynamic mr image find well diagnose invasive pt cancer assessment basal cell status proliferative pattern flat papillary urothelial lesion contribution new classification urothelial tumor urinary bladder world health organization publish new classification papillary urothelial tumor urinary bladder intend represent reproducible easy use classification system well separate patient true malignancy bladder cancer patient increase risk develope bladder cancer problem differential diagnosis various lesion remain probably critical distinction papilloma papillary urothelial neoplasm low malignant potential lmp grade papillary carcinoma conversely problem distinction reactive atypia atypia unknown significance dysplasia good distinction dysplasia carcinoma situ cis unresolved whether urothelial basal cell status assessment hematoxylin eosin stain slide complete cytokeratin immunohistochemistry anticytokeratin clone betae may help improve previously mention diagnostic dilemma investigate basal cell status assessment helpful differentiation dysplasia cis dysplasia ck ihc show predominantly basal label pattern whereas cis label urothelial layer see basal cell status assessment can separate group pta gib papillary carcinoma group continuous basal ck label low mib label index li compare group diffuse label pattern significantly high mib li whether group carcinoma well assign group papillary urothelial neoplasm lmp discuss association p codon exon urinary bladder cancer risk north indian population p frequently mutate gene form human cancer respond diverse stress include uvr induce dna damage regulate many downstream gene initiate cell cycle arrest dna repair apoptosis p gene variant codon pro ser codon exon evaluate bladder cancer bc risk north indians present study encode region p gene analyze hospital base study bc healthy control age gender match similar ethnicity genotype assess polymerase chain reaction restriction fragment length polymorphism technique statistically evaluate use spss software ver significant association find p codon polymorphism bc risk whereas p codon p pro ser polymorphism show no association bc risk individual carry heterozygous genotype arg trp arg gln p codon polymorphism show high bc risk p combination heterozygous variant genotype also show high risk bc p minor allele trp gln carrier p codon demonstrate fold risk bc furthermore haplotype analysis reveal glu pro trp gln haplotype associate fold risk bc protective role observe tumor stage grade bc patient p codon p thus evident study single nucleotide polymorphism evaluate p codon exon gene polymorphism implication risk bc north indian population precision medicine urothelial bladder cancer update tumour genomics immunotherapy effective management advance urothelial bladder cancer challenge new discovery improve understand molecular bladder cancer subtype reveal numerous potentially targetable genomic alteration demonstrate efficacy treatment harness immune system finding begin change paradigm bladder cancer therapy example dna repair pathway mutation gene ercc fancc atm rb other predict response neoadjuvant platinum base chemotherapy target therapy basis mutation status furthermore increase numb pan cancer clinical trial commonly refer basket umbrella trial enroll patient basis molecular genetic predictor response study promise provide improve insight true utility personalize medicine treatment bladder cancer many cancer type finally therapy modulate immune response show great benefit many cancer type several immune checkpoint inhibitor target programme cell death protein pd ligand pdl cytotoxic lymphocyte associate protein ctla already approve use bladder cancer represent important change urological oncologist tool kit decade advance also provide opportunity personalization bladder cancer therapy implement hexaminolevulinate hcl blue light cystoscopy nurse perspective hexaminolevulinate hcl diagnostic image agent use blue light cystoscopy help detect non muscle invasive bladder cancer blue light cystoscopy perform use hexaminolevulinate hcl find detect papillary non muscle invasive bladder tumor cystoscopy perform use standard white light bladder instillation retention requirement hexaminolevulinate cystoscopy affect patient flow perioperative set technique necessitate change nurse practice care patient know suspect non muscle invasive bladder cancer nurse personnel one facility follow aorn guideline preoperative patient care ambulatory set address staff preoperative nurse assessment anesthesia evaluation preoperative teach relate implement blue light cystoscopy glucuronidation ugt isozyme bladder new target treatment uroepithelial carcinoma bladder cancer link numerous toxin concentrate bladder absorb blood filter kidney excessive carcinogenic load bladder urothelium may result development cancer however enzyme within bladder metabolize carcinogen substrate safe importantly protein namely ugt uridine diphospho glucuronosyltransferases show possibly prevent bladder cancer also study show ugt expression decrease uroepithelial carcinoma may allow accumulation carcinogen bladder review discuss ugt system protective role bladder cancer ugt genetic mutation modulate risk chemical environmental toxin good target ugt enzyme nuclear receptor improve detection recurrent bladder cancer use bard bta stat test objective report long term result survival toxicity pattern failure different organ spare strategy patient muscle invasive bladder cancer material method monoinstitutional prospective analysis consecutive bladder spare protocol combine maximal transurethral resection bladder tumor mturbt radiotherapy rt cisplatin base chemotherapy protocol consist neoadjuvant methotrexate cisplatin vinblastine follow endoscopic evaluation consolidative rt gy complete responder protocol involve alter fractionation rt gy concurrent weekly cisplatin evaluation gy protocol consist rt gy concomitant weekly cisplatin nonresponders undergo radical cystectomy probability overall survival os cancer specific survival css metastasis free survival mfs calculate use kaplan meier product limit estimate cox regression multivariate analysis perform detect potential risk factor os css mfs result year bladder preservation rate year os css mfs rate respectively no statistically significant difference os different treatment protocol multivariate analysis mturbt bladder complete response induction therapy independent correlate improve os mfs development invasive bladder recurrence independently associate wrong css mfs conclusion ten year result indicate bladder spare treatment successful approach muscle invasive bladder cancer select patient mturbt bladder tumor complete response induction therapy remain relevant predictive factor rationale use cyclooxygenase inhibitor prevention treatment bladder cancer next tobacco saccharin may substance study epidemiologically patient bladder cancer participate back pain follow instillation bcg superficial bladder cancer not reactive complication review mycobacterium bovis bcg vertebral osteomyelitis case mycobacterium bovis bacillus calmette gu rin bcg instillation use bladder cancer treatment adverse effect occur osteoarticular complication mainly reactive arthritis true infection describe vertebral osteomyelitis make review bovis bcg vertebral osteomyelitis instillation bladder cancer use pubmed search add three new french case twenty seven case bcg vertebral osteomyelitis report pubmed case male average year old median time diagnosis \\ufeff1 last instillation month respectively half vertebral osteomyelitis thoracic lumbar half sensitivo motor deficit present diagnosis case infectious location common mainly infectious abdominal aortic aneurysm rifampicin ethambutol isoniazid usual therapy poor outcome report one spine surgery bovis bcg vertebral osteomyelitis follow bladder instillation bladder cancer rare complication however late onset back pain instillation differentiate reactive arthritis concomitant septic location infectious abdominal aortic aneurysm must know fluorescence cystoscopy nonmuscle invasive bladder cancer honeymoon blue light special objective prognosis patient apparently localize operable muscle invasive bladder cancer depend large extent presence absence subclinical microscopic distant metastasis time surgery expression protein show correlate risk metastasis animal tumour model system clinical investigation tumour type purpose present study investigate prognostic potential protein expression predict distant metastatic relapse muscle invasive bladder cancer method analyze consecutive patient treat transitional cell bladder cancer preoperative radiotherapy cystectomy pretherapeutic biopsy bladder tumour investigate immunohistochemical expression protein result along clinical histopathological datum compare pattern relapse yr follow period result focal protein expression emerge significant independent predictor distant metastatic relapse distant metastasis free survival multivariate analysis conclusion potential role marker denote patient high low risk distant relapse independent clinical stage grade analytic clinical evaluation new urinary tumor marker bladder tumor fibronectin diagnosis follow bladder cancer bladder cancer 4 common malignant neoplasm man 10 common woman cystoscopy present gold standard detection monitor bladder cancer however invasive expensive procedure therefore development biomarker purpose screen diagnosis prediction prognosis bladder cancer require bladder tumor fibronectin one new urinary tumor marker aim study evaluate diagnostic performance urinary bladder tumor fibronectin detect monitor bladder cancer total patient diagnosis bladder cancer patient diagnosis benign prostatic hyperplasia patient diagnosis prostate cancer year age match healthy individual enroll study patient diagnose cystoscopy histopathological evaluation tumor superficial invasive bladder cancer patient follow clinically datum pertinent disease recurrence progression bladder tumor fibronectin btf ng ml determine solid phase two site chemiluminescent immunometric commercial diagnostic assay develope immulite automate immunoassay system diagnostic product corporation los angeles ca usa measure value normalize urinary creatinine obtain datum evaluate receiver operate characteristic roc curve analysis optimal cut establish ng mg cut render overall sensitivity specificity analytic evaluation btf test display promise result term non invasive vitro test diagnosis bladder cancer although not satisfactory prediction recurrence progression disease correlate good stage one reliable prognostic factor conclusion urinary bladder tumor fibronectin test warrant clinical evaluation current intravesical therapy non muscle invasive bladder cancer introduction transurethral resection bladder tumour turbt still standard initial treatment non muscle invasive bladder cancer nmibc however even radical resection recurrence progression commonly see intravesical therapy provide direct contact agent bladder mucosa clearly improve outcome especially high risk disease area cover role good initial turbt emphasize risk assessment tool discuss different intravesical therapy enumerate accord late literature emphasis bacillus calmette gu rin bcg include discussion optimal dose schedule new development mention expert opinion radical turbt essential good prognosis optimal visualisation tumour fluorescence technique use low threshold especially case suspicion carcinoma situ cis increase completeness resection lead little persist disease little need adjuvant treatment turbt do doubt radical resection judge pathologist surgeon risk assessment essential available tool outdate single post operative instillation spi chemotherapy indicate low risk disease bcg treatment choice high grade disease bcg give maintenance awareness deterioration prognosis progression great importance bcg failure cystectomy strongly advise chemotherapy combination hyperthermia seem new promise treatment retinoid chemoprevention bladder cancer bladder cancer strongly relate tobacco use estimate cause new cancer case death unite state approximately two third new us case superficial tumor predominantly low grade papillary standard therapeutic resection without intravesical therapy superficial bladder tumor recurrence rate within month resection morbidity substantial frequent cystoscopy recurrence resection possible cystectomy progression invasive cancer therefore new approach include chemoprevention need datum suggest bladder carcinogenesis multi step multifocal field effect process possibly involve spread premalignant clone prerequisite effective chemopreventive approach date retinoid well study chemopreventive agent site achieve mix clinical result cis retinoic acid etretinate superficial bladder tumor review include epidemiology biology bladder carcinogenesis addition preclinical clinical retinoid datum focus promise avenue current retinoid chemoprevention bladder potent apoptosis induce retinoid fenretinide hpr currently three phase iii trial case squamous cell carcinoma arise urinary bladder diverticulum year old man admit hospital chief compliant difficulty urination low abdominal pain macrohematuria cystoscopy non papillary tumor see diverticulum right side urinary bladder make diagnosis urinary bladder cancer perform total cystectomy retroperitoneal node dissection construction ileal neobladder histologically squamous cell carcinoma pt pn seven month operation patient die recurrent disease radical cystectomy urinary diversion elderly patient increase comorbidity radical cystectomy urinary diversion accept standard care invasive bladder cancer orthotopic neobladders prefer method bladder substitution male female patient even select patient locally advance tumor complication rate orthotopic bladder substitute similar low morbidity rate conduit formation continent cutaneous diversion due progress perioperative management intensive care surgery cystectomy part classical treatment option bladder cancer elderly patient acceptable morbidity rate however indication cystectomy people old year base rigorous preoperative risk assessment asa status life expectancy year independent tumor transurethral resection alone propose patient poor performance status value radical cystectomy bladder cancer pelvic node involvement patient bladder cancer treat cystectomy urinary diversion january may pelvic lymphadenectomy perform patient pelvic node involvement show pathology study preoperative clinical stage show bladder muscle invasion case node invasion find case radiation therapy case without radiation therapy p little operative mortality case patient survive operation die cancer within average month twenty seven show pelvic node involve show patient node involve difference survival rate not statistically significant p two patient die disease not relate tumor alive year operation case report differential diagnosis isolate iliac lymphadenopathy follow bacillus calmette gu rin treatment high risk superficial bladder cancer report unusual case patient g pt transitional cell carcinoma tcc bladder treat repeat transurethral resection maintenance intravesical bacillus calmette gu rin bcg therapy month follow symptomatic solitary iliac lymph node mass identify biopsied histology demonstrate granulomatous tissue absence intravesical bladder tumour recurrence follow month anti tuberculous medication mass progress repeat biopsy reveal undifferentiated carcinoma bladder primary rare case metastatic superficial bladder cancer progression without local recurrence bcg therapy view diagnostic challenge granulocyte macrophage colony stimulate factor surface modify mb bladder cancer stem cell vaccine metastatic bladder cancer mb bladder cancer cell vaccine effective bladder cancer mouse model previous study however part tumor regrew vaccine can not eliminate cancer stem cell cscs mb bladder cancer stem cell mcscs isolate combination limit dilution method serum free culture medium method mcscs possess high expression cd cd oct nanog abcg ability differentiation high proliferative ability low susceptibility chemotherapy great migration vitro strong tumorigenic ability vivo streptavidin mouse granulocyte macrophage colony stimulate factor sa mgm csf mcscs vaccine prepare sa mgm csf mcscs vaccine extend survival mouse inhibit growth tumor protective therapeutic memorial specific immune response experiment level immunoglobulin g ratio dendritic cell cd cd cell high experimental group compare four control group good cytotoxicity assay demonstrate sa mgm csf mcscs vaccine induce antitumor immune response metastatic bladder cancer bladder tumor antigen bta test compare void urine cytology detection bladder neoplasm purpose test detect recurrent bladder neoplasm limit none consistently accurate recent study suggest bladder tumor antigen bta test agglutination reaction basement membrane complex superior void urine cytology clinical practice compare bta void urine cytology bladder washings cystoscopy emphasize diagnostic yield among patient cause basement membrane complex bladder cancer material method random void urine specimen patient history bladder neoplasm collect cystoscopy bladder wash urine also obtain patient inflammatory bladder condition include history prostate cancer urine test bta accord commercial kit positive result indicate yellow test pad blind result urine bladder wash examine microscopically positive test malignant suspicious cell bladder biopsy perform endoscopic lesion see specimen group category group biopsy prove bladder neoplasm group history bladder cancer not biopsy prove group history prostate cancer group no history urological cancer result void urine cytology positive specimen patient biopsy prove bladder neoplasm compare bta relative yield void urine cytology versus bta not change group case positive bladder wash positive cystoscopy assume bladder cancer relative yield alter subsequent short term followup void urine specimen group patient group patient scant cell overall diagnostic yield superior bladder wash false positive bta occur patient no history urological prostate cancer no false positive void urine cytology interpretation group conclusion bta not superior void urine cytology detect bladder neoplasm may limit false positive reaction patient cause basement membrane complex urine void urine sample may limit high frequency hypocellularity patient hypocellular urine specimen biopsy prove bladder cancer bladder wash yield well result require instrumentation no test include cystoscopy accurate always quality control indicator transurethral resection non muscle invasive bladder cancer complete transurethral resection bladder tumor turbt initial procedure choice non muscle invasive bladder cancer quality far optimal clinical practice evaluate exist body evidence substantiate current quality control indicator qcis turbt literature search perform use pubmed embase select article review accord level evidence disease recurrence progression use primary end point no hard evidence support complete resection qci rationally important indicator turbt repeat resection important qci high risk disease patient evidence suggest may not necessary detrusor muscle present initial resection specimen presence detrusor muscle resection specimen validate qci turbt adjuvant intravesical instillation scientifically prove qci bladder perforation controversial qci exist literature no evidence indicate ideal time frame initial turbt thus initial therapy \\ufeff1 week diagnosis not good qci three propose qcis turbt support evidence literature analysis indicate use complete resection repeat resection presence detrusor muscle intravesical instillation qcis minimize recurrence progression increase beneficial outcome short term mortality associate definitive chemoradiotherapy versus radical cystectomy muscle invasive bladder cancer background muscle invasive bladder cancer mibc may manage radical cystectomy rc chemoradiotherapy crt patient selection rc important avoid treatment relate mortality study address knowledge gap quantify short term mortality approach good predictor thereof material method national cancer database query clinically stage mibc receive either crt rc statistic include cumulative incidence comparison day mortality patient treat either crt rc cox regression evaluate predictor thereof result patient undergo rc crt crude rate post treatment mortality day versus p day versus p patient treat rc crt respectively stratify age wrong day mortality rc observe patient age year conclusion study describe day mortality follow rc versus crt approach yield statistically similar treatment relate mortality rate patient year age however wrong post treatment mortality observe use rc patient year age result may utilize well inform share decision make patient provider weigh rc crt mibc chromium urothelial carcinoma bladder introduction objective many epidemiological experimental study report strong role chemical carcinogen etiology bladder cancer however involvement heavy metal tumourigenesis urothelial carcinoma bladder poorly investigate therefore aim study examine relationship chromium cr bladder cancer material method chromium concentration two sample series bladder cancer tissue serum patient neoplasm match control group amount trace element every tissue sample determine use atomic absorption spectrometry correlate tumour stage result median chromium concentration level reach statistically high value bladder cancer tissue compare non cancer tissue ng g ng g respectively p median cr level serum patient carcinoma show no statistical difference compare control group g l g l respectively p median level cr bladder tissue depend stage tumour compare tissue without neoplasm observe relationship non muscle invasive muscle invasive tumour p p respectively conclusion study show patient urothelial carcinoma bladder high tissue cr level people without tumour no difference find cr serum level two group patient investigation bacillus calmette gu rin immunotherapy bladder cancer review immunological aspect clinical effect bcg infection bacillus calmette gu rin bcg immunotherapy bladder cancer use since \\ufeff1 evidence ability low recurrence progression rate publish today bcg immunotherapy choice care high grade non muscle invasive bladder cancer nmibc transurethral resection article present indication procedure bcg instillation outline effect recurrence progression nmibc bcg induce immunity nmibc not yet fully understand animal study point towards bcg induce specific tumour immunity describe current knowledge immunity induce internalization bcg bacillus urothelial cell cytokine chemokine mediate recruitment neutrophil monocyte macrophage cell b cell natural killer cell addition describe process train immunity non specific protective effect bcg recent study also indicate dysbiosis urinary microbiome may cause low urinary tract dysfunction side effect bcg bladder instillation range common mild transient symptom dysuria flu like symptom severe rarely occur need experimental research bladder cancer role regional lymphadenectomy surgical management high grade invasive bladder cancer evolve last several decade grow body evidence suggest extend lymph node dissection may provide not improve prognostic information also clinically significant therapeutic benefit lymph node positive negative patient undergo radical cystectomy extent primary bladder tumor numb lymph node remove lymph node tumor burden important prognostic variable patient undergo cystectomy addition concept lymph node density may improve stratification lymph node positive patient historical development contemporary rationale extend pelvic lymphadenectomy patient undergo radical cystectomy review importance urinary cytology future role flow cytometry study recently complete laboratory evaluate role flow cytometry comparison urinary cytology clinical practice set ascertain utility new method routine diagnostic pathology patient follow know bladder cancer urinary cytology yield positive result per cent case flow cytometry yield per cent positivity rate diagnostic accuracy two modality combine per cent low diagnostic yield flow cytometry occur patient treat topical chemotherapy bladder cancer apparent false negative result flow cytometry may due paucity cell epithelial denudation topical agent inhibition tumor growth chemotherapeutic agent mask small aneuploid cell population large inflammatory cell population result suggest urinary cytology flow cytometry complementary laboratory test diagnostic evaluation bladder cancer patient clinical practice prompt diagnosis key bladder cancer bladder cancer frequently diagnose cancer involve urinary tract 7 common cancer uk delay diagnosis associate high grade muscle invasive disease potential progress rapidly metastasise often fatal urothelial cancer transitional cell carcinoma predominant histological subtype europe account bladder cancer haematuria typically intermittent frank painless time present throughout micturition classical common presentation bladder cancer however irritative symptom dysuria urgency urge incontinence frequency good obstructive symptom also experience fatigue weight loss anorexia renal failure respiratory symptom suprapubic palpable mass usually sign advance metastatic malignancy cigarette smoker four time risk bladder cancer compare non smoker risk factor include exposure aniline dye use cyclophosphamide history pelvic radiation exposure chemical carcinogen associate certain industry spinal cord injury require long term indwell catheter type diabetes treat pioglitazone condylomata acuminata frank haematuria high diagnostic yield malignancy involve urinary tract initial routine test direct towards identify variety potential non malignant cause thorough physical examination undertake identify evidence bleed diathesis metastatic malignancy suggest laboratory investigation include fbc coagulation creatinine psa diagnosis bladder cancer base urine cytology cystoscopy pathological assessment bladder biopsy elective bladder spare treatment muscle invasive bladder cancer objetives radical cystectomy standard treatment localise muscle invasive bladder cancer mibc offer bladder spare treatment turb chemotherapy radiotherapy select patient alternative material method analyze retrospectively patient diagnose mibc march october mean age year patient candidate curative treatment undergo strict selection criterium stage primary tumor solitary lesion small cm macroscopic disease free status turb negative random biopsy without hydronephrosis stage ct evaluation normal restage turb tumor bed biopsy show disease free status microscopic muscle invasion patient undergo turb alone turb chemotherapy turb chemotherapy radiotherapy result mean follow month patient remain disease free recurrent non muscle invasive bladder cancer complete clinical response bladder preserve year overall year survival rate cancer specific survival rate conclusion although radical cystectomy standard treatment localise mibc strictly select case bladder spare treatment offer alternative good long term result mirna accelerate proliferation migration bladder cancer via inhibit kmt uncover biological function mirna progression bladder cancer underlie mechanism potential mirnas bind kmt predict online bioinformatics expression level bladder cancer tissue adjacent one determine pearson correlation analysis survival analysis potential mirna candidate mirna target regulate kmt bladder cancer select subsequently expression level mirna kmt non muscle invasive bladder cancer nmibc muscle invasive bladder cancer mibc detect mirna level bladder cancer cell line determine good interaction kmt mirna verify ca tumour marker transitional bladder carcinoma monoclonal antibody ca useful tumour marker gastrointestinal carcinoma report assessment value bladder cancer patient find raise level patient infiltrate carcinoma superficial carcinoma recurrence rate high patient raise level since elevate level normal value recurrence within month carcinoma mean ca level high normal g tumour mean level slightly normal statistically significant difference emerge compare ta carcinoma long study serial determination can assess role ca prognostic indicator bladder cancer molecular credentialing rodent bladder carcinogenesis model cancer urinary bladder often result exposure chemical carcinogen model disease develope expose rodent n butyl n hydroxybutyl nitrosamine oh bbn resultant tumor histologically similar human disease little know genetic similarity latter knowledge would help identify corroborate gene find important human bladder cancer suggest biologically appropriate mechanistic study address need compare gene expression profile associate urothelial carcinoma three different species mouse rat human find many human gene homologous differentially express carcinogen induce rodent tumor also differentially express human disease preferentially associate progression non muscle invasive muscle invasive disease also find overall gene expression profile rodent tumor correspond closely invasive human tumor rather non muscle invasive tumor finally provide list gene likely candidate drive disease process virtue concordant regulation tumor three species surgical management patient clinical stage bladder cancer single institution experience introduction patient clinical ct bladder cancer bca infrequently undergo radical cystectomy rc investigate reliability preoperative clinical stage perioperative survival outcome patient treat rc due ct b bca disease single tertiary care institution method study rely bca patient treat rc pelvic lymph node dissection plnd single institution january december compare accuracy clinical assessment final pathology result moreover evaluate perioperative outcome complication rate survival surgery result median follow month overall patient present ct stage preoperative evaluation conversely pathological disease confirm patient stage initially ct no difference record complication day readmission day death rate ct vs ct vs ct b p multivariable cox regression analysis predict cancer specific mortality clinical stage vs clinical clinical stage vs clinical age predictor wrong survival rc p conclusion record poor concordance preoperative image pathology ct patient no difference major perioperative outcome acceptable survival expectancy report patient treat ct disease fluorescence guide endoscopy improvement management bladder cancer white light cystoscopy cytology standard tool diagnose bladder cancer white light cystoscopy excellent detect macroscopic exophytic tumor sensitivity poor flat tumor carcinoma situ use fluorescence cystoscopy transurethral bladder resection improve tumor detection particulary carcinoma situ fluorescence cystoscopy reduce residual tumor rate especially voluminous multifocal tumor consecutive low recurrence fluorescence recommend diagnose treat bladder cancer alternative method diagnosis stage bladder cancer survey conventional diagnostic measure bladder carcinoma give importance additional method pelvic arteriography phlebography lymphography lymphoscanning evaluate thirty five year noninvasive bladder carcinoma plea use papillary intraurothelial neoplasia new terminology since introduction world health organization terminology bladder cancer noninvasive epithelial bladder tumor consistently label bladder carcinoma classification removal carcinoma label small subset noninvasive bladder carcinoma indolent behavior create entity papillary urothelial neoplasm low malignant potential remain noninvasive carcinoma urothelial tract retain label overview analyze clinical pathologic molecular genomic finding support evidence base nomenclature papillary neoplastic lesion urinary tract line tendency last decade label flat precancerous lesion various organ intraepithelial neoplasm may also refer dysplasia carcinoma situ urinary tract low high grade intraurothelial neoplasia respectively harmonize nomenclature propose term low high grade papillary urothelial carcinoma replace low high grade papillary intraurothelial neoplasiafor noninvasive urothelial cancer change management base pathologic 2 opinion among bladder cancer patient present comprehensive cancer center implication clinical practice objective evaluate incidence degree change pathologic 2 opinion bladder biopsy comprehensive cancer center initially perform refer community hospital secondary objective determine impact potential change would patient treatment material method dedicate genitourinary pathologist review transurethral biopsy bladder prostatic urethra major minor treatment change define alter recommendation cystectomy systemic chemotherapy primary cancer diagnosis alteration intravesical regimen respectively result patient pathologic change 2 opinion grade stage muscle specimen presence absence carcinoma situ outside pathology not address presence absence lymphovascular invasion invasive case ct lymphovascular invasion mix variant nonurothelial histology detect patient result reclassification pathologist potential treatment alteration account case impart major change change recommendation radical cystectomy complete change primary tumor type change chemotherapy regimen conclusion amount degree pathologic change potential impact treatment emphasize importance bladder cancer patient histology review genitourinary dedicate pathologist cohort patient can see treatment alteration major change diagnosis management urothelial carcinoma bladder bladder carcinoma 4 common cancer man 9 common cancer woman unite state approximately new case bladder carcinoma man woman approximately death expect unite state bladder carcinoma classify urothelial carcinoma uc arise urothelium epithelium also know transitional cell epithelium line urinary tract extend renal pelvis ureter bladder urethra urothelial carcinoma bladder may present non muscle invasive muscle invasive metastatic malignancy noninvasive tumor treatment cystoscopic resection intravesical therapy direct reduce recurrence prevent progression advance stage goal invasive tumor combination radical cystectomy perioperative cisplatin base combination chemotherapy enhance outcome reduce high risk distant recurrence outcome metastatic uc dismal current cisplatin base combination chemotherapy progressive disease frontline chemotherapy characterize short survival therefore clinical trial focus metastatic uc important primary care physician recognize early sign symptom bladder carcinoma initiate proper work refer promptly urologist evaluate suspicious sign symptom role bladder preserve strategy treatment muscle invasive bladder cancer single modality bladder spare therapy muscle invasive bladder cancer include transurethral resection systemic chemotherapy radiotherapy demonstrate result insufficient local control primary tumor good decrease long term survival patient compare radical cystectomy therefore multimodality treatment protocol aim bladder preservation involve aforementioned approach establish argument combine systemic chemotherapy radiation sensitize tumor tissue radiotherapy eradicate occult metastasis already develope many patient time \\ufeff1 diagnosis show clinical outcome observe approach approximate radical cystectomy additionally substantial numb patient survive intact bladder however bladder preserve approach costly require close co operation different clinical specialist good close follow good long term result obtain cystectomy creation orthotopic neobladder make possible advantage bladder preservation strategy questionable consideration quality life issue additionally side effect relate bladder spare therapy may result increase morbidity mortality patient fact need undergo surgery due recurrent progressive disease multimodality bladder spare treatment therapeutic option offer patient centre dedicate multidisciplinary team disposal however radical cystectomy remain standard care muscle invasive bladder tumor single cell analysis transcriptional heterogeneity squamous cell carcinoma urinary bladder cell cell expression heterogeneity within single tumor common phenotype among various cancer type include squamous cell carcinoma study fundamental importance heterogeneity cell function potential mechanism perform single cell rna seq scrna seq human squamous cell carcinoma bladder sccb correspond physiologically normal epithelium extensive differentially express gene uncover compare cancer normal single cell preferentially enrich cancer correlate pathway p signal bladder cancer pathway furthermore diversely express gene particularly enrich mapk signal pathway cacng cacna e cacna h involve cancer evolution heterogeneity formation co expression network hub gene analysis reveal several remarkable hub gene regulatory module cancer relate pou f nkd cyp c linc gcc q gene rarely report human disease gene within interest module highly correlate other can treat potential target sccb patient finding fundamental implication sccb biology therapeutic strategy ethnic distribution glutathione transferase mu gstm null genotype individual application bladder cancer susceptibility polycyclic aromatic hydrocarbon find cigarette smoke food industrial material potential human carcinogen deficiency detoxify enzyme glutathione transferase may affect metabolic fate chemical raise cancer risk expose individual gstm null genotype common form glutathione transferase deficiency knowledge ethnic distribution would useful epidemiologic study measure frequency gstm null genotype among healthy black white asian indians chinese japanese koreans filipinos samoans hispanics rapid genotype do use pcr assay dry blood spot blotter paper dna template frequency null genotype range among black among samoans pcr assay also apply pilot study bladder cancer case kaiser permanente medical center harbor city california dna case obtain paraffin embed surgical specimen overall odd ratio bladder cancer gstm null genotype confidence interval indicate no statistical difference null genotype frequency among bladder cancer patient compare healthy population large epidemiologic study accomplish dry blood spot paraffin embed tissue specimen may useful assessment treatment bladder cancer ionize radiation introduction patient bladder urothelial cancer not suitable not choose curative treatment intractable hematuria disastrous condition article try review literature extract stepwise approach palliative treatment hematuria patient material method medline search help medical subject heading system use different combination term urinary bladder neoplasm hematuria carboprost cyclophosphamide cystitis alum hyperbaric oxygenation article separately review two author verify eventually decision tree develope management gross hematuria patient bladder cancer result although not report randomize control trial prospectively design study available case series rather expressive draw logical approach formalin grave adverse effect profile recommend special circumstance management case gross hematuria bladder cancer etiology bleed important determinant conclusion hematuria context advance bladder neoplasm effectively treat few side effect use available modality logical holistic approach propose decision tree management hematuria context however regard lack good design trial treatment method base individualize scenario clinical experience bring account patient preference demonstration nitrosamine human urine preliminary observation possible etiology bladder cancer association chronic urinary tract infection recent study underscore importance oxygen supply bladder cancer tumour growth stimulate production vasoactive factor increase oxygen delivery tissue vasodilatation vasoconstrictor mediator can impair vasodilatation reduce oxygen supply iso pgf alpha potent vasoconstrictor agent aim work determine iso pgf alpha release healthy bladder mucosa superficial bladder cancer order investigate pathophysiological vasoconstrictor answer superficial bladder cancer study conduct sample patient every subject study iso pgf alpha release assay healthy bladder mucosa superficial bladder tumour iso pgf alpha release significantly reduce p little superficial bladder cancer compare healthy bladder mucosa inhibition production powerful vasoconstrictor iso pgf alpha vascular homeostatic mechanism bladder cancer represent response tumor tend contrast antagonist effect vasodilatation necessary support oxygen supply non papillary carcinoma situ bladder clinicopathologic study case treat radical cystoprostatourethrectomy two case carcinoma situ bladder treat radical cystoprostatourethrectomy evaluted histologic study totally embed epithelium clinical symptomatology consist urinary frequency diminish bladder capacity pain void urinary cytology multiple biopsy essential diagnosis lesion resect specimen case fix formalin totally embed step section map histopathologic study case atypical epithelium carcinoma situ focus microinvasion affect bladder mucosa extend continuously distal ureter good prostatic urethra since lesion subsequently may result invasive bladder cancer often involve prostatic urethra distal ureter case radical cystoprostatourethrectomy recommend use methylation marker diagnostic prognostic indicator bladder cancer urothelial carcinoma urinary bladder diverse biological functional characteristic numerous factor likely involve recurrence progression patient survival several molecular marker use evaluate development prognosis bladder cancer study limit value therefore new molecular parameter useful predict prognosis bladder cancer patient particularly patient high risk progression recurrence require recent progress understand epigenetic modification gene silence provide new opportunity detection treatment prevention cancer methylation important molecular mechanism bladder cancer may utility prognostic diagnostic marker review discuss epigenetic issue involve detection prediction bladder cancer high throughput tissue microarray analysis cyclin e gene amplification overexpression urinary bladder cancer study comparative genomic hybridization reveal q chromosomal region frequently amplify bladder cancer cyclin e gene ccne code regulatory subunit cyclin dependent kinase map q investigate role cyclin e alteration bladder cancer tissue microarray specimen bladder cancer patient construct analyze ccne amplification fluorescence situ hybridization cyclin e protein overexpression immunohistochemistry fluorescence situ hybridization analysis show amplification evaluable tumor amplification significantly associate stage grade p immunohistochemically detectable cyclin e expression strong weak negative interpretable tumor majority ccne amplify tumor strongly immunohistochemistry positive p frequency protein expression increase stage pta pt p decrease stage pt p pt versus pt low cyclin e expression associate poor overall survival patient p no prognostic impact independent stage conclude cyclin e overexpression characteristic subset bladder carcinoma especially stage early invasion analysis prognostic impact ccne gene amplification protein expression array bladder cancer accomplish period week illustrate tissue microarray technology remarkably facilitate evaluation clinical relevance molecular alteration cancer evaluation 2 look transurethral resection restage patient nonmuscle invasive bladder cancer purpose evaluation 2 look transurethral resection tur avoidance stage error determination risk factor upstage patient nonmuscle invasive bladder cancer patient method analytic prospective cohort study include patient stage bladder cancer patient undergo 2 look tur within week initial resection histopathologic finding 2 tur bladder tumor turbt compare initial one result specimen obtain 2 turbt show no tumor patient patient residual cancer stage patient pt low stage high stage upstage change treatment strategy case appearance size grade stage tumor initial resection consider independent risk factor upstage detect 2 look turbt conclusion 2 turbt valuable procedure accurate stage nonmuscle invasive bladder cancer change treatment strategy significant proportion patient 2 turbt indicate high grade large size cm nodular tumor significant risk detect muscle invasive disease molecular profile bladder cancer involvement tgf beta pathway bladder cancer progression human bladder cancer model nine cell sublines derive bl cell line use evaluate gene relate disease progression molecular profile sublines non tumorigenic invasive nude mouse perform identify differentially express gene quantitative real time pcr analysis six transform growth factor beta tgf beta pathway gene use entire panel nine cell line perform bone morphogenetic protein expression significantly associate vivo tumorigenicity cell line p bladder cancer portal man health bladder cancer 4 common cancer among man unite state fold high incidence woman globally tobacco smoke remain significantly common man contribute half case bladder cancer prevent bladder cancer urologist promote smoke cessation patient present early age concern sexual dysfunction infertility pelvic pain vasectomy bladder cancer also provide entry point man healthcare system time urologist discuss coordinate attention male health issue cardiovascular illness depression addiction assume role man health physician urologist significant benefit man urologic overall health target risk factor behavior treatment delay muscle invasive bladder cancer infiltrate transitional cell carcinoma urinary bladder induce ingestion n nitro furyl thiazolyl formamide fanft female wistar rat month carcinogen exposure animal divide different treatment group receive cyclophosphamide intraperitoneally single injection bcg either intralesionally weekly subcutaneously combination cyclophosphamide follow subcutaneous bcg treatment effect determine body weight measurement bladder tumour weight month compare control group statistically significant difference bladder tumour weight find treatment bcg alone combination cyclophosphamide intralesional bcg result insignificant increase tumour weight pre postoperative nurse patient bladder cancer social rehabilitation problem daily live patient ileal conduit new rapid immunoassay kit assay fibrinogen degradation product fdp study patient cancer bladder control patient specificity kit demonstrate small numb false positive result bladder cancer patient low stage small superficial tumor fdp positive per cent combination urinary cytologic examination fdp increase accuracy positive result per cent rapid fdp test supplement urinary cytology follow detection early bladder cancer metastasis suppressor mtss act putative tumour suppressor human bladder cancer background metastasis suppressor mtss propose function cytoskeletal associate protein may play role aggressiveness cancer cell recent study demonstrate clinical significance mtss certain type cancer role bladder cancer remain unknown investigate expression mtss normal malignant human bladder tissue molecular interaction within bladder cancer cell material method expression mtss human bladder tissue bladder cancer cell line assess mrna protein level use reverse transcription pcr rt pcr immunohistochemistry respectively full length mtss cdna amplify normal mammary tissue effect mtss overexpression cellular function examine bladder cancer cell use variety vitro assay result transitional cell bladder tissue stain positively mtss however cancer cell tumour tissue not stain mtss similarly bladder cancer cell line mtss almost absent rt cell ej cell line express low level mtss overexpression mtss reduce growth adhesion bladder cell line vitro however overexpression mtss no bear invasion migration bladder cell line vitro conclusion mtss express low level absent human bladder cancer cell mtss level inversely correlate growth adhesion bladder cancer cell vitro mtss appear potential tumour suppressor human bladder cancer treatment invasive bladder cancer lesson past perspective future radical cystectomy lymphadenectomy gold standard treatment invasive bladder cancer however treatment alone not always provide satisfactory result disease extend outside bladder review discuss several clinical issue diagnosis treatment invasive disease although quality diagnostic image modality improve still not sensitive enough stage disease especially early invasive disease addition lack serum marker hinder appropriate monitor patient disease regard surgical aspect lymphadenectomy area dissection standard numb node retrieve method pathological examination establish clinical benefit surgery clearly define neoadjuvant chemotherapy invasive disease promise improvement survival patient chemotherapy regimen effective little toxic mvac methotrexate vinblastine doxorubicin cisplatin report several phase iii clinical trial launch determine benefit adjuvant neoadjuvant chemotherapy newly develope agent however still lack chemotherapy regimen effective mvac crucial issue treatment invasive disease alternative option disease may bladder preservation transurethral resection tumor follow chemoradiotherapy however patient indicate treatment may limit early invasive disease certain favorable clinical pathological feature follow bladder cancer right examination right time schedule follow fu bladder cancer patient predominantly base study low level evidence result guideline recommendation often found expert consensus fu non muscle invasive bladder cancer nmibc include cystoscopy cytology standard image modality low extent fu muscle invasive bladder cancer mibc depend primarily therapeutic modality choose stage disease scenario fu complement functional quality life relate aspect apply even fu palliative situation individual focus examination may consequence term survival symptom relief treatment infiltrate bladder cancer report congress french association urology paper discuss method complex treatment invasive bladder cancer include radiation therapy regional intraarterial chemotherapy cisplatin drug selective hyperglycemia local shf hyperthermia complete local response report patient stage ii iv tumor partial no response method appear effective safe offer good perspective bladder cancer treatment predictive factor residual cancer 2 transurethral resection non muscle invasive bladder cancer one major problem cancer chemotherapy development drug resistance treatment two mechanism consider cause drug resistance natural acquire consider cancer compose multiple clonal subpopulation cancer cell study separate three clone c c c nbt human bladder cancer cell line limit dilution examine growth rate transplantability nude mouse perform chromosomal analysis three clone double time c hour c c hour respectively clone transplantable nude mouse can not find histological difference among chromosome number c c c respectively can also find karyotypic difference among can therefore consider three clone different biological feature study difference drug sensitivity among three clone parent cell line cell x good incubate microplates ten different chemotherapeutic agent hour h thymidine microci ml add hour cell harvest uptake h thymidine count liquid scintillation counter accord reaction pattern chemotherapeutic agent divide three group radio isotope uptake three clone parent cell line proportionally inhibit increase drug concentration carboplatin glycolato diammine platinum ii ifosfamide abstract truncate word early vs delay radical cystectomy high risk carcinoma not invade bladder muscle delay cystectomy reduce cancer specific survival background study quantify risk urinary bladder neoplasm cancer patient take account age \\ufeff1 diagnosis gender patient lead time diagnosis method use standardise incidence ratio sir compare incidence bladder tumour cancer patient incidence rate general swedish population total male female patient develope bladder tumour little year \\ufeff1 cancer diagnosis result bladder renal pelvis cancer sir bladder neoplasm high female male patient man affect lung stomach larynx tumour belong population high risk bladder cancer treatment breast ovarian cervical cancer seem contribute subsequent development bladder neoplasm long latency year observe testicular cervical endometrial cancer detection bias important role prostate cancer chemotherapy cyclophosphamide cisplatin also radiotherapy seem increase risk subsequent neoplasm bladder conclusion population base result may help urologist assess risk bladder neoplasm cancer survivor datum guide ongoing study investigate effectiveness bladder cancer screen cancer patient current role radiation therapy bladder cancer radiation therapy continue expand role management bladder cancer utilization chemoradiation part management increase likelihood keep native bladder positive impact quality life without compromise cure remain sustain interest concept bladder conservation organ spare approach potentially equivalent radical cystectomy regard disease specific survival addition radiation therapy may play meaningful role management non muscle invasive bladder cancer reduce likelihood local recurrence prevent delay cystectomy recently technique radiation therapy improve considerably role radiation therapy subsequently expand lead well outcome well understand biology fractionation tumor response cell culture system study invasion evaluate therapeutics bladder cancer bladder cancer significant health problem estimate people die year unite state bladder cancer bladder cancer non invasive unlikely metastasize progress invasive growth pattern half patient invasive cancer develop lethal metastatic relapse thus understand mechanism invasive progression bladder cancer crucial predict patient outcome prevent lethal metastasis article present three dimensional cancer invasion model allow incorporation tumor cell stromal component mimic vivo condition occur bladder tumor microenvironment model provide opportunity observe invasive process real time use time lapse image interrogate molecular pathway involve use confocal immunofluorescent image screen compound potential block invasion protocol focus bladder cancer likely similar method can use examine invasion motility tumor type good malignant priapism secondary bladder cancer total case bladder cancer spinal cord injury man quadriplegics paraplegic see medical center since man hyperreflexic bladder associate detrusor sphincter dyssynergia upper tract change note patient distal ureterectasis mild hydronephrosis man not historical film compare result histology transitional cell carcinoma man squamous cell carcinoma four patient present muscle invasion present diffuse carcinoma situ involve penile urethra three patient present superficial transitional cell carcinoma progression muscle invasion within month patient invasive disease undergo radical operation urinary diversion although followup short range month patient good no evidence disease die no evidence disease find low incidence bladder cancer decrease percentage squamous cell carcinoma previous report may reflect improvement low tract management patient survival appropriate bladder cancer treatment appear correlate good ambulatory population bladder tumor aromatic amine wilhelm hueper know today environmental factor must regard significant cause urinary bladder carcinoma germany urinary bladder carcinoma 2 common urological tumor among man common among woman occupational bladder case recognize compensate per year scientific study problem reach back th century however surgeon ludwig rehn firstly describe case occupational bladder tumor fuchsine worker frankfurt extremely significant discovery follow description large numb case urinary bladder tumor among worker paint industry nevertheless impossible induce bladder cancer animal aromatic amine many year pathologist wilhelm c hueper \\ufeff1 induce bladder cancer animal experiment apply beta naphthylamine dog base experiment corroborate epidemiologic study beta naphthylamine ban germany many country review highlight work life two pioneer medical researcher unusual finding benign urachal tumor author determine recurrence progression year patient non muscle invasive urothelial carcinoma undergo transurethral resection bladder tumor turbt compare result calculate risk accord european organization research treatment cancer eortc total patient nmibc treat transurethral resection bladder cancer accord eortc score system patient categorize term numb tumor tumor size prior recurrence rate category carcinoma situ pathologic grade score sum accord sum score recurrence group progression group divide subgroup low intermediate high risk respectively recurrence rate progression rate group compare eortc risk table mean patient age year range diagnosis seventy eight patient recurrent disease tumor large cm diameter multiple lesion carcinoma situ stage lesion high grade disease recurrence rate group predict eortc risk respectively patient progression disease eortc model successfully stratify recurrence progression risk cohort however discriminative ability eortc table decrease patient progression detection exfoliate bladder cancer cell monoclonal antibody tumor associate cell surface antigen monoclonal antibody mabs human tumor antigen potential tumor detection treatment bladder carcinoma detection exfoliate tumor cell urinary specimen may accomplish mabs react tumor prognostic index bladder prognostic index bilharzial relate invasive bladder cancer purpose bladder cancer still common solid tumor among adult male egypt prevalence bilharzial infestation especially countryside prospective study record prognostic factor patient invasive bladder cancer standard radical cystectomy perform develop prognostic index bladder prognostic index define high risk patient vulnerable disease relapse surgery may benefit additional therapy patient method study perform january december patient histopathologically prove invasive bladder cancer associate bilharziasis undergo radical cystectomy anterior pelvic exenteration surgery patient regularly follow minimum year result patient include male female squamous cell carcinoma common type tumor grade ii total patient tumor operable inoperable operative relate mortality year postoperatively free overall survival rate whole group patient respectively tumor pathologic stage grade nodal affection significant factor impact survival p respectively prognostic index use design model predict individual patient risk factor recurrence patient assign one risk group accord score achieve prognostic index low risk intermediate risk high risk risk group distinctly different rate disease free survival e low intermediate high risk group respectively conclusion although prognostic index appear significant clinical relevance need validate large numb patient can surrogate variable biologic factor responsible heterogeneity bladder cancer tobacco smoke bladder cancer coffee non drinker fifty nine patient history bladder cancer evaluate three serially void urine flow cytometry cytology within hour precede cystoscopy bladder wash biopsy evaluation patient biopsy prove cancer reveal one two three void urine specimen sensitivity flow cytometry detect bladder cancer respectively whereas sensitivity void urine cytology respectively bladder wash flow cytometry sensitivity interpretation void urine flow cytometry base control group volunteer negative void urine cytology control group demonstrate minimum analyzable cell necessary reliable histogram consider patient void urine flow cytometry bladder wash flow cytometry void urine cytology acceptable analysis specimen respectively void urine specimen appear little suitable bladder irrigation specimen evaluation flow cytometry void urine flow cytometry little sensitive detect bladder cancer void urinary cytology bladder wash flow cytometry not effective use bladder cancer screen test management superficial bladder cancer community set past four five year urologist private practice gain experience use mitomycin treatment superficial bladder cancer indication use mitomycin include carcinoma situ cis two three recurrence successive cytoscopic examination superficial transitional cell carcinoma presence multiple transitional cell carcinoma time initial examination believe tumor can not remove cystoscopically prophylaxis regimen mitomycin change time currently standard regimen mg mitomycin cc sterile water give intravesically week eight week follow routine cystoscopic examination every three month maintenance therapy indicate mg mitomycin month result follow use regimen private practice encourage complication minimal patient discontinue therapy side effect patient undergo radical cystectomy recurrent disease partial cystectomy mitomycin therapy patient still receive treatment include patient not respond initial treatment follow possible recurrence mitomycin therapy appear effective control superficial bladder cancer possibly carcinoma situ minimal side effect good patient compliance ileocaecal vs ileal neobladder radical cystectomy patient bladder cancer comparative study objective compare ileocaecal orthotopic bladder standard procedure egypt year ileal neobladder no ideal continent orthotopic bladder replacement patient cystectomy bladder cancer patient method june december patient invasive bladder cancer randomize two group group comprise patient radical cystectomy reconstruction ileal neobladder median age year man two woman group b include ileocaecal bladder substitution radical cystectomy median age year man three woman result complication rate surgery group two death one acute myocardial infarction haematemesis group b complication rate two death one massive pulmonary embolism live cell failure daytime continence achieve patient group group b mean sd postvoid residual urine volume large group group b vs ml acidosis hyponatraemia evident patient group none group b p pelvicalyceal system preserve patient group group b year follow mean sd renal cortical thickness little group group b cm respectively although cystometric capacity great basal pressure little group b not reflect degree diurnal nocturnal continence back pressure renal unit conclusion continence pouch similar renal unit preserve well ileocaecal ileal neobladder residual urine volume great ileal neobladder potential complication infection stone formation acidosis evident manage superficial bladder cancer overview percent bladder cancer transitional cell carcinoma tcc superficial tcc define transitional cell tumor confine mucosa stage ta carcinoma situ invade lamina propria stage treat patient superficial bladder cancer urologist face numb important task \\ufeff1 initial tumor tumor must remove 2 part urothelium must assess presence premalignant malignant abnormality 3 depth extent invasion e tumor stage must determine 4 clinician must decide whether additional treatment e g intravesical chemotherapy immunotherapy cystectomy radiotherapy indicate finally patient must monitor development subsequent tumor article provide overview management superficial bladder cancer xrcc polymorphism associate survival among chinese bladder cancer patient receive epirubicin mitomycin c association dna repair gene polymorphism bladder cancer risk widely study however study examine correlation bladder cancer instillation agent sensitivity aim study examine association polymorphism dna repair gene namely x ray repair cross complement group xrcc r r bladder cancer recurrence risk recruit patient treat epirubicin treat mitomycin c genomic dna use examine xrcc r r genotype taqman pcr analysis combination analysis xrcc r r examination xrcc diplotypes perform reveal possible correlation r cc r tt genotype confer short survival time r ac aa r cc ct genotype patient treat epirubicin not treat mitomycin c mmc adjust model hazard ratio hr confidence interval ci r ac aa compare cc hr ci r cc ct compare tt combination analysis show significantly increase recurrence free survival rfs among patient simultaneously carry r ac aa r cc ct genotype hr ci compare carry genotype diplotype analysis demonstrate c c diplotype associate low risk recurrence compare common wild c c diplotype hr ci result suggest r cc r tt genotype confer high sensitivity epirubicin instillation moreover c c diplotype present significantly low recurrence risk diplotypes endpoint clinical trial muscle invasive bladder cancer radical cystectomy remain gold standard treatment muscle invasive bladder cancer although surgery achieve excellent local control within year almost patient relapse subsequently progression systemic disease develope randomize trial cisplatin base chemotherapy regimen neoadjuvant set show potential improve survival suboptimal trial design insufficient number patient lack standardization chemotherapy regimen use plague adjuvant study give lethality recurrent transitional cell carcinoma bladder perioperative cisplatin base chemotherapy consider standard care evaluation multiple recurrence event superficial bladder cancer patient treat intravesical bacillus calmette gu rin therapy use andersen gill model evaluate factor affect recurrence intravesical bacillus calmette gu rin bcg therapy tokyo strain review datum patient superficial bladder cancer pta n pt n treat median follow period month factor affect \\ufeff1 tumour recurrence evaluate use cox proportional hazard model affect multiple recurrence andersen gill model year recurrence free rate patient recurrence frequency define time per patient month follow greatly decrease sd instillation therapy p patient pt tumour tend early recurrence pta tumour p multivariate analysis use cox proportional hazard model reveal history bladder cancer pathological stage independent factor affect \\ufeff1 tumour recurrence bcg therapy multiple endpoint recurrence evaluate use andersen gill model numb tumour good history bladder cancer pathological stage demonstrate significant link tumour recurrence bcg therapy year progression free year survival rate patient respectively intravesical recurrence may involve multiple event clinical course patient bladder cancer andersen gill model appear useful evaluation risk factor genetic polymorphism xrcc thr meet c r bladder cancer risk meta analysis research study relationship bladder cancer presence x ray cross complement group xrcc genetic polymorphism thr meet report inconsistent result objective study quantitatively evaluate association polymorphism bladder cancer susceptibility comprehensive research conduct pubmed medline embase web science database aug pool odd ratio confidence interval calculate use fix random effect model statistical analysis perform stata software case control study select meta analysis total bladder cancer case control include combine result base study suggest xrcc thr meet associate bladder cancer risk homozygote recessive model stratify ethnicity significant association find caucasians homozygote recessive model meta analysis suggest xrcc thr meet polymorphism risk factor bladder cancer risk however good design study require confirm finding high dose short course preoperative radiation therapy immediate single stage radical cystectomy pelvic node dissection management bladder cancer objective g protein couple receptor gpr report associate several cancer role bladder cancer not report purpose study evaluate clinical significance gpr bladder cancer method expression gpr pathological tissue correspond normal tissue bladder cancer patient detect via quantitative real time polymerase chain reaction qrt pcr western blot perform detect gpr expression bladder cancer tissue adjacent normal tissue chi square test analyze relationship gpr expression clinical feature bladder cancer patient additionally kaplan meier method adopt estimate overall survival bladder cancer patient prognostic value gpr evaluate cox regression analysis result expression gpr mrna protein pathological tissue significantly high adjacent normal tissue p moreover similar result find bladder cancer patient healthy control p gpr expression associate tumor size p tnm stage p result kaplan meier analysis suggest patient high expression gpr short overall survival time low expression log rank test p cox regression analysis indicate gpr can act independent biomarker bladder cancer prognosis hr ci p conclusion abnormal expression gpr associate bladder cancer gpr potential biomarker therapy prognosis bladder cancer photodynamic diagnosis therapy bladder cancer high frequency bladder cancer polish population relatively low sensitivity cancer detection early stage main reason search sensitive diagnostic test photodynamic diagnosis base accumulation photosensitizers porphirin derive compound emit fluorescence laser light promise tool detect small poorly differentiate neoplastic change hand use photodynamic therapy laser light photosensitizers generate free oxygen radical destroy neoplastic tissue photodynamic therapy perfect tool bladder cancer treatment especially case early stage multicentric neoplastic change difficult resect traditional endoscopic way genetic variation chromosome p q bladder cancer risk finding los angeles shanghai bladder case control study genome wide association study associate common variation chromosome p q lung cancer risk p locus also associate increase bladder cancer risk recent report q locus associate nicotine dependence self report numb cigarette smoke per day study propose association lung cancer may mediate difference smoke behavior investigate role variation p r r r r q r r bladder cancer etiology two case control study conduct separately los angeles county ca usa case control shanghai china case control replicate association p locus bladder cancer among non hispanic white nhw los angeles r per c allele odd ratio confidence interval ci p among chinese shanghai ci biomarker bladder cancer detail molecular insight bladder cancer biology may allow detail prognostication optimization treatment objective improve patient outcome quality life however bladder cancer research search biomarker call question even obtain notoriety unlikely single marker able improve prognostication patient bladder cancer beyond grade stage combination multiple independent marker may precisely predict outcome previous review identify seven biomarker study within set bladder cancer prognosis programme bcpp year multicentre programme research base university birmingham fund cancer research uk investigate effectiveness predict recurrence progression part ongoing quality assurance process bcpp present update review select biomarker good highlight recent important development bladder cancer research evans blue selective dye marker white light diagnosis non muscle invasive bladder cancer vitro study objective develop diagnostic method rely preferential accumulation dye non muscle invasive bladder cancer nmibc visible conjunction white light cystoscopy wlc material method investigate detail permeation evans blue urothelial cell carcinoma ucc spheroid prepare j rt human cell line spheroid compose normal human urothelial nhu cell gain insight differential accumulation spheroid investigate ultrastructurally use transmission electron microscopy tem result find exposure evans blue h ucc spheroid accumulate dramatically dye spheroid compose nhu cell use tem find malignant spheroid contain similar ultrastructural characteristic e wide intercellular space decrease numb desmosome like cell attachment clinical sample non papillary carcinoma situ bladder conclusion believe present finding can important future development clinical diagnostics early bladder cancer detection stage grade involve wlc 2 primary bladder cancer follow pelvic irradiation malignancy five case radiation induce bladder cancer treat center \\ufeff1 primary neoplasm uterine cervical cancer three patient uterine endometrial cancer one patient hodgkin disease one patient additional treatment primary neoplasm include panhysterectomy patient endometrial cancer cyclophosphamide base combination chemotherapy patient hodgkin disease mean age development bladder cancer year average time interval irradiation development bladder cancer year bladder cancer invasive treatment modality include anterior pelvic exenteration one patient partial cystectomy one patient reirradiation two patient include use intraoperative electron therapy one patient tur plus endoscopic nd yag laser treatment one patient four patient alive without disease mean follow period month diagnosis bladder cancer bias relative survival method use incorrect life table lung bladder cancer smoke status ethnicity new zealand relative survival excess mortality approach commonly use estimate compare net survival cancer approach base assumption underlie non cancer mortality rate cancer patient general population assumption likely violate particularly context smoke relate cancer magnitude bias not estimate objective article estimate bias relative survival ratio rsrs excess mortality rate ratio emrrs use total population compare correct subpopulation specific life table analysis conduct link census cancer datum include smoke status people lung bladder cancer use sex specific standard practice sex ethnic specific sex smoke specific sex ethnic smoke specific life table five year rsrs use sex specific life table compare fully stratify life table underestimate current smoke maori population example current smoker male bladder cancer rsr sex specific life table compare fully stratify role androgen receptor development progression bladder cancer man high risk develope bladder cancer woman since bladder cancer cell line tissue find express androgen receptor effort make inspect whether androgen mediate androgen receptor signal implicate bladder carcinogenesis good cancer progression mount evidence support view bladder cancer member endocrine relate tumor may clearly explain gender specific difference incidence however underlie mechanism androgen receptor signal regulate bladder cancer growth still far fully characterize moreover remain controversial whether androgen receptor pathway always play dominant role bladder cancer progression review summarize available datum involvement androgen receptor signal bladder cancer particular current evidence demonstrate stimulatory effect androgen tumor progression convincingly tumorigenesis via androgen receptor pathway may offer great potential androgen deprivation therapeutic chemopreventive option patient bladder cancer research progress potential urinary marker early detection diagnosis follow human bladder cancer objective summarize evaluate various urinary marker early detection diagnosis follow human bladder cancer method medline pubmed search late literature urinary marker bladder cancer perform review publish report make critical analysis result urinary marker tend little specific cytology yield false positive result demonstrate advantage term sensitivity especially detect low grade superficial tumor tumor marker appear good candidate early detection diagnosis follow human bladder cancer conclusion numb urinary marker currently available appear applicable clinical detection diagnosis follow bladder cancer however study require determine accuracy widespread applicability eight year experience preoperative angiographic lymphographic stage bladder cancer experience preoperative stage bladder cancer bilateral selective hypogastric arteriography accumulate since patient study selective angiography radical cystectomy late series patient compare previous experience demonstrate angiographic stage accuracy detect bladder invasion occult metastasis rate exceed clinical stage alone arteriographic stage lesion supplement lymphography approach per cent accuracy falsely negative lymphograms currently extremely uncommon per cent several illustrate instance angiographic stage prove even accurate pathologic stage limit cystectomy specimen effect laminin motility invasion bladder cancer examine correlation laminin malignancy bladder cancer patient use strain invasive bladder cancer cell determine whether laminin cause bladder cancer motility invasion investigate correlation laminin g distribution patient outcome perform semiquantitative immunohistochemical analysis paraffin embed sample use antibody b specific laminin chain evaluate role laminin nbt ii cell motility invasion use scratch assay boyden chamber chemoinvasion system tumor stage grade significantly correlate loss laminin chain basement membrane p retention cytoplasm p kruskal wallis test kaplan meier survival curve reveal association risk progression cytoplasmic retention laminin chain addition vitro scratch assay show increase migration cell treat laminin cluster boyden chamber assay show laminin potentiate nbt ii cell invasion immunohistochemistry result show bladder cancer patient high malignancy express laminin vitro scratch invasion assay show laminin stimulate motility invasion bladder cancer cell invasion assay explain correlation laminin expression bladder cancer malignancy surgical treatment cancer bladder saguenay lac saint jean area abnormal incidence bladder cancer bas identify incidence effect important industrial environment etiology identify review surgical treatment actually do follow evaluation make choice medical environment ileal conduit detubularised ileal bladder replacement radical cystectomy period statistic statement do show patient survival accordance grade stage appropriate treatment give b stage conclusion institute group stimulus industrial environment improve survival next decade reduce expression retinoblastoma rb gene protein relate cell proliferation prognosis transitional cell bladder cancer archival biopsy specimen transitional cell bladder cancer n analyse immunohisto chemically expression retinoblastoma rb gene protein intensity stain rb protein fraction positive nucleus analyse relate several prognostic factor survival six per cent tumour totally negative rb protein abnormal weak expression find case fraction positive nucleus abnormal expression weak highly significantly interrelate p low value fraction rb protein positive nucleus relate large fraction phase p high mitotic index p overexpression epidermal growth factor receptor p p protein p normal rb protein expression pattern relate low phase value p whereas inter comparison full empty bladder purpose compare inter wall motion radiotherapy rt bladder cancer full empty bladder protocol material method bladder volume fill rate bladder wall movement retrospectively analyze patient little set delineable pre post treatment cone beam ct cbct scan eight patient treat empty bladder eb protocol sixteen patient full bladder fb protocol result plan ct scan cbct scan set analyze average time pre post irradiation cbct min range min median fill rate ml min not differ eb fb random variation bladder volume inter fraction wall movement slightly not significantly large fb whereas intra fraction bladder wall movement slightly not significantly small fb large inter intra fraction bladder wall movement find cranial anterior direction conclusion empty full bladder protocol show similar inter intra fraction wall motion therefore treatment choice can purely base organ risk criterium coffee consumption bladder cancer nonsmoker pool analysis background coffee consumption associate excess bladder cancer risk result epidemiological study inconsistent association long debate part due potential confound smoke examine risk associate coffee consumption nonsmoker pool analysis ten european bladder cancer case control study method pool datum set comprise case hospital population control never smoke enroll ten study conduct denmark germany greece france italy spain information coffee consumption occupation code follow standard criterium unconditional logistic regression apply adjust age study center occupation gender result seventy nine percent study population report drink coffee heavy drinker report drink average ten cup per day no excess risk ever coffee drinker ci compare never drinker risk not increase monotonically dose statistically significant excess risk see subject drink ten cup per day ci excess see man woman no evidence association risk duration type coffee consumption pool result not dependent finding specific study depend type control overall excess risk observe study use hospital control conclusion nonsmoker heavy coffee drinker may small excess risk bladder cancer although result not attribute confound smoke possibility bias control selection not discard basis result small proportion cancer bladder among nonsmoker can attribute coffee drink bladder cancer diagnosis treatment therapeutic procedure bladder cancer practice department urology university vienna medical school present transurethral resection prefer comparison open surgery surgical procedure always follow postoperative radiotherapy possibility hemostasis inoperable carcinoma bilateral intravasal occlusion iliac artery emphasize paraneoplastic retinopathy associate occult bladder cancer aim report \\ufeff1 case cancer associate retinopathy car present bladder cancer diagnosis year old woman history bilateral vision loss undergo subsequent complete ophthalmic examination include fluorescein angiography full field electroretinogram erg serology include serum antibody car positron emission tomography compute tomography deletion map chromosome q smad protein expression analysis urinary bladder carcinoma objective investigate role loss heterozygosity loh chromosome q carcinogenesis progression urinary bladder cancer provide clue early detection positional clone relate gene method deletion map perform q use microsatellite marker immunohistochemistry stain use evaluate expression level two tumor suppressor candidate smad smad region result loh little one microsatellite q detect patient bladder cancer minimal deletion region include tumor suppressor candidate smad immunohistochemical study reveal case regulate smad protein case regulate smad protein smad protein expression regulate case regulate smad expression see one case conclusion loh q closely link bladder cancer irregular expression tumor suppressor candidate smad smad may play important role initiation progression bladder neoplasm potent cytotoxic effect novel nuclear factor kappab inhibitor dehydroxymethylepoxyquinomicin human bladder cancer cell produce various cytokine objective explore potential therapeutic effect nuclear factor kappab nf kappab inhibitor dehydroxymethylepoxyquinomicin dhmeq ku cell originally derive patient invasive bladder cancer exhibit mark leukocytosis produce multiple cytokine model clinically advance bladder cancer nf kappab constitutively activate use study method expression p protein fractionate ku cell determine western blot analysis dna bind activity nf kappab detect electrophoretic mobility shift assay cytotoxic effect induction apoptosis dhmeq analyze cytokine supernatant ku cell culture without dhmeq measure enzyme link immunosorbent assay elisa athymic nude mouse bear ku subcutaneous tumor subject intraperitoneal administration mg kg dhmeq week tumor growth monitor microvessel density vascular endothelial growth factor expression apoptotic index tumor evaluate tissue immunohistochemistry result nf kappab constitutively activate ku cell dhmeq reversibly inhibit dna bind activity nf kappab block nuclear translocation cell viability production cytokine significantly dose dependently suppress dhmeq significant apoptosis also induce vivo study mean tumor volume mouse treat dhmeq significantly small control immunohistochemical analysis tumor reveal mark reduction microvessel density vascular endothelial growth factor expression induction apoptosis conclusion blockade nf kappab function dhmeq may useful new molecular target treatment highly aggressive bladder cancer bioactive exosomes possibility diagnosis management bladder cancer background recently leucine rich repeat immunoglobulin like domain lrig negative regulator egfr discover novel agent suppress bladder cancer aim study investigate impact lrig biological feature aggressive bladder cancer cell possible mechanism enhance apoptosis induce upregulation lrig method study examine mrna protein expression lrig egfr bladder cancer normal bladder meanwhile overexpress lrig adenovirus vector bladder cancer cell line use real time pcr western blot co immunoprecipitation analysis order examine effect lrig gene egfr furthermore evaluate impact lrig gene function human bladder cancer cell egfr signal result expression lrig decrease expression egfr increase majority bladder cancer ratio egfr lrig increase tumor versus normal tissue find upregulation lrig induce cell apoptosis cell growth inhibition reverse invasion bladder cancer cell line vitro inhibit phosphorylation downstream mapk akt signal pathway conclusion take together finding provide us insight lrig function conclude lrig evolve bladder cancer rare feedback negative attenuator egfr thus can offer novel therapeutic target treat patient bladder cancer efficacy tur week initial tur treatment locally advance bladder cancer background radical cystectomy usually perform patient advance bladder cancer choice surgical procedure whether bladder preserve therapy radical cystectomy sometime plague us bladder cancer treatment clear guideline treatment locally advance bladder cancer n devise radical treatment patient locally advance bladder cancer without radical cystectomy patient method perform tur treatment week initial tur patient grade locally advance bladder cancer diagnose pelvic ct scan transurethral ultrasonography bimanual examination anesthesia result can successfully preserve case bladder use devise tur period month median month method significantly reduce cystectomy rate locally advance case compare cystectomy rate prior p conclusion method significance treatment locally advance papillary bladder cancer bladder preserve therapy careful observation prognostic significance p kip expression bladder cancer importance marker urological cancer good recognise many attempt make find one prognostic significance author new york find low expression p kip patient bladder cancer significant predictor pelvic recurrence progression metastasis death author switzerland examine patient primary solitary distal ureteric tcc find distal ureteric resection patient feasible long term oncological outcome appear comparable radical treatment condition objective define prognostic significance p kip expression bladder cancer overall disease specific metastasis free pelvic recurrence free survival identify clinical pathological correlate p kip immunophenotypes patient method tumour sample evaluable patient bladder cancer assess immunohistochemistry p kip e f expression immunoreactivity p kip correlate clinicopathological variable e f immunoreactivity outcome multivariate analysis use assess predictor outcome median follow month overall month patient alive last follow result fraction tumour cell p kip nuclear immunoreactivity patient high grade tumour low e f nuclear reactivity low mean percentage p kip reactivity p respectively multivariate analysis percentage p kip reactivity significant independent predictor pelvic recurrence p progression metastasis p death disease p death cause p low expression portend wrong prognosis suspicion vascular invasion significant independent predictor progression metastasis p death disease death cause p lymph node involvement significant independent predictor progression metastasis p conclusion low expression p kip significant independent predictor pelvic recurrence progression metastasis death disease death cause patient bladder cancer efficacy safety potassium titanyl clinically non muscle invasive bladder cancer purpose although transurethral resection bladder tumor turbt still regard thegold standard treatment clinical non muscle invasive bladder cancer alternative surgical option remain investigate aim evaluate efficacy safety potassium titanyl phosphate ktp laser treatment primary clinically non muscle invasive bladder cancer compare standard transurethral resection bladder tumor material method datum primary non muscle invasive bladder cancer patient treat either ktp laser vaporization pvb group turbt analyze retrospectively preoperative condition intraoperative complication obturator nerve reflex bladder perforation postoperative characteristic catheterization time tumor recurrence compare result patient demographics tumor characteristic two group comparable pvb superior turbt term intraoperative complication obturator nerve reflex p postoperative bladder irrigation p postoperative catheterization time p recurrence rate pvb also low turbt conclusion result indicate pvb feasible safe effective alternative surgical approach management primary clinically non muscle invasive bladder cancer especially lifetime oral take anticoagulation medicine few perioperative complication low recurrence round table conference case find diagnosis treatment primary cancer bladder tuesday june background health insurance key mediator health care disparity outcome bladder cancer one costly disease treat may especially sensitive patient insurance status method surveillance epidemiology end result registry national cancer datum base use identify individual young year diagnose bladder cancer association insurance status privately insure insure medicaid uninsured follow outcome evaluate diagnosis advance disease cancer specific survival delay treatment long day treatment high volume hospital receipt neoadjuvant chemotherapy nac result compare private insurance uninsured medicaid insure individual nearly twice likely receive diagnosis muscle invasive bladder cancer odd ratio uninsured individual confidence interval ci medicaid insure individual ci chlorinate drink water bladder cancer effect misclassification risk estimate datum present iowa portion national bladder cancer case control study demonstrate effect misclassification depress odd ratio estimate year exposure chlorinate drink water bladder cancer four method method quantify chlorination exposure sequentially decrease degree misclassification present bladder cancer case population base control fulfill criterium inclusion study twenty eight risk factor bladder cancer consider along chlorinate drink water exposure estimate method stepwise regression model include significant factor cigarette smoke p little chlorination exposure p irradiation pelvic area p replacement chlorinate drink water exposure estimate method remain three method result model include cigarette smoke irradiation pelvic area not chlorination exposure thus misclassification chlorination exposure signify difference observe not observe association bladder cancer abo blood group rhesus factor not associate outcome radical cystectomy non metastatic urothelial carcinoma bladder aim investigate role abo blood group rhesus factor predictor outcome patient undergo radical cystectomy rc non metastatic urothelial carcinoma bladder material method datum consecutive patient treat rc retrospectively analyze effect recurrence free survival cancer specific overall mortality assess use kaplan meier multivariable cox regression method result overall patient express b ab phenotype respectively rhesus negative median follow year interquartile range year no individual blood group associate clinicopathological characteristic whereas rhesus positive patient high rate pt disease vs p abo blood group not associate outcome rhesus positive patient increase risk short recurrence free survival cancer specific overall mortality compare rhesus negative patient p multivariable analysis adjust effect standard characteristic association disappear conclusion result study show neither abo blood group rhesus factor associate oncological outcome clinical relevance blood group rhesus factor bladder cancer remain questionable v isoform specific erbium complex highly specific bladder cancer image photodynamic therapy synthesize bifunctional erbium porphyrin tumor image pdt agent er r capable kill bladder cancer cell via selective bind integrin v isoform overexpress cell membrane bacillus calmette gu rin treatment non muscle invasive bladder cancer bacillus calmette gu rin bcg use intravesical treatment non muscle invasive bladder cancer nmibc nearly year however use still subject controversy objective paper review role bcg treatment patient nmibc clinical trial meta analysis guideline relate administration safety efficacy intravesical bcg review intravesical bcg effective intravesical chemotherapy decrease risk recurrence progression muscle invasive disease however associate local systemic side effect gold standard patient high risk progression maintenance bcg require order achieve well therapeutic result however optimal dose induction maintenance schedule duration treatment unknown may different patient patient fail bcg treatment poor prognosis cystectomy recommend treatment patient low risk recurrence progression not receive bcg side effect intermediate risk patient may treat either intravesical chemotherapy bcg however patient high risk progression bcg recognize treatment choice research urgently need identify marker associate bcg failure develop effective alternative cystectomy patient fail bcg prognosis bladder cancer study cytometric morphometric immunohistochemical technique bladder cancer affect people sweden every year adequate treatment prognostic information essential prognostic factor apply date still lack satisfactory predictive value investigation conduct bladder tumour know prognosis order improve prognostication method new modify technique measurement dna content formalin fix paraffin embed bladder tumour tissue develope introduce new enzyme density gradient centrifugation perform flow cytometry result comparable obtain analyse fresh freeze tissue dna ploidy find correlate positively stage histological grade progression methenamine silver stain technique facilitate identification mitosis develope apply determine mitotic frequency density result prove yield prognostic marker superior subjective grade intermediate grade tumour can separate two prognostically highly different group reduce pcna antigenicity archival formalin fix paraffin embed bladder tumour tissue observe antigen expression can retrieve heat slide distill water microwave oven application citrate buff can improve stain correlate prognosis no independent prognostic value image analysis apply attempt develop computer base grade system analysis feulgen stain tissue section perform object base method digitize segment analyze image automatically furthermore texture analysis method estimate grey scale co occurrence probability matrix digitize image develope type grade find correlate significantly subjective grade superficial bladder tumor result preventive treatment recurrence intravesical instillation bcg two third newly diagnose bladder tumor superficial transitional cell carcinoma local relapse occur patient transurethral resection initial tumor risk muscle invasion retrospective study consecutive patient perform assess role intravesical bcg therapy prophylaxis recurrence superficial bladder cancer treatment protocol describe eighty two patient previously recurrent tumor give bcg directly multiple large high grade widespread tumor seventy patient p tolerate treatment good experience serious complication systemic bcg infection bladder contracture patient give bcg \\ufeff1 tumor p tumor free mean follow month patient previous recurrent tumor p improve treatment patient twelve tumor become muscle invasive require aggressive intervention intravesical bcg effective prevent recurrence superficial bladder cancer however side effect risk muscle invasion require close monitor intravesical administration exogenous microrna therapy mouse orthotopic human bladder cancer xenograft previously report level microrna mir attenuate human bladder cancer cell current study investigate whether intravesical administration mir can potential therapeutic strategy control bladder cancer use orthotopic human bladder cancer xenograft model follow transfection j b v cell mir effect ectopic expression mir examine perform mtt western blot analysis hoechst stain wind heal assay vitro also mouse orthotopic human bladder cancer model establish inoculate j b v cell bladder wall mouse anti cancer effect intravesical injection mir mouse assess transfection j b v cell mir induce apoptosis suppression cell migration vitro western blot show level c myc socs fscn e cadherin catenin catenin decrease pi k akt erk signal pathway increase compensatory fashion vivo mouse treat mir show inhibition tumor growth significant prolongation animal survival p vs control western blot show apoptosis cell motility relate gene significantly decrease see vitro furthermore pi k akt erk signal pathway activate compensatory manner vitro decrease vivo intravesical administration exogenous mir thus conclude valid therapy bladder cancer human bladder cancer xenograft model treatment result total cystectomy patient bladder cancer assess treatment outcome total cystectomy patient man woman bladder cancer treat public toyooka hospital patient age vary mean overall actuarial survival rate year respectively year survival rate grade grade disease year survival rate accord pathological stage pt pt pt pt disease statistical difference note year survival rate patient pt disease pt patient pt disease show relatively high survival rate year survival rate patient negative lymph node positive lymph node although can not demonstrate efficacy preoperative radiotherapy combination radiation chemotherapy suggest improve survival cystectomy patient receive simultaneous urethrectomy show high year survival rate compare not treatment bladder cancer control trial pre operative radiotherapy radical cystectomy versus radical radiotherapy heterogeneous nuclear ribonucleoprotein l hnrnp l promoter various kind cancer action bladder cancer bc unclear study investigate function underlie mechanism hnrnp l bladder carcinogenesis result demonstrate enhance hnrnp l expression bc tissue associate poor overall survival bc patient depletion hnrnp l significantly suppress cell proliferation vitro inhibit xenograft tumor growth vivo furthermore downregulation hnrnp l result g phase cell cycle arrest enhance apoptosis accompany inhibition emt cell migration cellular change reverse ectopic expression hnrnp l deletion hnrnp l result decrease expression bcl enhance expression caspase inhibition mapk signal pathway finding demonstrate hnrnp l contribute poor prognosis tumor progression bc inhibit intrinsic apoptotic signal enhance mapk signal pathway improve predict radiosensitivity muscle invasive bladder cancer purpose muscle invasive bladder cancer common urological malignancy relatively poor prognosis year survival rate range review method improve outcome condition particular emphasis principal bladder preserve treatment modality radiation therapy material method perform literature search use medline isi web science use keyword radiotherapy radiosensitization bladder neoplasia ascertain current status radiation therapy radiosensitizing agent treatment muscle invasive bladder cancer result several method aim improve outcome follow radiation therapy muscle invasive bladder cancer describe method range modification application radiation therapy use conventional radiosensitizing agent accelerate radiotherapy carbon dioxide oxygen nicotinamide finally use novel agent interact oncogenic product use assay predict tumor sensitivity individual basis represent additional potential method improve prognosis follow radiation therapy conclusion ability predict tumor radiosensitivity subsequent implementation radiosensitizing technique likely improve result treatment center radiation therapy suggest bladder spare approach remain treatment option muscle invasive bladder cancer variant new entity bladder cancer pathological evaluation bladder cancer typically reveal great tumour heterogeneity therefore common observation urothelial carcinoma exhibit wide variety histopathological pattern not surprise pattern distinctive recognise specific variant urothelial carcinoma classification recently revise world health organisation classification tumour urinary system male genital organ current classification clarify terminological issue provide well definition criterium also incorporate new entity many variant important prognostic therapeutic implication worth know urologist oncologist also represent diagnostic challenge daily pathology practice review discuss feature variant urothelial carcinoma context current clinical practice histological variation new entity bladder cancer not include current classification urothelial tumour briefly discuss alteration beta n butyl n hydroxybutyl nitrosamine induce murine bladder cancer abnormal degradation beta catenin cause alteration glycogen synthase kinase beta gsk beta consensus motif important step carcinogenesis hypothesize beta gamma catenin may play important role pathogenesis bladder cancer test hypothesis analysis beta gamma catenin murine human bladder cancer murine bladder cancer model prepare use n butyl n hydroxybutyl nitrosamine bbn week old male b f mouse week bbn treatment bladder specimen harvest analyze protein gene expression beta gamma catenin mutational analysis nh terminal regulatory domain beta gamma catenin perform specimen pcr single strand conformational polymorphism sscp analysis mutation confirm direct dna sequence dye terminator method human bladder cancer specimen normal tissue dysplasia carcinoma situ carcinoma grade also analyze beta gamma catenin expression beta gamma catenin analyze mutation sscp direct dna sequence intracellular accumulation beta gamma catenin observe invasive carcinoma specimen no intracellular accumulation management superficial g pta pt bladder cancer total patient superficial g pta pt bladder cancer g pta g pt present review patient g pta follow eighteen year g recurrence develope invasive cancer great pt develope receive radiotherapy respond completely no cancer relate death contrast patient basement membrane breach pt high grade tumor g develope recurrence invasion muscle great pt among cancer relate death secondary malignancy bladder avoid diagnostic pitfall although rare secondary tumor bladder present diagnostic dilemma pathologist consider differential diagnosis primary bladder cancer investigate clinicopathologic image characteristic metastatic tumor bladder retrospectively review surgical pathology database site identify case secondary bladder tumor clinical pathologic image finding review mean age diagnosis year range female significantly high proportion secondary bladder tumor compare male p total patient clinical history situ invasive malignancy another organ patient image support metastatic tumor patient prior history urothelial carcinoma total case female originally misdiagnose primary bladder malignancy correct clinicoradiologic correlation overall colorectal origin common follow cervical ovarian primary cervical ovarian origin predominate female cohort follow endometrial colorectal prostate primary common among male respectively secondary bladder tumor mimic urothelial carcinoma cohort gynecological colorectal prostatic origin common clinical history image immunohistochemical study useful avoid diagnostic pitfall cytokeratin fragment diagnosis bladder carcinoma result previous study evaluate accuracy serum urinary measurement cytokeratin fragment cyfra diagnosis bladder cancer inconsistent read great interest recent systematic review diagnostic accuracy cyfra bladder cancer huang et al systematic analysis demonstrate pool sensitivity specificity serum urine cyfra confidence interval ci ci ci ci respectively area summary receiver operate characteristic curve serum urine cyfra ci ci bladder neoplasm recent study underscore importance oxygen supply bladder cancer tumour growth stimulate production vasoactive factor increase oxygen delivery tissue vasodilatation vasoconstrictor mediator can impair vasodilatation reduce oxygen supply iso pgf alpha potent vasoconstrictor agent aim work determine iso pgf alpha release healthy bladder mucosa superficial bladder cancer order investigate pathophysiological vasoconstrictor answer superficial bladder cancer study conduct sample patient every subject study iso pgf alpha release assay healthy bladder mucosa superficial bladder tumour iso pgf alpha release significantly reduce p little superficial bladder cancer compare healthy bladder mucosa inhibition production powerful vasoconstrictor iso pgf alpha vascular homeostatic mechanism bladder cancer represent response tumor tend contrast antagonist effect vasodilatation necessary support oxygen supply diagnosis clinically occult bladder cancer vivo stain methylene blue vivo stain bladder mucosa methylene blue normal saline perform randomly select patient know previously treat transitional cell tumour bladder routine check cystoscopy fail demonstrate mucosal abnormality patient differential stain bladder mucosa result no mucosal stain cold cup biopsy obtain stain good unstained area although positive stain not prove presence pre malignant malignant area lack stain likely exclude mucosal abnormality sensitivity initial transurethral resection biopsy bladder tumor detect bladder cancer variant radical cystectomy purpose determine ability bladder biopsy transurethral resection bladder accurately predict bladder cancer variant radical cystectomy since certain variant may affect prognosis treatment material method retrospectively evaluate record patient undergo biopsy transurethral resection bladder follow radical cystectomy frequency variant morphology sensitivity precystectomy material determine use pathological finding radical cystectomy final result result bladder cancer variant identify patient initial biopsy transurethral resection final pathological evaluation radical cystectomy common variant urothelial carcinoma squamous differentiation patient follow micropapillary urothelial carcinoma patient variant morphology identify biopsy transurethral resection bladder not final radical cystectomy pathological assessment remain patient show variant morphology radical cystectomy without variant morphology precede biopsy transurethral resection sensitivity variant detection show broad range variant subtype overall initial biopsy transurethral resection sensitivity predict variant morphology radical cystectomy conclusion overall sensitivity predict bladder cancer variant biopsy transurethral resection bladder sample relatively low likely due sample tumor heterogeneity rather inaccurate pathological diagnosis additional predictive marker variant morphology may useful determine tumor contain aggressive variant may alter outcome therapy validate predictor outcome radical cystectomy bladder cancer background assessment surgical risk essential patient counsel decision make provide rationale adjustment patient population health care move fee service value base reimbursement model modify frailty index mfi propose risk stratification tool radical cystectomy rc objective current study validate potential use mfi use institutional cohort method retrospective review patient undergo rc bladder cancer conduct author institution addition detail clinicopathologic treatment parameter patient categorize accord mfi charlson comorbidity index cci american society anesthesiologist asa classification covariate analyze determine association month complication rate accord clavien dindo system month readmission rate hospitalization length hospitalization cost result total patient include analysis overall complication rate major clavien grade complication rate readmission rate receiver operate curve analysis demonstrate weak association index major complication rc area curve confidence interval ci asa classification ci cci score ci mfi no significant difference rate major complication stratify result accord mfi cci asa class length hospitalization associate cost correlate mfi conclusion frailty not associate postoperative complication provide little additional predictive ability asa classification cci score research require identify patient likely suffer significant complication rc microhematuria find mass screen apparently healthy male preparation urinary sediment adapt mass screen purpose procedure characterize careful collection transfer sediment rigidly control work scheme test limit population screen program healthy male participant capacity sample per manhours achieve procedure find effective collect cellular content serious cytolysis due hour delay micturition process unexpected find presence erythrocyte sample per cent smear ten rbc hpf present significance feature still study may prove useful prescreening criterion cytologic assessment bladder cancer large population serum metabolic profile identify distinct metabolic signature bladder cancer smoker key metabolic enzyme associate patient survival background current system predict outcome smoker bladder cancer insufficient due complex genomic transcriptomic heterogeneity study aim identify serum metabolite associate gene relate survival population method perform lc ms base target metabolomic analysis metabolite serum obtain two independent cohort bladder cancer never smoker smoker healthy smoker healthy never smoker subset differential metabolite validate use biocrates absoluteidq p kit gene associate differential metabolite integrate publicly available cohort cancer genome atla tcga obtain intersect signature specific bladder cancer smoker result forty metabolite fdr identify differential bladder cancer never smoker smoker increase abundance amino acid tyrosine phenylalanine proline serine valine isoleucine glycine asparagine taurine observe bladder cancer smoker integration differential metabolomic gene signature transcriptomics datum tcga cohort reveal intersection gene show significant correlation patient survival bladder cancer smoker importantly catechol methyltransferase iodotyrosine deiodinase tubulin tyrosine ligase show significant association patient survival publicly available bladder cancer smoker dataset not clinical association never smoker conclusion serum metabolic profile bladder cancer smoker reveal dysregulated amino acid metabolism provide distinct gene signature show prognostic value predict bladder cancer smoker survival impact serum metabolic signature derive gene act predictive tool study bladder cancer progression smoker new hypothesis natural history bladder cancer base study tumor dna level flow cytometry bladder tumor study nuclear dna content flow cytometry bimodal dna profile present follow finding concern aneuploid 2 peak tumor remarkable aneuploid peak dna index distribution discontinuous no peak aneuploid peak importance 2 peak cell percentage versus tumor cell sample increase dna index decrease percentage average dna index increase dna index decrease aneuploid peak mitotic activity increase dna index decrease percentage g cell aneuploid peak range dna index range dna index finding favor dynamic bladder cancer natural history tumor suppose share clonal evolution stage \\ufeff1 stage transform tumor cell dna profile unimodal dna index region 2 stage due chromosomic non dysjunction mitosis 2 peak appear dna index 3 stage dna index aneuploid 2 peak progressively decrease consequence non vital chromosome loss tumor cell suggest dna index define flow cytometry not absolute prognostic value per se combination tumor mitotic activity abstract truncate word update chemotherapy treatment urothelial carcinoma urothelial carcinoma 5 common malignancy diagnose year unite state neoadjuvant adjuvant chemotherapy give decrease risk recurrent metastatic disease robust clinical datum support former bladder preservation utilize trimodality approach maximal transurethral resection follow concurrent chemotherapy radiation appropriate select patient gemcitabine cisplatin current standard care \\ufeff1 line treatment fit patient metastatic disease optimal 2 line therapy remain undefined target agent investigation clinical trial participation encourage patient urothelial carcinoma bladder help improve treatment regimen outcome synopsis chemotherapy commonly use treatment urothelial carcinoma bladder paper review role chemotherapy neoadjuvant adjuvant bladder spare metastatic setting role fluorescence situ hybridization predict patient response intravesical bacillus calmette gu rin therapy bladder cancer diagnostic background aim study systematically review relevant study assess role fluorescence situ hybridization fish test predict patient response bacillus calmette gu rin bcg therapy transurethral resection bladder tumor turbt method search pubmed embase cochrane library inception july use quality assessment tool diagnosis accuracy study quadas assess quality pool sensitivity specificity area curve auc baseline post bcg fish test predict tumor recurrence hazard ratio hr confidence interval cis fagan nomogram apply assess predictive accuracy post bcg fish test result total study participant overlook primary bladder cancer metastasis dry bone study th century cal milano cemetery skeletal collection objective aim article provide additional documentation bone metastasis help anthropologist recognize condition potentially suggest diagnosis bladder carcinoma differential diagnosis material method thirteen individual clinically diagnose bladder carcinoma th century milano cemetery skeletal collection macroscopically study document bone metastasis bladder cancer result bone metastasis find macroscopic observation three individual study sample metastasis mostly mix nature although osteoblastic osteolytic also occur particular mix osteoblastic metastasis exhibit different distribution pattern even affect bone vertebra skull rib proximal humerus pelvis proximal femur sacrum sternum commonly affect osteolytic lesion include coalesce superficial pit lesion perforate bone cortex proliferative lesion manifest spongiosclerosis periosteal new bone mix metastasis osteolytic lesion expose thicken trabecular bone coalescent porosity reactive new bone conclusion bladder carcinoma metastasis mostly mix exhibit periosteal reaction perforation bone cortex spongiosclerosis coalesce porosity significance bladder carcinoma rarely consider differential diagnosis primary organ study report macroscopic aspect bone metastasis bladder carcinoma may help anthropologist diagnose condition skeleton limitation absence evidence not evidence absence lesion may hide macroscopic observation therefore miss research radiographic analysis comparison neoplasm provide additional detail diagnosis bladder cancer bone metastasis clinical evaluation urinary serum carcinoembryonic antigen bladder cancer urinary carcinoembryonic antigen like activity increase ng per ml per cent patient transitional cell carcinoma bladder frequency abnormal carcinoembryonic antigen value correlate extent grade tumor however urinary tract infection produce abnormal carcinoembryonic antigen value non cancer patient use urinary carcinoembryonic antigen measurement urine cytologic examination diagnosis transitional cell carcinoma give well diagnostic yield use either test alone transitional cell carcinoma patient abnormal preoperative urinary carcinoembryonic antigen value postoperative urinary carcinoembryonic antigen value useful determine completeness tumor resection however total cystectomy creation ileal conduit ureterosigmoidostomy urinary carcinoembryonic antigen value increase markedly postoperatively serum carcinoembryonic antigen value little value diagnosis transitional cell carcinoma smoke bladder cancer spain effect tobacco type time environmental tobacco smoke gender examine effect dose type tobacco cessation inhalation environmental tobacco smoke exposure bladder cancer risk among patient newly diagnose bladder cancer control recruit hospital spain use unconditional logistic regression estimate odd ratio confidence interval ci association bladder cancer risk various characteristic cigarette smoke current smoker man ci woman ci former smoker man ci woman ci significantly increase risk bladder cancer compare nonsmoker observe significant positive trend risk increase duration amount smoke adjustment duration risk high smoker black tobacco smoker blond tobacco ci compare risk current smoker significant inverse trend risk increase time since quit smoke blond tobacco observe year cessation ci no trend risk cessation smoke black tobacco apparent compare man inhale mouth risk increase man inhale throat ci chest ci cumulative occupational exposure environmental tobacco smoke seem confer increase risk among female nonsmoker not among male nonsmoker eliminate effect cigarette smoke bladder cancer risk study population male female incidence ratio decrease suggest nearly entire male excess bladder cancer observe spain explain cigarette smoke rather occupational environmental exposure bladder carcinogen therapeutic indication bladder cancer review consecutive patient undergo radical cystectomy bladder cancer prior follow year survival rate year pathologic stage important prognostic factor series advance bladder cancer rechallenged immune checkpoint inhibitor case report nd yag laser therapy good define role treatment superficial bladder cancer indicate one need destroy present tumor available result suggest tumor recurrence reduce definitive evidence lack laser main advantage procedure carry without anesthesia outpatient basis noncontact technique associate minimal morbidity reduce pain bleed nd yag laser use invasive bladder cancer would appear adequate palliation indication benefit must compare conventional palliative tur radiation therapy laser therapy tumor upper urinary tract still infancy urothelial cancer multifocal disease critical caveat case bladder cancer tumor recurrence routine access upper tract accurate assessment grade stage tumor multifocality disease paramount importance not yet perfect photodynamic therapy intrigue modality much potential future development present reduce ability control superficial cancer particularly compare available form treatment intravesical bcg significant associate morbidity use remain investigational management muscle invasive bladder cancer victoria background management outcome muscle invasive bladder cancer describe article method retrospective survey medical practitioner involve management bladder cancer conduct survey obtain little year follow datum patient sample take public private health sector victoria case muscle invasive bladder cancer diagnose main outcome measure include report management stage treatment survival result complete questionnaire return case man mean age year case present macroscopic haematuria majority transitional cell carcinoma variety treatment give various sequence case initial surveillance eventually case proceed definitive management either radiotherapy cystectomy addition chemotherapy give patient time patient subsequently die die bladder cancer crude year survival disease specific survival multivariate analysis identify follow predictor great disease specific survival grade histopathology p primary p n disease p disease p radiation dose bed gy cystectomy p conclusion muscle invasive bladder cancer victoria typically occur elderly patient notable proportion patient not proceed onto definitive treatment disease stage cystectomy use high dose radiation associate well outcome chemotherapy give approximately one 3 patient point disease management datum similar population base datum north america provide baseline potential change management bladder cancer compare prognostic value lymphovascular invasion high grade stage pt bladder cancer purpose high grade hg stage pt bladder cancer high recurrence progression rate non muscle invasive bladder cancer prognostic factor recurrence progression identify multifocal hg pt concomitant carcinome situ tumor diameter cm infiltration deep lamina propria persistence pt tumor 2 transurethral resection bladder objective study determine whether presence lymphovascular invasion lvi also prognostic factor must take account material method retrospective study perform patient hg stage pt bladder cancer patient treat conservatively transurethral resection bladder plus bacille calmette gu rin therapy patient undergo early cystectomy mean sd follow month classic prognostic factor lvi analyze term overall survival specific survival recurrence free survival progression free survival result thirty six percent patient lvi chip \\ufeff1 transurethral resection bladder five year overall survival specific survival respectively multivariate analysis risk factor show significant reduction overall survival presence lvi p presence lvi also factor poor prognosis case delay cystectomy p not case early cystectomy conclusion identification lvi \\ufeff1 resection hg stage pt bladder cancer significant prognostic factor overall survival tobacco smoke coffee cocoa tea consumption relation mortality urinary bladder cancer italy paper examine change mortality urinary bladder cancer italy year relation change smoke habit coffee cocoa tea consumption author find sex age mortality increase throughout period although rate relative increase consistently much low gradual woman man analysis age cohort period variation seem bladder cancer mortality also influence change smoke habit pattern variation quality diagnosis increase death risk sex italy cohort bear around relate occupational exposure nucleotide excision repair gene polymorphism may predict acute toxicity patient treat chemoradiotherapy bladder cancer aim platinum base chemoradiotherapy crt bladder conservation therapy show promise result muscle invasive bladder cancer however treatment relate toxicity remain major consideration therapeutic plan common polymorphism gene involve dna repair encode enzyme repair dna damage platinum agent ionize radiation report result modulation repair capacity investigate association functional genetic polymorphism involve dna repair acute toxicity crt determine predictive value polymorphism toxicity material method study group comprise bladder cancer patient treat platinum base crt seven polymorphism xpc ly gln r xpd ly gln r xpg asp r xrcc arg gln r xrcc thr meet r tp arg pro r mdm snp g r genotype result two total variant allele nucleotide excision repair gene include xpc xpd xpg significantly associate grade neutropenia adjust odd ratio aor ci p no significant association genotype grade great nausea vomit diarrhea grade hematological toxicity significantly associate gln gln ly gln gln gln genotype xpc compare ly ly aor ci p aor ci p respectively conclusion result suggest nucleotide excision repair gene polymorphism especially xpc may potentially predictive factor acute toxicity crt bladder cancer help individual patient selection bladder conservation therapy however study large sample size need draw final conclusion protocol pathologic examination cystectomy cystoprostatectomy specimen proposal standardize form present practice guideline examination bladder specimen remove bladder cancer propose example standardize form report approach take place look well quality facilitate use morphologic datum transitional cell carcinoma ureter renal pelvis transitional cell carcinoma tcc ureter renal pelvis relatively uncommon smoke occupational carcinogen analgesic abuse balkan nephropathy risk factor cytogenetic study reveal frequent aberration partial complete loss chromosome approximately patient upper urinary tract uut tcc bladder cancer point course whereas incidence uut tcc primary bladder cancer excretory urography retrograde pyelography conventional diagnostic tool however ureteropyeloscopy combine cytology biopsy accurate grade stage disease significant impact survival nephroureterectomy bladder cuff excision mainstay treatment local resection may appropriate distal ureteral lesion especially disease low grade stage advance endourology make possible treat many tumor conservatively ureteroscopic certain extent percutaneous surgical approach widely use today especially patient low grade low stage disease endoscopic close surveillance mandatory patient adjuvant topical therapy appear safe confirmation benefit await result large study recently laparoscopic technique become viable alternative open surgery long term cancer control datum lack aggressive surgical resection not affect outcome patient advance disease adjuvant radiotherapy ineffective systemic chemotherapy result low complete response rate patient metastasis restoration lrig suppress bladder cancer cell growth directly target egfr activity background recently leucine rich repeat immunoglobulin like domain lrig negative regulator egfr discover novel agent suppress bladder cancer aim study investigate impact lrig biological feature aggressive bladder cancer cell possible mechanism enhance apoptosis induce upregulation lrig method study examine mrna protein expression lrig egfr bladder cancer normal bladder meanwhile overexpress lrig adenovirus vector bladder cancer cell line use real time pcr western blot co immunoprecipitation analysis order examine effect lrig gene egfr furthermore evaluate impact lrig gene function human bladder cancer cell egfr signal result expression lrig decrease expression egfr increase majority bladder cancer ratio egfr lrig increase tumor versus normal tissue find upregulation lrig induce cell apoptosis cell growth inhibition reverse invasion bladder cancer cell line vitro inhibit phosphorylation downstream mapk akt signal pathway conclusion take together finding provide us insight lrig function conclude lrig evolve bladder cancer rare feedback negative attenuator egfr thus can offer novel therapeutic target treat patient bladder cancer guideline guideline non muscle invasive bladder cancer non muscle invasive bladder cancer nmibc represent vast majority bladder cancer diagnosis definition represent spectrum disease variable clinical course notable significant risk recurrence potential progression management involve risk adapt strategy cystoscopic surveillance intravesical therapy goal bladder preservation safe multiple organizational guideline exist help practitioner manage complicate disease process adherence management principle among practise urologist reportedly low review four major organizational guideline nmibc american urological association aua society urologic oncology suo european association urology eau national comprehensive cancer network nccn national institute health care excellence nice guideline clinical reliability histological classification system compare system ta primary bladder tumor purpose histopathological grade remain important predictive factor prognosis nonmuscle invasive bladder cancer define clinical reliability international society urological pathology histological classification system compare system ta primary bladder tumor material method evaluate consecutive patient \\ufeff1 episode low grade pta bladder cancer transurethral resection bladder grade assign single uropathologist simultaneously low grade g g accord classification system respectively patient receive single early prophylaxis instillation mg epirubicin adjuvant treatment followup include urine cytology cystoscopy month resection every month thereafter year univariate multivariate analysis recurrence free progression free survival do kaplan meier method log rank test result mean patient age year median range patient female male accord system grade g patient g median followup month mean range year recurrence free survival rate low grade population g g group respectively p year progression free survival rate low grade population g g group respectively p conclusion classification system predict risk recurrence primary pta case accurately system classification accuracy predict risk progression study confirm clinical reliability new histological classification clinical practice prognostic point view sulforaphane inhibit nonmuscle invasive bladder cancer cell proliferation suppression hif mediate glycolysis hypoxia bladder cancer 4 common cancer among man bladder cancer nonmuscle invasive bladder cancer nmibc high recurrence rate nmibc bring patient physical agony high therapy cost patient family society imperative seek natural compound inhibit bladder cancer cell growth prevent bladder cancer recurrence cell proliferation one main feature solid tumor development rapid tumor cell growth usually lead hypoxia due low oxygen environment study find sulforaphane natural chemical abundant cruciferous vegetable can suppress bladder cancer cell proliferation hypoxia significantly strong normoxia p sulforaphane inhibit bladder cancer cell proliferation normoxia inhibit cell proliferation hypoxia rt cell consistently sulforaphane inhibit cell proliferation normoxia inhibit cell proliferation hypoxia rt cell moreover reveal sulforaphane decrease glycolytic metabolism hypoxia microenvironment downregulating hypoxia induce hif block hif trans localization nucleus nmibc cell line study discover food source compound inhibit bladder cancer cell proliferation provide experimental evidence develope new bladder cancer preventive therapeutic strategy contrary regulation bladder cancer cell proliferation invasion dexamethasone mediate glucocorticoid receptor signal patient advance bladder cancer glucocorticoid frequently give reduce acute toxicity particularly hyperemesis chemotherapy good improve cachectic condition however remain unclear whether glucocorticoid directly affect development progression bladder cancer glucocorticoid receptor pathway glucocorticoid receptor expression \\ufeff1 investigate human bladder cancer line tissue microarray effect dexamethasone glucocorticoid receptor transcription cell proliferation apoptosis cell cycle invasion examine bladder cancer line finally mouse xenograft model bladder cancer use assess efficacy dexamethasone tumor progression cell line tissue examine find express glucocorticoid receptor dexamethasone increase glucocorticoid receptor mediate reporter activity cell proliferation inhibit apoptosis presence absence cisplatin contrast dexamethasone suppress cell invasion expression relate gene mmp mmp interleukin il vegf activity mmp mmp also induce mesenchymal epithelial transition addition dexamethasone increase b protein level cytosolic accumulation nf b xenograft bear mouse dexamethasone slightly augment growth inoculate tumor completely prevent development bloody ascites suggestive peritoneal dissemination tumor cell actual metastasis assay dexamethasone effect abolish glucocorticoid receptor antagonist glucocorticoid receptor knockdown via rna interference thus glucocorticoid receptor activation result promotion cell proliferation via inhibit apoptosis yet repression cell invasion metastasis result may provide basis develope improve chemotherapy regimen include exclude glucocorticoid receptor agonist antagonist urothelial carcinoma chromosomal alteration detect fluorescence situ hybridization urothelial carcinoma rare histologic variant bladder cancer fluorescence situ hybridization fish urovysion probe set abbott molecular des plaines il use assess bladder cancer chromosomal abnormality include adenocarcinoma urachal adenocarcinoma small cell carcinoma squamous cell carcinoma typical urothelial carcinoma fish also use assess benign urothelium case significant increase p mean numb chromosome vs chromosome vs chromosome vs centromeric signal observe cell patient cancer compare patient without cancer tumor demonstrate polysomic signal pattern cell remain tumor specimen high percentage cell demonstrate homozygous p deletion datum study suggest chromosomal abnormality detectable fish urothelial carcinoma also common rare histologic variant bladder cancer aggressive superficial bladder cancer urinary bladder cancer account approximately cancer human treatment urinary bladder not satisfactory present study aim elucidate effect gene silence survivin inhibition bladder cancer cell study construct survivin shrna carry lentiviral vector bladder cancer cell line cell bj cell transduce construct shrna survivin frequency apoptotic bladder cancer cell assess flow cytometry result show transfection survivin shrna significantly inhibit cell proliferation bj cell bj cell accumulate g stage portion sub g stage increase fraction bladder cancer cell undergo apoptosis note among eight apoptosis associate protein amount bax bad significantly increase survivin deficient bladder cancer cell finding suggest survivin may therapeutic target bladder cancer selectively inhibit cell proliferation bladder cancer cell survivin promise biomarker detection prognosis bladder cancer survivin kda member inhibitor apoptosis protein family overexpress many malignancy rarely detect normal differentiate adult tissue functionally survivin inhibit apoptosis promote cell proliferation induce enhance angiogenesis transitional cell carcinoma urinary bladder survivin show promise biomarker cancer diagnosis prognosis prediction response intravesical systemic therapy moreover pre clinical bladder tumor model inhibition survivin expression function show impede tumor cell proliferation markedly induce spontaneous chemotherapy induce apoptosis preliminary finding confirm large prospective trial furthermore simplify quantitative reproducible assay need develope validate detection survivin different isoform time evaluate refine transurethral resection bladder cancer association know prognostic variable alter immunostaining nuclear protein retinoblastoma rb p study homogeneous series locally advance bladder cancer predictive value immunostaining local response intend radical radiotherapy investigate among patient treat intend radical radiotherapy total patient evaluable respect local response treatment paraffin embed specimen tumour prior irradiation immunostained monoclonal antibody pmg rb p nuclear protein heat microwave oven min w alter expression rb p observe tumour respectively p overexpression associate high tumour grade however result p rb immunostaining procedure no predictive value tumor response radiation treatment local control cancer specific mortality advance bladder cancer intravesical chemotherapy immunotherapy administer patient bladder cancer hope decrease rate recurrence importantly reduce rate progression far bacille calmette gu rin agent decrease progression rate thus increase survival bacille calmette gu rin show achieve outcome selectively spare certain sequence fibronectin degradation critical fragment show motility stimulate activity may enhance tumor invasion vivo vitro study show cathepsin b inhibitor prevent degradation human basement membrane laminin \\ufeff1 step tumor invasion cathepsin b inhibitor either alone combination bacille calmette gu rin may valuable prevent progression superficial bladder tumor future clinical study bacille calmette gu rin repeatedly show 2 course bacille calmette gu rin patient local failure not jeopardize patient survival adjuvant chemotherapy patient locally advance disease regionally involve lymph node improve progression free survival control study establish verdict adjuvant chemotherapy advancement molecular genetic study relevant modern technology understand tumor behavior improve dramatically classic knowledge become outdate every day prognostic factor outcome radical cystectomy bladder cancer retrospective study homogeneous patient cohort purpose pathological predictor outcome patient undergo radical cystectomy bladder cancer need datum available literature retrospectively analyze homogeneous contemporary series patient treat radical surgery monotherapy bladder cancer identify independent predictor survival material method evaluate patient bladder cancer treat radical cystectomy pelvic node dissection urinary diversion staff single institution february february patient treat radiation therapy chemotherapy not undergo formal pelvic node dissection exclude study end point univariate multivariate analysis overall year survival result univariate analysis reveal tumor stage nodal involvement ureteral obstruction vascular lymphatic perineural invasion prognostic predictor survival p however tumor stage p nodal involvement p independent prognostic variable survival multivariate analysis conclusion tumor stage nodal involvement independent predictor survival use select optimal therapy radical cystectomy stratify patient control trial evaluate new prognostic factor radiochemotherapy transurethral resection effective treatment method g bladder cancer aim conservative therapy use deep transurethral resection tur follow radiochemotherapy novel treatment strategy stage ti grade tig transitional cell carcinoma tcc bladder aim study present long term result radiochemotherapy g tcc patient material method total patient tig tcc bladder undergo tur subsequent radiochemotherapy protocol institution follow tur median dose range gy radiation therapy apply bladder simultaneous chemotherapy initiate use cisplatin carboplatin fluorouracil completion protocol response evaluate repeat tur check cystoscopy perform regular interval median patient age range year median follow range month result complete response achieve patient complete responder patient experience superficial ta recurrence patient progression patient refractory superficial invasive relapse salvage cystectomy mandate overall progression rate overall disease free survival rate respectively year followup patient suffer reduce bladder capacity patient undergo cystectomy due shrink bladder conclusion combine multimodality therapy safe curative treatment option patient g tcc bladder hand dedicate multimodality team therefore reasonable justify radiochemotherapy combine tur \\ufeff1 line treatment g tumor urine telomerase bladder cancer detection purpose review summarize literature relate urothelial carcinoma squamous differentiation response chemotherapy radiation therapy method english literature pubmed extensively search article pertain urothelial carcinoma squamous differentiation response chemotherapy radiation article reference list scrutinize ensure relevant literature identify result urothelial carcinoma squamous differentiation generally treat pure urothelial carcinoma however remain unclear mix histology portend different prognosis patient bladder cancer particularly regard response chemotherapy radiation initial study suggest wrong response therapy mix histology recent datum challenge observation unfortunately literature limit type quality existent study mix result among datum available conclusion final word whether urothelial carcinoma squamous differentiation respond differently chemotherapy radiation therapy remain uncertain important question warrant careful study future multiplex protein signature detection bladder cancer void urine sample purpose accurate urine assay bladder cancer detection would benefit patient health care system extensive genomic proteomic profile urine component previously identify panel biomarker facilitate detection bladder cancer void urine sample study confirm diagnostic molecular signature diverse multicenter cohort material method perform case control phase ii study analyze void urine subject bladder cancer vary urological disorder urinary concentration biomarker il mmp pai vegf ang ca apoe assess enzyme link immunosorbent assay diagnostic performance panel test biomarker evaluate use rocs descriptive statistical value eg sensitivity specificity result seven urine biomarker increase subject bladder cancer relative without bladder cancer biomarker assess new model auroc ci sensitivity specificity contrast sensitivity void urine cytology urovysion cytogenetic test cohort respectively study limitation include analysis perform bank urine sample lack void urine cytology cytogenetic test datum control conclusion study provide evidence report panel diagnostic biomarker reliably achieve noninvasive detection bladder cancer high sensitivity currently available urine base assay top coamplification urinary bladder cancer neu one frequently amplify oncogene potential therapeutic target bladder cancer breast cancer adjacent top gene molecular target several anticancer drug frequently coamplified together study amplification expression top association tumor phenotype clinical outcome bladder cancer tissue microarray contain bladder tumor sample analyze fish immunohistochemistry overall amplification frequency top amplification frequently see advance stage pt tumor lectin possible tool improve urinary bladder cancer management urinary bladder cancer 9 common cancer develope country poor prognosis outcome patient due challenge diagnosis limit treatment possibility bladder cancer arise mainly urothelial cell line lumen urothelial cell form three five layer urothelium maintain blood urine barrier carbohydrate cover apical surface superficial urothelial cell e umbrella cell crucial function composition carbohydrate cover alter urothelial cancer transformation bladder cancer associate carbohydrate change promise field diagnosis therapy management lectin carbohydrate bind protein use detect subtle alteration carbohydrate composition urothelial cancer transformation extensive research various lectin application already conduct result often contradictory confuse none application reach clinical trial review literature discuss current bladder cancer management ii lectin base assay detection various cancer subtype iii lectin base strategy innovative bladder cancer treatment finally iv lectin nanotheranostics personalize bladder cancer management intravesical bacillus calmette guerin treat bladder cancer bladder cancer continue lead cause malignant neoplasm man since bacillus calmette guerin bcg recommend treatment superficial bladder malignancy bcg treatment indication administration side effect patient education nurse implication discuss clinical pitfall diagnosis nonmuscle invasive bladder cancer current global economic crisis impose healthcare system reduce unnecessary investigation increase early detection tumor decrease cost advance disease several diagnostic pitfall may occur deal bladder cancer bc particularly nonmuscle invasive nmibc one hematuria common sign nmibc often underestimate urinary cytology highly specific prognostic value dna methylation bladder cancer purpose grow numb research manifest dna methylation consider biomarker prognosis bladder cancer bc however result still discrepancy material method meta analysis conduct accordance prisma guideline study evaluate practicability methylate dna prognostic marker bc thoroughly search via pubmed web science cochrane library database january st may th association dna methylation overall survival os progression free survival pf analyze hazard ratio hr odd ratio ors confidence interval cis calculate assess correlation methylate dna prognostic value bc use multivariate survival analysis result nineteen study include patient methylate dna poor os compare unmethylated dna combine hr ci simultaneously methylate dna considerably associate short pf hr ci furthermore dna methylation significant association gender male vs female ci grade vs ci tumor diameter cm vs cm ci numb tumor single vs multiple ci stage ta vs ci ta vs ci conclusion dna methylation negative correlate prognosis bc patient may become promise biomarker radiotherapy combine chemotherapy treatment muscle invasive bladder carcinoma levin measure attributable risk extend account confound maximum likelihood estimate confidence interval extend measure present estimate confidence interval apply match stratify case control study statistical method illustrate use datum study factor womanhood relate breast cancer datum study cigarette smoke relate bladder cancer result computer simulation use describe behavior estimate confidence interval sample size small relative numb stratum confound factor carbonic anhydrase ix bladder cancer diagnostic prognostic therapeutic molecular marker background objective study evaluate role carbonic anhydrase ix caix urothelial carcinoma bladder method tissue microarray construct contain tissue sample patient immunohistochemical stain perform use antibody mn percentage positive cell evaluate association tumor classification grade survival assess result normal urothelial tissue sample negative caix expression whereas bladder cancer express caix caix expression high noninvasive ta versus invasive tumor p low grade versus high grade bladder cancer p metastasis versus correspond primary tumor p patient nonmuscle invasive carcinoma undergo transurethral resection tur high caix expression associate poor recurrence free survival p addition patient tumor undergo tur high caix expression convey fold high risk progression muscle invasive disease p patient undergo cystectomy high caix expression associate wrong overall survival p multivariate cox model reveal caix expression strong independent prognostic factor recurrence free survival hazard ratio p overall survival hazard ratio p conclusion caix express differentially noninvasive versus invasive tumor low grade versus high grade bladder cancer primary tumor versus metastasis current result indicate caix strong predictor recurrence progression overall survival patient bladder cancer integration caix expression conventional prognostic model significantly improve predictive accuracy datum suggest tripartite role caix diagnostic prognostic therapeutic molecular marker bladder cancer single instillation mitomycin c reduce st year recurrence follow transurethral resection non muscle invasive bladder cancer objective study impact single instillation mg mitomycin c mmc within \\ufeff1 hour transurethral resection tur \\ufeff1 year recurrence non muscle invasive bladder cancer method study two group patient similar demographics tumour profile compare assess \\ufeff1 year tumour recurrence pattern group receive mmc within minute tur group b patient tur bladder tumour patient chart review demographic profile preoperative diagnosis image use cytological work tumour profile cystoscopy image use patient record also review subsequent check cystoscopy recurrence adjuvant treatment like intravesical chemo immunotherapy etc also note result analyse use commercially available statistical package spss level significance result patient group b respectively demographic profile term age gender distribution tumour characteristic size site multiplicity pathological evaluation include tumour grade presence carcinoma situ similar p p respectively \\ufeff1 year recurrence rate group whereas group b p conclusion \\ufeff1 year recurrence rate significantly decrease mmc instill follow tur mmc safe cost effective low grade low volume tumour would not require treatment mmc give immediately follow tur prognostic impact returb high grade primary bladder cancer purpose evaluate whether pathological outcome returb prognostic impact recurrence progression primitive hg bladder cancer material method patient affect primitive hg tcc bladder undergo restage turb returb patient muscle invasive disease returb undergo radical cystectomy non muscle invasive residual nmi rt no residual tumour nrt receive intravesical bcg therapy compare recurrence progression nmirt patient nrt patient restage turb patient follow every month cystoscopy urine cytology result patient enroll study returb residual cancer detect valuable patient upstage follow month difference recurrence progression rate nrt nmirt patient p lt p respectively recurrence free progression free survival significantly high nrt compare nmirt patient p lt p respectively conclusion returb allow identify considerable numb residual understaged cancer patient nmirt returb wrong prognosis nrt term recurrence progression free survival outcome seem suggest prognostic impact finding returb can valid tool management high grade tcc new italian guideline bladder cancer base world health organization classification objective provide evidence base recommendation bladder cancer management method multidisciplinary guideline panel compose urologist medical oncologist radiotherapist general practitioner radiologist epidemiologist methodologist conduct structure review previous report search medline database january december milestone paper publish january accept analysis level evidence grade recommendation establish use grade system result reference identify retrieve eliminate specify reason elimination include analysis good milestone report consensus conference hold discuss discrepancy scientific evidence clinical practice attend delegate various speciality conclusion recommendation bladder cancer management provide diagnostic value transurethral biopsy bladder cancer select patient definitive external irradiation fail control bladder cancer potentially salvage cystectomy patient cancer center undergo salvage cystectomy year survival rate per cent postoperative hospital mortality rate per cent infectious complication develope 3 patient ureteroileal urine leak develope per cent incidence complication not dissimilar radical cystectomy without prior large dose irradiation chronic inflammation bladder cancer relation schistosomiasis bladder cancer good establish account high rate bladder cancer numb develope country include egypt develope country transitional cell carcinoma predominant type bladder cancer whereas schistosomiasis endemic region squamous cell carcinoma common type review experimental observational datum infection inflammation bladder cancer summarize special emphasis transitional cell carcinoma finding numerous study suggest inflammation likely important role bladder carcinogenesis develope country future study need focus great detail risk factor increase inflammation bladder examine genetic susceptibility inflammatory pathway include marker inflammation measure prior cancer diagnosis understand role inflammation transitional cell carcinogenesis may provide important insight prevent 6 common cancer unite state storz professional image enhancement system spy nonmuscle invasive bladder cancer study multicenter international randomize control study background intravesical therapy bacillus calmette guerin bcg aim reduce incidence tumour recurrence follow transurethral resection tur patient superficial bladder cancer objective objective review compare incidence tumour recurrence standard therapy transurethral resection versus transurethral resection plus intravesical bacillus calmette guerin search strategy search cochrane control trial register march medline february embase february cancerlit february healthstar february database abstract review effectiveness february bath information datum service proceeding american society clinical oncology hand search selection criterium randomise quasi randomise trial transurethral resection alone versus transurethral resection plus intravesical bacillus calmette guerin patient ta bladder cancer medium high risk tumour recurrence eligible inclusion datum collection analysis four reviewer assess trial quality two abstract datum independently peto odd ratio log hazard ratio determine compare numb patient disease recurrence month rate recurrence respectively main result six randomise trial include involve eligible patient significantly few patient disease recurrence month bcg plus tur group compare receive tur alone odd ratio ci overall log hazard ratio recurrence variance indicate significant benefit bcg treatment reduce tumour recurrence toxicity associate bcg consist mainly cystitis haematuria fever urinary frequency no bcg induce death report reviewer conclusion patient medium high risk ta bladder cancer immunotherapy intravesical bcg follow tur appear provide significant advantage tur alone delay tumour recurrence diagnosis treatment bladder cancer bladder cancer 6 prevalent malignancy unite state common type bladder cancer urothelial transitional cell carcinoma cystoscopy remain mainstay diagnosis surveillance fluorescence cystoscopy offer improvement detection flat neoplastic lesion carcinoma situ non muscle invasive bladder cancer typically manage transurethral resection perioperative intravesical chemotherapy intravesical bacille calmette gu rin therapy prefer mitomycin high risk disease progression muscle invasive disease standard management radical cystectomy patient neoadjuvant chemotherapy postoperative adjuvant chemotherapy consider base pathologic risk positive lymph node pathologic stage multidrug systemic chemotherapy involve cisplatin commonly use no major organization recommend screen bladder cancer preoperative lymphocyte monocyte platelet lymphocyte ratio predictor overall survival patient bladder cancer undergo radical cystectomy although pretreatment neutrophil lymphocyte ratio nlr lymphocyte monocyte ratio lmr platelet lymphocyte ratio plr reportedly associate clinical outcome many cancer role patient bladder cancer bca undergo radical cystectomy rc not widely investigate analyze relationship preoperative nlr lmr plr overall survival os bca patient undergo rc os curve draw use kaplan meier method evaluate use log rank test relationship os potential confound variable determine use cox proportional hazard regression model decrease lmr associate short os p os low plr group significantly long high plr group p nlr not significantly associate oncological outcome however adjust confound variable patient high lmr group indicate decrease mortality low lmr group hazard ratio confidence interval p plr not independent predictor os result show preoperative lmr well prognostic factor bca patient undergo rc compare nlr plr histone deacetylase inhibitor belinostat pxd suppress bladder cancer cell growth vitro vivo background treatment option patient recurrent superficial bladder cancer limit necessitate aggressive exploration new treatment strategy effectively prevent recurrence progression invasive disease assess effect belinostat previously pxd novel histone deacetylase inhibitor panel human bladder cancer cell line represent superficial invasive disease transgenic mouse model superficial bladder cancer method growth inhibition cell cycle distribution effect belinostat j rt urothelial line assess ha ras transgenic mouse establish superficial bladder cancer randomize receive either belinostat vehicle alone assess bladder weight hematuria gene expression profile immunohistochemistry ihc result belinostat significant linear p status correlate risk progression stage bladder cancer background publish study yield inconsistent result relationship p status progression stage non muscle invasive bladder cancer nmibc therefore perform meta analysis evaluate prognostic value p nmibc method systematically search relevant literature medline embase web science datum pool together individual study meta analysis perform study quality assess use newcastle ottawa scale pool risk ratio rrs ci calculate estimate effect size moreover subgroup analysis carry result total study comprise patient subject final analysis p overexpression significantly associate high progression rate nmibc rr ci moderate heterogeneity observe across study p subgroup analysis stratify stage p overexpression predictor progression grade nmibc rr ci addition subgroup analysis stratify intravesical therapy p overexpression predictor progression nmibc receive bacillus calmette gu rin intravesical therapy rr ci furthermore exclude study possibly contribute heterogeneity sensitivity analysis association p overexpression significantly correlate progression nmibc rr ci without evidence heterogeneity p conclusion adjuvant neoadjuvant therapy bladder prostatic cancer since radiotherapy plan advance bladder cancer base compute tomography ct since use three dimensional plan system treatment plan patient refer department prognosis patient high grade bladder carcinoma pathological feature clinical outcome grade transitional cell carcinoma bladder exclude cis encounter study clarify clinical characteristic disease subject study patient consist male female age year mean age year survival rate accord factor calculate kaplan meier method survival curve compare generalize wilcoxon test grade bladder cancer often papillary sessile cm diameter show tendency multiple occurrence histopathologically often high stage pt frequently vascular invasion total cystectomy not consider absolute necessity pt g bladder cancer patient experience not improve prognosis however bladder preserve operation require strict postoperative follow up operation year survival rate high no recurrence group recurrence group come tend well group undergo intravesical instillation chemotherapy prevention recurrence group without therapy ample intravesical instillation chemotherapy bladder preserve operation seem improve postoperative course bladder cancer patient total cystectomy may unavoidable patient pt no effect postoperative adjuvant chemotherapy note series establishment multidisciplinary approach consider need improvement prognosis high stage bladder cancer regional lymph node status patient bladder cancer find pathological stage radical cystectomy follow systemic chemotherapy purpose review goal surveillance curative treatment bladder cancer identify bladder cancer recurrence early stage also close follow metabolic functional consequence urinary diversion review propose follow scheme base available literature recent find follow patient undergo curative treatment invasive bladder cancer cover many aspect recurrence see within year curative treatment therefore awareness specific sign symptom indicate local regional distant upper urinary tract urethral recurrence important apart oncological follow also metabolic functional aspect play vital role surveillance summary time no consensus well follow strategy follow strategy base literature suggest proceeding total cystectomy editorial overview hyaluronan ha carbohydrate extracellular matrix tumor promote effect variety cancer present study address role ha matrix progression prognosis human bladder cancer study expression function ha relate gene method tissue sample patient different stage transitional cell bladder cancer undergo surgical treatment bladder cancer university hospital essen analyse mrna expression level ha synthase ha receptor rhamm cd evaluate real time rt pcr comparison healthy bladder tissue control uni multivariate cox proportional hazard survival regression analysis impact gene expression level survival assess vitro knock rhamm cd isoenzyme achieve sirna lentiviral shrna j bladder cancer cell transfect cell analyse vitro regard proliferation cell cycle apoptosis j cell knock rhamm xenografted male nu nu athymic mouse monitor tumor progression vivo result invasive tumor stage rhamm mrna expression level elevate whereas v reduce compare non invasive tumor subsequently kaplan meier analysis reveal reduce bladder cancer specific survival patient high rhamm mrna low v expression elevate rhamm invasive tumor confirm rhamm immunohistochemistry furthermore multivariate analysis reveal rhamm expression associate poor prognosis independent survival factor hr ci p lentiviral rhamm knock reveal reduce j cell proliferation vitro reduce xenograft tumor growth vivo conclusion datum suggest rhamm play crucial role mediate progression muscle invasive bladder cancer recommend rhamm evaluation prognostic marker therapeutic target bladder cancer therapy validation protein panel noninvasive detection recurrent non muscle invasive bladder cancer context patient non muscle invasive bladder cancer nmibc experience relapse disease objective establish panel protein biomarker incorporate multiplexed microarray bca chip classifier diagnose recurrent nmibc material method urine sample patient test diagnostic performance evaluate receiver operate characteristic roc analysis result multi biomarker panel ecadh il mmp en vegf past recurrence bcg therapy stage diagnosis identify yield area curve discussion conclusion biomarker panel represent potential diagnostic tool noninvasive diagnosis recurrent nmibc molecular pathway bladder cancer part purpose review therapy invasive bladder cancer aim cure besides radical organ remove surgery bladder spare alternative available report current status quality life issue therapy invasive bladder cancer recent finding consensus not reach definition concept quality life result numerous way measure reasonable believe individually self assess level quality life affect total post therapeutic symptom burden clinical application nmp management transitional cell carcinoma bladder combination noninvasive quantitative immunoassay nmp void urinary cytology prior cystoscopy evaluate patient urothelial transitional cell carcinoma fifty six patient history transitional cell carcinoma evaluate void urine obtain nmp cytology prior cystoscopy one hundred twenty three nmp assay cytology cystoscopy perform type anesthesia use cystoscopic evaluation determine nmp value patient cystoscopy result consider positive biopsy confirm malignancy reference value use nmp u ml nmp cytology combination nmp cytology compare cystoscopy pathologic grade stage thirty four recurrent transitional cell carcinoma episode occur low grade ii high grade lentiviral vector mediate gene transfer human bladder cancer cell line background aim currently treatment non muscle invasive bladder cancer cause significant deterioration patient quality life qol therefore development novel therapeutic option without deterioration qol important study assess anti tumor effect lentivirus mediate gene transfection tumor suppressor gene human bladder cancer cell material method lentiviral vector contain tumor suppressor gene p p pten transfect human bladder cancer cell line j umuc normal human uroepithelial cell line sv huc result significant growth inhibition observe bladder cancer cell transfection p pten vector however effect p vector limit normal cell lentiviral vector not exhibit significant growth inhibitory effect conclusion lentiviral vector mediate gene transfection useful application gene therapy bladder cancer collective diagnostic biomarker identify high risk subpopulation hematuria patient exploit heterogeneity large scale biomarker datum background ineffective risk stratification delay diagnosis serious disease patient hematuria apply system biology approach analyze clinical demographic biomarker measurement n collect hematuric patient urothelial cancer uc control confound pathology method basis biomarker conduct agglomerative hierarchical cluster identify patient biomarker cluster explore relationship patient cluster clinical characteristic use chi square analysis determine classification error area receiver operate curve random forest classifier rfc patient subpopulation use biomarker cluster reduce dimensionality datum result agglomerative cluster identify five patient cluster seven biomarker cluster final diagnosis category non randomly distribute across five patient cluster addition two patient cluster enrich patient low cancer risk characteristic biomarker contribute diagnostic classifier two patient cluster similar contrast three patient cluster significantly enrich patient harbor high cancer risk characteristic include proteinuria aggressive pathological stage grade malignant cytology patient three cluster include control patient serious disease patient cancer uc biomarker contribute diagnostic classifier large high cancer risk cluster different contribute classifier low cancer risk cluster biomarker contribute subpopulation split accord smoke status gender medication different conclusion system biology approach apply study allow hematuric patient cluster naturally basis heterogeneity within biomarker datum five distinct risk subpopulation finding highlight approach promise unlock potential biomarker especially valuable field diagnostic bladder cancer biomarker urgently require clinician can interpret risk classification score context clinical parameter time triage can reduce cystoscopy enable priority diagnosis aggressive disease lead improve patient outcome reduce cost bacterial infection urine patient bladder cancer retrospective study patient bladder cancer radiotherapy follow diagnostic conservative surgery bacterial infection urine evaluate incidence urine infection patient sterile urine patient investigation urine infection not perform infection cause gram negative bacillus no dependence infection incidence tumor stage incidence diabetes mellitus prostatic gland size tumor location near internal ostium urethra find thus cancer transurethral diagnostic transurethral abdominal operation hospital stay appear primary importance development infection prevent serious late postradiation reaction important manage infection start radiotherapy feature infection therapy bladder cancer patient discuss impact blue light cystoscopy diagnosis treatment bladder cancer photodynamic diagnostic technique blue light cystoscopy blc take advantage preferential uptake accumulation protoporphyrins neoplastic tissue emit red fluorescence illuminate blue light nm wavelength allow enhance visualization small papillary tumor flat carcinoma situ lesion may miss white light cystoscopy wlc compel evidence ability blc detect additional tumor translate improve recurrence rate compare wlc however impact blc regard progression rate patient manage intravesical therapy not yet know work require optimize integration blc clinical practice future blc appear promise urothelial cancer mucosally confine disease aggressive ras association domain family protein rassf putative tumor suppressor gene locate p regard play important role regulation different type human tumor previous report demonstrate frequency rassf methylation significantly high patient group compare control relationship rassf promoter methylation pathological feature tumor grade bladder cancer remain controversial therefore eukaryotic initiation factor e superficial muscle invasive bladder cancer correlation vascular endothelial growth factor expression tumour progression vascular endothelial growth factor vegf important factor mediate tumour angiogenesis vegf mrna differentially express bladder cancer high expression superficial tumour stage pta pt contrast low expression muscle invasive tumour stage pt investigate mechanism regulate vegf expression bladder cancer vegf mrna protein measure normal bladder n primary bladder cancer n vegf protein level correlate mrna expression normal bladder r p bladder cancer r p whilst vegf mrna expression threefold high superficial compare muscle invasive bladder cancer p no difference vegf protein p accordingly median protein mrna ratio increase fold increase tumour stage p suggest translational regulation expression eukaryotic initiation factor e cd overexpression prognostic factor potential therapeutic target bladder cancer cd also name extracellular matrix metalloproteinase inducer emmprin show involve progression malignancy regulate expression vascular endothelial growth factor vegf matrix metalloproteinase mmps goal study evaluate role cd biology bladder cancer determine potential therapeutic target cd protein expression detect immunohistochemistry bladder cancer use tissue microarray annotate patient follow immunohistochemistry cd protein expression associate poor prognosis p lymph node status p tumor stage p histologic grade p multivariate analysis show cd overexpression independent prognostic factor p infection bladder cancer cell adenovirus express small interfere rna sirna cd efficiently inhibit cd protein mrna expression result decrease proliferation soft agar colony formation migration invasion cell vitro moreover downregulation cd reduce secretion mmp mmp expression vegf cell finding suggest cd overexpression play important role progression bladder cancer cd can potential target bladder cancer therapy combine therapy patient invasive bladder cancer organ preservation investigate inmuscle invasivebladder cancer past year alternative standard radical cystectomy however morbidity radical cystectomy early report good result radical transuretheral resection bladder tumor turbt stimulate interest combine treatment muscle invasive bladder cancer organ preservation require trimodal schedule include transuretheral surgery mega voltage radical external beam radiotherapy ebrt adjuvant chemotherapy act result point effectiveness combine therapy urinary bladder old patient invasive advance cancer stage result demonstrate effectness intra arterial act use combination ebrt evaluation potential target gene p amplicon urinary bladder cancer amplification p one frequent chromosomal alteration high grade invasive urinary bladder cancer order determine amplification level know gene inside kb core amplicon construct small tissue microarray tma primary bladder cancer bladder cancer cell line know p amplification analyze panel overlap fish probe construct bacterial artificial chromosome bacs high amplification rate observe transcription factor e f adjacent gene nm function not know detail analysis gene additional large section analysis do primary bladder cancer bladder cancer cell line show e f nm always coamplified amplification level term numb gene copy slightly high copy per nucleus e f compare nm gene copy study demonstrate e f nm locate top p amplicon bladder cancer remain study one two gene drive p amplification gene contribute jointly aggressive feature p amplify bladder cancer meta analysis occupational exposure painter lung bladder cancer morbidity mortality international agency research cancer iarc classify occupational paint human carcinogen base lung bladder cancer however no specific exposure implicate author conduct comprehensive tissue response hexyl aminolevulinate induce photodynamic treatment syngeneic orthotopic rat bladder cancer model possible pathway action orthotopic bladder cancer model rat mimic human bladder cancer respect urothelial tumorigenesis progression utilize model pt superficial stage analyze tissue response hexyl aminolevulinate induce photodynamic therapy hal pdt comparison untreated rat hal pdt cause little change tumor free rat bladder induce inflammatory change increase lymphocyte mononuclear cell infiltration rat bladder tumor immunohistochemistry reveal hal pdt without effect proliferate cell nuclear antigen expression within tumor increase caspase expression normal urothelium tumor transmission electron microscopy reveal severe mitochondrial damage formation apoptotic body vacuole lipofuscin body no microvillus form niche hal pdt treat bladder cancer rat bioinformatics analysis gene expression profile indicate activation cell receptor signal pathway bladder cancer rat without pdt hal pdt increase expression cd cd ra tumor determine immunohistochemistry suggest pathway action hal pdt may include little activation mitochondrial apoptosis autophagy breakdown cancer stem cell niche importantly enhancement cell activation classification suitable classification predict prognosis non muscle invasive bladder cancer background predict recurrence progression non muscle invasive bladder cancer nmibc critical urologist histological grade provide significant prognostic information especially prediction progression currently classification co exist system well predict rumor recurrence progression still matt debate methodology principal finding patient diagnose non muscle invasive bladder cancer enroll retrospective study paraffin section assess experience urological pathologist accord classification tumor recurrence progression follow patient follow correspond year recurrence free survival rate g g g year progression free survival rate respectively year recurrence free survival rate papillary urothelial neoplasm low malignant potential punlmp low grade papillary urothelial carcinoma lgpuc high grade papillary urothelial carcinoma hgpuc respectively year progression free survival rate respectively multivariate analysis classification significantly associate tumor recurrence progression p p respectively classification correlate tumor progression p not prove variable predict risk recurrence p kaplan meier plot show classification significantly associate progression free survival p log rank test prediction recurrence significant difference observe tumor grade classify use grade system p log rank test significant overlap observe punlmp lg plot use grade system p log rank test conclusion significance classification effective predict tumor progression non muscle invasive bladder cancer classification suitable predict tumor recurrence early indicator bladder carcinogenesis produce non genotoxic agent several early indicator non genotoxic bladder tumorigenicity non invasive indication polydipsia diuresis change urine ph urinary cation concentration especially na ca indicator require invasive technique increase bladder weight increase cell replication assess dna label histologically epithelial hyperplasia sem use characterize bladder surface change reduction bladder tissue ca implicate one mechanism lead bladder cancer wherever multiple species test non genotoxic bladder carcinogen induce bladder response rat true whether criterion complete carcinogenesis promotion short term indicator also evident response vary greatly within rat strain dependent upon diet feed variable make relevance result obtain rat bladder questionable significance man relation chronic study clear male rat age lose capacity concentrate urine probably endemic age progressive loss functional renal tissue also clear bladder grow accommodate increase urine output thus likely agent treatment cause bladder damage may associate increase neoplasia expression age male rat no species show degree spontaneous nephrosis see male rat condition rat strain diet dependent finally recognize early indicator bladder tumorigenesis useful warn sign compound likely yield unique response mechanism study detail facilitate discussion parameter identify early indicator bladder tumorigenesis associate non genotoxic agent propose mechanism cancer development information lead proposal critique mechanism present thought systematic review meta analysis adjuvant chemotherapy muscle invasive bladder cancer patient advocacy organization play critical role increase public awareness specific cancer demand improvement approach treatment organization also increase participation clinical trial help raise fund research not cancer patient represent advocacy organization found bladder cancer advocacy network no patient advocacy group bladder cancer despite prevalence disease work health care professional new advocacy organization facilitate advance research treatment lead possibly cure bladder cancer giant scrotal lymphedema unique onset sign muscle invasive bladder cancer risk misdiagnosis year old male present complain void low urinary tract symptom associate genital weightiness past year grossly lesion interest scrotum kg mass scrotum minimally tender intact skin bereave erythema inflammation low limb lymphedema inguinal crural lymphadenopathy despite repeat urinary cytology negative abdominal ct urethrocystoscopy confirm muscle invasive transitional cell carcinoma affect bladder surgical strategy include direct excision giant scrotum local tissue reconstruction radical cystectomy ileal conduit \\ufeff1 time note giant scrotal lymphedema unique onset sign muscle invasive transitional cell carcinoma bladder otherwise clinically silent clinical set differential diagnosis always carry bladder cancer life threaten disease require aggressive approach adriamycin mediate potentiation cytotoxicity freshly isolate bladder cancer cell autologous non activate peripheral blood lymphocyte tumor infiltrate lymphocyte purpose previous study indicate cancer patient lack functional anti tumor cytotoxic lymphocyte however anti tumor cytotoxic lymphocyte may coexist immunoresistant tumor cell reason anti tumor cytotoxic activity lymphocyte may reveal tumor cell sensitize kill report adriamycin adr exhibit various immunomodulating activity present study investigate effect adr susceptibility freshly isolate bladder cancer cell lysis autologous non activate peripheral blood lymphocyte pbl tumor infiltrate lymphocyte til material method cytotoxicity determine day microculture tetrazolium dye assay result treatment adr resistant fresh bladder cancer cell adr microg ml hour enhance susceptibility lysis autologous pbl adr induce enhancement susceptibility fresh bladder cancer cell lysis pbl also observe lymphokine activate killer cell purify natural killer cell lymphocyte use effector cell furthermore cytotoxicity freshly derive til autologous bladder cancer cell minimal significant cytotoxicity observe adr treat bladder cancer cell adr analog epirubicin pirarubicin also enhance susceptibility bladder cancer cell lysis autologous pbl treatment bladder cancer cell adr no effect expression mhc class cancer cell frequency bladder cancer target cell conjugate autologous pbl treatment bladder cancer cell adr augment sensitivity anti fas monoclonal antibody tumor necrosis factor pretreatment effector cell adr no effect cytotoxic function conclusion finding demonstrate pbl til patient bladder cancer exhibit anti tumor cytotoxic function function not manifest due development acquisition tumor cell resistance kill however resistance bladder cancer cell kill cytotoxic lymphocyte overcome cancer cell sensitize subtoxic concentration adr finding suggest treatment bladder cancer patient low dose adr may sensitize cancer cell kill autologous circulate tumor infiltrate lymphocyte may novel immunotherapeutic modality treatment drug resistant immune resistant bladder cancer update critical analysis treatment strategy newly diagnose context high grade formerly g bladder cancer bca high propensity recur progress result decision pertain treatment difficult treatment bacillus calmette gu rin bcg risk progression metastasis may preserve bladder cystectomy may offer well opportunity cure associate morbidity risk mortality may constitute potential overtreatment many case g tumour purpose review continue refer high grade lesion g objective review current literature management g bca provide recommendation treatment evidence acquisition national center biotechnology information ncbi pubmed search relevant article publish january perform use medical subject heading g bladder cancer article relevant treatment g bca retain evidence synthesis diagnosis g disease difficult pathologic stage often unreliable risk significant understaging initial transurethral resection tur bladder tumour secondary restage tur recommend case g single dose immediate post tur chemotherapy recommend bladder spare approach intravesical bcg give induction maintenance dose immediate early radical cystectomy rc offer patient recurrent multifocal g disease high risk progression fail bcg treatment conclusion bladder preservation rc appropriate option g bca risk stratification patient base pathologic feature initial tur recurrence select appropriate bladder preservation compare cystectomy strongly consider prophylactic urethrectomy male patient bladder cancer paper trace development use chemotherapy management advance bladder carcinoma europe numb agent include cisplatin methotrexate vinblastine adriamycin fluorouracil cyclophosphamide investigate singly combination phase ii study envisage ideal combination chemotherapy regimen give last complete response ultimately use along limit ablative surgery management localise advance bladder cancer careful application increase knowledge biology transitional cell carcinoma strict adherence rigid criterium response assessment new agent appear last offer hope improvement prognosis invasive bladder cancer recent clinical trial superficial bladder cancer present review address literature regard management superficial bladder cancer publish since march no definitive winner among urinary marker bladder cancer lack specificity insufficiently test pathologist continue effort improve prediction evolution superficial bladder cancer recurrent infiltrative disease study confirm value previously describe prognostic factor recurrence progression add refinement transurethral resection not complete believe fluorescence detection flat bladder carcinoma demonstrate improve diagnosis treatment necessity perform repeat transurethral resection high grade superficial bladder cancer become evident identification work mechanism bacille calmette gu rin superficial bladder cancer remain important objective may help improve treatment schedule avoid morbidity associate bacille calmette gu rin administration patient high risk may benefit long term maintenance bacille calmette gu rin therapy valrubicin keyhole limpet haemocyanin appear promise agent treatment superficial bladder cancer case primary urinary bladder ureter cancer choriocarcinoma year old man plan laparoscopic right nephrouretectomy right low ureteral cancer pt g two month prior surgery examine continue macrohematuria mm tumor urinary bladder tumor right upper low urinary tract compute tomographic ct examination cystoscopy not metastasis diagnose ct n right ureteral cancer ct n bladder cancer right nephrouretectomy cystectomy perform histopathologic examination reveal urothelial carcinoma choriocarcinoma treatment bladder cancer elderly background germany bladder cancer 4 common malignancy male occupy th place female case occur patient age year objective elderly patient nonmuscle invasive bladder cancer appear harbor high risk disease recurrence progression undergo treatment careful surveillance young counterpart elderly patient muscle invasive bladder cancer undergo radical cystectomy increase risk perioperative morbidity mortality refer experience high volume center conclusion beside radical cystectomy standard treatment several bladder spare approach transurethral resection chemotherapy radiotherapy chemoradiotherapy available may treatment alternative carefully select case valid randomize comparison approach radical cystectomy however still lack management superficial bladder cancer review currently available trial evidence several clinical recommendation bladder tumor management become apparent transurethral resection do procedure prone overestimate underestimate stage restage transurethral resection patient tumor therefore perform datum support immediate postoperative instillation chemotherapeutic agent patient solitary low grade papillary tumor whereas patient multiple lesion may benefit intensive adjuvant regimen although use intravesical immunotherapy reduce tumor progression maintenance therapy controversial bacillus calmette gu rin demonstrate significant benefit tumor prophylaxis no obvious residual disease present early radical cystectomy beneficial perform patient refractory tumor carcinoma situ progression muscle invasion review present overview management nonmuscle invasive bladder cancer common intravesical chemotherapeutic agent describe good impact chemotherapy recurrence progression tumor effect intravesical immunotherapy bladder cancer explore good role early cystectomy role neoadjuvant chemotherapy invasive bladder cancer background epidemiologic study drink water disinfection byproduct focus primarily carcinogenic potential chlorination byproduct drink water ozonated france decade able assess carcinogenic risk disinfection byproduct generate ozonation chlorination method use datum case control study bladder cancer conduct french hospital compare case control can reconstruct little residential exposure drink water contaminant year period result take potential confounder exposure chlorination byproduct account risk bladder cancer decrease duration exposure ozonated water increase ci year year simultaneously risk bladder cancer increase duration exposure chlorinate surface water estimate trihalomethane content water datum suggest ozonation reduce risk associate chlorination surface water ozonation alone can independent beneficial effect bladder cancer risk conclusion result consistent experimental evidence ozonation combination chlorination decrease concentration trihalomethane treat water eliminate mutagenicity raw water effect restage transurethral resection recurrence progression rate patient nonmuscle invasive bladder cancer treat intravesical bacillus calmette gu rin purpose determine whether restage resection initiate induction intravesical bacillus calmette gu rin improve recurrence free rate patient high risk nonmuscle invasive bladder cancer material method retrospectively analyze datum patient treat institution intravesical bacillus calmette gu rin nonmuscle invasive high risk bladder cancer patient undergo 2 resection except already receive bacillus calmette gu rin time initial consultation refuse restage resection patient assess every month minimum year univariate multivariate regression use identify predictor regulation lncrna tug enhance radiosensitivity bladder cancer via suppress hmgb expression background long non code rnas lncrnas report regulate sensitivity different cancer cell chemoradiotherapy aberrant expression lncrna taurine upregulated gene tug find involve development bladder cancer however function underlie mechanism radioresistance bladder cancer remain unclear method quantitative real time pcr qrt pcr conduct measure expression tug hmgb mrna bladder cancer tissue cell line hmgb protein level test western blot assay different dose x ray use radiation treatment bladder cancer cell colony survival cell viability detect clonogenic assay cck kit respectively cell apoptosis determine flow cytometry xenograft mouse model construct observe effect tug tumor growth vivo result level tug hmgb remarkably increase bladder cancer tissue cell line radiation treatment markedly elevate expression tug hmgb tug knockdown inhibit cell proliferation promote cell apoptosis decrease colony survival sw biu cell radiation moreover tug depletion suppress hmgb mrna protein level furthermore overexpression hmgb reverse tug knockdown induce effect bladder cancer cell radiation treatment dramatically reduce tumor volume weight xenograft model effect obvious combine tug silence conclusion lncrna tug knockdown enhance radiosensitivity bladder cancer suppress hmgb expression tug act potential regulator radioresistance bladder cancer may represent promise therapeutic target bladder cancer patient incidence extent location unsuspected pelvic lymph node metastasis patient undergo radical cystectomy bladder cancer march december patient per cent undergo radical cystectomy unsuspected metastasis patient per cent node involve mean size involve node cm mean size metastasis cm patient positive node metastasis not observe bifurcation common iliac artery lateral external iliac artery patient primary bladder tumor localize clearly side bladder unsuspected metastasis observe ipsilateral lymph node accordance finding advocate restrict pelvic lymphadenectomy patient gross examination reveal no evidence nodal metastasis radical cystectomy experimental chemotherapy bladder cancer systemic intravesical herein discuss biochemistry occupational urinary tract cancer review history occupational aromatic amine cancer experimental production aromatic amine cancer aromatic amine double cancer risk factor clonal development superficial invasive bladder cancer bladder cancer classically associate exogenous risk factor large literature identify risk factor associate genesis transitional cell carcinoma recently effort make identify host factor evaluate possible change tumour presentation biology include grade stage association risk factor available literature appear demonstrate alteration tumour biology associate environmental carcinogen various study suggest consistent upgrade bladder cancer stage grade result cigarette smoke high risk occupational exposure important however factor associate increase risk bladder cancer extensively evaluate assess validity concept organ conservation deeply invasive bladder cancer purpose inflammatory reaction link bladder cancer diet drive systemic inflammation may consider modifiable risk factor bladder cancer examine association diet pro inflammatory potential bladder cancer risk use novel edip empirical dietary inflammatory pattern score comprise predefine food group determine pattern predictive plasma inflammatory marker material method follow total woman nhs nurse health study nhs ii good man hpfs health professional follow study multivariable adjust cox regression model use estimate rr ci bladder cancer across edip score quintile perform inverse variance weight meta analysis pool estimate across cohort stratify smoke status result person year observation incident bladder cancer case identify overall high edip score reflect dietary pattern pro inflammatory potential not associate high risk bladder cancer quintile vs pool multivariable adjust rr ci p trend result consistent across individual cohort quintile vs nhs rr ci p trend nhs ii rr ci p trend hpfs rr ci p trend result similar regardless smoke status conclusion observe no association diet pro inflammatory potential bladder cancer risk although additional study need explore nutritional pathway potential bladder cancer prevention result suggest diet associate inflammation not associate bladder cancer risk transurethral resection sequential chemo immunoprophylaxis primary g bladder cancer objective g superficial bladder cancer consider high risk progression institution early cystectomy advocate author personal experience suggest conservative treatment turbt follow intravesical prophylaxis may adequate majority case purpose present phase ii study assess tolerability efficacy sequential intravesical administration chemotherapeutic agent epirubicin follow bcg turbt material method patient primary g superficial bladder cancer without evidence this upper tract tumor undergo turbt intravesical prophylaxis weekly epirubicin mg week follow weekly bcg connaught mg week control cystoscopy bladder map tur suspicious area perform week patient follow month urinary cytology cystoscopy result sequential chemo immunoprophylaxis generally good tolerate mean follow month recurrent tumor find patient progressive disease case progression patient die disease conclusion sequential chemo immunoprophylaxis epirubicin follow bcg good tolerate seem efficacious primary g bladder cancer recurrence progression disease specific mortality rate acceptable study seem confirm previous datum show turbt intravesical prophylaxis appropriate treatment majority g tumor evaluation year result treatment patient bladder cancer cystectomy follow preoperative irradiation rad purpose assess whether online adaptive radiotherapy bladder cancer feasible across multiple radiation oncology department use different image delivery record technology material method multi centre feasibility study online adaptive radiotherapy use choice three plan day conduct department patient muscle invasive bladder cancer include department activate part pilot study familial urinary bladder cancer urothelial cell carcinoma 5 common cancer costly treat largely new case present superficial disease rarely fatal tend recur require long term follow repeat intervention standard care intravesical chemo immunotherapy effective associate considerable side effect profile approximately patient either fail respond treatment suffer recurrent disease within year muscle invasive bladder cancer life threaten show modest chemosensitivity usually require radical cystectomy although bladder cancer fairly good genetically characterize clinical trial molecularly target agent comparison solid tumor lung breast prostate numb largely unsuccessful no new agent register last year hence bladder cancer represent considerable opportunity challenge molecularly target therapy ras association domain family promise prognostic marker recurrent nonmuscle invasive bladder cancer aim study investigate value rassf methylation prognostic marker bladder cancer rassf hypermethylation specimen primary bc tissue assess use methylation specific pcr among patient recurrent nmibc rassf methylation identify independent predictor cancer progression introduction aberrant methylation promoter cpg island important inactivation mechanism tumor suppressor tumor relate gene ras association domain family rassf promoter hypermethylation show associate bladder cancer bc prognostic value remain unclear aim present study investigate value rassf methylation prognostic marker bc material method primary bc tissue obtain patient include specimen nonmuscle invasive bladder cancer nmibc specimen muscle invasive bladder cancer mibc rassf hypermethylation assess use methylation specific polymerase chain reaction ms pcr association rassf hypermethylation clinicopathologic feature prognostic significance rassf hypermethylation evaluate kaplan meier multivariate cox regression analysis result rassf promoter hypermethylation detect bcs occur frequently mibc nmibc p nmibc rassf methylation associate advance tumor stage p high grade p among patient recurrent nmibc rassf methylation associate short time progression kaplan meier analysis log rank test p identify independent predictor cancer progression multivariate cox regression analysis hazard ratio hr p conclusion result suggest methylate rassf may potential prognostic marker patient recurrent nmibc immunotherapy urothelial carcinoma bladder bcg vaccine target therapy bladder cancer high prevalence man woman bladder cancer usually originate urothelium case classify nonmuscle invasive bladder cancer urothelial bladder carcinoma usually manage transurethral resection bladder tumor role transurethral resection bladder tumor also essential bladder cancer stage local prophylaxis use nonmuscle invasive bladder cancer reduce risk recurrence local chemoprophylaxis sufficient low middle risk patient intravesical instillation mycobacterium bovis bacillus calmetteguerin bcg prefer high risk bladder cancer chemotherapy alone combination locoregional treatment use advance bladder cancer new immunotherapy modality prove efficacy several clinical study advance bladder cancer management ta situ bladder carcinoma new since recent time change make management nonmuscle invasive bladder cancer 2 look resection efficient patient high risk superficial tumor interest resection fluorescence still discuss new classification high grade low grade tumor progressively replace g g g grade classification new prognosis marker appear lamina propria invasion microstaging prostatic urethra involvement immediate postoperative instillation chemotherapy decrease risk recurrence patient stage ta bladder cancer intravesical mitomycin c optimize significantly enhance efficacy intravesical bacillus calmette gu rin bcg appear treatment choice management carcinoma situ superior mitomycin c reduce tumor recurrence high risk nonmuscle invasive bladder cancer addition intravesical bcg significantly reduce risk progression transurethral resection patient nonmuscle invasive bladder cancer receive maintenance treatment use tumor colony assay predict chemotherapeutic drug response murine bladder cancer tumor colony assay tca evaluate ability predict anticancer drug response n nitro furyl thiazolyl formamide fanft induce murine bladder tumor mbt model ten anticancer drug evaluate vivo vitro use four mbt cell line drug response use optimum criterium drug response tca accurately predict drug response murine model time true positive predictive rate true negative predictive rate drug test tumor cell immediately removal mouse result barbiturate smoke bladder cancer risk phenobarbital treatment observe negative associate bladder cancer risk study suggest phenobarbital may induce cigarette smoke bladder cancer female hospital base case control study woman bladder cancer female surgical control compare life long smoke habit relative risk associate cigarette smoke proportion bladder cancer attributable habit estimate comparison parallel study man seem age diagnosis age start smoke play different role two sex surgery invasive bladder cancer pathologic stage necessary purpose review lymphovascular invasion correlate metastatic ability cancer study urological tumour every location include prognostic factor tnm tumour lymph node metastasis classification germ cell testicular tumour purpose evaluation look predictive value lymphovascular invasion locally advance bladder cancer recent finding study carry patient undergo cystectomy report lymphovascular invasion incidence case agree correlation presence lymphovascular invasion disease evolution author consider blood vessel invasion statistically significant independent prognostic factor other find happen lymph node negative case summary paper stress prognostic value lymphovascular invasion independent factor still doubt use clinical decision make owe poor diagnosis reproducibility would necessary reach consensus strict diagnostic criterium soon possible able incorporate prognostic factor clinical practice phase ii trial cis dichlorodiammineplatinum ii cancer bilharzial bladder purpose histopathological grade remain important predictive factor prognosis nonmuscle invasive bladder cancer define clinical reliability international society urological pathology histological classification system compare system ta primary bladder tumor material method evaluate consecutive patient \\ufeff1 episode low grade pta bladder cancer transurethral resection bladder grade assign single uropathologist simultaneously low grade g g accord classification system respectively patient receive single early prophylaxis instillation mg epirubicin adjuvant treatment followup include urine cytology cystoscopy month resection every month thereafter year univariate multivariate analysis recurrence free progression free survival do kaplan meier method log rank test result mean patient age year median range patient female male accord system grade g patient g median followup month mean range year recurrence free survival rate low grade population g g group respectively p year progression free survival rate low grade population g g group respectively p conclusion classification system predict risk recurrence primary pta case accurately system classification accuracy predict risk progression study confirm clinical reliability new histological classification clinical practice prognostic point view effect different bacillus calmette guerin substrains growth inhibition bladder cancer cell cytokine secretion bcg activate peripheral blood mononuclear cell pbmcs background bladder carcinoma common malignancy urinary tract approximately patient present non muscle invasive bladder cancer nmibc standard primary treatment nimbc transurethral resection tur follow intravesical bacillus calmette guerin bcg immunotherapy bcg accept effective agent clinical use nmibc various bcg substrains use worldwide bladder cancer immunotherapy although impact use bcg substrain bcg antitumor capacity little investigate objective aim study compare antitumor capacity ability trigger cytokine production three bcg substrains stimulation local innate immunity vitro material method human bladder cancer cell line co culture bcg substrains moreau tice rivm alone bcg pretreated dcs dendric cell allogenic pbmcs derive donor inhibition cell growth evaluate h thymidine incorporation production th cytokine ifn tnf il th cytokine il il measure culture bcg activate pbmcs elisa test result approximately two fold inhibition cell proliferation observe direct cytotoxic effect test bcg substrains cell however bcg inhibit growth tumor cell mainly activate effector cell innate immunity fold inhibition cell proliferation observe cell co culture allogenic bcg pretreated dcs pbmcs derive donor pbmcs activate compare live bcg substrains secrete large amount tnf ifn cytokine conclusion test bcg substrains little direct inhibitory effect cell proliferation moreau evolutionarily early bcg substrain show similar strong indirect antitumor effect evolutionarily late bcg substrains tice rivm history non muscle invasive bladder cancer may wrong prognostic impact ct bladder cancer patient treat radical cystectomy purpose investigate whether history non muscle invasive bladder cancer nmibc play prognostic role patient muscle invasive bladder cancer mibc treat radical cystectomy era neoadjuvant chemotherapy establish standard therapy mibc patient method total patient diagnose ct bladder cancer treat open radical cystectomy institution include initially diagnose mibc without history nmibc define primary mibc group n mibc progress nmibc define progressive mibc n result rate ct tumor significantly high primary mibc group progressive mibc group p five year recurrence free survival cancer specific survival css rate primary mibc group versus progressive mibc group versus p versus p respectively progressive mibc hazard ratio p independently associate cancer death primary mibc group year css rate patient treat neoadjuvant chemotherapy significantly high patient without p progressive mibc group no significant difference observe css patient treat without neoadjuvant chemotherapy conclusion mibc progress nmibc significantly wrong clinical outcome mibc without history nmibc may not respond good neoadjuvant chemotherapy result informative even nmibc patient treat conservative intravesical therapy current state classification stage bladder cancer background metastasis consider important clinical obstacle treatment human cancer include bladder cancer post transcriptional regulation emerge robust effector metastasis mirnas involve cancer development progression act tumor suppressor oncogene study focus microrna function anti metastatic microrna suppress angiogenesis bladder cancer directly target cd method expression mir detect quantitative real time pcr oligonucleotide lentivirus use overexpress mir tube formation assay transwell assay use examine effect bladder cancer tube formation migration invasion vitro animal model use examine effect metastasis angiogenesis vivo luciferase assay carry verify precise target mir result not prove mir significantly downregulated bladder cancer tissue cell line also circulate mir level reduce bladder cancer level positively relevance gain function experiment investigate increase mir expression suppress tube formation reduce cell migration invasion vivo metastasis assay also demonstrate overexpression mir markedly inhibit bladder cancer metastasis cd endothelial cell specific marker stain tumor evaluate blood vessel density immunohistochemistry result show blood vessel quantification reduce dramatically tumor express mir combine previous study bioinformatics analysis expect cd gene direct target mir sirna mediate knockdown cd partially phenocopied mir overexpression suggest pro apoptotic role mir may mediate primarily cd regulation whereas restore expression cd attenuate function mir bladder cancer cell additionally identify emt epithelial mesenchymal transition relate protein can regulate mir indicate mir can partially reserve emt conclusion study define major metastasis angiogenesis suppressive role mir microrna function tumor suppressor bladder cancer directly target cd would helpful therapeutic approach block bladder cancer metastasis c reactive protein level predict prognosis patient muscle invasive bladder cancer treat chemoradiotherapy objective investigate effect c reactive protein crp level prognosis patient muscle invasive bladder cancer treat chemoradiotherapy chrt increasingly recognize presence systemic inflammatory response associate poor survival various malignancy patient method clinical record patient bladder urothelial carcinoma ct n treat chrt review retrospectively chrt comprise external beam radiotherapy bladder gy two cycle cisplatin mg week interval elevate crp define mg dl survival rate calculate use kaplan meier method multivariate analysis use identify significant factor associate prognosis use cox proportional hazard model result median range follow month patient die bladder cancer year cancer specific survival css rate ten patient high crp level chrt mg dl css rate significantly wrong remain patient p multivariate analysis show crp ct stage independent prognostic indicator css hazard ratio confidence interval p among patient elevate crp crp level become normal chrt six one alive no evidence recurrence metastasis follow contrast four no crp normalization chrt die within year conclusion knowledge \\ufeff1 study report elevation crp treatment predict poor prognosis patient muscle invasive bladder cancer receive chrt furthermore failure crp level normalize chrt associate extremely poor survival peritoneal carcinomatosis robotic assist radical cystectomy among patient metastatic urothelial cancer bladder develop peritoneal carcinomatosis majority case peritoneal carcinomatosis associate multiple metastatic site peritoneal metastasis single site metastatic deposit rare describe follow laparoscopic radical nephroureterectomy cystectomy report patient develope peritoneal carcinomatosis single site metastasis month robotic assist radical cystectomy extend pelvic lymphadenectomy extracorporeal formation ileal neobladder organ confine muscle invasive poorly differentiate bladder cancer indication robotic assist radical cancer surgery urothelial carcinoma upper low urinary tract patient locally advance poorly differentiate cancer make caution jarow jp et al clinical trial design development new therapy non muscle invasive bladder cancer report food drug administration american urological association public workshop urology bladder cancer remarkably variable natural history noninvasive low grade talg lesion propensity recur pose little threat patient longevity non muscle invasive high grade ta this hg lesion effectively treat intravesical bcg subset may progress muscle invasive metastatic bladder cancer muscle invasive cancer uniformly lethal inadequately treat subset patient benefit perioperative chemotherapy may adequately treat bladder preservation strategy ability accurately predict variable natural history essential optimize treatment stage disease prognosis often influence multiple parameter e g tumor grade stage age comorbidity treatment e g radical cystectomy vs bcg different endpoint relevant base stage disease recurrence talg progression ta this hg survival historically prediction endpoint decision make accomplish physician judgment basic decision aid risk classification system however method risk estimation unable fully account complex tumor biology behavior bladder cancer potentially lead inaccurate prediction inappropriate treatment assignment nomograms capable incorporate multiple variable generate accurate risk estimate tailor individual patient may greatly facilitate patient counsel treatment selection although use become widespread bladder cancer nomograms remain relatively nascent field study development novel nomograms account clinical stage bladder cancer need effect concomitant carcinoma situ neoadjuvant chemotherapy urothelial cell carcinoma bladder inferior pathological outcome no effect survival purpose generally believe carcinoma situ refractory chemotherapy specific datum lack validate evaluate effect concomitant clinical carcinoma situ cancer specific outcome neoadjuvant chemotherapy muscle invasive bladder cancer material method perform institutional review board approve multi institutional retrospective review record patient treat neoadjuvant chemotherapy follow radical cystectomy muscle invasive bladder cancer pretreatment clinical variable collect patient stratify presence clinical carcinoma situ precystectomy transurethral bladder tumor resection specimen pathological outcome include complete response rate pt n mx neoadjuvant chemotherapy compare group recurrence free cancer specific overall survival analyze result patient meet study criterium concomitant carcinoma situ condition associate significant decrease pathological complete response rate vs p difference significant univariate multivariable analysis ci p ci p respectively despite decrease complete response rate clinical carcinoma situ not associate difference recurrence free cancer specific overall survival additionally stage pathological carcinoma situ disease consider complete response no significant change recurrence free cancer specific overall survival conclusion concomitant carcinoma situ associate decrease complete response rate not appear impact survival outcome sarcopenia patient bladder cancer undergo radical cystectomy impact cancer specific cause mortality background author evaluate sarcopenia predictor cancer specific survival css overall survival os among patient urothelial cancer bladder undergo radical cystectomy rc method lumbar skeletal muscle index smi patient treat rc urothelial cancer measure sarcopenia classify accord international consensus definition smi cm man cm woman css os estimate use kaplan meier method compare log rank test variable associate css cause mortality summarize hazard ratio hr result patient sarcopenic patient sarcopenia old otherwise similar patient without sarcopenia respect sex charlson comorbidity index american society anesthesiologist score eastern cooperative oncology group performance status receipt neoadjuvant chemotherapy tnm stage disease tumor grade p median follow year time patient die include die bladder cancer sarcopenic patient significantly wrong year css vs p os vs p compare patient without sarcopenia moreover sarcopenia find independently associate increase css hr p cause mortality hr p multivariable analysis conclusion presence sarcopenia find significantly increase patient risk css cause mortality undergo rc bladder cancer comparative evaluation predictive value urovysion aurka fish test urine sediment cell diagnosis bladder cancer informative value two test base fish exfoliate urothelial cell urine sediment aurka urovysion compare group patient person history bladder cancer coincidence result fish assay find preliminary datum offer possibility replace expensive urovysion kit little expensive aurka fish probe can use monitor recurrence bladder cancer patient imperative cystectomy patient risk ileal conduit ureterocutaneostomy due demographic trend incidence bladder cancer rise base progress perioperative management radical cystectomy become feasible also elderly patient muscle invasive bladder cancer also cause increase age relate comorbidity question arise optimal urinary diversion patient risk ileal conduit accept standard due safe bladder cancer saguenay lac saint jean area abnormal incidence bladder cancer bas identify incidence effect important industrial environment etiology identify review surgical treatment actually do follow evaluation make choice medical environment ileal conduit detubularised ileal bladder replacement radical cystectomy period statistic statement do show patient survival accordance grade stage appropriate treatment give b stage conclusion institute group stimulus industrial environment improve survival next decade immune function determination patient bladder cancer patient bladder cancer evaluate clinically immune responsiveness stage disease battery test describe attempt correlate stage disease immune responsiveness aberrantly express plod promote cancer aggressiveness bladder cancer potential prognostic marker therapeutic target bladder cancer bc 9 malignant tumor worldwide bc patient develop muscle invasive bc mibc year survival rate approximately due metastasis urgent need novel therapeutic diagnostic target mibc analysis novel antitumor microrna mirna mediate cancer network effective strategy explore therapeutic target prognostic marker cancer previous mirna analysis reveal mir p act antitumor mirna bc cell investigate mir p regulation bc molecular pathogenesis procollagen lysine oxoglutarate dioxygenase plod find directly regulate mir p aberrant expression plod observe bc clinical specimen high plod expression significantly associate poor prognosis disease free survival p overall survival p multivariate analysis show plod expression independent prognostic factor bc patient hazard ratio p furthermore downregulation plod sirnas specific inhibitor significantly decrease bc cell aggressiveness aberrant expression plod closely associate bc pathogenesis summary present study show plod may potential prognostic marker therapeutic target bc intraoperative ultrasonic control radicalness transurethral resection bladder cancer patient bladder cancer stage undergo transurethral resection bladder wall affect tumor ultrasound control removal radicality evidence obtain transurethral ultrasound scan compare finding histological examination tissue remove accuracy control make make possible follow tumor invasion tumor margin along periphery accordance blastomatosis stage author develope technique transurethral resection bladder wall transurethral ultrasonic scan control removal radicality richard j sylvester adrian p van der meijden willem oosterlinck j alfred witjes christian bouffioux louis denis donald w w newling predict recurrence progression individual patient stage ta bladder cancer use eortc risk table combine analysis patient seven eortc trial eur urol initiate prospective phase ii trial assess outcome complete surgical removal metastasis bladder cancer regard survival quality life patient male female median age year range year treat surgical complete resection bladder cancer metastasis patient asymptomatic n symptomatic n secondary metastasis bladder cancer refractory methotrexate vinblastine doxorubicin cisplatin vac therapy include remove secondary metastasis lymph node peritoneum skin bone lung live measure survival performance score median survival time month year survival rate year survival rate prognosis unfavorable independent site metastasis however patient symptomatic secondary metastasis benefit surgery regard quality life e g performance score assess improvement performance score p surgical removal metastasis bladder cancer refractory systemic therapy impact quality life limit patient symptomatic disease bladder carcinoma year old female spina bifida patient present case year old spina bifida patient present poorly differentiate n bladder carcinoma sarcomatoid differentiation tumorigenesis pathological perspective tumor spread epigenetically regulate gene bladder cancer article describe tumorigenesis bladder cancer pathological perspective three dimension morphology genetic epigenetics field cancerization tumor cell migration seed two main hypothesis use explain synchronous metachronous tumor urinary tract detail histological map completely embed cystectomy specimen find single tumor focus nearly bladder accompany surround preinvasive carcinoma situ substantiate finding study analyze tp mutation loss heterozygosity various tumor site identical tp mutation suggest clonal relationship tumor focus situ lineage trace via cytochrome c oxidase succinate dehydrogenase enzyme histochemistry subsequent mitochondrial dna mutation analysis definitive evidence clonal relationship bladder tumor remain inconclusive find indication theory intraurothelial migration seed prominent mechanism tumorigenesis gene inactivation epigenetic dna methylation analyze dna methylation various gene previously find rna expression analysis downregulated bladder cancer importantly epigenetically silence itih associate early relapse pt high grade tumor functionally show enhance invasive metastatic phenotype tumor cell suggest putative tumor suppressive role thus epigenetic gene silence additional mechanism tumorigenesis especially tumor progression racial difference bladder cancer risk case control study determine incidence rate transitional cell bladder cancer white unite state approximately twice black author examine datum large population base case control study bladder cancer conduct involve case control relative risk transitional cell carcinoma white compare black adjustment major bladder cancer risk factor whereas adjustment cigarette smoke occupation confidence interval ci adjustment risk factor include history bladder infection family history urinary tract cancer not alter estimate elevate risk white compare black limit however case whose disease confine mucosa submucosa among case whose disease extend bladder musculature beyond white slightly reduce risk compare black suggest white may diagnose condition go undetected black unlikely group progress extensive disease population base nature study possible determine bladder cancer incidence among white sex reduce level among black total incidence unite state would fall per cent bladder cancer purpose review article review recent literature concern important issue management patient bladder cancer brief overview aspect bladder cancer include etiology diagnosis treatment discuss focus recent advance recent finding bladder cancer significant cause morbidity mortality treatment bladder cancer base individual patient risk assessment include multidisciplinary approach patient superficial bladder cancer research focus improve optimize intravesical therapy reduce tumor recurrence progression good method well select appropriate treatment patient high risk feature important prognostic therapeutic role lymphadenectomy radical cystectomy become apparent recent work attempt well define consider standard lymph node dissection finally attempt improve survival advance make use systemic chemotherapy perioperative setting good treatment metastatic bladder cancer summary research continue improve understand bladder cancer ongoing investigation currently translate bedside refinement diagnosis treatment patient bladder cancer late invasive recurrence despite long term surveillance superficial bladder cancer superficial transitional cell carcinoma bladder associate recurrence rate within year recurrence superficial recurrence disease free year unusual review tumor registry reveal patient follow superficial disease veteran administration center baltimore patient identify either stage ta stage papillary transitional cell carcinoma complete little year surveillance without tumor recurrence invasive transitional cell carcinoma bladder require cystectomy develope patient remain tumor free year stage ta stage patient organ confine disease alive no evidence disease month year cystectomy result demonstrate superficial low grade transitional cell carcinoma bladder become muscle invasive despite careful surveillance long dormant period series yearly cystoscopy urine cytology identify tumor recurrence metastasis develope suggest long term surveillance require patient superficial bladder cancer bilharzial carcinoma urinary bladder note unusual case objective grow evidence show menthol potent anticancer activity various human cancer via transient receptor potential melastatin trpm dependent pathway trpm independent manner however effect bladder cancer remain obscure present investigation examine expression trpm role menthol cell human bladder cancer cell line method rt pcr western blot immunocytochemistry use confirm expression location trpm cell result trpm highly express cell locate cell membrane cytoplasm use small interfere rna silence expression trpm find menthol can increase concentration intracellular calcium decrease cell viability via trpm channel cell also find menthol can induce cell death trpm cell rather cell cycle arrest apoptosis moreover detection mitochondrial membrane potential show menthol can induce mitochondrial membrane depolarization cell conclusion present study demonstrate menthol induce mitochondrial membrane depolarization via trpm channel cell human bladder cancer cell line result cell death would helpful explore precise mechanism action menthol bladder cancer view possible use intravesical chemotherapy bladder cancer focus sexuality background bladder cancer diagnosis effect treatment significant impact patient physical emotional psychological good healthcare provider tend focus aspect care patient concern change regard sexual health often overlook objective purpose article provide oncology nurse overview cause treatment sexual dysfunction relate patient bladder cancer method datum extract use key word phrase bladder cancer cystoscopy cystectomy pelvic exenteration sexual dysfunction finding oncology nurse ideal healthcare provider assess sexual health concern patient bladder cancer oncology nurse valuable resource patient give permission discuss sexual health educate partner potential implication treatment sexuality review treatment option facilitate referral provider specialize treat sexual dysfunction prediction bacillus calmette guerin response patient bladder cancer transurethral resection bladder tumor use genetic variation base genomic study purpose aim comprehensively review contemporary literature genetic epigenetic biomarker associate prediction bacillus calmette guerin bcg response transurethral resection bladder tumor discuss application biomarker precision cancer care bladder cancer method perform systematic review publish literature database pubmed embase use follow key word bladder cancer bcg gene methylation study associate cell line animal model muscle invasive bladder cancer exclude result genetic variation associate bcg response classify three category germline variation somatic variation epigenetic alteration gene relate bcg response mainly involve single nucleotide polymorphism copy numb variation gene methylation conclusion although gene alteration currently promise predictive marker bcg response study bladder cancer dna biomarker relate germline variation candidate gene result not consistent one study relate somatic variation evaluation large scale validation study conduct assess potential clinical application finding addition biomarker base different omics technology consider future study fluorescence detection bladder cancer use urine cytology bladder cancer 4 common malignant disease worldwide account cancer case singapore 9 common form cancer high mortality rate bladder cancer reduce early treatment follow pre cancerous screen currently gold standard screen bladder tumor histological examination biopsy specimen invasive time consume study ex vivo urine fluorescence cytology investigate offer alternative timely biopsy free mean detect bladder cancer sediment patient urine sample extract incubate novel photosensitizer hypericin laser confocal microscopy use capture fluorescence image excitation wavelength nm image subsequently process single exfoliate bladder cancer cell cell base cellular size intensity histogram target cell feature vector derive histogram moment use represent sample difference distribution feature vector normal low grade cancerous bladder cancer cell observe diagnostic algorithm discriminate normal low grade cancerous cell elucidate report study suggest fluorescence intensity profile hypericin bladder cell potentially provide automate quantitative mean early bladder cancer diagnosis cure bladder cancer need multidisciplinary effort homozygous hemizygous deletion p early common genetic alteration bladder cancer identification two cell cycle regulator cdkn cdkn b map common region deletion prompt hypothesis critical tumor suppressor gene malignancy however controversy whether gene even important target bladder cancer oncogenesis remain clearly determine effect p alteration map homozygous deletion perform detail mutational expression analysis cdkn cdkn b closely link gene methylthioadenoside phosphorylase mtap establish bladder cancer cell line nine line exhibit large kb homozygous deletion p deletion include little one exon cdkn eight nine include cdkn b six nine include mtap mtap function correlate genomic deletion sscp sequence analysis not reveal inactivate point mutation cdkn cdkn b cell line without homozygous deletion express cdkn cdkn b mrna good encode p protein p protein level vary widely correlate absent prb expression conclude p deletion bladder cancer usually inactivate cdkn cdkn b mtap gene cdkn common target mechanism inactivate gene bladder cancer appear uncommon lymph node dissection bladder cancer stand radical cystectomy lymphadenectomy remain standard care treatment muscle invasive bladder cancer lymphadenectomy central component operation continue play diagnostic therapeutic role routinely available preoperative image limit diagnostic accuracy rely mostly size identify nodal metastasis increase value lymphadenectomy merit lymphadenectomy not question extent lymphadenectomy require provide maximum benefit limit morbidity remain controversial furthermore although robotic assist surgery gain popularity many center concern remain regard learn curve require skill need replicate quality open lymphadenectomy research effort focus unresolved issue several trial currently ongoing help address knowledge deficit area update focus current state lymphadenectomy bladder cancer highlight recent advance intake linolenic acid fatty acid relation risk bladder cancer result new hampshire case control study role dietary fat bladder cancer aetiology currently unclear due study equivocal finding lack information important dietary fatty acid aim present study investigate association intake major dietary fat fatty acid risk bladder cancer loss periplakin expression associate pathological stage cancer specific survival patient urothelial carcinoma urinary bladder objective study determine periplakin expression normal urothelium bladder cancer tissue relationship clinicopathological finding immunohistochemical stain periplakin carry archival radical cystectomy specimen immunoreactivity stratify scale immunohistochemical stain periplakin show significantly low bladder cancer tissue compare non cancerous tissue include inflammation hyperplasia normal urothelium loss periplakin expression associate pathological stage p multivariate cox regression analysis loss periplakin expression positive lymph node status independent prognostic factor cancer specific survival p odd ratio confidence interval respectively new molecular marker may aid identify select bladder cancer patient undergo radical cystectomy may potentially benefit neoadjuvant adjuvant therapy comprehensive investigation toward indicative protein bladder cancer urine survey cell secretomes verify urine protein urine ideal material study cancer relate protein biomarker bladder whereas exploration candidate confront technique challenge herein propose comprehensive strategy search urine protein relate bladder cancer strategy consist three core combination screen biomarker candidate secrete protein derive bladder cancer cell line verify patient urine define differential protein two dimensional electrophoresis de isobaric tag relative absolute quantitation itraq couple lc ms ms implement quantitative proteomics profile target analysis proteomic survey total protein find abundance secrete protein cancer cell line different normal protein identify urine sample multiple reaction monitor mrm base quantification adapt verify bladder cancer relate protein individual urine sample result differential urine protein link cancer candidate receiver operate characteristic analysis reveal combination co ldhb sensitive cancer indicator group discovery bladder cancer indicator strategy pave avenue biomarker validation bladder rupture intravesical bcg therapy case report year old man receive transurethral resection tur ofbladder tumor histopathological diagnosis urothelial carcinoma high grade pt ptis surgical specimen obtain 2 tur show no residual malignancy histopathologically intravesical bacillus calmette guerin bcg instillation therapy initiate month 2 tur complain low abdominal pain painful urination day follow 2 instillation bcg compute tomography cystography demonstrate rupture ofthe urinary bladder week ofconservative treatment symptom persist open repair ofthe bladder perform intravesical bcg therapy widely accept treatment bladder cancer high grade ta carcinoma situ present case thin ofthe bladder wall delay wind heal cause turs abdominal pressure may factor lead bladder rupture addition inflammation bladder due bcg instillation although bladder rupture cause intravesical bcg therapy not report must aware ofthe possibility ofthis rare condition especially consecutive turs case aggressively grow bladder cancer patient long term cystostomy due spinal cord injury patient year old man cystostomy catheter insert year age neuropathic bladder due cervical spinal cord injury year age purulent discharge around cystotomy continue approximately month examination reveal formation subcutaneous tumor around cystostomy elevate carcinoembryonic antigen cea level ng ml blood urothelial carcinoma detect use open biopsy consider primary urothelial carcinoma bladder progress along cystostomy clinical stage ct n diagnose intrapelvic lymph node metastasis evident image four course gemcitabine cisplatin chemotherapy administer partial response obtain cystectomy ileal conduit formation perform main aim improve difficulty urination however retroperitoneal lymph node live metastasis observe month postoperation rapid enlargement patient die approximately month surgery cea level observe ng ml die report case discussion literature concern association long term indwell catheter patient spinal cord injury development bladder cancer fruit vegetable intake incidence bladder cancer male prospective cohort background previous epidemiologic study fruit vegetable intake bladder cancer risk yield inconsistent result especially regard type fruit vegetable consume examine total fruit vegetable intake good intake subtype fruit vegetable relation bladder cancer risk large male prospective cohort study method two hundred fifty two case incident bladder cancer diagnose january among man enroll health professional follow study participant cohort complete item food frequency questionnaire subsequently use logistic regression analysis examine fruit vegetable intake relation bladder cancer risk adjust age history cigarette smoke current smoke status geographic region total fluid intake caloric intake result observe weak inverse association not statistically significant total fruit vegetable intake bladder cancer risk intake cruciferous vegetable inversely associate risk relative risk confidence interval high category cruciferous vegetable intake compare low intake yellow green leafy vegetable carotenoid rich vegetable not associate risk individual cruciferous vegetable except coleslaw inversely relate bladder cancer risk association broccoli cabbage statistically significant conclusion datum study indicate high cruciferous vegetable consumption may reduce bladder cancer risk vegetable fruit may not confer appreciable benefit cancer schistosomiasis cancer bladder objective presence lymph node metastasis bladder cancer consider sign poor prognosis present study perform analyze influence numb positive lymph node survival therapeutic value lymphadenectomy pn patient method january january patient age year mean undergo radical cystectomy pelvic lymphadenectomy carcinoma bladder record patient available review uicc classification system use result cancer specific mortality pno patient pn patient pn patient obtain follow cancer specific mortality stratify accord category pnot pnot b pnit pnit b pn b conclusion presence positive regional lymph node pn appear worsen patient survival particularly primary tumor b wrong case cancer specific mortality patient discharge increase pno patient pn patient p radical cystectomy highly effective curative apno patient presence multiple positive lymph node carry poor prognosis patient dye mean month perioperative strategy patient muscle invasive bladder cancer radical cystectomy bilateral pelvic lymph node dissection standard care patient muscle invasive bladder cancer year survival rate not exceed consequently multidisciplinary approach include perioperative chemotherapy radiation therapy require improve result datum clinical trial meta analysis neoadjuvant chemotherapy show significant benefit overall survival absolute benefit five year provide cisplatin base combination chemotherapy use report trial not support routine use adjuvant chemotherapy current role radiation therapy limit highly select case combination external radiotherapy partial cystectomy interstitial brachytherapy prediction lymph node metastasis patient bladder cancer use whole transcriptome gene expression signature purpose clinical stage patient muscle invasive bladder cancer miss lymph node metastasis patient high risk disease recurrence improve clinical stage critical guide management material method whole transcriptome expression profile generate patient undergo radical cystectomy extend pelvic lymph node dissection cohort divide randomly discovery set patient validation set discovery set feature identify model knn k near neighbor classifier predict pathological lymph node metastasis two previously describe bladder cancer gene signature include rf gene cancer recurrence signature ln gene lymph node signature also model discovery set comparison auc use compare performance signature result validation set knn achieve auc range predict lymph node positive case significantly outperform rf ln auc range range respectively knn show significant odd predict ln metastasis range every increase score p rf ln nonsignificant range range respectively conclusion new knn signature superior previously describe gene signature predict lymph node metastasis validate prospectively transurethral resection bladder tumor sample knn can use guide patient high risk early multimodal therapy bladder cancer determination via two urinary metabolite biomarker pattern approach purpose study use metabonomic profile identify potential specific biomarker pattern urine noninvasive bladder cancer bc detection strategy liquid chromatography mass spectrometry base method utilize reverse phase liquid chromatography hydrophilic interaction chromatography separation perform follow multivariate datum analysis discriminate global urine profile bc patient healthy control datum column combine combination prove effective reliable partial little square discriminant analysis follow critical selection criterion several metabolite show significant difference expression level detect receiver operate characteristic analysis use evaluation potential biomarker carnitine c component combine biomarker pattern sensitivity specificity respectively patient respectively low grade bc patient metabolic pathway component carnitine c discuss result indicate metabonomics practicable tool bc diagnosis give high efficacy economization combine biomarker pattern show well performance single metabolite discriminate bladder cancer patient especially low grade bc patient healthy control infiltrate bladder carcinoma influence complementary treatment local control survival analyze patient transitional bladder cancer stage accord treatment different group consider group patient treat tur radical cystectomy group patient also receive external beam radiotherapy gy week prior cystectomy group patient also treat intraoperative radiotherapy gy course neoadjuvant chemotherapy result suggest local control rate increase significantly intensity treatment group patient pt similar result achieve multivariate analysis univariate analysis survival show ganglionar status vascular embolism treatment intensity covariate associate multivariate analysis demonstrate renal function type complementary treatment covariate associate survival take group survival relate pathologic stage vascular embolism renal function conclusion significant influence complementary treatment local control survival suggest strongly systematic utilization infiltrate bladder cancer unveil new risk factor associate bladder cancer lebanon background no accurate evaluation smoke water pollution bladder cancer conduct lebanese population aim examine significance smoke one main water pollutant trihalomethanes thm bladder cancer risk method population attributable fraction paf use quantify contribution risk factor smoke thms bladder cancer lebanon calculate paf risk factor use proportion population expose relative risk risk factor relative risk risk factor obtain publish meta analysis population risk value obtain report chronic disease risk factor surveillance lebanon conduct world health organization national study semerjian et al conduct multipathway exposure assessment select public drink water lebanon risk factor smoke thms respectively result bladder cancer case result smoke lebanon among male female respectively case attribute mid term exposure thm contamination drink water estimate conclusion paper highlight negative impact smoke bladder cancer risk add overlook often underestimate risk thms type cancer thus imperative national base study assess thm exposure gender smoke status implement determine real risk behind byproduct problem urinary bladder cancer attempt therapeutic standard particular uncertainty carcinoma urinary bladder result diagnostic therapeutic deficiency cause find dignity inclination dissemination tumour bladder present help diagnostic method disposal difficult establish exact clinical stage nevertheless try set certain therapeutic central point purpose malignant tumour urinary bladder subdivide three group take consideration tumour infiltration good tumour grade adequate therapeutic measure discuss curative adjuvant palliative aim superficial bladder cancer decrease risk recurrence bladder cancer appear develop two alternative pathway papillary bladder cancer common pathway little aggressive course frequently herald hematuria whereas carcinoma situ appear aggressive difficult detect superficial bladder cancer high propensity recurrence low rate progression transurethral resection frequently employ diagnosis treatment risk tumor recurrence relate numb tumor presentation finding \\ufeff1 follow cystoscopy even patient low risk recurrence need periodic cystoscopic examination patient high risk recurrence may benefit adjuvant intravesical chemotherapy immunotherapy bacillus calmette gu rin bcg appear effective drug intravesical therapy high rate side effect treatment choice carcinoma situ new treatment strategy include perioperative intravesical chemotherapy chemoprevention bladder spare multimodality treatment muscle invasive bladder cancer objective determine long term result bladder spare approach treatment muscle invasive bladder cancer method ninety four patient invasive transitional cell carcinoma bladder treat transurethral resection follow cycle cisplatin base chemotherapy patient treat cgy radiation patient segmental cystectomy surveillance patient fail respond chemotherapy radiation therapy develope recurrent muscle invasive disease follow undergo salvage cystectomy patient carefully follow median follow year result initial therapy patient alive bladder preserve thirty develope local recurrence follow median follow year ultimate relapse free survival stage p patient enroll bladder preservation however currently survive patient bladder intact initially enroll population alive preserve bladder year survival patient cystectomy point study compare bladder preserve versus respectively p conclusion long term result multimodality therapy attempt bladder preservation show no definitive improvement survival compare modern series cystectomy alone disappointingly low rate disease free bladder preservation find high rate locally recurrent disease preserve bladder also note decrease survival patient bladder preservation compare without preservation bladder preservation although possible limit select group patient random biopsy recurrence risk patient bladder cancer background study relationship recurrence rate primary superficial bladder cancer random biopsy method perform transurethral resection primary superficial bladder cancer patient case random biopsy also perform non recurrence rate examine many recurrence facters result non recurrence rate group random biopsy not significantly different observe group patient without random biopsy chi test generalize wilcoxon test multivariate analysis intravesical instillation therapy important inhibition factor recurrence rate primary superficial bladder cancer analyse recurrence rate two non treat group without random biopsy patient respectively no significant difference rate recurrence two group observe however note recurrence bladder cancer biopsy position patient conclusion appear random biopsy may effect recurrence implantation tumor cell study need clarify whether random biopsy risk factor recurrence rate primary superficial bladder cancer loss hydroxyprostaglandin dehydrogenase expression contribute bladder cancer progression prostaglandin e know contribute cancer progression inactivate catabolic enzyme hydroxyprostaglandin dehydrogenase pgdh tumor suppressor activity lung colon breast gastric cancer therefore evaluate expression pgdh human bladder cancer tissue specimen cell line immunoperoxidase stain bladder cancer tissue demonstrate pgdh highly express normal urothelial cell reduce many low stage ta this bladder cancer pgdh completely lose invasive bladder cancer eight cancer cell line test two relatively cryotherapy bladder cancer aim evaluate prognostic effect histological sub type patient metastatic bladder cancer base surveillance epidemiology end result database total eligible patient include histological subtype transitional cell carcinoma tcc adenocarcinoma squamous cell carcinoma sqcc small cell carcinoma significant association adenocarcinoma well survival outcome p sqcc wrong outcome p observe multivariate analysis adenocarcinoma significantly associate long sqcc short survival time compare tcc overall patient single metastatic site multiple site involve single site metastasis well survival outcome multiple metastasis p histological sub type presence multiple metastatic site independent predictor survival time prospective depth research need determine optimal therapeutic strategy different histological subtype bladder cancer different metastatic pattern local regional systemic attack bladder cancer background previous study show systematic difference nordic country population base relative survival follow kidney urinary bladder cancer diagnosis comparison bladder cancer time nordic registry complicate variable code practice respect inclusion situ case invasive tumour material method five year relative survival patient urinary cancer diagnose nordic country follow death study contrast development incidence mortality result survival follow bladder cancer high kidney cancer high man survival increase year country kidney cancer bladder cancer danish kidney cancer patient rate increase year low country especially among woman result survival denmark point low elsewhere danish bladder cancer patient survival last period point low among man point low among woman nordic country difference mainly find \\ufeff1 year follow diagnosis high excess mortality denmark observe survival decrease high age diagnosis conclusion increase year relative survival nordic country kidney bladder cancer promise kidney cancer high percentage detect coincidentally image investigation disease can play role denmark low survival despite know practice include benign condition invasive bladder cancer low danish survival kidney bladder cancer \\ufeff1 year diagnosis can due late diagnosis average high co morbidity smoke relate disease perhaps little adequate cancer treatment management denmark mir p suppress growth bladder cancer cell via target yin yang bladder cancer identify one malignant cancer high incidence mortality underlie mechanism regulate tumorigenesis bladder cancer deserve investigation find mir p downregulated human bladder cancer cell line tissue overexpression mir p significantly inhibit growth bladder cancer cell depletion mir p exert opposite effect bioinformatics analysis molecular mechanism study identify mir p target transcription factor yin yang yy decrease expression level yy highly express yy attenuate potential tumor suppressive function mir p expression mir p negative correlate yy bladder cancer tissue result indicate mir p may serve promise target bladder cancer diagnosis therapy chemohyperthermia use mmc non muscle invasive bladder cancer current status future perspective effort decrease recurrence progression rate non muscle invasive bladder cancer nmibc transurethral resection bladder tumor follow intravesical instillation use mitomycin c mmc bacillus calmette gu rin bcg spite adjuvant treatment modality recurrence progression rate remain high limitation current standard therapy shortage bcg search alternative form treatment nmibc intravesical mmc combine hyperthermia especially rf induce qht extensively investigate past year one alternative intermediate high risk nmibc several different technique device create hyperthermia bladder wall raise temperature bcg response prediction cytokine gene variant bladder cancer purpose bladder cancer bc one widespread cancer afflict man woman also major philosophical impact health care worldwide despite elaborate characterization risk factor treatment option bc still major epidemiological problem worldwide incidence linger upswing year last three decade intravesical immunotherapy biological response modifier mycobacterium bovis bacillus calmette guerin bcg establish effective adjuvant treatment avert local recurrence tumor progression follow transurethral resection non muscle invasive bladder cancer design method pubmed database search article manuscript select provide datum regard correlation bcg therapy response different cytokine gene variant result not clear bacillus calmette guerin bcg work treat bc may stimulate immune response cause inflammation bladder wall destroy cancer cell within bladder lot report indicate correlation various cytokine respect bcg therapy bc exact mechanism debate conclusion research continue establish effectual strain bcg well dosage schedule treatment bladder cancer hand critical part therapy find correlation different cytokine bcg therapy give well insight not mechanism also well therapeutic option clinical study radical cystectomy lymph node positive bladder cancer background impact pelvic lymph node dissection survival patient lymph node positive bladder cancer controversial analyze record bladder cancer patient treat radical cystectomy method patient transitional cell carcinoma bladder treat radical cystectomy tokyo metropolitan komagome general hospital sixteen patient pathologically prove nodal metastasis patient record review regard pathological status outcome compare negative lymph node patient two patient pn can not completely undergo lymph node dissection exclude analysis recurrence survival result male female age mean year significant difference patient positive lymph node negative rate grade rate infiltration cancer vein lymphatic bladder wall frequency patient positive lymph node pt pt pt pt b pt none ptis pta pt challenge treatment bladder cancer seventy eighty percent patient newly diagnose bladder cancer present superficial tumor ta this however continuum superficial muscle invasive cancer advance case usually associate little differentiate histology aneuploidy common site metastasis include regional lymph node bone lung skin live low cure rate achieve radical cystectomy strong evidence bladder cancer outset systemic disease limitation local treatment good document local control rate radiation treatment radical cystectomy no improvement surgical cure see use preoperative radiation past year since initial report effectiveness cisplatin treatment advance bladder cancer steady flow chemotherapeutic agent singly combination show effective treatment tumor response rate cr rate increase use combination chemotherapy not translate survival advance disease great month search effective agent combination continue attention also give role neoadjuvant adjuvant chemotherapy effort improve cure rate achieve surgery alone although radical cystectomy continent diversion neobladder construction select case remain standard care unite state patient muscle invasive bladder cancer several group explore therapeutic strategy aim bladder preservation early approach goal bladder preservation consist radiation treatment monotherapy largely abandon aggressive turbt small tumor past year massachusetts general hospital mgh radiation therapy oncology group rtog study patient muscle invade bladder cancer utilize tri modality treatment visibly complete transurethral resection follow radiation concurrent radiosensitizing chemotherapy subsequently adjuvant chemotherapy thus chemotherapy use two phasis treatment radiosensitizers give concurrently radiation treatment adjuvant treatment recognize survival improve successful treatment micrometastases base preliminary information report effectiveness gemcitabine cisplatin advance disease combination choose adjuvant regimen one early protocol recently complete report current protocol utilize bellmunt regimen adjuvant program high rr advance disease study ongoing early report tolerance three drug regimen encourage treatment option muscularis propria invasive bladder tumor broadly divide spare bladder involve remove unite state radical cystectomy pelvic lymph node dissection standard method use treat patient tumor hyperthermic treatment peplomycin bestatin superficial bladder cancer order study effect bestatin superficial bladder cancer drug use combination hyperthermia peplomycin therapy study make use follow group group hyperthermic treatment peplomycin use case bladder cancer group bestatin give combination hyperthermia peplomycin case bladder cancer result complete partial regression obtain case group respectively therefore combine use peplomycin bestatin hyperthermic treatment superficial bladder cancer appear effective degeneration tumor cell irregularity tumor structure interstitial edema fibrosis cell infiltration observe surgical specimen take effective case although mechanism action bestatin tumor clearly demonstrate upon histological examination prospective study evaluate surgery chemo radiation muscle invasive bladder cancer aim aim study compare two standard treatment approach muscle invasive carcinoma urinary bladder radical cystectomy chemo radiation material method transitional cell carcinoma tcc bladder stage n n n include study patient allot two arm study arm consist radical cystectomy adjuvant cmv chemotherapy give node positive disease arm b receive cycle neoadjuvant cmv chemo therapy follow concurrent chemo radiation result forty four patient recruit study thirty patient surgical arm patient chemo radiation arm actuarial two year survival rate surgical arm chemo radiation arm no statistically significant difference disease free survival also two group conclusion chemo radiation yield equivalent survival result radical cystectomy worth give preference chemo radiation give well quality life patient new concept stage follow bladder carcinoma article present new stage system method properly assess bladder carcinoma computerize tomography ct scan transurethral ultrasound practical clinical modality follow bladder cancer include cytology random biopsy present addition tumor marker also new method detect recurrence predict invasion abo h antigen test chromosome analysis flow cytometry review attempt understand well cellular nuclear abnormality malignant transitional cell bladder cancer bladder preservation learn know bladder preservation patient muscle invasive bladder cancer potential offer quality life advantage owe lack randomize trial oncological equivalence surgery not demonstrate new article provide comprehensive overview current status procedure raise timely important question diagnostic work treatment bladder cancer current development forty percent patient superficial bladder carcinoma progress towards muscle invasive carcinoma despite initial therapy emergent technology diagnostics therapy superficial bladder carcinoma include fluorescence cystoscopy able reduce recurrence progression rate nevertheless date no trial able show benefit regard cancer specific overall survival use new technology lymph vessel invasion introduce new prognostic marker muscle invasive bladder carcinoma easily incorporate routine clinical practice furthermore adjuvant chemotherapy identify along lymph node density statistically significant marker survival muscle invasive bladder carcinoma investigate prospective clinical trial metastatic bladder carcinoma vinflunine approve 2 line chemotherapy patient fail cisplatin base chemotherapy article critically review emergent development last month comment clinical efficacy treatment bladder carcinoma significance age comorbidity prognostic indicator patient bladder cancer aim study determine impact age comorbidity status overall bladder cancer specific survival bladder cancer patient obtain medical information pertain population patient newly diagnose bladder cancer chung ang university hospital cancer registry adult comorbidity evaluation ace test previously validate adult cancer patient use assess comorbidity evaluate difference demographic clinical characteristic include patient good difference treatment receive categorize age median age time bladder cancer diagnosis entire cohort year median follow time month patient include study little one comorbid condition die follow period patient stratify age find old patient high proportion severe comorbidity p young patient low proportion undergo radical cystectomy invasive bladder cancer ibc p multivariate analysis find old age predictive low overall survival os bladder cancer specific survival bcss rate among patient superficial bladder cancer sbc low os rate among patient ibc also find moderate severe comorbidity status treatment bladder conserve approach predictive low os cancer specific survival rate among patient ibc disparity overall death bladder cancer death show sbc increase along age high comorbidity age comorbidity find independent predictive factor os bcss among bladder cancer patient explain disparity observe overall bladder cancer specific mortality rate transabdominal ultrasound surveillance bladder cancer transabdominal ultrasound may limit useful role surveillance bladder cancer advantage diagnostic method easy use repeat many time necessary without harm discomfort patient extension physical examination clinician politic allow take use frequently use routinely understand limitation urologist hope use ultrasound safe helpful aid diagnosis bladder cancer several decade use wealth health organization grade system bladder neoplasm new grade system adopt lead expert field urogenital pathology express concern categorization system regard nomenclature grade category use several molecular genetic study provide another perspective classification urothelial neoplasm two important development identification mutation fibroblast growth factor receptor gene urothelial carcinoma discovery cdna profile characteristic different subset bladder cancer strong correlation molecular finding classification prognosis combination immunotherapy genitourinary malignancy purpose review combination immunotherapy already show promise several tumor type melanoma nonsmall cell lung cancer study ongoing evaluate approach malignancy trial continue expand additional immune therapy show efficacy single agent cancer purpose review outline current landscape immunotherapy genitourinary cancer highlight ongoing pend combination immunotherapy trial bladder kidney prostate cancer recent finding immunotherapy agent long part treatment armamentarium patient bladder kidney prostate cancer contribute response variable toxicity last year checkpoint blockade immunotherapy food drug administration approve renal bladder cancer whereas novel vaccine continue test prostate cancer efficacy couple mostly mild toxicity modern immunotherapy make agent perfect vehicle combination sequence prime study maximize benefit publish recently present combination immunotherapy study genitourinary malignancy summarize summary immune therapy strategy integral treatment bladder kidney prostate cancer though current experience combination immunotherapy cancer limit ongoing mature study combination immunotherapy discuss herein may lead improve outcome patient change standard care learn correlative datum tumor microenvironment systemic immune response follow immunotherapy integral future design combination immunotherapy trial bcg induce interleukin upregulation bcg internalization good poorly differentiate human bladder cancer cell line intravesical bacillus calmette guerin bcg successful therapy superficial bladder cancer however work mechanism bcg intravesical instillation not completely understand functional role urothelial tumor cell initiation bcg induce immune reaction consider possibility causal relationship bcg induce interleukin il synthesis bcg internalization urothelial tumor cell examine series human transitional bladder cancer tcc cell line different degree differentiation result show good differentiate tcc cell line rt sbc sbc not possess capacity internalize bcg associate inability upregulate il synthesis stimulate bcg moreover cell line express low level constitutive il synthesis contrast poorly differentiate tcc cell tcc sup j able internalize bcg j not tcc sup cell bcg internalization appear result upregulation il synthesis constitutive il synthesis high grade cell line find cell line dependent tcc sup j cell exhibit high level constitutive il synthesis whereas cell exhibit low level possible relationship bcg internalization il upregulation study detail cell line exhibit low constitutive high bcg inducible il synthesis use anti bcg antibody alphabcg cytochalasin b internalization inhibitor upregulation il synthesis significantly inhibit alphabcg cytochalasin b indicate internalization prerequisite bcg induce upregulation il synthesis conclusion upregulation il production due bcg internalization poorly differentiate bladder carcinoma cell may part mode action intravesical bcg therapy quality life assessment bladder cancer clinical trial conceptual methodological practical issue ability retinoid compound trans cis inhibit growth bladder tumour cell investigate primary tissue culture significant decrease tumour growth evident human bladder cancer patient since retinoid compound able delay progression induction tumour primary tissue culture trial use intravesical agent may warrant disease classification bladder tumor register questionnaire sixty one surgical department denmark ask use three possible diagnosis carcinoma situ vesicae urinariae neoplasma benignum vesicae urinariae neoplasma malignum vesicae urinariae c bladder tumour specific reference different stage grade tumour answer department demonstrate great variation classification bladder tumour variation result registration datum not valid statistical outcome real incidence benign malignant bladder tumour denmark consensus danish bladder cancer committee publish concern criterium use different diagnosis bladder tumour however future make possible department make uniform classification potential usefulness bladder cancer marker result salvage cystectomy persistent recurrent tumour follow definite radiotherapy patient review calculate five year survival rate stage significantly well survival low pathological stage operative mortality conclude salvage cystectomy suitable supplement treatment bladder cancer spite considerable operative mortality complication rate transurethral resection superficial bladder cancer technically safe oncologically anything perfect bladder tumor morphological treatment efficacy datum obtain relevant patient year age support benefit surgery combine treatment bladder cancer elderly patient spite difficulty cause concomitant disease defective adaptation high grade poorly differentiate cancer bladder cause frequent recurrence metastasis occur patient two time little often young patient transurethral electroresection bladder removal tumor follow intravesical immunoprophylaxis recurrence think radical treatment elderly patient bladder cancer stage stage cystectomy preferable position ureter straight ileocecal angle provide well result urine derivation cystectomy transurethral electroresection optimal treatment elderly patient bladder cancer stage prostatic adenoma indication transurethral adenomectomy presence bladder cancer must maximally extend adenomatous node provoke infravesical obstruction speed recurrence bladder cancer bladder cancer asco endorse eau muscle invasive bladder cancer guideline objective report experience eosinophilic cystitis ec present invasive bladder cancer material method recently treat three patient bladder masse mimick neoplasm biopsy prove diagnosis ec datum three patient present result two female one male age year three patient irritative bladder symptom suprapubic pain hematuria bladder mass detect pelvic examination three patient confirm radiologic test cystoscopy one patient mass cause bilateral hydroureteronephrosis upper tract normal two elevate serum leukocyte evident three case peripheral eosinophilia observe one biopsy show ec three patient treat transurethral resection lesion follow combination corticosteroid antibiotic antihistaminics patient experience mark improvement follow duration month conclusion ec rare disease addition symptom frequency dysuria hematuria suprapubic pain disease may present bladder mass mimick invasive bladder cancer resection lesion mandatory systemic treatment corticosteroid antihistaminics antibiotic early detection prompt treatment usually result good prognosis current practice management superficial bladder cancer netherlands belgian flanders survey objective no national guideline diagnosis therapy follow superficial bladder cancer netherlands belgium actual patient management may differ urologist purpose study get insight current way urologist diagnose treat follow patient superficial bladder cancer method practise urologist netherlands n flemish speak belgium flanders n receive questionnaire regard current management patient superficial bladder cancer result compare guideline provide european association urology eau also comparison make two country university community hospital result result show wide variation current practice superficial bladder cancer although majority urologist not follow eau guideline current practice roughly match guideline no major difference two country different type hospital discrepancy current practice guideline mostly frequent use technique diagnosis treatment follow conclusion need clear guideline superficial bladder cancer effective implementation guideline everyday practice poor survival female bladder cancer limit age year population wide linkage study new south wale australia although man diagnose bladder cancer bc rate three time high woman woman experience poor survival cause gender difference not clear aim study investigate discrepancy survival bc gender explore potential explanation difference use population wide linkage study use new south wale nsw central cancer registry invasive bc case diagnose identify record link nsw admit patient datum collection apdc retrieve treatment detail registry birth death marriage australian bureau statistic obtain death detail total new case bc identify no difference identify proportion patient present different stage gender however disease specific survival dss wrong female compare male localize regional disease p difference apparent individual age year no difference identify young multivariable cox regression analysis cohort individual age year reveal stage age comorbidity sex remain independent variable p predict dss population wide analysis female age year suffer wrong dss compare male difference not account stage presentation comorbidity independent age bc postmenopausal female may biologically aggressive different adhesion migration property human hcv non malignant urothelial bladder cancer cell role glycosylation tumour cell alteration cellular glycosylation may play key role metastatic behaviour study use cell line different behaviour vivo hcv non malignant transitional epithelium bladder transitional cell carcinoma difference behaviour may due part difference cellular glycosylation pattern glycan chain analysis glycoprotein perform use specific lectin functional role carbohydrate study treat cell swainsonine inhibitor golgi alpha mannosidase ii vitro adhesion migration assay adhesion swainsonine treat hcv cell increase fibronectin type iv collagen fold respectively whereas adhesion laminin virtually unchanged swainsonine treatment hcv cell increase cell swainsonine treatment reduce rate cell migration conclude beta branch tri tetraantennary complex type glycans important function adhesion migration study cell line datum support view oligosaccharide involve several step metastatic process transitional cell carcinoma bladder patient renal pelvic ureteral cancer review case transitional cell carcinoma renal pelvis ureter special reference coexistence subsequent development bladder cancer bladder cancer associate upper urinary tract neoplasm case per cent patient treat radical total cystectomy stage nephroureterocystectomy incidence ureteral stump cancer nephrectomy alone incomplete nephroureterectomy per cent patient twelve surgically remove specimen renal pelvis ureter bladder examine extensively histological association pre neoplastic disease atypical hyperplasia carcinoma situ every specimen change urothelium adjacent remote obvious tumor contemporary update neoadjuvant therapy bladder cancer administration neoadjuvant chemotherapy precede radical cystectomy patient bladder cancer remain matt debate result prospective randomize study demonstrate overall absolute survival benefit year provide cisplatin base combination regimen use owe perception modest survival benefit medical community slow adopt use neoadjuvant chemotherapy reason underuse neoadjuvant chemotherapy range patient ineligibility fear delay potentially curative surgery nonresponders instead several institution adopt individualize bladder cancer multi omic profile refine molecular view isoflavone formononetin main active component astragalus membranaceus possess anti tumorigenic property however role formononetin human bladder cancer bca not fully elucidate aim present study investigate anti tumor effect formononetin bca cell potential molecular mechanism cell treat different concentration formononetin cell proliferation assess mtt assay cell apoptosis hoechst stain assay cell invasiveness transwell invasion assay microrna mir expression real time pcr protein level phosphatase tensin homolog pten phosphorylate homolog akt p akt western blot result show formononetin significantly inhibit proliferation cell time dose dependent manner cell treat formononetin display obvious morphological change apoptosis low invasiveness addition mir expression significantly decrease formononetin treat cell follow increase pten regulation p akt collectively result suggest formononetin exert superficial bladder cancer comment evaluation management despite elaborate characterization risk factor bladder cancer still major epidemiological problem whose incidence continue rise year urothelial carcinoma recognize disease alteration several cellular process prevalent little aggressive recurrent noninvasive tumor characterize constitutive activation ras mapk pathway little common aggressive invasive tumor high mortality rate characterize alteration p retinoblastoma pathway several diagnostic test attempt identify molecular alteration tumor cell exfoliate urine whereas prognostic test try identify aberration predict tumor behavior identify therapeutic target future bladder cancer patient management rely use molecular test reliably diagnose presence disease predict individual tumor behavior suggest potential target therapeutics alternative cytology management non muscle invasive bladder cancer natural history non muscle invasive bladder cancer characterize high probability recurrence case high grade tumor progression muscle invasive cancer mandate follow strategy design identify recurrence bladder early evolution order facilitate early intervention ablation urine cytology consider gold standard urine biomarker although specificity exceed overall sensitivity range expert hand tumor grade operator dependent cytology excellent test detection high grade disease sensitivity particularly weak detection low grade tumor spawn entire field research vitro diagnostic test cell base assay order improve diagnostic accuracy detection incident recurrent disease date us food drug administration approve dipstick immunoassay market point care test point care test intend use adjunct cystoscopy cytology may role office evaluation hematuria patient monoclonal antibody base test combine cytology may improve diagnostic accuracy superior cytology alone recently approve cell base assay utilize fluorescent situ hybridization technology may help resolve suspicious cytology provide early additional information biology bladder urothelium beyond provide cytology marker disease relatively late evolution novel promise marker various stage clinical test panel biomarker may serve future feasible alternative urine cytology cystoscopy screen detection follow non muscle invasive bladder cancer predictive value sox expression transurethral resection specimen patient bladder cancer sox think important regulator self renewal embryonic stem cell accord cancer stem cell csc theory overexpression sox potentially involve carcinogenesis can affect tumor recurrence metastasis previous study prove sox may prognostic marker multiple human malignancy purpose study investigate clinicopathological significance sox expression human non muscle invasive bladder cancer examine sox expression pair non muscle invasive bladder cancer tissue adjacent non cancerous tissue quantitative real time rt pcr qrtrt pcr addition analyze sox ki expression non muscle invasive bladder cancer sample bladder cancer cell line immunohistochemistry immunofluorescence assay recurrence free survival determine kaplan meier method log rank test cox regression adopt univariate multivariate analysis prognostic factor expression sox significantly increase non muscle invasive bladder cancer tissue sox expression significantly correlate ki p expression sox significantly associate tumor size p tumor numb p tumor grade p patient high sox expression significantly poor recurrence free survival p compare patient low expression sox multivariate analysis sox expression tumor grade find independent prognostic factor recurrence free survival p datum suggest \\ufeff1 time high expression sox may contribute development non muscle invasive bladder cancer serve novel prognostic marker patient bladder cancer screen test detection bladder cancer eighty one individual urine cytology urinary carcinoembryonic antigen cea determination urinary immunoglobulin level perform effort evaluate various screen test diagnosis bladder cancer urinary cytology predictive value detect bladder cancer urinary cea little value detect vesical malignancy urinary immunoglobulin particularly igg iga significantly elevate presence bladder cancer surgical factor influence bladder cancer outcome cooperative group report purpose randomize cooperative group trial southwest oncology group intergroup report neoadjuvant chemotherapy improve survival patient locally advance bladder cancer treat radical cystectomy evaluate whether surgical factor patient enroll onto study predict bladder cancer outcome patient method surgical tumor factor record surgical pathologic report patient muscle invasive bladder cancer receive radical cystectomy cystectomy perform surgeon institution half patient receive neoadjuvant methotrexate vinblastine doxorubicin cisplatin mvac chemotherapy variable test univariate multivariate analysis association postcystectomy survival pcs local recurrence lr patient receive cystectomy result five year pcs lr rate respectively multivariate model adjust mvac p age p pathologic stage p node status p show surgical variable associate long pcs negative margin v positive hazard ratio hr p node remove v hr p association not differ treatment arm p test interaction treatment surgical variable predictor lr multivariate model adjust mvac p pathologic stage p node status p positive margin v negative odd ratio p few node remove v p conclusion surgical factor influence bladder cancer outcome cystectomy adjustment pathologic factor neoadjuvant chemotherapy usage management carcinoma situ bladder case surgical management view forego observation distinctive characteristic situ cancer bladder position disease follow variability biologic activity chronicity carcinoma situ bladder acknowledge however clear not case invasive bladder cancer represent progression situ stage usually currently detectable undifferentiated anaplastic cellular state advent biochemical predictor unqualified reliability identification crucial time invasion recommend radical cystectomy cure situ carcinoma provide patient reasonable surgical risk severely symptomatic histologic evidence extension lesion vesical neck urethra terminal ureter either histologic cytologic persistence cancer month course intravesical chemotherapy patient incidentally discover asymptomatic situ carcinoma seem focal variety disease circumstance month trial intravesical chemotherapy would reasonable scrupulous assessment progress cancer possible epidemiology bladder cancer case control study conduct male bladder cancer patient control general population control choose area gunma prefecture match age l subject age adjust smoke adjust odd ratio r confidence interval c calculate item risk factor bladder cancer man investigate r tend significantly high history smoke smoke per day smoke long whose brinkman index high begin smoke young inhale deep non smoker r past history complication cystitis age adjust benign prostatic hypertrophy age smoke adjust significantly high difference suppose cause bias significantly low age smoke adjust r bladder cancer man engage sale whose blood type drink milk frequently eat grain frequently age vegetable frequently past history complication hypertension numb case control \\ufeff1 degree family member develope cancer respectively suppose highly relate smoke follow lung cancer larynx cancer bladder cancer follow characteristic fail show significant difference subject bladder cancer control group height weight year ago job deal dye academic career marriage numb child alcohol drink use hair dye analgesic dhcr predict poor clinicopathological feature patient bladder cancer strobe compliant study investigate prognostic value dhcr patient bladder cancer bc use public bladder cancer microarray study evaluate expression dhcr normal bladder tissue bc cell investigate relationship expression dhcr clinical feature bc patient survival analysis perform investigate correlation dhcr expression survival bc patient gene set enrichment analysis conduct identify relevant mechanism result show dhcr regulate bc cell compare normal bladder tissue p result chi square test suggest bc patient dhcr low expression group prove well clinical characteristic include tumor grade disease progression stage n stage compare dhcr low expression group p p p p respectively bc patient dhcr low expression group associate well cancer specific survival overall survival p p respectively dhcr may promote proliferation bc cell several oncogenesis associate biological process estrogen response heme metabolism p pathway cholesterol homeostasis mtorc signal peroxisome xenobiotic metabolism glycolysis protein secretion thus dhcr may therapeutic target patient bc high expression level preoperative serum uroplakin iii associate biologically aggressive bladder cancer background uroplakins widely investigate potential marker patient bladder cancer protein specific urothelium however role uroplakin protein bladder cancer remain unknown study preoperative serum level uroplakin iii measure patient urothelial carcinoma urinary bladder examine possible association clinicopathological feature clinical outcome material method study include bladder cancer patient various stage healthy control uroplakin iii level detect preoperative serum use automate dot blot system micro dot blot array result significant increase serum uroplakin iii level patient bladder cancer compare healthy control p addition serum uroplakin iii level associate muscle invasive status high grade lymphovascular invasion p log rank test indicate high serum uroplakin iii significantly associate cancer specific mortality conclusion determination serum uroplakin iii level can valuable identify patient biologically aggressive bladder cancer decrease expression galectin predict tumour recurrence pta bladder cancer galectin gal glycoprotein involve various physiological cellular process alter expression loss function gal suggest involve pathogenesis progression various human cancer entity aim present investigation elucidate role galectin development progression non muscle invasive pta pt transitional cell carcinoma tcc urinary bladder gal analyze immunohistochemistry randomly select non muscle invasive bladder cancer specimen pta pt use tissue microarray technique compare various patient tumour characteristic test addition role gal association tumour recurrence progression investigate log rank test cox regression analysis gal find negative correlate tumour grade p within group non muscle invasive tcc gal can not differentiate pta pt tumour p within subgroup pta tumour loss gal determine likelihood development recurrent disease p student test furthermore demonstrate kaplan meier analysis expression level gal identify predict duration recurrence free survival p multivariate analysis gal find independent prognostic marker predict recurrence among cohort bladder tumour classify pta conclusion loss galectin appear involve carcinogenesis tcc serve valuable biological variable identify subgroup ta bladder cancer patient high risk development recurrent disease intravesical bacillus calmette gu rin instillation therapy non muscle invasive bladder cancer follow solid organ transplantation background solid organ recipient substantial risk develope bladder cancer high risk non muscle invasive bladder cancer nmibc frequent diagnosis theoretically adjuvant bacillus calmette gu rin bcg therapy contraindicate limit datum indicate feasibility objective study evaluate safety efficacy bcg follow solid organ transplantation material method review datum four solid organ recipient receive adjuvant bcg high risk nmibc institution additionally individual datum patient extract case series case report identify systematic review literature intestinal stricture complicate preoperative radiation therapy follow radical cystectomy january january patient invasive bladder cancer evaluate therapy patient select treatment preoperative radiation therapy follow radical cystectomy patient actually complete integrate therapy per cent clinical intestinal stricture three stricture occur month little month postoperatively stricture involve colon case ileum operation require case present case discuss pathophysiology treatment radiation injure intestine experience suggest preoperative radiation therapy conjunction radical cystectomy may associate development clinically significant bowel injury factor consider decision combine preoperative radiation therapy radical cystectomy treatment bladder cancer genotype study c ha ras locus human bladder tumor purpose clarify role c ha ras gene bladder cancer predisposition prognosis material method c ha ras locus study southern blot white blood cell tumor sample obtain patient bladder cancer ta comparison unaffected patient survival analysis perform result patient bladder cancer present different c ha ras allele different genotype heterozygosity case loss heterozygosity tumor case frequent allele kb present patient heterozygosity correlate vascular invasion tumor p small subgroup patient rare allele genotype allele genotype occur often patient tumor p allele genotype aneuploid tumor p p tumor vascular invasion p p however study majority patient high risk tumor possess common allele genotype survival analysis show neither proportion lung bladder cancer male result occupation systematic approach study conduct several country investigate relationship occupation cancer man review compare estimate proportion cancer due occupational exposure occur general population analyze source variation explore systematic standardize evaluation study lung bladder cancer undertake investigation allow confound tobacco smoke include proportion lung cancer attributable occupation range consider exposure asbestos study high proportion subject expose ionize radiation bladder cancer estimate study several investigation no similar attempt systematic comparison possible cancer immunotherapy non metastatic urothelial cancer back future introduction successful result immuno oncological drug metastatic urothelial cancer trigger interest researcher test non metastatic set conventional treatment modality space limit sometimes toxic no improvement see last year beyond patient fail intravesical bcg mitomycin c non muscle invasive bladder cancer no effective therapeutic alternative exist besides cystectomy neoadjuvant set cisplatin base chemotherapy provide limit benefit term disease recurrence metastasis expense toxic effect good news preliminary study show great promise use immunotherapy local loco regional disease large study way confirm excite potential benefit immunotherapy direction area cover review present overview development happen introduction immunotherapy non metastatic urothelial cancer treatment expert opinion immunotherapy non metastatic disease set urothelial cancer evolve early result tend anticipate predominant role come time large comparative trial progress gather robust practice change evidence bring paradigm shift treatment landscape year experience management invasive bladder cancer radical cystectomy background spindle kinetochore associate protein ska component ska essential proper chromosome segregation recently ska find express several type human cancer however report relationship ska expression prognosis bladder cancer particular lack objective clarify clinical significance ska prognostic biomarker early recurrence progression patient non muscle invasive bladder cancer nmibc method differential expression level ska nmibc tissue determine immunohistochemical stain quantitative real time pcr western blot analysis perform confirm immunohistochemistry result recurrence progression free interval assess kaplan meier method difference group calculate log rank statistic prognostic value ska early recurrence progression analyze multivariate cox proportional hazard regression model result ska expression significantly different various nmibc tissue kaplan meier analysis reveal patient high ska expression show high early recurrence p progression p rate although univariate cox regression analysis reveal several factor impact recurrence progression upon multivariate analysis high ska expression independent predictor early recurrence hazard ratio hr confidence interval ci p progression hr ci p conclusion high ska expression associate early recurrence progression patient nmibc indicate ska may serve promise prognostic biomarker disease variation diagnostic evaluation among person hematuria influence gender race risk factor bladder cancer purpose seek determine whether race gender numb bladder cancer risk factor significant predictor hematuria evaluation material method use self report datum sccs southern community cohort study link medicare claim datum evaluation subject diagnose incident hematuria consider complete image cystoscopy perform within day diagnosis exposure interest race gender risk factor bladder cancer result patient evaluation complete adjust analysis african american patient little likely caucasian patient undergo aspect evaluation include urology referral ci cystoscopy ci image ci woman little likely man refer urologist ci also although patient risk factor high odd urology referral ci adjust analysis indicate effect apparent among man conclusion patient incident hematuria diagnosis undergo complete hematuria evaluation gender substantial effect referral urology control socioeconomic factor otherwise unclear role quality evaluation african american patient markedly low rate thorough evaluation caucasian patient numb risk factor predict referral urology among man otherwise poor predictor evaluation opportunity improvement increase completion hematuria evaluation particularly patient high risk vulnerable diagnostic contribution bladder wash multiple biopsy bladder cancer superior diagnostic contribution bladder wash compare routine urinary cytology demonstrate prospective study random mucosal biopsy normal look mucosa take time treatment \\ufeff1 control cystoscopy reveal presence multiple cancerous precancerous lesion variety patient heterogeneity bladder cancer recognize adequate follow treatment history present condition occupational bladder cancer country purpose examine history present condition occupational bladder cancer country chemical carcinogenesis study career bladder cancer object method perform consideration literature mainly document ministry health labor welfare labor standard bureau accident compensation element document document association formation product industry result production aromatic amine start country \\ufeff1 occupational bladder cancer case report arrive great amount production time aromatic amine cause communist china trade production import benzidine naphthylamine prohibit safe hygiene method official announcement time people expose material occupational bladder cancer people register numb authorize workman comp start case urinary tract system tumor duty expose benzidine case urinary tract system tumor duty expose naphthylamine one case urinary tract tumor dianisidine total case occupational urinary tract cancer patient almost reach retirement age think reach end conclusion report history present condition occupational bladder cancer occur people aromatic amine revelation country comment trend recent occupational bladder cancer consideration literature clinical innovation urologic oncology background bladder cancer heterogeneous group tumor biological clinical point view conventional cytogenetics molecular genetic technique show non random aberration bladder cancer certain chromosomal change find highly correlate tumor grade stage aim study evaluate fluorescence situ hybridization fish numerical aberration chromosome x bladder cancer compare incidence nucleus aneusomies different grade histological stage tumor material method fish technique use dna probe specific chromosome x apply male bladder tumor specimen directly process cytogenetic study result polysomies chromosome x observe case examine numerical aberration chromosome observe case case numerical aberration chromosome polysomy case loss observe statistical analysis show numerical aberration chromosome x not link histological stage probable correlation observe aneusomies x tumor grade compare result pt grade iii tumor pt grade ii statistical analysis show aneusomies especially polysomy correlate pt grade iii tumor p p respectively uncertain correlation polysomy x pt grade iii tumor find p conclusion result may suggest genetic instability associate pt grade iii tumor may account considerable potential aggression tumor however draw definite conclusion large numb case must study stage advance bladder cancer neoadjuvant chemotherapy possible mvec protocol patient advance transitional cell carcinoma bladder neoadjuvant chemotherapy accord mvec regimen give subsequent radical cystectomy show stage patient preoperative clinical stage reveal regression bladder cancer case grade see patient discrepancy preoperative clinical stage histopathological stage radical cystectomy invasive tumour surgery necessary even clinical stage not reveal tumour chemotherapy bladder cancer present spontaneous subcapsular urinoma kidney intravesical mitomycin c effective agent treatment superficial transitional cell carcinoma bladder per cent overall response rate report side effect minor present case severe bladder contracture intravesical therapy mitomycin c use nomograms predictive tool bladder cancer bladder cancer common genitourinary malignancy demonstrate great variation risk tumor recurrence progression follow treatment dramatic difference clinical behavior dictate vastly differ treatment may range simple surveillance combination radical surgery systemic chemotherapy non muscle invasive bladder cancer prediction risk recurrence progression necessary assess need intravesical therapy possible early cystectomy contrast prediction advance disease response primary treatment cystectomy response systemic chemotherapy play important role treatment assignment patient muscle invasive disease estimate risk traditional risk group scheme present tnm stage system use guide patient treatment recently improve prognostic tool nomograms develope provide accurate assessment outcome clinician enthusiastically work utilize statistical method bladder cancer summarize current status outcome predictive model bladder cancer focus particularly ability nomograms predict disease recurrence progression patient survival immunotherapy bladder cancer primary role immunotherapy bladder cancer treat superficial transitional cell carcinoma ie carcinoma situ ta immunotherapy form bacille calmette gu rin bcg interferon bropirimine keyhole limpet hemocyanin gene therapy intend treat exist residual tumor prevent recurrence tumor prevent progression disease prolong survival patient presently bcg commonly use effective immunotherapeutic agent superficial transitional cell carcinoma datum support bcg positive impact tumor recurrence disease progression survival proper attention maintenance schedule route administration dose strain viability essential obtain maximum benefit bcg immunotherapy review highlight summarize recent advance concern immunotherapy special emphasis bcg therapy transitional cell carcinoma active surveillance low risk non muscle invasive bladder cancer mid term result bladder cancer italian active surveillance bias project objective report oncological safety risk progression patient non muscle invasive bladder cancer nmibc include active surveillance programme diagnosis recurrence patient method prospective study enroll patient history pathologically confirm low grade pta pt nmibc diagnose tumour recurrence inclusion criterium consist negative urine cytology presence lesion diameter mm absence carcinoma situ cis persistent gross haematuria primary outcome interest adherence need proceed treatment define progression numb dimension positive cytology symptom gross haematuria persistent intervention resection electro fulguration finally assess grade stage transurethral resection bladder tumour perform result study population consist patient previous diagnosis nmibc event prospectively recruit since mean patient age year median follow month median time patient remain month disease progression patient no patient progress muscle invasive disease patient increase numb size tumour nine haematuria four positive cytology five patient whole series progress high grade tumour grade present associate cis overall adherence follow schedule conclusion datum show protocol nmibc can reasonable option select group patient small recurrent cancer new treatment bladder cancer objective comment new histological classification tumor urinary system male genital organ expose state art urothelial carcinogenesis molecular modification bladder cancer consequence treatment material method systematic review literature search perform datum base pubmed focus follow keyword bladder cancer molecular subtype result new histological classification tumor urinary system confirm importance pathology determine care patient especially grade histological type infiltration take account difficulty cancer genome atla report genetic modification bladder cancer recently several study explore molecular anomaly bladder cancer elaborate molecular classification analyze predictive value accord group different molecular subtype define urobasal urobasal b genomically unstable infiltrate squamous cell carcinoma like p like luminal bladder cancer latter subgroup seem chemoresistant conclusion molecular biology classification allow well understand bladder cancer can complete near future histological datum improve patient management acridine orange flow cytometry urinary bladder washings detection transitional cell carcinoma bladder influence prior local therapy analysis cellular dna rna content bladder irrigation specimen patient history transitional cell carcinoma tcc bladder perform use acridine orange flow cytometry fcm washings patient prior intravesical chemotherapy radiation therapy compare patient no history treatment tumor resection evaluate reliability fcm detection tumor influence prior local therapy reliability five fcm pattern define basis dna rna index relationship peripheral blood lymphocyte fcm result compare cytologic finding case cystoscopic finding case histologic datum case presence single diploid stem line associate absence bladder tumor case patient treat surgery alone radiation therapy residual tumor patient expose prior local chemotherapy elevate rna content diploid cell population not provide additional diagnostic information presence aneuploid stem line associate tumor case regardless prior therapy aneuploidy predict appearance tumor four six patient negative cystoscopy tetraploidy great total cell population associate tumor patient treat surgery alone whereas no tumor find patient undergo prior chemotherapy radiation therapy study stress importance prior treatment history evaluate result dna fcm bladder cancer demonstrate unreliability fcm diploid tetraploid cell population patient previously treat local chemotherapy radiation however also support prior observation dna aneuploidy dna tetraploidy useful detect predict bladder cancer patient submit surgery alone current concept transurethral resection bladder cancer transurethral resection bladder cancer en bloc resection purpose review transurethral resection bladder cancer turb critical step management nonmuscle invasive bladder cancer nmibc review present new improvement strategy technique turb good technological development use tumour visualization removal recent finding goal turb perform complete resection nmibc tumor visualization procedure improve enhance optical technology fluorescence guide photodynamic diagnosis pdd narrow band image nbi use turb improve tumour detection potentially reduce recurrence rate influence progression however remain controversial turb perform use monopolar bipolar electrocautery without significant difference result safety overcome limitation traditional turb technique en bloc resection introduce improve quality tumour removal select case early resection turb within week initial procedure recommend summary turb fundamental step diagnosis treatment nmibc urologist aware promise innovation include new image surgical technique potential benefit hopefully new technology performance turb bring improve outcome alter indication criterium turb invasive bladder cancer possible future treatment consideration aim review provide date review available literature photodynamic diagnosis pdd nonmuscle invasive bladder cancer present technique comprehensive approach finally discuss relevance pdd clinical practice term indication outcome development trend literature search conduct july use medline embase via ovid database identify publish study pdd nonmuscle invasive bladder cancer english language human base full manuscript report case series study participant concern clinical evidence technique efficacy safety datum include evidence show pdd significantly improve detection bladder cancer compare standard white light cystoscopy prove effective diagnosis carcinoma situ condition seem facilitate complete resection result low residual tumor rate turn consecutively lead high recurrence free survival rate literature search demonstrate mid long term follow pdd show acceptable outcome term tumor detection good low residual tumor low recurrence rate compare white light cystoscopy prove safe good tolerate major limitation pdd low specificity elevate cost predictive value flow cytometric information clinical management stage ta bladder cancer two blind retrospective flow cytometric study perform archival stage ta papillary grade transitional cell carcinoma bladder learn whether deoxyribonucleic acid histogram pattern predict disease recurrence progression patient aneuploid histogram predict experience recurrent disease case recurrent disease ploidy pattern change recurrence find predict disease progression histogram sequence aneuploid two third aneuploid tumor incident experience invasion approximately 3 lack repetitive aneuploidy invasion furthermore patient aneuploid lesion half progression within year two third within year 2 aneuploid lesion therefore appear disease deoxyribonucleic acid histogram provide prognostic information beyond obtain tumor grade stage total partial prostate spare cystectomy invasive bladder cancer long term implication erectile function objective review long term result patient treat either total partial prostate spare cystectomy focus erectile function ef en bloc radical cystectomy rc without urethrectomy method choice manage invasive bladder carcinoma inherent risk subsequent urinary incontinence erectile dysfunction mark effect quality life especially young patient patient method assess man mean age year either prostate apex spare cystectomy pasc total prostate spare cystectomy tpsc six mean follow month pasc month tpsc evaluation surgery include standard bladder cancer stage prostate specific antigen level digital rectal examination complete medical history attention clinical observation sixty nine case situ carcinoma urinary bladder course screen urological outpatient urine cytological examination cytological indication cancer find patient absence cystoscopically visible bladder tumor sixty nine patient biopsy prove situ carcinoma bladder transitional type anaplastic follow datum effect therapy available patient treat various mean include total cystectomy partial cystectomy transurethral fulguration intravesical thiotepa external radiation duration symptom diagnosis remarkably long prolong course situ lesion also noteworthy difference observe behavior situ bladder carcinoma may due addition difference host resistance existence two pathogenetic form bladder cancer one arise extensive field abnormal epithelium develope focal area abnormality tissue polypeptide antigen monitor advance bladder cancer mvec chemotherapy patient advance bladder cancer treat mvec chemotherapy methotrexate vinblastine epirubicin cisplatinum patient suffer locally advance disease pt n patient regional lymph node metastasis find pt n patient distant metastasis note urethral recurrence follow neobladder bladder cancer patient risk factor urethral recurrence neobladder bladder cancer patient study patient male female undergo neobladder treatment bladder cancer observation time cystectomy range month median ten male patient urethral recurrence patient multiple bladder cancer include bladder neck urethral recurrence find macrohematuria follow cystourethroscopy inguinal lymph node swell one complain macrohematuria positive urinary cytology male patient undergo total nephroureterectomy renal pelvic ureteral cancer radical cystectomy urethral recurrence two patient urethral recurrence die cancer renal pelvic ureteral cancer five year cause specific survival patient urethral recurrence without urethral recurrence respectively urethral recurrence not significant effect survival patient multiple bladder cancer include bladder neck renal pelvic ureteral cancer radical cystectomy high risk urethral recurrence urinary cytology limit value detection urethral recurrence dwi image biomarker bladder cancer objective dwi increasingly apply management bladder cancer article discuss role dwi image biomarker bladder cancer conclusion dwi signal derive motion water molecule represent physiologic characteristic tissue interest emerge evidence highlight utility dwi bladder cancer detection characterization dwi potentially useful tool individualize treatment strategy soy isoflavone intake bladder cancer risk japan takayama study background grow evidence suggest soy isoflavone play protective role development cancer however epidemiological study investigate association soy isoflavone intake bladder cancer method evaluate association soy isoflavone intake bladder cancer incidence population base prospective study japan subject man woman age year old september soy isoflavone intake assess via validate food frequency questionnaire control total energy intake cancer incidence mainly confirm regional population base cancer registry bladder cancer define code c accord international classification disease health relate problem th revision result mean follow year man woman develope bladder cancer adjustment multiple confounder compare low quartile soy food intake estimate hazard ratio 2 3 high quartile soy food intake respectively man p trend correspond value respectively woman p trend similar inverse association observe isoflavone intake bladder cancer risk conclusion significant decrease risk bladder cancer observe among man high intake total soy isoflavone impact find potential benefit consume soy food bladder cancer promise warrant study cancer epidemiol biomarker prev aacr immunoperoxidase stain carcinoembryonic antigen urinary bladder cancer immunoperoxidase study presence carcinoembryonic antigen cea primary cancer urinary bladder metastasis bladder non malignant diseased bladder normal bladder tissue reveal approximately percent urothelial carcinoma transitional cell squamous cell type contain detectable quantity antigen tissue devoid stainable cea thus appear incidence positive cea immunoperoxidase stain formalin fix paraffin embed tumour tissue section much little frequency blood urinary cea elevation patient urothelial cancer bcg immunotherapy superficial bladder cancer aim platinum base neoadjuvant chemotherapy nac improve overall survival muscle invasive bladder cancer mibc pathological complete response pcr radical cystectomy nac associate well overall survival no establish predictive biomarker response nac mibc aim study find laboratory variable associate pcr follow nac material method carry retrospective review mibc patient treat nac follow radical cystectomy sheba medical center overall survival calculate use kaplan meier product limit method compare patient achieve not achieve pcr use log rank test baseline pre surgery laboratory value collect compare patient subsequently achieve pcr not use logistic regression result fifty eight patient undergo radical cystectomy nac median follow range month diagnosis patient document pathological outcome radical cystectomy achieve pcr complete responder complete responder follow datum still alive time last follow study july patient not achieve pcr significantly wrong overall survival complete responder p baseline lymphocyte count neutrophil lymphocyte ratio nlr platelet lymphocyte ratio plr significantly associate response p p p respectively univariate analysis whereas baseline albumin haemoglobin neutrophil platelet total white blood count not significantly associate response lymphocyte count significantly high responder non responder throughout three time point p use generalise linear mix model conclusion high baseline level lymphocyte associate achievement pcr radical cystectomy nac turn associate significantly long overall survival result suggest chemosensitivity mibc associate lymphocyte count antitumor effect novel nuclear factor kappa b activation inhibitor bladder cancer cell nuclear factor nf kappab transcription factor not induce control various gene include inflammatory cytokine also activate gene suppress apoptosis clearly demonstrate certain advance human bladder cancer cell constitutively acquire ability activate nf kappab not protect cancer cell apoptotic cell death also upregulates production various cytokine may increase malignant potential disease cause paraneoplastic syndrome nf kappab inhibitor may therefore useful anticancer agent nf kappab function inhibitor dehydroxymethyl derivative epoxyquinomicin c dhmeq recently design synthesize effectiveness dhmeq advance human bladder cancer cell line ku nf kappab constitutively activate investigate dna bind activity nf kappab completely inhibit follow h exposure microg ml dhmeq mark level apoptosis observe h dhmeq administration result confirm nf kappab activation maintain viability ku cell dhmeq inhibit constitutively activate nf kappab consequently apoptosis induce however still possible dhmeq cause apoptotic cell death mechanism not yet fully investigate author conclude dhmeq can represent new treatment strategy advance bladder cancer diagnosis treatment octogenarian neoplastic patient bladder cancer age risk factor occurrence bladder cancer bladder cancer disease elderly choice treatment relay stage non invasive muscle invasive bladder cancer non invasive bladder cancer usually treat transurethral resection bladder turb follow intravesical therapy bcg chemotherapeutic agent gold standard treatment muscle invasive bladder cancer radical cystectomy elderly particular octogenarian wrong tolerance aggressive therapy due high incidence side effect complication problem can significantly occur intravesical bcg therapy radical cystectomy urologist face treatment octogenarian affect bladder cancer answer many question case non invasive bladder cancer possible use drug use young patient bcg vs chemotherapeutic agent time kind follow octogenarian affect muscle invasive bladder cancer undergo radical cystectomy little invasive treatment kind diversion prefer possible propose orthotopic neobladder octogenarian patient choice treatment make basis careful evaluation patient consider not patient age also comorbidity life expectancy disparity bladder cancer outcome base key sociodemographic characteristic purpose review review impact several key patient characteristic oncologic outcome bladder cancer bc summarize analyze narrative fashion recent finding bulk publish literature suggest female black poor cancer specific outcome group tend present wrong disease may drive difference access timely quality care attempt assess association smoke status history bc outcome hinder quality heterogeneity datum although several study link smoke high rate recurrence poor survival marry particularly man may improve survival radical cystectomy rc limit datum suggest socioeconomic education level may associate poor survival however datum limit grow body investigation suggest significant difference oncologic outcome bc patient base race gender smoke status socioeconomic status other focus investigation need validate finding investigate root cause difference offer solution mitigate marker lesion experiment bladder cancer learn purpose marker lesion experiment single bladder tumor deliberately leave unresected late ablation intravesical instillation novel agent benefit clear eg opportunity examine effect therapy measurable disease safety medical ethic experiment little obvious review goal inclusion criterium definition success agent use effectiveness safety ethic marker lesion study suggest framework future experiment material method publish bladder cancer study use marker lesion concept identify medline search march result total good document marker lesion study identify involve patient agent study cytotoxins mitomycin c epirubicin gemcitabine valrubicin apaziquone immune response modifier bacillus calmette guerin tumor necrosis factor alpha interferon alpha granulocyte macrophage colony stimulate factor high complete response rate intermediate risk patient attain apaziquone patient achieve complete response agent also prophylactic benefit year recurrence free rate compare not achieve complete response complete response rate bacillus calmette guerin trial range marker lesion experiment deem safe progression disease patient high risk patient select conclusion marker lesion study appropriate evaluation novel anticancer therapeutics patient multiple recurrent noninvasive low grade tumor intermediate risk recruit primary end point complete response recurrence rate year prognostic value tumor associate macrophage count human bladder cancer background determine tumor associate macrophage tam count investigate importance predict clinical outcome prognosis patient bladder cancer method tam count microvessel count mvc determine immunohistochemically patient bladder cancer include superficial bladder cancer invasive bladder cancer examine relationship tam count clinical outcome prognosis bladder cancer cystectomy rate distant metastasis rate vascular invasion rate year survival rate compare patient low high tam count result tam count invasive bladder cancer significantly high superficial bladder cancer p mvc invasive bladder cancer also significantly high superficial bladder cancer p positive correlation tam count mvc r p immunohistochemical stain use cd horseradish peroxidase monoclonal antibody show infiltrate cell invasive superficial bladder cancer patient high tam count show significantly high rate cystectomy distant metastasis vascular invasion low tam count year survival rate estimate use kaplan meier method significantly low patient high tam count low tam count p conclusion result suggest determination tam count bladder cancer tissue value predict clinical outcome prognosis select appropriate treatment strategy patient bladder cancer conservative treatment bladder epitheliomas partial cystectomy iridium curietherapy patient treat bladder cancer henri mondor hospital use treatment protocol combine low dose pre operative external beam radiation follow iliac node dissection limit partial cystectomy sometimes tumor trans urethral resection curietherapy iridium year disease free survival rate local recurrence plus 2 tumor within bladder result compare conservative modality treatment bladder cancer pelvic lymph node metastasis bladder cancer outcome patient radical cystectomy pelvic lymphadenectomy analyze occupational smoke history bladder cancer patient barcelona city general hospital spain patient no history occupational risk smoke occupational history associate high bladder cancer incidence current smoker diagnostic delay delay initiation treatment analyze patient delay visit general practitioner three month onset hematuria take three month see urologist begin treatment hospital \\ufeff1 three month diagnosis great proportion infiltrative tumour see patient year visit delay hematuria bladder preservation optimize radiotherapy integrate treatment strategy radical cystectomy rc remain standard care muscle invasive transitional cell carcinoma bladder series single institution cooperative group trial long term follow show combine modality therapy bladder preservation provide select patient excellent chance long term survival intact function bladder strategy preserve bladder develope past year continue refinement radiation therapy chemotherapy patient selection hallmark modern bladder preserve therapy include careful patient selection ii combine therapy maximum transurethral resection bladder tumour radiation concurrent chemotherapy iii cystoscopic assessment response therapy prompt salvage cystectomy nonresponders iv careful follow cystoscopic surveillance prompt cystectomy invasive recurrence contemporary bladder preserve approach patient clinically stage muscle invasive bladder cancer achieve complete response rate year survival rate survival rate intact bladder although no randomize study compare rc combine therapy bladder preservation long term datum show overall disease specific survival rate contemporary rc series clinically stage patient bladder cancer comparable bladder preserve protocol thus combine modality therapy bladder preservation become safe test effective alternative rc select patient muscle invasive bladder cancer desire keep bladder future work continue refine bladder preserve approach improve survival local control experimental study attachment collagen utilize establish cell line human urinary bladder cancer accurate preoperative stage bladder cancer essential determine extent disease optimal treatment current gold standard transurethral resection bladder tumor turbt follow compute tomography ct image provide excellent stage specificity often understages disease lead pathologic upstage adverse outcome patient undergo radical cystectomy new image modality multiparametric magnetic resonance mr image positron emission tomography pet combine ct mr provide promise image alternative may improve accuracy stage local distant disease identification biomarker associate progression prognosis bladder cancer via co expression analysis background bladder cancer one common genitourinary malignancy high rate recurrence progression prognosis patient bladder cancer especially muscle invasive bladder cancer remain poor despite systemic therapy objective explore underlie disease mechanism identify effective biomarker bladder cancer method weight gene co expression network analysis wgcna protein protein interaction ppi network analysis apply identify hub gene correlate bladder cancer progression survival analysis conduct identify potential biomarker correlate prognosis bladder cancer finally validation analysis potential biomarker conduct series bioinformatics analysis result base result weight gene co expression network analysis protein protein interaction network analysis ten hub gene closely correlate bladder cancer progression identify relevant module survival analysis gene indicate elevate expression six potential biomarker col fn col fbn col thbs significantly associate wrong overall survival furthermore potential biomarker validate association progression bladder cancer bladder cancer sample high expression gene significantly enrich gene set associate ecm receptor interaction conclusion study identify several biomarker associate bladder cancer progression prognosis novel finding may important clinical implication diagnosis treatment prognosis prediction urinary ph superficial bladder cancer background preoperative stage f fluorodeoxyglucose f fdg positron emission tomography pet combine compute tomography ct use evaluation metastatic disease patient invasive bladder cancer use quantification maximum standardize uptake value suvmax regional lymph node lns suggest increase diagnostic ability detection malignancy objective assessment utility clinical relevance suvmax f fdg pet detect regional nodal metastasis patient consider radical cystectomy design set participant identify total patient urothelial carcinoma undergo radical cystectomy extend ln dissection additionally patient identify preoperative biopsy patient undergo f fdg pet ct treatment recommendation pathological finding compare preoperative pet ct stage analyse regional patient base model accord suvmax value outcome measurement statistical analysis total lns identify patient locoregional involvement lns confirm patient result limitation suvmax analysis sensitivity confidence interval specificity suvmax base analysis sensitivity specificity two year follow imply high suvmax correlate high recurrence risk independent conventional pathological finding conclusion f fdg pet ct use suvmax lns useful tool preoperative evaluation pelvic ln metastasis invasive bladder cancer contribute selection patient personalize treatment patient summary report establish possible identify disease bladder cancer lymphatic tissue surround bladder use scan analysis assist selection treatment patient bladder cancer may spare patient unnecessary procedure urinary immunoglobulin diagnosis bladder cancer urinary immunoglobulin level measure urine patient histologically diagnose bladder cancer present six patient culture prove urinary tract infection control individual statistically significantly high immunoglobulin level urine patient bladder cancer either individual urinary tract infection control individual urinary immunoglobulin may potentially useful test diagnosis follow bladder cancer patient bladder cancer woman bladder cancer see mainly man incidence woman increase still approximately three four time low man particular transitional cell cancer seem relatively common man woman ratio non transitional cell cancer also frequent man ratio man smoke important know factor bladder cancer woman coffee drink also show weak correlation odd ratio find twice high woman man estimate percentage bladder cancer attribute occupational exposure unite state woman compare man urinary tract infection relate bladder cancer role human papilloma virus infection important cervical cancer unclear bladder cancer development surprisingly bladder cancer often high stage initial diagnosis woman current tumor marker no explanation different prognosis man woman postulate treatment superficial bladder cancer tumor similar man woman recent year orthotopic bladder replacement improve quality life cystectomy invasive disease perioperative chemotherapy advance bladder cancer part neoadjuvant treatment despite local tumor control patient locally advance bladder cancer lymphogenic metastasize urothelial carcinoma risk systemic progress radical cystectomy gold standard treatment muscle invasive bladder tumor pelvic lymphadenectomy remain integral part surgical treatment however extent lymph node dissection depend diagnostic curative intent controversial addition treatment option systemic chemotherapy combine radio chemotherapy need improve outcome locally advance metastasize disease therefore administration additional therapy surgical treatment intensively study application neoadjuvant concept good definite role adjuvant chemotherapy currently contentious topic subject meta analysis prospective randomize trial addition bladder preservation part multimodality treatment still discuss option select patient unsuitable radical cystectomy article give overview current concept use neoadjuvant systemic chemotherapy treatment advance urothelial cancer long term versus short term doxorubicin hydrochloride instillation transurethral resection superficial bladder cancer prospective randomize study influence short term instillation therapy versus long term instillation therapy transurethral resection superficial transitional cell bladder cancer tumor recurrence tumor progression patient survival evaluate datum patient enter study evaluable transurethral resection initial tumor random biopsy bladder patient divide two group random group doxorubicin weekly week afterwards no treatment short term regimen group doxorubicin weekly week afterwards monthly instillation year long term regimen follow year neither frequency recurrence tumor progression survival rate improve significantly long term instillation regimen blood group antigen bladder cancer objective goal work evaluate usefulness nmp bladderchek diagnosis follow bladder cancer compare cystoscopy urine cytology method group asymptomatic patient follow bladder cancer undergo cystoscopy cytology nmp bladderchek group patient history hematuria undergo cystoscopy nmp bladderchek result group patient tumor relapse sensitivity nmp test citology cystoscopy specificity respectively group patient bladder cancer sensitivity nmp bladderchek cystoscopy specificity nmp bladderchek cystoscopy conclusion low sensitivity nmp bladder chek invalidate alternative method cystoscopy follow bladder cancer recommend screen patient without history bladder cancer increase risk smoker patient dysuria hematuria rapid induction bladder cancer rat n methyl n nitrosourea histology objective analyse role ct scan preoperative determination bladder lymph node involvement infiltrative bladder cancer possible impact surgical management patient method retrospective study include patient diagnosis infiltrative bladder cancer ability ct scan bladder lymph node stage evaluate compare result finding radical surgery potential impact image technique change surgical attitude evaluate result perivesical involvement estimation ct scan right underestimate overestimate advance perivesical involvement low sensitivity ct scan perivesical stage locally advance tumour high specificity oscillate pt pt reference lymph node stage correct case although percentage depend almost exclusively patient negative node n however understaging rate correspond majority n patient datum offer sensitivity specificity positive predictive value negative predictive value finally reliability bladder stage patient lymph node involvement n patient establish correctly estimate low case understaging rate ct scan would modify surgical attitude patient advance tumour conclusion impact ct scan infiltrative bladder cancer clinical stage relatively low high benefit obtain patient suspect advance disease limitation group would result significative cost reduction low risk unappropriate surgical management immunological characteristic experimental bladder cancer annual symposium german research association bladder carcinoma dfbk organize february th th sseldorf \\ufeff1 day eight international guest speaker invite dfbk department urology heinrich heine university sseldorf present current state research bladder cancer bc topic genomic change molecular classification non muscle invasive muscle invasive bc prospect limit proteome technology urine diagnostics function chromatin regulator bladder carcinogenesis cellular reaction aneuploidy organoid technology biobanking good novel aspect immunotherapy bc 2 day dedicate new result idea dfbk member bc pathomechanisms diagnostics therapeutic approach importantly discussion development collaborative project additional information available http www forschungsverbund blasenkarzinom de cytogenetics bladder cancer rearrangement short arm chromosome presence nonrandom chromosomal defect report numb leukemia lymphoma solid tumor primary karyotypic change describe bladder carcinoma report find chromosomal derivative marker three case bladder cancer marker observe interpretable metaphase obtain direct method involvement short arm chromosome carcinogenetic process discuss indication result partial bladder resection bladder cancer prognostic role systemic inflammatory response sir marker unclear patient non muscle invasive bladder cancer nmibc aim investigate prognostic role various sir marker oncological outcome non muscle invasive bladder cancer nmibc patient single institution korea neutrophil lymphocyte ratio nlr derive nlr dnlr platelet lymphocyte ratio plr examine sir marker retrospectively collect datum nmibc patient undergo transurethral resection bladder turb exclude patient study population finally consist individual overall survival os cancer specific survival css recurrence free survival rfs progression free survival pf analyze use kaplan meier estimate multivariate cox regression model adopt identify predictor oncological outcome notably elevate nlr dnlr plr associate poor os outcome patient increase nlr not dnlr plr poor css estimate compare low nlr however no significant difference find rfs pf accord sir status multivariate cox regression analysis elevate nlr identify key predictor os hazard ratio hr confidence interval ci addition age hr ci hemoglobin hr ci high grade tumor hr ci respect css increase nlr also identify independent predictor hr ci summary result indicate nlr reliable sir marker predict oncological outcome particularly mortality outcome effect time interval diagnosis muscle invasive bladder cancer radical cystectomy stage survival netherlands cancer registry analysis introduction datum single center series suggest delay time radical cystectomy rc month diagnosis muscle invasive bladder cancer mibc associate pathological upstage decrease survival however limit datum available population base study study effect delay rc assess nationwide cohort material method patient undergo rc primary clinical n urothelial bladder cancer select use netherlands cancer registry database datum netherlands cancer registry supplement datum nationwide network registry histo cytopathology database case incomplete information cohort divide patient undergo rc month group vs patient undergo rc month group ii median time mibc diagnosis rc variable associate delay rc effect delay rc stage overall survival os evaluate patient undergo neoadjuvant therapy patient not result total patient include median follow time year live patient year decease patient median time mibc diagnosis rc day interquartile range day patient undergo rc month patient old year odd ratio ci refer rc ci treat university hospital ci progression survival transitional cell bladder cancer comparison establish prognostic factor phase fraction dna ploidy dna flow cytometric fcm datum histological feature clinical stage bladder tumour patient relate outcome mean follow year aneuploidy detect tumour diploid intratumour heterogenity dna ploidy find case aneuploidy high phase fraction spf relate clinical stage histological grade papillarity p little aneuploidy p little high spf p little predict metastasis pelvic lymph node distant site category p little spf p little histological grade p little papillarity p dna aneuploidy p g fraction p predict cancer relate survival multivariate analysis show dna aneuploidy important predictor progression category p category important predictor lymph node involvement p metastasis p follow fcm parameter ta tumour spf predict progression independently p fcm offer accurate prognostic information ta tumour conventional method invasive tumour fcm offer quantitative prognostic information term pelvic lymph node metastasis metastasis distant site bcan think tank session molecular detection bladder cancer path progress initial detection bladder cancer surveillance cancer recurrence progression central topic field urologic oncology session rd annual bladder cancer think tank meet focus urine base marker bladder cancer screen surveillance review key point presentation good recommendation work group task critically evaluate information discuss session although practicality marker challenge resound consensus continue research effort direct develope evaluate marker screen early detection warrant combine radiotherapy surgery chemotherapy carcinoma bladder investigate possible relationship diet risk bladder cancer serbia hospital base case control study carry study include newly diagnose bladder cancer patient numb control match sex age year type residence rural urban dietary information obtain use food frequency questionnaire initial bladder tumor marker hematuria molecular diagnostics stand bladder cancer common malignancy usa currently detection initial tumor recurrent disease base evaluation void urinary specimen often follow cystoscopy high rate recurrence cystoscopy regularly repeat aim halt progression disease patient process fraught anxiety pain high cost result intense work do field bladder tumor marker goal identify bladder cancer early initial diagnosis recurrence know tumor possibility identify marker can noninvasively differentiate benign malignant cause hematuria identify recurrence prior pathologic progression objective area research currently large numb tumor marker exist scrutinize laboratory clinical trial present many widely use test marker background detail provide mechanism detection malignant cell result recent trial future direction study novel modality tumor detection also present next year no doubt bring new marker lead elimination other study continue refine role marker clinical practice ultimate efficacy need bear large scale clinical trial multitude setting organ conservation invasive bladder cancer transurethral resection chemotherapy radiation result urodynamic quality life study purpose transurethral resection chemotherapy radiation salvage cystectomy may use alternative immediate radical cystectomy management invasive bladder cancer concern exist function retain bladder therapy material method patient clinical bladder cancer treat massachusetts general hospital trimodality therapy alive native bladder disease free patient ask undergo urodynamic study complete quality life questionnaire total participate component study median time trimodality therapy year range result patient normally function bladder urodynamic study decrease bladder compliance see bladder hypersensitivity involuntary detrusor contraction incontinence present woman questionnaire show flow symptom occur urgency control problem woman wear pad distress urinary symptom half common prevalence bowel symptom occur record level distress majority man retain sexual function global health relate quality life high conclusion majority patient treat trimodality therapy retain good bladder function 5 evidence bowel dysfunction autophagy induce adenoviral mediate interferon alpha treatment interferon resistant bladder cancer normal urothelial cell cell death protective mechanism not bystander factor produce previously show adenoviral mediate interferon alpha ad ifnalpha treatment highly cytotoxic tumor cell resistant ifnalpha protein report autophagy produce ad ifnalpha treatment either ifn resistant bladder cancer cell uc ku normal urothelial cell line tert nhuc ad ifnalpha infection autophagosomes early stage autophagy see cancer cell whereas autophagolysosomes late stage autophagy observe mostly normal cell electron microscopy condition medium either normal bladder cancer cell obtain ad ifnalpha infection however produce no autophagy place bladder cancer cell although mark cytotoxicity observe indicate autophagy see relate direct effect ad ifnalpha transfection expression rather bystander factor produce addition autophagic change see use lysotracker red dnd normal cancer cell also document ad ifnalpha treatment produce autophagic protein form light chain lc ii cancer cell not normal cell turn inhibit autophagic inhibitor methyladenine inhibition autophagy result significant increase apoptotic cell death measure sub g population hypothesize autophagy see normal urothelial cell protective response allow complete provide survival mechanism ad ifn treatment whereas autophagy produce ifn resistant cancer cell not allow complete insufficient significantly suppress cytotoxicity bladder cancer co exist ovarian cancer coincidentally detect transvaginal ultrasonography objective evaluate diagnostic performance new noninvasive urinary bladder cancer ubc rapid test select urine void sample detection transitional cell carcinoma tcc bladder assess differential sensitivity biomarker regard relevant histologic clinical parameter bladder cancer method two hundred sixty seven subject enter study classify five group patient active tcc bladder group follow patient tcc free disease confirm cystoscopy group patient benign urologic disease group patient malignant pathologic condition group healthy subject group ubc rapid test measure immunochromatographic method qualitatively detect presence fragment cytokeratins urine ubc rapid test difference regard stage grade tumor size pattern growth focality recurrence also evaluate result sensitivity group specificity group positive negative predictive value group respectively global accuracy false positive rate group respectively sensitivity ubc rapid test associate histologic clinical characteristic bladder cancer not enough reach statistical significance conclusion ubc rapid test appear promise noninvasive adjunct may guide urologist decision perform cytoscopy detection tcc bladder study appear merit assess potential diagnostic role dnfb reaction bladder cancer immunological study state determination reactivity primary antigen dinitrofluorbenzol mean epicutaneous skin test begin therapy may give essential reference spread tumour prognosis course control patient carcinoma urinary bladder therefore consist not clinical also immunological examination thoughtful practical timely radiation therapy guideline patient muscle invasive bladder cancer mediterranean diet diet rich cereal fruit vegetable associate lower risk variety cancer digestive tract bladder previous study show high phenolic content dietary component produce urine can associate high antimutagenic property urine low arylamine dna adduct exfoliate bladder cell conduct case control study bladder cancer patient hospital control total aromatic dna adduct measure white blood cell wbc subject p post label genetically base metabolic polymorphism analyse pcr rflp nat gstm gstt gstp comt nqo subject interview tobacco use dietary habit risk factor odd ratio risk bladder cancer accord presence absence wbc dna adduct detection limit ralx confidence interval ci dose response relationship level adduct apparent association case control status presence wbc dna adduct significantly strong subject consume few portion fruit vegetable per day ci portion vegetable heavy consumer consumer portion daily consumer portion similar low estimate find intake fruit no association notice tobacco smoke wbc dna adduct nat among several genotype consider associate statistically significant way risk bladder cancer ci level wbc dna adduct report suggest fruit vegetable can protect bladder cancer inhibit formation dna adduct hsp no diagnostic prognostic significance prostate bladder cancer heat shock protein hsp cytosol protein unknown function concentrate many estrogen sensitive normal target organ express vary degree many tumor include ductal carcinoma breast malignant fibrous histiocytoma mfh soft tissue adenocarcinoma prostate transitional cell carcinoma tcc urinary bladder overexpression hsp independent prognostic significance patient breast cancer mfh potential predictive value prostate bladder cancer not evaluate differential expression hsp may occur invasive cancer host tissue can aid diagnosis vary expression among invasive cancer may potential prognostic significance can influence use adjuvant therapy test hypothesis hsp expression evaluate immunohistochemistry archival formalin fix paraffin embed section primary prostate bladder carcinoma outcome patient know prostate cancer specimen patient undergo radical prostatectomy stage n no normal glandular element invasive cancer express protein bladder cancer specimen patient undergo radical cystectomy stage b n n cancer overexpress protein hsp not correlate degree histologic differentiation stage nodal status local recurrence metastasis survival observation conclude hsp expression neither diagnostic prognostic significance not serve predictive biologic marker important genitourinary cancer examine management muscle invasive bladder cancer medical oncologist unite state background neoadjuvant chemotherapy nact treatment muscle invasive bladder cancer mibc remain underutilize unite state despite evidence support use objective examine perioperative chemotherapy management patient mibc medical oncologist medoncs move toward standardization practice participant method question survey email medoncs belong bladder cancer advocacy network american society clinical oncology completion may october result total medoncs complete survey base academic center referral urologist nact treatment mibc bladder cancer spain mortality trend study make mortality tendency due bladder cancer make various industrialize country show evidence increase time death rate situation also see spain characteristic analyze actual increase risk death due bladder cancer male find definite tendency woman not observe characteristic tendency curve indicate grave importance tumor can eventually spain need adopt policy adequate intervention bladder cancer risk assessment quantitative fluorescence image analysis tumor marker exfoliate bladder cell background detection potentially highly curable low grade bladder cancer noninvasive technique remain unsolved problem conventional cytology detect tumor sensitivity addition dna measurement cytology improve sensitivity incrementally tumor associate antigen potentially offer additional diagnostic marker method study antibody tumor associate antigen express mainly low grade tumor cell test sensitivity specificity alone combination dna ploidy cytology void urine sample asymptomatic control subject urine bladder washings patient cancer symptomatic control patient collect cell double label monoclonal antibody hoechst case blind numb positive cell score two independent observer result high grade low grade transitional cell carcinoma tcc detect equal efficiency p versus symptomatic control patient urine sample prove high specificity detect cancer patient monitor recurrence without current detectable cancer intermediate control subject patient cancer suggest marker also respond dysplasia field disease patient outlet obstruction not significantly differ patient previous tcc p combine dna ploidy measurement cytology sensitivity low grade high grade tumor respectively conclusion antibody potentially can improve specificity sensitivity detection low grade bladder tumor symptomatic asymptomatic patient good monitor recurrence therapeutic response assessment individual risk analysis result prophylactic superficial bladder cancer study patient cystectomized average year unsuccessful curative radiotherapy technically difficult procedure high mortality rate none patient survive year improve quality life main subjective impression tumor free specimen effect radio induce downstaging no guarantee long term survival patient without histological tumor cell cystectomy lymph node specimen die metastic disease indication salvage cystectomy untreatable bladder hemorrhage instance emergency frequently recurrent tumor subjectively unbearable state disease cadherin switch bladder cancer purpose progression presentation muscle invasive disease represent critical clinical step bladder cancer necessitate aggressive therapy carry significantly wrong survival rate bladder tumor typically show decrease expression cell cell adhesion molecule e cadherin grade stage progress accompany increase expression n cadherin p cadherin muscle invasive tumor phenomenon describe cadherin switch may represent key step invasion introduce concept cadherin mediate cell adhesion biology describe cadherin switch detail bladder cancer material method perform pubmed search article summarize important concept cadherin biology present primary evidence cadherin expression bladder cancer result cadherin switch promote malignant invasive phenotype bladder cancer patient laboratory base experimental system bladder cancer novel switch n cadherin p cadherin expression occur although precise time nature process remain unknown similarly associate signal pathway remain fully elucidate conclusion cadherin switch important process late molecular pathogenesis bladder cancer may hold answer development muscle invasive metastatic disease thus cadherin cell adhesion molecule represent strong candidate biological molecular target prevent disease progression investigation warrant angiogenesis schistosoma haematobium associate urinary bladder cancer schistosoma haematobium parasitic flatworm infect million people mostly develope world causative agent urogenital schistosomiasis associate high incidence squamous cell carcinoma scc bladder infection egg deposit bladder cause intense inflammatory reaction angiogenesis define formation new blood vessel preexist one recognize key event cell proliferation carcinogenesis spread malignant lesion grow amount evidence point angiogenesis play key role schistosomiasis associate bladder cancer thus identify biomarker process play important role study cancer review recent finding role angiogenesis bladder cancer growth factor induce assist development particularly scc bladder associate urogenital schistosomiasis formation artificial bladder intestine base long term experience radical surgery patient invasive bladder cancer author come conclusion establishment intestinal bladder postcystectomy recovery physiological uresis proper therapeutic approach extra intraperitoneal position transplant decide upon regard type stage cystectomy prior method derivation technique one multistage operation present clinical practice evidence rapid recovery urethral uresis obtain application primary continuous suture artificial intestinal bladder ideal enterocystoplasty end surgery urodynamic low urinary tract finding provide technique develope author offer new surgical opportunity bladder cancer patient follow cystectomy superficial bladder cancer need long term follow clinical trial objective explore apoptosis induce effect arsenic trioxide human bladder cancer cell elucidate possible mechanism method treatment growth inhibition rate human bladder cancer cell line biu study mtt cell count method dna synthesis rate detect h tdr assay morphological change cancer cell observe light electronic microscopy cell apoptosis rate detect tdt mediate dutp nick end label tunel bcl gene expression biu cell observe strept avidin biotin complex sabc immunohistochemical method result can effectively inhibit growth biu p time concentration dependent inhibition rate mumol l dna synthesis cancer cell p partial cancer cell present characteristic morphological change apoptosis depend time exposure drug p bcl expression biu cell decrease significantly p conclusion significantly induce apoptosis bladder cancer cell regulate expression bcl gene inhibit dna synthesis provide potentially effective method prevention cure human bladder cancer bladder cancer current management background case bladder cancer diagnose australia bladder cancer relatively common disease high morbidity leave untreated bladder cancer categorise either nonmuscle invasive bladder cancer muscle invasive bladder cancer treatment vary significantly type objective article provide update presentation bladder cancer risk factor investigation treatment discuss role chemotherapy neoadjuvant adjuvant treatment discussion bladder cancer commonly present microscopic macroscopic haematuria evaluation require patient macroscopic haematuria patient persistent microscopic haematuria risk patient single episode microscopic haematuria evaluation consist image urine cytology cystoscopy nonmuscle invasive bladder cancer patient undergo tumour resection adjuvant intravesical treatment muscle invasive bladder cancer patient optimally treat cystectomy urinary diversion comparison sensitivity specificity urine cytology urinary nuclear matrix protein multitarget fluorescence situ hybridization assay detection bladder cancer objective study aim compare sensitivity specificity positive predictive value ppv negative predictive value npv urine cytology bladderchek nuclear matrix protein nmp urovysion fluorescence situ hybridization fish test patient newly diagnose bladder cancer recurrent bladder cancer bladder cancer remission surveillance material method void urine sample obtain patient suspect know bladder cancer undergo diagnostic surveillance cystoscopy control subject without disease divide four use urine culture cytology nmp bladderchek urovysion fish test sensitivity specificity ppv npv test calculate comparison make ability test detect bladder cancer three category patient list result patient bladder cancer newly diagnose recurrent disease remission sensitivity test newly diagnose patient urine cytology nmp fish patient recurrent disease urine cytology nmp fish mean specificity urine cytology nmp fish respectively conclusion test use study detection bladder cancer nmp appear cost effective rapid relatively high sensitivity specificity category patient nmp test may consider new gold standard assessment patient know suspect bladder cancer perioperative chemotherapy advance bladder cancer despite radical cystectomy patient locally advance disease patient lymphatic metastasis die tumor relate provide rationale additional effective systemic therapy follow surgery addition previous surgery consecutive histopathological cell base evaluation offer advantage expose patient adjuvant systemic chemotherapy belong define high risk group regional lymph node metastasis range little nearly lesion therefore extend lymph node dissection integral part surgical treatment gain importance pathological assessment adequate numb lymph node increase likelihood proper stage decision therapy depend accurate stage standardization lymphadenectomy desirable paper provide overview current concept use adjuvant systemic chemotherapy treatment advance urothelial cancer long term oncologic outcome radical cystectomy bladder cancer single institution aim study evaluate experience use radical cystectomy treat patient bladder cancer describe association pathologic feature clinical outcome patient undergo radical cystectomy bladder cancer evaluate patient population consist man woman overall yr recurrence free survival rfs rate respectively yr cancer specific survival css rate respectively multivariate analysis show factor significantly predictive rfs css include extravesical extension p lymph node metastasis p lymphovascular invasion p p yr rfs rate patient lymph node metastasis respectively yr css rate respectively adjuvant chemotherapy significantly improve rfs p css p patient lymph node metastasis radical cystectomy provide good survival result patient invasive bladder cancer pathologic feature significantly associate prognosis include extravesical extension node metastasis lymphovascular invasion adjuvant chemotherapy improve survival patient advance stage disease expression profile variation integration gene bladder urothelial carcinoma bladder cancer common cancer worldwide incidence continue increase approximately case bladder cancer result death annually study aim integrate bladder cancer genome copy numb variation information bladder cancer gene transcription level expression datum construct causal target module network range bladder cancer relate genome explore control mechanism underlie bladder cancer phenotype expression regulation major bladder cancer gene select module initial module network expand search screen network bootstrap time obtain key regulator key candidate regulatory gene expand identify expression change gene module may regulation conclusion series module associate term cancer bladder consider constitute potential network neoadjuvant chemotherapy bladder spare surgery invasive bladder cancer ten year outcome purpose evaluate year outcome patient invasive n stage accord tumor node metastasis system bladder cancer respond completely combination methotrexate vinblastine adriamycin cisplatin mvac chemotherapy follow bladder spare surgery patient method surgical candidate receive neoadjuvant mvac achieve complete clinical response transurethral resection tur primary tumor site request follow tur alone partial cystectomy elect radical cystectomy patient follow median year range year result patient bladder spare surgery alive include intact function bladder twenty four patient develope bladder tumor recurrence month invasive superficial thirteen patient require salvage cystectomy die include new invasive neoplasm patient radical cystectomy alive conclusion majority patient invasive bladder tumor achieve status neoadjuvant mvac chemotherapy preserve bladder year bladder spare surgery bladder remain risk new invasive tumor cystectomy salvage majority not relapse patient efficient delivery radical cystectomy neoadjuvant chemotherapy muscle invasive bladder cancer multidisciplinary approach background cystectomy delay day diagnosis muscle invasive bladder cancer mibc adversely affect pathologic stage survival outcome patient undergo primary surgery neoadjuvant chemotherapy nac impact time cystectomy delivery outcome uncertain poor communication urologic medical oncologist result cystectomy delay systemic treatment author report hypothesize delay cystectomy delivery nac associate adverse survival outcome method eligible cohort patient mibc receive nac undergo radical cystectomy author institution genitourinary team strive schedule patient surgery time initial evaluation \\ufeff1 chemotherapy cycle clinicopathologic characteristic include time cystectomy chemotherapy delivery vital status reason excessive surgical delay analyze retrospectively use institutional database cox proportional regression model use test association time cystectomy delivery survival result median follow patient year median time cystectomy week week \\ufeff1 last day nac respectively multivariate analysis time cystectomy delivery termination nac not significantly alter risk survival common reason cystectomy delivery beyond week patient procedural schedule conclusion cystectomy delivery within week nac not compromise patient survival thus provide reasonable window patient recovery surgical intervention use grade recurrent tumor guide therapy bacillus calmette guerin low grade recurrence not benign background tumor recur bacillus calmette guerin bcg therapy consider high risk patient often recommend undergo radical cystectomy rc however nuance associate grade tumor recurrence bcg treatment not good understand objective characterize pattern bladder cancer progression cancer specific survival css patient recurrence dichotomized low grade lg versus high grade hg intravesical bcg treatment assess safety continue bladder spare therapy patient design set participant perform institutional review board approve review bladder cancer database overall non muscle invasive bladder cancer nmibc patient find nmibc recurrence bcg therapy recurrence lg hg baseline clinicopathologic characteristic include age gender primary tumor grade stage size multiplicity concurrent carcinoma situ also evaluate primary endpoint progression free survival pf progression define development muscle invasive bladder cancer mibc distant metastasis addition recurrence free survival rfs hg rfs cystectomy free survival cfs css also compare multivariable analysis perform use cox regression model test two side p consider statistically significant intervention intravesical therapy versus salvage rc result limitation overall estimate yr pf confidence interval ci dichotomized grade recurrent tumor pf great patient lg recurrence ci hg recurrence ci p furthermore patient whose initial recurrence bcg therapy lg improve subsequent rfs median vs mo p hg rfs median vs mo p cfs estimate yr cfs vs p compare hg initial recurrence univariate multivariate analysis grade tumor recurrence bcg independent predictor time progression mibc distant metastasis hazard ratio ci p conclusion grade tumor recurrence intravesical bcg important predictor bladder cancer progression mibc metastatic urothelial carcinoma patient lg recurrence little half progression event compare hg recurrence estimate yr progression rate still hence patient carefully counsel bladder spare therapy also implication clinical trial design patient summary bladder cancer recur bacillus calmette guerin treatment many factor determine clinical outcome although low grade recurrent tumor confer little aggressive course disease progression still occur hence continue vigilance important impact malpractice cap use outcome radical cystectomy bladder cancer datum surveillance epidemiology end result program purpose impact malpractice award insurance premium health care delivery generate much concern knowledge no datum exist regard impact cap upper limit award noneconomic damage also term pain suffer health care delivery pattern outcome investigate effect cap use outcome follow aggressive surgical treatment radical cystectomy patient bladder cancer material method perform retrospective cohort study patient bladder cancer undergo radical cystectomy identify surveillance epidemiology end result seer program database cystectomy rate post cystectomy disease specific survival compare seer region without cap control variable result significantly great proportion patient stage iii iv bladder cancer undergo cystectomy seer region cap cap status significant predictor survival bladder cancer conclusion radical cystectomy bladder cancer perform often even advance bladder cancer geographic region cap positive impact survival institution cap may beneficial effect pattern health care beyond merely decrease insurance premium cost rapid detection urinary long non code rna urothelial carcinoma associate one use pcr free nanoparticle base assay develope specific hybridization assay direct detection long non code rna urothelial carcinoma associate lncrna uca total rna extract urine pellet sample bladder carcinoma patient control compare develope nanoassay quantitative real time polymerase chain reaction biological pathway bladder carcinogenesis transformation normal urothelium histologically different neoplastic state good characterize current clinical management superficial invasive bladder cancer benefit recent scientific discovery ability define novel treatment strategy include surgical chemotherapeutic gene therapy rely understand basic mechanism underlie human bladder carcinogenesis many vitro culture system vivo animal model develope recent year use define key molecular event associate development bladder cancer biological pathway normal urothelium may progress superficial invasive disease discuss framework recent advance field effect exogenous wild type p gene transfection expression cell cycle relate protein bladder cancer cell line cell cycle regulatory protein important indicator determine progression cell cycle recent experimental evidence show active cdk cyclin complex help cell pass r point point no return cell become commit new round replication widely know p ink arrest cell g phase expression exogenous p ink gene affect activity cdk cyclin remain unclear study use exogenous wild type p gene antibody p cdk cyclin rb protein primer gene examine expression exogenous neoadjuvant chemotherapy bladder cancer purpose review literature tumor marker use prognosis transitional bladder cancer exist problem regard grade local stage tumor also discuss method publish literature transitional bladder cancer marker identify use medline search critically analyse result significant interobserver difference grade new grade system also problem local stage low correlation clinic stage pathologic stage major tumor marker study prognosis transitional bladder cancer flow cytometry kariocytometric study oncogene p bcl neu c erbb chromosomic alteration chromosome proliferation marker ki mib cyclin dependent kinase inhibitor cyclin cyclin e p wafl p kipl vascular endothelial growth factor growth factor fibroblastic epidermal hepatocyte platelet derive metalloproteinase cell adhesion molecule other conclusion present no prognostic marker bladder cancer superior conventional grade stage despite imperfection standarization assay method bladder tumor marker need permit conclusive reproducible result become clinic tool controversy result several study make mean putative prognostic marker transitional bladder cancer questionable understand urothelial carcinoma cancer pathway urothelial carcinoma uc common histological subtype bladder cancer present papillary tumor invasive often lethal form study uc molecular biology candidate gene genome wide approach follow argue cancer pathway perspective useful integrate finding approach accord view papillary cancer typically exhibit activation mapk pathway consequence oncogenic mutation fgfr hras increase cyclin expression contrast invasive uc characterize severe disturbance proximate cell cycle regulator e g rb cdkn p ink decrease dependency mitogenic signal addition disturbance permit promote turn exacerbate chromosomal instability enhance loss tp function another vicious cycle defective cell cycle regulation interact dna methylation alteration transition toward invasive uc may require concomitant interact defect cell cycle regulation control genomic stability intriguingly neither canonical wnt beta catenin hedgehog signal appear play major role uc may reflect origin differentiate urothelial cell possess high regenerative potential rather stem cell population occupation bladder cancer cohort study sweden follow study occupational exposure bladder cancer increase risk observe adjustment smoke physician administrator manager clerical worker sale agent among man assistant nurse among woman physician reason may early diagnosis group sedentary type work may role bladder cancer aetiology costimulatory molecule b h immune escape bladder cancer clinical significance b h recently describe member b family costimulatory molecule think involve tumor immune escape induce cell apoptosis order investigate relationship b h immune escape bladder cancer b h expression case bladder cancer detect use immunohistochemical method survival curve construct use kaplan meier method independent prognostic factor evaluate use cox regression model result show positive rate b h immunostaining normal bladder tissue bladder cancer respectively expression b h strongly associate pathological grade clinical stage recurrence p survival rate significantly low patient b h positive group b h negative group multi variable analysis reveal b h can regard independent factor evaluate prognosis bladder cancer conclude expression b h strongly associate neoplastic progression prognosis bladder cancer manipulation b h may become beneficial target immunotherapy human bladder cancer loss gata bladder cancer promote cell migration invasion transcription factor gata know breast tumor suppressor good urothelial marker loss often see high grade invasive bladder cancer nonetheless gata function bladder cancer cell remain largely unknown study assess effect gata silence via rna interference cell migration invasion proliferation bladder cancer gata expression downregulated four bladder cancer line examine compare non neoplastic urothelial line svhuc knockdown gata bladder cancer line tcc sup j result promotion cell migration invasion good increase expression relate molecule vascular endothelial growth factor matrix metalloproteinase mmp mmp activity mmp mmp gata loss also associate increase level mesenchymal marker n cadherin decrease level epithelial marker catenin consistent finding enforce expression gata umuc inhibit cell migration invasion however gata show marginal effect bladder cancer cell viability expression cell cycle apoptosis relate molecule additionally contrast bladder cancer line no significant effect gata silence cell migration see svhuc finding suggest gata play important role prevention bladder cancer progression metastasis inhibit cell migration invasion good epithelial mesenchymal transition potential urinary biomarker early bladder cancer diagnosis carcinoma urinary bladder rank among top ten common cancer worldwide approximately disease superficial limit mucosa lamina propria time presentation however majority tumor recur progress muscle invasive disease cystoscopic surveillance urinary bladder remain standard care identify recurrence follow not invasive procedure sensitivity cystoscopy low tumor miss urinary cytology recognize limitation use adjunct procedure pend discovery alternate urinary biomarker past decade tremendous advancement produce urinary biomarker urinary bladder cancer research reflect advancement genomics proteomics ideal biomarker able replace cystoscopic examination cost effective unfortunately identify protein molecular biomarker fail test article critically appraise status urinary biomarker urinary bladder cancer addition highlight difficulty research area molecular biology target therapy urothelial carcinoma metastatic urothelial cancer uc associate poor prognosis \\ufeff1 line set platinum base chemotherapy standard care resistance rapidly occur no validate treatment prove increase survival platinum failure urgent unmet medical need develop new efficacious cytotoxic agent well understand molecular signal pathway regulate uc lead development new innovative therapeutic strategy despite many recent drug show modest activity single agent combine standard chemotherapy not seem enhance efficacy ongoing research produce however generation new drug show promise result clinical trial paper aim review important mechanism bladder cancer tumorigenesis describe new therapeutic option currently undergo evaluation clinical trial improve radiotherapy bladder cancer opportunity integrate new technology urinary bladder cancer know common cancer diagnose across world result significant mortality morbidity rate among patient retinoblastoma rb protein main tumor suppressor control cellular response potentially oncogenic stimulation rb phosphorylation can disrupt e f complex formation result diverse transcription factor dysfunction study investigate rb involve control urinary bladder cancer progression result indicate rb expression reduce mouse urinary bladder tumor suppression lead urinary bladder cancer progression vivo vitro rb mutation directly result tumor size low survival rate vivo rb knockdown vitro promote bladder tumor cell proliferation migration invasion interestingly rb knockout knockdown result autophagy apoptosis inhibition via suppress p caspase signal pathway enhance bladder cancer development vitro vivo finding reveal rb deficiency accelerate urinary bladder cancer progression expose important role rb suppress urinary bladder cancer treatment future external validation extranodal extension lymph node density predictor survival node positive bladder cancer radical cystectomy background prognostic factor pathologic node positive patient radical cystectomy debate extranodal extension ene lymph node density lnd strong predictor survival aim study assess factor predictive survival evaluate prognostic significance tumor node metastasis stage system tnm nodal classification retrospective cohort node positive bladder cancer radical cystectomy method retrospectively review datum patient node positive bladder cancer radical cystectomy node pathological examination perform two experience uropathologists cox regression analysis perform identify factor predictive progression result median numb remove lymph node range median numb positive lymph node range overall progression free cancer specific survival multivariate analysis ene lnd cutoff adjuvant chemotherapy independent predictor progression free survival p neither tnm nodal classification associate recurrence conclusion ene lnd strong predictor clinical outcome patient node positive bladder cancer treat cystectomy actual tnm classification can probably improve use criterium allow well prognostic classification node positive bladder cancer radical cystectomy biomarker risk assessment bladder cancer detection cohort expose benzidine objective aim elucidate risk factor intravesical recurrence utility lymphadenectomy follow cystectomy non urothelial bladder cancer systematic review introduction non urothelial bladder cancer patient represent rare challenge group advance bladder cancer date largely drive study investigate common urothelial bladder tumor new evidence emerge support lymphadenectomy standard surgical management muscle invasive bladder cancer aim explore utility lymphadenectomy non urothelial bladder cancer evidence acquisition systematic review available preoperative irradiation radical cystectomy stage squamous cell carcinoma bladder treat patient muscle invasive pure squamous cell carcinoma bladder preoperative radiation cystectomy operation tumor patient downstaged stage stage stage b patient no residual tumor pt actuarial year survival rate patient disease recur pelvis patient none whose tumor downstaged die cancer median survival patient pelvic recurrence month without recurrence month p no patient whose tumor downstaged recurrence die bladder cancer conclude irradiation cystectomy patient squamous cell bladder cancer may protect pelvic recurrence predominant cause death effective adjuvant chemotherapy not available treat squamous cell carcinoma transitional cell carcinoma recommend irradiation cystectomy locally advance squamous cell carcinoma bladder bladder cancer produce granulocyte colony stimulate factor g csf case report case bladder cancer produce granulocyte colony stimulate factor g csf report year old male admit hospital gross hematuria leukocytosis diagnose advance bladder cancer white blood cell wbc count serum granulocyte colony stimulate factor g csf level elevate peak wbc microliter peak g csf pg ml immediately normalize cystectomy histopathological diagnosis transitional cell carcinoma grade pt pn immunohistochemical examination positive g csf g csf receptor no recurrence cancer month since operation without additional therapy rationale en bloc pelvic lymph node dissection bladder cancer patient nodal metastasis long term result august june consecutive patient undergo curative pelvic lymphadenectomy en bloc radical cystectomy bladder cancer patient pathologically prove nodal metastasis incidence positive node increase increase pathological stage primary tumor stage pis stage p stage p stage p stage p b stage p median followup patient still alive year range recurrent bladder cancer document patient median interval progression year pelvic recurrence \\ufeff1 site progression uncommon occur patient actuarial year survival rate respectively increase risk progression death associate advance pathological tumor stage stage p b great p p respectively positive node p p respectively no significant difference survival interval progression among patient receive preoperative irradiation adjuvant chemotherapy compare treat surgery alone retrospective analysis substantiate philosophy single stage pelvic lymphadenectomy en bloc radical cystectomy provide long term progression free survival particularly patient localize primary tumor minimal metastatic nodal disease application new technology bladder cancer diagnosis treatment recent advance image technology may offer ability augment bladder cancer diagnosis stage treatment fluorescence cystoscopy show numerous clinical study improve detection papillary flat bladder lesion conventional cystoscopy photosensitizing agent like aminolevulinic acid ala derivative hexaminolevulinate hal undergo extensive investigation prospective clinical trial demonstrate improve diagnostic ability enhance tumor resection reduce tumor recurrence optical coherence tomography emerge technology show promise reveal subsurface information bladder lesion real time potentially lead accurate stage narrow band image may augment standard endoscopic tool provide increase contrast normal abnormal tissue virtual cystoscopy may allow non invasive tumor diagnosis treatment plan surveillance aim provide overview strength weakness image modality examine potential impact diagnosis management bladder cancer androgen receptor signal regulate cell growth vulnerability doxorubicin bladder cancer purpose several report androgen receptor bladder cancer case androgen receptor expression function androgen androgen receptor signal bladder cancer remain unclear investigate androgen receptor expression role androgen androgen receptor signal bladder cancer material method evaluate ar mrna expression bladder cancer tissue quantitative real time polymerase chain reaction role androgen receptor cell growth drug sensitivity also evaluate vitro vivo several bladder cancer cell line result ar mrna expression inversely correlate bladder cancer grade stage spread several bladder cancer cell line umuc mbt markedly express androgen receptor transcript protein cell line androgen androgen receptor signal blockade use androgen deprivation blockade knockdown antiandrogen agent decrease cell growth colony formation cell viability androgen receptor expression implicate doxorubicin resistance inversely androgen receptor deprivation knockdown make umuc cell sensitive doxorubicin finally castration slightly suppress umuc tumor growth vivo although not attain statistical significance conclusion ar transcript expression inversely correlate bladder cancer clinicopathological characteristic androgen androgen receptor signal important role growth vulnerability doxorubicin bladder cancer cell express androgen receptor androgen androgen receptor signal may possible prophylactic therapeutic target bladder cancer show androgen receptor expression segmental resection bladder cancer urine metabolomics use identify biomarker clinical disease however inter individual variation effect factor need evaluate study explore urine metabolome cohort health adult patient benign bladder lesion patient bladder cancer bca use liquid chromatography couple high resolution mass spectrometry inter individual analysis healthy control bca patient show urine metabolome relatively stable analysis indicate sex age affect inter individual variation urine metabolome metabolic pathway tryptophan metabolism citrate cycle pantothenate coa biosynthesis find relate sex age eliminate age sex interference additional bca urine metabolomic biomarker explore use age sex match urine sample test group health adult vs patient bca metabolic profile urine can significantly differentiate case cancer control high grade low grade bca metabolite panel consist trans dodecenoylcarnitine serinyl valine feruloyl hydroxyputrescine hydroxynonanoyl carnitine discover good predictive ability bca area curve auc cross validation auc panel indolylacryloylglycine n galacturonyl l lysine aspartyl glutamate use establish robust model high low grade bca distinction auc cross validation auc external sample control vs bca validation verify acceptable accuracy model bca detection study show urinary metabolomics useful strategy differential analysis biomarker discovery result therapy different group risk superficial bladder cancer approximately tumor occur low urinary tract morbidity lethality constantly rise tumor register europe usa transitional cell carcinoma primary bladder cancer morbidity russian male rise share patient superficial bladder cancer sbc go period accord national bladder cancer group rise incidence relapse sbc associate urothelial dysplasia positive test urinary sediment therapy occurrence four tumor large cm prevention muscular invasion vital management sbc sometimes aggressive modality early cystectomy radiotherapy recommend case high risk pathology conversely certain palliative measure short transurethral resection bladder adjuvant intravesical therapy regard sufficient similar treatment outcome radical cystectomy radical radiotherapy invasive bladder cancer treat unite kingdom specialist treatment center purpose conduct retrospective analysis within large university teach hospital compare outcome patient receive either radical surgery radiotherapy curative treatment bladder cancer patient method march december patient treat radically muscle invasive bladder cancer datum collect patient note statistical analysis perform use kaplan meier method cox proportional hazard regression analysis compare radiotherapy surgical outcome datum result no difference overall cause specific distant recurrence free survival year two group despite radiotherapy group old median age year vs year local bladder recurrence radiotherapy group solitary no significant difference distant recurrence free survival recent cohort median age radiotherapy patient not cystectomy patient high cohort year vs year radiotherapy year vs year surgery conclusion although patient undergo radical cystectomy significantly young radiotherapy patient treatment modality not influence survival bladder cancer patient increasingly elderly group radical radiotherapy viable treatment option patient advantage organ preservation comparison aminolevulinic acid hexylester aminolevulinate induce protoporphyrin ix distribution human bladder cancer purpose successful photodynamic therapy epithelial cancer require specific photosensitization malignant tissue evaluate intensity localization protoporphyrin ix ppix superficial transitional cell carcinoma nonmalignant cell human bladder follow topical administration precursor either aminolevulinic acid ala hexylester aminolevulinate hal material method solution ala hal instill bladder patient present recurrent transitional cell carcinoma distribution ppix bladder wall study freeze biopsy use fluorescence microscopy correlate pathological finding result topical bladder instillation mmol ala administer hour mmol hal administer hour give similar result regard intensity tissue distribution ppix fluorescence whereas mmol hal administer hour follow hour rest time hour concept induce ppix fluorescence twice high fluorescence remain limit cancer cell trace ppix fluorescence observe suburothelial connective tissue chorion none bladder smooth muscle regardless experiment condition conclusion hal excellent precursor ppix synthesis bladder cancer hour topical administration condition yield high ppix fluorescence intensity fluorescence contrast normal malignant urothelial cell approach allow us optimize ppix tissue distribution photodynamic therapy superficial bladder cancer toward validation aneusomy detection fluorescence situ hybridization bladder cancer comparative analysis cytology cytogenetics clinical feature predict recurrence define clinical test limitation fluorescence situ hybridization fish regard potential new tool clinical management bladder cancer work detect cytogenetic aberration noncycling exfoliate cell bladder irrigation however clinical validation step must address define true predictive potential clinical set toward validation fish use bladder washings prior incorporation large prospective clinical trial pilot study design determine clinical potential define test limitation optimize panel probe specific bladder cancer detection outline protocol datum collection parameter correlation standard cytogenetics clinicopathological feature bladder cancer investigate exfoliate cell obtain benign bladder washings serve normal control result pilot study suggest follow fish cytology complementary test procedure however fish datum provide valuable ploidy specific genotypic information recurrent tumor suspicious case b chromosomal aberration define fish associate tumor grade stage e simple numerical aberration associate low grade tumor high grade invasive tumor exhibit multiple nonrandom chromosomal aberration vast intratumor heterogeneity c somatic pair homologous centromeric association give false positive result appear link prior therapy dual hybridization reference gene specific probe must use control somatic pair e focal deep muscle invasive lesion no surface exposure may yield false negative result datum suggest fish analysis use cell isolate bladder washings powerful technique hold promise early cancer detection monitor treatment outcome predict recurrence disease cryosurgical treatment bladder cancer continuous intraarterial perfusion cytostatics patient arterial embolization profuse hematuria patient carry study group patient locally advance urinary bladder cancer endovascular therapy provide contribution treatment pathology situation may use cope life threaten complication prepare patient radical surgery inoperable case procedure may serve palliation combination chemotherapy ifosfamide fluorouracil etoposide cisplatin perioperative treatment lymph node positive bladder carcinoma patient treat radical cystectomy objective evaluate efficacy toxicity perioperative combination chemotherapy ifosfamide fluorouracil etoposide cisplatin ifep bladder cancer patient regional lymph node metastasis treat radical cystectomy method review medical record consecutive patient undergo radical cystectomy invasive urothelial carcinoma bladder patient regional lymph node metastasis regard render surgically disease free pt n cm treat perioperative ifep chemotherapy subject present study result median follow patient month range grade bone marrow toxicity see four patient respectively neither chemotherapy relate death febrile neutropenia occur year overall cancer specific survival rate respectively overall survival rate patient pt disease significantly wrong patient pt four n patient survive year free disease conclusion perioperative ifep therapy appear effective treatment lymph node positive bladder cancer patient undergo radical cystectomy study may warrant curative treatment muscle invasive bladder cancer elderly patient systematic review context incidence muscle invasive bladder cancer mibc increase age increase life expectancy numb elderly mibc patient expect increase exist guideline management mibc not preclude curative treatment elderly patient however necessary assess risk benefit treatment avoid overtreatment result decrease health relate quality life without prolong survival objective report overall survival os cancer specific survival css morbidity curative treatment elderly patient define age yr nonmetastatic mibc compare outcome young mibc patient evidence acquisition systematic review perform use medline pubmed embase database article include address one three research question article include patient clear age stratification include evidence synthesis forty two article retrieve review no article directly address use geriatric assessment os css worsen significantly age radical cystectomy radiotherapy regimen pom significantly increase age morbidity seem comparable young old patient conclusion although proportion elderly patient mibc benefit curative treatment observe wrong os css pom age impact age late morbidity little clear prospective study evaluate geriatric assessment critically need optimize mibc management elderly patient summary perform systematic review evaluate outcome complication rate elderly patient muscle invasive bladder cancer observe overall survival cancer specific survival significantly decrease perioperative mortality significantly increase age impact age late morbidity little clear need geriatric assessment select patient benefit curative treatment rb deficiency accelerate progression carcinoma urinary bladder vivo vitro inhibit autophagy apoptosis urinary bladder cancer know common cancer diagnose across world result significant mortality morbidity rate among patient retinoblastoma rb protein main tumor suppressor control cellular response potentially oncogenic stimulation rb phosphorylation can disrupt e f complex formation result diverse transcription factor dysfunction study investigate rb involve control urinary bladder cancer progression result indicate rb expression reduce mouse urinary bladder tumor suppression lead urinary bladder cancer progression vivo vitro rb mutation directly result tumor size low survival rate vivo rb knockdown vitro promote bladder tumor cell proliferation migration invasion interestingly rb knockout knockdown result autophagy apoptosis inhibition via suppress p caspase signal pathway enhance bladder cancer development vitro vivo finding reveal rb deficiency accelerate urinary bladder cancer progression expose important role rb suppress urinary bladder cancer treatment future variant histology bladder cancer current understand pathologic subtype purpose review urothelial carcinoma uc characterize variant morphology however diagnosis variant challenge part due evolve diagnostic criterium review discuss diagnostic criterium molecular feature prognostic implication uc variant evolve subtype uc also briefly discuss recent finding classification tumor urinary system refine morphologic criterium diagnosis uc variant many follow aggressive clinical course conclusive datum effect survival lack molecular alteration characteristic variant may amenable target therapy accurate identification variant histology uc important implication patient management despite identification distinct molecular alteration variant current molecular classifier invasive uc not significantly analyze subtype open area future research inverse association selenium bladder cancer due confound smoke selenium link reduce risk bladder cancer study smoke good establish risk factor bladder cancer associate low selenium level body investigate selenium bladder cancer association subject maine new hampshire vermont new england bladder cancer case control study interview participant provide information variety factor include comprehensive smoke history submit toenail sample measure selenium level estimate odd ratio confidence interval among case control use logistic regression control smoke see no evidence association selenium level bladder cancer 4 quartile vs \\ufeff1 quartile odd ratio confidence interval ci result restrict regular smoker appear inverse association ci however pack year smoke consider association attenuate ci indicate potential confound smoke despite report inverse association selenium bladder cancer overall result combine depth evaluation study suggest confound smoke intensity duration can explain association study highlight need carefully evaluate confound association smoke selenium bladder cancer association genetic variation psca bladder cancer susceptibility chinese population recently two genome wide association study identify significant association prostate stem cell antigen psca r c polymorphism risk diffuse type gastric cancer asians bladder cancer caucasians respectively psca report highly express bladder cancer consider useful marker diagnosis progression bladder cancer determine whether r polymorphism associate risk bladder cancer chinese population conduct hospital base case control study case control sixteen normal bladder tissue adjacent tumor use evaluate functionality polymorphism genotype r polymorphism assess association risk bladder cancer messenger rna mrna expression normal bladder tissue significant increase risk bladder cancer find r ct tt genotype adjust odd ratio confidence interval compare cc genotype furthermore analysis psca mrna expression identify clear correlation r expression level psca mrna result indicate r polymorphism psca gene may play role bladder cancer carcinogenesis can serve biomarker genetic susceptibility bladder cancer chinese population strategy molecular expression profile bladder cancer carcinoma urinary bladder involve alteration multiple cellular pathway dictate pathology disease clinical outcome patient include alteration regulation cell cycle apoptotic mechanism signal transduction tumor angiogenesis interrogation alteration multiple molecule associate pathway lead development biomarker panel capable predict individual patient outcome response specific treatment respect gene expression profile two broad approach may identify global approach pathway specific approach global approach involve high throughput effort profile entire genome pathway specific approach quantify select gene across several pathway former high potential discovery novel signature latter important generate reproducible concise panel potential rapid clinical implementation combination approach need identification validation robust marker panel potential clinical importance bladder cancer usefulness inchworm sign dwi predict pt bladder cancer progression objective evaluate significance presence absence inchworm sign dwi recurrence progression bladder cancer material method retrospectively analyze patient pt urothelial carcinoma undergo dwi prior transurethral resection dwi dominant tumor scrutinize inchworm sign b mm association presence inchworm sign progression recurrence analyze progression define recurrence stage high n result inchworm sign see case absent case among confirm tumor recurrence remain confirm recurrence median time post turb month time recurrence tumor progress one inchworm sign positive seven inchworm sign negative case progression rate inchworm sign negative case significantly high inchworm sign positive case hazard ratio p whereas no significant difference recurrence rate two group absence inchworm sign histological grade independent risk factor progression p respectively conclusion absence inchworm sign dwi significant prognostic factor progression bladder cancer morphological evaluation dwi signal may therefore useful adjunct preoperative assessment biological aggressiveness key point inchworm sign simple diagnostic criterion characterize shape tumor signal dwi potentially serve image biomarker predict clinical aggressiveness absence inchworm sign dwi significant indicator progression bladder cancer bladder cancer diagnosis management bladder cancer nice bladder cancer diagnosis management bladder cancer context incidence bladder cancer three four time great man woman however woman diagnose advance disease presentation little favorable outcome treatment objective review literature potential biologic mechanism underlie differential gender risk bladder cancer evidence regard gender disparity bladder cancer presentation management outcome evidence acquisition literature search english language publication include analysis association gender bladder cancer perform use pubmed ninety seven article select analysis consensus author evidence synthesis show gender difference bladder cancer incidence independent difference exposure risk include smoke status potential molecular mechanism include disparate metabolism carcinogen hepatic enzyme man woman result differential exposure urothelium carcinogen addition activity sex steroid hormone pathway may play role bladder cancer development demonstration androgen estrogen biologic effect bladder cancer vitro vivo importantly gender difference exist timeliness completeness hematuria evaluation woman experience significantly great delay urologic referral undergo guideline concordant image little frequently correspondingly woman advance tumor time bladder cancer diagnosis interestingly high cancer specific mortality note among woman even adjust tumor stage treatment modality conclusion numerous potential biologic epidemiologic factor probably underlie gender difference observe bladder cancer incidence stage diagnosis outcome continue evaluation define clinical application manipulation sex steroid pathway improve standardization hematuria evaluation woman may improve future patient outcome reduce disparity patient summary describe scientific basis clinical evidence explain great incidence bladder cancer man adverse presentation outcome disease woman identify goal improve patient survival reduce gender disparity bladder cancer usefulness urinary nuclear matrix protein nmp marker transitional cell carcinoma bladder objective purpose study evaluate immunoassay urinary nuclear matrix protein nmp novel marker urothelial cancer patient method nmp value determine patient healthy volunteer subject provide single void urine sample analysis time entry study sample assay level nmp result cut value set u ml positive rate urinary nmp bladder cancer whereas post treatment case benign disease compare healthy volunteer cut value provide sensitivity specificity bladder cancer group nmp level relate tumor size shape grade stage conclusion despite many report suggest nmp promise urinary marker monitor transitional cell carcinoma study not support usefulness substitute tool urinary cytology control bladder tumor technique extension radical surgery treatment vesical cancer objective bladder cancer commonly malignant tumor urogenital tract next prostate cancer high incidence china curcumin major component curcuma longa multiple biological effect include identification dna hypermethylation sox association bladder cancer progression use cpg microarray cpg island array represent high throughput epigenomic discovery platform identify global disease specific promoter hypermethylation candidate along bladder cancer progression dna obtain pair invasive bladder tumour profile vs respective normal urothelium use differential methylation hybridisation custom make cpg array n clone promoter hypermethylation clone simultaneously show little tumour sox select validation bisulphite genomic sequence methylation specific polymerase chain reaction bladder cancer cell n primary bladder tumour n hypermethylation observe bladder cancer cell associate lack gene expression restore vitro demethylating agent primary bladder tumour sox hypermethylation present case moreover sox hypermethylation significantly associate tumour grade overall survival thus high throughput epigenomic strategy serve identify novel hypermethylated candidate bladder cancer vitro analysis support role methylation silence sox gene association sox hypermethylation tumour progression clinical outcome suggest relevant clinical implication stratify patient affect bladder cancer management node positive bladder cancer neoadjuvant chemotherapy radical cystectomy survey current uk practice introduction lack publish evidence study do explore decision rationale uro oncology consultant regard treatment patient muscle invasive bladder cancer positive lymph node radical cystectomy rc neoadjuvant chemotherapy nac material method electronic survey send uk pelvic cancer center regard choice nac regimen indication reimaging choice indication adjuvant chemotherapy ac patient nodal disease nac rc choice indication chemotherapy regimen disease continue progress patient advance bladder cancer guideline use survey result consultant uro oncologist uk pelvic cancer center respond treat median patient per year nac rc three cycle gemcitabine cisplatin common nac regimen respondent give downstaging cn cn positive patient respectively forty five percent would not give ac nac rc patient positive lymph node patient performance status follow response nac key factor dictate use ac presence disease progression participant would use taxane fifty two percent responder not follow guideline conclusion unite kingdom treatment patient nodal disease nac rc variable little evidence base management patient creation national international guideline may help clinician optimize care patient management bladder cancer nurse view new case bladder cancer diagnose uk year haematuria common present symptom always investigate superficial cancer usually treat transurethral resection intravesical therapy radical cystectomy radiotherapy chemotherapy use treat invasive disease cohort profile swedish national register urinary bladder cancer snrubc bladder cancer datum base sweden bladderbase purpose monitor quality bladder cancer care swedish national register urinary bladder cancer snrubc initiate order study trend incidence effect treatment survival man woman bladder cancer link snrubc national healthcare demographic register construct bladder cancer datum base sweden bladderbase participant snrubc nationwide register detail information bladder cancer case sweden compare swedish cancer register participant snrubc register datum tumour characteristic diagnosis treatment datum capture snrubc hold datum eligible participant follow year diagnosis non muscle invasive bladder cancer datum surgery detail complication participant treat radical cystectomy bladderbase include datum snrubc additional covariate follow datum link national register source comorbidity socioeconomic factor detail information readmission treatment side effect cause death finding date study base datum snrubc show inequality survival treatment indication gender region hospital volume bladderbase include participant register snrubc bladder cancer diagnose january december bladderbase initiator currently collaboration researcher snrubc investigate different aspect bladder cancer survival future plan snrubc bladderbase project open collaboration national international research team collaborator submit proposal study study file upload server remote access analysis information please contact correspond author simplify comorbidity score eastern cooperative oncology group performance score predict survival patient receive organ preserve treatment bladder cancer background aim study investigate three comorbidity scale eastern cooperative oncology group performance score ecog ps survival patient receive local irradiation bladder cancer patient method sixty four patient receive organ preserve radio chemotherapy radiotherapy urinary bladder cancer retrospectively evaluate charlson comorbidity index cci simplify comorbidity score scs age adjust charlson comorbidity index aac ecog ps analyze association survival result patient scs point significantly well survival point p five year survival rate respectively patient micropapillary component urothelial carcinoma detect transurethral resection bladder tumor tur bt tissue case report case urothelial carcinoma uc contain micropapillary carcinoma mpc component urinary bladder year old man report mpc component uc report variant feature poor prognosis rapid progression present case characteristic mpc component micropapillary growth association fine meshwork like stroma observe little fragment cancer tissue uc g obtain transurethral resection bladder tumor tur bt lymphatic invasion also detect uc cancer cell invade prostatic gland replace original epithelial cell unique insideout feature mpc component immunohistochemically obvious stain antibody epithelial membrane antigen ema immunohistochemical study cancer cell uc mpc component positive pancytokeratin ae ae cytokeratins carcinoembryonic antigen cea cam focally positive uc cell mib ki label index high cancer cell uc case uc g invasion muscularis propria layer urinary bladder also prostate mpc mpc component cancer recognize marker poor prognosis even detect little uc within tur bt tissue present case duodenal obstruction induce retroperitoneal progression bladder cancer report two case bladder cancer usually form papillary structure progression along cavity membranous structure surround bladder rectum retroperitoneum without formation discrete mass rare present two patient duodenal obstruction cause retroperitoneal progression bladder cancer compute tomography reveal bladder rectal wall thicken malignant target sign thicken mesorectal fascia abnormal tissue strand increase perirectal fat density cancer progress despite treatment indicate faint abnormal tissue strand increase retroperitoneal fat density along retromesenteric plane pelvis duodenum subsequently patient develope obstruction horizontal portion duodenum still without formation mass lesion two patient highlight challenge associate retroperitoneal invasion bladder cancer absence mass lesion underscore importance consider cancer progression patient bowel obstruction even no obvious mass lesion minor retroperitoneal finding progression along retromesenteric plane may key pathway via progressive bladder cancer result duodenal obstruction without minor mass lesion superficial bladder cancer epidemiology diagnosis management transurethral resection tur widely use manage early stage bladder cancer recent study confirm 2 restage tur associate low risk progression cancer relate death restage tur therefore recommend standard care patient stage bladder cancer genetic variant nampt predict bladder cancer risk prognosis individual southwest chinese han group nicotinamide phosphoribosyltransferase nampt serve useful biomarker tumorigenesis prediction cancer survival present study analyze snps nampt gene impact susceptibility prognosis patient bladder cancer bc r r r select genotype polymerase chain reaction pcr restriction fragment length polymorphism rflp method patient bladder cancer ethnicity match healthy control subject genotype method confirm dna sequence analysis statistically significant increase bladder cancer risk find associate c allele cc genotype r nevertheless decrease bladder cancer risk reveal associate allele genotype r stratify analysis reveal r statistically associate increase bladder cancer risk smoker increase invasiveness bladder cancer heterozygote r may prevent recurrence bladder cancer kaplan meier curve reveal statistically significant association r recurrence free survival total bladder cancer patient non muscle invasive bladder cancer patient statistically significant association r recurrence free survival muscle invasive bladder cancer patient multiple cox regression analysis identify r possible independent prognostic factor recurrence free survival total bladder cancer patient result suggest important role nampt pathogenesis bladder cancer snps nampt gene may novel genetic biomarker prognosis bladder cancer molecular marker bladder cancer purpose review bladder cancer diverse disease whose molecular phenotype elucidate review summarize currently know molecular pathway associate marker bladder cancer recent finding genetic epigenetic aberration closely associate tumor pathogenesis prognosis cell cycle marker extensively study recently apoptotic angiogenic pathway investigate study role multiple concurrent molecular alteration improve prognostic ability marker use tissue microarray high throughput molecular profile accelerate discovery new marker summary molecular biology paramount understand bladder cancer pathogenesis search new marker elucidate cross talk marker different pathway warrant molecular marker potential benefit improve detection prognosis treatment bladder cancer addition understand molecular profile individual patient can usher us new era improve prediction natural history disease provide personalize tailor treatment prospective trial still need however objectively establish true benefit marker prognostic therapeutic arena detect bladder cancer bladder cancer 5 common cancer western society global burden predict increase significantly foreseeable future bladder cancer transitional cell carcinoma urothelial origin urothelial carcinoma ucs presentation non muscle invasive stage ta tumour remainder muscle invasive stage bladder uc highly heterogeneous disease bladder cancer patient present ta tumour recurrence main issue patient present tumour progression main issue progression presentation muscle invasive disease represent critical step patient necessitate aggressive therapy carry significantly wrong survival rate therefore urgently require detail molecular insight pathogenesis muscle invasive bladder cancer disease adequately appropriately treat presentation progression stage ta abrogate risk recurrence follow treatment minimise recently identify bladder cancer stem cell consider mediator resistance current therapy therefore represent strong candidate biological target aim review discuss background basic science cell implication current future therapy dna methylation bladder cancer kohonen self organize map soms unsupervised artificial neural network anns good low density datum visualization easily deal complex nonlinear relationship variable evaluate molecular event characterize high low grade bc pathway tumor patient compare ability statistical cluster som stratify tumor accord risk progression advance disease univariable analysis tumor stage log rank p grade p hpv dna p chromosome loss p polymorphism r cdkn p associate progression multivariable analysis parameter identify tumor grade cox regression p ci presence hpv dna p ci independent predictor progression unsupervised hierarchical cluster group tumor discreet branch not stratify accord progression free survival log rank p genetic variable present som input neuron soms suitable complex datum integration allow easy visualization outcome may stratify bc progression robustly hierarchical cluster palmar keratosis cancer bladder lung case control study prevalence palmar keratosis bladder cancer patient lung cancer patient hospital control palmar keratosis common case especially among cancer bladder age year bladder cancer patient lung cancer patient control one keratosis prevalence increase age keratosis common male no feature can find distinguish keratosis case control prophylactic effect pirarubicin thp postoperative recurrence superficial bladder cancer term intravesical retention time order determine modality prophylactic intravesical instillation pirarubicin thp tetrahydropyranyladriamycin follow transurethral resection tur superficial bladder cancer prospective randomize study perform total patient randomize hour instillation min instillation b control c group prophylactic efficacy side effect analyze group group b mg thp \\ufeff1 dissolve ml distill water adjust ml saline administer intravesically week week start week tur recurrence free rate calculate evaluable patient one year recurrence free rate group group b group c one year recurrence free rate significantly high group group c adverse effect observe patient group group b no significant difference occurrence rate side effect two group take prophylactic efficacy side effect consideration hour instillation seem well min instillation bladder conservation treatment elderly population result prognostic factor muscle invasive bladder cancer objective report long term result bladder conservation strategy elderly patient muscle invasive bladder cancer evaluate different factor affect locoregional control patient survival method review record elderly patient age old treat curative intent radiotherapy without chemotherapy transurethral resection bladder carcinoma bladder twenty seven man woman identify median age range sixteen patient previous history superficial bladder cancer twenty five patient lesion patient lesion patient lesion majority patient unsuitable surgery medical reason whereas other refuse radical cystectomy patient treat radical radiation therapy without chemotherapy result median follow time month patient risk year overall survival stage lesion lesion significant prognostic factor overall survival univariate analysis performance status age ct bladder cancer patient year old man present gross hematuria past medical history indicate cigarette smoker pack year successfully treat carcinoma lung year ago receive chemotherapy radiation surgery mild copd good performance status laboratory study not indicate abnormality term renal function not significant cardiac disease medium build prostate cancer undergo successful radical prostatectomy year ago psa undetectable urinary incontinence wear two pad day undergo appropriate investigation gross hematuria ct scan abdomen pelvis normal exception cm posterior mass bladder no hydronephrosis no enlarge lymph node undergo transurethral resection solitary bladder tumor perform another urologist tumor describe large sessile locate posterior wall approximately cm bimanual examination not reveal mass pathology report state tumor high grade urothelial carcinoma invasion muscularis propria no lymphovascular invasion perform returbt procedure not identify obvious tumor prior resection site evident resect prior tumor site quite extensively depth width pathology reveal focal carcinoma situ ample muscle specimen fat good state free cancer patient receptive treatment approach long term experience chemoradiotherapy combine deep regional hyperthermia organ preservation high risk bladder cancer ta this background aim study evaluate efficacy safety chemoradiotherapy rct combine regional deep hyperthermia rht high risk bladder cancer transurethral resection bladder tumor tur bt material method patient pta ptis pt pt cn cm bladder cancer treat multimodal treatment tur bt patient receive radiotherapy rt bladder regional lymph node rct administer patient rct rht administer patient rt use patient treatment response evaluate week treatment tur bt result complete response cr overall treatment group rt rct rct rht cr significantly improve concurrent rct compare rt odd ratio confidence interval ci p little influence hyperthermia ci p overall survival os rct superior rt hazard ratio hr ci p five year os unadjusted kaplan meier estimate rct versus rt additional rht increase year os hr ci p rct rht compare rct show significantly well bladder preservation rate hr ci p median follow month median numb rht session five conclusion multimodal treatment consist maximal tur bt follow rt concomitant platinum base chemotherapy combine rht patient high grade bladder cancer improve local control bladder preservation rate os offer promise alternative surgical therapy like radical cystectomy implication practice radical cystectomy appropriate lymph node dissection long represent standard care muscle invasive bladder cancer medically fit patient despite many center report excellent environmental factor genetic susceptibility promote urinary bladder cancer cancer urinary bladder 2 common malignancy genitourinary tract currently account newly diagnose tumour western world urinary bladder carcinogenesis seem develop interaction environmental exposure genetic susceptibility smoke specific industrial chemical dietary nitrate arsenic represent important exogenous risk factor chromosomal abnormality silence certain gene abnormal methylation promoter region alteration tumour suppressor gene proto oncogene induce uncontrolled cell proliferation reduce apoptosis molecular mechanism report bladder carcinogenesis article discuss environmental risk factor bladder cancer review genetic epigenetic alteration include aberrant dna methylation deregulation micrornas expression also discuss role p retinoblastoma suppressor gene disease progression finally present recent report use molecular profile predict disease stage grade direct target therapy initial intravenous cis platinum therapy improve management invasive high risk bladder cancer august december patient invasive high risk bladder cancer treat initially mg per cis platinum intravenously dose week interval follow definitive treatment radiotherapy cystectomy high risk disease define basis little follow invasion beyond muscle stage b grade iii histology large tumor ureteral obstruction major symptomatic improvement note patient per cent dose cis platinum per cent objective response cis platinum objective response complete partial remission note patient per cent cis platinum plus definitive treatment month actuarial survival per cent year actuarial survival per cent although patient enter study year ago protocol good tolerate nausea vomit common side effect no death relate treatment ten patient per cent die cancer relevance initial cis platinum therapy management program evaluate multicenter randomize trial value random mucosal biopsy management superficial bladder cancer newly diagnose patient ta g g superficial transitional cell carcinoma bladder undergo four quadrant biopsy normal look bladder mucosa addition endoscopic treatment primary tumour tumour patient biopsy normal little one biopsy reveal dysplasia carcinoma situ g g carcinoma patient present single tumour abnormal biopsy compare present multiple tumour difference group statistically significant p incidence freedom new tumour year patient normal biopsy compare patient abnormal biopsy p patient present multiple tumour single tumour abnormal biopsy incidence freedom new tumour significantly low present single tumour normal mucosal biopsy p study show exercise perform random mucosal biopsy particularly useful patient present single tumour order identify likely develop new tumour long term patient can offer early prophylactic intravesical chemotherapy study not substantiate tumour implantation factor new tumour development superficial bladder cancer bladder tumour enugu nigeria clinicopathological feature tumour urinary bladder report transitional cell squamous cell carcinoma result support strong association schistosomiasis bladder cancer clusterin diagnostic prognostic marker transitional cell carcinoma bladder investigate feasibility profile measure concentration clusterin urine serum individual transitional cell carcinoma tcc bladder compare nontumor control addition analyze correlation expression clusterin specimen tcc various clinicopathologic parameter prognosis bladder cancer blood urine sample use patient tcc bladder patient benign urological disease enzyme link immunosorbent assay elisa perform clusterin serum urine quantitation clusterin mrna carry bladder tumor specimen radical cystectomy transurethral resection normal bladder specimen bph patient use rt pcr method correlation expression clusterin mrna clinicopathologic parameter analyze serum urine clusterin significantly high individual bladder cancer control p sensitivity specificity serum urine clusterin tumor marker tcc bladder find respectively clusterin expression significantly high tcc specimen normal tissue specimen p expression clusterin significantly high patient invasive tcc bladder patient superficial tcc control p overexpression clusterin mrna significantly associate tumor recurrence overall survival p recurrence free survival time patient overexpression clusterin significantly short patient weak expression clusterin month vs month clusterin may consider potential diagnostic prognostic biomarker bladder cancer use urine serum molecular biology technique mouse human urothelial cancer organoids tool bladder cancer research bladder cancer common malignancy relatively poor outcome lack culture model bladder epithelium urothelium hamper development new therapeutics present long term culture system normal mouse urothelium efficient culture system human bladder cancer cell call bladder cancer organoids consist structure epithelial cell recapitulate many aspect urothelium mouse bladder organoids culture efficiently genetically manipulate ease exemplify create genetic knockout tumor suppressor trp stag human bladder cancer organoids derive efficiently resect tumor biopsy culture passaged prolong period use feature human bladder organoids create live biobank consist bladder cancer organoids derive patient result organoids characterize histologically functionally organoid line contain basal luminal bladder cancer subtype base immunohistochemistry gene expression analysis common bladder cancer mutation like tp fgfr find organoids biobank finally perform limit drug test organoids bladder cancer biobank patient recognition datum mine model bcg plus interferon immunotherapy bladder cancer treatment bladder cancer 5 common malignant disease unite state annual incidence around new case death cost provide care patient bladder cancer disease high bladder cancer treatment option immunotherapy chemotherapy radiation therapy transurethral resection cystectomy use vary success rate research datum nationwide bacillus calmette gue rin bcg plus interferon alpha ifn alpha immunotherapy clinical trial consider datum mine algorithm use analyze effectiveness immunotherapy treatment understand prominent parameter interaction extract knowledge use build patient recognition model prediction treatment outcome datum analyze understand impact various parameter treatment outcome list significant parameter cumulative tumor size presence residual disease stage prior bladder cancer current state bladder cancer presence current bladder cancer provide decision make approach outline paper supplement additional knowledge basis lead comprehensive analytic road map bcg ifn alpha immunotherapy treatment provide individualize guideline stage treatment good measure success treatment treatment invasive bladder cancer author transl purpose purpose study determine whether angiogenesis measure microvessel density mvd presentation relate subsequent progression superficial bladder cancer sbc experimental design archive primary bladder tumor patient stain monoclonal antibody cluster determinant label vessel image analysis use count mvd randomly select area case result patient evaluate progress muscle invasive disease strong association find intensity angiogenesis clinical stage pt tumor high mvd pta disease median mvd significantly high presentation patient subsequently develope progressive sbc not progress p pt p grade disease p mvd p find predict subsequent disease progression univariable analysis mvd p pt disease p remain significant predictive factor subsequent disease progression multivariable analysis conclusion mvd sbc presentation significantly high case subsequently progress muscle invasive disease bladder cancer risk worker manufacture chemical rubber industry aim investigate bladder cancer risk worker factory manufacture chemical rubber industry method mortality cancer morbidity experience cohort male production worker chemical factory north wale investigate exposure estimate surrogate develope four chemical mercaptobenzothiazole mbt aniline phenyl beta naphthylamine pbn ortho toluidine two analytic approach use indirect standardization poisson regression result base mortality rate general population statistically significant p excess mortality bladder cancer study subject potentially expose one four chemical investigate observe standardize mortality ratio confidence interval no excess bladder cancer mortality remain worker similar contrast also show bladder cancer incidence study subject suffer bladder cancer malignant benign simultaneous analysis four exposure history variable poisson regression show significant positive trend bladder cancer risk relation cumulative duration employment ortho toluidine department p non significant positive trend relation cumulative duration employment pbn department cumulative exposure mbt conclusion member cohort suffer occupational bladder cancer exposure ortho toluidine appear responsible part excess manufacture pbn exposure mbt may also involve target therapy advance urothelial cancer bladder stand treatment advance urothelial cancer bladder evolve substantially recent year chemotherapy mainstay treatment confer survival advantage despite advance chemotherapy bladder cancer far satisfactory due severe side effect target therapy novel drug direct specific molecular pathway open promise new avenue improve patient outcome systematic review examine clinical datum novel target agent phase ii trial focus bevacizumab aflibercept sunitinib sorafenib gefitinib lapatinib trastuzumab besides present study novel promise target agent include pazopanib cetuximab everolimus although bevacizumab trastuzumab show promise result patient advance bladder cancer target agent not achieve clinical benefit disease see common epithelial cancer ultimately combination target therapy sequential therapy adjuvant neoadjuvant therapy may yield well outcome parameter incurability urinary bladder cancer curative treatment bladder cancer limit superficial tumor ta advance stage b treat palliatively even confine bladder n nevertheless differentiation curable incurable tumor difficult classification patient two different category usually do basis tumor infiltration lymph node involvement retrospective study available datum patient bladder cancer evaluate prognostic reliability order obtain safe basis therapeutic approach principal aim define parameter reliable prognostic significance prevent overtreatment entire course disease sip protein protect cell dna damage induce apoptosis independent prognostic value bladder cancer epithelial mesenchymal transition emt contribute cancer metastasis two zeb family member zeb zeb sip inhibit transcription e cadherin gene induce emt vitro however relevance human cancer insufficiently study perform comparative study sip zeb protein cancer cell line one form human malignancy carcinoma bladder whereas zeb protein express e cadherin negative carcinoma cell line part responsible high motility bladder cancer cell sip hardly ever detectable carcinoma cell culture however sip represent independent factor poor prognosis p series bladder cancer specimen obtain patient treat radiotherapy contrast zeb rarely express tumor tissue e cadherin status not correlate patient survival sip protect cell uv cisplatin induce apoptosis vitro no effect level dna damage anti apoptotic effect sip independent either cell cycle arrest loss cell cell adhesion associate reduce phosphorylation atm atr target uv treat cell prognostic value sip role dna damage response establish link genetic instability metastasis suggest potential importance protein therapeutic target addition conclude nature emt pathway rather deregulation sigma receptor expression level blood bladder healthy bladder cancer cattle expression sigma receptor r assay blood bladder sample healthy cattle blood bladder cattle deltapapillomavirus associate urothelial tumor sample bladder cattle neoplasia significantly high r sample bladder healthy cattle ci p addition significantly high r detect blood cattle bladder cancer blood healthy cattle ci p result provide evidence increase expression sr blood can useful circulate biomarker bladder cancer cattle pgrmc protein level also find increase blood bladder cattle cancer increase expression pgrmc transcript detect quantitative real time pcr sample cattle neoplasia furthermore electron microscopy reveal phagophores numerous autophagosomes ultrastructural hallmark autophagy lymphovascular invasion independent predictor recurrence survival purpose near infrared photoimmunotherapy nir pit localize molecular cancer therapy combine photosensitizer conjugate mab light energy cd innate immune checkpoint widely express bladder cancer cell absent luminal normal urothelium target cd nir pit potential selectively induce cancer cell death minimize damage normal urothelium experimental design cytotoxic effect nir pit anti cd ir investigate human bladder cancer cell line primary human bladder cancer cell derive fresh surgical sample phagocytosis assay perform evaluate macrophage activity nir pit anti cd ir administer murine xenograft tumor model human bladder cancer vivo molecular image nir pit result cytotoxicity cell line primary bladder cancer cell significantly increase light dose dependent manner cd target nir pit phagocytosis cancer cell significantly increase nir pit compare antibody alone p vivo fluorescence intensity anti cd ir tumor reach peak hour postinjection detectable little day single round cd target nir pit treat animal show significantly slow tumor growth compare control p repeat cd target nir pit treatment slow tumor growth p improve survival compare control conclusion cd target nir pit increase direct cancer cell death phagocytosis result inhibit tumor growth improve survival murine xenograft model human bladder cancer immunotherapy bladder cancer immunotherapy treatment solid malignancy base activation immune system tumor cell since intravesical instillation bacillus calmette gu rin bcg use widely treatment non muscle invasive bladder cancer nowadays recommend scientific guideline new target systemic immunotherapy particularly checkpoint inhibitor widely use several different cancer notably onco urology immune checkpoint molecule inhibitor open possibility treatment cancer already phase trial run without bcg localize muscle invasive metastatic bladder cancer improve selection appropriate urinary diversion follow radical cystectomy bladder cancer radical cystectomy represent gold standard treatment invasive bladder cancer follow cystectomy various option urinary diversion may offer patient article represent overview history urinary diversion explain current selection criterium use one experience bladder cancer center worldwide provide update current understand continence mechanism furthermore review current literature quality life patient different form urinary diversion excellent functional result achieve continent form urinary diversion important consider relative absolute contraindication choose form urinary diversion proper patient selection thorough standardize preoperative counsel critical achieve optimal result metabonomic profile bladder cancer early diagnosis life long surveillance clinically important improve bladder cancer new drug cisplatin base chemotherapy mvac cisplatin methotrexate adriamycin vinblastine gc cisplatin gemcitabine standard care patient advance urothelial tumor last twenty year great knowledge molecular biology bladder cancer lead identification promise target egfr vegf vegfr pathway role target therapy monotherapy combination chemotheray maintenance rare occurrence giant metastatic inguinal lymph node carcinoma bladder inguinal lymph node metastasis bladder cancer rare scenario today case inguinal lymph node metastasis bladder cancer report literature report rare giant inguinal lymph node metastasis transitional cell carcinoma bladder patient radical cystoprostatectomy chemotherapy radiotherapy give metastatic tumor remain unchanged ludwig rehn pioneer finding aetiology bladder tumour one hundred six year ago surgeon ludwig rehn frankfurt main hold pioneer lecture berlin possible origin bladder tumour thereby give decisive impulse cancer research general specifically investigation aetiological factor involve development urogenital tract tumour thereafter result intensify scientific discussion address issue although detail evaluation cause finally contribute tumour growth still ongoing work ludwig rehn bladder tumour among aniline worker considerably promote establishment urology specialise field within german clinical medicine therefore milestone history medicine gstm gstt polymorphism associate increase bladder cancer risk evidence update meta analysis background previous study indicate association gstm gstt gene polymorphism bladder cancer susceptibility result inconclusive perform meta analysis investigate association gstm gstt deletion polymorphism bladder cancer susceptibility method search study investigate association gstm gstt polymorphism bladder cancer susceptibility pubmed web knowledge cochrane central search library systematic review meta analysis perform subgroup analysis perform different ethnicity population base smoke status result search identify study gstm null gstt null gstm gstt double null genotype associate increase risk bladder cancer ci p ci p ci p subgroup analysis indicate gstm null genotype associate increase risk bladder cancer caucasians asians gstt null genotype associate increase risk bladder cancer caucasians gstm gstt double null genotype associate increase risk bladder cancer caucasians asians africans stratify analysis population base association indicate increase bladder cancer risk associate gstm null gstm gstt double null genotype hospital base population base study gstm deletion associate increase bladder cancer risk smoker nonsmoker non smoker gstm gstt double null genotype increase bladder cancer risk conclusion meta analysis demonstrate gstm null gstt null gstm gstt double null genotype associate increase bladder cancer risk editorial comment fdg pet ct preoperative lymph node stage invasive bladder cancer purpose bladder cancer expensive cancer treat follow unite state due often extend course treatment couple necessity frequent surveillance examination direct exposure carcinogen implicate bladder cancer development many potentially protective compound concentrate urine bladder cancer logical target chemoprevention material method perform medline search english language literature identify report chemoprevention bladder cancer study outcome evaluate mechanism action identify possible case multiple report compound critical comparison perform result putative chemopreventive agent bladder cancer result different study conflict megadose vitamin certain vitamin analogue pyridoxines associate promise finding vitamin c e selenium study show benefit balance study show no benefit compound soy green tea isothiocyanate suggest study protective other tumor promote conclusion bladder cancer chemopreventive agent study date result regard efficacy vary preclude possibility universal support health care provider specific role megadose multivitamin supplement demonstrate ability prevent bladder cancer recurrence single small study analogue vitamin b c e show beneficial disease process suggest compound may advocate caveat not specific protective role bladder cancer datum randomize prospective trial show benefit bladder cancer eliminate early initial recurrence suggest need long term administration choose agent additional prospective trial long term followup likely involve multiple institution require definitive recommendation make chemoprevention bladder cancer no oral agent recommend knowledge well chemopreventive strategy remain determine diagnosis therapy bladder cancer bladder cancer extremely common unite state extremely costly high cost surveillance patient office base surveillance may safe cost reduce alternative article attempt identify ideal candidate highlight surveillance strategy employ office base set immune complex urine serum patient bladder cancer urine serum patient bladder cancer test presence immune complex immune complex present frequently urine per cent serum per cent urinary immune complex elevate per cent patient no tumor group per cent superficial neoplasm group per cent infiltrate metastatic disease group compare favorably elevate serum immune complex per cent patient respectively incidence urinary immune complex statistically significant compare patient without active tumor p little group patient compare group p little p little respectively unlike serum immune complex urinary immune complex appear correlate presence stage bladder cancer genetically determine sparteine oxidation sulfadimidine acetylation polymorphism patient non occupational urinary bladder cancer result study reveal predominance percentage extensive metabolizers em sparteine among patient non occupational urinary bladder cancer comparison percentage extensive metabolizers healthy person difference not statistically significant however among ultrarapid em oxidators metabolic ratio mr difference mr frequency distribution patient bladder cancer healthy person statistically significant therefore study provide evidence possible relationship em sparteine oxidation phenotype susceptibility non occupational bladder cancer not statistically significant slight prevalence percentage slow acetylators sa among urinary bladder cancer patient comparison percentage sa among healthy person may confirm conclusion slow acetylator phenotype not associate increase risk development non occupational urinary bladder cancer face treatment non urothelial bladder cancer immunotherapy era non urothelial bladder cancer bc variant urothelial carcinoma account bcs give heterogeneity entity not good represent clinical trial treatment remain challenge checkpoint inhibitor therapy show role treatment urothelial bc contrast robust evidence regard use histological type lack aim provide comprehensive update non urothelial variant urothelial bc explore evidence immune checkpoint inhibitor therapy detail analysis literature conduct regard epidemiology aetiology diagnosis prognosis treatment outcome patient immunotherapy era grow body evidence suggest immune checkpoint inhibition may role play non urothelial bc similarly happen urothelial carcinoma concurrent cisplatin radiotherapy patient muscle invasive bladder cancer not candidate radical cystectomy purpose assess result prognostic factor patient bladder cancer treat conservatively concurrent cisplatin radiotherapy material method total patient localize muscle invasive bladder cancer not candidate radical cystectomy undergo concomitant chemotherapy radiation median patient age year patient stage b tumor benefit prior macroscopically complete transurethral resection pelvic irradiation consist gy follow boost bladder total dose gy continuous infusion cisplatin mg daily day deliver week radiation therapy result median followup month project year locoregional control rate patient complete response project overall year survival patient complete responder univariate analysis prognostic factor do local control survival local control statistically well patient good performance status stage disease complete initial transurethral resection without hydronephrosis term overall survival factor significant performance status stage absence hydronephrosis complete response multivariate analysis performance status hydronephrosis stage significant factor local control stage complete response strong determinant survival conclusion concurrent cisplatin radiation therapy potentially curative conservative treatment patient localize muscle invasive bladder cancer not candidate radical surgery particularly intravesical stage tumor extracellular vesicle mediate transfer membranous component highly malignant urinary carcinoma cell line non malignant rt urinary papilloma cell line communication report \\ufeff1 experimental evidence bladder cancer model membranous component label dio dye cholera toxin subunit b transport highly malignant non malignant rt cell extracellular vesicle take account presence stable membranous nanostructure find scan electron microscopy suggest possible uptake mechanism recipient cell fusion highly curve membranous region copenhagen bladder cancer project material consecutive patient tumour bladder three hospital great copenhagen period present result copenhagen bladder cancer project aim project describe manifestation bladder cancer mean numb examination parameter material may regard representative region percent patient man mean age year high patient deeply invasive tumour tumour low degree differentiation haematuria present symptom percent patient percent urinary tract infection sole \\ufeff1 symptom interval \\ufeff1 symptom hospitalisation average month little case deeply invasive tumour tumour low degree differentiation percent bladder tumour evaluate without invasion bladder nusculature percent tumour high degree differentiation grade ii squamous cell carcinoma find three percent adenocarcinoma one percent case benign papilloma correspond grade tumour find one percent case percent transitional cell tumour superficial show high degree differentiation grade ii tumour show invasive growth little percent case grade iii tumour little percent bladder tumour papillomatous percent case percent patient one tumour bladder intravenous urography show pathological condition percent patient initial evaluation response criterium patient superficial bladder cancer report workshop matrix metalloproteinase mmps family proteolytic enzyme degrade extracellular matrix component basement membrane essential role tumor invasion metastasis bladder cancer elevate mmp mmp expression tumor tissue correlate tumor stage grade prognosis report several study moreover high level serum urine mmp timp observe patient bladder cancer especially advance case however true role mmps timps bladder cancer progression not yet clarify discuss role clinical implication mmps bladder cancer value immediate intravesical instillation mitomycin c patient non muscle invasive bladder cancer prospective multicentre randomise study patient background efficacy immediate single chemotherapy instillation transurethral resection bladder tumour turbt patient non muscle invasive bladder cancer nmibc remain topic debate evidence even scarce immediate instillation follow adjuvant instillation objective compare effect mitomycin c mmc instillation within h instillation wk turbt patient nmibc without adjuvant instillation design set participant nmibc patient randomise immediate versus delay mmc instillation turbt patient categorise low risk lor intermediate risk imr high risk hir group total number instillation group respectively outcome measurement statistical analysis primary end point yr recurrence risk imr hir group yr risk lor group secondary outcome time recurrence incidence adverse event analysis perform log rank test cox regression test spss result limitation total patient eligible intention treat basis recurrence risk lor group yr follow p imr group yr follow p hir group yr follow p immediate delay instillation respectively patient recurrence risk confidence interval ci immediate ci delay instillation group p reduction relative recurrence risk hazard ratio ci p incidence adverse event not differ significantly treatment group immediate instillation delay instillation p risk group study differ slightly current guideline limitation study conclusion immediate single instillation turbt reduce recurrence risk nmibc patient independent numb adjuvant installation patient summary single instillation chemotherapy resection non muscle invasive bladder cancer reduce recurrence risk even patient treat adjuvant schedule instillation g urinary bladder carcinoma fact fiction objective record occurrence good differentiate bladder carcinoma report g swedish urinary bladder cancer registry review stage grade carcinoma scrutinize validity datum g tumour report registry period material method primary histopathological diagnosis case good differentiate bladder carcinoma report registry compare datum deliver local urologist also histopathology slide obtain local laboratory examine result fifty five case erroneously report registry tumour urologist even though clearly describe non infiltrate g tumour pathologist result examination pathology slide concordant judgement local pathologist case stage grade g tumour importantly evaluation not reveal single invasive g tumour simply provide urologist information problem possible reduce numb error report five conclusion good differentiate urothelial carcinoma g no propensity infiltrate bladder mucosa investigate specific problem datum collect swedish urinary bladder cancer registry validate bladder cancer diagnosis follow current status possible role extracellular vesicle diagnostic method currently use bladder cancer cystoscopy urine cytology cystoscopy invasive tool low sensitivity carcinoma situ urine cytology non invasive low cost method high specificity low sensitivity low grade urothelial tumor despite search urinary biomarker early non invasive detection bladder cancer no biomarker use present daily clinical practice extracellular vesicle ev recently study promise source biomarker role intercellular communication tumor progression review give overview food drug administration fda approve urine test detect bladder cancer use not widespread clinical practice also include non fda approve urinary biomarker review describe role ev bladder cancer possible role biomarker diagnosis follow bladder cancer patient review recently discover ev derive biomarker diagnosis bladder cancer iap death receptor target therapy bladder cancer gadolinium label diethylenetriaminepentaacetic acid gd dtpa enhance magnetic resonance image mri evaluate effort clarify whether mri can replace prove superior computerize tomography ct transurethral ultrasonography total bladder cancer patient evaluate mri perform superconducting magnet operate tesla image acquire multisections fast spin echo pulse sequence little 2 breath hold serial scan perform immediately gd dtpa venous injection finding different image technique compare histological stagings proper diagnosis make case gd dtpa enhance mri ct transurethral ultrasonography compare histological finding sensitivity specificity differentiate superficial muscle invasive tumor image method respectively gd dtpa enhance mri ct transurethral ultrasonography datum suggest stage bladder cancer gd dtpa enhance mri appear superior accurate stage obtain ct transurethral ultrasonography aspect bladder cancer prognosis patient bladder cancer metastatic regional lymph node dismal minimally alter current treatment modality year survival rate radical cystectomy bladder cancer patient positive regional lymph node per cent per cent patient die bladder cancer stratification patient group vary extent nodal disease show correlation level nodal involvement interval recurrence per cent patient die distant disease alone per cent pelvic recurrence indicate possible therapeutic effect systmatic bilateral pelvic lymphadenectomy implicate extrapelvic disease major determinant patient survival gene expression profile enrichment pathway different stage bladder cancer bladder cancer highly heterogeneous neoplasm examine gene expression profile bladder cancer stage ta use expression microarray analysis bladder tumor differentially express gene find test significance threshold kegg pathway enrichment analysis use study signal pathway gene find gene can use molecular marker predict transition ta among overlap ta stage six gene regulate ta stage regulate stage anxa atp v b ctgf gem il ra lcp gene regulate ta stage regulate stage acpp gnl ripk rapgef zer another gene change relative expression level stage gene include col col fn itga lgals spp vim postn col may involve bladder cancer progression affect extracellular matrix receptor interaction focal adhesion cytokine cytokine receptor interaction neuroactive ligand receptor interaction calcium signal pathway associate bladder cancer progression ta stage clinically relevant reduction risk recurrence superficial bladder cancer use aminolevulinic acid induce fluorescence diagnosis year result prospective randomize study objective several study show aminolevulinic acid ala induce fluorescence cystoscopy improve detection superficial bladder cancer result suggest reduce rate recurrent tumor use ala fluorescence bladder tumor resection perform prospective randomize trial investigate whether long term tumor recurrence residual tumor rate decrease use ala fluorescence diagnosis fd method total patient suspect superficial bladder carcinoma randomize transurethral resection tur use conventional white light wl fd tur repeat evaluate residual tumor rate addition patient follow median wl fd month evaluate recurrence free survival rfs result patient available efficacy analysis residual tumor rate wl arm versus fd arm p rfs rate year wl group fd group respectively reveal statistically significant difference favor fluorescent tur p conclusion ala induce fd significantly superior statistically conventional wl tur respect residual tumor rate rfs advantage decrease bladder tumor recurrence risk maintain high statistical significance little year difference rfs imply fd offer clinically relevant procedure reduce incidence tumor recurrence national practice pattern immediate postoperative instillation chemotherapy nonmuscle invasive bladder cancer purpose assess use intravesical postoperative chemotherapy among unite state urologist patient nonmuscle invasive bladder cancer material method national sample unite state base urologist retrospectively assess practice pattern involve intravesical postoperative chemotherapy transurethral resection patient nonmuscle invasive bladder cancer urologist review medical record last patient nonmuscle invasive bladder cancer complete case report form specific demographic pathological treatment information selection criterium include pathological patient factor histologically confirm diagnosis nonmuscle invasive bladder cancer transitional cell carcinoma completion initial treatment plan ongoing observation candidate recipient intravesical therapy no ongoing initial intravesical induction therapy result overall participation rate among sample eligible patient nonmuscle invasive bladder cancer receive instillation therapy initial treatment patient overall receive intravesical postoperative chemotherapy primary low risk patient often receive intravesical postoperative chemotherapy time patient receive immediate instillation within hour surgery however urologist survey never use intravesical postoperative chemotherapy use intravesical postoperative chemotherapy half time use intravesical postoperative chemotherapy time conclusion wide variation use intravesical postoperative chemotherapy exist among urologist unite state reason great diversity use intravesical postoperative chemotherapy speculative however physician awareness physician bias recurrence risk local pharmacy hospital practice factor likely contribute factor solitary cutaneous metastasis superficial bladder cancer cutaneous metastasis bladder cancer uncommon find present patient superficial bladder cancer whose \\ufeff1 manifestation disseminate disease solitary cutaneous metastasis scrotum urinary cell microrna base prognostic classifier non muscle invasive bladder cancer current prognostic tool non muscle invasive bladder cancer nmibc not enough discriminative capacity predict risk tumour progression study aim identify urinary cell micrornas may useful non invasive predictive biomarker tumour progression nmibc patient end urine sample nmibc patient include study rna extract urinary cell expression micrornas previously describe group analyse quantitative pcr tumour progression predict model develope cox regression analysis validate bootstrap regression analysis identify mir p mir p independent predictor tumour progression risk score derive model contain two micrornas able discriminate two group highly significant different probability tumour progression hr p maintain patient stratify accord tumour risk algorithm also able identify two group different cancer specific survival hr p although datum need externally validate mirna analysis urine appear valuable prognostic tool nmibc patient nomograms provide improve accuracy predict survival radical cystectomy aim develop multivariate nomograms determine probability cause bladder cancer specific survival radical cystectomy compare predictive accuracy american joint committee cancer ajcc stage method use cox proportional hazard regression analysis model variable consecutive patient treat radical cystectomy bilateral pelvic lymphadenectomy bladder transitional cell carcinoma variable include age patient gender pathologic stage pt pathologic grade carcinoma situ lymphovascular invasion lvi lymph node status pn neoadjuvant chemotherapy nach adjuvant chemotherapy ach adjuvant external beam radiotherapy axrt two hundred bootstrap resample use reduce overfit bias internal validation result mean follow month patient die patient die bladder cancer actuarial cause survival estimate confidence interval ci ci year cystectomy respectively actuarial cancer specific survival estimate year respectively accuracy nomogram prediction cause survival include patient age pt pn lvi nach ach axrt significantly superior p ajcc stage base risk group similarly accuracy nomogram prediction cancer specific survival include pt pn lvi nach axrt significantly superior p ajcc stage base risk group conclusion multivariate nomograms provide accurate relevant individualize prediction survival cystectomy compare conventional prediction model thereby allow improve patient counsel treatment selection quality life overall survival high risk patient radical cystectomy simple urinary derivation objective evaluate quality life qol overall survival radical cystectomy cutaneous ureterostomies locally advance bladder cancer elderly patient high surgical risk method fifty eight patient old year mean age locally advance bladder cancer group undergo radical cystectomy ureterocutaneous diversion patient complete eortc qlqc six month surgery assess functional clinical qol outcome evaluation carry control group group b patient mean age year refuse cystectomy questionnaire also administer patient group survive little month year result patient present asa score mean hospital stay day group day group b no intraoperative complication occur group postoperative overall survival evaluate within month group versus group b p conclusion radical cystectomy cutaneous ureterostomy represent valid alternative elderly patient invasive bladder cancer high operative risk comparison two group show statistically significant difference almost qol relate parameter short medium term overall survival primary high grade non muscle invasive bladder cancer high nf b expression tumor specimen distinguish patient risk disease progression investigate potential prognostic role nf b expression primary primary care update kidney bladder cancer urologic perspective past decade witness many substantive change approach diagnosis treatment kidney bladder cancer part base change understand carcinogenesis pathogenesis appreciation new concept classification incorporation new technology emerge article review advance update change make understand approach malignancy perspective urologic assessment management context primary care issue salvage cystectomy case combine abdominoperineal approach salvage cystectomy fail radical radiotherapy infiltrate bladder cancer major procedure rectal laceration lead life threaten complication advantage combine abdominoperineal approach emphasize series patient inhibition human bladder cancer growth calcium carbonate caip nanocomposite particle deliver aib sirna previously report inorganic amorphous calcium carbonate acc hybrid nanospheres functionalized ca ii ip compound caip promise gene vector vitro nonviral gene carrier acc caip nanocomposite particle npacc caip evaluate efficient vitro vivo delivery small interfere rna sirna target human amplify breast cancer aib nanoparticle capable form acc caip nanoparticle sirna complex transfer sirna target cell high transfection efficiency meanwhile acc caip nanoparticle sirna complex no obvious cytotoxicity human bladder cancer cell furthermore npacc caip effectively protect encapsulate sirna degradation aib knockdown mediate acc caip sirna complex transfection result cell proliferation inhibition apoptosis induction cell cycle arrest vitro npacc caip exhibit good tissue penetrability localize sirna deliver intratumoral injection npacc caip siaib can attenuate tumor growth downregulation pi k akt signal pathway vivo conclude acc caip nanoparticle promise system effective delivery sirna cancer gene therapy role wnt signal urothelial cell carcinoma urothelial cell carcinoma ucc bladder one common malignancy cause considerable morbidity mortality worldwide unique among epithelial carcinoma two distinct pathway tumourigenesis appear exist low grade recur papillary tumour usually contain oncogenic mutation fgfr hras whereas high grade muscle invasive tumour metastatic potential generally defect pathway control tumour suppressor p retinoblastoma last two decade numb transgenic mouse model ucc contain deletion mutation key tumour suppressor gene oncogene help us understand mechanism behind tumour development summary present work investigate role wnt signal cascade ucc enhance recovery protocol radical cystectomy bladder cancer daneshmand h ahmadi k schuckman p mitra j cai g miranda h djaladat j urol background neoadjuvant chemotherapy radical cystectomy muscle invasive bladder cancer commonly use treatment modality however term chemotherapeutic regimen numb cycle neoadjuvant chemotherapy yet no international consensus various study indicate efficacy several platinum base combination chemotherapeutic regimen determine efficacy two cycle neoadjuvant chemotherapy methotrexate vinblastine adriamycin cisplatin follow radical cystectomy patient method study population include patient clinical stage n bladder cancer undergo radical cystectomy clinical course compare patient treat two cycle vac neoadjuvant chemotherapy treat cystectomy alone result incidence pt group treat neoadjuvant chemotherapy probability disease free cause specific survival significantly high patient treat without neoadjuvant chemotherapy univariate cox proportional hazard regression analysis patient treat neoadjuvant chemotherapy pathological stage pathological finding venous involvement significant prognostic factor conclusion result retrospective study demonstrate clinical effectiveness two cycle neoadjuvant vac chemotherapy muscle invasive bladder cancer preventive effect intravesical ozone supplementation n methyl n nitrosourea induce non muscle invasive bladder cancer male rat although non muscle invasive bladder cancer nmibc widely see man laboratory study new intravesical therapy prevent nmibc conduct female animal addition ozone show beneficial agent intravesical application treatment various disorder current study evaluate immunohistopathological oxidative antioxidative effect intravesical treatment n methyl n nitrosourea mnu induce nmibc male wistar albino rat n divide four group sham n n mnu n mnu n mnu mnu group receive mnu group receive saline every week week mnu group receive ml saline place treatment whereas mnu group treat ml g ml th th week rat bladder collect th week immunohistopathology oxidant antioxidant quantitation oxidant antioxidant parameter determine elisa although survive rat mnu group preneoplastic neoplastic change completely normal urothelium observe rat mnu group p high grade lesion observe mnu group mnu group p oxidant antioxidant parameter significantly increase p group compare sham group however antioxidant superoxide dismutase remarkably high p mnu group compare mnu group \\ufeff1 methodologically pathologically good describe male rat orthotopic bladder carcinogenesis model intravesical mnu administration nmibc detection circulate uroplakin positive cell patient transitional cell carcinoma bladder purpose although transitional cell carcinoma bladder tcc metastasize frequently devastate consequence no marker available monitor process uroplakins group specific marker normal urothelium continuously express majority tccs detection uroplakin positive cell circulation would strong indication hematogenous dissemination tumor cell patient tcc material method total rnas extract peripheral blood patient tcc non metastatic metastatic healthy control reverse transcribe subject polymerase chain reaction amplification rt pcr use oligonucleotide primer human uroplakin ii gene uroplakin express human bladder cancer cell line rt use positive control establish sensitivity rt pcr assay result show pcr amplification mrna encode uroplakin ii upii kda urothelium specific marker constitute highly sensitive specific assay detect transitional cell carcinoma tissue assay detect single bladder cancer cell ml blood sample upii mrna detect blood sample patient metastatic bladder cancer without chemotherapy patient chemotherapy not non metastatic patient normal control conclusion uroplakin ii highly specific marker human tcc detection uroplakin ii peripheral blood associate metastatic spread bladder cancer cell specific sensitive detection uroplakin ii provide useful adjunct detect bladder cancer metastasis stage monitor chemotherapeutic response population base analysis radical cystectomy urinary diversion bladder cancer northern italy objective provide update figure urinary diversion length stay mortality cystectomy two region northern italy patient method discharge record patient undergo cystectomy bladder cancer extract regional archive hospital discharge datum partial vs radical cystectomy type urinary diversion obtain intervention code influence demographic characteristic year intervention presence comorbidity hospital cystectomy volume adoption continent diversion hospital mortality assess multilevel model result crude cystectomy rate close per share partial cystectomy decline continent diversion adopt radical cystectomy high rate young male patient treat high volume hospital median length stay decline day hospital mortality decrease conclusion \\ufeff1 population base report cystectomy bladder cancer continental europe evidence limit role partial cystectomy high proportion continent diversion decrease trend length stay hospital mortality apaziquone nonmuscle invasive bladder cancer apaziquone interest drug intravesical use patient nonmuscle invasive bladder cancer however research need prove actual benefit although apaziquone trial demonstrate potential new drug singular phase trial not reach primary endpoint date no new trial recruit development apaziquone seem stop screen bladder cancer high risk group delineation problem since various exogenous chemical occupation identify risk factor bladder cancer aromatic amine among notable chemical date numerous group worker case community resident increase risk bladder cancer come attention health official seek guidance concern screen bladder cancer person asymptomatic may not attain average length preclinical latency aromatic amine induce cancer although principal public health strategy combat occupational exposure carcinogen primary prevention screen another strategy use already expose know suspect carcinogen screen also use assess whether not environmental control need need improve decade question screen problematic regard occupational group know exposure document question face government labor industry academia recommend regard screen high risk group bladder cancer mortality worker expose aromatic amine analysis model carcinogenesis effect various factor evaluate relative risk multiplicative model absolute excess risk additive model bladder cancer among worker dyestuff factory northern italy worker expose aromatic amine fairly constant work condition employ little one year follow till end total man year risk model risk great worker directly involve aromatic amine manufacture intermittent exposure no mark effect age \\ufeff1 exposure absolute excess risk bladder cancer relative risk strongly negative relate age \\ufeff1 exposure multistage theory carcinogenesis pattern risk indicate early stage effect absolute excess risk increase sharply exposure continue rise although little sharply exposure cease relative risk however decrease cessation exposure indicate possible late stage effect thus result derive additive multiplicative model not contrast interpret term multistage theory carcinogenesis though not totally consistent single stage effect either early late aromatic amine may act stage somewhere \\ufeff1 penultimate one stage process carcinogenesis alternatively possible imprecision job classification observational problem may obscure trend produce fictitious trend effect variable age \\ufeff1 exposure time since last exposure finally pattern trend can emerge two stage \\ufeff1 penultimate stage association occurrence antibody simian vacuolating virus bladder cancer male smoker association occurrence antibody simian vacuolating virus bladder cancer male smoker find case control study conduct male patient bladder cancer control man risk bladder cancer increase year cigarette smoke epidemiological case control study bladder cancer male predominantly rural district case control study perform male bladder cancer patient equal numb male control person match age geographic area thirty determinant assume importance examine multivariate logistic analysis perform significant increment relative risk rr bladder cancer associate cigarette smoke rr history prostatic surgery rr nocturia rr previous venereal disease rr industrial work rr work oil gasoline rr work various unspecified chemical material rr non steroidal anti inflammatory drug treatment genitourinary malignancy focus clinical datum antitumour activity nsaids preclinical trial lead evaluation management various malignancy human evidence regard use treatment genitourinary tumour review focus primarily clinical datum majority available evidence come meet abstract publish manuscript detect efficacy selective cox inhibitor subcategory anti inflammatory drug promise prostate cancer either biochemical recurrence initial treatment advance disease not seem case renal tumour efficacy advance disease set not satisfactory despite good document rationale application nsaids bladder cancer management clinical evidence not available study need assess efficacy quantitative apparent diffusion coefficient measurement obtain tesla mri correlate biomarker bladder cancer proliferative activity purpose investigate association apparent diffusion coefficient adc value cell cycle proliferative biomarker p p ki order establish potential role noninvasive biomarker prediction cell cycle proliferative activity biological aggressiveness bladder cancer material method patient bladder cancer undergo tesla dw mri bladder tur b radical cystectomy eligible prospective irb approve study histological specimen immunohistochemically stain follow marker p p ki two board certify uropathologists review specimen blind dw mri result histological grade stage classify accord tnm classification respectively nonparametric univariate multivariate statistic include correlation logistic regression roc analysis apply result muscle invasive bladder cancer histologically confirm patient examine tissue biomarker significantly correlate adc value p respectively base multivariate analysis p adc independent prognostic factor muscle invasiveness bladder cancer p p conclusion adc value associate cell cycle proliferative biomarker thereby reflect invasive proliferative potential bladder cancer adc p independent prognostic factor muscle invasiveness bladder cancer diet bladder cancer case control study investigate possible relationship diet risk bladder cancer serbia hospital base case control study carry study include newly diagnose bladder cancer patient numb control match sex age year type residence rural urban dietary information obtain use food frequency questionnaire initial photodynamic diagnosis narrow band image management bladder cancer review background bladder cancer common malignancy urinary tract proper diagnosis efficient treatment still consider challenge urology today white light cystoscopy gold standard diagnosis follow endoscopic treatment bladder cancer improve efficacy bladder cancer management photodynamic diagnosis narrow band image introduce urological armamentarium objective method article present current state knowledge technical solution intend improve diagnosis management bladder cancer nonsystemic review relevant pubmed literature perform result photodynamic diagnosis narrow band image improve detection bladder cancer decrease recurrence rate bladder tumor conclusion although high cost equipment may limit introduction everyday use cost effective method bladder cancer management long term follow introduction integrate cancer pathway shorten diagnostic delay bladder cancer introduction aim present paper firstly investigate distribution diagnostic delay primary sector primary urological department highly specialize department patient cancer urinary bladder secondly paper aim investigate introduction wait time guarantee integrate cancer treatment pathway affect diagnostic delay material method study comprise case journal patient cystectomized department urology rigshospitalet total journal good review investigation time study view three time period symptom onset \\ufeff1 hospital contact phase examination \\ufeff1 hospital department referral phase referral receive specialize department cystectomy phase total diagnostic delay also study result study reveal reduction duration phasis phase particular observe significant reduction p conclusion introduction integrate cancer pathway reduce diagnostic delay cancer urinary bladder approximately one month day day prognostic value loss heterozygosity chromosome p non muscle invasive bladder cancer objective investigate prognostic value loss heterozygosity loh chromosome p patient non muscle invasive bladder cancer nmi bc method include study patient nmi bc loh analysis perform tumor tissue use microsatellite marker chromosome p association loh recurrence progression tumor evaluate result frequency loh p ptag ptag pt g tumor respectively recurrence occur patient none marker able predict recurrence progression occur case progression muscle invasive bladder cancer mi bc case loh ifn alpha significantly associate progression mi bc p case loh ifn alpha year progression free survival progression free survival mi bc compare respectively case conservation loh multivariable analysis loh ifn alpha remain statistically associate progression progression mi bc loh ifn alpha significant independent predict factor progression progression mi bc p hr progression hr muscle invasion conclusion study suggest loh ifn alpha independent prognostic factor progression mi bc loh analysis bladder tumor may help management nmi bc specifically can use select patient early aggressive treatment plan close follow schedule intravesical administration bcg vaccine treat recurrent superficial bladder cancer author consider general immunological effect intravesical bcg vaccine independent method immunotherapy superficial cancer bladder cb patient male female mean age year recurrence superficial cb n treat patient undergo transurethral transvesical bladder resection combine therapy intravesical immunotherapy cb recurrence bcg vaccine induce persistent change immune system stimulate lymphocyte activity phagocytic activity neutrophil cell function normalize function endogenic suppressor increase amount igm cic repeat course vaccine maintain immunological effect long time evaluation damage cause radiation chemical drug urinary bladder mucosa stage n v cancer evaluation damage cause radiation chemical drug urinary bladder mucosa stage n v cancer present therapeutic modality discuss author summarize experience offer recommendation optimal treatment disease also suggestion make work indication contraindication deal specific urinary bladder cancer vis avis stage possible complication characterize dimension clinical practice guideline evolution ever grow pace medical knowledge produce require clinical practice guideline cpgs regularly update since clinical decision support system cdsss effective mean implement guideline routine care revise knowledge source evolve one version another part keep unchanged whereas other little modify propose characterize formally different dimension recommendation evolution two successive guideline version knowledge model perspective atomic recommendation represent rule connect clinical condition recommend action plan use subsumption base comparison seven evolution pattern identify no change action plan refinement new action plan condition refinement recommendation refinement new practice unmatched recommendation method evaluate french bladder cancer guideline revision novel view pathogenesis complication intravesical bcg bladder cancer intravesical bacillus calmette gu rin bcg widely use high risk non muscle invasive bladder cancer report describe four case illustrate spectrum bcg induce complication vary granulomatous prostatitis sepsis considerable debate regard whether inflammation infection predominant mechanism pathogenesis bcg disease two patient systemic illness symptom \\ufeff1 resolve add prednisone indicate principal role inflammation systemic disease vitro test cell response mycobacterial growth inhibition assay perform patient systemic disease patient mild symptom show effective vitro growth reduction bcg patient sepsis organ involvement high cell response ineffective kill finding preliminary believe immunological assay describe report may provide well insight pathogenesis bcg disease individual patient justify research genetic aberration k ras proto oncogene bladder cancer relation pesticide exposure egypt bladder cancer one popular cancer account cancer case rank \\ufeff1 male male cancer incidence rural area among male near per exact etiology bladder cancer still unknown k ras gene know critical dna target chemical carcinogen pesticide occupational hazard exposure think directly genotoxic other may enhance mutagenicity carcinogenicity directly act genotoxic agent analysis relationship pesticide exposure mutation k ras gene human bladder cancer one hundred patient diagnose bladder cancer two hundred control attend outpatient clinic take consent fill questionnaire age sex occupation pesticide exposure surgically resect specimen collect sample use determine k ras mutation blood sample take analyze level acetylcholinesterase enzyme level p present study indicate pesticide exposure may play great role malignant transformation bladder cell mutation k ras gene significant correlation acetylcholinesterase enzyme level k ras mutation p result reveal level p significantly high comparison control group p finding give alarm decrease amount pesticide use area also p may use indicator bladder cancer nonmuscle invasive bladder cancer change change purpose nonmuscle invasive bladder cancer nmibc challenge disease manage primarily due vary clinical course management nmibc witness widespread change respect diagnosis treatment although transurethral resection tur adjuvant bacillus calmette guerin bcg still remain cornerstone new protocol come vogue achieve optimal care basis literature review aim establish change already occur expect future nmibc method medline search perform identify publish literature respect diagnosis treatment future perspective nmibc particular emphasis direct determinant quality tur new modification tur current status new macroscopic microscopic image role urinary biomarker clinical histologic molecular predictor high risk disease administration intravesical agent salvage therapy bcg recurrence current well practice guideline analyze result conclusion optimal tur restage select group incorporation new endoscopic image judicious administration intravesical chemo immunotherapeutic agent contribute well patient care although plethora urinary marker insufficient evidence use isolation future probably lie identification genetic marker determine disease recurrence nonresponders standard treatment early institution alternative target therapy chemotherapy metastatic unresectable bladder cancer cisplatin methotrexate doxorubicin vinblastine vac combination chemotherapy historic standard care patient advance urothelial tumor phase iii trial evaluate new combination gemcitabine cisplatin gc carboplatin paclitaxel docetaxel cisplatin interferon alpha fluorouracil cisplatin however new regimen fail demonstrate superiority term overall survival compare classic vac gc doublet prove new standard treatment alternative base improve toxicity profile similar survival result addition 3 agent paclitaxel regimen focus phase iii trial however case salvage cystectomy pelvic radiation radical cystectomy consider standard care muscle invasive bladder cancer mibc good high grade recurrent non muscle invasive bladder cancer numb reason urologic surgeon may find consider salvage cystectomy sc patient understand risk associate perform sc important patient counsel consider primary management mibc awareness unique complication occur alter surgical technique approach equip clinical staff knowledge properly monitor patient post operative surveillance identify treat situation review characterize outcome patient undergo sc elucidate special consideration must make perform surgery discuss outcome comparison primary surgery absence radiation bladder cancer cyclophosphamide therapy lupus nephritis progression carcinoma situ bladder invasive bladder carcinoma show essentially regulate p overexpression another study however loss heterozygosity chromosome also show essential progression muscle invasive disease routine random biopsy predict prognosis decide adjuvant intravesical therapy abandon result good design trial patient aforementioned study show recurrence progression rate can slightly improve cost intravesical therapy random biopsy do routinely survival patient undergo radical cystectomy show strongly affect primary tumor stage even patient positive node radical cystectomy lymph node dissection alone can beneficial node positive patient tumor confine bladder neoadjuvant chemotherapy bladder spare can recommend select patient significant reduction tumor size chemotherapy response adjuvant chemotherapy can prolong consolidation surgical intervention perform responder help new prognostic parameter obtain molecular genetic analysis already increase survival trend bladder carcinoma hopefully continue improve near future marker bladder cancer issue consider purpose determine association heparanase protein messenger rna expression bladder cancer invasion metastasis material method expression heparanase protein mrna assess immunohistochemical stain situ hybridization respectively bladder cancer specimen resect various stage disease knowledge \\ufeff1 systematic study heparanase protein mrna expression human bladder cancer result expression heparanase protein muscular invasive bladder cancer significantly high superficial cancer versus p high primary tumor patient lymph node metastatic cancer nonmetastatic cancer versus p high grade disease significantly high low grade disease versus p expression heparanase mrna also significantly high stage pt great stage pt little bladder cancer versus p metastatic n case significantly high nonmetastatic bladder cancer versus p heparanase gene protein show similar pattern expression bladder cancer conclusion study imply expression heparanase protein mrna associate bladder cancer invasion metastasis heparanase may role disease progression definitive radiation therapy bladder cancer result reflect intrinsic tumor character standard treatment muscle invasive bladder cancer surgical removal bladder construction neobladder recently important improvement make potential bladder conserve treatment use radiotherapy external beam radiotherapy undergo technological improvement result possible radiate tumour precisely decrease radiation healthy tissue radiochemotherapy improve local recurrence free overall survival compare radiotherapy alone result combine treatment comparable surgery additionally dutch radiotherapy department collect datum national database select patient confine bladder cancer patient treat external beam radiation limit surgery brachytherapy year local recurrence free survival bladder conserve treatment option muscle invasive bladder cancer discuss multidisciplinary meet restage transurethral resection non muscle invasive bladder cancer rate clinical understaging non muscle invasive bladder cancer nmibc initial transurethral resection tur significant particularly allogeneic stem cell seed tissue engineer bladder possible alternative bladder reconstruction treatment bladder cancer bladder cancer remain difficult management problem high recurrence rate functional disorder bladder post radical cystectomy autologous tissue engineer technique advance enough reconstruct functional bladder patient myelomeningocele not capable bladder cancer patient hand allogeneic stem cell share multipotential self renew multi differentiate ability autologous one would present anti tumor effect transplant recipient since stem cell seed tissue engineer technique bladder regeneration already feasible hypothesis propose allogeneic stem cell seed tissue engineer bladder would possible alternative functional bladder reconstruction treatment bladder cancer recurrence latent metastasis postoperatively quantitative analysis survivin mrna expression urine tumor tissue bladder cancer patient potential relevance disease detection prognosis suppression apoptosis may favor onset progression cancer survivin inhibitor apoptosis suggest novel diagnostic prognostic marker bladder cancer study survivin mrna expression measure sensitive real time pcr assay tumor tissue urine bladder cancer patient assess potential diagnostic prognostic relevance specimen patient bladder transitional cell carcinoma tcc analyze control normal urothelial tissue n urine benign disease patient n healthy individual n survivin transcript commonly detect tumor tissue not normal urothelium increase mrna level correlate progress pathologic stage p grade category p high level expression associate reduce time recurrence noninvasive tccs p log rank test trend toward short disease free survival muscle invasive tumor p urinary survivin analysis detect tcc high sensitivity equal specificity compare cytology result indicate tissue level survivin mrna predict disease free survival noninvasive tcc may role bladder cancer progression analyze rt pcr urine survivin highly specific biomarker tcc detection superficial bladder cancer time check cystoscopy \\ufeff1 year report prospective study patient present \\ufeff1 time small solitary non invasive moderately good differentiate transitional cell carcinoma bladder pattern recurrence \\ufeff1 year assess recurrence rate calculate patient without recurrence month remain clear \\ufeff1 year highly significant reduction recurrence rate free recurrence month suggest group 2 check cystoscopy year yearly cystoscopy thereafter finding support proposal pre emptive neo adjuvant intravenous chemotherapy invasive bladder cancer sensitivity bladder wash flow cytometry bwfcm void urinary cytology vuc cytology catheterized urine obtain time cystoscopy cuc review woman evaluate bladder cancer memorial sloan kettering cancer center june december comprise sixty four episode pathologically prove bladder cancer woman consider positive suspicious result jointly sensitivity bwfcm cuc vuc respectively positive result consider e suspicious result consider negative sensitivity bwfcm cuc vuc respectively sensitivity test little predominantly male population presumably relate presence squamous epithelium great frequency pyuria however bladder wash flow cytometry conventional cytology still valuable addition cystoscopic examination combination bwfcm conventional cytology sensitive either procedure alone xpc epigenetic silence couple p alteration significant impact bladder cancer outcome purpose vary xpc genetic relate bladder cancer susceptibility determine whether decrease xpc expression influence bladder cancer malignancy clinical outcome material method change xpc p expression detect immunochemistry bladder cancer include papillary neoplasm low malignant potential low high grade lesion stage ta stage xpc mrna methylation evaluate fresh tissue real time reverse transcriptase methylation specific polymerase chain reaction clinical value alter xpc p expression analyze bladder cancer include papillary neoplasm low malignant potential low high stage lesion stage ta stage kaplan meier method cox proportional hazard regression result xpc defect associate bladder cancer high pathological grade metastasis p mutation patient xpc p short survival bladder cancer without xpc p p cox regression analysis show xpc expression may potential predictive factor bladder cancer p bladder cancer xpc gene hypermethylation significantly high normal mucosa p conclusion low mrna may result xpc hypermethylation bladder cancer epigenetic defect xpc gene impact bladder cancer malignant behavior may also predict poor outcome bladder cancer case characterize p pathway alteration st john wort help fight bladder cancer white light cystoscopy cytology standard tool diagnose bladder cancer white light cystoscopy excellent detect macroscopic exophytic tumor sensitivity poor flat tumor carcinoma situ use fluorescence cystoscopy transurethral bladder resection improve tumor detection particulary carcinoma situ fluorescence cystoscopy reduce residual tumor rate especially voluminous multifocal tumor consecutive low recurrence fluorescence recommend diagnose treat bladder cancer bladder cancer patient long term haemodialysis report case bladder cancer long term haemodialysis relationship bladder cancer haemodialysis necessity periodic cytology bladder wash discuss urinary marker bladder carcinoma purpose transitional cell carcinoma bladder one common tumor genitourinary tract cystoscopy along cytology mainstay diagnose bladder cancer cytology specific diagnosis bladder carcinoma little sensitive particularly low grade disease cystoscopy hand invasive relatively costly technique may also inconclusive time particularly case cystitis simple noninvasive marker detect bladder cancer would helpful clinically useful urinary marker easy perform minimum requirement sample preparation high sensitivity specificity diagnosis review discuss various urinary marker role detection bladder cancer material method review literature urinary marker test may clinical usefulness result several urinary marker test bta stat bta trak nmp telomerase ha hase test immunocyt quanticyt fdp blca fish cyfra enough potential future clinical use bta stat nmp bladder check accudx fdp test presently point care test rest test laboratory base may need train technician majority urinary marker high sensitivity specificity cytology however void urinary cytology high specificity conclusion till no urinary marker test replace need cystoscopy however marker potential future clinical use rationale select exfoliate bladder cell micronucleus potential biomarker arsenic genotoxicity biomarker effect important potential epidemiology since may enable ascertainment exposure effect association relatively inexpensive cross sectional study confirmation short follow cessation exposure arsenic know cause human skin lung cancer may also cause various internal cancer include bladder kidney live cancer strong epidemiological association arsenic ingestion internal cancer bladder cancer epidemiological study taiwanese population expose high level arsenic drink water report relative risk bladder cancer good know environmental carcinogen population increase risk bladder cancer exposure smoke schistosomiasis infection elevate frequency micronucleus exfoliate bladder cell therefore propose bladder cell micronucleus assay can appropriate biological marker genotoxic effect arsenic exposure paper present rationale choose bladder cell micronucleus assay potential biomarker effect arsenic also briefly describe study conduct use biomarker currently expose population factor prognostic therapeutic significance patient bladder cancer cell proliferation transitional cell bladder cancer tcc determine mib immunolabeling volume correct mitotic index v index phase fraction measurement patient superficial ta bladder cancer result compare category grade dna ploidy mib score relate category p grade p dna ploidy p v index p fraction cell phase p mean mib score g g g carcinoma p mib score ta tumor tumor p v index g g g tumor p v index ta tumor tumor p grade tumor grade tumor grade tumor cell phase p grade tumor diploid aneuploid grade tumor diploid aneuploid grade tumor diploid aneuploid p ta tumor diploid aneuploid respectively whereas tumor diploid aneuploid p result show quantitative cell proliferation index associate category grade superficial bladder cancer prognostic value phase fraction mitotic index demonstrate several previous analysis prognostic factor value mib score bladder cancer prognosis remain establish follow study age diagnosis obesity smoke molecular subtype muscle invasive bladder cancer background heterogeneity muscle invasive bladder cancer mibc characterize use whole genome mrna expression datum show distinct molecular clinicopathological characteristic subtype however association risk factor molecular subtype not report method four previously publish scheme use categorize molecular subtype mibc patient cancer genome atla tcga datum gene expression rna seq demographic clinicopathological characteristic retrieve tcga datum portal polytomous logistic regression use estimate association subtype different scheme age diagnosis obesity smoke result quantitative variation evident distinct molecular subtype scheme show considerable consistency association risk factor generally compare patient luminal like tumor patient basal like subtype likely old yr vs year range obese obese vs normal range start smoke early age year vs year range conclusion different molecular subtype mibc may distinct risk profile large population base study detail information bladder cancer risk factor need define etiologic heterogeneity bladder cancer decrease expression rna bind motif protein correlate tumour progression poor prognosis urothelial bladder cancer background low nuclear expression rna bind motif protein rbm previously find associate poor prognosis several cancer form e g breast ovarian colorectal prostate cancer malignant melanoma aim study examine prognostic impact rbm expression urinary bladder cancer method immunohistochemical rbm expression examine tumour patient urothelial bladder cancer chi square spearman correlation test apply explore association rbm expression clinicopathological characteristic impact rbm expression disease specific survival dss year overall survival os progression free survival pf assess kaplan meier analysis cox proportional hazard model result reduce nuclear rbm expression significantly associate advance tumour stage p high grade tumour p negative rbm expression associate significantly short dss hr ci year os hr ci also multivariable analysis hr ci dss hr ci year os patient ta tumour express reduce rbm level kaplan meier analysis reveal significantly short pf p year os p conclusion loss rbm expression associate clinically aggressive tumour independent factor poor prognosis patient urothelial bladder cancer potentially useful biomarker treatment stratification surveillance disease progression novel long non code rna kmu promote growth chemoresistance bladder cancer background chemotherapy constitute one important adjuvant treatment bladder cancer however many patient usually develop chemoresistance chemotherapy present lncrna confirm not involve tumorigenesis progression also tumor chemoresistance however relationship lncrnas chemoresistance bladder cancer rarely report method novel lncrna kmu screen lncrnas microarray determination ic bladder cancer expression kmu evaluate qrt pcr correlation kmu clinicopathological parameter analyze clinical case effect kmu biological behavior chemoresistance investigate h tdr incorporation assay experiment effect kmu growth xenograft tumor survival nude mouse cisplatin examine xenograft mouse model result confirm kmu express high bladder cancer tissue pair control tissue moreover expression kmu significantly positively correlate grade stage metastasis recurrence bladder cancer significantly negative correlate prognosis addition kmu knockdown can significantly inhibit bladder cell proliferation adhesion migration chemoresistance promote apoptosis knockdown kmu inhibit growth xenograft nude mouse significantly prolong survival tumor bear mouse cisplatin conclusion novel lncrna kmu highly express bladder cancer tissue can promote proliferation progression closely relate malignant degree bladder cancer can also significantly enhance chemoresistance bladder cancer cell therefore expect new therapy target bladder cancer potential prognosis biomarker chemotherapy foxo inactivation induce cisplatin resistance bladder cancer find foxo shrna sublines foxo positive cell co treat foxo inhibitor significantly resistant cisplatin treatment pharmacological concentration compare respective control sublines mock treatment western blot demonstrate considerable increase expression level phosphorylate inactive form foxo p foxo cisplatin resistant sublines establish long term culture low increase dose cisplatin compare respective control immunohistochemistry surgical specimen patient muscle invasive bladder cancer undergo cisplatin base neoadjuvant therapy show strong trend associate p foxo positivity unfavorable response chemotherapy bambi gene epigenetically silence subset high grade bladder cancer bone morphogenetic protein bmp activin membrane bind inhibitor bambi transmembrane tgfri bmpri relate pseudoreceptor antagonize transform growth factor tgf beta bmp signal inhibit formation functional authentic receptor complex tgfri bmpri tgfrii bmprii assumption bambi gene expression epigenetically alter human bladder cancer progression screen expression bambi protein immunohistochemistry methylation status bambi promoter normal reactive urothelium bambi expression mostly overlap bmpri similar colocalization pattern note low grade papillary cancer high grade invasive cancer however mainly two reciprocal immunohistochemical expression pattern observe bambi low bmpri high bambi high bmpri low indicate bambi expression control not interfere responsiveness high grade cancer cell tgf beta bmp signal moreover methylation bambi gene correlate significantly negative bambi expression bladder tumor although bambi overexpression significantly increase numb apoptotic cell line knock small interfere rna show no remarkable change cell motility assay reveal treatment either tgf beta bmp htb line show mark increase numb migrate cell however decrease significantly force expression bambi since certain subset aggressive tumor often promote cell motility invasion survival induce epithelial mesenchymal transition tgf beta bmp autocrine paracrine manner hypermethylation bambi gene promoter lead bambi gene suppression may one epigenetic event affect invasiveness aggressiveness bladder cancer pattern failure radical cystectomy pt bladder cancer implication adjuvant radiation therapy purpose patient muscle invasive bladder cancer local regional failure lf report occur patient follow radical cystectomy goal study describe pattern lf good assess factor associate lf cohort patient pt bladder cancer information may implication towards use adjuvant radiation therapy method material patient pathologic n bladder cancer examine institutional radical cystectomy database preoperative demographics pathologic characteristic examine outcome include overall survival lf local regional failure define use follow image report scan location lf characterize variable test univariate multivariate analysis association lf overall survival result total patient pt n disease radical cystectomy bilateral pelvic lymph node dissection receive perioperative chemotherapy median age year old median follow month univariate analysis margin status pt stage pn stage associate lf p however multivariate analysis pt pn stage significantly associate lf p three stratum risk define include low risk patient pt n disease intermediate risk patient pt n pt n disease high risk patient pt n disease year incidence lf respectively common site pelvic relapse include external internal iliac lymph node lns obturator ln region notably patient lf local regional disease time recurrence conclusion patient pt n disease year risk lf exceed patient may likely benefit local adjuvant therapy mycobacterium cell wall alternative intravesical bacillus calmette guerin bcg therapy orthotopic murine bladder cancer purpose antitumor effect intravesical mycobacterium cell wall mcw therapy orthotopic heterotopic bladder tumor mouse assess magnetic resonance image mri material method live bacillus calmette guerin bcg organism replace cell wall extract derive outer capsule mycobacterium phlei alternative form intravesical therapy use aim reduce toxicity associate live mycobacterium organism without compromise efficacy response multiple dose intravesical mcw bcg assess mouse establish mbt tumor transurethral tumor implantation result serial mri bcg treat mouse reveal significant tumor regression mr image correlate good correspond histology whole mount bladder section treatment mcw also result significant inhibition tumor growth compare control untreated animal p although antitumor effect little pronounce live bcg treatment good tolerate mcw group no apparent ill effect flow cytometric fcm analysis bladder washings phenotype specific monoclonal antibody reveal predominantly cd cell infiltrate control bcg treat good mcw treat mouse cd helper inducer subset cell predominate cd suppressor cytotoxic subset bcg mcw treat animal cd cd ratio treat group differ significantly control untreated group conclusion intravesical mcw appear invoke similar inflammatory response mouse bladder mucosa live bcg organism retain antitumor action deserve evaluation potential antitumor agent bladder cancer phase ii clinical trial underway bladder cancer etiology natural carcinogen survival patient undergo cystectomy invasive carcinoma bladder improve significantly recent decade although improve survival accredit widely use preoperative radiation therapy review available datum raise question regard validity conclusion important disadvantage include increase morbidity associate long course rad preoperative radiation although disadvantage minimize short course regimen rad case efficacy remain unconvincing radical cystectomy residual recurrent tumour definitive radiotherapy salvage cystectomy result salvage cystectomy persistent recurrent tumour follow definite radiotherapy patient review calculate five year survival rate stage significantly well survival low pathological stage operative mortality conclude salvage cystectomy suitable supplement treatment bladder cancer spite considerable operative mortality complication rate flow cytometric study compare pair bladder wash void urine bladder cancer detection pair bladder washings void urine bladder cancer patient compare source exfoliate cell detection bladder carcinoma flow cytometry fcm bladder specimen fix ethanol within sixty minute collection find superior unfix bladder specimen percentage specimen good dna resolution great bladder washings unfix fix void urine unfix fix no difference dna resolution specimen remain unfix little one day one day two day suggest cell undergo majority degradation within critical period soon collection fix no difference dna resolution nineteen day suggest feasibility specimen transport central fcm laboratory eighteen percent unfix bladder washings percent unfix void urine specimen contain insufficient numb cell little time analysis compare percent bladder washings percent void urine fix ethanol flow cytometry cytology result concordant fix bladder washings fix void urine void urine unreliable provide consistent fcm datum due high numb specimen poor resolution insufficient cell not recommend substitute bladder wash screen high risk population monitor patient past history bladder cancer diagnostic accuracy optical coherence tomography bladder cancer systematic review meta analysis background bladder cancer 4 common malignancy man considerable disease burden globally multiple study focus accuracy optical coherence tomography bladder cancer diagnosis however finding inconsistent assess accuracy optical coherence tomography bladder cancer diagnosis method embase pubmed medline web science cochrane library database search relevant study early date available march study evaluate accuracy optical coherence tomography bladder cancer diagnosis include pool sensitivity specificity area curve value weight symmetric summary receiver operate curve calculate per lesion level result eleven study total lesion include final analysis pool result indicate optical coherence tomography differentiate bladder cancer benign lesion sensitivity confidence interval specificity confidence interval area curve moreover compare optical coherence tomography alone combine optical coherence tomography fluorescence cystoscopy increase diagnostic accuracy sensitivity vs specificity vs cross polarization optical coherence tomography can also distinguish bladder cancer normal tissue sensitivity confidence interval specificity confidence interval area curve conclusion optical coherence tomography accurately differentiate malignant benign bladder lesion particularly combine fluorescence cystoscopy reply krabbe et al purpose evaluate day death rate factor associate short term complication radical cystectomy muscle invasive urothelial bladder cancer method study include patient age year male female previously diagnose urothelial bladder cancer admit radical cystectomy tertiary center follow datum note age gender perioperative chemotherapy radiotherapy pre postoperative hemoglobin creatinine level tumor stage type surgery type diversion clavien classification patient follow day several complication note cardiovascular gastrointestinal local infectious complication anemia death rate also record result open cystectomy perform patient laparoscopic approach use patient ileal neobladder create patient noncontinent diversion death follow surgery follow complication rate note local infectious case postoperative anemia postoperative anemia independently associate open cystectomy p ileal neobladder odd ratio p male gender p clavien classification not differ open laparoscopic cystectomy p even though complication grade high former conclusion day death rate radical cystectomy muscle invasive urothelial bladder cancer low open cystectomy associate severe short term complication compare laparoscopic approach postoperative anemia associate type surgery diversion type male gender superficial bladder cancer risk recurrence potential role interferon therapy superficial bladder tumor cancer situ cis papillary transitional carcinoma bladder frequent presentation bladder cancer 2 common disease urethelial tract superficial tumor demonstrate tendency recur either stage grade deeply invasive tumor extent likelihood tumor recurrence predict base certain risk factor furthermore probability recurrence alter appropriate clinical intervention review literature much preliminary suggest interferon therapy bladder cancer may modify biologic behavior disease provide clinical benefit patient evidence multiplicative effect cigarette smoke occupational exposure aetiology bladder cancer case control study urinary tract cancer man ongoing province torino analysis tobacco smoke occupational history \\ufeff1 use diffusion weight mri monitor response lymph node metastatic bladder cancer treat chemotherary diffusion weight mri dw mri functional image assess molecular diffusion report case treatment response lymph node metastatic bladder cancer monitor dw mri year old man paraaortic lymph node metastasis bladder cancer paraaortic lymph node show high signal intensity dw mri four course treatment gemcitabine cisplatin lesion show reduction signal intensity dw mri increase apparent diffusion coefficient value signal change consistent change morphological image ct mri w w f fdg pet tumor marker case suggest dw mri useful monitor treatment response metastatic bladder cancer bladder cancer current diagnosis treatment modality year old man history bladder cancer present perineal pain penile priapism work show multiple lesion strictly locate penis biopsy confirm metastasis bladder cancer surgery judge unfeasible chemotherapy fail improve symptom radiotherapy therefore deliver whole penis result rapid clinical benefit persistent control disease penile metastasis rare no consensus exist concern management radiotherapy appear promise therapeutic option not palliate pain also control disease acetylator phenotype bladder cancer context use neoadjuvant adjuvant chemotherapy treatment muscle invasive bladder cancer still controversial objective determine optimal use chemotherapy neoadjuvant adjuvant setting patient advance urothelial cell carcinoma bladder preservation also discuss evidence acquisition critical review publish literature chemotherapy patient locally advance bladder cancer perform evidence synthesis presence occult micrometastases time radical cystectomy lead distant local failure patient locally advance transitional cell carcinoma bladder neoadjuvant adjuvant therapy evaluate patient locally advance bladder cancer study evaluate adjuvant chemotherapy limit inadequate statistical power detect meaningful clinical answer good experimental arm utilize inadequate chemotherapy conclusion aggregate available evidence suggest neoadjuvant cisplatin base combination chemotherapy consider standard care patient muscle invasive locally advance operable bladder cancer patient either unfit refuse radical cystectomy neoadjuvant chemotherapy without radiation render bladder preservation possible patient attain excellent clinical response introduction new cytotoxic drug need good design study address optimal utility perioperative therapy high risk patient bladder cancer catheter assist f fdg pet ct image primary bladder cancer prospective study objective purpose study prospectively investigate value standardize f fluorodeoxyglucose f fdg pet compute tomography ct protocol image primary bladder cancer use standardize bladder flush fill method include patient ct bladder cancer foley catheter insert f fdg injection pet ct image perform accord four bladder protocol bladder empty bladder empty flush bladder fill ml saline bladder fill ml saline tumour visibility assess compare histopathology ct cystoscopy result procedure successfully complete patient reference standard reveal bladder tumour patient sensitivity protocol confidence interval ci compare ci protocol conclusion flush subsequent retrograde fill bladder result high rate tumour visualization quantification flush alone inferior examine co occurrence bladder prostate cancer worthwhile investigation investigate possible reason co occurrence bladder prostate cancer discuss clinical relevance co occurrence bladder prostate cancer partly explain survival effect diagnostic bias radiotherapy prostate cancer may responsible significant increase secondary bladder cancer absolute effect small exist international consortium expand include secondary primary cancer good index tumor facilitate investigation common etiology help identify subgroup susceptible treatment induce carcinogenesis prognosis diagnosis bladder prostate cancer seem depend mainly prognosis bladder tumor ebag tumor promote prognostic factor bladder cancer upregulation ebag expression observe several malignant tumor advance breast prostate cancer indicate ebag may contribute tumor proliferation present study assess role ebag bladder cancer generate human bladder cancer ej cell stably express flag tag ebag ej ebag empty vector ej vector investigate whether ebag overexpression modulate cell growth migration vitro good vivo tumor formation ej transfectants xenograft model balb c nude mouse ebag overexpression promote ej cell migration effect ebag culture cell growth rather minimal tumorigenic experiment nude mouse show size ej ebag derive tumor significantly large ej vector derive tumor loss function study ebag use small interfere rna sirna xenograft parental ej cell show intra tumoral injection ebag sirna markedly reduce ej tumor formation compare control sirna furthermore immunohistochemical study ebag expression perform pathological bladder cancer specimen intense diffuse cytoplasmic immunostaining observe bladder cancer case positive ebag immunoreactivity closely correlate poor prognosis patient p independent prognostic predictor disease specific survival multivariate analysis p result indicate ebag would crucial regulator tumor progression potential prognostic marker bladder cancer comparison dynamic contrast enhance mri dynamic contrast enhance ct biomarker bladder cancer dynamic contrast enhance mri dce mri frequently use provide response biomarker clinical trial novel cancer therapeutics assessment physiological accuracy difficult dce ct provide independent probe similar pharmacokinetic process may model way dce mri provide purportedly equivalent physiological parameter study dce mri dce ct directly compare subject primary bladder cancer assess degree model parameter report model physiology rather artefact measurement technique determine interchangeability technique clinical trial set biomarker k trans obtain fit extend version kety model voxelwise dce mri dce ct datum excellent agreement mean across subject min dce mri min dce ct intermodality coefficient variation parameter v p derive dce ct significantly great derive dce mri compare p v e reasonable agreement low value study provide evidence biomarker k trans robust parameter indicative underlie physiology relatively independent method measurement epigenetic alteration bladder cancer purpose review epigenetics refer process alter gene expression without alter primary dna past decade grow focus epigenetic mechanism cancer research importance cancer biology review summarize epigenetic dysregulation bladder cancer recent finding epigenetic alteration overall share across various grade stage bladder cancer high grade invasive tumor demonstrate great degree intensity methylation may unique methylation pattern environmental exposure may influence epigenetic alteration directly independent genomic change non code rnas play important role cancer phenotype especially context integrative genomic analysis dna hypermethylation non code rnas potential robust bladder cancer biomarker however require study validation change chromatin histone modification attractive target therapy currently clinical trial epigenetic dysregulation may important key improve understand bladder cancer pathogenesis especially integrative genomic analysis deep understand pathway help identify clinically relevant biomarker therapeutic target validate diagnosis monitor prognosis treatment bladder cancer optimization differential photodynamic effectiveness normal tumor urothelial cell use aminolevulinic acid induce protoporphyrin ix sensitizer photodynamic therapy use aminolevulinic acid ala induce protoporphyrin ix promise tool bladder cancer therapy however little know cellular mechanism phototoxicity aim characterize cellular damage optimize differential photodynamic effectiveness tumor normal urothelial cell rt tumor urotsa normal urothelial cell use simulate papillary bladder tumor contrast normal urothelium photodynamically induce damage plasma membrane mitochondrion monitor flow cytometry propidium iodide exclusion analysis aggregate formation dye jc cell morphology investigate phase contrast fluorescence microscopy follow acridine orange stain long incubation time hr lead complete rt tumor cell kill accompany mark fraction damage normal urotsa cell short incubation interval hr also result complete rt tumor cell kill however urotsa cell retain cell property include intact plasma membrane active mitochondrion good intact cellular morphology phototoxicity depend not cellular sensitizer accumulation also intracellular localization analysis phototoxic mechanism important step plan combination therapy regimen e g dna damage agent datum indicate differential phototoxicity normal tumorous urothelium enhance use difference cellular protoporphyrin ix distribution follow short ala incubation time datum encourage vivo situation since short incubation time practical approach local photodynamic therapy early tumor stage not bladder also e g gastro intestinal tract bronchial mucosa predict response intravesical therapy non muscle invasive bladder cancer context ability predict response intravesical therapy ivt follow transurethral resection non muscle invasive bladder cancer hold important prognostic information however predictive tool available guide urologist objective review recent study investigate predictor response ivt evidence acquisition literature search conduct use pubmed database january april follow prefer report item systematic review meta analysis prisma criterium search strategy use combination mesh term administration intravesical urinary bladder neoplasm follow word biomarker predictive value test response recurrence progression limit search english language evidence synthesis risk stratification model utilize clinicopathological feature cost effective widely use tool currently available predict response ivt additionally urinary fluorescence situ hybridization test urinary cytokine base nomograms cytokine panel response intravesical therapy may enhance predictive ability protein base biomarker associate predict recurrence several gene base biomarker quantify mutation dna damage repair gene may predictive ability however genomic datum relatively new lack validation conclusion clinicopathological criterium remain widely utilize tool predict ivt response research validate protein genomic base biomarker need adoption clinical practice patient summary review contemporary study investigate predict response medication instill bladder intravesical therapy bladder cancer find predictive tool use clinical datum tumor stage grade determine outcome new biological gene protein cytokine marker test study conclude combination clinical datum level certain experimental marker fluorescence situ hybridization test urinary cytokine may improve predictive ability genetic test method may also yield additional predictive marker future need validation clinical therapeutic significance aberrant differentiation pattern bladder cancer pure urothelial carcinoma make bladder cancer remain represent urothelial carcinoma aberrant differentiation pattern nonurothelial carcinoma review topic often focus pathological feature histologic subtype review summarize clinical significance major histologic pattern analyze response standard treatment modality main limitation optimize management inability perform clinical trial owe rarity tumor circumvent degree extrapolate knowledge acquire common similar tumor organ site ultimately however multicenter clinical trial need organize address key management issue prognostic factor infiltrate tumor bladder france invasive bladder cancer frequent urologic malignancy prostate carcinoma treatment bladder cancer radical cystectomy new therapeutic approach chemoradiation combination conservative procedure neoadjuvant adjuvant chemotherapy still develope way rigorous selection patient need selection base prognostic criterium can divide four group volume tumor include tumor infiltration depth nodal status presence not hydronephrosis residual tumor mass transuretral resection ii histologic aspect tumor include histologic grade presence not epidermoid metaplasia situ carcinoma thrombus iii expression tumor marker tissue polypeptide antigen bladder tumor antigen iv biologic aspect tumor ploidy cytogenetic abnormality expression ki expression oncogene tumor suppressor gene expression tumor antigen growth factor receptor paper review prognostic value various parameter numb node remove good template dissection independently correlate cancer specific survival radical cystectomy muscle invasive bladder cancer purpose assess impact numb lymph node remove template dissection radical cystectomy bladder cancer patient survival rate material method evaluate consecutive patient undergo radical cystectomy muscle invasive high grade superficial bladder cancer exclusion criterium incomplete follow datum neo adjuvant adjuvant treatment patient divide group accord informative cut point numb lymph node retrieve template dissection cancer specific survival rate estimate kaplan meier method univariate multivariable forward stepwise cox proportional hazard regression apply analyze survival outcome result mean sd follow month mean sd age entire cohort population year cancer specific survival rate year respectively consider diagnosis treatment non muscle invasive bladder cancer aua suo guideline purpose although associate overall favorable survival rate heterogeneity non muscle invasive bladder cancer nmibc affect patient rate recurrence progression risk stratification influence evaluation treatment surveillance guideline attempt provide clinical framework management nmibc material method systematic review utilize research agency healthcare research quality ahrq additional supplementation author consultant methodologist evidence base statement base body evidence strength grade b c designate strong moderate conditional recommendation additional statement present form clinical principle expert opinion result risk stratify approach categorize patient broad group low intermediate high risk importantly evaluation treatment algorithm take account tumor characteristic uniquely consider patient response therapy statement vary level evidence none include grade evidence many grade c conclusion intensity scope care nmibc focus patient disease treatment response characteristic guideline attempt improve clinician ability evaluate treat patient high quality evidence future trial essential improve level care patient work relate bladder cancer risk male japanese worker estimation attributable fraction geographical correlation analysis one hundred forty nine relative risk rrs occupation bladder cancer extract case control study geometric mean calculate occupation summary rrs high risk occupation among summary rrs significantly exceed unity find petroleum worker rr dye worker rr machinist rr driver rr rubber worker rr printer rr clothe tailor rr wood worker carpenter rr miner rr textile worker rr mechanic rr engineer rr leather worker rr painter rr chemical worker rr estimate number male bladder cancer high risk occupation case respectively estimate numb work relate bladder cancer case attributable fraction active employee entire population geographical distribution male bladder cancer death japan positively correlate distribution worker transport communication industry tertiary industry include service wholesale retail finance insurance whereas negative correlate distribution worker agricultural industry finding suggest worker certain industry may high risk bladder cancer lifestyle modification associate urbanization industrialization can alternative explanation pathologist role multidisciplinary management bladder cancer pathologist play important role management bladder cancer member multidisciplinary team urologist radiation therapist medical oncologist therapeutic goal save bladder function long possible pathologic determinant utilize selection therapeutic modality describe consecutively treat patient transitional cell carcinoma patient form bladder tumor five year period base histologic type pathologic stage status urothelium patient treat resection intravesical instillation cytostatic drug bacille calmette gu rvin bcg seventy patient undergo radical cystectomy bladder substitution continent urinary diversion serial transurethral resection tur biopsy cytologic evaluation find adequate evaluate pathologic determinant progression survival except case grade papillary transitional carcinoma additional experimental study need develope nuclear ploidy molecular genetic study identify patient high risk progression patient radical cystectomy partial cystectomy live median month since surgery one intraoperative death one post operative death within day post operatively multidisciplinary treatment invasive bladder cancer understand dynamic human host tumor critical importance mathematical model develope bunimovich mendrazitsky et al explore immune response bladder cancer effect bcg treatment treatment exploit host immune system boost response enable host rid tumor although model extensively study use numerical simulation no analytic result global tumor dynamic originally present work analyze stability mathematical model bcg treatment bladder cancer base use quasi normal form stability theory tool employ critical case especially analysis linearize system insufficient goal gain deep insight bcg treatment bladder cancer base mathematical model biological consideration thereby bring us one step close design relevant clinical protocol diagnosis urothelial carcinoma general practitioner significance haematuria general practice physician confront newly diagnose bladder cancer patient little year role general practitioner restrict initial phase diagnosis sometimes final palliative stage disease diagnostic phase describe guideline urothelial carcinoma bladder hamper absence clear sign signal bladder cancer painless gross haematuria important clinical sign high predictive value especially old man value microscopic haematuria unclear patient microscopic haematuria not malignancy yet despite current guideline still advise additional test type haematuria however recommend patient not subject test add value demonstrate urinary thromboxane b thromboxane receptor bladder cancer opportunity detection monitor previously find increase expression thromboxane synthase txas thromboxane receptor tp beta isoform tissue patient bladder cancer study cell line mouse indicate potential significant role thromboxane signal pathway pathogenesis human bladder cancer study design determine change observe tissue patient bladder cancer mirror change urine patient find increase level thromboxane b txb major metabolite txas increase level tp receptor result raise possibility patient bladder cancer may follow progression remission disease quantitation substance urine low dose bacillus calmette guerin versus full dose intermediate high risk non muscle invasive bladder cancer markov model background compare efficacy low dose mg bacillus calmette gu rin bcg full dose mg bcg immunotherapy patient intermediate prognostic value lymphatic metastasis bladder cancer objective presence lymph node metastasis bladder cancer consider sign poor prognosis present study perform analyze influence numb positive lymph node survival therapeutic value lymphadenectomy pn patient method january january patient age year mean undergo radical cystectomy pelvic lymphadenectomy carcinoma bladder record patient available review uicc classification system use result cancer specific mortality pno patient pn patient pn patient obtain follow cancer specific mortality stratify accord category pnot pnot b pnit pnit b pn b conclusion presence positive regional lymph node pn appear worsen patient survival particularly primary tumor b wrong case cancer specific mortality patient discharge increase pno patient pn patient p radical cystectomy highly effective curative apno patient presence multiple positive lymph node carry poor prognosis patient dye mean month reply pmid last four part series bladder cancer smoke part present overview bladder cancer role smoke development anderson naish part discuss diagnosis management bladder cancer anderson naish b part examine perception belief relate smoke health anderson naish c part examine evidence efficacy health promotional measure help people stop smoke aim provide insight whether health education health promotion increase awareness impact smoke health wellbeing whether person subsequent behaviour change enough stop smoke finally discuss role healthcare professional help people achieve objective plan preoperative cisplatin radiation therapy locally advance bladder cancer cisplatin ddp active agent treatment disseminate bladder cancer addition direct tumor cytotoxicity recent animal clinical datum suggest synergism radiation therapy rt since improve survival preoperative rt largely restrict bladder cancer patient radiation induce downstaging p little may recognize author administer ddp rt preoperatively patient locally advance bladder tumor select cystectomy aim evaluate feasibility combination relation surgical hematologic complication immediate effect tumor downstaging disease progression survival two thousand rad rad x day deliver whole pelvis follow cystectomy day ddp mg give intravenously day rt twenty four patient receive preoperative ddp rt undergo attempt cystectomy however six patient nonresectable owe extensive pelvic disease additional five patient resectable pelvic lymph node metastasis pelvic complication develope patient none require reoperation no patient wind dehiscence transient myelosuppression similar induce rad preoperative rt alone tumor downstaging p little see patient patient no tumor find surgical specimen p distant metastasis alone detect patient cystectomy nodal metastasis disease free survival median follow month range month patient p little p great equal patient resect patient combine preoperative ddp rt prove safe feasible regimen result possibly great recognition radioresponsive bladder tumor cystectomy encourage early survival rate patient locally advance disease cancer urinary bladder new classification bladder cancer publish consequently not regard recent however still timely since pick consideration affect scheme tumour classification good genetic result include context morphology time high inter intra observer agreement strive matt high quality patient care classification not include cytological diagnosis think consider tumour tissue diagnosis style cytological diagnosis also affect tissue diagnosis low high grade tumour differentiate benign lesion include reactive change element classification transfer cytology especially unequivocal diagnosis high grade lesion low grade lesion correlate tissue salvage cystectomy follow fail definitive radiation therapy transitional cell carcinoma bladder perform salvage cystectomy patient recurrent transitional cell bladder cancer initially treat definitive radiation therapy r interval tumor diagnosis radiation range zero twenty one year mean year interval radiation therapy cystectomy range six month twelve year mean year early major complication occur patient one early one late postoperative death overall patient survival time diagnosis death present range two thirty one year mean year time radiation present death range one nineteen year mean year overall crude five year survival time cystectomy exclude patient operate per cent however patient die cancer five year breakdown survival patient stage demonstrate well survival patient carcinoma situ stage no neoplasm time cystectomy report confirm value salvage cystectomy radiation failure invasive transitional cell bladder cancer superficial bladder cancer g choice treatment purpose review prognosis patient high risk bladder cancer generally poor addition advance stage high grade tumor several histopathological subtype invasive bladder cancer identify aggressive conventional form however modality early detection aggressive neoplasm limit review examine pathological feature aggressive bladder cancer critically review performance select methodology commonly use detect lesion recent finding strategy include bladder tumor antigen assay nmp immunocyt urovysion hold promise early detection aggressive urothelial carcinoma bladder however approach currently limit sensitivity potential false positive result unlikely substitute cystoscopy summary molecular base detection technique represent potentially attractive strategy noninvasive detection aggressive bladder cancer use urine specimen source identification new marker development novel platform may improve detection future p mdm development progression bladder cancer objective early investigation demonstrate inactivation p tumor suppressor gene may play role development progression bladder cancer complex formation mdm oncogene product one mechanism inactivate p protein therefore mdm p protein investigate study potential interaction bladder cancer method archival bladder tissue specimen patient study immunohistochemistry use monoclonal antibody p mdm result no stain observe p mdm normal urothelium alteration gene rare dysplasia p accumulation observe tumor stage examine mdm overexpression increase carcinoma situ tumor present advance tumor alteration gene frequent high grade lesion investigate prognostic impact alteration patient superficial bladder tumor follow little year mean month multivariate analysis demonstrate multifocal disease p accumulation significantly correlate tumor progression p mdm overexpression alone no prognostic significance patient alteration gene high risk tumor progression p conclusion result demonstrate positive correlation p accumulation mdm overexpression progression bladder cancer may prognostic value carcinogen dna adduct bladder biopsy urothelial cell risk assessment exercise determine level dna adduct use p postlabelling biopsy bladder cancer patient exfoliate bladder cell healthy volunteer aim study estimate concentration dna adduct cancer case control accord level smoke b investigate whether bladder cancer case high level adduct bladder cell healthy control dose response relationship smoke level adduct level present among cancer case control cancer case control similar adduct level level smoke accord risk assessment exercise adduct level among heavy smoker roughly comparable find mouse dog treat bladder carcinogen dose induce lifetime risk bladder cancer urinary bladder cancer risk variant recent finding new challenge gwas confirmatory study objective investigate expression annexin anxa adriamycin resistant human bladder cancer cell line pumc adm compare parental cell line pumc relevance drug resistance bladder cancer good explore relevance anxa recurrent bladder cancer tissue pertinent relapse method qrt pcr western blot implement research level anxa two cell line pumc adm pumc immunohistochemistry apply explore anxa expression bladder cancer tissue different interval relapse association anxa clinicopathological parameter analyze result expression anxa downregulated drug resistant cell line pumc adm compare pumc bladder cancer tissue recur two year late exhibit high anxa level anxa expression level positively correlate stage not connect histological grade strongly expression level influence factor anxa recurrent tissue bladder cancer clarify \\ufeff1 time conclusion anxa may become promise marker predict recurrence drug resistance bladder cancer provide guidance surveillance normal tissue spare potential adaptive strategy radiotherapy bladder cancer background purpose improve outcome bladder radiotherapy improve treatment conformation investigate various adaptive treatment strategy involve board tumour target visualisation bladder strategy compare term amount normal tissue enclose within ptv percentage volume overlap ctvs e bladder plan repeat ct scan material method five male bladder cancer patient plan either repeat scan treatment include study tumour position simulate sup inf ant post leave right wall identify repeat scan base reference coordinate system reference origin position axis join centre mass prostate bladder point mid way centre mass bladder inferior bladder wall tumour position repeat ctvs overlap use translation correspond position plan ctv require isotropic anisotropic margin determine use previously publish margin calculation algorithm calculation perform find margin require enclose envelope cover repeat ctvs enclose repeat ctvs one one e simulate adaptation daily basis result compare optimise margin repeat scan firstly without positional correction ctv secondly apply optimum translation whole bladder result compare optimisation scan daily adaptation increase average percentage volume overlap various tumour position volume overlap achieve similar no translation isocentre average slightly high optimal translation average conclusion translation isocentre accord tumour position not compromise normal tissue irradiation compare no translation isocentre optimal translation isocentre superior term normal tissue spare early use aggressive therapy can prevent one 3 bladder cancer death nonmuscle invasive bladder cancer nmibc know heterogeneous malignancy require vary treatment modality follow schedule low grade ta papillary tumor categorize low risk nmibc favorable prognosis expand movement overdiagnosis overtreatment avoid consider economic impact patient quality life year since initial assessment active surveillance low risk nmibc suggest feasibility safety however urologist still unfamiliar treatment option ideal appropriately select patient review article focus active surveillance low risk nmibc discuss evidence rationale treatment option several issue resolve order advocate active surveillance standard option select patient specific follow protocol include interval cystoscopy urine cytology urine marker radiographic examination need optimize validate finally integrate available datum follow strategy propose new surveillance protocol active surveillance recurrent low risk bladder cancer sequential change superficial bladder cancer purpose many patient enter care cycle gross microscopic hematuria undergo cystoscopy rule bladder cancer sensitivity invasive examination limit leave many patient risk undetected cancer improve current clinical practice sensitive noninvasive screen method apply material method total urine sample collect patient hematuria include without bladder cancer dna cell urine epigenetically profile use independent assay methylation specific polymerase chain reaction perform twist snapshot methylation analysis do different locus otx onecut additionally sample analyze mutation status tert telomerase reverse transcriptase pik ca fgfr fibroblast growth factor receptor hras kras nras result combination twist onecut locus otx result well overall perform panel logistic regression analysis methylation marker mutation status fgfr tert hras patient age result accurate model sensitivity specificity auc ci internal validation lead optimism correct auc estimate bladder cancer prevalence hematuria cohort assay result negative predictive value conclusion epigenetic profile use twist onecut otx result high sensitivity specificity accurate risk prediction may result little extensive invasive examination patient low risk thereby reduce unnecessary patient burden health care cost current trend treatment bladder cancer purpose bladder cancer among lead cause cancer death worldwide datum bladder cancer burden valuable policy make aim estimate burden bladder cancer country age group gender sociodemographic status material method datum vital registration system cancer registry input estimate bladder cancer burden mortality estimate ensemble model approach incidence estimate divide mortality mortality incidence ratio prevalence estimate use mortality incidence ratio surrogate survival model year live disability use disability weight bladder cancer sequela year life lose calculate multiply numb death age standard life expectancy age disability adjust life year calculate sum year live disability year life lose moreover also estimate burden attributable bladder cancer risk factor smoke high fast plasma glucose use comparative risk assessment framework global burden disease study result incident case ui bladder cancer age standardize incidence rate ui bladder cancer lead death ui age standardize rate ui trimodality bladder spare approach without neoadjuvant chemotherapy background retrospectively review efficacy organ preservation experience muscle invasive bladder cancer trimodality therapy institution method july february seventy patient f median age year lymph node negative localize muscle invasive bladder cancer treat primarily trimodality approach include transurethral resection bladder tumor turbt prior combine chemotherapy radiotherapy ccrt radiotherapy consist initial large field size irradiation conformal technique crt follow cone tumor bed boost intensity modulate radiotherapy imrt technique median total dose deliver bladder tumor bed whole bladder gy gy respectively no patient receive neoadjuvant chemotherapy nac weekly cisplatin administer radiotherapy toxicity score accord rtog criterium tumor response evaluate cystoscopically radiographically month treatment result number patient lesion respectively overall survival os progression free survival pf year respectively median follow time month local regional control distant metastasis free survival year respectively complete response cr rate assess three month ccrt ten patient local recurrence initial cr n superficial recurrence one patient undergo radical cystectomy recurrence overall year bladder intact survival ci acute toxicity limit grade one patient develope late grade gu toxicity conclusion result suggest trimodality bladder spare approach without nac dose intensification can bladder cancer treatment improve 3 four part series bladder cancer smoke part one examine risk factor bladder cancer emphasize although many risk factor smoke main predispose factor disease part two present overview bladder cancer include diagnosis management disease part three seek determine extent people concept constitute good health influence perception belief look whether educational support specifically health promotion health education effective increase individual awareness danger smoke health consequently change exist behaviour dissuade become future smoker contemporary cystectomy pelvic node dissection compare preoperative radiation therapy plus cystectomy management invasive bladder cancer august august consecutive patient undergo single stage radical cystectomy pelvic lymph node dissection urinary diversion definitive management high grade invasive bladder cancer patient rad radiation therapy give day preoperatively patient undergo operation although not constitute prospective randomize study analysis group patient manage year period surgical team use identical surgical technique provide useful information question benefit preoperative radiation therapy management high grade invasive bladder cancer factor improve surgical technique meticulous pelvic node dissection good well preoperative postoperative care may responsible survival result contemporary surgery equal report follow combination therapy protocol use preoperative radiation therapy contemporary surgery without preoperative radiation therapy yield year survival rate free tumor per cent patient pathologic stage p p disease per cent p p b disease per cent p disease positive pelvic node treatment muscle invasive bladder cancer usa incidence bladder cancer three time high man woman 4 common cancer man prostate lung colorectal cancer muscle invasive urothelial urinary bladder cancer high mortality rate regardless intensive therapeutic effort radical surgery combination oncological treatment option development treatment well outcome regard disease specific survival treatment inflict morbidity likely occur next year significance meta analysis effect neoadjuvant chemotherapy development sentinel node dissection impact introduction robot assist surgery possibility perform minimally invasive surgery advance bladder cancer patient discuss salvage therapy non muscle invasive bladder cancer novel intravesical agent bacillus calmette guerin bcg refractory high grade non muscle invasive bladder cancer remain challenge problem radical cystectomy standard care carry significant morbidity therefore need effective treatment previous salvage intravesical therapy disappoint result evaluation urinary microrna reveal high sensitivity bladder cancer background urinary biomarker need improve care reduce cost manage bladder cancer current biomarker struggle identify high low grade cancer due differ molecular pathway change microrna mir expression see urothelial carcinogenesis phenotype specific manner hypothesise urinary mirs reflect low high grade pathway can detect bladder cancer overcome difference genetic event see within disease method investigate urinary sample n patient bladder cancer n age match control n fifteen mirs quantify use real time pcr result find mir stable within urinary cell despite adverse handle detect differential expression mirs patient cancer control mirs b b b anova p individually mir p well individual performance specificity positive negative predictive value concordance respectively combination mirs b b p detect bladder cancer high sensitivity sufficient specificity correct patient concordance conclusion use panel patient haematuria would find urothelial cell carcinoma reduce cystoscopy rate however two invasive cancer would miss bladder replacement entero cystoplasty radical cystectomy bladder cancer urethral kock pouch september march male patient invasive bladder cancer year old age undergo bladder replacement ileum urethral kock pouch radical cystectomy follow range month urodynamic evaluation show ileal bladder low pressure reservoir capacity increase ml ileal bladder empty strain without significant residual urine patient except one perform intermittent self catheterization patient continent daytime however patient require pad night occasional loss little urine excretory urograms reveal excellent upper tract function procedure suitable whenever urethra preserve cystectomy cancer haematuria adpkd not always benign aware haematuria patient autosomal dominant polycystic kidney disease adpkd common manifestation cause haematuria often benign common cause haemorrhage within renal cyst haematuria may also cause coincident malignancy diagnosis may miss not investigate thoroughly herein present case adpkd present us haematuria late find bladder cancer social determinant appropriate treatment muscle invasive bladder cancer background racial disparity guideline base appropriate treatment apt may significant drive force difference survival people nonmetastatic muscle invasive bladder cancer mibc hypothesize receipt apt influence factor race socioeconomic status irrespective neighborhood level difference healthcare variation practice pattern clinical characteristic patient nonmetastatic mibc method within national cancer database identify individual diagnose mibc multivariable logistic regression mix effect model use examine predictor apt cluster within institution result total individual clinically stage nonmetastatic lymph node negative mibc black individual comprise cohort mean age year sd male predominance little half receive apt few black individual receive apt compare white individual vs p cluster institution odd apt low black individual odd ratio confidence interval ci compare white individual nonmetastatic mibc restrict high volume center diverse population black individual low odd apt ci p compare white counterpart conclusion racial disparity treatment persist account various clinical factor social determinant health future effort focus address racial bias improve disparity bladder cancer treatment impact not deliver evidence base care due bias account access biology expect patient experience inferior outcome bladder cancer one enemy many front background bladder cancer bc predominantly affect elderly often cause death among patient muscle invasive disease clinician lack quantitative estimate compete mortality risk consider treatment bc aim determine bladder cancer specific mortality csm rate cause mortality ocm rate patient newly diagnose bc method patient n identify population base cancer registry diagnose median follow month iq range compete risk analysis perform within patient group outcome compare use gray test result year diagnosis patient dead bc cause year bc mortality rate vary ocm rate depend primarily tumour type patient age cancer specific mortality high old patient group elderly patient receive radical treatment invasive cancer vs patient vs year respectively female patient high risk non muscle invasive bc wrong csm equivalent male gray p conclusion bladder csm high among elderly female patient friend foe role peroxisome proliferator activate receptor gamma human bladder cancer peroxisome proliferator activate receptor ppar family important group transcription factor regulate immune surveillance cell proliferation fatty acid regulation angiogenesis function implicate pathogenesis bladder cancer one particular subtype ppargamma express high level bladder cancer specimen benign urothelium attractive molecular target development novel treatment strategy bladder cancer review summarize datum available regard relevance ppargamma bladder cancer discuss potential value ppar target treatment bladder cancer psychosocial adjustment general state health patient ileal conduit urinary diversion psychosocial adjustment general state health investigate patient male female subject ileal conduit urinary diversion account bladder cancer patient incontinence bladder dysfunction patient seventy per cent patient report unchanged overall social activity osa operation twenty per cent report little activity bladder cancer patient likely curtail social activity compare patient incontinence bladder dysfunction appliance relate problem mention half patient report decrease osa one 3 patient consider accidental leakage fear leakage negative aspect surgery factor relate alter body image common negative aspect report female despite psychosocial problem majority patient consider health good male individual work full time patient unchanged osa score high health index e consider healthy rest patient genetic association bladder cancer combination urinary bladder cancer ubc benign prostatic hyperplasia bph prognostically unfavourable factor assess clinical efficacy one stage transurethral resection ubc bph combination adjuvant immunotherapy examine patient ubc stage this ta bth patient undergo one two stage endoscopic operation tur urinary bladder prostate make patient stage stage tur urinary bladder tur prostate make control conduct postoperative immunotherapy bcg vaccine imuron adjuvant therapy patient postoperative ubc recurrence occur patient patient study group control p reoperation tur urinary bladder perform case ubc recurrence five year survival study group survive control group p conclusion make combination superficial ubc bph indication appear tur urinary bladder tur prostate adjuvant immunotherapy early elimination infravesical obstruction lower ubc recurrence rate improve patient quality life bladder cancer neurogenic patient retrospective study management follow introduction prevalence bladder cancer bc neurological patient seem similar general population however aggressive high rate muscle invasive form squamous cell carcinoma aim current study report etiology management outcome bc neurological population material method enroll neurological patient bc diagnose follow datum retrospectively report age gender duration disease mode discovery histological type treatment outcome result total patient include spinal cord injury parkinson disease multiple sclerosis head trauma brain stroke cerebral palsy spina bifida histological subtype follow transitional cell carcinoma squamous cell carcinoma scc one mucinous adenocarcinoma one sarcomatoid one neuroendocrine high grade tumor muscle invasive bladder cancer seven patient diagnose year history neurogenic bladder mean follow month month eight death observe relate bladder cancer study smoke habit void mode lithiasis infection history not relate aggressive pattern scc conclusion high rate muscle invasive bladder cancer aggressive pattern justify neuro urological follow even year neurogenic bladder level evidence molecular classification non muscle invasive bladder cancer pta low grade pt low grade pt high grade subgroup use methylation tumor suppressor gene role epigenetics distinguish pathological clinical subgroup bladder cancer not fully characterize evaluate whether methylation tumor suppressor gene tsgs would classify non muscle invasive nmi bladder cancer subgroup predict outcome retrospective design include follow paraffin embed primary nmi tumor type n pta low grade lg n pt lg n pt high grade hg n methylation tsgs measure use methylation specific multiplex ligation dependent probe amplification tsgs frequently methylate overall series stk mgmt rarb gata tsg methylation correlate clinicopathological variable subgroup overall nmi series methylation rarb cd pax gstp igsf cadm pycard cdh tp gata classify pta versus pt tumor whereas rarb cd gstp igsf chfr pycard tp stk gata distinguish lg versus hg tumor multivariate analysis indicate pax wt brca methylation independently predict recurrence ptalg pax atm chfr rb pt lg disease pycard pt hg disease pax rb overall series methylation tsgs provide molecular classification nmi disease accord clinicopathological factor furthermore tsg methylation predict recurrence nmi subgroup increase expression gene encode stearoyl coa desaturase human bladder cancer bladder cancer common disease significant cause death worldwide thus great interest identify diagnostic prognostic biomarker good gain understand molecular basis bladder cancer stearoyl coa desaturase gene scd highly overexpress many human cancer however expression scd not yet investigate patient bladder cancer document scd highly overexpress human bladder cancer b high expression scd frequently observe late stage disease patient lymph node metastasis c bladder cancer patient high scd mrna level poor survival rate normal scd expression overall \\ufeff1 report indicate association scd mrna level clinical indicator human bladder cancer study provide evidence support potential role scd biomarker human bladder cancer prognosis design clinical trial new therapy bladder cancer time new strategy multiple study general population suggest subject glutathione transferase gstm null genotype lack functional gstm high risk bladder cancer evaluate impact gstm null genotype bladder cancer cause occupational exposure benzidine determine influence benzidine metabolism carry three complementary investigation case control study bladder cancer among worker previously expose benzidine china cross sectional study urothelial cell dna adduct urinary mutagenicity worker currently expose benzidine india laboratory study ability human gstm conjugate benzidine know metabolite vitro no overall increase bladder cancer risk gstm null genotype among bladder cancer case control odd ratio confidence interval although indication highly expose worker gstm null genotype great risk bladder cancer compare similarly expose worker without allele however gstm genotype no impact urothelial cell dna adduct urinary mutagenicity level worker currently expose benzidine furthermore human gstm not conjugate benzidine metabolite result lead us conclude gstm null genotype not impact bladder cancer cause benzidine provide contrast association elevate bladder cancer risk general population urinary bladder cancer sonderjylland summary presentation certain aspect experience use radical cystectomy without prior irradiation treatment select patient bladder cancer memorial sloan kettering cancer center experimental model histogenesis tumor cell heterogeneity bladder cancer histogenetic relationship subtype bladder cancer not know common pattern transitional cell carcinoma adenocarcinoma squamous carcinoma exist independently although may coexist primary metastatic bladder cancer tumor predominantly compose transitional cell carcinoma may region squamous glandular differentiation morphologically identical tumor exhibit mark variation natural history response treatment study aspect biology human bladder cancer series cell line establish characterize xenograft tissue culture study show likely common origin transitional cell carcinoma adenocarcinoma squamous carcinoma bladder morphologically similar xenograft cell line vitro show broad range functional heterogeneity include ultrastructure tumor marker production ploidy cell surface characteristic response chemotherapy useful model heterogeneity response treatment establish new cytotoxic agent incidence recurrent bladder cancer patient require admission abdominal pain long cystectomy background malignant disease often consider workup acute abdomen especially history intra abdominal neoplastic disease treatment bladder cancer frequently involve intra abdominal procedure incidence recurrent bladder cancer cause acute abdomen unknown method retrospective year study cause abdominal pain patient history surgery bladder cancer review evaluation include analysis clinical laboratory radiologic pathologic datum prior hospitalization available result fourteen patient month cystectomy patient month noncystectomy procedure recurrent bladder cancer compute tomography use identify case recurrent cancer prior exploratory surgery conclusion abdominal pain require admission patient remote history cystectomy bladder cancer likely due recurrent disease comparison year overall survival patient g g grade ta bladder tumor compare long term overall survival os patient g g grade ta bladder cancer transurethral resection bladder tumor turbts secondary aim investigate clinical pathologic prognostic factor os ta patient except g high grade hg total patient retrospectively select ta nonmuscle invasive bladder cancer nmibc undergo turbt january december median follow month inclusion criterium ta \\ufeff1 manifestation g g grade no associate carcinoma situ cis seventy nine patient exclude due concomitant cis g hg tumor lose follow ethical approval obtain ethical committee mures county hospital statistical analysis perform use stata follow inclusion criterium patient primary g g ta tumor enroll recurrence observe progression patient ten year survival g patient ci g patient ci p univariable multivariable logistic regression analysis underline advance age diagnosis hazard ratio hr no bacillus calmette guerin bcg treatment hr independent predictor death year diagnosis long term analysis confirm patient good differentiate g moderately good differentiate g ta tumor similar os long os even report undergo bcg adjuvant therapy comparative study intelligent model prediction bladder cancer progression new technique prediction tumour behaviour need since statistical analysis low accuracy not applicable individual artificial intelligence have may provide suitable method compare predictive accuracy neuro fuzzy model nfm artificial neural network ann traditional statistical method prediction bladder cancer experimental molecular biomarker include p expression gene methylation conventional clinicopathological datum study cohort patient bladder cancer method model produce predict presence time tumour progression method have predict progression accuracy range superior logistic regression nfm appear well ann predict time progression impair interferon alpha production whole blood culture bladder cancer patient interferon alpha ifn alpha production investigate whole blood culture bladder cancer patient control subject ifn synthesis induce sendai virus ifn activity assay fl cell challenge vesicular stomatitis virus vsv mean level ifn alpha produce iu ml control subject iu ml bladder cancer patient ifn alpha production significantly suppress bladder cancer patient compare control subject p little impairment ifn alpha production correlate tumor grade show tendency toward decrease ifn alpha production closely associate advancement tumor stage result suggest decrease ifn alpha production may contribute disorder immunoregulation bladder cancer patient trimodality treatment conservative management infiltrate bladder cancer critical review literature although radical cystectomy still treatment choice patient infiltrate bladder cancer grow evidence effectiveness conservative approach develope treatment need elderly unfit patient unable undergo radical cystectomy conservative therapy become true alternative surgery highly select patient although transurethral bladder resection external radiotherapy systemic chemotherapy control disease single treatment well result observe combine moreover new irradiation technique new generation drug test attempt improve disease control conservative management require multidisciplinary involvement different specialty order give patient real alternative surgical treatment bcg product release therapy urinary bladder cancer purpose interest emerge urinary biomarker replace alternate followup cystoscopy routine bladder cancer surveillance assess whether patient would accept urine biomarker assay flexible cystoscopy monitor bladder cancer material method enroll consecutive patient previously diagnose superficial bladder tumor undergo outpatient flexible cystoscopy followup immediately cystoscopy patient complete pain intensity numerical rate interview standard gamble method apply determine minimal accept diagnostic accuracy urine test would favor cystoscopy bladder surveillance clinical demographic datum potential affect patient preference analyze result patient would accept result urine test replacement cystoscopy capable detect recurrent bladder tumor additional would accept urine test little accurate anxiety associate possibility miss cancer major determinant minimal accept accuracy male gender high pain intensity cystoscopy associate willingness accept small level uncertainty univariate multivariate analysis risk progression muscle invasion convenience followup not appear affect patient preference conclusion patient perspective urinary biomarker would likely require great diagnostic accuracy supplant cystoscopy routine bladder surveillance inadequate sensitivity may major impediment general acceptance urinary biomarker set use quasi normal form examine stability tumor free equilibrium mathematical model bcg treatment bladder cancer understand dynamic human host tumor critical importance mathematical model develope bunimovich mendrazitsky et al explore immune response bladder cancer effect bcg treatment treatment exploit host immune system boost response enable host rid tumor although model extensively study use numerical simulation no analytic result global tumor dynamic originally present work analyze stability mathematical model bcg treatment bladder cancer base use quasi normal form stability theory tool employ critical case especially analysis linearize system insufficient goal gain deep insight bcg treatment bladder cancer base mathematical model biological consideration thereby bring us one step close design relevant clinical protocol lymphovascular invasion predict poor prognosis high grade pt bladder cancer patient undergo transurethral resection one piece background lymphovascular invasion lvi high grade clinical bladder cancer usually consider poor prognostic factor often difficult achieve correct stage bladder cancer diagnose presence lvi inadequacy conventional transurethral resection specimen aim study evaluate prognostic value lvi patient correctly stage bladder cancer drink water source tap water consumption case control study datum population base case control interview study incident bladder cancer area unite state use estimate relative risk among white man case control woman case control accord beverage intake level type water source individual year year profile water source treatment develope link lifetime residential information historical water utility datum ancillary survey risk bladder cancer increase intake level beverage make tap water odd ratio high vs low quintile tap water consumption confidence interval ci chi trend p little risk gradient intake restrict person little year exposure chlorinate surface water not find among long term user nonchlorinated grind water ors high vs low quintile tap water intake respectively among subject great equal year exposure duration exposure chlorinate surface water associate bladder cancer risk among woman nonsmoker sex among non smoke respondent tap water consumption population median increase exposure duration level ci chi trend p great equal year residence place serve chlorinate surface water vs non chlorinate grind water user result extend finding early epidemiologic study consistent environmental chemistry toxicologic datum demonstrate presence genotoxic product chlorine disinfection treat surface water progress management metastatic bladder cancer background inadequate survival result single agent management advance bladder cancer prompt several trial involve multidrug combination increase response rate survival method since development mvac regimen methotrexate vinblastine doxorubicin cisplatin cmv regimen cisplatin methotrexate vinblastine regimen test evaluate result regimen include cisplatin combine gemcitabine paclitaxel docetaxel paclitaxel combine gemcitabine carboplatin result objective result observe various new combination promise objective response rate report regimen gemcitabine plus cisplatin paclitaxel plus cisplatin produce rate conclusion use combination cytotoxic chemotherapy regimen treat patient metastatic bladder cancer nearly double median survival month year survival approximately caution must exercise use new regimen survival may inferior compare mvac regimen radiotherapy localize bladder cancer evidence purpose review bladder spare bladder treatment recently rejuvenate introduction concomitant chemotherapy usually part multimodality therapy include endoscopic resection radiotherapy article review recent evidence role radiotherapy treatment localize bladder cancer recent finding several single institution series multimodality radiochemotherapy show consistently fair disease specific survival local control show complete response endoscopic resection development radiotherapy fractionation adaptive plan chemotherapy delivery clearly progress summary much evidence retrospective involve treat locally advance poor risk patient would seem right attempt prospectively evaluate treatment truly localize bladder cancer prognostic significance aurora expression human bladder cancer aurora oncogenic serine threonine kinase play important role tumorigenesis development chemoresistance human cancer aim study detect expression aurora gene bladder cancer tissue analyze association prognosis bladder cancer patient rt pcr perform detect expression aurora mrna case bladder cancer correspond non tumor tissue sample immunohistochemistry perform detect localization aurora protein case bladder cancer tissue sample association aurora protein expression clinico pathological factor survival bladder cancer patient statistically analyze find expression level aurora mrna bladder cancer tissue significantly high correspond non tumor tissue p moreover immunohistochemical stain result show localization aurora protein mainly locate cytoplasm bladder cancer cell high level aurora protein expression correlate pathological stage p lymph node metastasis p venous invasion p not factor include age gender tumor grade recurrence superficial cancer patient high expression level aurora protein show low disease free overall survival rate low expression level p respectively univariate multivariate analysis prognostic factor bladder cancer patient indicate aurora expression independent unfavorable prognostic factor hazard ratio confidence interval p study suggest overexpression aurora gene may play important role progression bladder cancer aurora expression independent factor predict prognosis bladder cancer patient postoperative adjuvant chemotherapy bladder cancer effect cisplatin administration case vascular invasion alteration p gene molecular biological difference superficial invasive bladder cancer investigate polymerase chain reaction single strand conformation polymorphism analysis direct sequence technique p gene mutation examine exon region bladder cancer one superficial bladder cancer find p gene mutation four invasive bladder cancer find p gene mutation p gene mutation find none cancer grade one cancer grade four cancer grade result suggest p gene play important role development human bladder cancer histologic change urinary bladder relation cigarette smoke use artificial sweetener total section urinary bladder epithelium subject examine random order histologic alteration particularly numb cell row presence extent cell atypical nucleus record case either individual never smoke smoke cigarette microscopic slide cell atypical nucleus find never smoke smoke little cigarette day smoke cigarette day day cigarette smoker percentage slide six cell row group respectively histologic finding urinary bladder relation smoke habit fully complement epidemiologic study show dose response cigarette smoke urinary bladder cancer no relationship find change urinary bladder epithelium use artificial sweetener clinical usefulness cea ca cyfra tumor marker urothelial bladder carcinoma objective evaluate usefulness measure serum cea ca cyfra level diagnosis monitor bladder cancer material method serum level cea ca cyfra measure patient bladder cancer absolute level marker positive rate compare clinical stage histological grade tumor change marker assess patient without disease progression correlation survival positivity negativity marker also evaluate result high serum level cyfra significantly correlate high tumor stage p high grade p contrast serum cea ca level not differ significantly among stage grade cyfra level increase significantly along disease progression ng ml p patient positive cyfra significantly wrong disease specific survival p log rank test conclusion serum cyfra seem marker advance high grade urothelial carcinoma bladder useful monitor disease predict prognosis contrast clinical usefulness cea ca tumor marker not demonstrate use nonsteroidal anti inflammatory drug bladder cancer risk meta analysis epidemiologic study purpose several epidemiologic study evaluate association nonsteroidal anti inflammatory drug nsaids bladder cancer risk result vary thus conduct comprehensive meta analysis study exclusively dedicate relationship commonly use analgesic bladder cancer risk method systematic literature search november perform pubmed database category analgesic acetaminophen aspirin non aspirin nsaids study specific risk estimate pool use random effect model result seventeen study cohort surgical management superficial bladder cancer stage ta cis transurethral surgery primary treatment patient superficial bladder cancer either electrical laser thermal destruction use often no prove therapeutic benefit one method treatment failure usually consequence new tumor occurrence rather failure eradicate exist visible tumor adjuvant intravesical chemotherapy immunotherapy improve result surgery alone circumstance pazopanib synergizes docetaxel treatment bladder cancer cell objective investigate efficacy pazopanib alone combination docetaxel bladder cancer cell bladder cancer express many potential therapeutic target biological agent include vascular endothelial growth factor receptor vegfr pazopanib small molecule inhibitor vegfr platelet derive growth factor receptor pdgfr c kit material method use human bladder cancer cell htb ht j rt crl sup htb treatment effect pazopanib cytotoxic chemotherapy assess use tetrazolium base assay combinatorial effect agent clonogenic growth examine western blot use assess change relevant downstream target include phospho akt phospho fak total akt total fak result single agent pazopanib modest activity however synergy see combination docetaxel pazopanib multiple cell line j cell select additional clonogenic test resistance single agent docetaxel chemotherapy nm docetaxel little effect clonogenic formation however combination pazopanib significant inhibition colony formation observe combination treatment additionally decrease phospho akt important mediator cell survival cell line whereas phospho fak expression variably affect conclusion present study demonstrate synergistic efficacy pazopanib docetaxel docetaxel resistant bladder cancer cell work support future evaluation pazopanib docetaxel treatment bladder cancer potential improve efficacy toxicity bcan think tank session overview risk cause bladder cancer article review proceeding cause risk session recently hold bcan bladder think tank understand association specific genetic change development particular form bladder cancer whether low grade invasive form may justify screen program early detection fundamental epidemiological issue causation association support high rate industrialize region parallel association cigarette smoke evolution molecular integrative epidemiology incorporate molecular cytogenetic marker host tumor tissue classic epidemiology develop risk assessment model identify high risk population animal model teach us something human bladder cancer address issue differentiation papillary low grade invasive high grade tumor diagnosis bladder tumor pathological risk stratification become important weakness current grade system molecular grade may provide new simple highly reproducible tool determine bladder cancer prognosis base current knowledge include gap knowledge education immediate top priority action item promotion smoke cessation also high priority action symptom bladder cancer particularly hematuria must emphasize medical lie give cost associate treatment surveillance bladder cancer comprehensive program support governmental fund source identify risk associate bladder cancer development would seem prudent role antisense oligonucleotide treatment bladder cancer intravesical systemic chemotherapy limit efficacy treatment bladder cancer patient limitation centre around inability induce apoptosis bladder tumour cell resistance apoptosis induction commonly associate overexpression antiapoptotic protein bcl strategy decrease cellular expression protein would enhance chemotherapy effectiveness one strategy use antisense oligonucleotide short sequence specific single strand dna rna molecule design bind rna target protein bind target rna protein production interrupt target protein level decease use target antiapoptotic protein antisense oligonucleotide therefore use pre treatment chemotherapy help chemosensitise tumour cell review outline rationale strategy work do date antisense oligonucleotide bladder cancer initial north american experience use olympus button electrode vaporization bladder tumor current treatment standard care patient present de novo recurrent bladder tumor transurethral resection bladder tumor turbt use monopolar bipolar electrocautery form degree loop electrode use since introduction intervention accomplish transurethrally diagnostic potentially therapeutic patient bladder cancer especially low grade non muscle invasive bladder tumor although usually safe sufficient technique create technical challenge especially dynamically change spherical space bladder bipolar energy available many year readily adopt endoscopic treatment benign prostatic enlargement refinement bipolar energy recent introduction olympus button electrode olympus southborough usa couple bipolar energy olympus button electrode not harness benefit little thermal spread also obviate many geometric challenge associate loop electrode resection either large inauspiciously place bladder tumor article detail initial experience vaporize bladder tumor olympus button electrode although still early experience able completely vaporize large tumor good tumor locate difficult part bladder access minimal blood loss no bladder perforation furthermore ability obtain adequate grade stage information not compromise use vaporization technique radical transurethral resection alone robotic partial cystectomy extend lymphadenectomy select patient muscle invasion little surgery improvement accuracy clinical stage refinement patient selection may allow improve outcome bladder preservation strategy muscle invasive bladder cancer incorporate radical transurethral resection tur partial cystectomy pc retrospective study patient treat radical cystectomy pelvic lymph node dissection report association great extent lymphadenectomy improve clinical outcome however no consensus regard optimal extent lymphadenectomy currently no report prospective randomize trial address issue regard cancer specific overall survival future advance understand appropriate extent lymphadenectomy require good design prospective clinical trial directly compare vary extent surgery ability provide local distant disease control disease specific survival bladder cancer prognostic index analysis patient treat radical radiation therapy patient histologically prove bladder cancer this nxmo treat external irradiation transurethral resection irradiation give degree arc technique photon beam cobalt unit tumor dose range gy day tdf analysis conduct log rank test cumulative percent survival cp year study point importance risk factor clinical stage cumulative survival bladder cancer prognostic factor associate relatively successful outcome p little karnofsky performance status vs other cp vs absence ureteral obstruction initial intravenous pyelogram cp vs negative urine culture cp vs normal bladder capacity cp vs low grade histology cp vs grossly complete resection vs datum analysis take consideration radical radiotherapy consider new clinical trial lack value routine preoperative bone live scan cystectomy candidate retrospective review patient bladder cancer reveal candidate cystectomy patient evaluate preoperatively radionuclide bone live scan attempt increase accuracy clinical stage face normal history physical examination live function test serum alkaline phosphatase routine preoperative bone live scan cystectomy candidate not contribute significantly clinical stage choice treatment since live bone scan add significantly cost illness use not routine reserve special case indicate histonedeacetylase mrna elevate expression clinical specimen bladder cancer objective hdacs among transcriptional regulatory element regulate key feature proliferation differentiation cell type include cancerous may also interfere stage cancer development migration invasion multi drug resistance angiogenesis prove information hdac role development bladder cancer limit cell line vitro lack comprehensive clinical vivo study lead us evaluate hdac expression human clinical specimen method analyze large group bladder cancer patient presence hhdac mrnas track use specific hdac primer cancer sample quantity hdac transcript quantify use real time qpcr method compare normal bladder sample healthy patient result hdac mrna expression significantly elevate bladder cancer specimen knowledge result \\ufeff1 show elevation vivo hdac mrna level clinically cancerous tissue patient bladder cancer conclusion conclude hhdac overexpression may implicate bladder cancer tumorigenesis express hdac mrna may potential diagnostic marker target treatment bladder cancer use hdaci drug future tab fig ref mirna panel biomarker bladder cancer aim specific mirna profile identify several sample patient bladder cancer result not always congruent partly contradictory comparison publish datum perform select potential marker material method literature search pubmed identify article publish prior june report regard detection mirnas urine blood rarely publish date nine respectively three article available result comparison publish datum prove utility mirnas diagnostic prognostic indicator bladder cancer urine sample bladder cancer patient seven mirnas concordantly express tumor tissue conclusion standardization strictly require pre analytics method mirna measurement superficial bladder cancer open question important topic basic research clinical aspect superficial bladder cancer discuss open question include prognostic relevance several new biological marker compare clinical trial even establish therapeutic procedure undergo critical analysis regard stage relate optimal treatment recurrence prophylaxis superficial bladder cancer beset many open question relate therapy choice optimal schedule quality life patient affect role kaposi sarcoma associate herpesvirus infection proliferation human bladder cancer cell exist evidence suggest possible role virus human bladder cancer development recently kaposi sarcoma associate herpesvirus kshv report frequently detect virus bladder cancer tissue croatian patient screen lawrence livermore microbial detection array current study investigate functional role kshv bladder cancer five bladder cancer cell line infect kshv tumour progression associate change investigate four kshv infect bladder cancer cell line establish two invasive bladder cancer cell line show high proliferation rate uninfected cell additionally kshv infect invasive bladder cancer cell show great numb colony also significantly large uninfected cell soft agar colony formation assay cdna microarray analysis show various gene associate cell proliferation cancer development upregulated kshv infect bladder cancer cell take together suggest kshv infection affect proliferation subset invasive bladder cancer cell may therefore play role oncogenic progression study require elucidate exact mechanism use kshv promote bladder cancer progression biochemistry occupational bladder cancer herein discuss biochemistry occupational urinary tract cancer review history occupational aromatic amine cancer experimental production aromatic amine cancer aromatic amine double cancer study association bladder cancer phenacetin use problem set pharmaco epidemiological study survey literature phenacetin appear responsible increase risk urothelial tumour human especially renal pelvis tumour observation suggest association bladder cancer phenacetin contain analgesic however assess association france case control study bladder cancer case control undertake point methodological difficulty difficulty recall definition control group non response possible french distinctive feature analgesic use result not able confirm suspect relationship bladder cancer phenacetin use prognostic significance urine cytology initial follow intravesical mitomycin c superficial bladder cancer seventy patient give course intravesical mitomycin c residual transitional cell carcinoma bladder follow partial resection biopsy patient reassess month initiation treatment cystoscopy cytology cystoscopic urine bladder washings twelve no visible cancer cystoscopic study positive urine cytologic finding incidence tumor recurrence cystectomy radiotherapy death due bladder cancer group cytologically positive partial responder analyze thirty three percent require cystectomy none undergo radiation therapy none die bladder cancer outcome compare complete responder negative cystoscopic cytologic result partial responder visible tumor reduction great conclude high grade carcinoma particularly carcinoma situ positive urine cytologic finding initial month follow visit follow treatment intravesical mitomycin c ominous prognostic indicator endoscopic biopsy evidence cancer office base management nonmuscle invasive bladder cancer bladder cancer extremely common unite state extremely costly high cost surveillance patient office base surveillance may safe cost reduce alternative article attempt identify ideal candidate highlight surveillance strategy employ office base set detection bladder cancer use novel nuclear matrix protein blca identify previously six nuclear matrix protein nmps bladder cancer specific study analyze expression one protein intravesical bacillus calmette guerin ta bladder cancer background intravesical therapy bacillus calmette guerin bcg aim reduce incidence tumour recurrence follow transurethral resection tur patient superficial bladder cancer objective objective review compare incidence tumour recurrence standard therapy transurethral resection versus transurethral resection plus intravesical bacillus calmette guerin search strategy search cochrane control trial register march medline february embase february cancerlit february healthstar february database abstract review effectiveness february bath information datum service proceeding american society clinical oncology hand search selection criterium randomise quasi randomise trial transurethral resection alone versus transurethral resection plus intravesical bacillus calmette guerin patient ta bladder cancer medium high risk tumour recurrence eligible inclusion datum collection analysis four reviewer assess trial quality two abstract datum independently peto odd ratio log hazard ratio determine compare numb patient disease recurrence month rate recurrence respectively main result six randomise trial include involve eligible patient significantly few patient disease recurrence month bcg plus tur group compare receive tur alone odd ratio ci overall log hazard ratio recurrence variance indicate significant benefit bcg treatment reduce tumour recurrence toxicity associate bcg consist mainly cystitis haematuria fever urinary frequency no bcg induce death report reviewer conclusion patient medium high risk ta bladder cancer immunotherapy intravesical bcg follow tur appear provide significant advantage tur alone delay tumour recurrence poster boy bladder cancer prostate commonly involve transitional cell carcinoma tcc patient bladder cancer numb clinicopathologic factor include multifocal carcinoma situ tumor location tumor stage associate prostatic tcc ptcc addition manner extent pathologic examination also make significant difference detection rate distinct pattern extent ptcc describe associate pathologic stage primary bladder tumor good prognosis preoperative transurethral biopsy prostatic urethra sensitive accurate method detect ptcc helpful surgical plan give high incidence ptcc prostatic adenocarcinoma radical cystoprostatectomy treatment choice loco regional control patient disease study necessary establish role neoadjuvant adjuvant therapy patient prostatic stroma invasion organ spare treatment bladder cancer background muscle invasive bladder cancer frequent disease germany accept therapy choice radical cystectomy due comorbidity radical removal bladder often associate increase perioperative morbidity therefore alternative radical procedure offer objective overview description focal therapeutic concept muscle invasive bladder cancer provide therapeutic alternative radical organ removal material method database research analysis discussion clinical trial present therapeutic concept focal therapy muscle invasive bladder cancer result chromosome loss frequent early event urothelial bladder cancer aim chromosome loss describe bladder cancer suggest age relate clinical significance chromosome loss largely unknown since small set male bladder cancer patient evaluate previous study aim study clarify potential relevance chromosome loss bladder cancer respect clinical outcome patient age method pre exist bladder cancer tissue microarray tma clinical follow datum include urothelial bladder cancer male patient utilise study chromosome loss analyse multicolour fluorescence situ hybridisation fish use centromere probe centromere x probe p immunostaining datum available patient previous study result chromosome loss see interpretable cancer male patient no significant difference patient age tumour year without year chromosome loss p chromosome loss equally frequent tumour grade p stage p also no association p immunostaining p chromosome loss not associate survival invasive urothelial cancer pt p increase risk recurrence pta tumour p increase progression risk pt tumour p conclusion datum study show chromosome loss frequent urothelial bladder cancer grade stage can imply loss chromosome early event bladder cancer development p mediate genomic instability evidently not require development chromosome loss since no correlation chromosome loss clinical outcome detection loss no clinical relevance urothelial bladder cancer effective treatment patient grade iii bladder cancer external beam irradiation prognosis recurrent case break preservation treatment vesical function \\ufeff1 treatment tend wrong comparison primary case especially partial cystectomy tendency preservation treatment vesical function apply low stage however application treatment tumor indicative invasive cancer difficult long term observation type bush type endoscopic classification not worsen recurrence treatment preservation vesical function repetition preservation treatment vesical function intravesical recurrence incur danger tumor get wrong even low grade low stage urinary cytology quantitative bta ubc test surveillance patient ptapt bladder urothelial carcinoma objective compare result urinary cytology quantitative detection human complement factor h relate protein bta trak urinary fragment cytokeratins ubc irma recurrence status patient ptapt bladder cancer define possible role method surveillance protocol method collect urine consecutive patient primary ptapt tumor \\ufeff1 transurethral resection turb follow cystoscopy sample urinary cytology quantitative bta ubc test perform compare result recurrence status tumor characteristic case recurrence construct receiver operator characteristic roc curve quantitative method addition evaluate individual cutoff base pretreatment level result mean follow month perform cystoscopy positive patient sensitivity specificity cytology bta ubc respectively sensitivity ptis detection respectively cutoff set sensitivity specificity bta ubc drop respectively individually calculate cutoff not provide significant benefit conclusion high specificity sensitivity ptis detection urinary cytology fulfill requirement adjunctive method cystoscopy quantitative bta ubc test low sensitivity detection bladder cancer recurrence not use routinely reduce numb cystoscopy follow concurrent adriamycin radiotherapy locally advance bladder cancer prospective phase study perform patient locally advance transitional cell carcinoma urinary bladder evaluate toxicity integrate treatment adriamycin mg group mg group b hyperfractionated accelerate radiotherapy local systemic toxicity adriamycin mg significantly low mg complete tumour remission achieve patient patient group group b case treatment can stop \\ufeff1 series plasma mir b p mir p distinguish patient bladder cancer healthy individual micrornas mirnas mirs act marker various cancer include bladder cancer bc plasma mirnas potential biomarker noninvasive diagnosis long term surveillance bc aim present study identify diagnostically reliable mirnas plasma examine potential monitor capacity mirnas measure reverse transcription quantitative polymerase chain reaction study perform discovery phase include plasma sample patient without bc prior transurethral resection turb result validate 2 phase involve patient plasma sample collect 2 turb radical cystectomy rc rc discovery step three elevate mirnas mir b p mir p mir b p two decrease mirnas mir b p mir p select potential mirna candidate validation mir b p mir p finally confirm discriminate cancer case control however disease monitor bc mirnas not suitable decline mirna level not observe patient tumor removal result suggest circulate mir b p mir p useful diagnostic potential bc rather unsuitable monitor marker disease reason apparent contradictory observation may due aspect biological variation circulate mirnas serial measurement can unreliable diagnosis treatment bladder cancer improve majority patient bladder cancer diagnose follow episode hematuria exception patient refer complete urologic evaluation include history physical examination flexible cystoscopy image upper urinary tract optional urine cytology find bladder tumor undergo transurethral resection combine purpose initial stage treatment delay diagnose invasive bladder cancer associate adverse outcome review cover diagnosis management bladder cancer addition discuss way improve outcome increase public awareness improvement tumor detection accurate stage regiment patient surveillance intradiverticular bladder tumor c assessment objective review role computerize tomography diagnosis intradiverticulum bladder cancer present image various case perform bibliographic review method case intra diverticulum bladder cancer identify retrospective review case pathological confirmation radiological finding review technique compare obtain diagnostic test result ct scan allow diagnosis disease extension lateral wall frequent diverticulum location intra diverticulum mass frequent clinical presentation two patient show tumor calcification one peripheral area allover tumor area vascular behavior tumor similar rest non intra diverticulum bladder neoplasm two case show main lumen involvement good tumor transitional cell carcinoma conclusion ct scan efficient diagnostic method intra diverticulum carcinoma good extension determination essential surgical plan value combine detection urinary livin survivin mrna expression early diagnosis bladder cancer objective evaluate value urine livin survivin mrna expression early diagnosis bladder cancer method fifty two case early bladder cancer case non urinary system tumor select combine detection urinary livin survivin urine cytology result livin survivin urine urinary cytology sensitivity specificity respectively urine survivin sensitivity specificity compare livin no significant difference p urinary livin survivin sensitive urine cytology difference statistically significant p conclusion combine urinary detection livin survivin mrna expression noninvasive early diagnosis bladder cancer sensitivity specificity combine effect high energy shock wave ionise radiation human bladder cancer cell line effect high energy shock wave hesw generate experimental siemens lithotripter combination c gamma ray examine vitro proliferation treatment immobilise pellet either single cell multicellular spheroid bladder cancer cell line rt determine use colony form assay cell cycle analysis survive cell cycle fraction calculate shock wave radiation application mode separately sequential combination different succession purpose characterize interaction treatment modality combination hesw ionise radiation turn act additively slightly supra additively biologic model carcinoma situ bladder apropos case case primary carcinoma situ describe symptomatology disease analyse role cytodiagnosis emphasise evolution variable case bladder become totally retract total cystectomy perform spite fact lesion remain intra urothelial invasive cancer developped case year diagnosis conservative treatment tur seem logical whilst carcinoma remain strictly situ bacillus calmette guerin bladder cancer helpful package no randomise control trial compare bcg rivm strain bcg medac versus bcg connaught strain immucyst package bcg medac far complete immucyst alcohol coffee bladder cancer risk review epidemiological study objective review epidemiological study evaluate association consumption coffee alcohol urinary bladder cancer search medline database observational study bladder neoplasm include information coffee alcohol drink look paper quote reference review risk factor bladder cancer study select inclusion result epidemiological study allow exclude strong association coffee bladder cancer several study report moderate increase risk coffee drinker compare nondrinkers no trend dose establish epidemiological datum alcohol drink bladder cancer suggestive no association although finding not always consistent habit explanation moderate increase risk observe investigation may attribute residual confound smoke association alcohol coffee yet unidentified risk factor bladder cancer diagnostic value circulate tumor cell detection bladder urothelial cancer systematic review meta analysis background diagnostic value prognostic significance circulate tumor cell ctc detection patient bladder cancer controversial perform meta analysis consolidate current evidence regard use ctc detection assay diagnose bladder urothelial cancer association ctc positivity advance remote disease method study investigate presence ctcs peripheral blood patient bladder cancer urothelial cancer identify review sensitivity specificity positive lr negative likelihood ratio lr ctc detection individual study calculate meta analyze random effect model overall odd ratio ctc positivity patient advance disease versus organ confine cancer also calculate result overall sensitivity ctc detection assay ci specificity lr lr ci ci ci ctc positive patient significantly likely advance stage iii iv disease compare ctc negative patient ci conclusion ctc evaluation confirm tumor diagnosis identify patient advance bladder cancer however due low overall sensitivity ctc detection assay not use initial screen test characterization uptake internalization exosomes bladder cancer cell bladder tumor represent special therapeutic challenge high recurrence rate require repeat intervention may progress invasive metastatic disease exosomes carry protein implicate bladder cancer progression implicate bladder cancer cell survival characterize exosome uptake internalization human bladder cancer cell use amnis imagestreamx image cytometer exosomes isolate ultracentrifugation bladder cancer culture condition supernatant label pkh analyze imagestreamx internal standard add determine concentration exosomes cocultured bladder cancer cell analyze internalization use idea software determine exosome uptake base numb pkh spot overall pkh fluorescence intensity use unlabeled bead know concentration size able determine concentration exosomes isolate bladder cancer cell measure exosome uptake recipient bladder cancer cell demonstrate uptake dose time dependent finally find uptake active specific partially block heparin treatment characterization cellular uptake internalization bladder cancer cell may shed light role exosomes bladder cancer recurrence progression apparent diffusion coefficient magnetic resonance image mri bladder cancer relation recurrence progression risk aim evaluate relationship apparent diffusion coefficient adc value bladder cancer recurrence progression risk post transurethral resection tur method forty one patient initial non muscle invasive bladder cancer undergo mri two radiologist measure adc value pathologist calculate recurrence progression score risk classify base score pearson correlation use analyze correlation adc value score risk group optimal cut value establish base receiver operate characteristic roc curve analysis furthermore relationship actual recurrence progression case adc value examine unpaird u test result significant correlation adc value recurrence score good progression score p p respectively also significant correlation adc value recurrence risk group good progression risk group p p respectively adc cut value roc analysis sensitivity specificity low intermediate recurrence risk group sensitivity specificity intermediate high recurrence risk group sensitivity specificity low intermediate progression risk group sensitivity specificity intermediate high progression risk group difference adc value recurrence nonrecurrence group unpaired test significant p conclusion adc mri bladder cancer can potentially useful non invasive measurement estimate risk recurrence progression plan day adaptive radiotherapy bladder cancer use helical tomotherapy background purpose study assess potential tomotherapy base image guide radiotherapy igrt increase accuracy bladder irradiation use plan day adaptive radiotherapy art technique material method ten patient muscle invasive bladder cancer undergo bladder preservation trimodality therapy ongoing trial patient receive gy whole bladder seven receive boost gy tumour bed art technique entail generation six imrt plan patient use six isotropic ptvs mm apply bladder volume ctv generate ptvs megavoltage ct mvct image do correct position error choose plan day result post treatment mvct scan scan use generate multiple anisotropic ptvs three hypothetical scenario overall coverage anterior superior wall require large margin wall maximum geographical miss spite igrt note superior anterior wall conclusion plan day art feasible promise technique optimal treatment dose escalation bladder cancer bladder cancer high precystectomy nlr increase risk development effective preventive strategy bladder cancer critical importance bladder cancer among common human malignancy typically recur treatment many plant derive isothiocyanate itcs show cancer preventive activity variety rodent organ know inhibit carcinogen activate enzyme induce carcinogen detoxify enzyme apoptosis cell cycle arrest differentiation cancer cell importantly orally ingest itcs efficiently absorb rapidly almost exclusively excrete concentrate urine n acetylcysteine conjugate nac itc nac itcs also possess anticarcinogenic activity perhaps due largely facile dissociation free itcs storage urine bladder make bladder epithelium line inner surface bladder give rise majority bladder cancer expose tissue itcs nac itcs upon ingestion storage urine bladder also increase release itcs nac itcs consequently amount itcs need orally achieve cancer prevention bladder may much low require organ result potential systemic adverse effect itcs may minimize use itcs chemoprevention bladder carcinogenesis take together itcs may especially useful prevention bladder cancer alteration dna methylome human bladder cancer bladder cancer 4 common cancer man unite state recurrence rate high among malignancy unmet need improve strategy early detection treatment monitor progression disease continue translate high mortality morbidity quest advance diagnostic therapeutic prognostic approach bladder cancer high priority achieve understand molecular mechanism initiation progression malignancy aberrant dna methylation single multiple cancer relate gene locus find human bladder tumor cancer cell line urine sediment correlate many clinicopathological feature disease include tumor relapse muscle invasiveness survival present review summarize publish research aberrant dna methylation connection human bladder cancer representative study highlight set forth current state knowledge gap knowledgebase future direction prime epigenetic field research identify potentially reversible drugable aberrant dna methylation event initiate promote bladder cancer development highlight biological marker early diagnosis effective therapy accurate prognosis malignancy urine cytology new marker advantage term bladder cancer high lifetime treatment surveillance cost per patient cancer new diagnostic tool ancillary test urine marker develope enhance sensitivity detect cancer cell exfoliate urinary tract reduce discomfort repeat cystoscopy several marker study other investigation provide advantage select case term detection rate new therapeutical approach non muscle invasive bladder cancer non muscle invasive bladder cancer give high tendency recur couple ever present possibility progress potentially life threaten muscle invasive disease remain challenge clinical problem optimal management begin early detection accurate risk assessment careful attention clinical histology feature prevention recurrence require sequential application tool completely remove visible disease avert reimplantation surgical resection ablate microscopic focus prevent emergence new primary tumor amidst field carcinogen expose urothelium previously standard adjunctive intravesical chemo immunotherapy obtain new vitality optimization strategy new drug rational drug combination provide potential improve efficacy reduce toxicity novel therapeutic modality investigation include activation host immune system enhancement cytotoxic effect chemotherapeutic agent new technological advance microwave chemothermotherapy offer hope well outcome even disease previously refractory conservative measure much research preclinical phase encourage result many study discuss suggest test human trial follow come year yet despite advance aggressive surgical management involve bladder removal continue indispensable life save maneuver must consider high risk case fail promptly respond measure although great stride continue make year diagnosis management bladder cancer considerably work need do order improve live patient disease microrna inhibit bladder cancer proliferation target cyclin microrna mir demonstrate regulate proliferation apoptosis many type cancer biological function bladder cancer remain unknown find expression mir downregulated bladder cancer comparison adjacent normal tissue enforce expression mir able inhibit cell proliferation tchu cell line result mir antisense oligonucleotide antisense mir molecular level result reveal cyclin expression negative regulate mir therefore datum report demonstrate mir important regulator bladder cancer contribute well understand important mis regulate mirnas characterisation bladder cancer cohort urological unit investigate frequency cigarette smoke patient diagnose bladder cancer datum obtain subject list private census washington county maryland case subject define person little year age diagnose bladder cancer icd code smoke information available control subject define random sample person frequency match age sex case control free bladder cancer smoke information available odd ratio current smoker association smoke bladder cancer adjust age sex statistically significant confidence interval chi square trend test combine mtor inhibition radiation improve antitumor activity bladder cancer cell vitro vivo novel strategy treatment purpose radiation therapy invasive bladder cancer allow organ preservation toxicity local control remain problematic improve efficacy treatment require radiosensitization tumor cell aim study investigate mammalian target rapamycin mtor downstream kinase phosphatidylinositol kinase pi k akt survival pathway may target radiation sensitization experimental design clonogenic assay perform use bladder cancer cell line um uc um uc um uc ku j bv jp order examine effect ionize radiation ir alone combination rad mtor inhibitor cell cycle analysis perform use flow cytometry vivo athymic mouse subcutaneously inject bladder cancer cell line treatment response rad mg kg daily fractionate ir total gy gy combination rad ir follow week tumor weight measure experimental endpoint result clonogenic assay reveal bladder cell line test additive effect observe combine treatment compare either treatment alone datum indicate effect due arrest g g phasis cell cycle treatment combine furthermore datum show arrest primarily regulate change level cyclin p p follow treatment vivo significant decrease tumor weight observe combine treatment compare either treatment alone control conclusion alter cell cycle inhibit mtor signal pathway combination radiation favorable outcome promise therapeutic modality bladder cancer separate surgical quality causality gain perspective debate lymph node count extent lymphadenectomy transitional cell carcinoma bladder particularly devastate due high rate recurrence difficulty retention treatment within bladder current cystoscopic approach detect stage tumor limit penetrative depth cystoscope light source intravesical dye highlight tumor surgical resection non specific address need improve specificity tumor detection follow report novel technology rely engineer core mesoporous silica msn surface modification generate contrast fluorescence magnetic resonance image mri particle surface functionalized include bladder cancer cell specific peptide cyc identify via phage display peptide possess nanomolar specificity bladder cancer cell homology across multiple species include mouse canine human study take advantage target expression bladder tumor not express normal bladder wall functionalized msn cyc improve bind efficiency specificity bladder cancer cell vitro vivo model msn instill bladder tumor bear mouse enhance weight mri signal improve detection tumor boundary finding support notion target nanomaterial present new option early detection eventual therapeutic intervention ultimately combination real time repeat mri evaluation tumor enhance nanoparticle contrast potential translation human clinical study tumor stage therapeutic monitor drug delivery comparison neoadjuvant adjuvant gemcitabine plus cisplatin chemotherapy muscle invasive bladder cancer aim radical cystectomy plus platinum base perioperative chemotherapy standard treatment patient clinically localize muscle invasive bladder cancer standard perioperative chemotherapy methotrexate vinblastine doxorubicin cisplatin mvac however no prospective randomize trial publish compare neoadjuvant adjuvant chemotherapy bladder cancer moreover efficacy perioperative chemotherapy gemcitabine plus cisplatin gc not clarify study compare clinical outcome neoadjuvant adjuvant chemotherapy patient receive gc method retrospectively review record patient schedule treat radical cystectomy plus perioperative chemotherapy gc institution primary outcome measure recurrence free survival rfs result total patient receive perioperative chemotherapy gc neoadjuvant adjuvant median numb cycle gc administer two group not significantly different median duration follow month follow period recurrence observe nine three patient neoadjuvant adjuvant group respectively rfs rate median follow neoadjuvant adjuvant group respectively no significant difference rfs median follow observe two group p conclusion result show no statistically significant difference rfs neoadjuvant adjuvant gc chemotherapy muscle invasive bladder cancer expect validate finding prospective randomize trial bladder cancer contemporary dilemma management bladder cancer 6 common malignant tumor course disease depend largely histological finding combination transurethral resection intravesical chemotherapy indicate superficial tumor able cure patient good differentiate cancer contrary muscle invasive poorly differentiate tumor take much little favorable course offer novel combine therapeutic approach little orthotopic continent bladder substitution seem possible recently observe trend towards improve overall survival may continue future emphasis prevention elimination carcinogen early detection squamous cell carcinogenesis squamous cell carcinoma urinary bladder contemporary review focus nonbilharzial squamous cell carcinoma bladder squamous cell carcinoma squamous metaplasia transitional cell carcinoma squamous differentiation infrequent finding western country common risk factor development consist chronic bladder irritation inflammation prognostic clinical relevance natural history squamous cell lesion investigation reveal individual premalignant characteristic recent development molecular characterization squamous alteration urinary tract indicate pathogenetic similarity interrelation may lead precise tumor classification risk stratification future nevertheless current clinical management patient premalignant malignant bladder squamous cell lesion remain challenge high evidence level study not available prognosis invasive squamous carcinoma poor review summarize available datum clinical presentation treatment outcome bladder squamous cell carcinoma metaplastic lesion transitional cell carcinoma squamous differentiation discuss implementable current advance understand bladder cancer tumorigenesis evaluation adaptive radiotherapy bladder cancer image base tumour control probability model clinical implementation adaptive radiotherapy strategy can benefit extend tool plan evaluation selection purpose investigate feasibility image base tumour control probability tcp model use bladder example tumour site potential benefit adaptive strategy material method two bladder cancer patient undergo plan ct daily cone beam ct cbct image treatment course include bladder outline every image series follow previously publish procedure various adaptive plan target volume ptvs generate inter fractional bladder variation observe \\ufeff1 four cbct session intensity modulate treatment plan deliver gy give ptv generate addition simultaneous integrate boost sib plan give gy boost tumour create use daily cbct image polynomial warp dose bladder volume element track fraction fraction tcp calculation employ track accumulate dose distribution together radiosensitivity parameter estimate publish datum local control bladder cancer perform dependence tcp simulate clonogenic cell distribution also explore result uniform clonogenic cell density whole bladder tcp vary gy plan sib plan low value find use small ptvs not geometrically enclose clinical target volume fraction increase clonogenic cell density tumour relative remain bladder tcp saturate approximately sib plan conclusion dose track tcp calculation provide additional information standard criterium geometrical coverage select case tcp model may useful tool plan evaluation selection multiple plan cytology lleal conduit urine bladder cancer patient diagnostic utility pitfall objective study cytomorphology urine obtain ileal conduit determine utility identify pitfall study design urine specimen case suspect prove bladder cancer receive period year analyze cytology laboratory case total bladder resection follow ileal conduit reconstruction follow cytologic analysis ileal conduit case form basis study result absence urothelial cell case smear predominantly show small scatter intestinal mucosal cell pyknotic nucleus extensive karyorrhexis numerous bacterium case cytology prove superior endoscopy radiology detect recurrent disease false negative case negativity attribute sample error false positive case dimensional cluster intestinal columnar cell erroneously diagnose adenocarcinoma conclusion urine obtain ileal conduit specimen show smear picture different specimen bladder thus imperative understand difference cytomorphology bladder urine ileal conduit urine minimize pitfall increase diagnostic utility epidemiological pathological prognostic characteristic bladder cancer elderly patient aim define present explanation epidemiological pathological prognostic difference bladder cancer elderly patient method bibliographical search perform medline bibliographic database nlm pubmed tool embase focus bladder cancer carcinogenesis elderly epidemiology prognosis result bladder cancer grow concern elderly \\ufeff1 foremost impact mainly consumer former user tobacco whose therefore frequently comorbidity associate consumption initiate carcinogenesis extend life length patient increase prevalence bladder cancer age promote carcinogenesis potentiate genetic abnormality reduce immune system performance age host destroy cancer cell delay diagnosis bladder cancer elderly patient explain make time can improve prognosis conclusion regardless variation therapeutic effect morbidity mortality treatment age promote occurrence aggressiveness bladder cancer incentive stop exposure carcinogen search bladder cancer patient hematuria not reduce advance age instead promote order improve prognosis treatment bladder cancer egypt part ii reconstruction technic group patient bladder carcinoma uniformly stage clinico radiologically pathologically accordance pathological stage treat follow close january no systemic chemotherapy regime use present study design assess value classical morphological parameter tumour extension histological subtype grade growth pattern prediction prognosis also evaluate adequacy current tnm classification th edition bladder cancer initial tumour stage appear useful criterion prediction prognosis nevertheless survival analysis confirm necessity modify present tnm classification routine clinical practice fact stage iii prove heterogeneous difference survival category pt pt b even statistically significant log rank p difference pt pt whole log rank p consequently invasion muscular layer reclassify common stage ii equivalent b category abcd system moreover stage iv also heterogeneous term survival despite overall life expectancy rather poor patient bladder carcinoma three subset different prognosis log rank p identify pt n ptxn ptxnym x represent numb therefore believe various subgroup distinguish future edition tnm classification current treatment modality involve role systemic chemotherapy aim bladder preservation make innovation even convenient new edition tnm classification bladder cancer apart tumour stage several microscopic morphological parameter valuable distinguish patient different prognosis pure transitional cell histology papillar growth low grade favourable datum fact tumour grade although somewhat subjective factor major prognostic importance pauwels distinction intermedium grade b also helpful assessment population intermediate prognosis similarly regard superficial tumour division infiltration level subepithelial connective tissue superficial deep muscularis mucosa also relevant even stratification grade bladder cancer current status diagnosis treatment bladder tumour variety appearance range purely mucosal minimally invasive lesion invasive cancer definite metastatic potential type tumour correspond particular treatment take account multiple factor none present time able definitely predict outcome tumour time discovery treatment endoscopic resection intravesical instillation design control recurrence superficial bladder tumour surgical resection bladder radiotherapy chemotherapy either alone combine radiotherapy design cure bladder cancer delay progression await therapeutic revolution recent effort attempt improve quality life patient escape treatment current perspective muscle invasive bladder cancer muscle infiltrate bladder cancer deal multimodality approach collaboration urologist medical oncologist radiotherapist neo adjuvant chemotherapy not prove improve survival may useful program bladder preservation response vac neo adjuvant chemotherapy important prognostic factor may represent patient selection factor not know whether well administer chemotherapy neo adjuvant adjuvant set may spare patient unnecessary chemotherapy international adjuvant chemotherapy trial coordinate eortc protocol hopefully clarify unanswered question concern whether not adjuvant chemotherapy immediately follow cystectomy improve survival molecular alteration associate bladder cancer progression clinically superficial tumor stage ta this account bladder neoplasm remain invasive metastatic lesion time initial presentation patient superficial tumor one recurrence initial treatment one 3 patient progress eventually die disease new method need identify monitor patient present high risk superficial tumor likely develop invasive carcinoma invasive muscle natural history quite variable highly lethal despite aggressive surgical resection radiotherapy chemotherapy overall cure rate remain range new biological determinant need proper selection therapy monitor review describe update molecular alteration reportedly associate bladder tumorigenesis cancer progression also review novel gene signal network identify use high throughput technology concept alteration affect genetic pathway become molecular biology exercise challenge evaluate target therapeutic development good translate progression outcome biomarker improve clinical management integration datum generate depth clinical evaluation histologic tumor characteristic validate biomarker can provide highly accurate predictive tool management bladder cancer patient specific induction bladder cancer mouse butyl hydroxybutyl nitrosamine effect hormonal modification sex difference response twenty three patient clinical n bladder cancer give trial trimodality therapy include transurethral resection tur systemic chemotherapy radiation complete therapy drop insufficient clinical effect local bladder recurrence see patient bladder preservation rate nineteen patient show complete histological response subsequent tur specimen not examine histological response thirteen patient show complete histological response maximal tur systemic chemotherapy tur chemotherapy radiotherapy bladder cancer patient cr rate cancer significantly high cancer year disease specific survival patient treat preservation therapy patient locally advance bladder cancer may benefit preservation therapy wavelength dependent photodynamic effect chemically induce rat bladder tumor follow intravesical instillation aminolevulinic acid purpose aim study determine photodynamic effect chemically induce rat bladder tumor intravesical instillation aminolevulinic acid ala pdt dependence laser wavelength light dose material method follow intravesical instillation ala solution mg ala isotonic saline sodium bicarbonate rat bladder tumor treat integral irradiation use laser light wavelength lambda nm lambda nm light dose range j cm result significantly high amount necrosis include damage normal urothelium obtain rat bladder tumor use laser light lambda nm conclusion ala assist photodynamic treatment superficial bladder cancer patient irradiation wavelength lambda nm recommend combine radiation chemotherapy locally advance bladder cancer micrornas mirnas short non code rnas play important role basic cellular process include differentiation proliferation apoptosis autophagy also involve various stage tumorigenesis play key role bladder cancer initiation progression notably alter expression mirnas tumor reflect body fluid include blood urine open avenue non invasive diagnosis prognosis many study demonstrate epigenetic change extensively alter tumoral microrna expression high reproducibility specificity sensitivity mirna level body fluid suggest potential use biomarker cancer screen diagnosis example recent technological advance make possible detect mirnas urine bladder cancer screen review focus mainly current knowledge future challenge incorporate mirnas body fluid like urine blood make clinical diagnosis assess prognosis bladder cancer bladder carcinoma cell line model pathobiology bladder cancer review literature establishment new progression series background tumour cell line represent valuable preclinical model decipher underlie biology identify potential therapy target pharmacologically useful compound approximately human bladder cancer cell line establish date mainly invasive metastatic tumour two namely j experimentally develope progression series model provide important insight late tumour progression event metastatic dissemination cell line available model non invasive papillary bladder cancer no progression series yet establish material method course establish doxorubicin resistant variant cell line human papillary bladder carcinoma cell line bftc unique cell colony identify apparently involve cell divergent growth pattern subsequent subculturing yield three daughter cell line bftc compact bftc diffuse und bftc diffuse fundamental characterization include basic cell morphology cell membrane expression e cadherin karyotype analysis invasion colony form capacity soft agar clonal origin newly establish daughter cell line assess mean molecular genetic method result can identify important difference multiple transformation relate trait among cell line bftc progression series diffuse cell line bftc diffuse und bftc diffuse differ bftc compact cell line grow little organize diffuse manner involve colony cell exhibit apparently normal cell cell adhesion good individual cell outside diminution cell cell adhesion accompany correspond decrease membranous e cadherin bftc diffuse cell line display dramatic increase overall chromosome numb result hypertetraploid karyotype time cell line one progression series acquire ability grow independent anchorage soft agar three cell line remain noninvasive allelic distribution highly polymorphic dna marker cell line bftc progression series provide unequivocal evidence common origin conclusion newly establish bftc progression series manifest two aspect early progression non invasive bladder carcinoma not exhibit progression series publish far namely dynamic change expression e cadherin complex karyotypic evolution may thus contribute important insight understand pathobiology bladder cancer multidisciplinary treatment invasive bladder cancer improve cure rate locally invasive bladder cancer patient perform radiation therapy prior radical cystectomy patient since total dose gy week irradiate pelvic cavity patient gy without hyperthermia week apply patient since treatment efficacy assess histopathologically accord evaluation system propose shimosato et al approximately patient respond good preoperative therapy among patient pt lesion show significantly favorable prognosis compare stage patient not respond radiation therapy however survival rate pt stage patient not correlate responsiveness radiation result suggest pt stage patient well candidate preoperative radiation therapy radical cystectomy alone adequate superficially invasive lesion systemic chemotherapy properly build treatment strategy locally far advance bladder cancer dna ploidy pattern flow cytometry indicator malignancy prognosis bladder cancer flow cytometry fcm bladder cancer unique characteristic \\ufeff1 bladder wash suitable material measure term single cell suspension urine appear inadequate low sensitivity detect bladder cancer 2 role fcm depend different feature superficial situ invasive bladder cancer superficial cancer fcm detect presence cancer predict intravesical recurrence evaluate response intravesical instillation therapy carcinoma situ frequent occurrence polyclonal aneuploid may indicate aggressive nature high grade malignancy early removal bladder may endorse unless bcg instillation effective invasive cancer fcm not seem useful fcm relate good prognostic parameter risk fracture radical cystectomy urinary diversion bladder cancer objective determine whether difference local review pathology multicentre study influence result treatment result prognostic factor analysis patient method randomize multicentre study superficial bladder cancer report influence local review pathology study outcome investigate result conformity local review pathology pt category grade combination local pathology undergrading frequent overgrading overstaging frequent understaging however risk recurrent disease separate stage grade group remain correct pathology result prognostic factor analysis regard risk recurrent disease carry cox hazard ratio tumour localization multiplicity patient age significant factor tumour grade size history gender not significant remain almost correction review pathology prognostic relevance tumour stage increase pathology correction conclusion conclude although review pathology cause considerable change pathology result not change result treatment hardly alter result prognostic factor analysis randomize study urinary tract reconstruction improve quality life man bladder cancer rationale locoregional stage lymphadenectomy prostate cancer lie accurate diagnosis occult micrometastases order stratify patient may benefit adjuvant therapeutic measure prostate cancer extend pelvic lymphadenectomy epla include lymphatic tissue along common iliac region ureteral cross cranial margin external internal iliac region obturator fossa show increase yield total lymph node lymph node metastasis significantly total numb lymph node remove fold high frequency micrometastatic lymph node approximately fold high compare standard lymphadenectomy furthermore frequency observe positive lymph node clinically localize locally advance prostate cancer significantly high predict nomograms partin table cart analysis although no prospective randomize trial demonstrate survival benefit associate epla may advantage minimal lymph node involvement progression free survival significantly improve patient undergo epla benefit compare standard lymphadenectomy various study document equal risk cancer associate mortality patient no positive lymph node since surgery associate morbidity epla not increase compare standard lymphadenectomy epla favour little intermediate high risk patient undergo radical prostatectomy low risk patient option epla discuss thoroughly future ongoing prospective trial demonstrate clear benefit term biochemical free cancer specific survival regard muscle invasive bladder cancer show lymph node dissection along external internal common iliac artery obturator fossa achieve accurate datum valid locoregional stage freeze section analysis reveal metastatic deposit along area extension lymphadenectomy include aortic bifurcation inferior mesenteric artery seem additional diagnostic value various study demonstrate extend pelvic lymphadenectomy result improvement progression free survival however no significant benefit regard cancer specific overall survival demonstrate nevertheless pelvic lymphadenectomy remain one significant prognosticators regard relapse rate demonstrate recently therefore perform thoroughly anatomically adequate detection bladder cancer multitarget multicolour fish comparative analysis archival cytology paraffin embed tissue detection bladder cancer multitarget multicolour fish comparative analysis archival cytology paraffin embed tissue evaluate possibility use specimen cytological diagnosis multitarget multicolour fish mtmcfish analysis order determine whether routinely process specimen use diagnosis also suitable ancillary procedure purpose positive sample void urine seven bladder washings select together representative section correspond immediately previous subsequent histological specimen two negative cytology slide add negative control fish analysis reveal normal pattern probe two negative control abnormal pattern positive case latter fish alteration find cytology sample correspond histological section superimposable cytological histological feature observe two case two different histology sample analyze result clearly show mtmcfish may successfully apply destained routinely process cytology slide risk factor upper tract recurrence patient undergo long term surveillance stage ta bladder cancer purpose evidence clear patient carcinoma situ high grade tcc bladder high risk develope uut tumor role image uut patient ta tumor remain controversial hypothesize numb frequency recurrence patient ta disease would allow us identify population undergo routine uut surveillance material method review database patient undergo resection stage ta tcc median followup year patient stratify accord presence uut occurrence rate time superficial recurrence grade initial bladder tumor result among patient no bladder recurrence tumor tumor tumor average time tumor month uut tumor develope patient average month initial bladder tumor high risk group consist patient bladder recurrence recur within month fold risk uut tumor conclusion stage ta bladder cancer patient recurrence bladder tumor median little month recurrence high risk develope uut tumor consider frequent uut surveillance experience treat cancer bladder experience treatment urinary bladder cancer base upon observation case present two hundred thirteen patient treat surgically perform case partial cystectomy case total cystectomy conservative treatment apply patient author opinion well method treat bladder cancer radical excision simple easy method implantation ureter rectum describe analysis lymphocyte subpopulation bladder follow endovesical immunotherapy use bcg author study mean immunohistochemical analysis lymphocyte subpopulation bladder biopsy patient treat urothelial bladder tumour this ta intravesical bcg group biopsy take optically healthy zone freeze lymphocyte population urothelium chorion study mean monoclonal antibody tq leu okm hla dr tac pan b four patient without bladder cancer constitute control group group b patient bladder cancer not treat intravesical bcg constitute group c group tq lymphocyte predominate urothelium chorion inversion ratio observe urothelium group b c p little chorion group b p little no significant difference ratio chorion group c group patient express presence receptor interleukin tac hla dr lymphocyte case lymphocytic infiltration associate presence eosinophil p little total absence nk cell observe no b lymphocyte detect apart rare lymphoid follicle arsenic drink water bladder cancer mortality unite state analysis base u county year observation study analyze relationship arsenic exposure drink water bladder cancer mortality county specific white male bladder cancer mortality datum county specific groundwater arsenic concentration datum obtain u county know exclusively dependent groundwater public drink water supply no arsenic relate increase bladder cancer mortality find exposure range microg l use stratify analysis regression analysis unweighted weight county population use mean median arsenic concentration result provide direct estimate arsenic relate cancer risk u resident exclude national research council risk estimate base southwest taiwan datum require adjust difference body mass water consumption rate u taiwanese resident evidence base principle bladder cancer diet bladder cancer present substantial challenge public health dietary factor influence risk bladder cancer incidence recurrence may offer innovative therapy prevention agent associate decrease risk bladder cancer include carrot selenium cruciferous vegetable fruit dietary component associate increase bladder cancer risk include pork barbecue meat fat soy excessive coffee consumption although definitive clinical trial yet perform promotion healthy lifestyle intervention base dietary factor increase vegetable fruit intake decrease meat fat intake consider care patient bladder cancer search novel therapeutics target insight clinical trial recent advance behind understand molecular mechanism bladder tumorigenesis contribute towards identification molecule act potential therapeutic target novel agent concurrently also lead understand effective therapy superficial invasive bladder cancer entail combination therapeutic agent target multiple tumorigenic pathway management bladder cancer patient case many solid tumor may witness radical transformation come year translate molecular understand disease novel clinical trial design screen technique gene expression profile bladder cancer identify potential therapeutic target despite advance management bladder cancer remain major cause cancer relate complication characterisation gene expression pattern bladder cancer allow identification pathway involve pathogenesis may stimulate development novel therapy target pathway cystoscopic bladder biopsy obtain patient control subject whole transcript base microarray analysis unsupervised hierarchical cluster use identify sample similar expression profile hypergeometric analysis use identify canonical pathway curate network statistically significant enrichment differentially express gene osteopontin opn expression validate immunohistochemistry hierarchical cluster define signature differentiate cancer healthy tissue muscle invasive non muscle invasive cancer healthy tissue grade grade pathway associate cell cycle proliferation markedly upregulated muscle invasive grade cancer gene associate classical complement pathway downregulated non muscle invasive cancer osteopontin markedly overexpress invasive cancer compare healthy tissue present study contribute grow body work gene expression signature bladder cancer datum support important role osteopontin bladder cancer identify several pathway worthy investigation extent pelvic lymphadenectomy impact outcome patient diagnose bladder cancer analysis datum surveillance epidemiology end result program datum base purpose benefit pelvic lymphadenectomy patient bladder cancer remain controversial analyze impact lymphadenectomy disease specific survival population base sample patient bladder cancer undergo radical cystectomy material method analysis include datum patient undergo radical cystectomy bladder cancer obtain surveillance epidemiology end result program cancer registry analyze impact numb lymph node examine numb positive lymph node ratio positive total numb lymph node resect disease specific overall survival independent patient age gender stage race radiation chemotherapy result median followup cystectomy case month range patient lymph node examine significantly high risk death bladder cancer great hr versus patient stage situ iii iv disease benefit extensive lymphadenectomy stage iv case total numb positive lymph node remove not correlate increase survival proportion excise lymph node positive metastatic bladder cancer tend correlate risk death disease conclusion result indicate significantly increase survival rate cystectomy patient bladder cancer diagnose stage iii iv disease relatively lymph node examine suggest even high stage disease may benefit extend pelvic lymphadenectomy cystectomy combine modality treatment organ preservation bladder cancer molecular marker predict outcome purpose invasive bladder cancer several group report value organ preservation combine treatment approach include transurethral resection standardization radical cystectomy pelvic lymph node dissection bladder cancer collaborative group report purpose propose standard radical cystectomy pelvic lymph node dissection surgical treatment patient invasive bladder cancer material method compile consecutive cystectomy experience experience surgeon last year institution evaluate patient tumor surgical variable margin status extent pelvic node dissection numb node examine surgeon volume associate bladder cancer outcome result total cystectomy case evaluate surgical margin numb node retrieve correlate patient age prior treatment pathological tumor stage extent node dissection not surgeon volume conclusion standard radical cystectomy establish achieve experience surgeon operate patient present diverse clinical situation positron emission tomography l methyl c methionine monitor therapy response muscle invasive transitional cell carcinoma urinary bladder objective investigate whether positron emission tomography pet l methyl c methionine tracer can use diagnostic purpose evaluation therapy patient vary stage urinary bladder cancer treat chemotherapy patient method pet employ separate examination involve patient man five woman median age year mean range localize metastatic transitional cell carcinoma urinary bladder four patient pet examination perform prior commencement chemotherapy one course three course result diagnostic accuracy pet poor technique not monitor therapeutic effect neoadjuvant chemotherapy produce result correlate therapy outcome pet identify patient respond little successfully therapy conclusion pet l methyl c methionine demonstrate alteration tumour metabolism long visible change appear compute tomography magnetic resonance image work require develop specific tracer new chemoradiation approach bladder cancer test rtog objective half diagnose patient bladder cancer bca recur little follow initial treatment thus patient monitor prognosis utmost importance however need intensive surveillance bca significantly burden patient health relate quality life aim present study expression analysis bcl l recently identify member bcl apoptosis relate gene family bca evaluation bcl l prognostic significance survival outcome patient method material study include patient bca tissue specimen obtain tumor area good adjacent normal bladder wall bcl l expression determine use quantitative real time polymerase chain reaction assay correlate patient clinicopathological feature follow survival datum result regulate bcl l expression level detect malignant bladder specimen compare normal one high bcl l expression associate short disease free survival patient bca focus patient tat non muscle invasive bca bcl l expression level correlate high recurrence rate \\ufeff1 follow cystoscopy unveil independent unfavorable predictor patient short term recurrence follow transurethral resection finally bcl l expression level also associate poor disease free survival high grade tat patient conclusion datum highlight unfavorable prognostic value bcl l patient bca support potential clinical use assessment tat patient recurrence risk fibulin regulate urothelial carcinoma bladder inhibit growth invasion human bladder cancer cell line purpose expression fibulin investigate urothelial carcinoma bladder normal bladder sample effect fibulin cell proliferation motility invasion explore bladder cancer cell line material method expression fibulin bladder carcinoma sample normal bladder sample detect western blot fibuin cdna clone p egfp n vector transfect bladder cancer cell line growth curve estimate dimethylthiazol yl diphenyl tetrazolium bromide assay cell numb count migration invasion transfect cell control cell measure boyden chamber assay result compare normal control mean sd expression fibulin low grade tumor high grade tumor p p respectively expression ta tumor tumor p p respectively difference low grade high grade tumor ta tumor not statistically significant p p respectively growth rate fibulin transfect gfp f cell remarkably reduce untransfected cell empty vector transfect gfp cell besides compare control cell gfp f cell show significant inhibition cell invasion slight inhibition cell migration conclusion fibulin regulate urothelial carcinoma bladder act tumor suppressor gene inhibit proliferation invasion bladder cancer cell toll like receptor role bladder cancer development progression immunotherapy bladder cancer one lead cause death worldwide main immune mechanism lead bladder cancer development treatment outcome yet elucidate toll like receptor tlrs play key role cancer tlrs express immune cell tumour cell drive immune response progression good treatment cancer identification signal pathway via tlrs can revolutionize improvement therapeutic strategy cancer future accord recent study tlrs agonist effective immunostimulants important role induction immune response immunotherapeutic potential several disease include cancer play important role bladder urothelium part immune defence uropathogens hand decrease tlrs expression find bladder tumour particularly non muscle invasive one bacillus calmette guerin bcg agonist tlr tlr approve us fda immunotherapy bladder cancer despite high efficiency immunotherapy bcg may cause toxicity adverse effect nowadays vitro vivo study conduct find alternative option non responder patient study tlr agonist bladder cancer treatment show promise result review discuss recent datum mechanism play tlrs bladder cancer development good therapeutic application tlr agonist cancer treatment immunotherapeutic strategy high risk bladder cancer transitional cell carcinoma tcc pathological diagnosis majority bladder cancer solid tumor entity responsive immunotherapy evidence substantial cure rate document use intravesical bacillus calmette gu rin bcg therapy select patient risk local urethral recurrence radical cystectomy bladder cancer radical cystectomy urinary diversion perform patient transitional cell cancer bladder followup year reveal per cent patient free urethral recurrence year cystectomy respectively statistical elimination urethral recurrence not improve survival rate significantly appear supplementation cystectomy simultaneous urethrectomy may not justify urethra not involve cancer define optimal therapy muscle invasive bladder cancer purpose define optimal curative strategy muscle invasive bladder cancer determine well deliver curative therapy material method review publish report deal treatment muscle invasive stage bladder cancer analyze cohort phase ii randomize phase iii study provide level evidence impact survival result cisplatin base chemotherapy combine high quality radical cystectomy complete pelvic lymph node dissection improve survival cystectomy alone surgery quality important predictor survival even patient receive chemotherapy neoadjuvant chemotherapy favor adjuvant chemotherapy well tolerate patient able receive effective therapy rather surgery conclusion neoadjuvant chemotherapy follow radical cystectomy complete pelvic lymph node dissection optimal curative strategy patient present muscle invasive bladder cancer molecular biological change bladder cancer large numb potential molecular marker bladder cancer identify although truly independent prognostic factor numb marker may need measure single tumour use combination use diagnosis prognosis transitional cell carcinoma tcc epidermal growth factor receptor immunoreactivity show independent predictor survival stage progression tp may independent predictor recurrence overall survival tcc confine bladder tp alteration may predict chemosensitivity patient tcc treat radical cystectomy present molecular technique fluorescence situ hybridization polymerase chain reaction restrict laboratory immunohistochemical method available hospital pathology department discrepancy conflict report usefulness molecular marker different study need address large prospective multi institutional study use standardize molecular technique quality care partial cystectomy bladder cancer case inappropriate use purpose partial cystectomy perceive little morbid little technically demand procedure radical cystectomy although select patient approximately appropriate candidate solitary tumor space time absence carcinoma situ quality care perspective overuse partial cystectomy may signify inappropriate delivery health care material method subject undergo extirpative treatment bladder cancer identify within surveillance epidemiology end result seer registry nationwide inpatient sample nis adjust model develope identify clinical factor independently associate use partial cystectomy bladder cancer treatment within sample result among patient undergo extirpative surgery bladder cancer seer nis respectively undergo partial cystectomy significant decrease use early late year note sample seer nis p partial cystectomy preferentially use elderly stage disease female black patient furthermore partial cystectomy commonly provide rural nonteaching low volume hospital conclusion trend national use partial cystectomy consistent nis seer patient currently treat partial lieu radical cystectomy partial cystectomy disproportionately use certain medical center nonteaching rural low volume patient population elderly black female stage disease reflect selective referral overuse neoadjuvant chemotherapy invasive bladder cancer interest case report report case year old woman histological diagnosis muscle invasive high grade transitional cell carcinoma clinical diagnosis tc metastatic disease treat platinum base combination chemotherapy obtain pathologic complete response neoadjuvant chemotherapy bladder cancer even limitation regard patient selection current development surgical technique current chemotherapy combination show improve overall survival year consider muscle invasive bladder cancer irrespective definitive treatment association tacc r polymorphism risk urinary bladder cancer synthesis base current evidence background possible association tacc r polymorphism urinary bladder cancer risk indicate publish literature perform meta analysis synthesis relevant datum summarize currently available evidence provide estimation increase precision method embase pubmed google scholar wanfang datum search r urinary bladder cancer use search term total eligible study identify case control investigate oxidative stress red blood cell bacillus calmette guerin intravesical instillation although bacillus calmette guerin bcg intravesical instillation widely accept effective modality treat bladder carcinoma situ prevent superficial bladder cancer recurrence mechanism action not yet fully understand antitumor effect bcg mostly relate local immunological event systemic activation immune system not exclude objective present study estimate systemic production oxidant intravesical bcg treatment systemic production oxidant estimate assess red blood cell rbc oxidative stress twelve patient undergo bcg immunotherapy bladder carcinoma situ rbc oxidative stress induce peroxynitrite determine luminol enhance chemiluminescence treatment period rbc oxidative stress reveal biphasic curve change initial fold increase drop pretreatment level follow th instillation intravesical bcg administration induce systemic production oxygen free radical may reflect systemic activation immune system epidemiology bladder cancer west yorkshire preliminary report non occupational aetiology objective report long term result survival toxicity pattern failure different organ spare strategy patient muscle invasive bladder cancer material method monoinstitutional prospective analysis consecutive bladder spare protocol combine maximal transurethral resection bladder tumor mturbt radiotherapy rt cisplatin base chemotherapy protocol consist neoadjuvant methotrexate cisplatin vinblastine follow endoscopic evaluation consolidative rt gy complete responder protocol involve alter fractionation rt gy concurrent weekly cisplatin evaluation gy protocol consist rt gy concomitant weekly cisplatin nonresponders undergo radical cystectomy probability overall survival os cancer specific survival css metastasis free survival mfs calculate use kaplan meier product limit estimate cox regression multivariate analysis perform detect potential risk factor os css mfs result year bladder preservation rate year os css mfs rate respectively no statistically significant difference os different treatment protocol multivariate analysis mturbt bladder complete response induction therapy independent correlate improve os mfs development invasive bladder recurrence independently associate wrong css mfs conclusion ten year result indicate bladder spare treatment successful approach muscle invasive bladder cancer select patient mturbt bladder tumor complete response induction therapy remain relevant predictive factor asymptomatic microscopic hematuria predictor neoplasia urinary tract objective danish hematuria guideline revise january revision recommend asymptomatic microscopic hematuria patient year old routinely urologically investigate revise guideline patient asymptomatic microscopic hematuria not recommend investigate irrespective age purpose study investigate whether asymptomatic microscopic hematuria predictive neoplasia urinary tract refer cohort patient method patient old year refer primary care private clinic public hospital central denmark region evaluation asymptomatic microscopic hematuria year period january december include retrospectively patient routinely investigate compute tomography urography outpatient flexible cystoscopy patient age gender record final diagnosis full investigation retrieve result total patient male female include eleven patient diagnose neoplasia urinary tract include non invasive ta bladder tumor n benign tumor kidney n invasive bladder cancer n carcinoma situ urinary bladder n none patient renal cancer upper urinary tract tumor final diagnosis conclusion minority patient malignancy non invasive tumor would miss base revise danish hematuria referral pathway forty year cisplatin base chemotherapy muscle invasive bladder cancer understand purpose year cisplatin base chemotherapy administer patient muscle invasive bladder cancer mibc well evidence efficacy find context neoadjuvant chemotherapy nac however benefit patient modest improvement year overall survival approximately patient still muscle invasive disease cystectomy despite nac select patient base likelihood response appear promise strategy improve modest benefit realize promise researcher investigate biomarker identify responder non responder prior nac method review discuss numb tissue liquid base biomarker associate response nac result conclusion elaborate biomarker methylation dna rna protein level give current status clinical trial implementation daily clinical practice particular detection alteration dna damage repair pathway good molecular subtype seem promise method identify responder nac furthermore illustrate liquid base biomarker circulate tumor dna ctdna patient blood urine appear offer elegant way biological characterization mibc recent datum show presence ctdna limit patient localize mibc consider nac disease stage ctdna patient urine may promise genomic characterization mibc however ctdna blood urine not yet rigorously investigate clinical context radical cystectomy treatment advance bladder cancer thirty two case advance bladder cancer pt b pt undergo radical cystectomy compare similar series patient stage submit different treatment radiotherapy chemotherapy combine treatment report literature survival rate year analyze relation anatomopathological stage cellular grade lymph node infiltration surgical risk relative mortality result confirm radical cystectomy presently effective treatment high morbidity mortality find high risk non muscle invasive bladder cancer objective give update review concern role combine regimen ct base microwave induce hyperthermia mwht ct mwht intravesical chemotherapy ict treatment non muscle invasive bladder cancer nmibc evidence acquisition review process follow prefer report item systematic review meta analysis prisma guideline electronic search medline embase cochrane library cancerlit clinicaltrials gov database undertake relevant conference abstract urology journal also include primary end point time recurrence secondary end point include time progression bladder preservation rate adverse event ae rate evidence synthesis total study meet inclusion criterium undergo datum extraction feasible datum combine use random effect case referent study occupational risk factor bladder cancer southern israel objective evaluate possible association occupational exposure risk factor male bladder cancer negev region southern israel enable preventive strategy apply method total male bladder cancer patient diagnose regional medical center study interview compare male without oncological disease match age country origin special questionnaire develope gather information demography life time occupational history smoke habit coffee consumption health status statistical analysis case referent datum do use spss package performance chi square test conditional logistic regression multiple classification analysis result significant association find bladder cancer occurrence three different group occupational exposure solvent p not compute due lack expose person among referent b dust p c exposure multiple chemical p nephrolithiasis p cigarette smoke p conclusion certain type occupational exposure different aromatic amine dye may consider contribute factor epidemiology bladder cancer well identification chemical work process use may help abate exposure thus lead reduction risk relatively common cancer intravesical irrigation distill water immediately transurethral resection late superficial bladder cancer retrospective study influence distill water use irrigation fluid immediately complete removal superficial bladder cancer recurrence bladder cancer evaluate thirty two percent recurrence develope \\ufeff1 year patient 2 year patient month year recurrence free rate respectively result support concept recurrence may arise tumor cell implantation time transurethral management bladder tumor may reduce effectively use distill water ileal neobladder woman bladder cancer cancer control functional aspect purpose review radical cystectomy urinary diversion accept standard care invasive bladder cancer although orthotopic neobladder prefer method urinary diversion man little experience available woman recent study report subject summarize review recent finding urethra spare cystectomy woman orthotopic urinary diversion perform safely appropriately select woman invasive bladder cancer excellent oncological outcome expect minimal risk urethral recurrence case negative freeze section proximal urethra orthotopic neobladder diversion offer excellent clinical functional result diversion choice woman follow cystectomy female sexual dysfunction avoid patient receive neurovascular preservation although quality life decline woman undergo non nerve spare radical cystectomy summary urethra spare cystectomy not compromise oncologic outcome woman bladder cancer excellent functional outcome void pattern orthotopic urinary diversion argue favor technique prefer method low urinary tract reconstruction radical cystectomy nerve spare radical cystectomy preserve female sexual function improve quality life molecular subtype profile urothelial carcinoma use subtype specific immunohistochemistry panel molecular subtype bladder cancer bc determine relatively small immunohistochemistry panel non muscle invasive nmi muscle invasive mi tumor analysis nmi tumor two marker need although classification dependent also pathological grade histological evaluation result classification three tumor cell phenotype nmi bc urothelial like uro genomically unstable gu basal scc like analysis mi tumor marker need large numb marker require classification mi bc reflect inclusion two additional phenotype exclusively find invasive tumor mesenchymal like mes like small cell neuroendocrine like sc ne like follow description perform approach ihc base subtype classification bladder cancer'"
      ]
     },
     "execution_count": 82,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "key_type_4 = ''\n",
    "for word in df_type_4:\n",
    "    key_type_4 = key_type_4 + ' ' + word\n",
    "key_type_4"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [],
   "source": [
    "from wordcloud import WordCloud\n",
    "\n",
    "wordcloud = WordCloud(width=800, height=800, background_color='white', min_font_size=14).generate(key_type_4)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x864 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "plt.figure(figsize=(12,12), facecolor = None)\n",
    "plt.imshow(wordcloud)\n",
    "plt.axis(\"off\")\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "8000    draft well medical treatment patient low risk ...\n",
       "8001    evolve field thyroid cancer refinement old cre...\n",
       "8002    new tnm classification thyroid cancer backgrou...\n",
       "8003    integrate analysis thyroid cancer public datas...\n",
       "8004    malignant tumor thyroid gland objective aim de...\n",
       "                              ...                        \n",
       "8995    surgical management recur metastatic thyroid c...\n",
       "8996    benign intranodal thyroid tissue mimick nodal ...\n",
       "8997    diffuse sclerosing variant thyroid papillary c...\n",
       "8998    prognostic impact tumour multifocality thyroid...\n",
       "8999    thyroid cancer seom clinical guideline thyroid...\n",
       "Name: Clean_Description, Length: 1000, dtype: object"
      ]
     },
     "execution_count": 85,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_cluster_5 = PubMed[(PubMed['CancerType'] == 'Thyroid')]['Clean_Description']\n",
    "df_cluster_5"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "' draft well medical treatment patient low risk thyroid cancer introduction incidence good differentiate low risk thyroid cancer increase globally last three decade thyroid cancer treatment relate suitable surgical procedure use adjuvant radio iodine therapy select patient evaluation prognostic factor risk stratification critical determine appropriate treatment survival patient low risk thyroid cancer excellent appropriate choice medical treatment result full recovery patient relapse risk increase size primary tumor along finding risk factor man method result study include total patient diagnose b tumor year population include woman average age year man average age year bulk file represent papillary carcinoma small group follicular carcinoma patient divide four group accord tumor size patient evaluate accord risk factor unifocality no risk factor multifocality bearing thyroid tumor metastasis regional lymph node distant metastasis combination risk factor group monitor set patient papillary follicular microcarcinoma mm histological input finding reveal one bear unifocal type cancer patient multifocality find patient local nodal metastasis demonstrate case pulmonary metastasis discove red case group b group study patient papillary follicular microcarcinoma size mm histological finding capture input one bear carcinoma patient patient multifocality case local nodal metastasis case bone metastasis group c group study patient papillary follicular microcarcinoma size mm histological initial find capture unifocal type cancer patient multifocality patient case local metastasis case pulmonary metastasis group patient monitor group breast size mm initial find capture one bear cancer patient multifocality patient case evidence local metastasis patient case distant lung metastasis patient risk factor find radioiodine treatment indicate include patient group patient year relapse observe patient patient not undergo radioiodine treatment relapse patient conclusion base analysis necessary stratify risk relapse accord risk factor case miss radioiodine therapy patient low risk cancer without confirm risk factor also necessary regular clinical laboratory ultrasound examination important distinguish patient risk factor may contribute disease recurrence way one hand prevent excessive treatment patient low risk thyroid cancer lead increase cost health care hand prevent reduce level care patient increase relapse evolve field thyroid cancer refinement old creation new paradigm secondary hemophagocytic lymphohistiocytosis hlh rare potentially fatal immune deficiency disorder develop response disease produce strong immunologic activation infection malignancy although secondary hlh report occur association various malignancy no report association thyroid cancer evaluate year old man present hlh investigation underlie cause hlh compute tomographic scan neck discover thyroid nodule confirm biopsy papillary thyroid carcinoma treat surgery follow radioactive iodine therapy remain without recurrence malignancy secondary hlh report document \\ufeff1 observation hlh associate thyroid cancer illustrate need include image neck evaluate patient secondary hlh underlie malignancy new tnm classification thyroid cancer background numerous study concern diagnosis treatment prognosis patient papillary thyroid carcinoma relatively address patient follicular carcinoma method author analyze experience patient undergo thyroid operation pure follicular thyroid carcinoma result patient woman man mean age year follow postoperatively mean year fifty two patient see initially solitary thyroid nodule symptom presentation median tumor size cm fine needle aspiration biopsy perform patient reveal follicular neoplasm patient inadequate specimen patient nineteen patient receive thyroid stimulate hormone tsh suppressive thyroid hormone therapy average month surgery tumor size remain patient increase decrease presentation six patient lymph node involvement three locally invasive tumor two distant metastasis initial operative treatment lobectomy patient total thyroidectomy patient lobectomy plus contralateral partial subtotal lobectomy patient lesser procedure patient twenty nine patient completion total thyroidectomy final surgical treatment consist total thyroidectomy patient among patient intraoperative freeze section correctly diagnose cancer permanent complication occur operation three patient die thyroid cancer one anaplastic transformation since thyroidectomy two live distant metastatic disease conclusion patient follicular thyroid cancer \\ufeff1 examine usually solitary thyroid nodule follicular neoplasm aspiration cytology nodule fail regress response tsh suppressive therapy freeze section rarely aid management prefer treatment follicular neoplasm lobectomy follow completion total thyroidectomy histologically prove carcinoma large cm total thyroidectomy allow use thyroglobulin radioiodine scan detect treat metastatic disease complication thyroidectomy uncommon mortality rate treat patient relatively low integrate analysis thyroid cancer public dataset reveal role papillary thyroid carcinoma ptc good differentiate thyroid tumor account approximately thyroid cancer case hand anaplastic thyroid carcinoma atc little frequent aggressive subtype poor prognosis micrornas mirnas small non code rnas emerge potent malignant tumor thyroid gland objective aim determine effect adjuvant radioactive iodine dose recurrence rate high risk papillary thyroid cancer method patient treat papillary thyroid cancer high volume center france unite state review patient consider high risk recurrence per american thyroid association guideline analyze group initial radioactive iodine dose intermediate median mci high dose median mci propensity score match perform control baseline characteristic result propensity match cohort patient pair equivalent rate gross extrathyroidal extension vs p positive margin vs p lymph node metastasis cm vs p extranodal extension vs p distant metastasis vs p median follow year interquartile ratio year intermediate dose radioactive iodine group significantly high rate recurrence patient high dose radioactive iodine group vs p conclusion high dose radioactive iodine associate low recurrence rate compare intermediate dose radioactive iodine patient american thyroid association high risk papillary thyroid cancer no difference outcome metastatic thyroid cancer patient use recombinant endogenous tsh objective present recombinant tsh not use treatment metastatic differentiate thyroid cancer patient aim study evaluate type tsh stimulation recombinant endogenous impact outcome patient design method compare outcome two propensity score match group metastatic patient stimulate either recombinant tsh n endogenous tsh n result expect match procedure clinical pathological feature cumulative activity administer two group similar year follow patient cure biochemical disease structural disease however patient obtain clinical benefit therapy term stabilization disease complete remission partial response consider two group separately not find difference outcome consider response therapy single type metastasis lymph node metastasis lung metastasis disappear none bone metastasis response therapy single type metastasis similar look two group separately conclusion study show overall clinical benefit therapy since majority patient remain affect stable disease ii preparation either recombinant endogenous tsh no impact therapy efficacy outcome two group patient radioiodine treatment surgery differentiate thyroid cancer reasonable option thyroid carcinoma common endocrine neoplasm human globally increase incidence thyroid follicular cell neuroendocrine parafollicular c cell susceptible neoplastic transformation result thyroid cancer differ phenotype unique associate genetic mutation clinical outcome past year several sophisticate genetically engineer mouse model thyroid cancer create understand genetic event lead thyroid carcinogenesis vivo significant mouse model papillary follicular anaplastic medullary thyroid carcinoma highlight particular emphasis relationship relevant oncogene model genetic event naturally occur human disease limitation model present need additional model well recapitulate certain aspect human disease discuss radionuclide research live kidney function thyroid cancer radioiodine therapy study make live renal function use radionuclide method thyroid cancer patient radio iodine therapy multimodality examination patient reveal no clinical manifestation hepatocellular renal failure even significant therapeutic activity gbq hepatography renography show decrease absorptive secretory hepatocytic function increase period hippuran half life decrease total renal function reveal change moderate nature stable relate hypothyrosis radiation factor molecular approach thyroid cancer diagnosis thyroid nodule common accurate diagnosis cancer benign disease important effective clinical management patient molecular marker helpful diagnostic tool particularly cytologically indeterminate thyroid nodule past year significant progress make develope molecular marker clinical use fine needle aspiration specimen include gene mutation panel gene expression classifier availability next generation sequence technology gene mutation panel expand interrogate multiple gene simultaneously provide yet accurate diagnostic information addition recently several new molecular marker thyroid cancer identify offer diagnostic prognostic therapeutic information may value guide individualize management patient thyroid nodule treatment strategy patient papillary microcarcinoma recently incidental detection papillary microcarcinoma pmc mean ultrasonography us increase still controversial deal pmc situation mortality rate patient pmc generally low pmc regard innocent cancer however patient pmc show unfavorable outcome associate clinically evident nodal metastasis extrathyroidal invasion distant metastasis important classify patient pmc high risk low risk group determine treatment method paper introduce strategy patient asymptomatic pmc include non surgical follow base patient inform decision persistent hypercalcitoninemia patient medullary thyroid cancer medullary thyroid carcinoma highly malignant progressive disease surgery effective treatment calcitonin significant marker medullary thyroid carcinoma due sensitivity represent useful tool follow outcome patient affect medullary thyroid carcinoma depend tumor size lymph node involvement adequacy primary surgical management present study author review experience cure medullary thyroid carcinoma forty one patient operate sporadic medullary thyroid carcinoma include indication surgery inclusive lymphectomy technique time redo surgery mean calcitonin level highlight disease extensively discuss patient elevate calcitonin level favorable outcome consider together various diagnostic tool employ patient workup fifty one case analysis papillary thyroid carcinoma familial aggregation introduction papillary thyroid cancer ptc common good differentiate cancer thyroid one fast grow group cancer probably increase use ultrasound hrusg evaluation thyroid recent year material method medline ovid database search perform collect information papillary thyroid carcinoma recently publish consensus guideline also use additional resource conclusion controversy regard extent thyroidectomy patient ptc relatively settle total thyoidectomy prefer approach nodule cm size lymph node ln metastasis not seem affect overall survival increase recurrence rate worthwhile offer ln dissection initial surgery lns ultrasonologically diagnose harbor malignancy expert hand rate recurrent laryngeal nerve injury hypoparathyroidism negligible neck dissection initial surgery remain negligible carry redo completion scenario evaluation thyroid calcification diagnosis cystic thyroid cancer objective aim study evaluate disease specific survival cost relate radioactive iodine therapy rai utilization patient early stage papillary thyroid carcinoma ptc method retrospective cohort study use surveillance epidemiology end result seer database result total patient ptc identify adjuvant rai rai administration not associate survival advantage patient ptc stage hazard ratio hr confidence interval ci p stage ii hr ci p patient ptc stage iii undergo adjuvant rai improve survival hr ci p rai use patient stage patient stage ii total expenditure adjuvant rai ptc stage throughout study period estimate usd million annual average usd million year decline rate utilization rai continue model project annual expenditure would decrease usd million year conclusion high prevalence adjuvant rai utilization early stage ptc cause financial burden health system no evidence survival benefit extemporaneous anatomo pathological test surgery thyroid cancer value limitation report experience surgical treatment thyroid cancer total partial thyroidectomy perform thyroid nodule primitive thyroid carcinoma intraoperative freeze section diagnosis perform patient study specificity sensitivity find datum histological type compare previous study false negative macroscopic aspect carcinoma size differenciation plurificality study order understand limit freeze section diagnosis high rate false negative find small good differenciated vesicular carcinoma study show high accuracy freeze section diagnosis allow improve intraoperative management thyroid cancer high specificity freeze section diagnosis strengthen reliance upon examination expression mirnas papillary thyroid carcinoma association clinical characteristic ptc background sensitivity specificity biomarker use clinical practice diagnosis papillary thyroid carcinoma ptc low essential develop novel diagnostic prognostic biomarker ptc objective explore expression mir mir mir il ptc tissue plasma association clinical characteristic ptc method investigate expression mir mir mir il plasma thyroid tissue ptc nodular goiter healthy people qrt pcr analyze association level clinical characteristic ptc result level il expression high level mir mir mir expression ptc tissue low compare nodular goiter tissue perineoplastic thyroid tissue level mir mir mir il expression ptc tissue associate clinical characteristic ptc include bilateral tumor multicentricity extrallyroidal invasion cervical lymph node metastasis distant metastasis clinical advance stage iii iv conclusion expression mir mir mir il ptc tissue may useful biomarker promise target diagnosis papillary thyroid carcinoma expression select adhesive molecule cadherin e cd lgal ca papillary thyroid carcinoma introduction aim study determine expression select adhesive molecule papillary thyroid carcinoma material method papillary thyroid carcinoma case nonmalignant goiter case analyze immunohistochemistry result galectin lgal sensitive specific marker present analyze tumor tumor margin presence ca respectively positive non malignant case cadherin e expression note primary tumor surround tissue non malignant goiter cd df observe primary tumor surround tissue reaction bba characteristic metastasis conclusion study confirm high diagnostic value galectin papillary thyroid carcinoma reveal similar efficiency ca cd df expression primary tumor intensive surround tissue diagnostical inportance not high often observe benign lesion use bba sensitive little specific high expression cadherin e benign lesion impair diagnostical application papillary thyroid cancer long noncoding rna pvt modulate thyroid cancer cell proliferation recruit ezh regulate thyroid stimulate hormone receptor tshr purpose study investigate potential role long noncoding rna lncrna pvt thyroid cancer cell proliferation explore possible mechanism total patient diagnose thyroid cancer papillary thyroid carcinoma ptc follicular thyroid carcinoma ftc anaplastic thyroid carcinoma atc renji hospital enroll study expression lncrna pvt thyroid cancer tissue cell line ihh ftc c analyze use rt polymerase chain reaction pcr western blot analysis effect lncrna pvt expression thyroid cancer cell proliferation cell cycle analyze use flow cytometry furthermore effect lncrna expression thyroid stimulate hormone receptor tshr expression polycomb enhancer zeste homolog ezh also analyze use rna immunoprecipitation rip assay chromatin immunoprecipitation chip assay respectively compare control lncrna pvt significantly regulate thyroid tissue good three kind tumor cell line p silence pvt significantly inhibit thyroid cell line ihh ftc c cell proliferation arrest cell cycle g g stage significantly decrease cyclin tshr expression p moreover lncrna pvt can enrich ezh silence pvt result decrease recruitment ezh study suggest lncrna pvt may contribute tumorigenesis thyroid cancer recruit ezh regulate tshr expression adenosine monophosphate activate protein kinase dependent mtor pathway involve flavokawain b induce autophagy thyroid cancer cell flavokawain b fkb natural kava chalcone show potent antitumor activity various type cancer although mechanism action remain unclear study report fkb profound effect metabolic state human thyroid cancer tca cell lead high autophagy flux upregulation amp activate protein kinase turn inhibit mtor activate beclin tca cell report autophagy induce fkb play prosurvival role tca cell vitro vivo conclusion finding provide evidence combination treatment fkb pharmacological autophagy inhibitor potential therapeutic strategy treatment tca heterophile antibody rarely influence measurement thyroglobulin thyroglobulin antibody differentiate thyroid cancer patient aim study determine impact heterophile antibody measurement serum thyroglobulin tg thyroglobulin recovery thyroglobulin antibody level differentiate thyroid carcinoma patient study serum sample individual patient follow hospital differentiate thyroid carcinoma control sample sample split half treat incubate sample h hab block tube remainder leave untreated subsequently thyroglobulin thyroglobulin antibody level measure block untreated sample difference two sample consider significant block sample deviate untreated one time standard deviation method measurement tg patient show moderate significant lower tg level block treatment not great affect clinical management none control show heterophile antibody interference thyroglobulin measurement neither dtc patient control possible heterophile antibody interference encounter thyroid carcinoma patient one control no interference find thyroglobulin antibody measurement possible heterophile antibody interference find test assume heterophile antibody interference not factor reckon daily practice tg measurement treatment follow differentiate thyroid carcinoma patient molecular genetic study medullary thyroid cancer around medullary thyroid carcinoma mtc case familial follow autosomal dominant mode inheritance case mtc part inherit cancer syndrome three distinct form man man b familial mtc fmtc man frequent syndrome follow fmtc man b man family fmtc family germ line missense mutation underlie disease affect one five cysteine codon extracellular domain ret proto oncogene mutate codon exon exon frequent mutation man fmtc occur codon laboratory mutation codon detect two independent method dna sequence restriction fragment length polymorphism polymerase chain reaction pcr rflp far examine person risk find positive case positive genetic diagnosis allow preventive thyroidectomy resultant cause specific survival similar general population event negative result family member affect proband relieve physical emotional consequence disease follow procedure plan screen know hungarian mtc patient relative expression melanoma associate antigen associate progression human thyroid cancer thyroid cancer exhibit spectrum relatively indolent tumor tumor invasive metastatic progress poorly differentiate carcinoma microarray expression analysis thyroid cancer cell line implicate member melanoma associate mage family cancer testis antigen thyroid cancer development progression perform study validate role mage human thyroid cancer tissue microarray tma sample patient thyroid cancer analyze immunohistochemistry ihc localize mage western blot fractionate protein mage transfect cell use confirm intracellular localization protein automate analysis tma sample evaluate subject statistical analysis mage immunoreactivity identify nuclear cytoplasmic compartment normal malignant tissue specificity stain prove fractionation study confirm mage expression nucleus cytoplasm normal thyroid tissue exhibit weak cytoplasmic strong nuclear mage reactivity tumor exhibit increase cytoplasmic mage score correlate clinical behavior large tumor high mage score positive significant correlation mage cytoplasmic score numb histologically prove lymph node metastasis statistically significant negative correlation cytoplasmic mage percentage p positive nucleus datum confirm recent datum regard low versus high activity remnant ablation differentiate thyroid cancer not generalizable beyond eligibility criterium objective report unusual occurrence recurrent hyperparathyroidism due papillary thyroid carcinoma method describe clinical history physical examination finding laboratory value image finding pathologic finding woman develope recurrent hyperparathyroidism year successful parathyroidectomy result year old woman present clinic recurrent primary hyperparathyroidism present nephrolithiasis undergo resection right superior parathyroid adenoma result clinical biochemical cure clinical course follow periodic interval symptom free normocalcemic develope nephrolithiasis document recurrent hyperparathyroidism image study suggest parathyroid adenoma near right inferior pole thyroid patient reoperative neck exploration no obvious parathyroid adenoma find right thyroid lobectomy perform result normalization intraoperative intact parathyroid hormone level incision close final pathology demonstrate no parathyroid adenoma instead cm papillary thyroid carcinoma stain positive parathyroid hormone month surgery remain clinically biochemically cure conclusion recurrent hyperparathyroidism occur secondary multiple cause case demonstrate challenge surgeon face manage recurrent disease highlight rare phenomenon papillary thyroid cancer cause recurrent hyperparathyroidism diagnostic therapeutic measure thyroid cancer sixty one patient admit treatment suspicion thyroid cancer multimodality diagnosis therapy use include medical history general local status laboratory finding x ray examination lung bone radioisotope radioimmunological vivo vitro test thyroid resection rapid histological examination total strumectomy curietherapy use substitute hormonotherapy dry thyroid extract feasibility scannographic method early diagnosis detection thyroid cancer reject suspicion recurrence metastasis emphasize indicate rapid histological examination determine volume surgical intervention therapy activity sufficient complete ablation thyroid residue prevention recurrence metastatic appearance organ irrespective histological type carcinoma patient follow year management thyroid cancer spain manage cervical lymph node metastasis good differentiate thyroid cancer either berry pick bp anatomic neck dissection not show alter survival nevertheless local control thyroid cancer important purpose study determine whether local recurrence rate comparative value serum thyroglobulin measurement iodine total body scan follow study patient treat differentiate thyroid cancer study attempt unify evaluation patient thyroid cancer diagnosis management thyroid cancer 9 common cancer woman singapore despite increase incidence thyroid cancer last decade survival improve due combination early cytological diagnosis low morbidity total thyroidectomy postoperative radioactive iodine therapy thyroid cancer one curable form cancer article provide overview thyroid cancer future direction diagnosis treatment recombinant human tsh rhtsh new perspective diagnosis therapy thyrotropin stimulate hormone tsh exert physiological stimulus growth function ability take iodine normal malignant follicular cell reason metastasis derive good differentiate thyroid cancer dtc effectively treat radioiodine procedure require strong tsh stimulus obtain withdraw l thyroxine lt therapy however social personal life patient withdraw lt therapy heavily affect hypothyroidism decade since development recombinant human tsh rhtsh molecule introduce clinical practice usa europe safe reliable alternative lt withdrawal several year main clinical application rhtsh diagnostic purpose e thyroglobulin stimulation recent demonstration efficacy prepare dtc patient radioiodine post surgical thyroid remnant ablation also application officially recognize worldwide validity rhtsh also demonstrate stimulate metastatic thyroid cancer cell employment not yet officially approve use patient contraindication hypothyroidism e compassionate use possible use rhtsh stimulation relate ability enhance fdg uptake pet scan metastatic dtc patient effectiveness conventional chemotherapy aim review recall rhtsh develope progressively introduce clinical management dtc patient thyroid cancer slovakia incidence mortality histological type datum thyroid cancer incidence mortality national cancer registry slovakia analyse represent one \\ufeff1 descriptive epidemiological study eastern europe incidence thyroid cancer increase period particularly among woman approximately per increase occur primarily papillary carcinoma lesser extent follicular carcinoma great proportional increase young age group contrast datum report area mortality also increase period reason increase not evident increase mortality certainly indicate potential improvement treatment thyroid cancer slovakia good study aetiological factor involve disease dual energy ct iodine quantification characterize focal thyroid lesion background determine usefulness dual energy ct dect iodine quantification classify focal thyroid lesion method retrospectively enroll total cytopathologically confirm focal thyroid lesion mean size cm draw region interest dect derive iodine map obtain iodine concentration value thyroid nodule ic n normalize ic n compare group papillary thyroid carcinoma ptc benign nodule cyst result lesion assign ptc benign nodule cyst group ic n high benign nodule low ptc low cyst median interquartile range p similarly normalize ic n value statistically different p multi class area curve use optimal cutoff value ic n normalize ic respectively conclusion dect iodine quantification can helpful classify focal thyroid lesion value ct add ultrasonography diagnosis lymph node metastasis patient thyroid cancer background benefit ct diagnosis lymph node metastasis patient thyroid cancer still unclear method three hundred fifty one patient thyroid cancer hospital prospectively enroll order compare diagnostic performance combination ultrasound ct ultrasound ct ultrasound alone prediction lymph node metastasis calculate patient base benefit ct add ultrasound result pathologically prove neck level ultrasound ct show high sensitivity central lateral compartment improve accuracy lateral compartment compare ultrasound alone retropharyngeal superior mediastinal compartment although ct can detect lymph node metastasis ultrasound can not patient base benefit demonstrate patient high patient cancer cm cancer cm conclusion patient thyroid cancer ct improve surgical plan enhance sensitivity lymph node metastasis detect lymph node metastasis overlook ultrasound alone thyroid surgery child although surgical condition thyroid gland uncommon child increase incidence thyroid cancer combine fact child hospital increasingly treat old adolescent mean important pediatric surgeon knowledge condition abnormality thyroid associate abnormality thyroid function hyperthyroidism hypothyroidism associate symmetrical asymmetrical enlargement gland thyroid cancer development problem since use radioactive iodine thyroid tumor progression cellular de differentiation may occur commonly accompany metastatic spread loss iodine uptake retinoic acid ra administration may increase iodine uptake patient suggest ra can promise therapeutic option radioiodine non responsive thyroid carcinoma although prospective study long term follow not report clinical prospective study assess value cis ra patient advance thyroid carcinoma impact major outcome tumor regression cancer relate death long term follow patient submit radioiodine therapy ra administration sixteen patient inoperable disease no significant radioiodine uptake post therapy scan select patient treat orally cis ra dose mg kg day week submit radioiodine therapy mci thyroxine withdrawal whole body scan obtain day radioactive iodine therapy recist criterium use evaluate response objective partial response rate observe stable disease rate progression disease rate five patient die group classify progression disease progression free survival rate pf range month median pf month ra may option advance de differentiate thyroid cancer due low rate side effect new insight risk stratification differentiate thyroid cancer purpose review numerous stage score system exist differentiate thyroid cancer dtc harbor limitation prompt investigation new factor prognostic implication dtc recent finding several new factor may involve dtc risk stratification emerge thyroid stimulate hormone molecular marker addition other controversial challenge age sex lymph node involvement summary purpose review present recent update literature new potential risk stratification predictor dtc surgical removal cancer thyroid gland differentiate thyroid cancer dtc common endocrine malignancy 5 common cancer woman dtc therapy require multimodal approach include surgery beyond scope paper however year post operative management dtc post thyroidectomy patient include radioactive iodine rai ablation therapy typical rai post operative dose recommendation mci remnant ablation mci locoregional nodal disease mci distant metastasis recent recommendation make decrease dose order limit perceive adverse effect rai include salivary gland dysfunction induce secondary primary malignancy significant controversy thus arise regard use rai particularly management low risk dtc patient debate include definition low risk patient rai dose selection whether not rai need patient allow reader form opinion regard quantitative criterium cytological analysis thyroid gland cancer background anaplastic thyroid cancer aggressive fatal malignancy many advance cancer characterize glucose dependency lead oxidative stress cellular proliferation therefore seek determine low glucose environment vitro ketogenic diet vivo can inhibit anaplastic thyroid cancer tumor growth combine antioxidant n acetylcysteine method vivo nude mouse inject anaplastic thyroid cancer cell line c n group group feed standard diet group feed ketogenic diet group give standard diet n acetylcysteine mm drink water group feed ketogenic diet n acetylcysteine tumor volume ketone glucose measure h e stain immunohistochemistry ki caspase perform tumor vitro c cell culture high glucose mm low glucose mm high glucose plus n acetylcysteine um low glucose plus n acetylcysteine hour perform cyquant proliferation thermo fisher scientific waltham seahorse glycolytic stress agilent santa clara ca reactive oxidative stress assay result ketogenic diet plus n acetylcysteine decrease vivo tumor volume compare standard diet mm vs mm p standard diet plus n acetylcysteine p blood ketone level significantly high mouse ketogenic diet group compare standard diet mmol l vs mmol l week p however blood glucose level not significantly different ketogenic diet standard diet group cell culture low glucose plus n acetylcysteine significantly reduce proliferation compare high glucose relative fluorescence unit vs relative fluorescence unit p addition n acetylcysteine low glucose lower glycolysis function compare high glucose mph min cell vs mph min cell p high glucose plus n acetylcysteine mph min cell vs mph min cell p low glucose plus n acetylcysteine decrease reactive oxidative stress compare high glucose relative fluorescence unit vs relative fluorescence unit p conclusion combination ketogenic diet glucose restriction antioxidant n acetylcysteine significantly reduce tumor growth vivo vitro study warrant explore metabolic therapy anaplastic thyroid cancer current management pediatric thyroid disease differentiate thyroid cancer purpose review article focus role ultrasound fine needle aspiration management benign nodule extent thyroid resection management regional lymph node disease risk stratification stage good differentiate thyroid cancer dtc child recent finding recent guideline american thyroid association focus specifically management thyroid nodule dtc child adolescent mark change previous version extrapolate adult guideline pediatric population dtc child distinct presentation clinical behavior compare adult disease overall excellent outcome pediatric patient lead risk stratification approach management low intermediate high risk disease grouping aim minimize potential morbidity treatment summary review focus pediatric thyroid disease include recent study debate regard management thyroid nodule dtc aurora kinase new molecular target thyroid cancer therapy genetic instability hallmark solid tumor include thyroid cancer think represent mean premalignant cell acquire novel functional capability responsible cancer cell growth tumour progression last year knowledge molecular process control mitotic phase cell cycle increase considerably different mitotic protein whose expression function find alter human cancer tissue associate tumour genetic instability aneuploidy include three member aurora kinase family aurora b c serine threonine kinase regulate multiple aspect chromosome segregation cytokinesis gene encode aurora kinase show induce cell malignant transformation overexpression detect several tumor derive cell line tissue often associate poor prognosis last decade specific inhibitor aurora kinase exhibit preclinical early phase clinical study good therapeutic efficacy several tumour type include highly aggressive anaplastic thyroid cancer medullary thyroid cancer present review \\ufeff1 focus aurora mitotic function normal cell shall describe main implication overexpression onset genetic instability consequent aneuploidy shall finally discuss effect functional inhibition aurora kinase thyroid cancer cell growth tumorigenicity emerge therapeutics advance thyroid malignancy rationale target approach introduction thyroid cancer emerge public health concern usa incidence double past decade make 8 commonly diagnose neoplasm despite alarm increase thyroid cancer patient benefit conventional approach surgery radioiodine radiotherapy tsh suppression levothyroxine often cure nevertheless minority aggressive tumor resistant cytotoxic historical therapy patient sorely need new treatment option area cover herein biology molecular characteristic common histological type thyroid cancer review provide context subsequent discussion recent development emerge therapeutics advance thyroid cancer expert opinion several kinase inhibitor especially target vegfr ret already demonstrate promise activity differentiate medullary thyroid cancer dtc mtc although minimal benefit dtc mtc cytotoxic chemotherapy use recombinant human thyroid stimulate hormone diagnosis recurrent thyroid cancer background recombinant human thyroid stimulate hormone rhtsh suggest diagnostic agent diagnosis recurrent thyroid cancer instead current practice thyroid hormone tht withdrawal method evidence base literature review use basis cost utility decision analytic model outcome measure safety efficacy diagnostic performance quality life cost effectiveness rhtsh result literature search identify six comparative study rhtsh versus tht withdrawal common adverse event associate use rhtsh headache nausea use diagnostic agent unadjusted sensitivity specificity rhtsh respectively thus use rhtsh instead tht withdrawal would result reduction diagnostic accuracy patient disease status misclassify use rhtsh result high quality life period prior diagnostic test tht withdrawal p impact diagnostic performance patient compliance follow modify quality life model year time frame incremental cost per qaly rhtsh relative tht withdrawal conclusion use rhtsh diagnostic agent appear safe little diagnostically accurate little cost effective whole healthcare cost basis use follow patient thyroid cancer previous negative radioiodine scan thyroid hormone withdrawal association thyroid cancer insulin resistance metabolic syndrome component systematic review meta analysis background thyroid cancer rapidly increase incidence worldwide past several decade incidence metabolic syndrome perform system review meta analysis association metabolic syndrome component insulin resistance thyroid cancer incidence method search several computer assist database pubmed embase isi web science identify study publish st january every study must report either risk estimate thyroid cancer incidence confidence interval ci relate datum speculate two investigator independently identify eligible study extract datum evaluate summary relative risk estimate use fix random effect method result find article meet inclusion criterium review increase risk thyroid cancer patient insulin resistance relative risk rr confidence interval ci p dysglycemia rr ci p high bmi rr ci p hypertension rr ci p however patient dyslipidemia total cholesterol rr ci p triglyceride rr ci p not associate thyroid cancer conclusion meta analysis show insulin resistance dysglycemia high bmi hypertension significantly increase thyroid cancer risk result may help identify people high risk thyroid cancer change healthy life style element thyroid tissue associate advance stage thyroid cancer korean woman excessive exposure heavy metal include cadmium lead know adverse effect various type cancer aim present study evaluate association blood tissue level heavy metal trace element different stage thyroid cancer korean woman ninety two korean woman undergo thyroidectomy include study blood thyroid tissue level cadmium lead mercury selenium zinc measure histopathological result cancer tumor node metastasis tnm stage cancer multifocality assess tissue level cadmium selenium zinc significantly high patient tnm stage compare stage tissue level cadmium great patient high tumor stage low stage also tissue level cadmium zinc high multifocal group unifocal group logistic multiple regression analysis show odd ratio advance tumor stage group increase high tissue cadmium level adjustment ci accumulation cadmium thyroid tissue may one important etiologic factor thyroid cancer progression aggravation korean woman clinical analysis thyroid cancer child objective analyze clinical characteristic prognosis thyroid cancer child method clinical datum child boy girl space occupy lesion thyroid hospitalize beijing child hospital affiliate capital medical university july december collect sixty two child thyroid cancer review respectively follow telephone result july december child thyroid cancer account child space occupy lesion thyroid numb child space occupy lesion thyroid every year numb child thyroid cancer every year one thyroid cancer follicular thyroid cancer other papillary thyroid cancer neck mass chief complaint patient two case bring hospital respiratory tract oppression chief complaint forty eight case get papillary thyroid cancer surgical management surgical management papillary thyroid cancer highly controversial department surgery ii kanazawa university hospital surgical management especially cervical lymph node metastasis change since conservative approach aggressive one order determine whether aggressive approach warrant retrospective multivariate analysis carry case papillary thyroid cancer patient follow year multivariate analysis conduct follow cox model analysis aggressive management appear no impact survival relapse free survival however age sex tumor size cervical lymphadenopathy confirm important prognostic factor survival relapse free survival primary thyroid cancer follow multiple skin metastasis interleukin il cxcl mediate biological effect two receptor cxcr cxcr cxcr recognize il granulocyte chemotactic protein cxcr bind multiple chemokine include il cxcl il cxcl implicate neoplastic feature thyroid cancer tc assess role autocrine circuit sustain il cxcl determine tc stem cell tc sc feature use immunohistochemistry find thyroid epithelial cancerous not normal cell stain positive il whose level correlate lymph nodal metastasis assess expression endogenous il cxcl elisa assay receptor cxcr cxcr flow cytometry panel tc cell line molecule express tc cell line grow adherence high level also thyrospheres enrich prognostically relevant factor papillary thyroid cancer papillary cancer well prognosis thyroid carcinoma five year survival rate operate patient due papillary thyroid carcinoma five year respectively ten year survival rate respectively prognostic relevant factor follow metastasis tumor stage tumor invasion vessel multifocal tumor growth age pt differentiation tumor size radioiodine therapy advance differentiate thyroid cancer clinical consideration multidisciplinary approach differentiate thyroid cancer dtc account thyroid cancer generally indolent tumor treat effectively surgery radioactive iodine thyroid stimulate hormone suppressive therapy however patient advance disease aerodigestive tract invasion distant metastasis radioiodine refractory disease poor prognosis review focus approach treat advance dtc include management gross extra thyroidal extension recurrent loco regional distant metastatic disease role external beam radiation therapy systemic treatment locally ablative treatment modality include surgery radiation therapy thermal ablation evolve use select patient recent year new therapeutic agent molecular target become available two multi kinase inhibitor sorafenib lenvatinib license iodine refractory dtc show advantage term progression free survival although impact overall survival not prove yet remarkable side effect emerge management advance thyroid cancer challenge multidisciplinary approach significantly improve outcome patient population follow study patient thyroid cancer surgical series cervico mediastinal thyroid cancer patient operate retrospectively review result compare obtain patient operate benign cervico mediastinal goiter thyroid cancer confine cervical region thyroidectomy perform patient operate thyroid carcinoma cervico mediastinal extension male female mean age year range year patient cervico mediastinal cancer significantly old patient benign cervico mediastinal goiter p time onset \\ufeff1 symptom surgery significantly long patient cervico mediastinal cancer benign cervico mediastinal goiter p cervical thyroid cancer sign symptom time surgery cervical mass patient cervical lymphadenopathy patient dyspnea dysphagia dysphonia venous stasis none patient asymptomatic total thyroidectomy functional lymphectomy perform case seven patient operate stage case operation debulking procedure near total thyroidectomy sternotomy perform two case differentiate thyroid cancer find patient medullary undifferentiated incidence medullary carcinoma significantly high compare cervical cancer p postoperative complication high occur benign cervico mediastinal goiter similar occur cervical cancer actuarial survival similar cervical cancer match age sex analysis show long clinical history goiter relate endothoracic development neoplastic transformation find encourage surgeon treat cervico mediastinal goiter promptly possible thyroid hormone withdrawal patient differentiate thyroid carcinoma one hundred thirty patient pilot survey consequence hypothyroidism pharmacoeconomic comparison recombinant thyrotropin administration study objective elucidate clinical quality life pharmacoeconomic effect hypothyroidism secondary thyroid hormone withdrawal withdrawal athyroid patient differentiate thyroid cancer dtc also intend compare societal cost withdrawal recombinant human thyroid stimulate hormone administration rhtsh population mail item pilot survey patient dtc undergo withdrawal diagnostic whole body scan dxwbs use survey result actual estimate cost datum retrospectively construct societal cost model compare withdrawal versus rhtsh perform sensitivity analysis increase conservatism assumption withdrawal cost one hundred thirty patient answer questionnaire among respondent symptomatic multisymptomatic hypothyroidism almost half seek medical attention hypothyroid complaint approximately one 3 drive motor vehicle hypothyroid median absence salaried work day per withdrawal pharmacoeconomic model societal cost per dxwbs approximately euro great withdrawal rhtsh sensitivity analysis societal cost rhtsh exceed withdrawal approximately euro conclusion hypothyroidism secondary withdrawal cause important morbidity safety risk productivity impairment rhtsh avoid drawback roughly equivalent societal cost withdrawal hormad methylation mediate epigenetic regulation gene expression thyroid cancer study aim investigate methylation level candidate gene impact thyroid carcinoma thca development infinium human methylation beadchip array illumina illumina hm k popular cpg microarray platform widely use biological medical research methylation level differentially express gene correspond cpg site analyse r programme expression hormad evaluate qrt pcr western blot methylation level examine via methylation specific pcr cell viability metastasis cell cycle apoptosis detect mtt assay transwell wind heal assay flow cytometry respectively treatment aza deoxycytidine aza tumour formation assay use analyse thyroid tumour growth nude mouse vivo methylation level differentially express gene analyse hormad significantly hypermethylated mrna expression inhibit thca cell treatment aza hormad expression regulate thca cell overexpression suppress thyroid cancer cell viability mobility invasiveness remarkably regulation hormad thca cell can prolong g g phase shorten phase impede cell mitosis good promote thyroid cancer cell apoptosis furthermore tumour formation assay show increase hormad level impede tumour growth vivo hypermethylation hormad can induce thca progression hypomethylation hormad retard cell growth mobility facilitate apoptosis increase mrna expression detection thyroid cancer fdg pet cancer screen program japanese nation wide survey background aim f fluorodeoxyglucose positron emission tomography association hyperparathyroidism nonmedullary thyroid carcinoma review case series patient operate primary hyperparathyroidism hpt one surgeon jna instance coincidental thyroid parathyroid disease benign thyroid lesion remain case hpt associate nonmedullary thyroid carcinoma treat resection parathyroid adenoma thyroidectomy one patient die unrelated cause carcinoma breast year follow surgery remain patient live good mean year year surgery no recurrence thyroid cancer relate mortality series contrast prior report six patient history prior radiotherapy suggest neck exploration hpt entire thyroid gland evaluate palpable nodule resect submit pathologic study radiation safety precaution iodine therapy study evaluate recurrence rate patient papillary thyroid carcinoma ptc low nonstimulated thyroglobulin tg measure 2 generation assay total thyroidectomy not submit ablation objective define whether low postoperative nonstimulated tg use criterion spare patient ptc therapy prospective study include patient ptc except microcarcinoma restrict thyroid tumor extensive extrathyroid invasion pt aggressive histology extensive lymph node ln involvement know residual disease thyroidectomy patient nonstimulated tg ng ml negative antithyroglobulin antibody tgab neck ultrasonography us show no anomaly find patient not submit ablation time follow range month median month patient continue nonstimulated tg ng ml negative us tg undetectable last assessment patient detectable five patient exhibit increase tg ln metastasis detect structural recurrence one patient progress increase tg disease not detect image method biochemical recurrence result obtain suggest patient ptc low nonstimulated tg measure 2 generation assay absence tgab negative neck us thyroidectomy not require ablation advance follow differentiate medullary thyroid cancer long term survival patient thyroid cancer possibility tumour recurrence year achievement disease free status illustrate importance lifelong follow individual review discuss innovative aspect follow protocol patient differentiate thyroid cancer papillary follicular hystotype medullary thyroid cancer particular focus place relevance new ultrasensitive assay thyroglobulin measurement option use recombinant human tsh stimulate thyroglobulin secretion method compensate loss diagnostic significance serum thyroglobulin level patient differentiate thyroid cancer circulate anti thyroglobulin antibody highlight good role postoperative calcitonin stimulation test clinical relevance determine double time calcitonin carcinoembryonic antigen patient medullary thyroid cancer moreover review give insight role molecular thyroid cancer test prognostic therapeutic purpose finally general overview traditional image procedure neck ultrasonography ct mri bone scintigraphy provide alongside comparison new nuclear image test pet langerhans cell histiocytosis associate papillary thyroid carcinoma thyroid cancer rare complex disease thyroid contain various cell type specific disease arise malignancy range indolent extremely aggressive several risk factor thyroid cancer suggest ionize radiation find causative effect exception tobacco ionize radiation probably study carcinogen not yet possible determine whether not specific cancer induce radiation epidemiological study therefore provide primary datum cancer risk man exposure ionize radiation current epidemiological knowledge radiation associate thyroid cancer review focus sharply increase risk recently find among child chernobyl area diagnosis therapy early cancer thyroid excess body weight associate moderately increase risk thyroid cancer adipocyte derive hormone leptin show enhance cell growth migration many cancer type limit evidence suggest leptin direct action thyroid gland no datum available effect leptin thyroid cancer cell evaluate action leptin gene expression cell growth cell cycle cell migration anaplastic aro follicular wro papillary cgth w thyroid carcinoma cell line expression gammagraphic nuclear magnetic resonance study diagnosis cancer thyroid thyroid stimulate hormone receptor messenger rna tshr mrna express thyroid cancer patient indicate tshr mrna potential biomarker thyroid cancer however system evaluation tshr mrna diagnostic biomarker thyroid cancer deficient performance tshr mrna thyroid cancer diagnosis evaluate study three common international database good chinese database apply literature research quality assessment include literature conduct quadas tool totally patient nine study eligible meta analysis include study global sensitivity specificity positivity tshr mrna thyroid cancer diagnosis value auc test performance thyroid cancer invade airway diagnosis management introduction aim study analyze outcome decision make process approach airway invasion thyroid tumor method retrospective study year experience thyroid surgery cancer invade airway clinical record surgical pathology report analyze assess principle procedural detail significant facilitate efficient diagnosis stage treatment medical therapy not evaluate result consecutive series thyroid cancer patient cancer airway invasion find case good differentiate pattern determine histology report airway relate symptom record patient flexible bronchoscopy perform patient rapidly evolve disease non resectable airway find case permanent tracheotomy perform case airway lumen restoration without stenting laryngectomy segmental airway resection reconstruction perioperative mortality record palliative treatment resect patient completely radical surgery not always achievable patient positive margin resection undergo adjuvant treatment show comparable survival radical surgery patient year tumor relapse occur case distant locoregional patient unresectable disease require treatment symptom relief survival poor conclusion although patient currently refer severely advance disease indication tracheotomy salvage procedure supportive care decrease time resection feasible differentiate tumor overall good outcome knowledge pathologically versus clinically negative lymph node associate reduce use radioactive iodine post thyroidectomy low risk papillary thyroid cancer cervical lymph node metastasis common papillary thyroid cancer ptc clinically negative lymph node confer uncertainty true lymph node status potentially prompt empiric postoperative radioactive iodine rai administration even low risk patient examine association clinically cn versus pathologically negative pn lymph node utilization rai low risk ptc use national cancer database adult ptc undergo total thyroidectomy stage ii tumor cm evaluate receipt rai base cn versus pn status cut point analysis conduct determine numb pn node associate great decrease odd receipt rai survival model multivariate analysis predict rai use conduct separately patient patient year patient meet study criterium cn versus pn patient pn node likely negative surgical margin multifocal disease p mean negative node report surgical pathology specimen pathologically negative lymph node provide well cut point associate reduce rai administration ci multivariable adjustment pn patient node examine little likely receive rai compare cn patient across age p patient age year r p patient pn node not differ rai use compare cn control unadjusted survival improve pn versus cn patient across age p not patient year p adjust survival age not differ p pathological confirmation negative lymph node patient ptc appear influence decision administer postoperative rai negative lymph node remove possible few excise lymph node may view clinician incidentally resect thus may suboptimally represent true nodal status central neck research warrant determine optimal numb lymph node resect standardize pathological diagnosis familial disease consider negative prognostic factor micropapillary thyroid carcinoma purpose increase aggressiveness familial papillary thyroid carcinoma fptc compare sporadic form report contrary biological behavior familial microptc fmptc still debate assess familial disease consider negative prognostic factor mptc clinical presentation outcome fmptc sporadic mptc smptc compare method retrospectively analyze mptc smptc n fmptc n patient follow median follow year fmptc define presence ptc two \\ufeff1 degree relative exclude hereditary syndrome associate ptc result fmptc patient frequently bilateral tumor versus p lymph node metastasis diagnosis versus p \\ufeff1 follow fmptc patient high rate structural disease low rate remission compare smptc p also multivariate model use chaid tree build algorithm familial disease correlate wrong clinical presentation outcome mptc patient familial disease associate high rate intermediate risk patient non incidental mptc high rate structural incomplete response mptc without lymph node metastasis p conclusion like macroptc familial form disease show negative prognostic factor also mptc therefore highly regard management mptc patient microrna regulate proliferation migration invasion thyroid cancer cell target bcl purpose thyroid cancer cause significant mortality new diagnose cancer thyroid cancer incidence thyroid cancer increase alarm rate therapeutic target lack study undertake investigate role therapeutic implication microrna mir thyroid cancer method expression analysis perform qrt pcr transfection perform lipofectamine reagent cell viability determine mtt assay apoptosis detect acridine orange ao ethidium bromide eb percentage apoptotic cell estimate annexin v propidium iodide pi stain wind heal transwell assay use monitor cell migration invasion protein expression determine western blot result expression mir find significantly decrease thyroid cancer cell ectopic expression mir promote apoptosis mda thyroid cancer cell percentage apoptotic mda cell thyroid cancer mir mimic transfect cell apoptosis promote mir overexpression also associate enhancement bax depletion bcl mda cell targetscan analysis show bcl target mir additionally expression bcl also enhance thyroid cancer cell mir ectopic expression can cause suppression bcl expression mda cell wind heal assay show mir overexpression cause decrease migration mda cell transwell assay show decline invasion mir mimic transfect mda cell conclusion sum mir may exhibit therapeutic implication thyroid cancer may prove useful thyroid cancer treatment thyroid cancer differentiate carcinoma background ethnicity infrequently cite risk factor thyroid cancer study aim determine whether patient filipino origin assess tertiary referral center increase risk thyroid cancer quantify risk method retrospective analysis filipino patient thyroid nodule undergo thyroidectomy individually match control accord demographics risk factor pre referral investigation result thyroid cancer find filipino patient compare control odd ratio malignancy filipinos confidence interval pathologic characteristic thyroid cancer not significantly different two group median follow filipino patient month range month year recurrence occur four filipino patient one patient anaplastic thyroid cancer die disease conclusion filipino patient thyroid nodule significantly increase risk thyroid cancer compare match control hence index suspicion malignancy high evaluate patient scintigraphic assessment thyroid cancer develope blood test detect presence thyroactive tissue patient evaluate ablative therapy differentiate thyroid carcinoma test base assumption thyroactive tissue present radioactive manufacture administration radioiodide release circulation twenty serum sample obtain patient time total body scan evaluate need therapy analyze chromatographically together internal marker presence label three patient also study day treatment dose return posttreatment scan chromatographic method use sep pak follow hplc remove radioiodide fraction result interpret negative positive base upon absence presence detectable count fraction twelve patient study positive total body scan demonstrate circulate seven patient negative whole body scan negative hand patient positive thyroglobulin assay negative total body scan test independent evidence presence thyroid cancer not concentrate radioiodine three patient positive scan test negative thyroglobulin assay conclude measurement circulate radioactive sensitive test presence normal malignant thyroactive tissue likely respond ablation national cancer datum base report thyroid carcinoma reflection practice pattern thyroid cancer represent one prevalent endocrine cancer relatively high incidence rate around world accompany unchanged fatality rate probe specific role linc mediation cellular process thyroid cancer include proliferation migration invasion methylation aristaless like homeobox alx thyroid cancer relate long noncoding rnas lncrnas gene analyze microarray base analysis antitumor effect linc examine gain loss function experiment addition bind linc promoter region alx interaction linc methylation relate protein detect late xenograft tumor nude mouse induce expect dig modulatory function linc tumor growth thyroid carcinoma microarray base analysis manifest linc overexpress whereas alx downregulated thyroid cancer result also verify thyroid cancer tissue besides result demonstrate linc bind alx promoter region linc recruit dnmt dnmt b protein promote methylation alx promoter region thus suppress alx expression finally downregulation linc upregulation alx repress akt mtor signal axis thus inhibit proliferative migratory invasive ability good epithelial mesenchymal transition emt thyroid cancer cell collectively downregulated linc suppress cell proliferation migration good invasion thyroid cancer inhibit methylation alx increase expression inactivation akt mtor signal pathway personalize therapy patient anaplastic thyroid cancer target genetic epigenetic alteration context anaplastic thyroid cancer atc lethal thyroid cancer one aggressive human carcinoma search effective treatment option research toward target personalize therapy prove path great potential gain deep understand genetic eg braf v e pik ca tp htert mutation etc epigenetic eg histone methylation histone de acetylation microrna regulatory circuit etc alteration drive atc able find target develope novel therapy improve live patient beyond development look effectiveness already approve target therapy eg anti braf v e selective inhibitor tyrosine kinase inhibitor histone deacetylase inhibitor inhibitor dna methylation etc potentially test atc learn molecular mechanism aid tumor progression design perform literature analysis medline pubmed web site study publish use follow main keyword anaplastic thyroid cancer genetic epigenetic alteration objective outline common pathway alter atc include braf v e erk mek pi k akt pathway examine current research look personalize potential target therapy atc mention tentatively advance clinical trial potential reach stage also review side effect current potential target therapy use patient advance thyroid cancer conclusion dna rna next generation sequence analysis fundamental unravel precise medicine therapy patient atc indeed give deep biological heterogeneity complexity high histological grade malignancy tumor microenvironment personalize therapeutic approach possibly base use combinatorial target therapy provide rational approach find optimal way improve treatment patient atc ultrasonography cytology predictor noninvasive follicular thyroid niftp neoplasm papillary like nuclear feature importance differential diagnosis invasive encapsulate follicular variant papillary thyroid cancer objective assess prognostic value detectable thyroglobulin tg initial surgery radioactive iodine therapy compare patient negative post therapeutic whole body scan wbs either detectable undetectable tg background differentiate thyroid cancer good prognosis however recurrence occur year initial treatment fluorine fluorodeoxyglucose dual head positron emission tomography detection recurrent differentiate thyroid cancer preliminary result follow patient thyroid cancer may difficult identify site recurrence presence persistently elevate rise thyroglobulin tg level negative iodine whole body scintigraphy wbs aim study assess feasibility employ fluorine fluorodeoxyglucose dual head positron emission tomography pet camera detect recurrent thyroid cancer patient elevate tg level negative wbs eleven patient suspect recurrent thyroid cancer five male six female mean age year range year study wbs fdg use dual head pet camera suspicion patient recurrent thyroid cancer base elevate tg level thyroid stimulate hormone tsh tg level good antibody tg measure week withdrawal tri iodothyronine patient pathological uptake see pet image no sign recurrent thyroid cancer wbs ultrasonography compute tomography magnetic resonance image perform follow fine needle aspiration cytology mean tg tsh level discontinuation l thyroxine ng ml range ng ml mu l range mu l respectively none patient antibody thyroglobulin seven ten patient negative wbs fdg pet show focally increase uptake head neck region one patient site increase uptake pet image correspond site increase uptake malignancy diameter little cm n not depict either ct us conclude detection recurrent thyroid cancer mean fdg dual head pet feasible patient elevate tg concentration negative wbs result justify prolongation study ultrasonography cervical lymph node ultrasonography excellent method image evaluation cervical lymph node article provide image rich review sonographic manifestation disease involve cervical lymph node emphasis expect anatomic distribution disease whole body scan incidental uptake due spermatocele year old man papillary thyroid cancer post total thyroidectomy refer post radioiodine whole body scan whole body image reveal intense uptake bed thyroid focal abnormal uptake testicular area subsequent spect ct demonstrate focal uptake correspond leave epididymis pathology report reveal spermatocele no immunohistochemical feature thyroid tissue many case unexpected radioiodine uptake report spermatocele can count another possibility incidental uptake despite unclear mechanism quality life patient thyroid cancer compare general population background since patient thyroid cancer good prognosis overall clinician may often assume quality life comparable general population hypothesize quality life thyroid cancer patient low compare general population control effect age gender method begin stay inpatient rehabilitation clinic cohort n patient thyroid cancer assess use quality life core questionnaire european organisation research treatment cancer incidental gallbladder cancer visualize posttreatment whole body scan year old woman papillary thyroid cancer post total thyroidectomy refer post treatment whole body scan image reveal focal uptake within gallbladder cholecystectomy subsequently perform pathology report show good differentiate adenocarcinoma give history papillary thyroid cancer iodine uptake reasonably explain metastasis however gallbladder metastasis extremely infrequent literature describe incidental radioiodine retention gallbladder false positive finding normal variant benign hepatobiliary condition primary gallbladder malignancy can count another possibility despite controversial mechanism uptake modify spiral tracheoplasty extensive window resection trachea advance thyroid cancer papillary thyroid carcinoma ptc occasionally invade tracheal cartilage adapt reconstructive procedure modify spiral tracheoplasty extensive tracheal defect resection locally advance thyroid cancer extensive window resection tracheal wall perform year old woman year old man ptc invade intraluminal trachea remain stump trachea separate esophageal wall rotate degree opposite direction posterior lateral wall anastomosed tracheocutaneous fistula create prevent postoperative airway obstruction postoperative course uneventful case tracheocutaneous fistula successfully close month initial surgery modify spiral tracheoplasty safe useful method recreate framework trachea extensive window resection advance thyroid cancer genetic non medullary thyroid cancer direct upper airway infiltration thyroid neoplasia rare occurrence unique case papillary thyroid neoplasia present pyriform fossa mass describe management problem patient discuss emphasise controversy radical conservative surgery possibility thyroid tumour result previous radioactive iodine prescribe thyrotoxicosis also consider development new clinical severity stage system patient nonmetastatic papillary thyroid carcinoma importance inclusion patient feature addition tumor morphology provide holistic stage system objective identify prognostically important variable papillary thyroid carcinoma ptc incorporate comprehensive functional severity stage system fsss clinical severity stage system csss validate model use multi institutional database design set participant retrospective cohort study adult year old newly diagnose treat nonmetastatic ptc siteman cancer center binary logistic regression use explore association year survival age comorbidity tumor morphologic feature conjunctive consolidation use create stage system incorporate important patient tumor information create fsss csss compare current ajcc stage system externally validate use national cancer database ncdb main outcome measure five year survival result cohort consist eligible patient ptc death cohort year survival rate median age patient year range woman conjunctive consolidation combine age comorbidity stage create new csss category year survival rate ci follow stage n stage b n stage c n significance intraoperative isotope detection primary secondary radical surgical treatment thyroid cancer diagnosis thyroid carcinoma make preoperatively total thyroidectomy excision lymph node involve neoplastic process indicate case carcinoma diagnose upon tissue examination strumectomy perform indication refer radical rethyroidectomy even macroscopically total thyroidectomy postoperative scintigraphy may reveal remnant thyroid tissue often place pyramidal lobe proximity laryngeal recurrent nerve small metastatic lymph node overlook \\ufeff1 operation order improve rate surgical cure intraoperative scintigraphy perform intraoperative evaluation totality operation perform patient case postoperative scintigraphy reveal iodine uptake range group patient radicalness total thyroidectomy total rethyroidectomy check intraoperatively gamma beam detector radioiodine uptake range postoperatively patient require radioiodine treatment due iodine uptake neck intraoperative use gamma beam detector allow improve totality thyroidectomy significant reduction numb patient require ablation radioiodine risk factor surgical tactic differentiate thyroid cancer differentiate thyroid cancer present various frequently astonish outcome not patient sometimes physician good dynamic progress neoplasm calculate depend type tumor say microscopic finding way spread prognostic factor age sex grade histologic malignancy advancement disease author paper try assess purposefulness individual choice surgical procedure accord analysis risk factor ames age therefore surgeon decide extent procedure depend factor role pet diagnosis treatment thyroid carcinoma iodine positron emit iodine isotope enable measurement iodine uptake use positron emission tomography pet numb situation use pet compute tomography ct improve current clinical practice diagnosis treatment thyroid cancer firstly pet ct aid stage patient well detection metastatic disease measurement metabolic tumour volume thus separate low risk high risk patient secondly much high sensitivity spatial resolution pet compare gamma scintigraphy also improve detection recurrent disease furthermore pet use patient specific radioiodine therapy radiation dosimetry simultaneous administration therapeutic dose tracer dose allow accurate measurement iodine uptake therapy decay scheme positron many gamma ray emit per decay often simultaneously pose challenge quantitative pet image improve correction method use reproductive factor not hormonal factor associate thyroid cancer risk systematic review meta analysis many study investigate association hormonal reproductive factor thyroid cancer risk provide contradictory inconclusive finding review aim precisely estimate association pool available epidemiological study independent study retrieve comprehensive literature search database pubmed embase overall common hormonal factor include oral contraceptive hormone replacement therapy not alter risk thyroid cancer old age menopause associate weakly increase risk thyroid cancer overall analysis rr ci elevate stimulate thyroglobulin level identification persistent papillary thyroid carcinoma background persistence papillary thyroid carcinoma usually associate elevate stimulate thyroglobulin level aim study evaluate association moderately elevate stimulate thyroglobulin level persistence papillary thyroid carcinoma one year thyroidectomy radioiodine ablation method cohort patient papillary thyroid carcinoma select available stimulate thyroglobulin level measurement absence thyroglobulin antibody one year initial treatment surgery radioiodine subject stratify accord whether stimulate thyroglobulin level ng ml ng ml result twenty seven patient include study stimulate thyroglobulin level ng ml value great ng ml median age gender proportion similar group expect median stimulate thyroglobulin level significantly great 2 group vs ng ml p stratify analysis aim associate stimulate thyroglobulin level disease persistence yield overall risk ci p subject level ng ml level ng ml overall risk ci p positive predictive value stimulate thyroglobulin level ng ml conclusion moderately elevate stimulate thyroglobulin level uncertain predictor papillary thyroid carcinoma persistence clinical evaluation upper mediastinal dissection differentiate thyroid carcinoma background extensive upper mediastinal dissection advance differentiate thyroid carcinoma occasionally require investigation undertake clarify indication mediastinal lymph node dissection route upper mediastinal metastasis method twenty one patient differentiate thyroid cancer undergo \\ufeff1 radical operation mediastinal dissection partial midline sternotomy enroll study patient find mediastinal lymph node metastasis result tumor size group metastatic disease much big group without metastatic disease histologic type age similar two group extent cervical lymph node metastasis significant group metastatic disease particular patient show two metastatic node along internal jugular vein tumor free side conclusion study indicate metastasis internal jugular chain side contralateral primary tumor would extremely important factor indication extensive upper mediastinal lymph node dissection median partial sternotomy patient differentiate thyroid carcinoma systematic thyroid screen myotonic dystrophy link thyroid volume insulin resistance background myotonic dystrophy dm neuromuscular disease relate dmpk gene mutation associate endocrine disorder cancer routine endocrine synchronous parathyroid adenoma papillary thyroid carcinoma mtc mibi scan finding simultaneous existence parathyroid adenoma thyroid nonmedullary carcinoma rarely observe year old female diagnose approximately year ago primary hyperparathyroidism phpt basis hypercalcemia elevate serum parathyroid hormone pth level clinically phpt diagnose patient examine tc mibi scintigraphy investigate parathyroid adenoma early tc mibi image show focal focus enhance activity retention thyroid leave lobe upper pole thyroid low pole inferior neighborhood however late image indicate thyroid activity washout persistence activity leave lobe low pole observe lesion leave lobe low pole neighborhood identify parathyroid adenoma one day thyroid scintigraphy also conduct correlate enhance activity retention leave lobe upper pole result thyroid scintigraphy show hypoactivity thyroid fine needle aspiration cytology process suggest nodule simultaneous existence parathyroid adenoma thyroid nonmedullary carcinoma rarely observe diagnosis treatment hyperparathyroidism crucial preoperative period even observe rarely parathyrotoxicosis diagnose patient develop thyroid cancer along parathyroid adenoma selective embolization thyroid artery preresective palliative treatment thyroid cancer although many tumour head neck successfully embolized numb publication application selective embolization thyroid artery seta limit aim present study evaluate safety efficacy possible indication contraindication preresective palliative seta thyroid cancer study group comprise patient thyroid tumour case advance inoperable anaplastic thyroid cancer atc case differentiate thyroid carcinoma dtc patient undergo seta superior inferior thyroid artery seta selective angiography thyroid artery perform ensure target artery completely occlude case seta decrease blood flow thyroid preresective seta limit bleed surgery decrease operate time observe massive increase thyroglobulin tg concentration case dtc start h seta not occur case atc although seta no influence mortality atc patient report improvement swallow breathe decrease pain conclude seta minimally invasive safe method limit blood flow thyroid tumour dtc patient seta cause ischaemic necrosis gland result important increase serum concentration tg therefore thyroidectomy perform \\ufeff1 h preresective embolization moreover seta may become attractive option palliative treatment atc patient intractable bleed pain sign tracheal oesophageal compression tumor suppressor role thyroid hormone beta receptor mouse model thyroid carcinogenesis create knockin mutant mouse target mutation pv thyroid hormone receptor beta gene trbetapv mouse trbetapv pv mouse not trbetapv mouse spontaneously develop follicular thyroid carcinoma identify genetic change trbeta gene can also induce thyroid carcinoma cross trbetapv mouse trbeta mouse trbetapv mouse mutation one trbeta allele absence wild type allele age also spontaneously develope follicular thyroid carcinoma pathological progression hyperplasia capsular vascular invasion anaplasia eventually metastasis lung not lymph node pathological progression thyroid carcinoma trbetapv mouse indistinguishable trbetapv pv mouse analysis expression pattern critical gene indicate activation signal pathway mediate tsh peptide growth factor epidermal growth factor fibroblast growth factor tgf beta tnf alpha nuclear factor kappab also suggest progressive repression pathway mediate peroxisome proliferator activate receptor gamma pattern alteration signal pathway similar observe trbeta pv pv mouse thyroid carcinogenesis result indicate absence wild type allele mutation one trbeta allele sufficient mutant mouse spontaneously develop follicular thyroid carcinoma result provide \\ufeff1 time vivo evidence suggest trbeta gene can function tumor suppressor gene importantly finding present possibility trbeta can serve novel therapeutic target thyroid cancer expression nek family normal cancer tissue immunohistochemical study background nek serine threonine protein kinase involve cell cycle checkpoint dna damage repair apoptosis alteration pathway frequently associate cell malignant cellular transformation thyroid cancer common malignant tumour endocrine system despite good treatment method numb case increase significantly recent year study expression nek nek nek nek different type normal malignant tissue use tissue microarray analysis identify neks potential marker thyroid malignancy method study case comprise multiple cancer tissue microarray include breast colon esophagus kidney lung pancreas prostate stomach thyroid uterine cervix good patient undergo thyroid resection thyroid cancer thyroid nodule expression nek nek nek nek analyze immunohistochemistry expression pattern evaluate term intensity two method semiquantitative quantitative compare normal cancer tissue result analyse expression member nek family tissue dependent manner compare normal tissue evaluate protein show low expression lung tumour however thyroid expression high malignant tissue especially nek nek nek concern characteristic thyroid tumour aggressiveness nek expression high tumour multifocality patient lymph node metastasis nek expression strong patient stage ii involve metastasis nek hand show high expression patient invasion metastasis patient tumour size cm furthermore work demonstrate \\ufeff1 time high specificity sensitivity safety completion thyroidectomy multicentric carcinoma role completion thyroidectomy lobectomy good differentiate thyroid carcinoma remain controversial purpose present study compare relative safety one stage versus two stage approach management thyroid cancer thirty consecutive patient thyroid carcinoma study patient freeze section diagnosis carcinoma allow total thyroidectomy initial operation patient carcinoma find permanent section thus completion thyroidectomy undertake 2 stage transient hypocalcemia occur one patient group one stage two stage one unilateral recurrent nerve paresis one stage group none two stage group conclude two stage procedure safe effective approach treatment thyroid cancer employ instance diagnosis malignancy insecure initial operation utility routine freeze section examination intraoperative diagnosis thyroid cancer background value routine freeze section examination intraoperative diagnosis thyroid cancer determination extent thyroidectomy controversial need evaluate institution institution basis method prospective evaluation patient nodular thyroid disease adequate fine needle aspiration biopsy fnab undergo thyroidectomy routine thyroid freeze section examination direct comparison fnab freeze section examination along cost benefit analysis freeze section examination complete result thyroid pathology carcinoma follicular adenoma multinodular goiter thyroiditis cyst patient sensitivity specificity accuracy freeze section examination respectively compare fnab p diagnosis defer patient freeze section examination show follicular neoplasm one freeze section examination obtain per patient alteration intraoperative management patient charge per patient total charge conclusion patient adequate fnab freeze section examination rarely affect intraoperative decision make thyroid surgery routine use not cost effective quantitative detection peripheral thyroglobulin mrna limit clinical value follow thyroid cancer patient background recurrence treatment differentiate thyroid cancer occur many year thyroidectomy periodic monitor serum thyroglobulin tg level perform patient however autoantibody interfere tg immunoassay occur blood approximately patient several early report suggest measure tg mrna reverse transcriptase polymerase chain reaction rt pcr can value especially patient tg autoantibody method use early describe breast cancer metastasis thyroid retrospective analysis background breast cancer metastasize thyroid gland relatively uncommon clinical practice objective retrospective analysis datum breast cancer patient thyroid metastasis tm method us suspect fine needle aspiration cytology fnac confirm tm breast cancer patient treat hospital retrospectively analyze datum evaluate pathologist radiologist blind patient datum result fnac immunohistochemistry confirm ultrasonography us suspect tm eight breast cancer patient clinically unilateral bilateral tm see symptomless metachronously month metastasize six eight case exhibit recurrence distant metastasis treat chemotherapy thyroidectomy two case pass away remain two patient no recurrence distant metastasis treat partial total thyroidectomy post chemotherapy us show homogenous thyroid parenchyma gather calcification reduce size reveal sensitiveness tm chemotherapy conclusion us useful screen tm breast cancer patient partial total thyroidectomy effective disease free survival isolate tm case control primary condition tm respond good chemotherapy recurrent breast cancer case without distant metastasis delay treatment papillary thyroid carcinoma arise struma ovarii patient history bilateral salpingo oophorectomy case report objective present case papillary thyroid carcinoma arise struma ovarii treat erroneously ovarian adenocarcinoma year method report clinical surgical laboratory image finding study patient review relevant literature result year old woman treat ovarian adenocarcinoma year determine likely papillary thyroid carcinoma arise struma ovarii \\ufeff1 report case thyroid carcinoma arise struma ovarii patient history bilateral salpingo oophorectomy possible etiology include residual ovarian tissue oophorectomy ectopic thyroid metastatic thyroid cancer conclusion important include struma ovarii thyroid carcinoma arise struma ovarii differential diagnosis even history bilateral salpingo oophorectomy case emphasize importance effective communication among pathologist oncologist surgeon ensure timely initiation appropriate therapy reduce patient morbidity circulate mir p mir may potential biomarker diagnosis papillary thyroid carcinoma objective no effective reliable biomarker distinguish benign thyroid nodule papillary thyroid carcinoma ptc study aim examine level plasma mirnas patient ptc benign nodule explore potential mirna biomarker ptc patient method genome wide plasma mirna expression profile determine mirna microarray significantly high level mirnas validate plasma tissue quantitative rt pcr level two mirnas test seven patient tumor excision potential value diagnosis ptc evaluate receiver operate characteristic curve roc result comparison patient benign nodule eight significantly high three low level plasma mirnas detect ptc patient validation indicate level plasma mir p mir mir p let significantly high ptc case benign nodule healthy control significantly high level mir p mir detect thyroid tissue ptc patient level plasma mir p mir seven patient significantly decrease tumor excision roc analysis reveal level plasma mir p cut mir sensitivity specificity distinguish ptc benign nodule respectively conclusion finding suggest level plasma mir p mir may valuable diagnosis ptc environmental factor contribute incidence thyroid cancer objective asse clinical presentation patient thyroid cancer prefer diagnostic work prefer surgical procedure method retrospective chart review patient undergo partial total thyroidectomy thyroid cancer akuh spss use analyze datum pearson chi square likelihood ratio use calculate test significance result total patient include review solitary thyroid nodule initial presentation three majority present neck swell enlarge goiter one every patient show evidence lymph node involvement distant metastasis aggressiveness disease not correlate age sex histological subtype no correlation size tumor presence local distant metastasis conclusion thyroid cancer aggressive disease pakistan majority patient present multinodular goiters significant numb lymph node metastasis high degree vigilance low threshold fine needle aspiration fna need evaluate patient thyroid goiter refractory thyroid cancer paradigm shift treatment not far thyroid cancer tc incidence france dramatically increase last two decade order try account observation french department health request public health agency coordinate multidisciplinary thyroid cancer committee tcc tcc analyse temporal incidence trend france evaluate contribution change diagnostic practice thyroid disease observe increase tc set guideline improve national surveillance system tc increase incidence tc real per year woman man respectively mainly due papillary type epidemic microcarcinomas operate cancer period associate extensiveness thyroidectomy multicentric study show significant increase ultrasonographic cytological procedure patient thyroid nodule good significant association increase tc prevalence among operate patient spread fine needle aspiration epidemiological evidence not favour link chernobyl accident tcc recommend national registry dedicate thyroid cancer youth year old adult addition strengthen french regional registry continuous registration incident case national hospital discharge survey cover territory propose system match pathological datum derive national standardize collection provide relevant model epidemiological survey tc stromal tiny black dot like sugar coat von kossa stain diagnostic clue hyalinizing trabecular tumor thyroid gland hyalinizing trabecular tumor htt rare low grade tumor prominent feature basement membranous stroma assume characteristic stromal finding htt relate calcium deposition examine htt sample von kossa special stain no report describe von kossa special stain stroma collect case htt case papillary thyroid carcinoma ptc match age gender tumor size surgical procedure characteristic control group compare stain pattern degree von kossa positivity htt ptc grade system von kossa stain adopt highlight difference von kossa stain htt reveal many tiny black dot around vessel hyalinized stroma like sugar coat high degree calcium deposition case whereas ptc show sparse stromal calcification case degree von kossa stain significantly different two group \\ufeff1 report describe abundant tiny black dot like sugar coat appearance von kossa stain htt propose find useful diagnostic clue htt treatment good differentiate thyroid cancer good differentiate thyroid cancer common malignancy thyroid gland yet optimal management remain controversial patient lesion operate without supplementary treatment conclude young patient stage disease safely treat subtotal thyroidectomy total thyroidectomy combine radioactive ablation indicate patient advance systemic disease nop candidate modifier locus familial non medullary thyroid cancer nonsyndromic familial non medullary thyroid cancer fnmtc represent thyroid cancer susceptibility gene remain unknown design multicenter study analyze family nonsyndromic fnmtc identify candidate susceptibility gene perform exome sequence dna four affect individual one kindred five case nonsyndromic fnmtc single nucleotide variant insertion deletion segregate affect member analyze sanger sequence additional family fnmtc two affect member seven three affect member good independent control group subject identify germline variant p asp nop gene r maf present affect member three family nonsyndromic fnmtc not present unaffected spouse functional study nop thyroid cancer cell line show oncogenic function immunohistochemistry exhibit increase nop protein expression tumor sample affect family member compare normal adjacent thyroid tissue give relatively high frequency variant general population finding suggest instead causative gene nop likely low penetrant gene implicate fnmtc possibly modifier increase world incidence thyroid cancer increase detection high radiation exposure objective describe incidence trend access histological change pattern thyroid cancer urban area beijing method total new case diagnose thyroid cancer urban area beijing extract population base datum base beijing cancer registry among male female coverage population person year person year respectively incidence age adjust incidence annual percentage change apc gender specific incidence change different histology pattern last year calculate result case diagnose thyroid cancer sex ratio male female incidence rate thyroid cancer urban area beijing increase dramatically increase rate adjust world population standardize incidence rate increase annual percentage change apc p among male incidence rate increase increase rate adjust world population standardize incidence rate male increase annual percentage change apc p among female incidence rate increase increase rate adjust world population standardize incidence rate female increase annual percentage change apc p incidence rate rank th th among male female respectively rank th th respectively among case case confirm histologically primary tumor account total case papillary carcinoma common subtype account total case among pathological type thyroid cancer proportion papillary carcinoma rise however proportion follicular carcinoma decrease conclusion incidence thyroid cancer urban area beijing keep increase mainly due rise papillary carcinoma risk factor papillary thyroid cancer focus strategy thyroid cancer prevention control conduct role radioactive iodine treatment good differentiate thyroid cancer prognosis differentiate thyroid cancer excellent completeness thyroidectomy removal involve regional metastasis important element management iodine role ablate residual thyroid treat regional distant metastasis effectiveness treatment confirm negative follow scan low undetectable tg therapy relatively specific tissue receive meaningful dose radiation acute long term complication occur therefore whether patient well prognosis treatment whether benefit treatment great side effect must determine every patient preoperative serum thyroglobulin adjunct fine needle aspiration predict good differentiate thyroid cancer background purpose fine needle aspiration biopsy fnab thyroid nodule yield indeterminate pathology management decision become complex preoperative predictor thyroid cancer must employ assess risk malignancy although thyroglobulin tg currently accept serum marker choice detection good differentiate thyroid cancer wdtc recurrence preoperative role workup thyroid nodule remain controversial purpose study evaluate potential role tg preoperative indicator primary wdtc specifically patient indeterminate fnab method retrospective review consecutive thyroidectomy patient patient indeterminate fnab serum level tg measure prior surgery predictive value various threshold level preoperative tg wdtc evaluate patient nonindeterminate fnab final pathology contain medullary carcinoma anaplastic carcinoma lymphoma exclude result eighty one percent patient indeterminate fnab preoperative tg microg l good differentiate cancer final pathology compare patient indeterminate cytology alone p rr addition mean preoperative tg level find significantly high patient wdtc compare benign pathology vs microg l p discussion conclusion result imply elevate preoperative serum tg level may predictive wdtc marker may useful aid make management decision patient indeterminate cytology serum hydroxyvitamin level not affect aggressiveness prognosis papillary thyroid cancer background vitamin deficiency know associate aggressiveness prognosis several cancer study evaluate effect preoperative serum vitamin level aggressiveness prognosis papillary thyroid cancer ptc method total patient ptc enroll hydroxyvitamin level measure blood sample surgery clinical pathologic recurrence datum access examine prognostic effect vitamin patient categorize four quartile preoperative serum vitamin level result enroll patient insufficient vitamin level ng ml vitamin level show positive correlation age body mass index bmi negative correlation serum thyrotropin level antithyroid peroxidase antibody titer association vitamin quartile risk extrathyroidal invasion lymph node metastasis advance cancer stage iii iv risk recurrence not significant adjust age sex bmi preoperative ionize calcium parathyroid hormone additionally serum vitamin not associate recurrent persistent ptc conclusion serum vitamin level not associate either disease aggressiveness poor outcome among patient ptc vitamin insufficiency lung metastasis pediatric thyroid cancer radiological pattern molecular genetic response therapy outcome context lung metastasis common pediatric thyroid cancer tc present analysis series lung metastasis pediatric tc patient method datum patient female male median age year range year analyze tumor include differentiate tc patient poorly differentiate tc patient result lung metastasis present three distinct radiological pattern lung uptake diagnostic radioactive iodine whole body scan dxwbs patient lung uptake dxwbs ct scan micrometastases cm patient lung uptake dxwbs ct scan macrometastases cm patient iodine therapy administer patient median three range one eight median cumulative administer activity mci range mci none patient achieve complete response biochemical response substantial median follow period year range year patient die patient biochemically incomplete response patient indeterminate response patient progressive structural disease patient stable structural disease mutational test tumor reveal two pik ca mutation single tumor conclusion lung metastasis common pediatric tc present frequently bilateral radioiodine avid micrometastases know single point mutation adult tc rare pediatric tc biochemical response iodine substantial resolution structural abnormality rare enter era precision management thyroid cancer background programme death ligand pd l expression emerge important predictive biomarker anti pd l cancer immunotherapy role clearly define various human cancer link poor prognosis resistance anticancer therapy role pd l thyroid cancer not good define fine needle aspiration cytology fnac author examine performance pd l immunostaining liquid base cytology lbc determine whether can biomarker malignancy aggressive disease method january march thyroid lesion diagnose fnac indeterminate lesion suspicious malignancy sfm malignant enroll pd l immunostaining perform lbc correspond histology sample result fnac cohort include benign negative control sample atypia undetermined significance follicular lesion undetermined significance aus flus sample follicular neoplasm suspicious follicular neoplasm fn sfn sample suspicious malignancy sfm malignant sample aus flus sample include goiters follicular adenoma fas noninvasive follicular thyroid neoplasm papillary like nuclear feature niftp invasive follicular variant papillary thyroid carcinoma fvptcs follicular carcinoma whereas fn sfn sample include fas malignancy fvptcs niftp papillary thyroid carcinoma ptcs oncocytic follicular carcinoma sfm sample diagnose histopathology fas niftps fvptcs ptcs whereas malignant specimen include niftps fvptcs ptcs increase plasma membrane cytoplasmic pd l expression find case include ptcs conventional variant negative pd l expression find niftps fas braf v e mutation identify pd l positive malignancy conclusion current datum suggest pd l expression thyroid gland may represent marker malignancy correlate ptc not niftp thyroid neoplasm pd l expression also ae enrich braf v e mutation suggest associate aggressive behavior telomerase reverse transcriptase mutation independent predictor disease free survival middle eastern papillary thyroid cancer papillary thyroid carcinoma ptc common type thyroid cancer tumor recurrence occur ptcs reach advance stage promoter mutation telomerase reverse transcriptase tert gene identify prognostic marker ptc however contribution tert promoter mutation cancer progression ptc patient still not fully understand study investigate incidence tert promoter mutation tert protein expression association clinicopathological outcome large cohort ptc sample use direct sequence technology immunohistochemistry furthermore two ptc cell line utilize investigate role tert mutation mediate metastasis two promoter hotspot mutation c c identify cohort significantly associate poor year disease free survival distant metastasis ptc tert protein overexpression note ptc cohort significantly associate poor prognostic marker old age extrathyroidal extension stage iv tumor significant association also find tert overexpression epithelial mesenchymal transition emt marker functional analysis show tert inhibition reduce cell growth invasion migration angiogenesis ptc via suppression emt ptc cell result suggest tert promoter mutation independent predictor disease free survival may drive metastasis downregulation tert can potentiate antitumor antimetastatic activity ptc pool analysis case control study thyroid cancer iv benign thyroid disease objective obtain precise estimate association thyroid cancer benign thyroid disease elucidate role potential confounder effect modifier method original datum case control study unite state asia europe pool base woman man cancer thyroid respectively control subject odd ratio ors correspond confidence interval cis obtain conditional regression model condition study age diagnosis adjust age radiotherapy result history hypothyroidism not associate cancer risk pool ors confidence interval ci woman ci man ors hyperthyroidism ci woman ci man woman however risk low absence allowance history goiter pool ors history goiter ci woman ci man risk history benign nodule adenoma especially high ci woman case versus control man excess risk goiter benign nodule adenoma great within year prior thyroid cancer diagnosis elevate present year cancer conclusion goiter benign nodule adenoma strong risk factor thyroid cancer apart radiation childhood technetium tetrofosmin image differentiate mix thyroid cancer report describe accurate localization metastatic lesion patient differentiate mix thyroid cancer use mtc tetrofosmin image yr old woman cytological diagnosis follicular thyroid cancer associate large amount goiter change study mtc tetrofosmin total body scintigraphy no significant tetrofosmin uptake observe thyroid nodule mainly show goiter abnormality abnormal increase tetrofosmin uptake however find metastatic tumor lesion locate cervical dorsal spine good leave low chest wall lung conclusion mtc tetrofosmin new radiopharmaceutical propose myocardial perfusion image may useful patient thyroid cancer ethical implication reclassification noninvasive follicular variant papillary thyroid carcinoma background several study highlight lack consensus diagnosis follicular variant papillary thyroid carcinoma fvptc international multidisciplinary panel address controversy assemble annual meet endocrine pathology society march lead recent publication reclassify encapsulate noninvasive fvptc efvptc benign neoplasm change histologic taxonomy warrant change clinical practice affect give diagnosis past consider financial psychological impact reclassification discuss ethical legal practical issue involve share information patient affect summary total direct indirect cost thyroid cancer surveillance patient significant high level clinically relevant distress affect patient papillary thyroid carcinoma estimate distress thermometer develope national comprehensive cancer network detect distress cancer patient although currently no legal opinion establish precedent recontacting patient whose clinical status alter change nomenclature prudent course would attend requirement medical ethic conclusion inform patient previous diagnosis efvptc disease reclassify benign expect dramatic effect surveillance need alleviate psychological impact live diagnosis cancer important evaluate pathologic slide patient risk ensure invasive nature tumor comprehensively evaluate notify patient change diagnosis availability entire tumor evaluation capsule may prove challenge portion population risk believe clinician professional duty make sincere reasonable effort convey information affect patient also believe cost saving respect need additional surgery radioactive iodine rigorous surveillance associate misinterpretation biology diagnosis efvptc little experience hand likely offset cost incur histologic review patient notification ret oncogene papillary thyroid carcinoma papillary thyroid carcinoma ptc common form thyroid cancer account great case surgical resection without postoperative radioiodine therapy remain standard care patient ptc prognosis generally excellent appropriate treatment despite significant number patient not respond maximal surgical medical therapy ultimately die disease mortality reflect incomplete understand oncogenic mechanism initiate drive promote ptc nonetheless significant insight pathologic subcellular event underlie ptc discover last decade remain area significant research interest chromosomal rearrangement result expression fusion protein involve rearrange transfection ret proto oncogene \\ufeff1 oncogenic event identify ptc member fusion protein family ret ptc family appear play oncogenic role approximately ptcs herein author review current understand clinicopathologic role ret ptc fusion protein ptc development progression molecular mechanism ret ptcs exert oncogenic effect thyroid epithelium solitary thyroid nodule selection patient surgery management solitary thyroid nodule especially nodule hypofunctional radionuclide scan still controversial major controversy center around selection patient surgery review patient recently operate suspect thyroid cancer naval regional medical center portsmouth virginia undertake us effort determine factor suggest presence malignancy preoperatively not surprisingly carcinoma frequently find solitary hypofunctional solid thyroid nodule although exception clinical criterium thyroid gland papillary carcinoma micropapillary pattern recently recognize poor prognostic find clinicopathologic survival analysis case micropapillary carcinoma histologic pattern rather independent entity aggressive clinical behavior regardless location histologically characterize papillary cell group clear space micropapillary pattern thyroid gland not study recently name hobnail feature oncocytic therefore poorly understand report case report clinicopathologic feature case obtain cohort papillary thyroid carcinoma correspond prevalence proportion micropapillary component account tumor slightly prevalent man correlate presence lymphovascular permeation survival analysis show low survival even short follow year conventional carcinoma without component p consistent poor overall survival short term year report carcinoma micropapillary pattern location believe owe difference survival patient conventional papillary carcinoma alive year versus little micropapillary pattern micropapillary pattern correctly identify state pathology report comprise little tumor external validation mskcc postoperative hypocalcaemia nomogram turkish papillary thyroid cancer patient prophylactic central neck dissection papillary thyroid cancer controversial retrospective cohort study aim assess possible advantage prophylactic central neck dissection total thyroidectomy cn papillary thyroid cancer total consecutive patient papillary thyroid cancer without clinical ultrasound nodal metastasis cn evaluate patient operate thyroid disease istituto europeo di oncologia milan italy patient group undergo thyroidectomy central neck dissection group b undergo thyroidectomy alone demographic clinical pathological feature analyse overall recurrence rate group group b mean follow group group b month group patient pn patient recurrence nodal involvement p survival rate not differ two group nine patient lose follow group patient old tumour large size accord pt distribution high extra capsular invasion rate observe two group equivalent far concern histological high risk variant multifocality nodal metastasis correlate stage pt vs pt p low risk nodal metastasis relate thyroiditis p conclusion central neck metastasis predictive recurrence without influence prognosis datum obtain possible great efficacy central neck dissection pt papillary thyroid cancer without thyroiditis suggest poorly differentiate anaplastic thyroid cancer background poorly differentiate thyroid carcinoma pdtc anaplastic undifferentiated thyroid carcinoma atc comprise small subset thyroid tumor associate poor prognosis account significant portion morbidity mortality relate thyroid cancer since management strategy vary two entity important clinician able differentiate pdtc atc method review literature pdtc atc compare clinical histopathologic feature important define disease process result pdtc atc display aggressive behavior increase locoregional distant disease case patient old large locally advance tumor pdtc may represent intermediate entity progression good differentiate thyroid carcinoma atc use surgical management may curative palliative differ pdtc atc role radiotherapy chemotherapy not good describe conclusion pdtc atc rare disease carry poor prognosis recognition different clinicopathologic feature important optimal management tumor transcriptome analysis papillary thyroid cancer harbor telomerase reverse transcriptase promoter mutation background telomerase reverse transcriptase tert promoter mutation recently identify important prognostic factor thyroid cancer study suggest tert may noncanonical function beyond telomere maintenance method clinicopathological information transcriptome datum papillary thyroid carcinoma ptc sample obtain cancer genome atla tcga propensity score match perform adjust potential confound variable tert promoter wild type group mutant group gene expression datum patient mutant group systemically compare patient wild type group result tumor tert promoter mutation high tert expression pathway central dna damage response cell cycle regulation significantly enrich among upregulated gene transporter metabolic activity overrepresented among downregulated gene no difference expression thyroid differentiation gene conclusion tert promoter mutation associate proliferative metabolic alteration ptc unilateral follicular variant papillary thyroid carcinoma unique kras mutation struma ovarii bilateral ovarian teratoma rare case report background struma ovarii rare form ovarian mature teratoma thyroid tissue predominant element rarity differential diagnosis benign malignant not clearly define believe malignant transformation similar molecular feature prognosis correspond malignant tumor originate thyroid case presentation report year old woman bilateral ovarian cyst incidentally detect ultrasound \\ufeff1 trimester pregnancy four month delivery healthy child without complication admit hospital acute abdominal pain laparoscopic leave adnexectomy perform initially regional hospital right cystectomy do late specialize clinic intraoperative freeze section final pathology reveal cyst leave ovary compose mature teratomatous element normal thyroid tissue non encapsulate focus follicular variant papillary thyroid carcinoma ptc normal cancerous thyroid tissue test braf ras mutation direct sequence ret ptc rearrangement rt pcr southern blot kras codon mutation ggt gtt transversion correspond gly val amino acid change identify absence genetic alteration commonly find ptc conclusion well knowledge \\ufeff1 time mutation describe papillary thyroid carcinoma arise struma ovarii find provide evidence even rare mutation specific ptc may occur tumor molecular test may useful adjunct common differential diagnostic method thyroid malignancy papillary thyroid carcinoma complicate tracheal squamous cell carcinoma case report outcome patient operate upon \\ufeff1 intention thyroid cancer analyze follow year no death due cancer occur case papillary cancer case present pulmonary metastasis global year survival rate case vesicular cancer include preoperative metastasis absence preoperative metastasis ans good differentiate form separate moderately differentiate form respective year survival year survival rate case anaplastic cancer year rate case medullary cancer target copz non oncogene addiction counteract viability thyroid tumor cell thyroid carcinoma generally associate good prognosis no effective treatment currently available aggressive form not cure standard therapy find novel therapeutic target tumor type previously perform sirna base functional screen identify gene essential sustain oncogenic phenotype thyroid tumor cell not require extent viability normal cell non oncogene addiction paradigm among find coatomer protein complex copz gene involve intracellular traffic autophagy lipid homeostasis paper investigate mechanism copz depletion lead thyroid tumor cell death show sirna mediate copz depletion cause abortive autophagy endoplasmic reticulum stress unfold protein response apoptosis interestingly observe mouse tumor xenograft locally treat sirna target copz show significant reduction tumor growth whole demonstrate \\ufeff1 time crucial role copz viability thyroid tumor cell suggest may consider attractive target novel therapeutic approach thyroid cancer thyrotoxicosis thyroid cancer paper concern result examination thyroid cancer patient cancer combine thyrotoxicosis succession occurrence possible way development combination consider study make nature endocrine change patient thyroid cancer combine thyrotoxicosis use clinical laboratory method show frequency combination thyroid cancer thyrotoxicosis make common woman diagnosis endocrine disease thyroid ultrasound us us assist procedure shadow array application patient thyroid nodule ultrasound us image represent indispensable tool assessment risk malignancy approximately four decade innovative technology successive improvement facilitate entry routine management greatly improve predictive value us feature not reliably rule thyroid cancer us guidance allow correct safe sample also small deeply locate thyroid lesion obtain way cytological microhistological specimen may reliably define nature thyroid nodule information histochemical molecular marker show promise classification remain indeterminate case prompt surgical treatment offer minority suspicious definitely malignant case individual warrant follow however initial evaluation year fraction benign lesion may grow become symptomatic case may benefit us guide minimally invasive procedure alternative surgery image guide percutaneous treatment often achieve relief neck complaint inexpensive perform outpatient basis risk major complication adequate train low importantly thyroid function preserve currently percutaneous ethanol injection cystic lesion thermal ablation laser radiofrequency solid nodule increasingly use disseminate beyond initial core facility centre expertise high patient volume use consider \\ufeff1 line treatment alternative surgery select patient benign enlarge symptomatic thyroid lesion epidemiology thyroid cancer author transl medical definition remain many year other change due progress diagnostic tool able distinguish marker symptom undetectable occult thyroid carcinoma general term indicate clinically different situation whereas incidentally detect papillary thyroid microcarcinoma important clinical point view fundamental therapeutic management determine biological parameter would define small group papillary thyroid microcarcinomas aggressive biological behaviour promise genetic molecular marker papillary thyroid carcinoma risk stratification discuss review preoperative evaluation marker obtain analysis ultrasonography guide fine needle biopsy specimen papillary thyroid microcarcinoma can valuable guide treatment type cancer treatment micropapillary carcinoma thyroid draw line two patient papillary thyroid cancer see consultation treat medical center cancer measure mm respectively patient treat two thyroid operation ablation believe apart lobectomy therapy not justify draw attention provide topic debate attempt prevent happen patient multifocal micropapillary thyroid cancer new indication total thyroidectomy american thyroid association guideline recommend total thyroidectomy tt thyroid cancer cm great liberal use neck sonography result increase incidence papillary cancer detect early stage approximately half micropapillary level occasionally multifocal concern regard safety routine tt especially young patient favorable cancer clinical significance detect multifocal micropapillary cancer raise record consecutively treat patient thyroid cancer review subset case good differentiate papillary thyroid cancer wdptc confine within capsule involve lobe undergo tt analyze patient stratify accord age tumor size evidence ipsilateral multifocality presence absence contralateral nonpalpable malignancy overall contralateral histologic malignancy demonstrate per cent incidence per cent subcentimeter little cm tumor significantly increase per cent tumor cm great p incidence significantly approach per cent subcentimeter multifocal tumor year old p one patient develope permanent hypocalcemia no recurrent nerve injury incidence bilateral cancer significant cm great wdptc patient subcentimeter multifocal tumor old year even high risk bilateral cancer tt advocate patient wdptc cm great also consider old year ipsilateral multifocal micropapillary cancer perform safely tert promoter mutation associate distant metastasis papillary thyroid carcinoma objective transcriptional activate mutation promoter telomerase reverse transcriptase tert gene report high frequency aggressive poorly differentiate anaplastic thyroid cancer contrast relevance mutation metastatic behavior good differentiate thyroid cancer still define aim work investigate frequency tert promoter mutation remarkable cohort good differentiate papillary thyroid carcinoma develope distant metastasis dm ptcs establish whether mutation may predictive metastatic behavior design analyze frequency tert promoter mutation group highly aggressive dm ptcs control analyze mutation group ptcs without distant metastasis control ptcs possible correlation tert promoter mutation braf v e mutation also investigate method tert promoter mutational status evaluate direct sequence hotspot harbor c c mutation result overall cohort ptcs analyze case carry mutation tert promoter noticeably dm ptcs mutate tert promoter control ptcs show mutation locus also observe positive association braf v e tert c mutation cohort dm ptcs conclusion result indicate tert promoter mutation associate development distant metastasis ptcs may help predict aggressive behavior type tumor diagnosis management differentiate thyroid cancer use molecular biology objective hypothesis define molecular biology clinical practice diagnosis surgical management prognostication differentiate thyroid cancer datum source ovid medline review method manuscript clinical correlate result papillary thyroid carcinoma harbor point mutation braf ras gene ret ptc rearrangement activate mitogen activate protein kinase pathway mutually exclusive mutation find ptc braf mutation find papillary thyroid cancer highly specific follicular carcinoma know harbor ras mutation pax ppar rearrangement mutation also mutually exclusive identify follicular carcinoma molecular classifier measure expression large numb gene microarray chip provide substantial negative predictive value pend validation conclusion cytologically classify follicular neoplasm follicular lesion undetermined significance collectively malignant final pathology approximately thyroid lobectomy perform solely diagnostic purpose benign molecular alteration test may reduce numb unnecessary thyroid procedure may reduce numb completion thyroidectomy may lead individualize operative postoperative management molecular test braf ras ret ptc pax ppar follicular lesion undetermined significance follicular neoplasm improve specificity whereas molecular classifier may add negative predictive value fine needle aspiration diagnosis development validation individualize diagnostic signature thyroid cancer new molecular signature need improve diagnosis thyroid cancer tc avoid unnecessary surgery study aim develop robust individualize diagnostic signature tc gene expression profile tumor nontumor sample microarray dataset gene expression omnibus geo database one rna sequence dataset cancer genome atla tcga total sample divide train set n test set n one independent validation set n train set frequent differentially express gene deg among include dataset use construct gene pair significant pair detect construct diagnostic signature penalize generalize linear model signature show good diagnostic ability tc train set area receiver operate characteristic curve auc test set auc tcga dataset auc subgroup analysis show consistent result consider type nontumor sample microarray platform compare two exist molecular signature diagnosis thyroid nodule signature auc also show high diagnostic ability auc gene signature auc gene signature conclusion study develope validate individualize diagnostic signature tc large scale prospective study need validate diagnostic ability carcinoma thyroid gland thyroid cancer not common cancer consist variety tumor different biological characteristic diagnosis therapeutic approach differ considerably depend subgroup tumor belong differentiate carcinoma constitute bulk thyroid carcinoma often retain feature thyroid gland take advantage management prognosis patient usually excellent undifferentiated carcinoma contrast aggressive tumor usually fatal within year diagnosis therefore aggressive therapeutic approach require transformation differentiate carcinoma undifferentiated carcinoma occur although infrequently importance proper management patient differentiate carcinoma obvious medullary carcinoma originate parafollicular cell various interest biological characteristic medium grade malignancy cytological diagnosis benign thyroid lesion real safe diagnosis patient objective fine needle aspiration cytology fnac category benign thyroid lesion btl constitute thyroid fnac correctly diagnose morphology alone important entity diagnosis btl denote lesion manage follow unless find conjunction compressive symptom although diagnosis quite simple case scant cellular colloid component may pose diagnostic issue herein describe experience evaluate btl two large academic institution evaluate clinical importance correct diagnosis btl define exact inherent risk false negative result fnr method january june patient btl undergo surgery nodule sample sonographic guidance us process either liquid base cytology lbc diff quik smear alcohol papanicolaou stain method result histological follow btl series include benign malignant lesion latter group include four follicular carcinoma fc two classic variant papillary thyroid carcinoma ptc one macrofollicular ptc six follicular variant ptc fvpc malignancy rate btl category conclusion diagnose expert cytopathologists btl represent robust diagnosis may reduce numb fnr additional diagnostic experience large case series can enable cytopathologists recognise morphological entity btl important additional aid extensive sample lesion reduce issue relate low cellularity development risk score system patient papillary thyroid cancer importance personalize therapeutics aggressive papillary thyroid cancer ptc increase accurate risk stratification require develop novel prognostic score system patient ptc n use mrna expression clinical datum cancer genome atla perform variable selection use network regularize high dimensional cox regression gene network pathway database risk score calculate use linear combination regression coefficient mrna expression risk score clinical variable assess several survival analysis risk score show high discriminatory power prediction event free survival good presence metastasis multivariate analysis risk score presence metastasis significant risk factor among clinical variable examine together current study develope risk score system help identify suitable therapeutic option ptc use tc sestamibi spect ct conventional image study negative localize suspect recurrence differentiate thyroid cancer method lesson clinical management purpose detection recurrent disease differentiate thyroid cancer dtc patient elevate rise serum thyroglobulin tg level multiple negative conventional image study challenge especially f fdg pet ct scan also negative report patient review literature diagnostic use tc sestamibi scan identify source elevate rise tg patient negative conventional image include negative f fdg pet ct scan patient method year old woman refer widely invasive metastatic follicular thyroid cancer bone metastasis leave mandible total thyroidectomy leave mandibular resection therapy mci gbq subsequent unstimulated serum tg level ng ml tgab negative six month follow stimulate tg ng ml tsh miu l tgab negative image study perform within prior month report negative recurrence metastasis include neck ultrasound diagnostic radioiodine scan chest ct f fdg pet ct patient inject mci mbq tc sestamibi intravenously whole body spect ct image acquire result tc sestamibi whole body posterior image demonstrate abnormal focal uptake right posterior calvarium correspond occipital lytic bone lesion spect ct patient undergo surgical resection skull metastasis pathology confirm metastatic follicular thyroid cancer five month post surgery suppress tg markedly reduce remain stable ng ml knowledge dtc recurrence location two set f fdg image evaluate thorough target interpretation underscore importance structure image report current literature utility tc sestamibi scan radioiodine f fdg pet ct image study negative sparse inconsistent conclusion tc sestamibi may role thyroid cancer localization physical exam neck ultrasound radioiodine scan chest abdomen ct f fdg pet ct not identify source elevate tg level dtc thyroid cancer since chernobyl accident hypothesis background prognostic value propose 8 edition american joint committee cancer ajcc tumor node metastasis tnm classification currently unclear aim study evaluate prognostic value 8 edition ajcc tnm classification method retrospectively assess patient differentiate thyroid carcinoma dtc undergo thyroidectomy tertiary korean hospital cancer specific survival css analyze use kaplan meier method compare use log rank test performance 8 edition tnm respect prediction css assess current 7 edition result upon reclassification accord 8 edition patient stage proportion stage ii tumor increase respectively whereas stage iii ivb formerly ivc 7 edition decrease respectively proportion variance explain pves ability 8 7 edition predict css respectively c index value confidence interval 8 edition 7 edition conclusion result demonstrate 8 edition tnm accurately predict css patient dtc 7 edition effect perioperative treatment hypoxia inducible factor alpha inhibitor orthotopic surgical mouse model thyroid cancer background aim despite excellent prognosis certain patient thyroid cancer suffer locally invasive disease not control conventional therapy previous study suggest hypoxia inducible factor alpha hif may important marker identification treatment target intractable thyroid cancer therefore present study establish orthotopic mouse surgical model thyroid cancer mimic clinical set evaluate effect perioperative treatment hif inhibitor material method seven thyroid cancer cell line snu bcpap ktc tpc difference thyroid cancer background hurthle cell cancer hcc consider variant follicular cancer fc many think distinct histologic tumor aggressive behavior method influence age diagnosis tumor stage gender extent operation disease free interval cause specific mortality year initial thyroidectomy analyze result year disease free interval fc hcc p year cause specific mortality fc patient hcc p risk factor hcc progression survival extrathyroidal invasion presence metastasis diagnosis male gender extent thyroidectomy whereas fc significant risk factor extrathyroidal invasion presence metastasis diagnosis conclusion patient hcc aggressive tumor patient fc datum suggest fc hcc classify distinct tumor regulatory cell plasmacytoid dendritic cell contribute immune escape papillary thyroid cancer coexist multinodular non toxic goiter immunosuppressive lymphocyte regulatory cell tregs plasmacytoid dendritic cell pdcs play crucial role tumor escape investigate role tregs pdcs papillary thyroid cancer ptc plus multinodular non toxic goiter mng thyroid tissue blood sample patient ptc plus mng mng alone analyze cd cell cd cell foxp treg icos foxp treg pdc number immunohistochemistry ihc immunofluorescence flow cytometry plasma concentration cytokine interleukin il transform growth factor tgf measure enzyme link immunosorbent assay good thyroid tissue peripheral blood number foxp treg significantly high patient ptc plus mng compare patient mng alone prognostic marker icos foxp tregs represent strong predictor disease progression total number foxp tregs furthermore positive correlation pdc icos foxp treg number tissue patient ptc plus mng observe suggest ptc derive pdcs may induce differentiation naive cd cell icos foxp tregs may one mechanism underlie tumor escape ptc plus mng patient result suggest tregs pdcs together contribute tumor escape patient ptc plus mng preparation radioactive iodine administration differentiate thyroid cancer patient objective recent year practice tsh suppression change thyroxine dose reduce significantly treatment patient low risk differentiate thyroid cancer goal study determine time need attain target tsh level miu l follow levothyroxine withdrawal patient treat thyroxine accord current guideline anticipation radioactive iodine rai administration design observational study patient thirteen consecutive patient differentiate thyroid cancer suppressive dose levothyroxine plan rai administration five patient receive cholestyramine attempt facilitate tsh recovery measurement serum tsh free free day interval result patient suppressive dose thyroxine separate occasion baseline tsh level miu l mean interval require reach target tsh concentration little miu l day ci range day cholestyramine no effect rate tsh recovery tsh concentration become detectable increase exponentially reach upper limit normal rarely take day attain target level conclusion attain target tsh level radioactive iodine administration require considerably short time currently recommend reduce preparation time may improve patient acceptance procedure efficacy surgeon perform ultrasound guide lymph node fine needle aspiration patient thyroid pathologic condition background although concept surgeon perform fine needle aspiration thyroid nodule establish experience surgeon perform lymph node fine needle aspiration scant aim study efficacy surgeon perform lymph node fine needle aspiration patient thyroid pathologic condition method institutional review board approve study patient thyroid pathologic condition undergo surgeon perform lymph node fine needle aspiration efficacy utility analyze result total patient benign nodular goiter n thyroid cancer n undergo lymph node fine needle aspiration preoperative workup postoperative follow insufficient aspiration rate indeterminate cytologic result patient suspicious lymph node definite diagnosis can obtain fine needle aspiration n fine needle aspiration indicate metastasis thyroid cancer n benign finding sensitivity specificity lymph node fine needle aspiration diagnose nodal metastasis respectively cytologic test thyroglobulin washout indicate concordance logistic regression spherical shape microcalcifications cystic appearance loss hilum ultrasound independently predict lymph node metastasis conclusion datum indicate adequate surgeon perform lymph node fine needle aspiration highly accurate diagnose nodal status thyroid pathologic condition recommend adoption technique feasible develop efficient comprehensive thyroid practice actual status preoperative diagnosis thyroid cancer albania introduction thyroid cancer common endocrine malignancy account almost human cancer good know majority case occur woman middle decade life thyroid cancer relatively rare disease hand clinically apparent thyroid nodule present adult population thyroid nodule not malignant report malignancy rate important surgeon know beforehand diagnosis malignancy order perform radical operation thyroid gland patient method study analyze preoperative clinical datum patient operate \\ufeff1 clinic general surgery uhc mother theresa tirana positive histopathologic diagnosis thyroid cancer datum comprise age sex age distribution blood group time lapse \\ufeff1 endocrinologic visit clinical examination sign symptom image functional test preoperative fna admission diagnosis associate disease preoperative treatment result study emerge patient diagnose preoperatively thyroid cancer another relate problem low percentage preoperative fna among sign symptom relate thyroid cancer find patient present dyspnea dysphagia respectively physical examination reveal apparent nodular growth thyroid gland nodular hard consistency case proper endocrinologist consultation lack case conclusion opinion close collaboration endocrinologist surgeon multidisciplinary frame key correct preoperative thyroid cancer diagnosis optimal treatment choroidal skin metastasis papillary thyroid cancer case review literature patient widely metastatic papillary thyroid cancer previously treat external beam radiation present purple nodular lesion face scalp biopsy nodule papillary carcinoma cell stain thyroglobulin subsequently develope decrease leave eye visual acuity fundoscopy reveal lesion typical choroidal metastasis dermal choroidal metastasis papillary thyroid carcinoma rare however significance clinical manifestation may overlook ignore unless diagnosis consider new skin nodule visual acuity decline patient papillary thyroid cancer may represent manifestation distant metastatic disease prompt thorough evaluation dermatological examination fundoscopy choroidal skin metastasis almost always occur patient advance disease initial presentation lesion possible instance thorough search additional site metastatic disease recommend occasionally metastasis may respond therapy external beam radiation predictor neck reoperation mortality initial total thyroidectomy differentiate thyroid cancer background era rise differentiate thyroid cancer incidence rate impact neck reoperation may inform intensity early intervention surveillance study seek define predictor neck reoperation assess impact survival method use california cancer registry link california office statewide health plan development record retrospective cohort study perform patient total near total thyroidectomy papillary follicular thyroid cancer follow primary outcome neck reoperation day year initial thyroid surgery use logistic cox proportional hazard regression impact sociodemographics tumor stage hospital thyroid cancer surgery volume neck reoperation survival determine result neck reoperation identify patient increase odd multivariable model male sex papillary thyroid cancer advance tumor stage associate neck reoperation among man neck reoperation associate asian pacific islander odd ratio confidence interval ci race ethnicity among woman neck reoperation associate young age year ci versus year asian pacific islander ci hispanic ci presentation practical management optimize radioiodine treatment good differentiate thyroid cancer ablation thyroid remnant radioiodine background last decade significant contribution make knowledge connection thyroid adipose tissue modern society face climb rate obesity metabolic syndrome accumulate evidence association obesity increase cancer risk aim review summarize clinical datum association thyroid cancer tc obesity briefly present plausible hypothesis explain interplay summary perform search pubmed database study publish english march use term thyroid cancer obesity body mass index although inconsistency among clinical study seem overweight obesity relate modestly increase tc risk various factor sex ethnicity body change certain life period example adolescence may influence association obesity tc risk preliminary datum link obesity little favorable clinicopathologic profile tc however validation large multicenter study need precise underlie mechanism not yet elucidate insulin igf axis adipokines leptin adiponectin may implicate link excess weight tc conclusion give rise prevalence tc development obesity epidemic important clarify connection tc good mediate pathway however unless association confirm causation prove screen tc overweight obese subject rapidly increase body general population not seem justify impact socioeconomic status use adjuvant radioactive iodine papillary thyroid cancer introduction effect socioeconomic status ses thyroid cancer treatment not study extensively purpose study determine impact ses use adjuvant radioactive iodine rai total thyroidectomy papillary thyroid cancer ptc hypothesize patient low ses little likely receive rai total thyroidectomy method case characteristic patient ptc cm size undergo total thyroidectomy extrapolate surveillance epidemiology end result database chi square test multivariate analysis perform compare demographics clinicopathologic feature use rai county level measure ses result low ses patient likely present positive lymph node year age group advance american joint committee cancer stage positive lymph node multifocal tumor extrathyroidal extension large tumor year age group among patient year age county high median household income high ses composite score significantly high rate rai use odd ratio confidence interval ci p ci p respectively among patient year age reside county high education level associate high rate rai use ci presence cancerous nodule lymph node novel indicator distant metastasis poor survival patient papillary thyroid carcinoma purpose several characteristic lymph node metastasis lnm predictor risk recurrence death examine patient papillary thyroid carcinoma ptc presence cancerous nodule characteristic lnms ptc not yet report objective study evaluate use cancerous nodule lymph node cnln determine risk distant metastasis survival patient ptc method retrospective observational cohort study enroll patient pathologically confirm ptc without initial distant metastasis undergo thyroidectomy neck dissection patient divide two group cnln group non cnln group accord presence cnln result multivariate analysis show presence special histologic variant cnln lateral lnm independent factor predictive distant metastasis distant metastasis find patient cnln non cnln group respectively p furthermore tumor specific death find patient cnln non cnln group respectively p patient cnln group short distant metastasis free survival overall survival patient non cnln group p conclusion presence cnln patient ptc novel indicator distant metastasis poor survival ptc patient accompany cnln undergo aggressive treatment careful follow prognostic index thyroid carcinoma study e r c thyroid cancer cooperative group macrofollicular variant papillary thyroid carcinoma mfv ptc define papillary thyroid carcinoma macrofollicles cross sectional area specimen aim study evaluate clinicopathologic characteristic mfv ptc treat yonsei university college medicine september july patient ptc treat institution patient diagnose mfv ptc final pathologic report mean age patient year old range year twelve lesion find patient preoperative ultrasonographic examination tumor look like benign nodule tumor nodule vary size cm great dimension microscopically macrofollicles surround cuboidal cell hyperchromatic nucleus occupy entire nodule mfv ptc show benign appearance ultrasonography avoid misdiagnosis mfv ptc clinician aware characteristic mfv ptc perform ultrasonography fine needle aspiration biopsy appropriately bethesda categorization thyroid nodule cytology prediction thyroid cancer type prognosis background since inception bethesda system report thyroid cytopathology tbs widely adopt category convey risk malignancy recommend next step though unclear category also predict type extent malignancy would greatly expand utility tbs provide prognostic information addition baseline cancer risk method patient prospectively enroll author thyroid nodule database histologically prove malignancy analyze primary ultrasound guide fine needle aspiration cytology aus atypia unknown significance fn follicular neoplasm susp suspicious malignant correlate type thyroid cancer histological feature know impact prognosis recurrence include lymph node metastasis lnm lymphovascular invasion extrathyroidal extension ete primary cytology separately correlate high risk malignancy result total malignancy identify primary cytology aus case fn case susp case case aus susp cytology progressively associate increase risk high risk disease p lnm p ete p margin positivity p notably malignancy aus cytology follicular variant papillary thyroid cancer compare susp cytology cytology contrast atypical thyroid fine needle aspiration past present future thyroid fine needle aspiration develope key test evaluation thyroid nodule although interpretation thyroid aspirate contain mild abnormality problematic introduction atypia undetermined significance follicular lesion undetermined significance aus flus category bethesda system report thyroid cytopathology tbsrtc help delineate case systematic clinically meaningful manner herein author review cytomorphologic feature associate aus flus interpretation summarize result study conduct since implementation tbsrtc incidence post chernobyl leukemia thyroid cancer child adolescent briansk region evaluation radiation risk leukemia thyroid cancer incidence child adolescent chemobyl accident bryansk region assess significant increase spontaneous incidence category population period report standardize thyroid cancer incidence region time federal level confidence interval respectively upward trend significant trend characteristic leukemia incidence exposure dose correlation not significant standardize leukemia incidence time federal level confidence interval respectively tally federal level within margin error finding clearly indicative exposure radiation factor high thyroid cancer incidence child adolescent bryansk region ongoing debate thyroid surgery freeze section analysis omit controversy concern role freeze section fs matt debate aim study identify role fs analysis intraoperative decision make analyze effect cost detect thyroid malignancy turkey consecutive patient operate thyroid cancer january august patient evaluate retrospectively patient subject fs intraoperative fs correctly identify pathology malignant patient true positive fs result change surgical strategy case false negative fs lesion define histologically papillary microcarcinoma follicular variant papillary cancer follicular cancer case sensitivity fnab intraoperative fs thyroid cancer patient respectively false negative fs result increase cost informative fs euro euro despite limitation result study reject idea role fs become limit recommend routine freeze section operative assessment thyroid nodule omit fs may suggest case fnab reveal malignancy childhood minimally invasive follicular carcinoma clinical feature immunohistochemistry analysis aim report two case childhood thyroid minimally invasive follicular carcinoma mifc highlight clinical feature laboratory finding diagnosis rare disease method patient age gender clinical feature laboratory finding pathology therapy review immunohistochemistry analysis perform resect masse section result total case thyroid cancer confirm pathological analysis account malignant solid tumour include nine thyroid papillary carcinoma two mifc one undifferentiated thyroid carcinoma two child mifc one year boy one year old girl thyroid mass find primary sign image finding show good define heterogeneous mass radionuclide scintigraphy mtc demonstrate small cold nodule right lobe thyroid two case histopathology confirm diagnosis mifc immunohistochemical stain positive thyroglobulin thyroid transcription factor galectin hector battifora mesothelial antigen cytokeratin ae ae cytokeratin proliferate cell nuclear antigen e cadherin two case one case cd vimentin desmin negative one case undertake lobectomy undertake subtotal thyreoidectomy l replacement therapy conclusion mifc exceedingly rare child include differential diagnosis thyroid mass diagnosis mifc depend mainly pathological finding contemporary management papillary carcinoma thyroid gland incidence thyroid cancer increase per year thyroid cancer become 8 common malignancy diagnose woman papillary cancer account thyroid cancer management papillary thyroid cancer challenge primarily no prospective randomize trial help guide therapeutic decision make purpose article discuss contemporary management papillary thyroid cancer include diagnosis pre operative evaluation surgical management postoperative thyroid hormone radioiodine therapy long term follow prognosis management recurrent metastatic disease role molecular marker enhance cytological diagnosis papillary cancer new molecular base therapy also review surgical management advance differentiate thyroid cancer concept wide field total thyroidectomy background patient young year age papillary thyroid carcinoma ptc excellent survival diffuse sclerosing variant dsv tall cell variant tcv ptc associate aggressiveness survival patient year age variant still unclear aim investigate clinicopathological feature survival variant age group year method adult patient year old dsv tcv conventional ptc cptc come surveillance epidemiology end result program kaplan meier method log rank test use analyze survival prognostic factor associate survival analyze cox multivariate regression result dsv tcv cptc age group year dsv tcv associate multifocality extrathyroidal extension lymph node distant metastasis p year disease specific survival dss tcv wrong cptc vs p no significant difference dsv cptc vs p cox multivariate regression show tcv independent predictor dss hr p conclusion age group year dsv tcv likely exhibit aggressive characteristic cptc patient year age dsv excellent survival likewise patient year age tcv carry wrong survival investigation recurrence risk patient year variant would contribute optimal clinical management make thyroid cancer rise chernobyl datum thyroid cancer incidence mortality national cancer registry slovakia analyse represent one \\ufeff1 descriptive epidemiological study eastern europe incidence thyroid cancer increase period particularly among woman approximately per increase occur primarily papillary carcinoma lesser extent follicular carcinoma great proportional increase young age group contrast datum report area mortality also increase period reason increase not evident increase mortality certainly indicate potential improvement treatment thyroid cancer slovakia good study aetiological factor involve disease thyroid carcinoma detect incidental f fdg uptake patient progressive cerebellar syndrome objective ultrasound guide needle localization technique use direct resection target axillary lymph node management breast cancer date one description technique localization method direct cancer resection neck offer support broad application technique report use successful identification resection recurrent papillary thyroid cancer paratracheal node dissection fail localize cancer method report case discuss relevant literature regard ultrasound guide localization resection recurrent good differentiate thyroid cancer result able achieve successful identification resection recurrent papillary thyroid cancer use technique conclusion technique may useful treatment select case recurrent thyroid cancer increase efficacy safety surgical resection panuveitis associate papillary carcinoma thyroid ocular involvement secondary thyroid carcinoma uncommon uveal metastasis may occur rarely responsible paraneoplastic syndrome report case year old woman present severe bilateral panuveitis venous vasculitis associate hyperthyroidism multinodular goiter complicate papillary carcinoma systemic steroid therapy initiate ocular symptom resolve completely total thyroidectomy cause panuveitis venous vasculitis rule \\ufeff1 report case panuveitis associate papillary thyroid carcinoma occurrence ocular symptom hyperthyroidism remission surgery support possibility association may not coincidental paraneoplastic phenomenon suspect tff base candidate gene discrimination benign malignant thyroid tumor region borderline iodine deficiency background advent microarray technology increase number marker gene propose distinguish benign malignant thyroid lesion however marker await confirmation independent study paper evaluate diagnostic potential propose candidate gene benign malignant thyroid pathology region borderline iodine deficiency method quantitative real time pcr perform ccnd plab pcsk hgd tff b galt lgals ets adm tg thyroid specimen include benign thyroid nodule follicular adenoma adenomatous nodule correspond normal thyroid tissue follicular carcinoma papillary carcinoma six undifferentiated carcinoma result single gene basis significant difference mrna expression find tff plab adm benign thyroid nodule thyroid malignancy use two marker gene set identify combination allow distinction benign malignant thyroid nodule discrimination follicular adenoma carcinoma however cancer prediction analysis minimum six gene per sample necessary allow correct prediction benign thyroid lesion thyroid cancer accuracy discriminative set tff plab tg adm hgd lgals conclusion confirm applicability numb recently propose marker gene distinction benign malignant thyroid tumor suggest diagnostic usefulness independent iodide supply propose discriminative marker set identify validation study together marker combination propose investigator evaluate multicenter trial observation calcification thyroid tumor determine cr ct detection calcification thyroid gland useful clinical diagnosis therapy thyroid cancer study evaluate usefulness fcr fuji compute radiography ct analyze correlation image finding calcification histological diagnosis fifty one case follicular adenoma case differentiate carcinoma undergo fcr ct case undergo operation receive histological examination calcification detect follicular adenoma differentiate carcinoma fcr follicular adenoma differentiate carcinoma ct among case without calcification fcr ct detect calcification difference result fcr ct find case small calcification low thyroid gland position differentiation tracheal cartilage calcification thyroid carcinoma calcification difficult case calcification difficult detect fcr alone patient follicular adenoma age year show high prevalence calcification young patient case differentiate carcinoma no relationship see age prevalence calcification classification calcification shape fcr show majority psammoma body good sharp irregular shape find differentiate carcinoma round calcification find follicular adenoma ct calcification inside tumor find follicular adenoma differentiate carcinoma fcr ct useful detection calcification conventional radiography great value screen thyroid tumor cytologic clinical feature niftp diagnose base preoperative background noninvasive follicular thyroid neoplasm papillary like nuclear feature niftp consider indolent neoplasm thyroid currently entity present diagnostic challenge preoperative fine needle aspiration fna cytology method case niftp noninvasive encapsulate follicular variant papillary thyroid carcinoma january august retrieve institution pathology database clinical cytopathologic feature review result total patient niftp identify thirty nine patient presurgical thyroid fnas show abnormal cytology niftps often classify indeterminate diagnostic category presurgical fnas include suspicious follicular neoplasm atypia undetermined significance suspicious malignancy six patient cytologic diagnosis papillary thyroid carcinoma thyroid fnas fourteen case abnormal fnas house cytology available review frequent cytologic feature observe niftps include architectural abnormality crowd cluster nuclear overlap predominance presence individual microfollicles abundant scatter isolate cell papillary like nuclear feature observe include nuclear enlargement eccentric nucleolus nuclear membrane irregularity pale chromatin nuclear groove elongate nuclear contour conclusion niftps frequently categorize atypia undetermined significance suspicious follicular neoplasm cytology recognition architectural nuclear feature niftp helpful distinguish niftps entity papillary thyroid carcinoma follicular neoplasm false positive whole body scan chronic parotitis case report although whole body scan useful method evaluate manage calculation biological effective dose piecewise define dose rate fit algorithmic solution biological effective dose bed calculation lea catcheside formula piecewise define function present datum patient treat metastatic thyroid cancer use illustrate solution lea catcheside formula g factor bed integrate numerically use large numb small trapezoidal fit integral algorithmically calculate bed compatible analytic calculation similarly value exponentially fit dose rate plot resolution piecewise define treatment metformin associate high remission rate diabetic patient thyroid cancer context clinical trial demonstrate metformin increase efficiency systemic therapy cancer patient objective examine whether efficacy conventional treatment differentiate thyroid cancer dtc affect therapy metformin diabetic patient design compare rate complete response cr diabetic treat metformin group mf n not treat group mf n control nondiabetic patient group c n also examine effect metformin dtc cell vitro result group comparable term age sex body mass index diabetes management frequency multifocal tumor growth extrathyroidal extension locoregional distant metastasis tumor size significantly small mf group compare mf c group vs vs cm respectively p multivariate model reveal extrathyroidal extension p distant metastasis p lack treatment metformin diabetic p decrease likelihood cr cox hazard model reveal age p locoregional metastasis p distant metastasis p lack treatment metformin patient diabetes p associate increase risk shorten progression free survival vitro datum reveal metformin inhibit cancer cell growth activate camp inducible protein kinase amp activate protein kinase ampk regulate p k ps metformin potentiate h inducible activation ampk attenuate perk p k tumor mf patient demonstrate low level phospho p k compare mf group conclusion tumor size small patient treat metformin suggest inhibition tumor growth drug among diabetic absence metformin therapy independent factor decrease likelihood cr increase risk short progression free survival vitro datum suggest p k ps likely molecular target metformin dtc cell follicular thyroid carcinoma skull metastasis thyroid carcinoma distant metastasis initial presentation uncommon skull metastasis occur rarely report incidence report two case follicular thyroid cancer skull involvement describe diagnostic therapeutic approach metastatic thyroid cancer present case year old female year old female present painless large slow grow masse skull patient undergo surgical excision skull masse histologically diagnose metastatic follicular thyroid cancer total thyroidectomy confirm diagnosis follicular thyroid carcinoma treat radioiodine suppressive levothyroxine achieve local control disease management metastatic thyroid cancer require multidisciplinary approach multimodality treatment distant metastasis surgically remove whenever possible initial aggressive treatment crucial management metastatic thyroid carcinoma provide well chance prolong patient survival regulate mir p promote reprogramme glucose metabolism cell malignancy increase level cd thyroid cancer background cd contribute increase aerobic glycolysis promote tumor growth accumulate evidence suggest cd exert variety function thyroid cancer tc progression molecular mechanism therapeutic value cd remain unclear method cd level tc tissue analyze assess relationship prognosis disease progression microrna mirna microarray bioinformatics approach use identify microrna regulator cd measurement expression function mirnas tc tissue cell line precursor mirna transfect cell use assess regulation cd mirna effect mirna tc cell via inhibition glycolysis cd target also evaluate result find mir p regulate cd negative correlate expression function moreover cd knockdown increase mir p expression significantly reduce viability migration invasion tc cell mechanistic study demonstrate directly repress expression cd protein mir p suppress aerobic glycolysis lactate production subsequently reduce tc cell viability migration invasion thereby exert tumor suppressor function conclusion novel connection identify mir p cd suggest new diagnostic prognostic role mir p cd inhibition may candidate therapeutic target therapy tc fine needle biopsy scintigram preoperative diagnosis thyroid lesion fine needle biopsy fnb thyroid examine patient case follicular cell without atypia find group patient clinical diagnosis nodular goitre operation perform patient case cytological find can correlate histopathological diagnosis patient thyroid carcinoma histologically verify carcinoma case cytologic examination show grave atypia change indicate carcinoma case cytological diagnosis falsely negative discuss moderate cellular atypia occur one case papillary carcinoma two case cytological examination give false positive diagnosis cancer represent thyroiditis lymphoid type scintigrams patient thyroid carcinoma also present cold nodule find patient hot nodule patient patient scintigrams normal another inconclusive result indicate thyroid scintigrams use supplement physical examination guidance fnb contribution fnb decision operate discuss conclude fnb valuable adjunct preoperative diagnosis thyroid lesion well diagnostic result obtain close cooperation clinician radiologist cytologist pathologist impact thyroid cancer post surgical radioactive iodine treatment live thyroid cancer survivor qualitative study background adjuvant treatment radioactive iodine rai often consider treatment good differentiate thyroid carcinoma wdtc explore recollection thyroid cancer survivor diagnosis wdtc adjuvant radioactive iodine rai treatment decision make relate rai treatment participant provide recommendation healthcare provider counsel future patient adjuvant rai treatment method conduct three focus group session include wdtc survivor recruit two canadian academic hospital participant prior history wdtc completely resect primary surgery offer adjuvant rai treatment open end question use generate discussion group saturation major theme achieve among group finding participant study twelve woman one participant receive rai treatment participant report thyroid cancer diagnosis life change result feeling fear uncertainty participant feel dismiss not serious disease participant report receive conflict message healthcare provider appropriateness adjuvant rai treatment insufficient information rai relate side effect occur presence not legitimize healthcare provider conclusion diagnosis treatment thyroid cancer significantly impact live survivor fear uncertainty relate cancer diagnosis feeling diagnosis dismiss not serious conflict message adjuvant rai treatment treatment relate side effect raise important concern thyroid cancer survivor thyroid cancer year review case introduction recently aggressive variant call good differentiate thyroid carcinoma identify tall cell variant columnar cell variant diffuse sclerosing variant insular carcinoma h rthle cell oncocytic oxyphilic carcinoma method evidence base review perform identify optimal treatment recommendation thyroid cancer intermediate differentiation conclusion although variation exist within group aggressive surgical medical management recommend neoplasia recommendation however view light fact current literature mainly consist case report case series limit review clinical presentation pathophysiology diagnosis surgical medical management thyroid cancer intermediate differentiation discuss mouse model papillary thyroid carcinoma thyroid carcinoma tc common endocrine malignancy frequency still rise papillary thyroid carcinoma ptc account tcs usually relate good prognosis however standard therapeutic approach not always sufficient disease progression sometimes observe datum highlight limitation understand molecular mechanism underlie tumorigenesis vary individual patient last year mouse model thyroid cancer develope order give answer question genetic background relation key molecular event pathway fundamental cancer many other among model genetically engineer mouse utmost importance regard input knowledge human tumorigenesis present review significant mouse model ptc describe particular emphasis brafv e induce one sake frequency ptc relation factor poor prognosis fact since identification become attractive target novel therapy present mouse model phenotype consequence particular genetic alteration describe good limitation use method ultrasonographic screen thyroid cancer screen hospital ultrasonography perform patient come thyroid cancer screen seventy eight patient thyroid cancer find screen operate patient thyroid cancer find method operate period department age patient surgery screen group young contrast group screen group patient small thyroid cancer high rate contrast group invasion surround organ primary cancer observe one patient screen group rate invasion statistically low contrast group twenty six patient benign thyroid disease detect screen operate period careful selection patient need pattern clinicopathologic risk factor lateral lymph node metastasis papillary thyroid carcinoma patient lateral cervical lymphadenopathy surgical extension lateral neck dissection lnd papillary thyroid carcinoma ptc clinical lateral lymph node metastasis llnm remain controversial aim study explore pattern clinicopathologic risk factor llnm ptc clinical unilateral lnd determine rational extent therapeutic lnd retrospective study review record consecutive patient ptc simultaneously undergo total thyroidectomy bilateral central lymph node dissection unilateral therapeutic lnd frequency pattern llnm analyze grossly llnm present patient level ii v lymph node metastasis lnm present patient respectively superior tumor location extrathyroidal extension ipsilateral contralateral bilateral central lnm clnm independent risk factor gross llnm age year superior lobe tumor extrathyroidal extension ipsilateral contralateral clnm independent risk factor level ii lnm age year superior middle lobe tumor extrathyroidal extension ipsilateral clnm independent risk factor level iii lnm superior lobe tumor ipsilateral contralateral bilateral clnm independent risk factor level iv lnm contralateral clnm independent risk factor level v lnm ptc patient clinical llnm predominant site llnm level ii iv not level v therapeutic elective lnd include lateral nodal level associate independent risk factor especially superior tumor location clnm aggressive variant papillary thyroid cancer purpose review aggressive variant papillary thyroid cancer ptc recognize increase frequency common include diffuse sclerosing variant tall cell variant insular thyroid cancer tumor may represent spectrum dedifferentiation classic ptc anaplastic thyroid cancer recent finding pathologist reach consensus diagnosis variant recognize important distinction clinical behavior preoperative study ultrasonography fine needle aspiration well molecular genetic marker help raise suspicion thyroid nodule possibly harbor aggressive cancer turn allow surgeon endocrinologist formulate complete operative plan include thyroidectomy possible lymphadenectomy postoperative radioactive iodine administration past study variant rely single institution small clinical series however recent population level analysis use national database surveillance epidemiology end result include large number case collect many year summary study allow identification temporal trend tumor incidence microrna inhibit papillary thyroid carcinoma cell biological progression directly target sox regulate epithelial mesenchymal transition erk akt signal pathway objective current study aim explore role mir sox papillary thyroid carcinoma ptc patient method fifty four pair human ptc specimen match normal thyroid tissue obtain meanwhile human thyroid epithelial cell nthy ori ptc cell culture effect mir ptc cell proliferation invasion migration detect cell proliferation assay transwell assay respectively sox expression tissue sample examine immunohistochemical stain analysis ihc correlation sox mir clarify dual luciferase reporter assay relative mrna protein expression detect quantitative real time polymerase chain reaction qrt pcr western blot addition xenograft model experiment perform result decline mir expression frequently identify ptc lead poor overall survival os wrong clinicopathologic feature ptc patient moreover functional assay indicate mir overexpression can notably repress ptc cell proliferation invasion migration ability regulate extracellular regulate protein kinase erk protein kinase b akt signal pathway epithelial mesenchymal transition emt addition result luciferase reporter assay demonstrate sox direct functional target mir ptc cell vivo mir restoration significantly suppress tumor growth xenograft ptc model conclusion finding indicate mir exert anti ptc function via target sox modulate erk akt signal pathway emt mir may potentially serve novel biomarker future therapeutics ptc berberine inhibit growth thyroid cancer cell line c tpc purpose thyroid cancer common malignancy korean female treat good prognosis however drug treat aggressive type thyroid cancer poorly differentiate anaplastic thyroid cancer not yet establish end analyze effect berberine human thyroid cancer cell line determine whether compound useful treatment aggressive thyroid cancer material method two thyroid cancer cell line c tpc adherent culture condition treat berberine analyze change cell growth cell cycle duration degree apoptosis result follow berberine treatment cell line show dose dependent reduction growth rate c cell show significantly increase level apoptosis follow berberine treatment whereas tpc cell show cell cycle arrest g g phase immunobloting p expression follow berberine treatment show berberine induce little regulation p c cell relatively high regulation p tpc cell conclusion result suggest berberine treatment thyroid cancer inhibit proliferation apoptosis cell cycle arrest thus berberine may novel anticancer drug treatment poorly differentiate anaplastic thyroid cancer change tsh level athyreotic patient differentiate thyroid cancer levothyroxine therapy influence dose adjustment purpose aim study describe spontaneous tsh level variation levothyroxine dose adjustment athyreotic patient differentiate thyroid cancer dtc real life practice method patient dtc retrospectively evaluate tertiary referral center october november hormone measurement tsh ft serum level l prescription information dose per kg per day medication record month month primary treatment surgery radioiodine therapy result cohort compose patient patient stable levothyroxine dose clinically meaningful spontaneous tsh variation define tsh mcui ml yearly follow visit furthermore athyreotic dtc patient stable dose tsh mcui ml tsh mcui ml follow visit investigate whether tsh variation would lead subsequent dose change dtc patient stable lt dose previous visit levothyroxine dose reduce increase due tsh variation evaluate decision change dose relation age specific tsh range patient dose adjust due tsh fall age specific range conclusion spontaneous serum tsh variation determine levothyroxine replacement therapy athyreotic patient dtc require multiple dose change flavonoid thyroid iodide uptake thyroid cancer review thyroid cancer common malignant tumor endocrine system incidence increase recent year great part differentiate carcinoma thyrocytes capable uptaking iodide case main therapeutic approach include thyroidectomy follow ablative therapy radioiodine however part patient capacity concentrate iodide lose due regulation sodium iodide symporter nis protein responsible transport iodide thyrocytes thus therapy radioiodide become ineffective limit therapeutic option reduce life expectancy patient excessive ingestion flavonoid associate thyroid dysfunction goiter nevertheless study show flavonoid beneficial thyroid cancer reduce cell proliferation increase cell death besides increase nis mrna level iodide uptake recent datum show flavonoid apingenin rutin capable increase nis function expression vivo herein review literature datum regard effect flavonoid thyroid cancer besides effect compound expression function sodium iodide symporter also discuss possibility use flavonoid adjuvant therapy thyroid cancer treat patient differentiate thyroid cancer thyroglobulin positive iodine diagnostic scan negative metastasis include comment role serum thyroglobulin monitor tumor surveillance differentiate thyroid cancer dtc patient especially high risk cancer relate death long term monitor detection recurrence metastasis conventional radiologic ultrasonographic image useful localization recurrent persistent disease patient ablation residual thyroid tissue measurement serum thyroglobulin tg level radioactive iodine rai image provide highly sensitive tool early detection serum tg reliable absence tg autoantibody sensitivity increase tsh stimulation either withdrawal thyroxine therapy administration recombinant tsh rtsh patient serum tg level positive rai whole body scan wbs negative patient either recurrent tumor small sensitivity diagnostic scan dissociation tg synthesis iodine trap mechanism recent literature suggest empiric high dose rai therapy tg positive diagnostic scan negative patient may result high rate visualization uptake posttherapy scan pt evidence subsequent improvement parameter disease activity also present almost report case micrometastases not visualize conventional image experience aggressive macrometastases negative diagnostic wbs not show significant uptake therapeutic dose rai small size micrometastases \\ufeff1 group patient possible defect iodine trap mechanism 2 group may explain apparent discrepancy base presently available information generalize recommendation rai therapy tg positive diagnostic scan negative patient await study meanwhile high risk patient absence alternative therapy empiric rai therapy justify glucose transporter gene expression relate thyroid neoplasm unfavorable prognosis immunohistochemical study purpose accelerate rate glucose metabolism mediate overexpression key regulatory glycolytic enzyme glucose transporter among characteristic biochemical marker malignant transform cell thyroid neoplasm however increase uptake glucose measure f fluoro deoxy glucose fdg positron emission tomography pet seem restrict aggressive high grade tumor whereas tumor favorable prognosis demonstrate no significant tracer uptake therefore study expression glucose transporter thyroid carcinoma different grade malignancy method section formalin fix paraffin embed tissue obtain patient thyroid cancer anaplastic papillary follicular tumor investigate polyclonal rabbit antiglucose transporter antibody reactive glucose transporter glut use heat pretreatment section stain perform avidin biotin conjugate immunoperoxidase reaction evaluate semiquantitatively result expression glut transporter cell membrane closely relate grade malignancy thyroid neoplasm fisher exact test p anaplastic tumor show high level glut expression cytoplasm cell membrane positive membranous stain differentiate tumor detect predominantly neoplasm unfavorable prognosis e g widely invasive follicular metastatic tumor whereas low no immunoreactivity can see thyroid nodule thyroid autoimmunity context environmental pollution evidence suggest industrialize country autoimmune disorder include chronic lymphocytic thyroiditis increase increase parallel one regard differentiate thyroid cancer increment mainly due papillary histotype numb study point association chronic lymphocytic thyroiditis differentiate thyroid cancer upward trend two thyroid disease sustain certain environmental factor pollute substance act endocrine disrupt chemical herein review experimental clinical literature highlight effect environmental occupational exposure pollute chemical development autoimmune thyroid disease differentiate thyroid cancer stakeholder start policymarkers become sensitive consequence thyroid result exposure edc indeed economic burden result consequence not quantify thus far use gene expression profile differentiate benign versus malignant thyroid tumor dna microarray allow quick complete evaluation cell transcriptional activity expression genomics powerful generate expression datum large numb gene simultaneously across multiple sample cancer research intrigue application expression array include assess molecular component neoplastic process utilize datum cancer classification miller ld et al cancer cell classification human cancer distinct group base molecular profile rather histological appearance may prove relevant specific cancer diagnosis cancer treatment regime several attempt formulate consensus classification treatment thyroid carcinoma base standard histopathological analysis result publish guideline diagnosis initial disease management sherman si lancet past decade no improvement make differential diagnosis thyroid tumor fine needle aspiration biopsy specifically suspicious indeterminate thyroid lesion suggest new approach explore therefore study develope gene expression approach diagnose benign versus malignant thyroid lesion patient thyroid tumor successfully build gene model able differentiate benign versus malignant thyroid tumor result support premise molecular classification system thyroid tumor possible turn may provide accurate diagnostic tool clinician manage patient suspicious thyroid lesion microrna profile sporadic hereditary medullary thyroid cancer identify predictor nodal metastasis prognosis potential therapeutic target purpose molecular basis hereditary medullary thyroid cancer hmtc good define little know molecular pathogenesis sporadic medullary thyroid cancer smtc addition micrornas mirnas show important diagnostic prognostic marker cancer not define mtc aim study mirna profile mtc identify prognostic biomarker potential therapeutic target experimental design mirna microarray profile carry fresh freeze tissue patient smtc n hmtc n differential expression three mirnas confirm validation cohort smtc hmtc sample n use quantitative reverse transcriptase pcr correlate clinical outcome functional role select mirna investigate vitro human medullary thyroid carcinoma cell line tt cell use cell proliferation assay western blot analysis result mirs overexpress p mir express p smtc versus hmtc overexpression mirs mtc predict lateral lymph node metastasis p p associate residual disease p distant metastasis p mortality p knock mir expression tt cell line induce significant decrease viable cell count upregulation protein lc b associate autophagy conclusion datum indicate mirnas play pivotal role biology mtc represent important class prognostic biomarker therapeutic target warrant investigation problem management thyroid cancer background papillary thyroid carcinoma ptc frequently involve lymph node lateral compartment ptc locate one lobe rarely metastasize bilateral lateral node study design evaluate clinicopathological feature patient ptc limit one lobe bilateral lateral neck metastasis lnm method january december patient unilateral ptc lnm analyse patient unilateral lnm ulnm bilateral lnm blnm clinicopathological characteristic two group analyse result no significant group difference age extrathyroidal extension multifocality one lobe thyroiditis psammomatous calcification male sex versus p central compartment metastasis versus p aggressive subtype ptc versus p delphian node metastasis versus versus p significantly frequent mean primary tumour size cm versus cm p significantly large blnm ulnm group conclusion although patient ptc locate one lobe blnm contralateral lateral compartment carefully evaluate blnm male patient primary tumour size cm aggressive subtype ptc central node metastasis delphian node metastasis survival curve case thyroid cancer study present stage stage survival curve case thyroid carcinoma observe year ancona regional hospital general surgery division study reveal prognosis good \\ufeff1 stage neither surgery medical radiological treatment effective prevent death incurable patient late stage therefore conclude early surgery useful operation conduct late stage papillary thyroid cancer patient interstitial q deletion include arid b f fluorodeoxyglucose fdg avid metastatic lesion associate poor response radioiodine ablation therapy rit papillary thyroid cancer ptc study evaluate significance preablative fdg positron emission tomography pet assessment risk factor frequency malignant fdg avid lymph node patient ptc undergo rit study include consecutive patient mean age female ptc refer \\ufeff1 rit undergo routine preablative fdg pet april february fdg avid lymph node falns identify use retrospective image review frequency malignant faln mfaln contribution persistent recurrent ptc risk factor analyze among patient falns mfalns benign falns bfalns mfaln contribute persistent recurrent ptc rit observe patient post rit follow among preoperative risk factor suspicious extrathyroidal extension lateral neck lymph node metastasis image study associate mfaln among postoperative risk factor n b stage high stimulate thyroglobulin high number metastatic lymph node dissect lymph node associate mfaln mfalns observe small numb patient ptc undergo rit contribute total recurrent persistent disease increase frequency mfalns associate advance ptc preablative fdg pet value evaluation patient rit resistant lesion may help determine treatment strategy value preoperative nuclear medicine diagnosis hyperthyroidism thyroid cancer optimal diagnostic procedure surgery thyrotoxicosis thyroid malignancy combination scintigraphy sonography fine needle aspiration biopsy diffuse toxic goiters differentiation immunogenic non immunogenic thyrotoxicosis predominant toxic nodular goiters sonographic localisation relation thyroid capsule necessary prevent recurrent autonomy malignomas subclassified fine needle aspiration biopsy calcitonin differentiate carcinoma necessary aggressive conservative surgical treatment thyroidectomy differentiate carcinoma high uptake require surgical resection decrease radiation exposure therapy high risk thyroid cancer prolong survival early multimodality therapy eleven patient high risk thyroid carcinoma anaplastic mix anaplastic differentiate histology treat use early multimodality approach patient classify use prognostic index thyroid carcinoma develope eortc therapy consist four drug chemotherapy combination radioiodine bacille calmette guerin bcg immunotherapy treatment design maximize effect anaplastic differentiate tumor component prolong disease free survival month patient clear cell small cell mix anaplastic histology currently five patient complete remission year treatment good tolerate long term participation care multispecialty team produce promise result hope valuable basis multicenter trial preoperative determination serum thyroglobulin identify patient differentiate thyroid cancer may present recurrence without increase thyroglobulin thyroglobulin consider reliable marker recurrent disease patient cancer canada fact sheet series incidence thyroid cancer increase rapidly cancer canada mortality remain low stable last year numb thyroid cancer case increase case per year thyroid cancer three time common female male thyroid cancer diagnose canadians year age apparent increase incidence likely due improve widely available diagnostic technique fine needle aspiration biopsy management thyroid nodule prospective study carry patient thyroid nodule case fine needle aspiration fna cytology use clinical management specimen take satisfactory cytology clearly malignant diagnosis confirm surgical operation diagnosis follicular neoplasm suspicious malignancy make patient operation do adenoma find cancer multinodular goiter case benign diagnosis make follow clinically datum review literature plan management patient thyroid nodule outline fna biopsy thyroid excellent method eliminate unnecessary operation patient thyroid nodule fine needle biopsy thyroid aid diagnosis thyroid cancer prostate specific membrane antigen psma type transmembrane protein highly express prostate cancer cell present case year old man metastatic papillary carcinoma thyroid rise thyroglobulin level negative whole body radioiodine scan total thyroidectomy consider limit treatment option available decide perform ga psma hbed cc pet ct scan reveal intense radiotracer uptake mediastinal leave supraclavicular lymph node brain metastasis bilateral lung nodule skeletal site patient also undergo f fdg pet ct demonstrate similar finding however numb lesion detect brain little compare ga psma pet ct association synchronous medullary papillary thyroid carcinoma primary hyperparathyroidism \\ufeff1 case report literature review objective report case patient symptomatic primary hyperparathyroidism find thorough radiological investigation also papillary medullary thyroid carcinoma case report year old female diagnose primary hyperparathyroidism radiological investigation find suspicious area within thyroid lobe late diagnose focus papillary medullary thyroid carcinoma appropriate treatment commence report similar occurrence synchronous thyroid parathyroid pathology discuss conclusion knowledge \\ufeff1 report case two synchronous thyroid cancer occur context primary hyperparathyroidism strongly recommend thorough radiological investigation patient primary hyperparathyroidism prevent miss concurrent thyroid cancer determination thyroglobulin aftercare thyroid cancer patient analysis palliative surgical intervention patient neglect papillary follicular medullary thyroid cancer make period majority patient old year hematogenic dissemination case palliative operation complete permanent tracheostomy perforation low flap wind decrease postoperative purulence five year late patient alive patient papillary follicular thyroid cancer medullary cancer long year patient papillary follicular thyroid cancer survive support validity palliative intervention differentiate thyroid cancer follicular cell origin polybrominated diphenyl ether pbdes alter thyroid hormone homeostasis relationship thyroid cancer unknown investigate whether serum concentration pbde associate thyroid cancer conduct nest cystic form cervical lymphadenopathy guideline french society otorhinolaryngology head neck surgery sforl part diagnostic procedure lymphadenopathy case cervical mass cystic aspect objective author present guideline french society otorhinolaryngology head neck surgery society diagnostic procedure lymphadenopathy case cervical mass cystic aspect method multidisciplinary work group entrust review scientific literature topic guideline draw read editorial group independent work group final version draw guideline grade b c expert opinion decrease level evidence result adult present cystic cervical mass recommend suspect cervical lymphadenopathy order decrease frequency cystic metastasis head neck squamous cell carcinoma undifferentiated nasopharyngeal carcinoma thyroid papillary carcinoma grade c discovery cystic cervical mass ultrasound architectural element indicate lymph node thyroid nodule sign malignancy screen especially mass locate level iii iv vi grade malignant lymphadenopathy suspect case cervical mass cystic component ct grade b benign malignant status not diagnose radiological datum ct mri grade fdg pet ct perform particularly case inconclusive ultrasound guide fine needle aspiration biopsy grade c incidence thyroid malignancy among goitrous thyroid lesion sarawak general hospital introduction thyroid cancer common among endocrine malignancy worldwide prevalence goitre general population estimate percent incidence malignancy goitrous thyroid ten percent postulate goitrous thyroid precursor lesion development malignant thyroid disease sarawak state good know endemic goitre study focus establish incidence thyroid malignancy among goitrous thyroid swelling method study hospital base retrospective study archive collection surgically remove thyroid specimen sarawak general hospital malaysia case group cancer non cancer group cancer group include papillary thyroid carcinoma ptc ptc follicular variant follicular carcinoma anaplastic carcinoma ana result total thyroid case undergo surgical removal year collect percent male percent female observe high prevalence thyroid swell case occur age group year low prevalence occur age group year percent vs percent ethnicity ibans malays find high prevalence percent percent respectively low prevalence observe indians percent case percent find cancerous rest percent non cancerous thyroid swelling histologically high incidence carcinoma ptc percent low ana percent conclusion base observation although goitrous thyroid swell quite common problem sarawak thyroid malignancy not major issue among thyroid malignancy ptc common histological type malignancy hla dr differentiate thyroid cancer lack association nonmedullary type possible association medullary type one hundred twenty seven white european patient differentiate thyroid cancer type human lymphocyte antigen hla dr specificity no significant deviation hla dr distribution observe normal patient control neither entire group patient group nonmedullary type thyroid cancer papillary follicular nonradiation associate also subdivision patient nonmedullary thyroid cancer accord age diagnosis presence metastasis presence thyroglobulin antibody serum show no significant deviation hla dr distribution patient medullary thyroid cancer sporadic n inherit isolate n form no multiple endocrine neoplasia significant increase hla dr case comparison control patient p correct relative risk datum suggest contrast previous report no genetic influence development nonmedullary type differentiate thyroid cancer medullary thyroid cancer without multiple endocrine neoplasia however may associate hla dr clinician view management terminology papillary thyroid microcarcinoma qualitative study background grow acceptance increase thyroid cancer incidence part result overdiagnosis small low risk papillary microcarcinomas pmcs indolent clinical course although surgery cornerstone treatment patient pmcs recent management guideline shift toward inclusion conservative treatment active surveillance little evidence clinician experience manage pmc patient attitude toward treatment option include willingness accept nonsurgical option aim study understand clinician perceive diagnosis pmc potential change terminology treatment option available patient method qualitative study use external radiotherapy prior thyroid cancer case control study purpose aim investigation study previous radiotherapy malignant disease risk factor thyroid cancer method material use swedish cancer registry case thyroid cancer another malignant disease little one year previously live within catchment area hospital trace total case thyroid cancer identify another previous malignant disease constitute case study control four person little two malignant disease thyroid cancer exclude select case cancer registry result ten patient thyroid cancer 2 tumor early irradiate treatment dose include thyroid gland compare control patient eight ten case previous irradiation thyroid gland papillary cancer median latency year estimate radiation dose thyroid vary gy external radiotherapy give crude odd ratio confidence interval thyroid cancer weight odd ratio calculate confidence interval conclusion case control study give non significantly increase odd ratio thyroid cancer patient external radiotherapy include thyroid gland gerhardt syndrome reveal thyroid cancer introduction loss ability concentrate one important cause radioiodine refractory disease papillary thyroid carcinoma ptc recent advantage serum micrornas mirnas open new realm possibility noninvasive diagnosis prognosis many cancer aim current study identify differential expression profile circulation mirnas ptc patient non avid lung metastasis method expression mirnas examine use mirna microarray chip significantly change mirnas microarray verify use qrt pcr potential mirnas regulate target gene preliminary biological function forecast bioinformatic analysis result compare avid lung metastasis kind significantly differential serum mirnas include upregulated mirnas grave ophthalmopathy radiation treatment thyroid cancer objective describe patient metastatic thyroid cancer develope grave ophthalmopathy treatment radioiodine external beam radiation method present case report include clinical laboratory radiologic finding brief review literature result year old woman total thyroidectomy neck dissection follow treatment year early papillary thyroid cancer present follow management recent neck dissection recurrent disease thyroglobulin antibody treat preparation recombinant human thyroid stimulate hormone post treatment scan reveal uptake right iliac crest fludeoxyglucose f positron emission tomography compute tomography fusion scan reveal osseous metastasis right pelvis external beam radiotherapy deliver area approximately month late develope periocular swell excessive tear magnetic resonance image orbit reveal enlargement extraocular muscle serum thyroid stimulate immunoglobulin greatly elevate conclusion case corroborate early report suggest radiation associate thyroid injury patient thyroid cancer may follow grave ophthalmopathy appearance thyroid stimulate immunoglobulin serum evidence not sufficient recommend aggressive approach familial nonmedullary thyroid cancer introduction thyroid carcinoma classically diagnose base certain histological criterium case definitive diagnosis may challenge morphological feature equivocal study evaluate usefulness cytokeratin ck immunohistochemical marker differentiate different histological type malignant thyroid neoplasm particularly papillary thyroid carcinoma ptc benign thyroid lesion material method collect malignant benign thyroid lesion diagnose histology universiti kebangsaan malaysia medical centre january december case immunohistochemically stain ck evaluate independent observer immunostaining pattern score base intensity proportion stain finally grade negative weak positive moderate positive strong positive addition immunostaining score malignant case correlate tnm pathological tumour stage result cytokeratin stain expression high malignant benign thyroid lesion p prominent among classical ptc four ptc case show negative weak stain follicular variant ptc benign condition mostly negative show weak positivity no correlation ck expression tnm primary tumour stage pt conclusion cytokeratin useful marker differentiate malignant benign thyroid condition particularly classical ptc provide interpretation correlation morphology take consideration intensity proportion positive stain comprehensive characterization mitochondrial genome papillary thyroid cancer nuclear genetic alteration widely investigate papillary thyroid cancer ptc however characteristic mitochondrial genome remain uncertain sequence entire mitochondrial genome ptcs normal thyroid tissue blood sample healthy individual variation site detect ptcs among variation novel nearly half ptcs heteroplasmic variation among ptcs specimen harbor total somatic mutation distribute site thirty three variation include seven nonsense frameshift non synonymous variation select bioinformatic software regard pathogenic pathogenic mutation associate old age p advance tumor stage p addition tend novel p heteroplasmic p somatic p mtdna copy numb increase two 3 ptcs average content tumor nearly four time high adjacent normal tissue p three sub haplogroups n b b g eight single nucleotide polymorphism mtsnps g c g c g g c g associate occurrence ptc report comprehensive characterization mitochondrial genome demonstrate significance pathogenesis progression ptc help clarify molecular mechanism underlie ptc offer potential biomarker therapeutic target future clinical practice change trend mortality thyroid cancer belgrade population purpose thyroid cancer patient favorable prognosis aim study analyze change trend mortality thyroid cancer belgrade period method mortality datum obtain belgrade office statistic mortality rate per inhabitant standardize accord segi world population regression analysis use estimate thyroid cancer mortality trend period result average percent death due thyroid cancer among death almost fold high female male good among death due malignancy female male year period average standardize mortality rate time high female per male per observe period mortality rate thyroid cancer increase woman decrease man particular year age group male significant trend mortality decrease year detect conclusion belgrade classify region low risk dye due thyroid malignancy increase trend thyroid cancer mortality female examine period call improvement method early detection disease differential diagnosis thyroid nodule surgical treatment thyroid cancer can perform stage not life threaten use recombinant thyrotropin follow patient differentiate thyroid cancer many clinician care patient treat differentiate thyroid cancer recombinant thyrotropin stimulate iodine uptake thyroid tissue safe effective diagnostic agent patient require radioiodine scan routine follow combination whole body radioiodine scan serum thyroglobulin measurement identify virtually patient distant metastatic disease serum thyroglobulin ng ml positive whole body scan recombinant thyrotropin stimulation suggest residual thyroid tissue neoplastic disease use recombinant thyrotropin few adverse effect alternative withdrawal thyroid hormone replacement although nausea headache report however recombinant thyrotropin expensive improvement diagnosis thyroid cancer introduction aim study investigate role nutritional habit addiction incidence thyroid carcinoma material method study risk factor affect incidence thyroid carcinoma conduct patient include register thyroid carcinoma purpose questionnaire prepare questionnaire cover personal information medical history individual risk factor thyroid carcinoma nutritional habit alcohol consumption smoke statistical analysis conduct result register comprise patient thyroid carcinoma woman healthy subject patient declare frequent consumption milk dairy product patient thyroid carcinoma consume cruciferous plant significantly often healthy subject p whereas egg consumption among group patient similar low consumption fish average table salt consumption typical group alcohol consumption similar group respectively patient thyroid cancer smoke little frequently subject control group logistic regression analysis show carcinoma risk increase patient consume cruciferous vegetable brassica regular intake relate fold ci high risk thyroid carcinoma incidence despite demonstrate decrease risk thyroid cancer smoke not consider protective factor conclusion not possible determine unequivocally causative factor growth incidence thyroid cancer olsztyn province appear one environmental factor cause increase overconsumption cruciferous vegetable misclassification cytologic diagnosis patient follicular lesion follicular neoplasm thyroid gland papillary thyroid carcinoma ptc common thyroid cancer nuclear magnetic resonance nmr base metabolomic technique gold standard metabolite structural elucidation provide different coverage information compare metabolomic technique firstly conduct nmr base metabolomics study regard detail metabolic change especially metabolic pathway change relate ptc pathogenesis h nmr base metabolomic technique adopt conju nction multivariate analysis analyze match tumor normal thyroid tissue obtain patient result annotate kyoto encyclopedia gene genome kegg human metabolome database analyze use module pathway analysis enrichment analysis metaboanalyst base analytic technique establish model principal component analysis pca partial little square discriminant analysis pl da orthogonal partial little square discriminant analysis opls da can discriminate ptc normal thyroid tissue find robust differentiate metabolite two opls da model identify kegg pathway pathway small molecular pathway database significantly relate ptc use pathway analysis enrichment analysis respectively identify metabolism relate ptc include branch chain amino acid metabolism leucine valine amino acid metabolism glycine taurine glycolysis lactate tricarboxylic acid cycle citrate choline metabolism choline ethanolamine glycerolphosphocholine lipid metabolism low density lipoprotein low density lipoprotein conclusion ptc characterize increase glycolysis inhibit tricarboxylic acid cycle increase oncogenic amino acid good abnormal choline lipid metabolism finding study provide new insight detail metabolic change ptc hold great potential treatment ptc role cytokine retinoic acid regulation human thyroid cancer cell growth purpose study investigate effect cytokine retinoic acid human thyroid cancer cell growth cellular proliferation study cgth w sw cell line perform various cytokine trans retinoic acid ra cell numb determine cell count incorporation h thymidine dna inhibitory effect tumour necrosis factor alpha massive internal jugular vein tumor thrombus derive squamous cell carcinoma head neck two case report purpose tumor thrombosis internal jugular vein ijv extremely rare disease report case exclusively associate differentiate thyroid cancer present study describe two case ijv tumor thrombosis originate squamous cell carcinoma scc \\ufeff1 case report method case year old man diagnose advance supraglottic scc massive tumor thrombus ijv treat bio radiotherapy follow radical surgery case year old woman undergo radical surgery scc thyroid tumor thrombosis ijv result case rapidly develope local recurrence distant metastasis die within month surgery conclusion ijv tumor thrombosis originate scc apparently reflect extremely aggressive state tumor recognition precaution condition essential development clinically effective treatment strategy fetal cell microchimerism papillary thyroid cancer role outcome disease fetal cell microchimerism fcm define persistence fetal cell maternal organ circulation without apparent rejection hypothesize protect toward onset neoplastic disease verify role fcm papillary thyroid cancer ptc enroll parous woman ptc little one male pregnancy precede diagnosis ptc p healthy woman male child hc p nonparous woman ptc ptc np presence circulate male dna assess amplification chromosome specific gene sry sensitivity male cell million female cell significantly high frequency fcm find hc p ptc p woman vs p among ptc p patient positive presence fcm fmc low prevalence extrathyroidal extension p lymph node metastasis p without fcm fmc moreover fmc patient frequently remission fmc case vs p interestingly show \\ufeff1 time positive effect tumor presentation outcome specifically relate fcm not effect pregnancy conclusion circulate fcm significantly frequent healthy parous woman woman ptc moreover presence circulate fetal male cell associate significantly low extrathyroidal extension good prognosis suggest protective role phenomenon toward onset progression thyroid cancer bleomycin beneficial thyroid cancer recently italy reimbursement use rhtsh prepare patient radiometabolic treatment iodine avid metastasis differentiate thyroid cancer make possible intramuscular administration rhtsh increase radioiodine uptake thyroglobulin production thyroid cell addition previous indication use rhtsh mainly serum thyreoglobulin assay without scintigraphy ablation remnant low risk patient reimbursement allow treatment radioiodine iodine avid time trend geographic variation thyroid cancer incidence tumor size france background aim investigation study geographic time trend thyroid cancer incidence accord tumor size france method incidence datum provide six french registry period cover seven administrative district five tumor size group distinguish mm mm mm mm unknown size papillary cancer diagnose woman analyze accord tumor size geographic area world age standardize rate calculate annual percent change rate estimate tumor size group geographic area loglinear poisson regression model use study geographic discrepancy time trend incidence result six french registry include papillary thyroid cancer woman et thyroid cancer incidence increase six geographic area geographical variation time trend incidence registry reflect geographical variation time trend incidence small size tumor little mm conclusion wide geographic variation thyroid cancer incidence notice small size tumor may correlate geographic variation medical practice diagnosis treatment prognostic factor long term outcome papillary thyroid carcinoma papillary thyroid carcinoma ptc frequent endocrine cancer common thyroid cancer potential risk factor incidence ptc include radiation exposure iodine deficiency family history thyroid cancer ptc usually indolent prognosis favourable year survival generally report exceed palpation growth thyroid nodule frequent clinical manifestation ptc evaluate physical examination neck ultrasound fine needle aspiration cytology fnac therapeutic management ptc include surgical treatment combine therapy life long tsh suppressive thyroid hormone replacement external beam radiation take account select aggressive tumour nevertheless good prognosis ptc prevalence persistence recurrent disease not trans curable biomolecular study permit individuate aggressive ptc subtype significant attention clinical examination us fnac thyroid nodular disease able guarantee precocious diagnosis radical surgical treatment aggressive variant papillary thyroid carcinoma hobnail tall cell columnar solid papillary thyroid carcinoma common endocrine cancer usually associate good survival however variant papillary thyroid carcinoma may behave aggressively classic papillary thyroid carcinoma tall cell variant papillary thyroid carcinoma common aggressive variant papillary thyroid carcinoma aggressive behavior ascribe histologic subtype clinicopathologic feature issue remain controversial columnar variant papillary thyroid carcinoma aggressive particularly old patient large tumor show diffusely infiltrative growth pattern extrathyroidal extension papillary thyroid carcinoma designate solid trabecular variant nearly tumor not belong variant solid trabecular nest insular appearance tumor must distinguish poorly differentiate thyroid carcinoma growth pattern lack nuclear feature papillary thyroid carcinoma may show tumor necrosis high mitotic activity new 4 edition classification tumour endocrine organ hobnail variant papillary thyroid carcinoma moderately differentiate papillary thyroid carcinoma variant aggressive clinical behavior significant mortality variant histologically unique important recognize due aggressive behavior braf mutation assessment papillary thyroid cancer ready use clinical practice background atypia undetermined significance controversial category thyroid fine needle aspiration fna not question clinical utility also existence expression uncertainty current study perform investigate potential impact eliminate category sensitivity specificity detect thyroid neoplasm fna method forty case originally diagnose atypia undetermined significance histologic follow select present study case reinterpret blindly experience reviewer eliminate atypia undetermined significance diagnostic possibility reclassify case either benign follicular neoplasm suspicious malignancy malignant twenty six case atypia undetermined significance randomly select reevaluate month late study intraobserver variation result eliminate atypia undetermined significance category sensitivity detect papillary thyroid carcinoma ptc reduce p atypia undetermined significance case reclassify benign ptc reclassify follicular neoplasm suspicious malignancy histologically prove benign lesion unanimous interobserver intraobserver agreement observe case conclusion eliminate diagnosis atypia undetermined significance substantially decrease sensitivity thyroid fnas increase false positive false negative rate addition increase interobserver intraobserver variability therefore atypia undetermined significance category not eliminate advocate minimize use adenocarcinoma thyroid hyperthyroidism functional metastasis study thiouracil radioiodine case paraganglioma locate thyroid cartilage midline report tumor appearance carotid body tumor odd location can not explain basis previously know area paraganglionic tissue find since paraganglioma also hitherto describe within thyroid gland clinician pathologist alike caution unusually locate paragangliomas may expect future cutaneous metastasis papillary thyroid carcinoma neck case report review literature papillary thyroid carcinoma common subtype thyroid malignancy rarely present cutaneous metastatic spread despite metastatic cutaneous lesion present slow indolent grow nodule head neck lesion frequently appear set diffuse dramatic metastatic disease bleak prognosis give rarity metastatic lesion diagnosis may delay often initial diagnosis incorrect several case report publish literature note unusual interest presentation thyroid carcinoma cutaneous metastasis present classic case patient prior diagnosis thyroid carcinoma present slowly grow ulcerate lesion neck nine year partial thyroidectomy characteristic histopathology microscopic examination furthermore review literature regard papillary thyroid carcinoma cutaneous metastasis diagnostic challenge lesion present practitioner incidental nonincidental canine thyroid tumor assess multidetector row compute tomography single centre cross sectional study dog thyroid nodule common dog increasingly likely detect increase use advance image modality unsuspected nonpalpable asymptomatic lesion define thyroid incidentaloma may discover image study unrelated thyroid gland objective single center cross sectional study assess prevalence compute tomography ct characteristic incidental nonincidental thyroid tumor large population dog use prospective recruitment patient undergo ct examination various reason period unilateral bilateral thyroid masse detect dog prevalence confidence interval ci seventy nine lesion malignant benign masse discover incidentally dog overall prevalence incidentaloma ci masse thyroid carcinoma among ct variable assess mineralization vascular invasion tissue invasion detect malignant tumor intratumoral vascularization significantly associate presence thyroid malignancy p although incidental thyroid nodule dog relatively rare often malignant finding indicate neck thoroughly assess middle age old patient undergo body ct various reason thyroid nodule detect incidentally ct sample avoid miss thyroid cancer serum thyroglobulin differentiate thyroid cancer radioisotope department motol establish st june part research institute endocrinology found assoc prof karel silink begin department include bed main activity consist radioiodine treatment hyperthyroidism since attention pay treatment thyroid cancer tradition continue till time article review main direction development department since begin present radiation thyroid cancer learn context increase thyroid cancer incidence little partially attribute increase detection show considerable regional variation objective investigate whether regional variation cancer incidence associate variation thyroid disease management design conduct retrospective population base cohort study involve link datum belgian health insurance database belgian cancer registry compare thyroid relate procedure region high low cancer incidence main outcome measure primary outcome measure rate tsh test image fine needle aspiration cytology fnac thyroid surgery secondary study outcome proportion subject thyrotoxicosis nodular disease treat surgery subject treat surgery precede fnac synchronous lymph node dissection thyroid cancer diagnosis surgery result rate tsh test similar rate image low low incidence region rate fnac similar whereas rate surgery low low incidence region ci vs ci per person year high incidence region p low incidence region compare high incidence region surgery represent little choose therapy euthyroid nodular disease patient ci vs ci p proportionally surgery precede fnac cancer diagnose total thyroidectomy thyroid cancer patient preoperative fnac synchronous lymph node dissection conclusion regional variation thyroid cancer incidence mark low risk disease associate different usage thyroid image surgery support variable detection key determinant geographic variation cyclooxygenase cox gene polymorphism patient differentiate thyroid carcinoma turkish population background aim common thyroid malignancy papillary follicular thyroid carcinoma account approximately thyroid cancer recent study report relevance cyclooxygenase cox gene polymorphism human carcinogenesis aim study investigate relationship thyroid carcinoma cox gene polymorphism turkish population material method include total differentiate thyroid cancer patient mean age year male female healthy control subject mean age year male female frequency g c c g gene polymorphism cox promoter region investigate thyroid cancer patient control group use role ultrasound elastography prediction malignancy thyroid nodule background ultrasonography consider useful distinguish solid cystic thyroid nodule stratify nodule risk cancer low medium high ultrasound us elastography apply study hardness elasticity nodule differentiate malignant benign lesion elastography possibly solve dilemma reach accurate diagnosis cytologically know indeterminate nodule aim evaluate sensitivity specificity us elastography diagnosis thyroid cancer patient method prospective study include patient total numb nodule euthyroid laboratory investigation do include ft ft tsh exclude hot nodule neck us us elastography fine needle aspiration do patient us elastography score system use result four study nodule malignant roc curve elastography score e score show high sensitivity specificity diagnosis malignant thyroid nodule cut value e score high significance p area curve sensitivity specificity e score sensitivity specificity conclusion us elastography use increase sensitivity specificity us detection malignant thyroid nodule seem great potential new tool diagnosis thyroid cancer anaplastic thyroid cancer present hyperthyroidism primary thyroid malignancy typically not interfere thyroid function patient report anaplastic thyroid carcinoma present hyperthyroidism believe \\ufeff1 case describe prior onset thyroidal process patient clinically euthyroid conclude mechanism thyrotoxicosis analogous subacute thyroiditis rapid tissue necrosis resultant release thyroid hormone pet ct image differentiate thyroid cancer patient distinguish lymph node metastasis thyroid remnant use kinetic quantity adequate therapy plan stage patient differentiate thyroid cancer dtc correct assignment thyroid remnant tr lymph node metastasis lms important patient method retrospectively analyze whether kinetic quantity help improve lm assignment use serial pet ct datum patient total lesion tr n lm n receive pre therapy pet ct lesion dosimetry use image h h administration lesion maximum activity concentration mac h effective half life ehl determine moreover product mac ehl also investigate quantity refer caq cumulate activity proportional quantity addition difference endogenous exogenous thyroid stimulate hormone tsh stimulation papillary ptc follicular thyroid cancer ftc investigate result conclusion median mac ehl caq value tr significantly high lm clinically relevant cut value can not determine high overlap region no significant difference three quantity find mode tsh stimulation significant difference mac caq ptc ftc thyroid cancer case surgical goiter sixty five year old woman hospitalize examination swell leave arm gallium scintigraphy show radioactivity leave lobe thyroid gland junction internal jugular vein subclavian vein operation prove obstruction leave internal jugular vein subclavian vein due tumor thrombus accompany anaplastic thyroid cancer gallium scintigraphy extremely useful grasp extent feature tumor benefit risk balance reoperation persistent medullary thyroid cancer objective investigation aim explore prospect cure persistent medullary thyroid cancer mtc stratify basal calcitonin level reoperation numb lymph node metastasis previously remove outside facility background no evidence base information support balance surgical benefit risk persistent mtc method retrospective study patient persistent mtc refer tertiary surgical center compare patient previously untreated mtc refer institution time period evaluate biochemical cure rate systematic lymph node dissection result relationship incremental serum calcitonin level reoperation numb lymph node metastasis reoperation biochemical cure strong previous removal r lymph node metastasis r elsewhere disappear lymph node metastasis clear hospital nonsignificant serum calcitonin level pg ml low reoperation biochemical cure rate patient patient previous removal lymph node metastasis respectively rate plummet patient previous clearance lymph node metastasis serum calcitonin level exceed pg ml reoperation biochemical cure exceptional patient conclusion serum calcitonin level pg ml low reoperation previous removal few lymph node metastasis systematic lymph node dissection seem worthwhile persistent mtc finding need validate independent series adopt widely new standard care cytological characteristic papillary thyroid carcinoma lbc specimen compare conventional specimen background cytological finding conventional specimen c liquid base cytology specimen lbc not quite aim article clarify cytological finding papillary thyroid carcinoma ptc characteristic lbc method case diagnose single institution march september ptc case c lbc review additionally compare finding lbc adenomatous hyperplastic nodule follicular neoplasm fn case result compare c incidence trabecular hobnail pattern collagenous stroma naked capillary intercellular space convolute nucleus eosinophilic nucleolus perinucleolar halo increase pale nucleus observe one ptc case specificity convolute nucleus perinucleolar halo respectively conclusion convolute nucleus perinucleolar halo may become new indicator ptc lbc contrarily aware pale nucleus rarely observe lbc thyroid cancer stem like cell epithelial mesenchymal transition thyroid cancer cancer stem like cell subpopulation self renew stem cell cancer resistant chemotherapy radiation therapy evidence support existence cancer stem like cell thyroid many solid tissue cancer rapidly accumulate cell study use specific biomarker cd cd aldehyde dehydrogenase enzyme putative cancer central neck dissection use bilateral axillo breast approach robotic thyroidectomy comparison conventional open procedure propensity score match background despite advancement surgical robot technology da vinci assist central neck dissection cnd thyroid cancer remain challenge aim study evaluate feasibility robotic thyroidectomy cnd method march july consecutive patient undergo thyroidectomy cnd papillary thyroid carcinoma retrospectively review thyroid surgeon perform either open thyroidectomy cnd n robotic thyroidectomy cnd n use bilateral axillo breast approach baba propensity score match use clinicopathologic factor use generate match cohort compose patient result mean age body mass index tumor size low undergo baba compare open procedure propensity match evaluation stimulate thyroglobulin level not show significant difference group cohort match significant difference age body mass index tumor size group no long present match cohort show numb retrieve lymph node low baba open thyroidectomy p conclusion baba robotic thyroidectomy reveal little extensive cnd obtain compare open procedure baba may suitable thyroid cancer without lymphadenopathy central neck compartment conversely baba not recommend patient thyroid cancer multiple lymph node metastasis low central neck compartment suspect controversy diagnosis management thyroid cancer non surgical treatment thyroid cancer outline success chemotherapy radiotherapy dependent numb tumour cell present immediate postoperative treatment therefore often valuable role x ray therapy radio iodine hormone chemotherapy discuss different histological type thyroid suppression medical ablation differentiate thyroid cancer patient thyroid cancer benefit treatment exogenous thyroid hormone two reason provide adequate level thyroid hormone peripheral tissue reduce level thyrotropin may important growth factor patient differentiate malignant neoplasm use radioactive iodine thyroid cancer highly controversial appropriate application follicular cancer old patient distant function metastasis value papillary cancer questionable particularly young patient great need effective basic clinical research natural course differentiate thyroid cancer effect specific therapy surgical approach level vi papillary thyroid carcinoma overview one controversial issue treatment thyroid cancer management central neck node patient papillary thyroid carcinoma ptc lymph node involvement common patient ptc may negative affect recurrence rate probably survival although therapeutic compartment orient central neck dissection standard treatment patient clinical nodal involvement cn ptc role extension elective prophylactic central neck dissection pcnd patient clinically node negative cn neoplasm remain controversial recent year order decrease risk postoperative complication relate pcnd unilateral central neck dissection emerge alternative approach bilateral central neck dissection radioiodine uptake ovarian mature teratoma detect spect ct year old woman undergo near total thyroidectomy papillary carcinoma radioiodine therapy serum thyroid stimulate hormone level iu ml thyroglobulin level g l antithyroglobulin negative receive mci ablation residual thyroid tissue therapy whole body scan demonstrate focal uptake right pelvic area localize right ovary spect ct fusion image ovarian cyst resect histopathological examination reveal mature teratoma without thyroid tissue component month follow whole body radioiodine scan normal serum thyroglobulin undetectable thyroid fine needle aspirate post bethesda update bethesda system report thyroid cytopathology formulate standardize report thyroid cytology specimen streamline management algorithm although category benign malignant nondiagnostic standardize improve remain follicular lesion undetermined significance follicular neoplasm suspicious malignancy remain fraught interobserver variability uncertainty regard management algorithm recent ongoing morphologic molecular study aim resolve issue summarize multiple metastasis thyroid cancer cranium pituitary gland two dog two dog year old female american eskimo dog year old male maltese dog present thalamic syndrome include lower level consciousness poor postural response presence masse neck region dog magnetic resonance image reveal multiple masse inside cranium include pituitary gland one dog die status epilepticus two day magnetic resonance image die two month magnetic resonance image respiratory failure dog histopathologically diagnose multiple metastasis thyroid cancer occur inside cranium include pituitary gland author knowledge \\ufeff1 time tumour pattern report dog possible not uncommon challenge active surveillance protocol low risk papillary thyroid microcarcinoma unite state detection recurrent metastatic thyroid cancer remain considerable challenge patient present rise thyroglobulin level negative whole body scintigraphy case patient follicular thyroid cancer subsequent fdg pet scan show solitary hypermetabolic cervical lesion definitive management multidisciplinary approach mind radioguided surgical excision come play use tc sestamibi lead successful removal lesion histopathology however reveal parathyroid adenoma highlight importance consider differential diagnosis apparent case recurrence avoid potential pitfall management recurrent persistent metastatic lymph node good differentiate thyroid cancer multifactorial decision make guide thyroid cancer care collaborative background good differentiate thyroid cancer wdtc recur patient guideline american thyroid association ata national comprehensive cancer network nccn provide valuable parameter management recurrent disease fail guide clinician multitude factor take account thyroid cancer care collaborative tccc web base repository patient clinical information ten clinical decision make module cdmms process information display individualize treatment recommendation method conduct review literature analysis management patient recurrent persistent wdtc result surgery remain common treatment recurrent persistent wdtc perform limit morbidity experience hand however careful observation may recommend course select patient reoperation yield biochemical remission rate report incidence permanent unexpected nerve paralysis incidence permanent hypoparathyroidism external beam radiotherapy percutaneous ethanol ablation report therapeutic alternative radioactive iodine primary therapy report previously metastatic lymph node currently advocate ata adjuvant surgery conclusion management recurrent lymph node multifactorial decision well determine multidisciplinary team cdmms allow easy adoption contemporary knowledge make information accessible patient clinician tall cell variant papillary thyroid carcinoma clinical pathological feature outcome background tall cell variant tcv relatively rare variant papillary thyroid cancer since controversy exist whether not tcv wrong outcome aim study retrospectively compare clinicopathological feature outcome group tcv patient large group patient classical papillary thyroid carcinoma cptc subject method datum tcv cptc patient analyze among cptc also select high risk cptc group no treat protocol use tcv patient datum manage cox analysis result compare cptc patient tcv subject display significantly high rate extrathyroid extension multivariate analysis tcv not independent variable prediction high risk persistent recurrent disease last follow observation no difference disease status tcv cptc patient moreover high risk cptc patient significant increase persistent recurrent disease conclusion study although tcv histotype associate high prevalence extrathyroid extension characterize outcome not significantly different cptc patient favorable high risk cptc patient tcv patient classify high risk base specific pathological clinical feature accord current guideline treat aggressively total thyroidectomy neck lymph node dissection ablative radioiodine treatment long non code rna zfas novel potential biomarker predict prognosis thyroid cancer background thyroid cancer type endocrine cancer rapidly increase incidence recent study indicate long non code rnas lncrnas play crucial role thyroid cancer tumorigenesis progression however role lncrnas thyroid cancer still unclear material method use tcga cancer genome atla gse gse gse dataset analyze expression pattern zfas znfx antisense rna correlation zfas clinicopathological feature thyroid cancer analyze cell proliferation cell cycle assay use validate role zfas thyroid cancer cell line david database annotation visualization integrate discover system use perform go gene ontology kegg kyoto encyclopedia gene genome pathway analysis starbase dataset cytoscape use perform cerna competitive endogenous rna network result demonstrate zfas highly express thyroid cancer compare normal sample moreover upregulation zfas positively correlate clinicopathological feature poor prognosis thyroid cancer functional validation show knockdown zfas suppress cell proliferation cell cycle thyroid cancer cell bioinformatics analysis show zfas associate translation rrna process intra golgi vesicle mediate transport ribosome ubiquitin mediate proteolysis conclusion study suggest zfas can serve biomarker thyroid cancer thyroid nodule evaluation fine needle biopsy sixty three consecutive unselected patient solitary cold nodule thyroid submit surgery prior surgery clinical evaluation fine needle aspiration fna biopsy nodule result study show fna biopsy correct predict cancer cancer sensitivity nodule benign fna biopsy right benign nodule specificity comparison clinical criterium alone correct suspect eight cancer sensitivity correctly identify benign nodule specificity association clinical criterium result fna biopsy would identify cancer group progress molecular base management differentiate thyroid cancer substantial development occur past year clinical translational research thyroid cancer diagnostic molecular marker ret ptc ras braf v e mutation galectin new gene expression classifier outstanding example improve diagnosis thyroid nodule braf mutation prognostic genetic marker improve risk stratification hence tailor management patient thyroid cancer include conventionally low risk novel molecular target treatment hold great promise radioiodine refractory surgically inoperable thyroid cancer show clinical trial treatment likely become component standard treatment regimen patient thyroid cancer near future novel molecular base management strategy thyroid nodule thyroid cancer excite development unprecedented era molecular thyroid cancer medicine fine needle aspiration biopsy thyroid nodule diagnostic method minimize need surgery fine needle aspiration biopsy accurate cost effective method evaluate thyroid nodule experience endocrinologist cytopathologist available aspiration biopsy diagnostic procedure choice experience straub clinic hospital honolulu halve numb operation suspect thyroid cancer novel drug treatment progressive radioiodine refractory differentiate thyroid cancer systemic therapy option emerge treatment progressive radioiodine refractory differentiate thyroid carcinoma approve therapy target tumor angiogenesis lenvatinib sorafenib improve progression free survival old subset lenvatinib prolong overall survival treatment base target specific somatic genetic alteration also available potentially also may prolong progression free survival not yet approve use food drug administration specific disease novel approach may benefit select patient include resensitization therapy allow radioiodine utilization new immunotherapy concept intracranial incidental lesion neck ct scan thyroid cancer patient radiation remain factor show unequivocally cause nonmedullary thyroid cancer recent advance include analysis pilot study serum selenium vitamin thyrotropin concentration patient thyroid cancer background low serum selenium concentration associate diagnosis differentiate thyroid cancer small study selenium deficient area conduct pilot study explore association selenium concentration diagnosis thyroid cancer area selenium sufficiency unite state low hydroxyvitamin concentration associate several malignancy also examine hydroxyvitamin level method study design pilot study prediagnostic selenium hydroxyvitamin concentration identify euthyroid patient academic medical center schedule thyroidectomy thyroid cancer suspicion thyroid cancer nodular disease blood sample obtain two four week prior thyroidectomy sample analyze thyrotropin tsh free thyroxine total triiodothyronine selenium hydroxyvitamin level concentration analyte correlate whether patient diagnose benign malignant disease follow thyroidectomy patient thyroid cancer concentration selenium hydroxyvitamin correlate various prognostic feature result although selenium concentration not significantly low patient thyroid cancer serum selenium concentration inversely correlate disease stage p no association vitamin concentration diagnosis thyroid cancer within thyroid cancer patient vitamin concentration not associate disease stage prognostic feature contrast tsh concentration significantly high patient thyroid cancer positively correlate numb involve lymph node p disease stage p conclusion datum confirm association serum tsh advance thyroid cancer addition also suggest potential association selenium concentration high thyroid cancer stage no association see hydroxyvitamin concentration large prospective study require confirm association confirm future study would need determine association causative nature causation exist seem likely selenium concentration would influence thyroid cancer development via independent mechanism tsh thyroid autonomy cyst thyroid cancer objective understand mechanism underlie thyroid cancer immune escape lead identification new molecular target efficacy biomarker purpose perform immune expression profile thyroid cancer obtain comprehensive view immune mechanism activate cancer progression method study conduct retrospectively papillary thyroid carcinoma ptcs poorly differentiate thyroid carcinoma pdtc anaplastic thyroid carcinoma atcs normal thyroid not tissue sample gene expression profile obtain rna sample use nanostring platform ncounter pancancer immune profile panel result gene expression comparison atc ptc pdtc vs not show high numb regulate gene cancer sample detail immune relate gene set significantly upregulated atc ptc pdtc atc approximately half ptc show microenvironment infiltrate macrophage cell cd effector phenotype part appear functionally exhaust conversely pdtc not sample remain part ptc display poor absent infiltration immune cell interestingly upregulation inhibitory immune checkpoint mediator include pdl pdl pd lag tim pvr tigit can detect atc ptc conclusion datum indicate existence two major immune phenotype thyroid carcinoma atc like one include hot alter immunosuppressed tumor knockdown sox inhibit proliferation invasion emt thyroid cancer cell sex determine region sry box sox member sox transcription factor family increase evidence report sox play different role various type malignancy however role sox papillary thyroid cancer ptc still unclear aim study investigate role sox ptc result show sox upregulated ptc tissue cell line addition knockdown sox significantly inhibit ptc proliferation colony formation migration invasion good epithelial mesenchymal transition emt phenotype tpc bcpap cell moreover knockdown sox significantly inhibit expression level catenin cyclin c myc ptc cell conclusion \\ufeff1 report demonstrate knockdown sox inhibit ptc cell proliferation invasion emt process via suppress wnt catenin signal pathway thus sox may act novel molecular target prevention treatment ptc abnormal uptake l lung patient thyroid cancer metastasis not year old woman background cystic bronchiectasis right lung childhood refer endocrinology study multinodular goiter patient not report personal family background thyroid cancer analysis show follow hormone level free g dl ln tsh u ml ln ultrasound show several leave thyroid lobe node small cm hypoechogenic good define large one right thyroid lobe cm hypoechogenic increase central vascularization microcalcifications absence halo ultrasound guide fine needle aspiration puncture fnap perform node result puncture suspicion malignancy decide perform surgical treatment total thyroidectomy initial stage accord american joint committee cancer ajcc pt nxm pathology report reveal several focus follicular papillary microcarcinoma cm thyroid lobe patient treat suppressive dose oral levothyroxine avoid tumor growth four month surgery receive ablative dose radioactive iodine due multifocality tumor lack knowledge lymph node involvement one year late thyroid ultrasound perform not show suspicious image malignancy level tg tshr undetectable total diagnostic body scan tshr perform show abnormal deposit radiotracer right lung heterogeneous characteristic suggest possibility metastasis appropriate dose adjuvant radioactive iodine differentiate thyroid cancer purpose review incidence good differentiate thyroid cancer wdtc increase us population major public health concern although surgery mainstay treatment radioactive iodine rai routinely use adjuvant therapy remnant ablation treatment metastatic disease despite excellent prognosis stable mortality rate use rai increase many low intermediate risk wdtc patient without clear indication change outcome result current treatment paradigm shift towards risk stratify approach recent finding although widespread acceptance rai improve overall recurrence free survival patient metastatic disease controversy remain regard radioactive remnant ablation use low intermediate risk patient additional study show reduce dose rai provide similar rate remnant ablation adjuvant therapy low intermediate risk patient without adversely affect recurrence rate mortality summary recent study suggest potential new paradigm radioactive remnant ablation dose indication use risk stratification important determine proper use dose rai update utility secondary node dissection papillary thyroid cancer background detection recurrent persistent thyroid cancer improve significantly past decade disease detect early recently treat patient localize patient long initial treatment update review recent literature regard utility secondary node dissection papillary thyroid carcinoma outcome include disease free status measure biochemically clinically result utility secondary node dissection measure clinically detectable disease exceed series utility measure biochemically modest rate biochemical cure range depend upon strictness definition patient selection predominately radioiodine scan negative patient use strict definition biochemical cure undetectable stimulate thyroglobulin tg little ng ml rate report biochemical cure rate reportedly stimulate tg little ng ml basal tg little ng ml high preoperative tg level little likely achieve biochemical cure radioiodine avid disease appear amenable cure patient achieve negative stimulate tg repeat treatment radio assist surgery complication rate secondary nodal surgery appear similar initial surgery experience hand however bilateral reoperative central neck dissection associate significantly high complication rate unilateral summary surgical resolution clinically detectable disease likely biochemical cure rate modest great likelihood biochemical cure occur patient radioiodine avid disease radioiodine negative patient may high likelihood biochemical cure low preoperative detectable tg level thyroid cancer management guideline background insular thyroid carcinoma itc rare aggressive thyroid malignancy method patient itc n report national cancer datum base evaluate patient tumor treatment characteristic outcome result compare papillary thyroid carcinoma ptc follicular thyroid carcinoma ftc patient itc cancer old often man large tumor likely present distant metastasis little likely r resection likely receive external beam radiation chemotherapy significantly wrong survival multivariate cox regression identify age year hazard ratio hr presence little comorbidity hr positive lymph node hr presence metastasis hr positive margin hr radioactive iodine therapy hr significant independent predictor survival itc conclusion treatment recommendation incorporate use radioactive iodine complete surgical resection clearance involve nodal basin wiley periodical inc head neck thyroid carcinoma rhabdoid phenotype case report review literature objective paper aim comprehensively document rare case thyroid carcinoma rhabdoid phenotype literature review disease method year old man present rapidly enlarge painful leave lateral cervical mass ct scan reveal tumor leave thyroid gland multiple leave cervical lymphadenopathy leave level ii iv level vi fine needle aspiration cytology report carcinoma type undetermined total thyroidectomy central compartment leave neck dissection perform result pathology report show rhabdoid phenotype thyroid carcinoma final stage pt n conclusion although classification thyroid tumor histology not define disease entity case report last year english literature review reveal case thyroid carcinoma rhabdoid phenotype major treatment thyroid carcinoma rhabdoid phenotype surgery benefit adjuvant therapy radiotherapy systemic chemotherapy not clear prognosis thyroid carcinoma rhabdoid phenotype extremely poor mean survival month highly sensitive thyroglobulin measurement differentiate thyroid carcinoma management differentiate thyroid cancer infrequent disease generally good prognosis initial treatment total thyroidectomy couple ablation thyroid remnant iodine thyroid cell source thyroglobulin human body circulate thyroglobulin measurement basis differentiate thyroid cancer follow due suboptimal sensitivity old assay thyroglobulin measurement stimulation endogenous exogenous thyrotropin still recommend unmask occult disease however development thyroglobulin assay improve functional sensitivity allow us detect small amount thyroid tissue even thyrotropin suppress consequence undetectable thyroglobulin thyroxine treatment sufficient evidence forgo thyrotropin stimulation many case highly sensitive assay employ hand increase concentration highly sensitive assay early reliable indicator recurrent disease result limit follow protocol warrant detection recurrence differentiate thyroid cancer reduce patient burden medical cost role eif ax thyroid cancer tumourigenesis progression purpose eif ax gene recently describe new thyroid cancer relate gene mutation mainly report poorly differentiate pdtc anaplastic thyroid cancer atc also good differentiate thyroid cancer wdtc benign thyroid lesion although little frequently aim address whether eif ax mutation present different stage thyroid tumourigenesis hyperplasia good differentiate poorly differentiate undifferentiated lesion clarify role process method analyse eif ax gene series pdtc atc case coexistent good differentiate region benign lesion eif ax mutant case also assess presence ras gene mutation result identify mutation p ala splice eif ax gene two pdtcs neither present rare case solitary subcutaneous scalp metastasis follicular thyroid carcinoma reveal positron emission tomography compute tomography case report review differentiate thyroid cancer frequently metastasize regional cervical lymph node advance case metastasis see lung skeleton metastasis skin subcutaneous tissue rare present year old female patient solitary scalp metastasis follicular thyroid carcinoma ftc reveal positron emission tomography pet compute tomography ct image pet show flourodeoxiglucose avid lesion leave vertex scalp scalp lesion remove totally histopathological examination reveal good differentiate thyroid cancer metastasis thyroid cancer chornobyl accident ukraine experience implementation follow programme thyroid cancer incidence annual variation pattern influence gender age exposure analyze population group ukraine expose ionize radiation chornobyl accident significant radiation risk demonstrate recovery operation worker evacuee prypiat town exclusion zone radiation induce excess thyroid cancer confirm among people expose child adolescent subject relatively high average thyroid radiation dose excess observe population group expose adult female age group moment accident age specific thyroid cancer incidence rate significantly high high exposure region versus low exposure one year follow since available ukrainian datum suggest wide survey population application thyroid ultrasound examination improve early detection cancer marginally lead bias completeness registration disease screen effect association serum tsh concentration thyroid cancer incidence objective investigate association serum tsh concentration thyroid cancer incidence method three hundred thirty patient thyroid tumor undergo surgical treatment include study case malignancy case benign tumor datum serum tsh level gender age tumor type numb tumor detect ultrasonic inspection retrospectively analyze association thyroid cancer incidence explore result proportion thyroid cancer group young twenty year old seventy year respectively significantly high group age year p incidence thyroid cancer male patient significantly high female patient p incidence thyroid cancer patient single nodule significantly high patient multiple nodule p group tsh level low miu l high miu l incidence thyroid cancer respectively significantly high group tsh level miu l p proportion patient thyroid cancer also increase increase serum tsh level normal range p high serum tsh level p male p single thyroid nodule p independent risk factor thyroid cancer conclusion high serum tsh level male single thyroid nodule factor lead high incidence thyroid cancer significance lymph node dissection vi area cn thyroid papillary carcinoma objective significance lymph node dissection vi area cn thyroid papillary carcinoma method collect case patient diagnose cno thyroid papillary carcinoma perform thyroid gland lobe isthmic portion excision include lateral vi area lymph node clean specimen pathologic examine determinate size position invasion thyroid papillary carcinoma numb metastasis lymph node etc result patient perform lymph node vi area group clean case vi area lymph node metastasis transfer rate vi area metastasis rate tracheal side lymph node lymph node throat group lymph node trachea group lymph node near trachea laryngeal recurrent nerve ventral group next trachea laryngeal recurrent nerve dorsal lymph node group conclusion cn thyroid papillary carcinoma vi zone lymph node metastasis rate high region vi lymph node metastasis rate high low order paratracheal lymph node prelaryngeal lymph node pretracheal lymph node metastasis rate paratracheal throat back nerve ventral lymph node high central lymph node differentiate thyroid cancer present initially distant metastasis background initial presentation distant metastasis patient differentiate thyroid cancer rare event interestingly manage appropriately long term survival group patient approximately intend review experience patient present initially distant metastatic disease large series differentiate thyroid cancer patient method entire series consecutive patient treat memorial sloan kettering cancer center patient present initially distant metastasis male female patient range age year mean age year patient analyze prognostic factor survival curve draw kaplan meier method univariate multivariate analysis perform cox regression model result patient present distant metastasis patient present papillary thyroid cancer incidence high patient follicular thyroid cancer interest note high incidence presentation distant metastatic disease patient age follicular thyroid carcinoma long term survival group compare patient present without distant metastasis p no statistical difference survival patient age conclusion even though presence distant metastasis time initial presentation cancer consider grave prognosis patient differentiate thyroid cancer long term survival still incidence distant metastasis high patient follicular thyroid cancer appropriate initial evaluation treatment lead satisfactory long term survival external radiotherapy treatment cancer thyroid body apropos case background purpose study compare incidence thyroid cancer among patient primary non thyroid cancer show focal thyroid uptake f fluoro deoxy glucose fdg positron emission tomography compute tomography pet ct material method review total fdg pet cts perform institution march june retrospective review conduct non thyroid cancer patient male n female n thyroid incidentaloma fdg pet ct patient diagnostic confirmation do ultrasound guide fine needle aspiration biopsy fnab result among fdg pet ct scan subject show focal thyroid uptake among patient undergo fnab include study patient demonstrate papillary thyroid carcinoma final pathologic finding divide patient group depend primary cancer conclusion patient cancer non thyroid origin incidental fdg uptake thyroid gland observe associate risk good differentiate thyroid carcinoma however no statistically significant difference malignant risk focal fdg uptake thyroid gland accord underlie primary non thyroid cancer type freeze biopsy central compartment papillary thyroid cancer quantitative nodal analysis background nodal metastasis papillary thyroid cancer ptc usually occur central compartment ipsilateral neck spread laterally purpose study evaluate diagnostic accuracy freeze biopsy quantitative nodal evaluation central neck metastasis ptc method patient ptc undergo total thyroidectomy bilateral central neck dissection cnd tissue ipsilateral cnd examine freeze biopsy result among patient central neck metastasis sensitivity specificity freeze biopsy central neck metastasis respectively positive predictive value negative predictive value respectively diagnostic accuracy exact numb metastatic node compare permanent biopsy conclusion freeze biopsy quantitative analysis central compartment useful tool precise evaluation central lymphatic status intraoperatively high sensitivity specificity current problem primary recurrent thyroid cancer treatment background ultrasound us risk stratification system rsss develope reduce numb unnecessary fine needle aspiration fnas thyroid nodule system design primarily identify papillary thyroid carcinoma thus performance follicular thyroid carcinoma ftc debatable present study undertake investigate accuracy rsss select ftcs fna method patient ftc undergo us examination institution select us image review retrospectively ftcs reclassify accord american association clinical endocrinologist american college endocrinology associazione medici endocrinologi aace ace ame american college radiology acr tirads american thyroid association british thyroid association european thyroid association korean society thyroid radiology korean society radiology thyroid image report datum system tirads risk class indication fna assess result forty five ftcs consecutive patient include study median tumor diameter mm range ovoid isoechoic nodule without lobulated margin frequent presentation ftcs classify accord rsss common category intermediate high risk though case not classifiable ftcs classify high risk high suspicion malignant case statistically significant difference among system fna indicate case good agreement among aace ace ame acr tirads tirads conclusion current rsss show high performance select ftcs fna result mainly due dimensional rsss cutoff indicate fna contrary give report unsuspicious echo structural presentation ftc recognize limitation cytological assessment detect caution advise use us manage cytologically indeterminate nodule tsh suppressive treatment differentiate thyroid cancer dogma review tsh suppressive therapy st part treatment protocol differentiate thyroid carcinoma dtc however little evidence clinical effectiveness side st not free side effect relate subclinical hyperthyroidism status induce patient long time period widespread use st patient recently question individualize treatment base characteristic particular case propose action thyroid hormone ths depend bind specific nuclear receptor however 2 pathway mediate membrane receptor locate integrin v recently establish postulate proliferative angiogenic effect attribute ths would depend 2 mechanism not know whether tumorigenic action show neoplasm may impact dtc objective study review relationship st cancer particularly regard tumor evolution occurrence 2 primary neoplasm one future challenge field dtc establish specific role tsh ths malignant thyroid cell order able define optimize therapeutic scheme expression profile micrornas target gene papillary thyroid carcinoma incidence thyroid cancer recently experience rapid increase china papillary thyroid carcinoma ptc account nearly human thyroid cancer present study differential expression micrornas mirnas target gene identify order analyze potential role mirnas biomarker papillary thyroid carcinogenesis one hundred twenty six ptc sample collect patient china japan union hospital china gene mirna expression profile examine illumina beadchips verify real time rt pcr gene ontology go category determine pathway analysis carry use kegg mirna target gene predict implement three computational analysis program targetscans diana microt pictar two hundred forty eight mirnas gene find significantly deregulate gene p mirna p ptc tissue compare match normal thyroid tissue hsa mir target gene meet hsa mir p target gene itgav hsa mir target gene itga hsa mir target gene itga hsa mir target gene kit axin hsa mir target gene axin foxo hsa mir target gene kit identify together function target gene elucidate role mirnas papillary thyroid carcinogenesis suggest use mirnas biomarker early diagnosis finding provide basis future study field mirna base cancer therapy long term outcome comprehensive central compartment dissection patient recurrent persistent papillary thyroid carcinoma background persistent recurrent papillary thyroid carcinoma ptc occur patient initial thyroid surgery often radioactive iodine treatment identify efficacy safety long term outcome current surgical management paradigm persistent recurrent ptc central compartment interdisciplinary thyroid cancer clinical research program tertiary thyroid cancer referral center method retrospectively analyze standardize approach comprehensive bilateral level vi vii lymph node dissection snd vi vii cytologically confirm ptc central compartment result patient median age range undergo snd vi vii patient already undergo surgical procedure persistent recurrent disease distant metastasis presentation postoperatively patient thyroglobulin tg positive no evidence disease anti tg antibody present patient not anti tg antibody postoperatively fourteen patient hypoparathyroid presentation become permanently hypoparathyroid surgery four patient experience recurrent laryngeal nerve paralysis rlnp previously function nerve unanticipated rlnp observe one nerve risk external beam radiation give patient additional patient develope distant metastasis follow last follow patient no detectable tg no evidence disease median year surgery patient without evidence central disease develope central compartment recurrence within median interval month recurrence patient undergo subsequent surgical procedure thus result overall central compartment control rate kaplan meier disease specific survival year patient year old year old log rank p predictor central compartment recurrence malignancy thyroid remnant note within central compartment surgical specimen conclusion bilateral comprehensive level vi vii dissection safe effective extrathyroidal thyroid cancer result tracheal shave tracheal resection extrathyroidal thyroid cancer invade laryngotracheal system uicc stage pt represent progressive process infiltration tracheal wall layer outer inner part trachea tumor usually present high proliferation activity correlate reduce long term prognosis contrast intraluminal manifestation require complete wall resection case non transmural invasion complete tumor removal sometimes achieve extraluminal tangential resection shave tangential resection however associate high frequency microscopically invade resection margin r resection rate available comparative study retrospective maximum ebm level analyze oncological outcome show inconsistent result recently publish study however complete wall resection good differentiate thyroid cancer tracheal invasion find associate long recurrence free tumor specific survival compare shave deep larynx invasion associate reduce long term prognosis compare invasion trachea salvage resection therefore perform select case increase incidence thyroid cancer latina italy possible role detection subclinical disease objective describe thyroid cancer incidence trend geographical pattern latina province lazio italy use population base cancer registry method extract latina cancer registry case thyroid cancer case classify accord morphological type diameter datum diagnostic procedure latina province resident extract regional outpatient procedure information system result total case diagnose standardize incidence per male n female n respectively annual percent change apc ci ci male female respectively increase mostly due papillary n small mm cancer n no difference age year n apc neck ultrasound perform ci ci biopsy cytology ci ci man woman respectively geographic pattern biopsy cytology similar cancer incidence not neck ultrasound conclusion latina increase thyroid cancer incidence rapid rest italy particularly type good prognosis tumor size histotype suggest increase detection instead increase disease occurrence datum diagnostic procedure reimbursement not provide explanation differentiate thyroid cancer etiopathogenic clinical datum prognostic factor surgical treatment thyroid cancer common among endocrine malignant neoplasm cause grow good external factor influence primary malfunction thyroid cell common papillary cancer region iodine level low incidence follicular cancer increase postoperative procedure depend type stage cancer nowadays center deal thyroid cancer treatment primary radical surgery follow low possibility miss cancer thyroid remnant easy postoperative follow supplementary treatment management coexistent cutaneous myeloid sarcoma patient invasive papillary carcinoma thyroid rare presentation extrathyroidal thyroid cancer invade laryngotracheal system uicc stage pt represent progressive process infiltration tracheal wall layer outer inner part trachea tumor usually present high proliferation activity correlate reduce long term prognosis contrast intraluminal manifestation require complete wall resection case non transmural invasion complete tumor removal sometimes achieve extraluminal tangential resection shave tangential resection however associate high frequency microscopically invade resection margin r resection rate available comparative study retrospective maximum ebm level analyze oncological outcome show inconsistent result recently publish study however complete wall resection good differentiate thyroid cancer tracheal invasion find associate long recurrence free tumor specific survival compare shave deep larynx invasion associate reduce long term prognosis compare invasion trachea salvage resection therefore perform select case malignancy risk characteristic thyroid nodule two consecutive result atypia undetermined significance follicular lesion undetermined significance cytology purpose evaluate malignancy risk characteristic thyroid nodule two atypia undetermined significance follicular lesion undetermined significance aus flus result compare characteristic malignancy two aus flus result one aus flus result method thyroid nodule initial aus flus result undergo repeat fine needle aspiration fna obtain repeat aus flus result thyroid image report datum system tirads category assign clinico pathological characteristic compare benign malignant nodule malignancy two consecutive aus flus result one aus flus result result thirty one percent nodule two aus flus result confirm nodule malignant age gender nodule size ultrasound feature tirads category not differ benign malignant nodule malignancy one two aus flus result malignancy two aus flus result high proportion follicular variant papillary thyroid carcinoma ptc vs p conclusion thyroid nodule two aus flus result high malignancy risk little high proportion follicular variant ptc surgery consider regardless ultrasound feature key point thyroid nodule two consecutive aus flus result high malignancy risk ultrasound feature little useful nodule two aus flus result follicular variant ptc frequent malignancy two aus flus result multifocal papillary thyroid cancer increase risk central lymph node metastasis background papillary thyroid cancer ptc common thyroid malignancy strong predilection lymph node metastasis commonly central neck compartment level vi study evaluate lymph node metastasis multifocal ptc role level vi dissection management ptc remain controversial retrospective analysis evaluate rate level vi lymph node positivity multifocal ptc compare unifocal disease order inform surgical decision make well method patient ptc undergo total radioprotective property sodium humate radiation induce mutagenesis culture lymphocyte thyroid cancer patient investigate effect sodium humate level cytogenetic damage culture lymphocyte patient thyroid cancer irradiation material method metaphase analysis chromosome aberration culture peripheral blood lymphocyte individual thyroid cancer perform irradiation lymphocyte vitro dose gy c source early g phase cell cycle sodium humate add cell culture min phytohemagglutinin stimulation concentration g ml result sodium humate exhibit antimutagenic property preparation concentration g ml effective concentration g ml reduce average incidence radiation induce chromosome aberration respectively pronounce antimutagenic effect sodium humate reduction frequency chromosomal type aberration however efficiency vary individual patient thyroid cancer conclusion sodium humate can consider potential therapeutic modifier radiation damage thyroid nodule differentiate thyroid cancer incidence thyroid nodule thyroid cancer increase last several decade change influence several factor include status iodine sufficiency access health care system perhaps significantly increase use radiological image thorough evaluation thyroid nodule include review patient medical family history follow thyroid ultrasound fine needle aspiration biopsy similar adult majority nodule child benign however fold high risk nodule find pediatric patient year malignant compare adult differentiate thyroid carcinoma dtc common malignancy approximately papillary thyroid carcinoma remainder follicular thyroid carcinoma proper evaluation management prognosis pediatric patient dtc excellent however risk treatment complication recurrence relatively high development pediatric specific guideline evaluation management thyroid nodule dtc good creation center surgical medical expertise crucial order optimize care gain well understand factor impact disease specific morbidity thyroid cancer impact emerge technology clinical practice guideline clinical practice guideline available evaluation management thyroid nodule thyroid cancer nevertheless uncertainty associate protocol due genomic variation among patient incomplete evidence base addition deviation protocol due physician bias different level train shortcoming may eventually disappear emerge technology enter mainstream medicine intervention include well risk stratification routine use diagnostic molecular marker panel cytological analysis thyroid fine needle aspiration specimen good hybridize image modality little aggressive therapy low intermediate risk thyroid cancer patient molecular target therapy pretargeted radioimmunotherapy novel minimally invasive surgical technique response oh no equation reanalysis datum reveal even strong association hashimoto thyroiditis differentiate thyroid cancer purpose aim study assess prognostic factor treatment efficacy particular increase serum thyroglobulin tg level time \\ufeff1 ablative radioiodine treatment patient differentiate thyroid carcinoma dtc method retrospective chart review perform patient treat dtc total thyroidectomy ablation examine month late diagnostic whole body scan serum tg measurement thyroid hormone treatment withdrawal time ablative radioiodine treatment serum tg level determine administration tgd day late tgd tg variation express ratio tgd tgd \\ufeff1 post ablation follow examination unsuccessful ablation define tg level ng ml abnormal uptake result ablation unsuccessful patient univariate analysis show high tgd level low tgd tgd ratio extrathyroidal invasion uptake neck exclude thyroid bed ablative treatment distant metastasis significantly associate unsuccessful ablation logistic multivariate analysis tgd level ng ml tgd tgd ratio independently associate successful ablation receiver operate characteristic curve analysis determine tgd tgd ratio great positive predictive value successful ablation tgd tgd tgd ratio consider tgd ng ml tgd ng ml tgd tgd ratio ablation unsuccessful patient conclusion datum show tgd tgd ratio may use new prognostic indicator treatment efficacy patient dtc fine needle aspiration primary langerhans cell histiocytosis thyroid gland potential mimic papillary thyroid carcinoma clinical presentation langerhans cell histiocytosis lch primary solitary nodule thyroid gland rare result report cytologic feature thyroid aspirate pose diagnostic pitfall case conclusion foster familiarity cytomorphology report significant association tp arg pro polymorphism susceptibility differentiate thyroid cancer background among various polymorphic variant tp gene codon polymorphism arg pro find associate cancer susceptibility study investigate effect thyroid cancer risk objective case control study conduct elucidate possible role snp risk factor thyroid cancer development examine correlation various clinicopathological variable method study test genotype distribution pcr rflp thyroid cancer patient cancer free control kashmir valley result genotype frequency arg arg gg arg pro gc pro pro cc genotype among case control respectively proline allele frequency significantly high arginine frequency patient group c significant association find variant genotype codon tp gene young age group female gender urban dweller non smoker patient elevate tsh level p conclusion evident study arg pro snp tp gene connect high susceptibility thyroid cancer especially young age group female gender non smoker patient elevate tsh level hence implicate thyroid carcinogenesis risk factor persistent disease papillary thyroid carcinoma lymph node metastasis purpose know presence neck lymph node ln metastasis correlate persistent disease papillary thyroid carcinoma ptc patient appropriate therapy patient become disease free whereas may still persistent disease present study aim determine potential variable affect clinical course disease persistent disease pattern ptc patient ln metastasis material method study group include consecutive ptc patient ln metastasis clinicopathological characteristic persistent disease pattern follow period examine identify risk factor persistent disease use univariate multivariate analysis result end median follow month patient become disease free patient persistent disease univariate analysis show male sex old age initial diagnose year large tumor size cm presence lateral cervical ln metastasis extrathyroidal invasion high numb metastatic ln significant predictor persistent disease multivariate analysis show extrathyroidal involvement presence lateral cervical ln metastasis old age initial diagnosis year independent predictor persistent disease conclusion despite presence ln involvement patient may become disease free therapy patient extrathyroidal invasion lateral cervical ln involvement little year old initial diagnosis likely persistent disease however disease control achieve close clinical follow therapy unusual presentation papillary thyroid carcinoma two case papillary carcinoma common cancer thyroid presentation may unexpected \\ufeff1 case year old girl complain painful enlargement right thyroid lobe upon basis ct scan reveal punctuate calcification suggest psammoma body right side cold nodule thyroid radioiodine scan patient thyroidectomy 2 case discovery papillary carcinoma year old woman thyroidectomy grave disease association may not fortuitous cancer can aggressive group patient tsi play pathogenic role clinical epidemiology tracheal invasion thyroid cancer japanese population functional outcome effect age background although tracheal invasion thyroid cancer life threaten epidemiology development remain unclear study aim determine epidemiology prevalence incidence risk factor functional outcome tracheal invasion thyroid cancer among japanese patient eligible brachiocephalic vein thrombus papillary thyroid cancer report case differentiate thyroid cancer sometimes show microscopic vascular invasion rarely cause tumor thrombus great vein preoperative diagnosis latter condition difficult patient not overt symptom important operative plan encounter year old woman papillary thyroid cancer tumor thrombus extend brachiocephalic vein superior vena cavum tumor successfully treat surgical resection knowledge case far report herein report case review literature discuss associate diagnostic problem treatment include area age gender symptom pathology extension outcome decrease apolipoprotein increase complement component potential marker papillary thyroid carcinoma proteomic study background thyroid carcinoma comprise fast rise incidence cancer past decade currently diagnosis thyroid tumor perform alter expression gap junction protein connexin associate papillary thyroid carcinoma compare noncancer pathology thyroid background gap junction membrane structure compose connexins cx allow diffusion small molecule cell involve tissue homeostasis various organ dysfunction associate gap junction defect verify possible involvement thyroid pathology expression connexin cx major cx human thyroid evaluate variety disease include cancer method sample various thyroid pathology collect analyze presence cx immunofluorescence confocal microscopy different pattern cx localization identify normal membrane abnormal cytoplasmic lack detection analysis cx expression perform quantitative reverse transcriptase polymerase chain reaction immunohistochemistry subset papillary carcinoma compare nontumoral thyroid tissue result presence cx commonly alter thyroid cancer abnormal cx stain detect cancer adenoma multinodular goiter grave disease thyroiditis papillary carcinoma sample deregulation cx expression mostly consequence decrease cx mrna case compare normal tissue cx mrna not downregulated case loss membrane stain aberrant cytoplasmic distribution protein observe conclusion result show aberration cx expression associate thyroid papillary carcinoma acr appropriateness criterium thyroid carcinoma acr head neck cancer appropriateness criterium committee review relevant medical literature provide guidance manage patient thyroid carcinoma american college radiology appropriateness criteriaare evidence base guideline specific clinical condition review every year multidisciplinary expert panel guideline development review include extensive analysis current medical literature peer review journal application good establish consensus methodology modify delphi rate appropriateness image treatment procedure panel instance evidence lack not definitive expert opinion may use recommend image treatment thyroid cancer common endocrine malignancy unite state often present localize palpable nodule surgery mainstay treatment wdtc patient undergo complete resection disease good outcome follow surgery thyroxine supplementation begin suppress tsh unchecked stimulate residual disease metastatic progression adjuvant treatment radioactive iodine rai use iodine frequently use diagnostic therapeutic purpose use ebrt thyroid cancer not test good design randomize control trial therefore consider case case basis chemotherapy play minimal role management wdtc novel biologic agent systemic therapy option actively investigate patient metastatic thyroid cancer not iodine avid encourage enroll clinical trial explore novel systemic agent success postoperative therapy young belarusian patient differentiate thyroid cancer chernobyl depend radiation absorb dose blood thyroglobulin level purpose differentiate thyroid carcinoma dtc child young adult rare often aggressive advance stage diagnosis cohort young belarusian patient advance dtc chernobyl retrospectively study parameter influence success postoperative therapy method include study patient female male median age year range year total thyroidectomy belarus subsequent therapy follow germany patient classify n n median weight adjust activity administer thyroid hormone withdrawal mbq kg range mbq kg tnm stage gender administer activity whole body residence time blood dose ablation tg tsh level date age time treatment test effect rate complete remission cr cr define negative scan stimulate tg level ng ml follow result cr observe patient \\ufeff1 treatment multivariate analysis group identify tg level p log tg radiation absorb dose blood p independent determinant parameter unimportant p regression model able correctly predict cr patient conclusion child young adult advance dtc rate cr postoperative therapy dependent preablative tg level radiation absorb dose blood though present result must confirm prospective study imply preablative dosimetry may improve rate cr effect dialysis kinetic dosimetry thyroid cancer patient pharmacokinetic model currently accept post surgical treatment patient thyroid carcinoma administration ablative dose treatment good establish base extensive experience model however patient renal disease reduce iodine removal rate result controversial thyroid dose potentially excessive red bone marrow dose difference opinion regard dose recommendation range reduction dose increase dose compare conventional amount determination suitable dose must take account vary dialysis protocol absorb dose consideration thyroid sensitive tissue red bone marrow specific aim study develop simple yet comprehensive compartmental model kinetic patient thyroid carcinoma end stage renal disease account dialysis provide absorb dose estimate thyroid good red bone marrow stella compartmental model software program use develop kinetic model include blood pool thyroid gastrointestinal tract kidney bladder conventional dialysis machine benchmark perform demonstrate validity model datum obtain icrp mird dose estimate report no iodine kinetic simulate normal patient thyroid cancer patient patient thyroid cancer renal failure undergo two standard type dialysis hemodialysis continuous ambulatory peritoneal dialysis capd result work show thyroid dose patient thyroid cancer renal failure hemodialysis capd slightly high dose patient thyroid cancer normal renal function result indicate red bone marrow dose patient thyroid cancer renal failure dialysis significantly high red bone marrow dose patient thyroid cancer normal renal function thus patient can benefit reduction administer activity thyroid dose red bone marrow dose patient standard hemodialysis depend dialysis frequency time interval administration \\ufeff1 dialysis result study provide guideline much activity patient dialysis receive base thyroid red bone marrow absorb dose gy mbq consideration study help clarify contradictory recommendation regard dose thyroid carcinoma patient renal failure letter undifferentiated cancer thyroid cure use adriamycin surgery background purpose anaplastic thyroid carcinoma atc rare aggressive malignancy potential pathologic misclassification complicate interpretation publish datum one standard treatment option locoregionally advance disease weekly low dose doxorubicin concurrent radiation therapy previously develope institution evaluate recent experience approach include pathologic confirmation case material method retrospective review perform patient identify memorial sloan kettering cancer center mskcc cancer database inclusion criterium pathologically confirm atc locoregional disease encompassable within radiation portal treatment curative intent mskcc plan weekly doxorubicin mg concurrent radiation principle outcome assess locoregional progression free survival lr pf overall survival os result thirty seven patient include median radiotherapy dose gy gy administer hyperfractionated impact metastatic lymph node risk stratification differentiate thyroid cancer reach high level understand background revise american thyroid association ata management guideline differentiate thyroid cancer emphasize variety clinicopathologic feature metastatic lymph node determine risk recurrence mere presence positive node not sufficient confer reliable prognostic significance numb size lymph node good presence extranodal extension ene impact risk stratification moreover presence clinically evident lymph node important determine risk recurrence patient place risk spectrum ramification management differentiate thyroid cancer however inherent inconsistency identification characterization metastatic lymph node moreover significance ene must clarify summary many obstacle consistent report metastatic lymph node constitute clinically evident lymph node not good define lack precision vary depend clinical context good experience surgeon ultrasonographer numb lymph node sample surgeon report pathologist may vary institution institution literature ene limit fact definition ene not standardize nevertheless manuscript review herein suggest ene confer wrong prognosis ata risk stratification metastatic lymph node publish guideline combine clinicopathological feature variably identify report across institution review bring question significance numb node ene factor use important stratify variable late guideline conclusion metastatic lymph node not carry prognostic significance risk assignment base ata guideline limit lack standardization clinical pathologic definition lymph node sample report study review limitation prior study ene conclude body evidence report study suggest ene increase risk recurrence impact ene lymph node thyroid cancer risk stratification reconsider skip metastasis papillary thyroid carcinoma difficult predict clinical practice background cervical lymph node metastasis common papillary thyroid cancer ptc typically spread predictable stepwise fashion clinical practice however lateral lymph node metastasis llnm without central lymph node metastasis clnm skip metastasis not rare ptc aim study investigate incidence risk factor pattern skip metastasis ptc method total patient ptc suspicious lln diagnose pre operation examination undergo total thyroidectomy central lymph node dissection plus lateral lymph node dissection january december enroll study clinicopathological feature collect pattern cervical lymph node metastasis skip metastasis analyze result llnm rate diagnose postoperative pathology examination significantly associate extrathyroid extension ete primary tumor locate upper pole clnm p skip metastasis rate frequently find microcarcinoma patient especially primary tumor size cm p however skip metastasis unrelated remain factor examine conclusion small cancer pre operation diagnosis llnm likely skip metastasis especially primary tumor size little cm diameter however type metastasis appear develop random fashion thus additional research need identify potential predictive factor primary tumor locate upper pole rapid diagnosis recurrence tall cell variant papillary thyroid cancer endogenous tsh stimulation background aim estimate lifetime cumulative risk thyroid cancer crtc \\ufeff1 degree relative patient non medullary thyroid cancer nmtc include papillary ptc follicular oxyphilic anaplastic thyroid carcinoma histology age diagnosis patient relative design population base cohort \\ufeff1 degree relative nmtc patient diagnose nordic country follow cancer incidence standardise incidence ratio sir calculate use histology specific age specific sex specific period specific country specific incidence rate reference result year crtc female relative patient ptc represent threefold increase general population risk sir ci man crtc sir ci ptc patient diagnose age year family crtc female relative male twin fold increase risk concordant ptc family history follicular oxyphilic anaplastic carcinoma increase crtc relative although no familial case concordant oxyphilic anaplastic carcinoma find familial risk discordant histology type nmtc interchangeably high type example high risk ptc \\ufeff1 degree relative follicular sir ci anaplastic sir ci carcinoma early patient diagnose ptc family high sir young relative tendency towards concordant age diagnosis thyroid cancer among relative ptc patient conclusion study provide clinically relevant risk estimate family member nmtc patient thyroidectomy vs active surveillance subcentimeter papillary thyroid cancer cost conundrum background recently american joint committee cancer publish th edition cancer stage manual major change regard stage thyroid cancer include raise age cutoff year use clinical genetic datum papillary thyroid cancer ptc case aim compare overall survival os recurrence free survival rfs different age cutoff value also investigate efficacy new stage system genomic level method download gene expression datum somatic mutation profile copy numb alteration datum clinical datum ptc patient cancer genome atla datum portal use multiple statistical analysis multiplatform genomic analysis evaluate efficacy th edition result use year cutoff value analyze rfs kaplan meier plot show significant p value not use year p vs p cutoff value significant analyze os p age vs p age look stage dependent survival th th edition significant p value p vs p rfs p vs p os multiplatform genomic analysis show patient year differently express gene compare age group signal pathway analysis reveal patient year alter pathway associate aggressiveness thyroid cancer conclusion conclusion \\ufeff1 study show clinical genetic evidence support alter age cutoff point year ajcc th edition ptc patient brito et al overdiagnosis thyroid cancer grave disease recombinant human tsh rhtsh revolutionize care patient differentiate thyroid cancer since approval clinical use europe usa rhtsh greatly enhance surveillance patient allow avoidance hypothyroidism tsh stimulation previously hypothyroid state require tsh stimulate diagnostic whole body radio iodine scan dxwbs thyroglobulin tg level patient generally prefer rhtsh mechanism tsh stimulation symptom hypothyroidism completely avoid currently rhtsh approve diagnostic monitor differentiate thyroid cancer patient many potential use rhtsh include facilitation treatment patient thyroid cancer nodular goiter diagnostic therapeutic role rhtsh patient differentiate thyroid cancer nodular goiter discuss review radiologic feature papillary carcinoma 2 branchial cleave cyst clinically may difficult differentiate benign branchial cleave cyst bcc malignant bcc papillary carcinoma preoperatively radiological feature review retrospectively benign bcc malignant bcc papillary carcinoma use compute tomography ct magnetic resonance mr image patient mass right upper lateral neck without lesion thyroid gland two patient mass upper medial part bcc ct image one patient show good circumscribe mass upper portion bcc mr image two patient receive bcc removal one patient undergo total thyroidectomy include removal bcc result case papillary carcinoma bcc detect incidentally surgical resection bcc however differentiate benign bcc malignant bcc primary papillary carcinoma carefully review radiologic image surgery comparison three prognostic index differentiate thyroid cancer investigate epidemiological datum correlation coefficient among three prognostic index tnm age degroot patient differentiate thyroid carcinoma mean age year sex ratio f seventy eight case papillary follicular carcinoma surgical complication vocal cord paralysis case hypoparathyroidism case four case not find surgical complication patient subject main limit procedure follow month one patient dead due thyroid cancer patient tumor relapse find positive correlation tnm age age degroot degroot tnm index concordance k p series follicular cancer prevalence low literature report result suggest tnm degroot age index may similar prognostic value differentiate thyroid cancer anaplastic thyroid carcinoma current diagnosis treatment background anaplastic thyroid carcinoma atc account primary malignant thyroid neoplasm one aggressive solid tumor human generally rapidly fatal mean survival six month diagnosis multimodality treatment surgery external beam radiotherapy chemotherapy fundamental importance local control disease enhance survival design evaluate consecutive patient atc observe mayo clinic review relevant article publish major english language medical journal use medline database select bibliography article available personal file result atc usually not concentrate radioiodine express thyroglobulin essential verify diagnosis histologically insular thyroid cancer lymphoma medullary thyroid cancer occasionally confuse undifferentiated neoplasm immunohistochemical study helpful establish diagnosis multimodal therapy development effective systemic chemotherapeutic agent result improvement survival although no single agent yet identify conclusion aggressive multimodality treatment regimen show promise improve local control patient atc however survival rate remain low despite intense application therapy no standardize successful treatment protocol establish ultrasonography survey thyroid cancer fukushima prefecture thyroid cancer one major health concern accident fukushima dai ichi nuclear power station nps currently ultrasonography survey perform person reside fukushima prefecture time accident age year expect thyroid cancer prevalence fukushima prefecture assess base ultrasonography survey ukrainians expose age year release chernobyl nps accident difference equipment study protocol two survey radiation risk thyroid cancer incidence among survivor atomic bombing hiroshima nagasaki preliminary estimate thyroid dose due fukushima accident use prediction baseline radiation relate thyroid cancer risk estimate prevalence thyroid cancer ci \\ufeff1 screen campaign fukushima prefecture compare incidence rate japan ultrasonography survey predict increase baseline thyroid cancer incidence factor ci condition continue screen thyroid cancer \\ufeff1 fifty year accident predict detect screen population prediction radiation relate thyroid cancer expose fraction ten thousand person screen population fukushima prefecture large uncertainty well estimate average risk depend average dose thyroid primary metastatic malignant tumour poor prognosis may mimic subacute thyroiditis time change diagnostic criterium case report review literature background diagnosis subacute thyroiditis sit base mainly presence painful thyroid goitre significant increase erythrocyte sedimentation rate esr proceed accord diagnostic criterium may lead incorrect diagnosis treatment extremely dangerous situation diagnosis sit erroneously make base criterium ultrasound us image fine needle aspiration biopsy fnab lead delay diagnosis malignant tumour poor prognosis case presentation five patient typical sit symptom present anaplastic thyroid cancer metastatic thyroid tumour finally diagnose cause initial symptom resemble sit patient initially misdiagnose proper diagnosis malignancy delay conclusion author propose new diagnostic criterium sit strongly suggest thyroid gland us include main criterium sit diagnosis together fnab result exclude presence malignant tumour papillary thyroid carcinoma child congenital dyshormonogenetic hypothyroidism case report introduction papillary thyroid carcinoma ptc rare childhood disease development ptc dyshormonogenetic congenital hypothyroidism ch infrequent case report literature objective report case ptc boy dyshormonogenetic ch without goitre expose ionise radiation evaluate relationship factor development ptc case report present boy dyshormonogenetic ch since birth early hormonal substitution initiate subsequent normal level thyrotropin thyroid hormone also congenital cardiomyopathy expose interventional treatment heart catheterisation approximately chest x ray paediatric dose thyroid nodule find thyroid echography age year old fine needle aspiration biopsy confirm high probability thyroid carcinoma bethesda pre surgical thorax cerebral scan show no evidence metastasis patient undergo total thyroidectomy pathological examination reveal cm papillary thyroid micro carcinoma right lobe no evidence dissemination conclusion genetic mutation radiation exposure may play important role development ptc may common pathway dyshormonogenetic ch thyroid carcinoma need investigation evaluation radionuclide therapy residue surgery papillary thyroid carcinoma objective assess efficacy radioactive iodine rai treatment residual papillary thyroid cancer ptc surgery method total patient diagnose ptc undergo course rai therapy residual ptc surgery hospital include study stage stage iii stage iv case operate due presence suspicious residual tumor indicate ct excision thyroid tumor residue perform case neck dissection case side suspicious thyroid neck residual tumor examine pathologically surgery response evaluation criterium solid tumor recist use evaluate efficacy surgery treatment residual tumor test use identify variable associate rai calculate propensity score receive rai surgery result patient age year median age year mean time surgery receive rai mean dose apply rai mci mci no significant difference tumor size pre rai post rai find p postoperative pathological examination suspicious thyroid neck residual tumor confirm ptc cervical lymph metastasis ptc conclusion residue metastasis ptc operation reoperation priority rai therapy no obvious therapeutic effect limit select case distant metastasis unsuitable operation iodine uptake function take adjuvant treatment radical resection cervical lesion immunohistochemical expression cxcr thyroid carcinoma thyroid benign lesion different tumor entity expression chemokine receptor cxcr link tumor dissemination poor prognosis aim study examine immunohistochemical expression cxcr thyroid carcinoma thyroid benign lesion use monoclonal anti cxcr antibody perform immunohistochemical stain tissue section case obtain ruijin hospital affiliate shanghai jiaotong university school medicine shanghai china study cxcr expression thyroid carcinoma group include papillary thyroid carcinoma follicular thyroid carcinoma poorly differentiate thyroid carcinoma medullary thyroid carcinoma find high benign lesion group include case hashimoto thyroiditis nodular goiters follicular adenoma p within carcinoma group malignant thyroid carcinoma group include poorly differentiate thyroid carcinoma medullary thyroid carcinoma show high ratio cxcr positivity compare little malignant thyroid carcinoma group include papillary thyroid carcinoma follicular thyroid carcinoma p study suggest cxcr expression may frequent cancer specific event thyroid carcinoma may involve malignancy transformation progression thyroid carcinoma comparative serum proteomic analysis identify afamin downregulated protein papillary thyroid carcinoma patient non avid lung metastasis background loss uptake ability metastasis differentiate thyroid carcinoma dtc become major obstacle radioiodine treatment however no effective way screen uptake ability metastasis identification differentially express protein serum proteomics may contribute understand mechanism underlie dedifferentiation dtc material method serum sample obtain papillary thyroid carcinoma patient non avid lung metastasis avid lung metastasis differential protein analysis perform use two dimensional gel electrophoresis candidate protein spot show difference expression two group identify mean matrix assist laser desorption ionization time flight mass spectrometry validate western blot result find afamin downregulated serum papillary thyroid carcinoma patient non avid lung metastasis conclusion afamin may potential serum biomarker early screen uptake ability dtc metastasis can therefore value guide radioiodine treatment decision selective use sorafenib treatment thyroid cancer sorafenib multiple kinase inhibitor mki approve treatment primary advance renal cell carcinoma advance primary live cancer recently approve several health agency around world \\ufeff1 available mki treatment radioactive iodine refractory advance progressive differentiate thyroid cancer sorafenib target c raf b raf vegf receptor pdgf receptor ret c kit flt multifunctional inhibitor sorafenib potential inhibit tumor growth progression metastasis angiogenesis downregulating mechanism protect tumor apoptosis show increase progression free survival several phase ii trial lead phase iii trial decision show improvement progression free survival month patient sorafenib compare placebo adverse event drug common usually manageable development resistance year almost rule patient show partial response stabilization disease sorafenib make necessary think plan subsequent therapy may include use another mki lenvatinib 2 approve mki advance differentiate thyroid cancer include patient clinical trial label use mkis give sorafenib early approval center access prescription goal review improve care patient describe key aspect prescriber need master order optimize outcome prognostic value preoperative tumor volume tumor diameter n papillary thyroid cancer purpose current tnm stage system papillary thyroid cancer ptc base tumor diameter may not precisely reflect true tumor burden therefore investigate whether preoperative tumor volume may accurately reflect tumor burden predict prognosis patient n ptc preoperative tumor diameter material method retrospectively review datum patient n ptc exclusion total patient ultimately include tumor volume v calculate patient use preoperative ultrasonography patient group accord tumor diameter vs b tumor volume v vs v b recurrence free survival rfs rate compare group result mean follow time month cohort experience rfs optimal volume cut define cm no difference rfs rate b group age v v b group year age however year old patient v b group significantly poor rfs rate v group result confirm multivariate analysis conclusion result indicate preoperative tumor volume may useful predict prognosis tumor diameter year old patient n ptc familial syndrome associate thyroid cancer era personalize medicine background good differentiate thyroid cancer account thyroid malignancy patient familial disease compare patient medullary thyroid cancer mtc familial form however account patient thyroid cancer case familial thyroid cancer nonmedullary nmftc show present familial cancer syndrome familial adenomatous polyposis cowden syndrome carney complex pendred syndrome werner syndrome review discuss contemporary management patient familial syndrome associate thyroid cancer base individual risk develope thyroid cancer summary progress genetic familial thyroid cancer patient mtc mutation patient isolate nmftc not good define mtc likely autosomal dominant reduce penetrance patient familial syndrome likely susceptibility gene increase risk thyroid cancer patient familial syndrome nmftc papillary thyroid carcinoma suggest specific gene papillary thyroid carcinoma may also present many case patient know familial syndrome define risk thyroid cancer conclusion patient familial syndrome associate thyroid cancer individually categorize base syndrome risk develope thyroid cancer clinician must also knowledgeable recognize possibility underlie familial syndrome patient present thyroid cancer childhood thyroid cancer belarus background circulate cell free tumor dna ctdna plasma promise noninvasive instrument cancer monitor detection braf v e ctdna patient papillary thyroid carcinoma ptc may represent indicator tumor aggressiveness progression method eighty three plasma sample collect patient thyroid nodule undergo surgery patient ptc cause distant metastasis total ptcs group evaluate braf mutation tumor tissue ctdna plasma sample real time polymerase chain reaction pcr digital pcr result ptcs braf v e mutate correspond ctdna negative use technique conclusion although highly sensitive technique use study circulate braf v e allele never detect plasma patient ptc therefore result raise question clinical usefulness braf v e analysis ctdna patient ptc preoperative assessment extrathyroidal extension papillary thyroid carcinoma ultrasound magnetic resonance image comparative study purpose purpose study assess compare diagnostic performance preoperative ultrasonography us magnetic resonance image mri predict extrathyroidal extension ete patient papillary thyroid carcinoma ptc material method retrospective study approve institutional review board preoperative us mri perform patient undergo surgery ptc may december us mri feature ete case retrospectively independently investigate two radiologist diagnostic performance us mri include sensitivity specificity positive predictive value ppv negative predictive value npv ete accuracy predict ete analyze result high sensitivity npv predict minimal ete observe us respectively compare mri respectively p p respectively meanwhile mri show high sensitivity us assess extensive ete p mri also show significantly high specificity ppv us assess overall ete p p respectively conclusion preoperative us use \\ufeff1 line predict minimal ete mri add extensive ete assessment compare us mri high specificity ppv detect overall ete ptc role laryngectomy locally advance thyroid carcinoma review case locally advance disease larynx invasion challenge surgeon laryngectomy almost never necessary thyroid carcinoma aim study review clinical outcome patient locally advance thyroid carcinoma invade larynx undergo laryngectomy case series patient treat tertiary care hospital review datum type operation method reconstruction complication overall survival patient operate larynx invasion present female mean age year besides total thyroidectomy neck dissection four patient undergo total pharyngolaryngectomy total laryngectomy one diagnosis poorly differentiate thyroid cancer radioiodine scan thyrotropin alfa stimulation background constitutively active thyrotropin receptor tshr mutation common etiology non autoimmune hyperthyroidism nah thus far functionality mutation test vitro vivo model lack method understand pathophysiology nah patient derive constitutively active tshr h mutation introduce murine tshr homologous recombination result model subclinical overt hyperthyroidism observe depend age sex genotype homozygous mouse present hyperthyroidism two month age heterozygous animal show suppress thyrotropin interestingly six month age thyroid hormone concentration mutant mouse analogous wild type mouse show colloid goiter flatten thyrocytes strikingly one year age nearly homozygous mouse present large papillary thyroid carcinoma mechanistically papillary thyroid carcinoma phenotype associate overactive thyroid strongly increase stainings proliferation perk treatment thyroid cancer introduction papillary thyroid cancer ptc common endocrine malignancy represent thyroid cancer case manifest age estimate incidence case per people child diagnose advance stage disease good therapeutic response low mortality objective present four family case ptc discuss particular characteristic importance early diagnosis case report family member affect family papillary thyroid carcinoma present pediatric case manifest direct member adult case diagnose therefore pediatric patient early detect despite timely treatment disease advance time diagnosis pediatric case female male average age year old diagnosis discussion family variety papillary thyroid carcinoma direct member affect represent papillary cancer transmit autosomal dominant inheritance incomplete penetrance variable expressivity occur young age sporadic type aggressive great local invasion recurrence lymphatic metastasis associate benign thyroid disease often multifocal conclusion family papillary thyroid cancer disease wrong prognosis sporadic variety therefore high index suspicion require affect family early diagnosis treatment mtor protein target thyroid cancer introduction mammalian target rapamycin mtor protein downstream effector phosphatidilinositol kinase pi k akt pathway regulate not cell proliferation viability also iodide uptake thyroid cell genetic alteration pi k akt mtor pathway common thyroid cancer progression thus protein attractive target cancer therapy far specific mtor inhibitor rapamycin analog develope study anti cancer agent area cover review discuss evidence justify potential use mtor signal pathway inhibitor therapeutic agent thyroid cancer expert opinion near future mtor target drug may represent new approach therapy thyroid cancer patient rapamycin analog already develope currently clinically test besides antiproliferative action mtor inhibition stimulatory effect thyroid iodide uptake also useful treatment recurrent thyroid cancer therefore rapamycin analog able increase iodide uptake thyroid cancer either alone combination agent represent new approach treatment thyroid cancer may possibly improve treatment patient radioiodine therapy not effective use recombinant human thyrotropin rhtsh management differentiate thyroid cancer article focus conventional surgical management thyroid cancer review long stand good accept main principle practice also cover new controversy technique conventional thyroidectomy include change indication thyroidectomy intraoperative management recurrent superior laryngeal nerve parathyroid gland extent thyroidectomy importance outcome measurement quality improvement somatostatin role thyroid cancer somatostatin neuropeptide exert downregulatory effect various physiological process somatostatin analogue use image management various tumour type role thyroid cancer not yet fully elucidate systematic review literature use keyword thyroid cancer somatostatin reveal reference paper summarize current knowledge role somatostatin thyroid cancer assess future potential prognostic value clinical lymph node metastasis macroscopic extrathyroid extension papillary thyroid carcinoma papillary thyroid carcinoma ptc macroscopic extrathyroid extension ex clinical node metastasis n prominent prognostic factor ex divide two grade uicc tnm classification minimal massive ex massive ex significantly affect patient prognosis whereas minimal ex little prognostic value n also divide two grade tnm classification n n b depend location metastasis n b grade high n however massive ex n positive ptc include patient wide range biological characteristic prognosis depend degree ex n clinicopathological feature age gender tumor size also influence prognosis evaluation biological characteristic ptc patient ex n consider degree relationship ex n clinicopathological feature value technetium scintigraphy iodine uptake measurement follow differentiate thyroid cancer measurement serum thyroglobulin tg level whole body scintigraphy wbs use follow patient differentiate thyroid cancer dtc study design evaluate significance persistent uptake thyroid bed patient dtc follow surgery radioactive iodine ablation tc thyroid scintigraphy t thyroid uptake iu also perform determine clinical impact patient management patient method sixty two non metastatic patient man woman mean age year range undergo surgical thyroidectomy dtc evaluate prospectively patient undergo technetium iodine scintigraphy although serum tg level measure patient iu available result tg value range ng ml median ng ml patient hypothyroid state wbs detect residual tissue neck patient however t positive uptake thyroid bed range median twelve patient positive negative t uptake value p iu value patient not uptake thyroid bed t whereas iu patient neck uptake t p conclusion result study demonstrate concordance t depend iu level suspension replacement therapy measurement iu t considerable value evaluate patient response therapy substantially reduce need repetitive radioiodine scan unnecessary treatment dose patient undetectable tg value effect raw vegetable fruit intake thyroid cancer risk among woman thyroid cancer common cancer among korean woman however datum dietary factor relate thyroid cancer risk objective present study evaluate association raw vegetable fruit intake thyroid cancer case control study include histologically confirm malignant thyroid cancer case benign case control not nodule thyroid ultrasonography match case age year food nutrient intake estimate use quantitative ffq item conditional logistic regression analysis use obtain correspond ci intake total vegetable not associate malignant thyroid cancer inversely associate benign case high raw vegetable intake inversely associate thyroid cancer risk malignant benign case p trend malignant benign case among fruit persimmon intake inverse association thyroid cancer risk malignant benign case p trend malignant case p trend benign case tangerine intake inverse association malignant case p trend frequency consumption raw vegetable persimmon also consistent inverse association malignant benign case result suggest high consumption raw vegetable persimmon tangerine may decrease thyroid cancer risk help prevent early stage thyroid cancer adolescent mid life diet subsequent risk thyroid cancer nih aarp diet health study although thyroid cancer suspect nutritional etiology prospective study examine relationship diet thyroid cancer lack nih aarp diet health study participant age year complete item food frequency questionnaire diet age year adolescence year baseline mid life median year follow individual man woman diagnose thyroid cancer multivariable adjust hazard ratio hr confidence interval cis calculate intake food food group compare high low quartile adolescent intake chicken turkey hr ci thyroid cancer diagnosis treatment prognosis review marshfield clinic experience natural killer activity thyroid cancer patient study cytotoxic capacity find elevate tumourless patient case highly differentiate histologic type compare result patient metastasis anaplastic tumour value patient progressive phase disease significantly wrong compare healthy control no connection find natural killer activity time elapse since operation new therapeutic approach metastatic thyroid carcinoma treatment metastatic differentiate thyroid cancer dtc include use radioiodine suppressive thyroid hormone treatment 3 patient distant metastasis radioiodine uptake young year small metastasis good differentiate thyroid tumour cure radioiodine treatment patient no effective treatment modality however recent availability molecularly target treatment lead change treatment strategy dtc patient distant metastasis especially resistant radioiodine treatment survival potential patient papillary carcinoma thyroid gland hungary typically benign occasionally rapid fatal clinical course papillary thyroid cancer raise need individual survival probability estimation tailor treatment strategy exclusively give patient retrospective study perform papillary thyroid cancer patient mean follow time year establish clinical database uni multivariate analysis survival probability relate prognostic factor kaplan meier product limit method cox regression precise prognosis estimation next step important clinical event investigate survival function patient calculate basis markov renewal model basic concept approach follow patient individual disease course besides initial clinical category affect special event e g internal covariate local regional distant relapse patient experience throughout course disease supposition event cause specific death influence biological process parameter transient survival probability characterize speed course disease sequence clinical event determine individual survival curve patient calculate use former parameter independent significant clinical variable summation result overall cause specific survival function valid entire group patient age distant metastasis presentation extent surgical intervention primary tumour size dosage external irradiation degree tsh suppression prove statistically significant sequence independent prognostic factor concern cause specific survival multivariate study follow patient undergo local regional distant relapse thyroid cancer relate death use six independent clinical variable parameter relate interrelation four clinical event mean cause specific survival probability determine year respectively year individual survival probability prediction study case show no cancer relate death occur low risk group tumour relate death considerable high risk group death intermediate risk group construct survival function permit prediction individual survival probability extra study case give treatment condition within give population thus afford rationale individualization treatment papillary thyroid cancer patient cancer thyroid review case objective evaluate incidence thyroid carcinoma patient operate grave disease identify criterium may predict malignancy develop practical approach determine extensiveness thyroidectomy patient method retrospective study patient undergo thyroidectomy grave disease result patient undergo subtotal thyroidectomy grave disease period cancer thyroid nontoxic goiters voltage gate sodium channel subunit encode scn b scn b gene demonstrate important multifunctional signal molecule modulate cellular process cell adhesion cell migration study aim explore expression profile scn b papillary thyroid cancer ptc prognostic value term recurrence free survival rfs classical ptc addition also examine potential effect dna methylation expression retrospective study perform use datum available large database include gene expression omnibus geo dataset cancer genome atla tcga thyroid cancer thca result show scn b downregulated rna protein level ptc compare normal thyroid tissue preserve scn b expression independent indicator favorable rfs patient classical ptc no matt categorical variable hr ci p continuous variable hr ci p methylation status one cpg site chr scn b dna moderately negative correlation scn b expression ptc case pearson r classical ptc case pearson r comparison scn b dna copy numb alteration cnas not frequent may not influence mrna expression addition no somatic mutation find scn b dna base finding infer preserve scn b expression may independently predict favorable rfs classical ptc expression may suppress dna hypermethylation little likely influence dna cnas mutation identification validation potential target gene papillary thyroid cancer thyroid cancer tc one common endocrine malignancy incidence tc almost triple past three decade increase may partially overdiagnosis approximately cytological indeterminate thyroid nodule not evaluate mean fine needle aspiration present study aim identify potential crucial gene ptc provide new sight improve diagnosis thyroid lesion future study adopt integrate analysis gene expression profile ptc patient adjacent normal control datum cancer genome atla database tcga differentially express gene deg screen use limma package r software connectivity map cmap use predict potential drug ptc string cytoscape software employ perform go kegg pathway enrichment analysis module analysis deg rt qpcr use validate hub gene screen use module analysis total deg screen include regulate regulate deg go analysis show deg primary enrich cell adhesion extracellular region glycosaminoglycan bind kegg pathway analysis reveal deg primarily participate ecm receptor interaction ppi network module analysis identify seven hub gene include fn serpina ecm mmrn pro cfd timp rt qpcr result validate expression level seven hub gene consistent bioinformatics analysis finding identify seven hub gene may helpful development gene panel thyroid nodule diagnosis bilateral breast metastasis medullary thyroid cancer objective determine characteristic long term outcome radiation induce thyroid cancer child design retrospective review cohort irradiate patient receive childhood radiation treatment head neck area hospital patient forty one child young year thyroid cancer develope adult thyroid cancer develope case diagnose follow median year result child present clinically palpable lymph node often adult vs p recurrence vs p despite frequent recurrence one patient adult die thyroid cancer seventy percent recurrence occur \\ufeff1 year follow recurrence continue year adult previously identify factor predict risk recurrence none can identify child conclusion presentation relatively good outcome radiation induce thyroid cancer child similar nonirradiated child frequent late recurrence call lifelong follow crank shape sternotomy upper mediastinal lymph node dissection patient differentiate thyroid cancer describe modification reverse shape sternotomy conventional technique consist limit upper sternotomy transverse division sternum modification involve shift transverse division line one costal space right leave side perfect apposition divide upper low sternum technique use patient thyroid cancer mediastinal lymph node metastasis mediastinal tumor certain cardiac disorder efficacy ultrasound guide percutaneous ethanol injection treatment patient limit numb metastatic cervical lymph node papillary thyroid carcinoma context repeat neck exploration difficult task patient recurrent metastatic cervical lymph node papillary thyroid carcinoma ptc objective aim retrospective study assess efficacy ultrasound us guide percutaneous ethanol injection pei treatment metastatic cervical lymph node ptc material method sixty nine patient previously undergo thyroidectomy ptc select inclusion however three patient late exclude due lack follow lymph node status determine us guide fine needle aspiration biopsy raise level thyroglobulin washout cytological needle guide us ml ethanol inject metastatic lymph node result three patient eight metastatic lymph node total reassign surgery due progression multiple new metastasis leave patient neck lymph node include mean observation time month range total metastatic lymph node respond pei treatment completely nine incompletely two not respond four progress two lymph node previously consider successfully treat show evidence malignancy follow no significant side effect report conclusion us guide pei treatment metastatic lymph node seem excellent alternative surgery patient limit numb neck metastasis ptc procedure replace berry pick surgery primary endobronchial histiocytic sarcoma case papillary carcinoma thyroid complex clinical scenario histiocytic sarcoma rare malignant neoplasm show histiocytic differentiation document case year old man present cough breathlessness follow subtotal thyroidectomy infiltrate papillary thyroid carcinoma endobronchial growth see endoscopy histopathologic examination reveal neoplasm histiocytic lineage positivity leucocyte common antigen vimentin cd cd cd ro well knowledge primary endobronchial histiocytic sarcoma association infiltrate papillary thyroid carcinoma not report literature far case emphasize importance clinicopathologic radiologic correlation resolve difficult diagnostic dilemma pediatric thyroid cancer incidence mortality trend unite state importance incidence thyroid cancer increase annually increase often think attributable overdiagnosis adult previous study report annual increase incidence pediatric thyroid cancer however analysis limit period perform linear fashion not account change incidence trend time objective analyze trend pediatric thyroid cancer incidence base demographic tumor characteristic diagnosis design set participant cross sectional study include individual young year diagnosis thyroid cancer surveillance epidemiology end result seer database case thyroid cancer identify use international classification disease oncology 3 edition categorize histologic type stage tumor size main outcome measure annual percent change apc incidence rate calculate use joinpoint regression analysis result among patient include analysis female white patient age year overall incidence rate thyroid cancer increase annually per person year per person year incidence rate gradually increase apc ci markedly increase apc ci incidence rate large tumor mm gradually increase apc ci markedly increase apc ci rate not significantly different incidence rate small mm tumor incidence rate regionally extend thyroid cancer gradually increase apc ci markedly increase apc ci rate not significantly different incidence rate localize disease conclusion relevance incidence rate pediatric thyroid cancer increase rapidly finding suggest may co occur increase thyroid cancer pediatric population addition enhance detection increase incidence thyroid nodule thyroid cancer increase detection subclinical reservoir justify associate anxiety treatment incidence thyroid cancer increase last decade subject debate regard whether incidence reflective well diagnostic technique therefore well detection reflection true increase incidence increase incidence clearly manifest exponential increase diagnosis micropapillary thyroid carcinoma article review diagnosis thyroid cancer dilemma face clinician management micropapillary thyroid carcinoma advance molecular diagnostics use assist decision make process consider possibility overtreatment relatively indolent disease propose little aggressive management plan appropriate clinical scenario thyroid cancer pacific woman new zealand aim describe trend incidence rate thyroid cancer new zealand reliability fine needle aspiration patient familial nonmedullary thyroid cancer case control study describe often thyroid cancer occult cancer diagnose not diagnose fine needle aspiration fna patient thyroid nodule family history nonmedullary thyroid cancer fnmtc hypothesis patient thyroid nodule family history fnmtc seem similar patient thyroid nodule history exposure low dose therapeutic radiation report multifocal thyroid neoplasm malignant tumor common cytological examination may therefore little accurate patient family fnmtc examine histologically preoperative cytological examination positive cytology examination define biopsy document thyroid cancer interpret false negative study benign diagnosis make thyroid cancer present anywhere within thyroid include area sample not sample fna not palpable preoperatively randomize control group match age gender contain patient papillary thyroid cancer without familial disease study group patient treat total thyroidectomy include neck dissection thyroid lobectomy final histological examination patient study group multiple nodule thyroid cancer thyroid cancer diagnose fna patient false negative biopsy due sample error thyroid cancer not index nodule versus false negative biopsy control group two patient study group benign nodule accurately diagnose patient false negative biopsy history fnmtc cancer situate one small nodule one cancer occult cm one 3 patient study group history radiation irradiate group single nodule multiple nodule control group patient also history radiation irradiate group single nodule multiple nodule conclusion reliability fna patient fnmtc appear little accurate patient high incidence multifocal thyroid cancer coexistence benign nodule patient thyroid nodule family history thyroid cancer likely thyroid cancer also coexistent benign nodule must follow closely treat total near total thyroidectomy detection metastatic thyroid carcinoma administration therapeutic dose iodine patient thyroid cancer describe whose metastasis detect administration large therapeutic dose iodine suggest high dose iodine may permit diagnosis metastatic lesion not otherwise detect phenomenon may explain improve count statistic occur use high dose isotope case exceedingly high dose iodine may necessary successful tumor ablation medullary thyroid cancer epidemiological pattern factor contribute recurrence metastasis introduction medullary thyroid carcinoma mtc neuroendocrine thyroid carcinoma parafollicular c cell differentiation occur either sporadic hereditary form surgery still curative treatment efficacy chemotherapy radiotherapy poor method retrospective study patient treat surgically mtc oncology centre mansoura university january february result mean age diagnosis year median pathological size cm multifocal disease find patient extrathyroid extension case twenty patient pathologically node positive median numb positive lymph node four seven case metastatic diagnosis local recurrence occur six individual distant recurrence occur one median time surgery local recurrence month estimate mean disease free survival month disease free survival significantly relate age metastasis side nodal spread conclusion study cohort disease occur predominantly woman young patient age distant metastasis nodal spread significant prognostic factor study also demonstrate prognosis not affect nodal involvement also side involvement role hemithyroidectomy node negative unifocal disease small tumour size warrant investigation death relate pulmonary metastasis patient differentiate thyroid cancer objective purpose present study investigate predictive factor short disease specific survival patient pulmonary disease secondary differentiate thyroid cancer dtc method retrospective cohort study conduct year period include patient pulmonary disease secondary dtc follow among patient die disease dedifferentiation characteristic identify pathological examination metastatic disease lymph node distant metastasis define abrupt transformation good differentiate tumor high grade morphology lack original distinct histologic characteristic result tumor dedifferentiation mark cellular aberration radioiodine rai therapy resistance occur patient four die due pulmonary progression median survival group month compare month patient without dedifferentiation cumulative disease specific survival patient dedifferentiation follow versus among case without condition p log rank test moreover dedifferentiation independently associate short disease specific survival hazard ratio hr confidence interval ci p cox regression model age year hr ci p male sex hr ci p conclusion dtc patient pulmonary disease exhibit short disease specific survival particularly develope tumor dedifferentiation patient require special attention follow abbreviation ci confidence interval dtc differentiate thyroid cancer ftc follicular thyroid carcinoma hr hazard ratio iqr interquartile range ln lymph node lr likelihood ratio ptc papillary thyroid carcinoma rai radioiodine ptnm pathologic tumor node metastasis stage system prognostic factor recurrence locally advance differentiate thyroid cancer background objective present treatment outcome prognostic factor surgical management locally advance differentiate thyroid cancer dtc method retrospective review patient single tertiary referral institution do clinical pathology characteristic analyze investigate prognosticators base primary endpoint locoregional recurrence alone lrr total recurrence lrr distant metastasis dm recurrence free survival result recurrent laryngeal nerve n trachea n commonly invade organ tumor mean follow month lrr occur patient dm detect patient develope lrr dm multivariate analysis r resection positive margin pn b stage increase risk lrr fold ci p p respectively also increase risk total recurrence fold ci p ci p respectively patient pn b stage show well lrr free survival pn n stage p conclusion along careful preoperative evaluation extent primary neck disease obtain negative resection margin aggressive neck management critical improve oncologic outcome locally advance dtc thiazolidinediones antiblastics primary human anaplastic thyroid cancer cell objective no study evaluate antiproliferative effect thiazolidinediones antiblastics primary culture human anaplastic thyroid cancer cell design primary anaplastic cell proliferation evaluate incubation increase concentration rosiglitazone pioglitazone antiblastics bleomycin cisplatin gemcitabine proliferation assay management good differentiate thyroid cancer perspective head neck surgical oncologist objective review terminology controversy regard performance prophylactic lymph node dissection patient without evidence suggestive pathologic adenopathy method terminology lymph node level neck chest issue regard lymph node dissection review addition difference lymph node review discuss result management lymph node disease process become contentious aspect surgical decision make due ambiguity prognostic significance prevalence nodal metastasis early primary tumor performance prophylactic central compartment node dissection not technically difficult therapeutic node dissection clinically significant node encounter therefore reasonable consider technique important adjunct total thyroidectomy purpose enhance disease stage prevention nodal recurrence avoidance enter previously operate central compartment recent study review discuss detail literature regard prognostic significance extracapsular spread lymph node also present conclusion morphologic characteristic metastatic lymph node thyroid cancer vary greatly however report difference lack presence extracapsular extension lymph node prognostic significance clinician aware variation impact may recurrence risk disease specific survival analysis pattern occurrence thyroid carcinoma introduction ongoing discussion find medical literature reason change thyroid carcinoma incidence pattern last decade objective analyze clinical pathological characteristic thyroid carcinoma case decade method cross sectional study historical cohort medical record thyroid cancer case single center review patient include microcarcinoma case select qualitative analysis phase medical record review well understand thyroid nodule thyroid cancer diagnosis process result increase proportion case thyroid cancer diagnosis observe throughout decade new case predominantly tumor little cm histopathological sign low aggressiveness increase proportion case malignant cytological result among microcarcinomas conclusion trend increase thyroidectomy due cancer institution proportional increment case histopathological characteristic indicative early disease among microcarcinomas increase group represent cancer case not incidentally diagnose relate enhancement preoperative diagnostic method microrna prognostic marker diagnosis lymph node metastasis papillary thyroid carcinoma background objective investigate diagnostic potential microrna mir papillary thyroid carcinoma ptc diagnosis lymph node ln metastasis formalin fix paraffin embed ffpe tissue specimen correspond ptc tumor n normal counterpart normal tissue adjacent tumor nat n along serum ptc patient malignant tumor n benign lesion n analyze expression mir real time pcr method usefulness mir expression prognostic marker diagnosis ptc malignancy evaluate receiver operate curve roc report compare nat level mir ffpe tissue various stage ptc patient n significantly low mean sem vs p receiver operate curve roc analysis reveal area curve auc suggest mir expression reliable tissue biomarker ptc malignancy depth analysis specimen reveal mir level significantly low ptc patient lymph node ln metastasis without ln metastasis vs p calculate auc support notion mir expression also good indicator ptc lymph node involvement analysis serum cohort ptc patient indicate mir level patient malignant lesion n significantly low vs p benign one n parallel analysis serum mir level patient ln metastasis also show significantly low compare without ln metastasis vs p result roc analysis reveal auc malignancy lymph node involvement respectively suggest mir modest blood base biomarker ptc malignancy lymph node metastasis conclusion conclude mir expression reliable ffpe tissue biomarker ptc malignancy may potential become noninvasive blood base biomarker ptc diagnosis evaluation ln status overdiagnosis thyroid cancer not ethical issue pathologist good radiologist clinician common endocrine malignancy thyroid cancer researcher make great deal progress decipher molecular mechanism recent year many molecular change observe thyroid cancer use biomarker diagnosis prognosis therapeutic target treatment micrornas mirnas important part biological metabolic pathway regulation developmental stage signal transduction cell maintenance differentiation therefore dysregulation expose individual malignancy prove mirna expression dysregulated different type tumor like thyroid cancer cause tumor initiation progression paper review available datum mirna dysregulation different thyroid tumor include papillary follicular anaplastic medullary thyroid carcinoma aim introduce last update mirnas thyroid cancer relation radical neck dissection advance thyroid cancer try ascertain whether total thyroidectomy radical neck dissection offer survival recurrency advantage thyroid cancer january september rd surgical unit sf spiridon hospital ia operation perform malign thyroid disorder perform papillary foliculary cancer diagnosis confirm hystopathological examination patient medium age extreme year woman great proportion expect sex ratio f total thyroidectomy radical modify radical neck dissection perform immediate bleeding need reoperation haemostasis unilateral recurrent laryngeal nerve injury late complication case recurrency \\ufeff1 year total thyroidectomy radical neck dissection become ellective method advance thyroid cancer well result papillary cancer female age response treatment highly predictable cn patient papillary thyroid carcinoma background involvement macrometastatic lymph node recognize independent predictor adverse course papillary thyroid cancer ptc patient clinicopathological variable associate disease persistence recurrence clinically node negative cn disease not good define indication prophylactic central neck dissection pcnd patient group remain unclear good aim investigate risk factor associate short long term persistence recurrence ptc patient cn disease presentation compare patient ptc cervical lymph node involvement n response initial treatment subgroup patient method datum collect retrospectively consecutive patient ptc cn disease n disease treat follow single tertiary medical center pcnd not routinely perform ptc result compare patient n disease patient cn disease significantly small tumor low rate multifocality little extrathyroidal extension persistency rate year cn group n group last follow respectively p time point within cn group persistent disease year n significantly large tumor high stimulate thyroglobulin six structural residual disease four lymph node metastasis patient persistent disease initially treat total thyroidectomy radioiodine recurrence occur three patient year follow eight patient cn persistent disease three biochemical high american joint committee cancer stage extrathyroidal extension factor predict disease persistence last follow group conclusion patient cn ptc no distant metastasis usually disease free thyroidectomy without radioactive iodine not need intervention initial stage patient valid prognostic factor disease outcome macroscopic extranodal invasion risk factor tumor recurrence papillary thyroid cancer papillary thyroid cancer patient upon curative operation perform investigate clarify whether not macroscopic extranodal invasion risk factor recurrence divide three group group patient whose primary tumor show extrathyroidal invasion n group b whose metastatic lymph node show extranodal invasion n group c show extrathyroidal extranodal invasion n recurrence significantly high group b c group p conclude macroscopic extranodal invasion adjacent structure risk factor recurrence patient papillary thyroid cancer thyroid cancer incidence among liquidator chernobyl accident absence dependence radiation risk external radiation dose increase thyroid cancer incidence rate among child live chernobyl contaminate territory belarus russia ukraine widely accept current work deal thyroid cancer incidence cohort liquidator person live region russia north west volgo vyatsky central chernozemny povolzhsky north caucasus urals period total thyroid cancer case detect cohort find statistically significant increase thyroid cancer incidence rate liquidator compare baseline male population russia level sir ci demonstrate no dependence incidence rate due external radiation exposure err gy ci state morbidity goiter thyroid cancer diagnosis treatment papillary thyroid cancer ptc account thyroid malignancy tall cell variant tcv rare aggressive histotype ptc perform good differentiate carcinoma thyroid cribriform morular variant papillary thyroid carcinoma cmvptc usually inherit malignancy may present indicator familial adenomatous polyposis syndrome although may occasionally sporadic know cmvptc mutation include adenomatous polyposis coli apc catenin ctnnb gene despite malignant classification cmvptc consider good differentiate thyroid tumor generally good behavior contrast poorly differentiate thyroid carcinoma aggressive tumor report case cmvptc poorly differentiate feature young female without phenotypic feature familial adenomatous polyposis know germline alteration apc gene high throughput sequence show germline chromosome q deletion encompass apc gene component additional unique genetic alteration somatic component single nucleotide substitution c g nm locate one base pair downstream exon apc gene identify cmvptc component pathogenic frameshift deletion exon apc c del p ser argfs nm identify poorly differentiate thyroid carcinoma component no cancer associate gene identify technique case represent rare phenomenon poorly differentiate feature association cmvptc knowledge report poorly differentiate feature arise association inherit cmvptc value freeze section examination determine extent thyroid surgery patient indeterminate fine needle aspiration cytology objective determine usefulness intraoperative freeze section fs examination establish diagnosis thyroid cancer patient undergo thyroidectomy nodule indeterminate cytological feature determine cost effectiveness fs examination situation design retrospective medical record review result fine needle aspiration biopsy fnabs fs examination final pathologic examination compare cost effectiveness analysis routine fs examination compare cost additional surgical procedure perform set private surgical practice medical school affiliate teach hospital patient record patient undergo thyroidectomy january september review patient dominant thyroid nodule fnab result either highly suggestive papillary cancer indeterminate study result patient fnab result highly suggestive papillary cancer cancer accord final pathologic examination result diagnosis cancer make fs examination result patient remain patient whose fnab result indeterminate thyroid cancer malignancy diagnose fs examination result patient fs examination not perform patient would require 2 operation complete total thyroidectomy cost saving routine fs examination patient indeterminate fnab result us dollar per patient conclusion routine performance fs examination patient thyroid nodule indeterminate cytological feature cost effective way avoid 2 surgical procedure total thyroidectomy indicate patient fnab result highly suggestive papillary cancer fs examination not useful patient definitive operation base result fnab contemporary surgical management non medullary thyroid malignancy article review clinical feature good differentiate thyroid cancer examine various tool use evaluation patient primary recurrent setting contemporary treatment strategy emphasis place surgical treatment revisit non surgical modality include use radioactive iodine external beam radiotherapy chemotherapy discuss pregnancy risk factor thyroid cancer progression purpose review current review evaluate impact pregnancy woman thyroid cancer three different clinical situation newly diagnose differentiate thyroid cancer dtc active surveillance papillary thyroid microcarcinomas pmcs previously treat dtc recent finding recent pregnancy not associate high risk pathological feature dtc woman know pmcs active surveillance pregnancy not increase risk disease progression thus defer surgery newly diagnose dtc know pmcs delivery safe mother unborn child woman previously treat dtc plan pregnancy response therapy status excellent guide predict pregnancy associate disease progression recurrence summary clinical study consistently show pregnancy not associate significant disease progression newly diagnose thyroid cancer pmcs active surveillance previously treat dtc interaction braf induce ets factor mutant tert promoter papillary thyroid cancer synergistic effect brafv e tert promoter mutation poor clinical outcome papillary thyroid cancer ptc demonstrate potential mechanism phenomenon propose mapk pathway activation brafv e mutation may upregulate e twenty six ets transcription factor increase tert expression bind ets bind site generate tert promoter mutation however not yet fully prove article provide transcriptomic insight interaction brafv e tert promoter mutation mediate ets factor ptc rna sequence datum ptcs cancer genome atla ptcs institute analyze gene expression change relate molecular pathway result transcriptomic analysis validate vitro experiment tert mrna expression increase coexistence brafv e tert promoter mutation fold change q value vs no mutation ets family transcription factor etv etv etv upregulated brafv e mapk pathway activation brafv e induce ets factor selectively bind mutant tert promoter molecular pathway activate brafv e augment add tert promoter mutation pathway relate immune response adhesion molecule upregulated tert expression mechanism synergistic effect brafv e tert promoter mutation cancer invasiveness progression ptc may explain increase tert expression may result braf induce upregulation several ets transcription factor seom clinical guideline treatment thyroid cancer although thyroid cancer represent little malignant tumour increase incidence detect recent year appearance development new drug target specific molecular target attract attention doctor involve pathology especially medical oncologist reason important critical point treatment may substantially change establish agree update guideline guideline incorporate newly develope strategy although still preliminary evidence level surely important role especially relapse refractory tumour unsuitable surgical radio iodine treatment particular histological molecular feature tumour must take account order optimise therapeutic approach risk factor outcome postoperative recurrent good differentiate thyroid cancer single institution year experience objective identify risk factor outcome recurrent good differentiate thyroid cancer study design retrospective case control analysis set tertiary care academic center nashville tennessee subject method single center analysis review patient undergo initial surgical management good differentiate thyroid carcinoma patient dichotomized without recurrent good differentiate thyroid cancer demographic clinicopathologic risk factor carefully review univariate multiple regression survival analysis use evaluate predictor recurrence result thirty eight patient receive initial surgical intervention good differentiate thyroid carcinoma institution recur average time recurrence month male sex tumor size multifocality extrathyroidal extension lymphovascular invasion numb positive lymph node low lymph node yield significantly associate locoregional recurrence p multiple regression analysis show extrathyroidal extension numb positive lymph node low lymph node yield independent factor predictive posttreatment recurrence p metastatic lymph node ratio ratio positive lymph node extract lymph node yield associate increase risk recurrence p decrease year recurrence free survival p conclusion extrathyroidal extension numb positive lymph node low lymph node yield independent clinicopathologic risk factor postoperative recurrence good differentiate thyroid cancer metastatic lymph node ratio uncommonly use important prognosticator recurrence patient metastatic lymph node ratio counsel increase risk recurrence undergo close surveillance follow surgery histological perspective effect tumor associate macrophage tumor microenvironment surround papillary thyroid carcinoma tumor associate macrophage tam one noticeable element tumor microenvironment present study investigate relationship density cd immunolabeled like tam histological property tumor microenvironment clinipathological feature patient papillary thyroid carcinoma ptc percentage tam high tumor significant lymphocytic tumor response p tumor significant degree stromal tumor response p infiltrative tumor border p conventional variant papillary carcinoma p patient autoantibody thyroid peroxidase p tumor associate lymphocytic thyroiditis low number tam p conclusion \\ufeff1 time present study attempt establish full assessment interaction cd express like tam triad primary tumor tumor microenvironment tumor behavior marker autoimmunity thus alternatively polarize macrophage may act tumor progression dissemination accord various product may order tumor cell neighbor immune cell molecular study may reveal role various tumor may improve therapy strategy target tam various malignant tumor include ptcs low recurrence rate cohort differentiate thyroid carcinoma patient referral center experience background trend epidemiological profile differentiate thyroid cancer dtc shift disease spectrum study aim evaluate recurrence rate identify factor relate persistent disease contemporary cohort patient dtc method cohort dtc patient submit total thyroidectomy follow referral center include study disease free define no clinical image biochemical evidence tumor recurrence define evidence disease patient previously classify disease free result total patient include mean age diagnosis year female papillary thyroid cancer account case median tumor size cm lymph node involvement distant metastasis disease status initial therapy available patient disease free persistent disease biochemical structural disease multivariate model analysis variable male sex lateral lymph nodal involvement distant metastasis ata high risk classification independent prognostic factor persist disease four year follow two eight year patient classify disease free remain disease remission status patient recurrent disease eight present biochemical two cervical structural disease conclusion majority dtc patient consider disease free initial treatment remain status long term follow datum suggest little intensive follow may apply patient epithelial mesenchymal transition thyroid cancer comprehensive review metastatic progression solid tumor thyroid cancer complex process involve various factor current understand role epithelial mesenchymal transition emt thyroid carcinoma suggest emt implicate progression follicular thyroid cancer ftc papillary thyroid cancer ptc poorly differentiate thyroid carcinoma pdtc anaplastic thyroid cancer atc accord literature initiation emt program thyroid epithelial cell elevate numb stem cell contribute recurrent metastatic disease emt process orchestrate complex network transcription factor growth factor signal cascade epigenetic modulation tumor milieu factor show dysregulated thyroid carcinoma therefore molecular interference restore expression tumor suppressor thwart overexpress oncogene hopeful therapeutic method improve treatment progressive disease review summarize recent finding emt thyroid cancer focus main audit management thyroid cancer district general hospital objective thyroid cancer common endocrine malignancy yet appear present infrequently endocrinologist large district general hospital management good differentiate thyroid cancer remain controversial wide variation clinical practice aim survey determine characteristic patient diagnose thyroid cancer whether deficiency exist management subject diagnose thyroid cancer five year period use standard care base upon long term outcome datum recently publish usa guideline design patient retrospective case note survey patient newly register thyroid cancer north staffordshire estimate total population result annual incidence thyroid cancer two per good differentiate tumour comprise medical record obtain new case total identify fifteen subject present surgical emergency receive palliative treatment poor outcome two patient present metastatic medullary thyroid carcinoma total thirty one patient present thyroid nodule refer electively either surgical n ent n endocrinology n outpatient good differentiate papillary n follicular n tumour thirteen patient surgical treatment thyroid cancer surgery treatment choice thyroid cancer often follow thyroid hormone control local residual tumor distant metastasis hundred sixty two patient thyroid disease undergo surgery division surgical oncology cancer institute genoa thirty case present no malignant hot thyroid nodule case cancer case pathological diagnosis papillary carcinoma ten case follicular carcinoma four medullary carcinoma case ten papillary carcinoma two follicular carcinoma one medullary carcinoma lesion multicentric datum suggest total thyroidectomy perform two step case not carry important post operative morbidity offer great potential cure case one patient die cancer radical surgery possible detect treat metastasis thyroid cancer child adolescent molecular genetic background thyroid cancer main endocrine malignancy incidence steadily grow alarm increase child adolescent population pediatric thyroid carcinoma differ adult one phenotype good genetic carcinoma tend clinically aggressive frequent local distant metastasis however long term prognosis well comparison adult thyroid cancer due rarity disease lack datum genetic change age group knowledge genetic background thyroid cancer child help precise diagnosis prognosis disease personalize treatment key word adolescent carcinoma gene genetic child mutation next generation sequence thyroid microrna modulate papillary thyroid cancer cell development regulate scai purpose intend evaluate expression mechanism human microrna immunohistochemical expression rbp lsd papillary thyroid carcinoma purpose investigate prognostic significance lsd rbp expression patient papillary thyroid carcinoma material method lsd rbp expression detect immunohistochemistry surgically resect sample thyroid adenoma papillary thyroid carcinoma paracancerous tissue result member histone demethylases lsd rbp localize mainly thyroid cell nucleus despite fact rbp lsd expression high papillary thyroid carcinoma paracancerous tissue u p u p thyroid adenoma u p u p not show us statistical correlation r p like lsd u p rbp expression little frequently paracancerous tissue thyroid adenoma u p neither lsd rbp expression significantly associate age gender stage status tumor size lymph node metastasis p conclusion lsd rbp good relate occurrence malignant transformation papillary thyroid carcinoma though positive expression lsd rbp use estimate potentiality thyroid carcinoma help adjuvant treatment lsd sensitive molecular marker rbp thyroid cancer diagnosis thyroid follicular neoplasm good indication endoscopic surgery endoscopic thyroidectomy safe feasible alternative compare conventional open thyroidectomy patient small thyroid cancer benign thyroid tumor however despite many advantage endoscopic surgery result unexpected complication recently author experience case follicular thyroid cancer recurrence develope around operative bed along port insertion site endoscopic thyroidectomy large follicular neoplasm author suggest small follicular neoplasm good indication endoscopic thyroidectomy large follicular neoplasm not view indicator endoscopic surgery possibility malignancy rupture manipulation ethical consideration counsel patient thyroid cancer surgery vs observation reply context papillary thyroid cancer ptc common endocrine malignancy comparison document recall history exposure diagnostic x ray information concern possible cancer risk attributable lifetime exposure diagnostic x ray come study x ray history ascertain interview questionnaire little know accuracy information author assess agreement medical x ray history obtain interview review medical record thyroid cancer case control study conduct sweden case control member prepay health plan unite state case control study substantial disagreement find number x ray examination report interview medical record indication relatively poor report among control particularly certain type x ray examination large number examination estimate risk associate exposure diagnostic x ray similar regardless whether interview medical record datum use even though ordinal dose classification base two source differ considerably population high frequency exposure spurious association number x ray examination estimate thyroid dose may arise difference recall however present datum report error case control seem largely nondifferential thyroglossal cyst primary site papillary thyroid carcinoma metastatic jugular lymph node chain primary clinical application f fdg pet ct fluorine label flurodeoxyglucose positron emission tomography compute tomography differentiate thyroid carcinoma identification active disease thyroglobulin tg positive ng ml whole body iodine scan negative patient impact fdg pet ct diagnosis surveillance cure progression free survival differentiate thyroid carcinoma patient remain see five main indication fdg pet ct thyroid cancer recommend revise american thyroid association guideline review aim provide complete picture pet image thyroid malignancy enumerate indication literature review review also highlight recent advance target molecular image currently differentiate thyroid cancer well image use conventional single photon emission compute tomography base radioiodine tracer although utility fdg pet good differentiate thyroid cancer patient iodine negative raise tg good establish evidence emerge advantage fdg pet ct histological type thyroid malignancy hurthle cell medullary anaplastic malignancy novel pet radiotracers iodine f dopa radiotoxicity therapy thyroid cancer assessment micronucleus assay b lymphocyte investigate cytologic radiation damage thyroid cancer therapy use micronucleus assay mna b lymphocyte exclusively oppose previous study mna lymphocyte subset use method study thyroid cancer patient treat gbq peripheral lymphocyte harvest b lymphocyte isolate immunomagnetic method assay frequency micronucleus result frequency micronucleus among b cell therapy significantly increase relative untreated control subject induce increase micronucleus frequency among b cell significantly great among lymphocyte conclusion compare mna lymphocyte mna among specifically b cell may sensitively detect cytologic radiation damage associate therapy thyroid cancer positron emission tomography thyroid emphasis thyroid cancer role positron emission tomography pet use f fluorodeoxyglucose fdg management thyroid cancer discuss important ensure patient relax uptake fdg tense active muscle neck larynx misinterpret metastasis major role pet patient stage disease uncertain usually result discordant negative scan positive serum thyroglobulin tg value pet identify source tg production patient pet scan negative good differentiate cancer retain ability trap iodine result flip flop negative pet positive radio iodine scan positive pet negative radioiodine scan pet also valuable identify source calcitonin production patient medullary thyroid cancer focal uptake see thyroid patient scan non thyroidal reason likelihood primary thyroid cancer high contrast diffuse uptake fdg thyroid usually result auto immune thyroid disorder national trend prevalence mortality rate thyroid cancer use datum ministry health peru introduction incidence thyroid cancer increase worldwide peru report describe national regional epidemiology thyroid cancer objective incidence thyroid cancer increase worldwide peru report describe national regional epidemiology thyroid cancer method descriptive study trend conduct secondary datum obtain public information source peru icd c code record evaluate age group year region age standardize prevalence period mortality period calculate region year study result period case thyroid cancer record age group high frequency year prevalence increase case per inhabitant period thyroid cancer thyroid disorder prior study suggest iodine depletion mean enhance radioiodine uptake metastasis good differentiate thyroid cancer datum not available regard secondary effect maneuver iodine clearance total body radiation accordingly measure inorganic iodine clearance total body iodine tumor total body retention radioactive iodine diet diuretic regimen design induce iodine depletion total body iodine decrease p little amount radioiodine take retain tumor tissue increase range follow depletion regimen three study two patient however iodine clearance decrease range total body radiation per standard mci dose increase range consequently increase lesion irradiation relative increment deliver total body range conclude iodine depletion regimen little effective prior study suggest lymph node metastasis tall cell thyroid cancer negative f fdg pet ct detect f choline pet ct year old woman undergo thyroidectomy remnant ablation sensitive immunodetection radiotoxicity iodine therapy thyroid cancer use h ax focus dna damage lymphocyte purpose purpose study evaluate degree radiotoxicity lymphocyte thyroid cancer iodine therapy use h ax focus immunodetection method study focus patient undergo therapy differentiate thyroid cancer surgery patient receive gbq venous blood sample collect patient therapy day thereafter lymphocyte isolate blood sample subject h ax immunofluorescence stain result numb mean sd focus per lymphocyte nucleus radioiodine therapy difference statistically significant p absorb dose estimate patient gy apply standard line vitro external radiation dose conclusion h ax focus immunodetection lymphocyte may detect radiation induce dna damage associate therapy thyroid cancer may facilitate estimation radiation dose absorb therapy bethesda system report thyroid cytopathology institutional experience outcome indeterminate category objective study investigate efficacy bethesda system tbs report thyroid cytopathology determine risk malignancy indeterminate case case comprise atypia follicular lesion undetermined significance aus flus follicular neoplasia suspicious follicular neoplasia fn sfn suspicious malignancy sm category aus flus case subcategorize accord pattern malignancy rate subcategory calculate method total thyroid fine needle aspiration fna case analyse indeterminate case enroll study aus flus case subcategorize four pattern follow papillary thyroid carcinoma ptc pattern microfollicle pattern atypical cell pattern h rthle cell pattern result malignancy rate aus flus fn sfn sm respectively malignancy rate aus flus subcategory follow ptc pattern microfollicle pattern atypical cell pattern h rthle cell pattern conclusion bethesda system categorize thyroid fnas increase risk malignancy advocate however finding suggest risk malignancy aus flus may high estimate particularly aus flus case focal feature suggestive ptc seem associate much high risk malignancy pattern randomize control trial computerize decision aid adjuvant radioactive iodine treatment patient early stage papillary thyroid cancer purpose decision make adjuvant radioactive iodine rai treatment early stage papillary thyroid cancer ptc complex uncertainty medical evidence use parallel two arm randomize control trial design examine impact patient direct computerize decision aid da medical knowledge decisional conflict patient early stage ptc consider choice treat adjuvant rai not da describe rationale possible risk benefit medical evidence uncertainty relate choice patient method recruit patient early stage ptc thyroidectomy participant assign use central computerize randomization either da group usual care intervention usual care alone control medical knowledge ptc rai treatment primary outcome good decisional conflict secondary outcome measure use validate questionnaire respective score compare group result consistent ptc epidemiology participant woman mean age year range year medical knowledge ptc rai treatment significantly great decisional conflict significantly reduce da group compare control group respective p value use adjuvant rai treatment not significantly different group da group control seven p conclusion computerize da improve inform decision make patient early stage ptc consider adjuvant rai treatment das useful patient face decision subject medical evidence uncertainty surgical practice pattern treatment papillary thyroid microcarcinoma background recently debate regard total thyroidectomy vs hemithyroidectomy papillary thyroid microcarcinoma ptmc objective determine whether significant difference treatment ptmc depend physician experience age train location method question survey distribute otolaryngologists general surgeon endocrine surgeon include clinical scenario question query clinical reason demographic question train surgical volume location age demographic variable use analyze response clinical scenario bivariate multivariate statistic result total responder complete survey give single subcentimeter ptmc surgeon recommend no surgery hemithyroidectomy yet believe completion thyroidectomy necessary otolaryngologists choose total thyroidectomy frequently surgeon south west give ptmc lymphatic invasion responder recommend completion thyroidectomy otolaryngologists incline toward completion surgery give multifocal ptmc choose completion thyroidectomy surgeon south west recommend total thyroidectomy frequently compare northeast improve survival surgeon preference need thyroid suppression rate relatively insignificant ease patient follow multifocality disease judge significant influence national guideline current literature rate somewhat minimally significant conclusion survey surgeon seem follow national guideline regard surgical treatment ptmc however significant difference treatment perception ptmc exist base surgical train location preoperative differentiation noninvasive follicular thyroid neoplasm papillary like nuclear feature niftp non niftp background recent concept propose noninvasive encapsulate follicular variant papillary thyroid carcinoma reclassify noninvasive follicular thyroid neoplasm papillary like nuclear feature niftp benign aim identify difference niftp non niftp preoperatively method retrospective study include total patient follicular variant papillary thyroid carcinoma fvptc surgically confirm three university hospital clinical factor biopsy technique ultrasonography us image characteristic compare niftp non niftp group result total niftp non niftp observe niftps need surgery indicate ultrasonography guide fine needle aspiration us fna ultrasonography guide core needle biopsy us cnb p non niftp no significant difference note rate surgical indication us fna us cnb vs p common biopsy diagnosis niftp bethesda category v us fna group category iv us cnb group us diagnosis niftp significantly low rate high suspicion malignancy non niftp vs p central nodal metastasis find one case niftp patient none distance metastasis recurrence conclusion noninvasive follicular thyroid neoplasm papillary like nuclear feature lack malignant us feature well triage use us cnb use us fna facilitate surgical management us evaluation pivotal determine next step fvptc management length cost hospital stay radioiodine ablation thyroid cancer patient comparison preparation thyroid hormone withdrawal thyrogen purpose treatment thyroid cancer consist thyroidectomy radioiodine ablation follow thyroid stimulate hormone tsh stimulation similar ablation rate obtain either thyroid hormone withdrawal thw rhtsh rhtsh elimination radioiodine rapid thus reduce whole body retention potentially result short hospital stay aim study assess financial impact reduce length hospital stay use rhtsh method case control study thyroid cancer patient treat postoperatively mbq mci radioiodine patient receive rhtsh match patient submit thw accord covariate influence radioiodine retention length hospitalization loh estimate method accord threshold radioiodine retention patient discharge hospital economic analysis conduct hospital perspective simulation perform result threshold mbq loh day day rhtsh thw respectively cost ablation stay respectively euro french context acquisition cost rhtsh compensate reduction length hospitalization conclusion increase iodine excretion rhtsh allow short hospitalization length partially compensate acquisition cost high throughput drug library screen identify colchicine thyroid cancer inhibitor employ high throughput drug library screen platform identify novel agent affect thyroid cancer cell use human thyroid cancer cell line screen collection approximately small molecule biological pharmacologial property parallel primary screen yield numb hit differentially active thyroid melanoma cell amongst compound specifically target thyroid cancer cell colchicine emerge effective candidate colchicine inhibit cell growth correlate g cell cycle arrest apoptosis effect hamper inhibition mek jnk contrast inhibition p mapk little effect akt no impact colchicine action systemic colchicine inhibit thyroid cancer progression xenografted mouse finding demonstrate screen platform effective vehicle drug reposition show colchicine warrant attention good define clinical niche thyroid cancer characteristic significance minimal maximal extrathyroidal extension papillary thyroid carcinoma objective maximal extrathyroidal extension ete know important prognostic factor papillary thyroid carcinoma ptc however significance minimal ete controversial aim study investigate clinicopathologic characteristic prognostic significance minimal vs maximal ete ptc material method group patient undergo thyroidectomy ptc tertiary hospital january december study retrospectively patient classify three group absence ete minimal maximal ete minimal ete group categorize two subgroup accord invasion strap muscle no invasion sti sti result gender not differ three group patient mean age patient maximal ete significantly high belong group tumor size bilaterality lymph node metastasis stage increase significantly accord degree ete recurrence survival rate not differ absence minimal ete group sti sti subgroup minimal ete however maximal ete group significantly high recurrence low survival rate group p conclusion maximal ete significant factor poor prognosis however minimal ete not associate increase recurrence decrease survival patient ptc current status thyroid cancer screen korea result nationwide interview survey objective since thyroid cancer increase rapidly korea although cause increase not clear thyroid cancer screen can identify one cause purpose study examine screen rate thyroid cancer relate factor use nationwide datum method study population derive korea national cancer screen survey kncss annual cross sectional survey use nationally representative random sample investigate cancer screen rate total korean adult participate screen method thyroid cancer restrict thyroid ultrasonography logistic regression use identify factor associate undergo thyroid cancer screen result participant man woman undergo thyroid ultrasonography multiple analysis age residence belief cancer screen regular health check up smoke alcohol drink exercise associate thyroid cancer screen subject undergo cancer screen gastric colorectal breast cervical likely thyroid ultrasonogram not get screen conclusion present numb characteristic examinee utilize ultrasonography thyroid screen tool korea although result reveal cancer screen may play major role increase thyroid cancer incidence research need determine cause rapidly increase incidence thyroid cancer korea papillary thyroid carcinoma pleomorphic tumor giant cell pregnant woman case report background papillary thyroid carcinoma pleomorphic tumor giant cell ptc pc characterize occurrence bizarre pleomorphic cell within small area conventional ptc histologic distinction ptc pc ptc focal anaplastic thyroid cancer atc component denote classification papillary thyroid carcinoma spindle giant cell carcinoma ptc sgc debate however prognosis think different excellent ptc pc poor ptc sgc therefore diagnostic challenge significant endocrine pathologist recognize herein report histological clinical workup ptc pc case particular focus molecular analysis facilitate establishment final diagnosis case presentation patient pregnant year old female present mm conventional ptc focal area undifferentiated cell exhibit exaggerate nuclear pleomorphism no focus extrathyroidal extension angioinvasion lymph node engagement see immunohistochemical analysis reveal pleomorphic cell exhibit retain differentiation molecular genetic analysis demonstrate codon v missense mutation braf gene no tp tert promoter mutation absence aggressive phenotype addition lack mutation two major atc relate gene lead diagnosis ptc pc postoperative mri show no evidence metastatic disease radioiodine ablation perform seven month post operatively spect ct image not show sign residual tissue good without sign disease month radiation induce papillary thyroid cancer distinct clinical entity purpose review present current status knowledge regard radiation induce papillary thyroid cancer riptc define epidemiologic pathologic clinical characteristic ensue possible therapeutic prognostic consequence recent finding cumulative evidence show riptc resemble sporadic papillary thyroid cancer ptc comparable age term clinical pathological feature prognosis therefore aggressive treatment not seem require manage riptc prognosis comparable never irradiate patient summary radiation exposure childhood good document risk factor development ptc therefore increase exposure medical environmental radiation may part responsible along increase screen recent burgeon incidence ptc specific morphological molecular portrait riptc unlikely exist aggressive histologic clinical feature initially report radiation induce case consistent expectation nonradiation relate ptc comparable age aggressive histology nodal distant metastasis correlate early age onset rather radiation exposure although relapse frequent child long term cancer specific mortality approximately low observe adult comparable irradiate nonirradiated cohort riptc not require aggressive surgery adjuvant treatment prognosis good sporadic ptc match stage treatment receive role lymphnodal dissection treatment differentiate thyroid cancer background aim study investigate whether diffuse hepatic thyroid bed uptake post ablative whole body scan pawbs patient differentiate thyroid cancer dtc relevance clinical outcome parameter patient method retrospectively review patient dtc treat pusan national university hospital grade hepatic thyroid bed uptake whole body scan classify visual assessment recurrence free survival evaluate kaplan meier method cox regression analysis result male patient tumor large cm p multiple tumor focus p involve margin p high tnm stage p likely relapse thyroid bed grade p live uptake grade p also reveal significant prognostic factor intense thyroid bed uptake faint hepatic activity relate poor prognosis conclusion suggest increase retention thyroid bed little visualization live pawbs mean poor prognosis would relate amount remnant thyroid tissue ineffective destruction proposal separation nuclear atypia architectural atypia bethesda category iii aus flus base differ rate thyroid malignancy objective bethesda category iii atypia undetermined significance follicular lesion undetermined significance include sparsely cellular specimen nuclear atypia n architectural atypia study investigate whether two type atypia different rate malignancy rom method cytologic histologic diagnosis resect thyroid nodule record rom calculate bethesda category n subcategory possible noninvasive follicular thyroid neoplasm papillary like nuclear feature review remove malignancy rom recalculate result total nodule include rom n high p similar suspicious follicular neoplasm p rom approach benign p conclusion strong consideration give separate n nuclear atypia high risk papillary thyroid carcinoma architectural atypia high chance benign convey different rom vemurafenib redifferentiation braf mutant rai refractory thyroid cancer context brafv e mutant thyroid cancer often refractory radioiodine rai objective investigate utility molecular underpinning enhance lesional iodide uptake braf inhibitor vemurafenib patient rai refractory rair design pilot trial enroll june january set academic cancer center patient patient rair braf mutant thyroid cancer intervention patient undergo thyrotropin stimulate iodine positron emission tomography scan week vemurafenib increase rai concentration exceed predefine lesional dosimetry threshold responder treat iodine response evaluate image serum thyroglobulin three patient undergo research biopsy evaluate impact vemurafenib mitogen activate protein kinase mapk signal thyroid differentiation main outcome measure proportion patient vemurafenib increase rai incorporation warrant result twelve braf mutant patient enroll evaluable four patient responder vemurafenib treat result tumor regression month analysis research tumor biopsy demonstrate vemurafenib inhibition mapk pathway associate increase thyroid gene expression rai uptake mean pretreatment serum thyroglobulin value high among responder among nonresponders vs ng ml p conclusion vemurafenib restore rai uptake efficacy subset braf mutant rair patient probably upregulating thyroid specific gene expression via mapk pathway inhibition high baseline thyroglobulin value among responder suggest tumor differentiation status may predictor vemurafenib benefit result phase clinical study use dendritic cell vaccination thyroid cancer objective assess feasibility efficacy dendritic cell dc therapy advance thyroid papillary follicular cancer design six japanese patient man woman age year mean year diagnose advance thyroid cancer refractory distant metastasis papillary n follicular n enroll patient \\ufeff1 vaccinate weekly week autologous tumor lysate pulse monocyte derive mature dcs follow fortnightly vaccination week total vaccination lowdose kiu interleukin also administer day vaccination clinical response adverse effect delay type hypersensitivity skin test dth ifn production peripheral cd lymphocyte evaluate main outcome patient disease assess stable progressive no adverse event observe result dth ifn production peripheral lymphocyte not correlate clinical response conclusion dc immunotherapy can administer patient thyroid papillary follicular cancer without substantial side effect thyroid cancer denmark period cancer statistic numb due important role dna repair pathway numerous study carry explore relationship polymorphism x ray repair cross complement group xrcc gene thyroid cancer risk previous report produce conflict result thus perform update comprehensive meta analysis well investigate association xrcc polymorphism thyroid cancer risk total nine study include case control examine effect xrcc arg arg gln arg trp polymorphism susceptibility thyroid cancer study xrcc arg polymorphism find associate increase thyroid cancer risk caucasian population allelic contrast odd ratio ci p z p q dominant model ci p z p q arg gln polymorphism associate significant decrease risk allelic contrast ci p z p q dominant model ci p z p q recessive model ci p z p q arg trp snp confer increase risk thyroid cancer mix population allelic contrast ci p z conclude present meta analysis demonstrate polymorphism xrcc gene may associate develope thyroid cancer selective internal radiation therapy live metastasis papillary thyroid carcinoma papillary carcinoma thyroid ptc common neoplasm thyroid gland usually invade lymphatic rather blood vessel hematogenous metastasis ptc rare distant metastasis live even rare selective internal radiation therapy microsphere good recognize technique treatment live metastasis herein present case ptc radioactive iodine negative hepatic metastasis detect f fdg pet ct treat selective internal radiation therapy glucose uptake evaluate f fluorodeoxyglucose positron emission tomography noninvasive follicular thyroid neoplasm papillary like nuclear feature objective explore clinical significance metastasis lymph node sternocleidomastoid sternohyoid muscle lnss papillary thyroid cancer ptc method total patient ptc undergo thyroidectomy lnss dissection retrospectively analyze univariate multivariate logistic regression analysis use determine independent risk factor lnss metastasis ptc result rate detectable lnss metastasis rate case lnss metastasis coexistence cervical lymph node metastasis univariate logistic regression analysis show multiple focal cancer tumor locate low pole thyroid belt shape muscle invasion lateral cervical lymph node metastasis cn numb cervical lymph node metastasis numb lymph node metastasis level risk factor lnss metastasis p multivariate logistic regression analysis suggest tumor locate low pole thyroid numb cervical lymph node metastasis independent risk factor lnss metastasis p give numb cervical lymph node metastasis predictor lnss metastasis sensitivity specificity accuracy rate conclusion lnss metastasis commom ptc metastasis rate ptc low pole thyroid numb cervical lymph node metastasis independent risk lnss metastasis evaluation medag gene expression papillary thyroid microcarcinoma association histological feature regional lymph node metastasis prognosis papillary thyroid microcarcinoma account large proportion papillary thyroid carcinoma especially among new case many ptmc patient regional lymph node metastasis experience recurrence even death however risk factor mechanism ptmc relate factor unknown study differentially express gene identify microarray cancer genome atla follow analysis use kyoto encyclopedia gene genome immunohistochemistry immunofluorescence western blot oil red stain carry evaluate expression level functional alteration mesenteric estrogen dependent adipogenesis expression observe almost case papillary thyroid microcarcinomas location expression associate histological subtype high expression correlate metastasis poor disease free survival furthermore enrichment analysis indicate mesenteric estrogen dependent adipogenesis expression may associate metabolic reprogramme influence metastasis prognosis finding contribute well understand mesenteric estrogen dependent adipogenesis affect metastasis prognosis papillary thyroid microcarcinoma patient suggest mesenteric estrogen dependent adipogenesis expression may novel prognostic marker patient treatment good differentiate thyroid cancer aggressive hemithyroidectomy versus total thyroidectomy recent literature show hemithyroidectomy safe alternative total thyroidectomy treatment patient good differentiate thyroid cancer cm diameter low risk recurrence accord criterium american thyroid association guideline patient whole transcriptome profile thyroid nodule identify expression base signature accurate thyroid cancer diagnosis purpose due limitation fine needle aspiration biopsy fnab cytopathology many individual present thyroid nodule eventually undergo thyroid surgery diagnose thyroid cancer objective study use whole transcriptome profile develop validate genomic classifier significantly improve accuracy preoperative thyroid cancer diagnosis material method nucleic acid extract amplify microarray expression analysis affymetrix human exon st genechips mm diameter formalin fix paraffin embed thyroid tumor tissue core train group thyroidectomy specimen cancer benign lesion use assess differential expression subsequent generation genomic classifier classifier validate blind fashion group formalin fix paraffin embed thyroid fnab specimen result expression profile thyroidectomy train fnab validation specimen pass series quality control step analyze genomic classifier compose marker correspond gene overall validate accuracy patient fnab specimen positive negative predictive value respectively majority identify marker make classifier represent non protein encode rnas conclusion whole transcriptome profile thyroid nodule surgical specimen allow development genomic classifier improve accuracy preoperative thyroid cancer fnab diagnosis thyroid cancer ct purpose purpose evaluate impact adjuvant radioactive iodine therapy rai prognosis assess progression free survival pf overall survival os patient affect differentiate thyroid carcinoma dtc lymph node relapse previously treat lymphadenectomy method retrospectively evaluate dtc patient treat lymph node dissection disease relapse patient previously undergo total thyroidectomy radioiodine remnant ablation rra use clinical histological datum obtain follow assess response outcome mean univariate multivariate time event analysis assess impact rai outcome pf os prognostic role thyroglobulin tg level suppression levothyroxine tg measure month lymphadenectomy risk factor result evaluate patient age diagnosis median year interquartile range treat rai median follow time year patient show disease progression die kaplan meier pf os curve show age diagnosis tumor histology tumor size dtc aggressive variant tg associate prognosis patient tg ng ml treat rai show well pf log rank pp os p untreated patient no effect rai observe patient tg ng ml multivariate model show age tg vs ng ml hr ci p rai yes vs no hr ci p remain independent factor associate pf age tg remain significantly associate os hr ci p nonetheless patient treat rai show low risk mortality hr ci p untreated patient conclusion rai lymphadenectomy dtc relapse significantly associate well pf patient tg ng ml metastatic thyroid cancer incidental find neck dissection significance management occult thyroid cancer occasional incidental find surgery indication usually consider minor clinical significance however appropriate approach incidentally find metastatic thyroid cancer little clear especially occur context another malignancy aggressive potential among patient treat squamous cancer tongue university texas anderson cancer center eight patient coexist differentiate thyroid cancer metastatic cervical lymph node find incidentally regional lymph node dissection eight patient include three woman five man median age year range year tumor papillary variety four patient follicular four one patient no gross microscopic primary tumor can identify thyroidectomy another patient no gross tumor evident whole organ section reveal area fibrosis consistent primary lesion two patient primary lesion little cm maximal diameter four patient no surgery physical exam radiologic evaluation fail show intrathyroidal lesion clinically relevant thyroid cancer not develop patient duration document follow year three patient die progressive tongue cancer one patient unrelated pulmonary disease four patient remain alive without evidence disease year available follow abstract truncate word comparison mean platelet volume platelet count neutrophil lymphocyte ratio platelet lymphocyte ratio euthyroid overt hypothyroid subclinical hyperthyroid phasis papillary thyroid carcinoma introduction thyroid hormone essential normal development differentiation metabolic balance physiological function tissue mean platelet volume mpv indicate mean platelet size reflect platelet production rate stimulation increase platelet size observe association know cardiovascular risk factor neutrophil lymphocyte ratio nlr platelet lymphocyte ratio plr know marker systemic inflammatory response study aim investigate effect thyroid hormone change compare platelet count mpv value nlr plr thyroid papillary carcinoma method forty nine female nine male comprise total patient include study clinical laboratory parameter patient record follow three phasis disease euthyroid phase thyroid surgery overt hypothyroid oh phase radioactive iodine rai treatment subclinical hyperthyroid sch phase six month rai treatment result mean thyroid stimulate hormone tsh value patient euthyroid oh sch phasis iu ml respectively mean mpv value patient euthyroid oh sch phasis fl respectively mpv significantly high sch phase euthyroid phase p platelet count nlr plr not statistically different euthyroid oh sch phasis conclusion result study demonstrate level mpv increase significantly sch phase patient papillary thyroid carcinoma ptc increase mpv value contribute increase risk cardiovascular complication finding suggest mpv valuable practical parameter monitor haemostatic condition thyroid disorder no significant difference observe platelet count nlr plr stage ptc prognostic factor good differentiate thyroid cancer differentiate thyroid carcinoma malignant neoplasm follow indolent course infrequent metastasis long survival however case behave aggressive fashion despite every attempt treat cause death patient numerous investigation carry define marker affect prognostic course tumor three type prognostic marker clinicopathological pathological morphological biological \\ufeff1 group include age sex size tumor multifocality vascular extrathyroidal invasion grade metastasis 2 category collect morphological feature like tumor subtype association autoimmune thyroid disease ploidy last group feature oncogene ret ret ptc rearrangement accurate evaluation previous prognostic marker basis treatment scheme discuss last section therapeutic management thyroid cancer remote metastasis experience operate case medullary thyroid cancer may autosomal dominantly inherit calcitonin sensitive tumour marker medullary thyroid cancer essential measure calcitonin \\ufeff1 grade relative patient order expose familial incident subclinical disease patient medullary thyroid cancer no history familial disease nine close relative elevate calcitonin identify four different family eight nine thyroidectomized five find medullary thyroid cancer one definite c cell hyperplasia two equivocal c cell hyperplasia last two elevate basal serum calcitonin level increase no increase intravenous pentagastrin bolus injection thyroidectomy not modify result dna analysis may necessary draw conclusion hereditary situation patient internal jugular vein tumor thrombus associate thyroid carcinoma thyroid carcinoma usually present asymptomatic thyroid nodule thyroid cancer may show microscopic vascular invasion however internal jugular vein tumor thrombus rare complication thyroid cancer unique case internal jugular vein tumor thrombus associate thyroid carcinoma present discuss non interventional approach papillary thyroid microcarcinomas active surveillance dilemma background recent study suggest papillary thyroid microcarcinomas ptmi follicular variant papillary thyroid cancer fvptc little aggressive overall observation argue objective assess whether ptmi fvptc indeed low risk can safely follow without intervention method prospectively collect datum subject ptc pathology post thyroidectomy odd ratio calculate fisher exact test difference mean calculate use mann whitney test result meet inclusion criterium macrocarcinomas ptma ptmi ptma statistically significantly likely present multifocal vs extrathyroidal extension vs lymph node involvement vs local invasion vs p not distant metastasis vs p therefore ptmi measure cm harbor aggressive feature also identify case fvptc subject non fvptc fvptc low incidence multifocality vs extrathyroidal extension vs lymphatic involvement vs not distant metastasis local invasion p therefore fvptc measure cm also harbor aggressive feature conclusion ptmi fvptc aggressive feature substantial enough require careful evaluation independent original tumor size default active surveillance multiplexed target mass spectrometry assay protein family uncover isoform specific expression thyroid tumour background mount evidence demonstrate causal role protein tumourigenesis several isoform show utility biomarker several type cancer family comprise small isoform many implicate important cellular function proliferation motility survival furthermore vivo experiment prove role protein tumour growth disease progression study show prognostic value involvement resistance chemotherapy drug take together aspect highlight protein potential therapeutic target promise panel cancer biomarker work develope mass spectrometry ms base method multiplexed specific analysis entire protein family tumour tissue apply investigate expression isoform context thyroid cancer main endocrine malignancy method select reaction monitor srm ms stable isotope label label free analysis employ investigate expression protein isoform thyroid tissue sample specimen include normal thyroid tissue tumour tissue consist follicular adenoma fa follicular carcinoma ftc papillary carcinoma ptc result multiplexed target mass spectrometry method lead detection eleven protein isoform across tissue label label free analysis show significant difference result confirm western blot putative interaction partner annexin show high overexpression ptc compare normal thyroid also elevate ptc reduce expression observe fa compare tissue fa ftc show reduction annexin expression conclusion target mass spectrometry allow multiplexed specific analysis protein isoform tumour tissue specimen reveal novel candidate ptc biomarker result show annexin can help discriminate follicular papillary tumour diagnostic functional significance reduction follicular tumour require investigation kartagener syndrome papillary thyroid carcinoma unusual combination case papillary thyroid carcinoma patient situs inversus associate bronchiectasis chronic sinusitis kartagener syndrome report tall cell diffuse sclerosing variant papillary thyroid cancer outcome predict value risk stratification method purpose tall cell tcv diffuse sclerosing dsv variant aggressive variant papillary thyroid cancer ptc compare risk recurrent persistent disease patient tcv dsv classical ptc cptc evaluate prognostic accuracy initial vs ongoing risk stratification method consecutive series dsv n tcv n cptc n patient retrospectively analyze tcv dsv patient \\ufeff1 risk stratify recurrent persistent disease without consider histotype risk factor subsequently month initial treatment classify basis response therapy ongoing risk stratification result extrathyroidal extension frequent dsv tcv cptc patient p moreover dsv tumor high rate recurrent persistent disease compare cptc treat protocol total thyroidectomy follow treatment p initial treatment tcv dsv patient classify low risk ongoing risk stratification excellent response low risk high tcv dsv patient relative initial stratification p use ongoing risk classification positive predictive value ppv persistent recurrent disease high relative initial risk stratification tcv ppv vs dsv ppv vs p conclusion series dsv not tcv patient poor outcome cptc treat protocol moreover ongoing risk stratification predict outcome well initial classification tcv dsv patient increase detection increase incidence thyroid cancer background propose increase incidence thyroid cancer due increase detection method use administrative datum compare year rate diagnostic image test neck compute axial tomography ct magnetic resonance image mri non obstetrical ultrasound us incidence thyroid cancer population province ontario canada result woman man different rate test rate reflect rate new diagnosis thyroid cancer conclusion rise incidence thyroid disease woman associate increase number diagnostic image test association acromegaly thyroid carcinoma critical review literature patient acromegaly may high rate cancer possibly due increase plasma level igf know promote cellular growth simple multinodular goiters common among acromegalics report thyroid carcinoma rare true incidence unclear review relevant literature context case patient acromegaly persistently elevate igf level subsequently diagnose thyroid carcinoma incidence potential pathophysiologic mechanism benign malignant thyroid disease acromegaly discuss conclude acromegalic patient persistently elevate igf level one ensure careful monitor goiter thyroid nodule include fine needle aspiration nodule cm large thyroid cancer age covid covid modify way practice medicine thyroid cancer several significant impact \\ufeff1 diagnosis delay due social isolation reduce access investigation staff redeployment secondly treatment plan need take account risk patient staff nosocomial transmission virus finally specific concern respect interaction virus treatment cancer papillary thyroid microcarcinomas comparative study characteristic risk factor presentation two cancer registry context papillary thyroid microcarcinoma ptmc indolent neoplasia often asymptomatic discover incidentally ptmcs however exhibit aggressive behavior frequently recur even cause cancer relate death objective aim study evaluate prevalence ptmcs associate risk factor presentation thyroid cancer registry area different genetic environmental characteristic design patient conduct retrospective observational study incident case ptmcs record year period sicilian regional registry thyroid cancer srrtc surveillance epidemiology end result seer us registry set study take place academic hospital result incidence ptmcs much high sicily ptmc diagnose age standardize incidence rate world population asrw per unite state ptmc period asrw per within srrtc significantly high incidence observe volcanic area asrw vs rest sicily sicily female male ratio high ptmc patient young registry significant inverse correlation observe age tumor size young patient exhibit high frequency nodal metastasis conclusion ptmc incidence twice high sicily compare unite state within sicily incidence twice high volcanic area young patient ptmcs large presentation exhibit risk factor registry ptmcs exhibit risk factor suggest may require surgery follow similar large carcinoma genetic alteration thyroid cancer role mouse model thyroid carcinoma common endocrine neoplasm human globally increase incidence thyroid follicular cell neuroendocrine parafollicular c cell susceptible neoplastic transformation result thyroid cancer differ phenotype unique associate genetic mutation clinical outcome past year several sophisticate genetically engineer mouse model thyroid cancer create understand genetic event lead thyroid carcinogenesis vivo significant mouse model papillary follicular anaplastic medullary thyroid carcinoma highlight particular emphasis relationship relevant oncogene model genetic event naturally occur human disease limitation model present need additional model well recapitulate certain aspect human disease discuss thyroid hormone suppression therapy thyroid hormone suppression therapy design low serum thyrotropin tsh level use dose thyroid hormone excess would normally require maintain euthyroid state basis therapy knowledge tsh growth factor thyroid cancer low serum tsh level may associate decrease disease activity however clinical study not document improve outcome tsh suppression except patient advance disease furthermore numb negative outcome relate aggressive thyroid hormone therapy include osteoporosis fracture cardiovascular disease therefore grade approach tsh suppression recommend american thyroid association base initial risk ongoing risk assessment f fdg pet recurrent differentiate thyroid cancer systematic meta analysis background positron emission tomography pet fluor deoxy glucose fdg widely use diagnose recurrent metastatic disease patient differentiate thyroid cancer dtc purpose assess diagnostic accuracy fdg pet dtc patient ablative therapy material method systematic search conduct medline pubmed embase cochrane library web science open grey look english language original article performance fdg pet series little patient dtc undergo ablative therapy include total thyroidectomy diagnostic performance measure pool use reitsma bivariate model result thirty four publication meet inclusion criterium pool sensitivity specificity confidence interval ci ci respectively area curve conclusion f fdg pet useful method detect recurrent dtc patient undergo ablative therapy cd express thyroid cancer cell undifferentiated radioresistant survive radioiodide therapy purpose therapy regularly use follow surgery part thyroid cancer management despite overall relatively good prognosis recurrent metastatic thyroid cancer not rare cd express cell show mark thyroid cancer stem cell possess characteristic stem cell ability initiate tumour however no study address influence cd express cell radioiodide therapy thyroid cancer aim study investigate whether cd cell contribute radioresistance thyroid cancer thus potentiate future recurrence metastasis method thyroid cancer cell line analyse cd expression radiosensitivity gene expression result anaplastic thyroid cancer cell line aro show high percentage cd cell high radioresistance irradiation cell cd population enrich due high apoptotic rate cd cell vivo treatment aro tumour result elevate expression cd oct nanog lin glut gene isolation cd cell exhibit high radioresistance high expression oct nanog sox lin glut cell line primarily culture papillary thyroid cancer cell low expression various thyroid specific gene namely nis tg tpo tshr ttf pax conclusion study demonstrate existence cd express thyroid cancer cell show high radioresistance undifferentiated status cell possess great potential survive radiotherapy may contribute recurrence thyroid cancer future therapeutic approach radioresistant thyroid cancer may focus selective eradication cd cell statin immunomodulation thyroid cancer background conventional image tc v dimercaptosunnic acid dmsa octreotide scintigraphy compute tomography ct magnetic resonance image mri rarely localize occult medullary thyroid cancer mtc role f fluoro deoxy glucose positron emission tomography fdg pet not good define aim study examine usefulness postoperative fdg pet localize mtc metastasis method fdg pet perform patient elevate serum tumor marker total thyroidectomy central compartment dissection additional neck dissection indication patient lesion base result compare finding conventional nuclear image validate morphological image ct mri ultrasonography include bone scintigraphy pathology possible clinical impact evaluate result fdg pet detect focus patient lesion base sensitivity octreotide detect focus sensitivity tc v dmsa scintigraphy morphological image detect focus respectively sensitivity no lesion find patient positive fdg pet finding lead surgical intervention nine patient undergo surgery removal residual tumor metastasis one patient achieve disease free status patient undergo surgery serum calcitonin level reduce average conclusion detection occult mtc lesion fdg pet superior conventional nuclear image well detection method yet available fdg pet postoperative follow clinical value may use guide reoperation additional morphological image preoperatively thyroid cancer thyroidal cretinism year old girl aim analyze impact combine treatment thyroidectomy radioactive iodine treatment hormonotherapy thyroxine outcome patient follicular thyroid carcinoma material method retrospective study include patient follicular carcinoma female male mean age year ci year treat institute oncology vilnius university patient undergo thyroidectomy hypothyroid patient week surgical treatment treat moderate radioiodine dose gbq dose administer every month patient follicular thyroid carcinoma give suppressive dose thyroxine combine treatment patient treat regularly observe gamma camera every month serum thyroglobulin evaluate result remnant thyroid tissue detect patient thyroidectomy radioiodine therapy radioiodine mean total dose gbq use destroy remnant thyroid tissue patient disseminate form follicular thyroid carcinoma mean total radioiodine dose gbq use majority patient euthyroid hyperthyroid treatment thyroid hormone patient treat level serum thyroglobulin ng ml overall year survival patient follicular thyroid cancer receive combine treatment respectively conclusion combine treatment thyroidectomy radioactive iodine treatment hormonotherapy thyroxine administer patient follicular thyroid carcinoma highly effective overall year survival respectively intraoperative radiotherapy treatment thyroid cancer pilot study preliminarily evaluate clinical feasibility efficacy intraoperative radiotherapy patient thyroid carcinoma nine thyroid cancer patient receive intraoperative radiotherapy use intrabeam system dose gy irradiation time range min min one case primary thyroid carcinoma case recurrent disease adverse effect recurrence survival analyze one patient poorly differentiate thyroid carcinoma recur month treatment one patient develope postoperative tracheal skin fistula one patient develope wind infection affect area treat surgical resection radiotherapy difficult know lead adverse effect nonetheless result indicate intraoperative radiotherapy relieve symptom associate thyroid cancer improve quality life patient thus appear feasible treat thyroid cancer patient intraoperative radiotherapy relationship negative mental adjustment cancer distress thyroid cancer patient purpose previous study report 3 cancer patient experience significant psychological distress diagnosis treatment cancer mental adjustment cancer good biologic demographic factor may associate distress investigate relationship mental adjustment distress patient thyroid cancer prior thyroidectomy material method one hundred fifty two thyroid cancer patient include final analysis global distress level screen distress thermometer patient evaluate concern mental adjustment cancer good demographic cancer relate characteristic thyroid function test also perform regression analysis perform discern significant factor associate distress thyroid cancer patient result regression model significant explain total variance distress patient group anxious preoccupation helpless hopeless factor mental adjustment cancer scale significantly associate distress thyroid cancer patient conclusion negative emotional response cancer diagnosis may associate distress thyroid cancer patient await thyroidectomy screen mental cope strategy begin cancer treatment may predict psychological distress cancer patient study efficacy psychiatric intervention cancer treatment may need patient show maladaptive psychological response cancer meet report th international expert symposium fukushima radiation health background symposium entitle chernobyl fukushima lesson solution fukushima thyroid question hold september fukushima aim symposium revisit recapitulate evidence study chernobyl order share multidisciplinary opinion view likely reason high rate thyroid cancer detect thyroid ultrasound examination program fukushima prefecture participant matter discuss high prevalence thyroid cancer young individual cause concern among fukushima resident general public may due putative radiation exposure fukushima daiichi nuclear power plant accident twenty six expert japan abroad include participant affiliate international organization review result radiation epidemiology investigation chernobyl present clinical experience diagnosis treatment follow patient radiation relate thyroid cancer scrutinize finding thyroid cancer fukushima conclusion conclusion draw symposium include understand contrast chernobyl dose public accident fukushima low give rise discernible excess risk thyroid cancer high detection rate thyroid cancer benign abnormality result use highly sensitive ultrasound equipment sophisticate protocol examination use thyroid ultrasound examination therefore not attributable radiation coordinate effort necessary avoid overdiagnosis overtreatment may carry health disbenefit clear communication screen participant family recommend regard examination conduct explain likely outcome risk include mean option treatment thyroid disorder detect change concept management differentiate thyroid cancer management patient differentiate thyroid cancer change significantly last decade mortality decrease result early detection refine surgical approach subsequent radioiodine ablation development sensitive method detect monitor disease recurrence latter facilitate serum thyroglobulin measurement use recombinant human thyrotropin use f deoxyglucose positron emission tomography select instance radioiodine image fail locate know suspect recurrent metastatic disease problem early intra cancer thyroid cancer consider one deadly cancer differentiation benign malignant structure difficult patient thyroid cancer work devote problem early clinical diagnosis thyroid cancer case primary thyroid cancer study pathomorphologic analysis thyroid cancer carry problem early detection thyroid cancer review conclude thyroid nodule fine needle aspirate biopsy intraoperative freeze section examination not allow accurate differentiation benign tumour malignant neoplasm novel diagnostic method early detection thyroid cancer need thyroid cancer discover two case hyperthyroidism apparently cure antithyroids objective follow patient low risk differentiate thyroid cancer treat total thyroidectomy radioiodine require neck sonography thyroglobulin tg need stimulate tg controversial goal study compare diagnostic performance sonography plus suppress stimulate tg low risk thyroid cancer method total thyroidectomy radioiodine patient low risk thyroid cancer retrospectively identify structural biochemical persistence recurrence compare diagnostic performance suppress stimulate tg detect persistence recurrence result include patient low risk thyroid cancer follow median year persistence recurrence find patient structural disease biochemical disease thyroglobulin not stimulate patient group stimulate group group patient structural neck persistence recurrence suppress tg ng ml suppress tg ng ml four patient undergo surgery surveilled patient suppress tg low ng ml end follow group stimulate tg not identify additional case structural persistence recurrence classify patient biochemical persistence recurrence one patient receive 2 dose radioiodine surveilled without disease end follow suppress stimulate tg negative predictive value persistence recurrence respectively conclusion low risk thyroid cancer treat total thyroidectomy radioiodine sonography suppress stimulate tg similar negative predictive value persistence recurrence importantly coexistence negative sonographic finding suppress tg low ng ml make addition stimulate tg unlikely identify clinically important disease malignant thyroid lymphoma present acute airway obstruction malignant thyroid lymphoma uncommon form thyroid cancer commonly present elderly woman patient demonstrate rapidly enlarge mass may show tracheal deviation chest roentgenogram radioisotopic scan thyroid often demonstrate cold cool process decrease uptake affect area often underlie lymphocytic thyroiditis process note unfavorable prognosis relate extracapsular extension blood vessel wall infiltration diffuse architectural pattern cervical lymph node involvement present two unusual case thyroid lymphoma present acute airway obstruction review literature concern subject one case present clinical radiographic appearance similar prevertebral space abscess cytotoxic effect carboplatinum epirubicin set elevate serum thyrotropin advance poorly differentiate thyroid cancer chemotherapy represent therapeutic option poorly differentiate thyroid carcinoma although effect limit short last aim study evaluate whether increase metabolic rate thyroid cancer cell tsh stimulation may result high response rate chemotherapy fourteen patient poorly differentiate thyroid carcinoma nonfunctioning diffuse lung metastasis detect compute tomography scan enter study combination carboplatinum epirubicin administer wk interval six course tsh stimulation achieve reduction daily dose l thyroxine result mild hypothyroidism eight patient administration recombinant human tsh six patient two additional patient not complete therapeutic protocol due severe hematological side effect result evaluate comparison lung compute tomography scan therapy one patient complete remission five patient partial remission seven patient disease stabilization one patient progress death overall rate positive response rise include patient stable disease serum thyroglobulin chemotherapy decline six patient respect basal level apparently no difference response rate observe exogenous endogenous tsh stimulation time analysis among patient complete treatment course patient still alive median survival start chemotherapy month range six patient not show progression lung disease whereas regrowth lung metastasis observe three patient month chemotherapy respectively five patient die disease include one progression lung disease chemotherapy three die brain bone metastasis one die refractory local tumor invasion no progression lung metastasis observe death four patient conclusion response rate poorly differentiate thyroid cancer chemotherapy observe study favorable promise tsh stimulation may contribute result surgical treatment thyroid cancer comparative analysis result surgical treatment patient malignant neoplasm thyroid gland accident chernobyl atomic power station present aggressive course thyroid cancer pediatric patient accident ensue necessity extend indication performance thyroidectomy radical intervention regional lymph collector note integrate analysis identify new lncrna marker reveal cerna network tumor recurrence papillary thyroid carcinoma build nomogram object risk tumor recurrence currently focus clinical attention treatment papillary thyroid carcinoma ptc study focus identification novel prognostic long noncoding rna lncrna signature tumor recurrence ptc method rna sequence profile patient ptc obtain tcga gene expression omnibus database differently express lncrna microrna mirna messenger rna mrna signature patient without tumor recurrence select lncrna mirna mrna compete endogenous rna cerna network tumor recurrence ptc construct identify lncrnas associate tumor relapse papillary carcinoma functional enrichment analysis perform adjust odd ratio estimate identify candidate prognostic lncrnas consider clinical covariate validation analysis conduct nomogram build base verify prognostic lncrnas clinical feature result lncrna mirna mrna cerna network tumor recurrence ptc construct functional enrichment analysis suggest identify lncrnas associate ptc adjust odd ratio indicate select lncrnas candidate biomarker predict tumor recurrence thyroid carcinoma among ttty verify novel prognostic marker validation analysis nomogram build base newly identify lncrna biomarker clinical covariate conclusion study lncrna ttty identify potential novel prognostic marker predict tumor recurrence ptc may provide useful information future molecular cohort study focus prognosis ptc low risk papillary thyroid cancer procedure choice thyroidectomy lymph node resection context thyroid nodule adenoma goiter consistently associate thyroid cancer risk study assess whether thyroid dysfunction thyroid autoimmunity influence risk objective examine thyroid cancer risk diagnosis wide range benign thyroid condition design hospital cancer registry linkage cohort study year set nationwide denmark participant patient diagnose hyperthyroidism n hypothyroidism n thyroiditis n nontoxic nodular goiter n simple goiter n unspecified goiter n adenoma n among resident denmark study period main outcome measure compute standardize incidence ratio sir differentiate thyroid cancer exclude \\ufeff1 month follow benign thyroid disease diagnosis result sir significantly elevate benign thyroid disease apart hypothyroidism sir high man woman early follow period elevate sir observe localize regional distant thyroid cancer exclude \\ufeff1 year follow hyperthyroidism n thyroid cancer case sir confidence interval ci nontoxic nodular goiter n sir ci simple goiter n sir ci unspecified goiter n sir ci adenoma n sir ci remain positively associate thyroid cancer risk conclusion find unexpected increase risk differentiate thyroid cancer include regional distant disease follow diagnosis hyperthyroidism thyroiditis can not solely attribute increase medical surveillance hypothyroidism little clearly associate thyroid cancer risk hematuria present symptom metastatic thyroid cancer year old man present admit hospital onset hematuria acute urinary retention find cm solid mass right obturator fossa compress bladder wall histology reveal presence distant metastasis thyroid cancer well knowledge \\ufeff1 case thyroid cancer present hematuria acute urinary retention cause distant metastasis intrapelvic soft tissue thyroid carcinoma clinical pathologic study case retrospective clinicopathological study thyroid carcinoma case follow year perform case selection unfavorable histologic type advance disease observe refer case medullary anaplastic tumor patient age young patient papillary follicular carcinoma actuarial survival rate show favorable outcome papillary carcinoma follow follicular medullary anaplastic tumor within papillary carcinoma group old age male sex adversely affect survival former appear relate clinical stage presentation clinically palpable papillary carcinoma poorly circumscribe show vascular invasion associate poor survival tumor without feature papillary carcinoma cm soft tissue invasion vascular invasion occult lymph node metastasis not effect disease free survival two death thyroid cancer observe group however patient present initially distant metastasis biology small lesion briefly discuss identification occult tumor whole specimen map solitary papillary thyroid carcinoma undertake study estimate accurate incidence spread pattern occult papillary thyroid carcinoma ptc patient preoperative diagnosis solitary ptc use whole specimen map specimen total thyroidectomy enroll prospectively whole thyroid map study consecutive patient undergo total thyroidectomy preoperative diagnosis solitary ptc thyroidectomy specimen serially section mm thickness whole thyroid map carry additional focus occult ptc frequency occult lesion detect whole contralateral lobe determine clinicopathologic factor associate multifocality assess whole thyroid map reveal occult ptc lesion miss preoperative ultrasound patient great majority occult ptc small mm size patient contralateral lesion find male sex independent predictor multifocality odd ratio ci adjust preoperative finding analysis pathologic parameter show male sex ci extrathyroidal extension ci implication lymph node metastasis survival patient though survival good differentiate thyroid cancer good specific population suffer great recurrence mortality define cohort significantly influence prognosis extent treatment study use large multi institutional database seek determine presence lymph node disease patient good differentiate thyroid cancer affect outcome surveillance epidemiology end result seer database large scale sample per cent u population use identify patient papillary follicular thyroid carcinoma identify prognostic implication lymph node metastasis additional factor include presence metastasis age tumor size compare use multivariate chi analysis patient identify lymph node status know multivariate analysis age year presence distant metastasis large tumor size lymph node involvement significantly predict poor outcome overall survival year per cent node negative per cent node positive patient p study show survival patient good differentiate thyroid cancer adversely affect lymph node metastasis optimum treatment cohort need delineation particular population great risk recurrence death impact neck failure survival old patient differentiate thyroid cancer background regional recurrence differentiate thyroid cancer dtc often salvage neck dissection without survival penalty unknown whether recurrence may associate inferior survival old patient method surveillance epidemiology end result seer medicare datum link identify patient age nonmetastatic dtc patient undergo neck dissection month initial diagnosis consider regional recurrent disease compare overall survival os cause specific survival css patient recurrent disease versus match cohort patient non recurrent dtc result patient treatment define recurrent disease patient recurrent disease inferior os p css p multivariate analysis demonstrate recurrent disease independently associate inferior year os hazard ratio hr p css hr p conclusion regional recurrence dtc may negative impact os css patient year old wiley periodical inc head neck sentinel lymph node biopsy technique thyroid pathology meta analysis introduction review different sentinel lymph node biopsy slnb technique patient thyroid neoplasm also compare detection rate different detection method patient material method medline database december search follow term thyroid cancer thyroid neoplasm sentinel lymph node study sentinel lymph node detect blue dye technique radiotracer patient suspect thyroid cancer analyse result twenty five study include meta analysis base technique use sentinel lymph node sln detection include study divide three group group consist study blue dye technique use detect slns group make study radioisotope technique use study technique use group group study blue dye technique use detect slns group four study radioisotope technique use detect slns group two study technique use group among patient group sln find patient detection rate study different vary among patient group sln detect 3 group patient method perform sln find patient detection rate study high conclusion analysis prove slnb technically fairly easy perform however nodal metastasis debatable prognostic value thyroid cancer clinical value slnb remain prove seem reasonable perform prospective study large group patient technique would use compare efficiency slnb elective selective central lymphadenectomy reduce local recurrence rate galectin diagnosis thyroid cancer fourty patient thyroid nodule examine benchmark study fna result histology report immunohistochemistry galectin expression perform galectin highly sensitive oncomarker papillary carcinoma thyroid gland sensitivity specificity diagnostic value classification thyroid nodule base characteristic sonographic textural feature correlate histopathology use hierarchical support vector machine study ultrasound image thyroid nodule classify facilitate clinical diagnosis management hierarchical support vector machine svm classification system use select characteristic sonographic textural feature represent major histopathologic component thyroid nodule two ultrasound system la l mention material method section use comparison seventy six thyroid nodular lesion region interest thyroid ultrasound image system recruit study parameter affect image acquisition keep condition lesion commonly use texture analysis method apply characterize thyroid ultrasound image image feature classify accord correspond pathologic finding estimate relevance performance classification svms use feature selector classifier thyroid nodule \\ufeff1 categorize two main type e follicle base fibrosis base nodule sum average follicle base nodule completely classify follicle cell follicle follicular cell follicle papillary cancer cell run length nonuniformity rlnu fibrosis base nodule classify sum square fibrosis cell fibrosis dominant cell fibrosis base neoplasm dominant cell separate fibrosis follicular cell fibrosis papillary cancer cell entropy hierarchical svm classification system achieve diagnostic accuracy besides well sonographic textural feature select system differentiation follicle fibrosis base thyroid nodule cell type mix follicle base thyroid nodule papillary cancer show high sonographic textural rlnu little follicular cell fibrosis base thyroid nodule papillary cancer show increase sonographic textural variance entropy papillary thyroid carcinoma nodular fasciitis like stroma usual entity distinctive morphology papillary thyroid carcinoma ptc common malignancy multiple variant rarely encounter routine surgical pathology practice ptc exuberant nodular fasciitis like stroma ptc nfs ptc fibromatosis like stroma ptc fms one variant report case ptc nfs tumor characterize abundant stromal component intervene epithelial component typical morphologic feature conventional ptc review literature rare variant discuss importance thorough search epithelial component within fibroproliferative lesion thyroid address diagnostic difficulty create tumor extensive stromal component thyroid metastasis study aim aim retrospective study report short series thyroid metastasis emphasize unusual occurrence poor prognosis patient method january december among patient operate thyroid malignancy patient thyroid metastasis mean age patient year range thyroid metastasis reveal primitive tumor n occur follow cancer already treat n primitive tumor renal n breast n lung carcinoma n melanoma n patient primitive tumor not detect thyroid metastasis apparently isolate patient surgical procedure total n partial n thyroidectomy cervicotomy biopsy n result eleven patient die little one year diagnosis metastasis one patient survive year another year one patient alive year diagnosis renal tumor year total thyroidectomy conclusion thyroid metastasis clinically rare much frequent post mortem examination may reveal primitive cancer often detect follow treatment primitive tumor thyroid metastasis isolate total thyroidectomy justify especially renal carcinoma long term survival report kidney thyroid cancer specific treatment algorithm spinal metastasis validation study background spinal metastasis sms kidney thyroid cancer several common feature suggest excisional surgery isolate removable sms improve survival propose simple treatment algorithm sms cancer study aim evaluate efficacy algorithm method perform retrospective analysis datum consecutive patient kidney thyroid cancer undergo excisional surgery sms patient retrospectively classify indicate group excisional sm surgery nonindicated group accord algorithm tokuhashi tomita score system patient indicate group expect survive year postoperatively whereas nonindicated group not positive predictive value negative predictive value npv calculate use predict versus actual survival time patient survival define time \\ufeff1 excisional surgery spinal lesion death last follow year result patient kidney cancer year survival rate respectively patient thyroid cancer year survival rate respectively algorithm compatible high positive predictive value npv whereas tokuhashi tomita score system low npvs respectively conclusion treatment algorithm sms kidney thyroid cancer useful determine adequate treatment include excisional surgery radiotherapy dose correlate incidence thyroid cancer survivor childhood tumor background threshold number define adequacy lymph node ln yield determine evaluation occult nodal disease papillary thyroid cancer ptc surgery study assess prevalence adequate ln yield estimate association patient clinicopathologic characteristic material method adult patient cn pt b pt cn cn pt ptc cm receive surgery ln resect identify national cancer database adequate yield define remove lns pt b pt pt stage respectively base recently publish literature univariable multivariable logistic regression use determine factor associate adequate yield result total patient include adequate ln yield rate adequate yield increase time adjustment patient academic facility likely adequate yield community center ci p patient advance tumor little likely adequate yield pt b versus pt versus pt adequate ln yield p patient adequate ln yield time likely receive radioactive iodine compare inadequate yield ci recombinant thyrotropin versus thyroid hormone withdrawal evaluate patient thyroid carcinoma patient previously treat thyroid carcinoma require lifelong monitor recurrent disease two diagnostic test play central role follow patient radioiodine whole body scan serum thyroglobulin measurement accurate thyroid stimulate hormone tsh stimulation temporary discontinuation thyroid hormone therapy previously sole effective approach tsh stimulate test however hormone withdrawal associate morbidity hypothyroidism occasional tumor progression introduction recombinant tsh rtsh stimulate test offer alternative therapy recent clinical trial show sensitivity combine new case diarrhea cause medullary cancer thyroid body animal model carcinogenesis pharmacological dose dehydroepiandrosterone dhea treatment appear reduce incidence chemically induce thyroid cancer dhea sulfate dhea secrete approximately equal amount serum level dhea time high no diurnal variation compare dhea hypothesis serum concentration dhea may associate thyroid cancer risk test population base prospective case control study datum practically complete nationwide cancer registry norway link datum file serum bank comprise blood sample norwegian man woman obtain national health survey total donor year blood sample receive diagnosis thyroid cancer identify serum bank eligible study case match control serum level dhea determine blindly control divide tertiles odd ratio case control determine relative group low serum dhea level risk develope thyroid cancer determine woman year age old woman age man subgroup case morphologically verify papillary thyroid cancer no significant association prediagnostic serum dhea concentration thyroid cancer risk observe datum indicate dhea within physiological concentration not reduce risk thyroid cancer thyroid cancer solitary thyroid nodule background energy metabolism describe deregulate cancer warburg effect consider major hallmark recently cellular heterogeneity tumor tumor microenvironment recognize play important role several metabolic pathway cancer however contribution papillary thyroid cancer ptc development metabolism still poorly understand method proteomic analysis five ptc perform cellular distribution several upregulated metabolic protein investigate cancerous stromal cell tumor result tandem mass spectrometry analysis reveal upregulation many metabolism relate protein among pyruvate carboxylase pc pc knockdown thyroid cell line alter proliferative motility capacity measurement oxygen consumption rate show enzyme involve replenishment tricarboxylic acid cycle immunostaining several upregulated metabolic protein show thyroid cancer cell increase mitochondrial oxidative metabolism compare stromal cell conclusion ptc active tricarboxylic acid cycle continuously replenish pc mediate anaplerosis specifically observe tumor cell cancer thyroid gland thyroid nodule common accurate diagnosis cancer benign disease important effective clinical management patient molecular marker helpful diagnostic tool particularly cytologically indeterminate thyroid nodule past year significant progress make develope molecular marker clinical use fine needle aspiration specimen include gene mutation panel gene expression classifier availability next generation sequence technology gene mutation panel expand interrogate multiple gene simultaneously provide yet accurate diagnostic information addition recently several new molecular marker thyroid cancer identify offer diagnostic prognostic therapeutic information may value guide individualize management patient thyroid nodule increase f fluorodeoxyglucose accumulation benign neurofibroma pitfall patient thyroid cancer case report thyroid carcinoma common endocrine maligancy worldwide incidence rise recent year differentiate thyroid carcinoma common thyroid malignancy include thyroid papillary carcinoma follicular thyroid carcinoma account percent thyroid carcinoma incidence currently surgical treatment iodine radiotherapy tsh suppressive therapy commonly accept effective treatment differentiate thyroid carcinoma patient cure still patient not sensitive general treatment lose treatment opportunity molecular target therapy agonistic suppressive treatment molecular biology target malignant tumor currently frontier research field malignancy treatment retrieve analyze relate literature molecular target therapy thyroid carcinoma pubmed past year article introduce current status molecular target therapy thyroid carcinoma mirna thyroid cancer meta analysis objective meta analysis perform observe whether difference mirna expression exist thyroid cancer normal thyroid btls benign thyroid lesion premise assess diagnostic efficacy thyroid cancer method systematic electronic literature search conduct include pubmed cochrane central register control trial web science combine fold change fc calculate pool estimate sensitivity specificity diagnostic odd ratio dor summary receiver operate characteristic sroc curve calculate result twenty seven article include meta analysis combine fc mirna thyroid cancer normal control mirna pool sensitivity ci specificity ci auc area curve value mirna pool sensitivity ci specificity ci mirna pool sensitivity ci specificity ci conclusion difference expression level mirna provide clue explore etiology thyroid cancer addition mirna promise molecular biomarker may significantly improve diagnostic accuracy thyroid cancer significance lymph node metastasis differentiate thyroid cancer age match patient differentiate carcinoma thyroid tumor recur per cent lymph node metastasis per cent without lymph node metastasis twenty four per cent patient nodal involvement initial examination die thyroid cancer whereas per cent without nodal involvement die thyroid cancer patient little forty year old no death without nodal metastasis bu three death per cent patient nodal metastasis patient forty year old nine per cent iwth nodal metastasis die tumor four per cent without nodal metastasis die tumor presence positive node death rate substantially great old young patient nodal involvement adverse effect prognosis appear little important age patient seven case carcinoma thyroid tongue tonsil background tier system propose radiologist report workup incidental thyroid nodule itn detect compute tomography ct magnetic resonance image mri positron emission tomography compute tomography pet ct show reduce workup rate remain concern miss malignancy study aim estimate proportion incidental cancer would miss relative thyroid cancer tier system apply itn see ct mri pet ct also aim characterize miss incidental cancer histology tumor stage method retrospective review perform consecutive patient thyroid cancer undergo surgery january december medical record review identify incidental thyroid cancer detect image patient incidental cancer detect ct mri pet ct categorize accord system tier system positive tier system negative system recommend tier system positive itn undergo workup ultrasound three tier system negative cancer cancer would miss system use practice tumor describe tumor type size stage determine potential impact tier system adopt result one hundred one patient image detect incidental cancer meet inclusion criterium originally detect ct mri pet ct eight tier system negative represent incidental cancer can categorize thyroid cancer treat institution year period three tier system negative tumor papillary histology median size mm interquartile range mm six tumor american joint committee cancer ajcc stage one ajcc stage ii one ajcc stage iii diagnosis conclusion base thyroid cancer diagnose decade incidental malignancy miss tier system represent thyroid malignancy three tier system negative incidental cancer small papillary cancer give cancer would miss little aggressive propose tier system can adopt clinical practice guide workup itn identify ct mri pet ct comparison efficacy various method thyroglobulin measurement differentiate thyroid cancer monitor patient differentiate thyroid carcinoma dtc thyroglobulin tg measurement require select optimal method use detection marker increase thyroglobulin concentration serum predictor tumor recurrence serum thyroglobulin assay falsify presence tg autoantibody present approximately dtc patient aim study comparison clinical utility two different method determine serum tg concentration monitor patient dtc thyroxine treatment tg concentration measure serum sample patient dtc replacement thyroid hormone use two method fluoroimmunometric assay ifma wallac delfia thyroglobulin immunoradiometric assay irma brahms dynotest tg value tg concentration recovery test detect year use ifma method value tg thyroglobulin autoantibody concentration measure year use irma method also include correlation tg value patient group good r p exclude patient incorrect recovery test determine irma correlation factor high r p estimation tg recovery test obtain irma assay eliminate monitor patient dtc ifma assay exclude nearly patient whereas estimation tg autoantibody patient irma method resistant interference allow monitor reliably great group patient dtc thyroxine treatment undifferentiated carcinoma thyroid anaplastic thyroid carcinoma rare highly lethal cancer case anaplastic carcinoma review surgical treatment radiotherapy chemotherapy perform case patient die disease within year mean survival month still controversy constitute adequate treatment anaplastic thyroid carcinoma combine multimodal therapy seem common management strategy aggressive disease change trend thyroglobulin antibody patient differentiate thyroid cancer treat total thyroidectomy without ablation background thyroglobulin tg antibody tgab interfere tg measurement use tg surrogate patient differentiate thyroid cancer dtc treat total thyroidectomy ttx radioiodine remnant ablation rra contrast datum patient usually follow short term follow report change tgab level patient treat ttx without rra aim study evaluate change tgab level dtc patient treat ttx not rra identify factor influence change method change tgab level dtc cm patient submit ttx not rra evaluate patient follow median year little three determination tgab neck ultrasound nus result tgab level show progressive decrease follow initial tgab level degree lymphocytic infiltration influence time not rate tgab disappearance no influence time rate decrease tgab observe association thyroperoxidase antibody tpoab level consider tgab cutoff value iu ml \\ufeff1 postoperative evaluation good indicator disappearance tgab within six year no tumor recurrence observe series one case progressive increase tgab anticipate reappearance benign thyroid tissue lymphocytic infiltration conclusion tgab level decline majority dtc patient treat ttx not ablate radioiodine level decrease rapidly surgical treatment continue decrease time time disappearance influence initial tgab level degree lymphocytic infiltration no influence actual tpoab level observe increase tgab level not overlook since indicate presence reappearance either normal thyroid tissue tumor recurrence thyroid bethesda report category suspicious papillary thyroid carcinoma pitfall clue optimize use category objective bethesda system report thyroid cytopathology classify indeterminate category base differ risk malignancy atypia undetermined significance aus follicular neoplasm suspicious follicular neoplasm flus suspicious malignancy vast majority case last category suspicious papillary thyroid carcinoma ptc aim present study identify pitfall clue improve usage suspicious category good improve outcome malignancy method review cytological feature air dry diff quik alcohol fix papanicolaou smear thyroid fine needle aspirate fnas surgical follow originally diagnose suspicious procedure datum specimen adequacy correlate follow histology report review cytological review complete incidental ptc not target fna exclude calculation correlation result cytological review retain diagnosis suspicious case remain categorize follow malignant neoplasm use centre instead flus aus reason overcall suspicious case include pseudopapillae syncytial sheet nuclear groove pinpoint nucleolus chronic lymphocytic thyroiditis h rthle cell neoplasm intranuclear inclusion parathyroid adenoma hyalinizing trabecular adenoma mesenchymal repair primary reason undercall ptc suspicious include cystic aspirate minor feature ptc histiocytoid cell bubblegum colloid syncytial sheet cellular swirl case cytoplasm similar h rthle cell also note cause difficulty accurate classification conclusion recognition pitfall clue help improve diagnosis patient treatment consequently reduce numb unnecessary thyroidectomy assessment american college radiology thyroid image report datum system thyroid nodule malignancy risk stratification pediatric population objective purpose study assess diagnostic performance american college radiology acr thyroid image report datum system tirads malignancy risk pediatric thyroid nodule material method two radiologist review ultrasound image tissue prove thyroid nodule child point give individual feature add determine acr ti rad category range benign high suspicion kappa coefficient generate assess intra interobserver agreement generalize linear mix effect model use estimate odd malignancy construction supplementary roc curve result fifty four nodule benign malignant median acr ti rad category interquartile range nineteen malignant nodule rate ti rad category substantial intraobserver agreement p moderate interobserver agreement p tirads category univariable analysis show every unit increase ti rad category likelihood malignancy increase time ci p adjust nodule size ti rad category remain marginally associate malignancy adjust odd ratio ci p auc ci optimal cut point ti rad category select ti rad category nodule time ci p likely category nodule malignant conclusion acr ti rad discriminate good malignant benign nodule pediatric population particularly ti rad category prognostic implication molecular test thyroid cancer thyroid cancer common endocrine malignancy incidence increase past decade patient thyroid cancer excellent prognosis recurrence rate within year initial treatment mortality possible date no prospective braf activate long noncoding rna modulate papillary thyroid carcinoma cell proliferation regulate thyroid stimulate hormone receptor purpose importance long noncoding rnas lncrnas tumorigenesis recently demonstrate however role lncrnas development thyroid cancer remain largely unknown material method use quantitative reverse transcription polymerase chain reaction expression three lncrnas include unusual manifestation parathyroid carcinoma set papillary thyroid cancer objective describe rare manifestation parathyroid carcinoma association papillary thyroid carcinoma method describe clinical history finding physical examination result laboratory study image finding histopathologic feature woman previously palpable thyroid nodule mild hypercalcemia result year old woman present endocrinology clinic reevaluation thyroid nodule long stand hyperparathyroidism initially undergo assessment year previously time intact parathyroid hormone level pg ml reference range serum calcium concentration mg dl reference range conjunction normal alkaline phosphatase creatinine hydroxyvitamin level subsequently find multifocal papillary thyroid cancer right thyroid lobe cm parathyroid carcinoma leave side conclusion synchronous parathyroid thyroid carcinoma extremely rare knowledge current case \\ufeff1 document patient parathyroid carcinoma clinical presentation consistent longstanding mild adenoma addition synchronous papillary thyroid carcinoma thyroid parathyroid tumour patient submit x ray scalp epilation tinea capitis eradication campaign north portugal tinea capitis attain epidemical proportion 5 6 decade portugal country start utilization griseofulvin well approach treat tinea capitis infection x ray scalp epilation combine topical antimycotic ointment long term side effect therapy thyroid disease namely thyroid cancer datum parathyroid lesion hyperplasia adenoma carcinoma scarce observe clinically individual irradiate childhood tinea capitis treatment north portugal main purpose evaluate thyroid parathyroid tumour possible sequela irradiation treatment individual cervical ultrasound serum calcium measurement propose fine needle aspiration cytology suggest whenever ultrasound thyroid nodule present suspicious feature observe frequency thyroid nodule frequency thyroid carcinoma nineteen carcinoma diagnose us whereas remain carcinoma diagnose treat prior observation carcinoma significantly frequent woman man benign excise lesion also significantly frequent woman patient irradiate young age seven woman consider asymptomatic clinical observation laboratory sign hyperparathyroidism datum obtain namely high thyroid cancer frequency corroborate previous datum childhood irradiate cohort highlight need close follow population order identify treat early undiagnosed head neck lesion no evidence increase parathyroid disease find cohort head neck x irradiate patient critical remark medullary cancer thyroid medullary carcinoma thyroid mct rather uncommon neoplasia must correctly identify allow proper therapy author basis series consist surgically treat tumor thyroid report case mct none case diagnosis make surgery therefore stress achieve early diagnosis usefulness careful appraisal clinical datum complete biochemical histo pathological evaluation suspicious case policy allow exclude possibility doubt thyroglobulin washout cervical lymph node fine needle aspiration biopsy patient differentiate thyroid cancer analysis different expression use post total thyroidectomy follow introduction although frequently use adjunct cytology patient differentiate thyroid cancer interpretation thyroglobulin washout remain unclear aim compare utility different analytic tool develop recommendation use post total thyroidectomy follow method institutional review board approve retrospective study patient undergo lymph node fine needle aspiration biopsy thyroglobulin washout post total thyroidectomy follow differentiate thyroid cancer utility thyroglobulin washout concentration thyroglobulin washout serum thyroglobulin ratio absolute thyroglobulin content compare result sixty four patient undergo fine needle aspiration thyroglobulin washout cervical lymph node fifty two lymph node find metastatic benign one patient pathologically confirm lymph node metastasis despite thyroglobulin washout optimal cutoff thyroglobulin washout thyroglobulin washout serum thyroglobulin ratio absolute thyroglobulin content predict metastatic involvement ng ml sensitive specific sensitive specific sensitive specific respectively 2 measure lack utility patient undetectable serum thyroglobulin conclusion use thyroglobulin washout concentration thyroglobulin washout serum thyroglobulin ratio drawback base variation technique clinical scenario absolute thyroglobulin content alternative may objective expression thyroglobulin washout utility braf mutation detection fine needle aspiration biopsy sample read suspicious papillary thyroid carcinoma background purpose study evaluate diagnostic utility braf mutation test thyroid nodule suspicious papillary thyroid carcinoma ptc cytology method chart review patient fine needle aspiration fna result suspicious ptc subsequent thyroidectomy perform correspond archive fna slide undergo braf mutation test result sixty six patient fna suspicious ptc undergo thyroidectomy forty two ptc diagnose final histopathology whereas benign finding thirty five patient histologically prove ptc undergo total thyroidectomy whereas undergo hemithyroidectomy braf mutation detect sample available test sensitivity specificity positive predictive value ppv negative predictive value npv diagnose ptc two patient undergo hemithyroidectomy subsequent completion thyroidectomy mutate braf detect conclusion braf test useful adjunct improve ppv patient suspicious ptc cytology final outcome indeterminate cytology thyroid nodule district general hospital background diagnostic thyroid lobectomy perform resolve dilemma indeterminate thy cytology thyroid nodule final histology nodule benign thereby subject group patient surgery associate risk aim determine proportion cancer patient indeterminate thyroid nodule patient method retrospective observational study patient undergo fine needle aspiration cytology fnac thyroid nodule month period district general hospital patient demographics cytology final histology result extract hospital database result final analysis patient indeterminate cytology patient cancer group follow diagnostic lobectomy conclusion till alternative robust technology become widely available need continue perform diagnostic lobectomy patient indeterminate cytology view high incidence thyroid cancer group patient advancement diagnosis treatment differentiate thyroid cancer recent molecular study describe numb abnormality associate pathogenesis thyroid carcinoma distinct molecular event often associate specific stage tumor development may serve prognostic factor therapeutic target well understand mechanism involve thyroid cancer pathogenesis hopefully help translate discovery improve patient care predictor thyroid carcinoma israel national cohort adolescent follow year introduction datum adolescent precursor thyroid cancer adulthood scant method order evaluate potential risk factor thyroid cancer link two national datum source military recruitment health examination israel national cancer register study population participant include jewish male age year examine jewish female age year examine cancer follow extend multivariable cox proportional hazard model use result person year follow incidence case thyroid cancer identify mean age diagnosis year woman year man woman substantially high incidence birth cohort adjust hazard ratio hr ci p height predict incidence sex birth cohort adjust hr p male p female per cm increment height male not female grade association education measure year school incidence thyroid cancer body mass index not associate incidence multivariable analysis male female examine onward include sex birth year height education excess risk female persist strongly hr ci association height conclusion female sex measure height adolescence late birth cohort independent predictor thyroid cancer young middle age adult israel study need unravel mechanism whereby height associate thyroid cancer increase diagnosis thyroid papillary carcinoma follicular variant south east anatolian region comparison characteristic classical papillary follicular variant thyroid cancer aim compare ratio thyroid cancer diagnose regional reference hospital pathology center sanliurfa city locate southeast anatolia evaluate characteristic relate follicular variant papillary thyroid carcinoma fvptc evaluate specimen last year thyroidectomy five pathologist criterium immunohistochemical evaluation chi square test use compare characteristic classical pure papillary thyroid carcinoma fvptc group stepwise multiple regression analysis use evaluate factor relate presence fvptc among thyroidectomy papillary thyroid carcinoma pure ptc fvpc also seven variant increase ratio fvptc ptc vs p radius vascular invasion extrathyroidal invasion show statistically significant difference pure ptc fvptc regression analysis radius p ci age p ci multicentricity p ci relate presence fvptc besides need study understand whether total prevalence fvptc high region relate factor study show ratio fvptc ptc high reference hospital age patient radius multicentricity nodule can alarm factor us suspect fvptc ultrasonic method study puncture biopsy diagnose thyroid nodule result diagnosis thyroid node patient analyze ultrasonic examination us assist puncture biopsy carry operation result compare one morphologic study perform surgery solitary node diagnose patient multiple specific ultrasonic symptom different form thyroid node reveal thyroid cancer image hypoechogenic node clear unclear contour heterogeneous structure multiple zone hyperechogenicity calcification adenoma present isoechogenic homogenic node clear border cystic cavity colloid node picture rathen often different morphologic form node similar thus ultrasonic examination permit detect morphologic structure node hypothetically sensitivity puncture biopsy goiter adenoma cancer respectively cancer not diagnose surgery case colloid goiter adenoma suspect case small cancer locate amidst colloid node differ ultrasonic symptom diagnosis malignant tumor nodular goiter highly precise morphologic form cancer verify cytologically majority case preoperative ultrasound evaluation laterocervical lymph node time experience modify treatment patient differentiate thyroid cancer since laterocervical lymphadenectomy never routinely perform patient undergo thyroidectomy differentiate cancer must ultrasound examination us aim study assess accuracy preoperative us conduct time surgery stage us time compare us perform sometime location surgical department screen diagnostic us time determine necessity always perform preoperative us surgery patient cytologic diagnosis fnab differentiate thyroid neoplasm tyr tyr recruit surgery department general specialist surgery tertiary care hospital cardarelli naples patient screen us prior admission hospital time rescanned operate room surgery time team surgeon experience field thyroid disease examination conduct time reveal sensitivity specificity examination perform time show sensitivity specificity statistical analysis show diagnostic time experience examiner make difference term ppv npv not assist identify lymph node lesion would remain indeterminate not specifically research surgery also help avoid surgical overtreatment systematic execution stage us time addition screen diagnostic us time result form appropriate therapeutic plan microrna inhibit papillary thyroid cancer progression directly target insulin receptor substrate regulate pi k akt pathway micrornas mirnas mirs widely dysregulated papillary thyroid cancer ptc dysregulated mirnas together target gene comprise complex network implicate regulation ptc pathogenesis knowledge functional role aberrantly express mirnas ptc underlie molecular mechanism may assist identification novel therapeutic target mir good study human cancer however expression status specific role regulatory mechanism mir ptc remain unclear present study aim detect mir expression ptc tissue cell line explore biological role mir malignant biological behavior ptc cell determine underlie mechanism action mir ptc cell result reveal mir downregulated ptc tissue cell line downregulation strongly associate tnm stage lymph node metastasis overexpression mir inhibit ptc cell proliferation colony formation migration invasion promote cell apoptosis reduce tumor growth vivo mechanistically insulin receptor substrate irs identify direct target mir ptc cell irs upregulated ptc tissue inversely correlate mir expression inhibition irs simulate tumor suppressor activity mir ptc cell restoration irs expression negate tumor suppress effect mir overexpression ptc cell notably mir directly target irs inhibit activation phosphoinositide kinase pi k protein kinase b akt pathway ptc cell vitro vivo overall finding indicate mir may inhibit malignant biological behavior ptc cell directly target irs regulate pi k akt pathway thus suggest mirna may promise therapeutic target ptc tpo genetic variant risk differentiate thyroid carcinoma two european population thyroid cancer risk involve interaction genetic environmental factor thyroperoxidase tpo key role iodine metabolism essential thyroid function mutation tpo gene common congenital hypothyroidism also sign implication tpo thyroid cancer perform case control association study genetic variant tpo differentiate thyroid carcinoma dtc dtc patient control include two european population italy dtc control spain dtc control multivariate logistic regression analysis perform separately population single nucleotide polymorphism snp three study polymorphism significant association detect dtc r r population p italian population snps show negative association r odd ratio confidence interval ci p r ci p whereas spanish population snps show positive association r ci p r ci p correspond association papillary follicular thyroid cancer similar dtc within population no association detect 3 tpo polymorphism italian spanish population result \\ufeff1 time point tpo gene involve risk dtc suggest importance interaction tpo variant unidentified population specific factor determine thyroid cancer risk stromal modulation role diagnosis papillary pattern thyroid lesion papillary pattern lesion thyroid may challenge many diagnostic pitfall tumor stroma play important part determination tumor phenotype cd think involve modulation cell adhesion signal transduction cd fibrocytes potent antigen present cell smooth muscle actin sma positivity can diagnostic fibroblast activation tumorigenesis aim examine expression cd alphasma stroma papillary thyroid hyperplasia papillary thyroid carcinoma papillary tumor uncertain malignant potential order elucidate possible differential distribution role total numb case papillary thyroid lesion study routine hande stain cd asma immunostaining asma not express benign papillary hyperplastic lesion express papillary carcinoma indicate tumor modulate stroma although stroma not good develope papillary lesion equivocal feature uncertain potentiality cd notable case high incidence malignant case asma good cd can predict neoplastic behavior point importance stromal role difference group suggest presence cd stromal cell early event carcinogensis associate neoplasia however asma cell likely associate malignant behavior metastatic potential add additional tool light microscopic picture help diagnosis problematic case hande characterization papillary thyroid microcarcinomas use sonographic feature malignant papillary thyroid cancer retrospective analysis diagnosis malignant thyroid nodule still clinical challenge study aim determine ultrasonographic characteristic papillary thyroid carcinoma ultrasonographic pathological datum thyroid nodule cohort chinese patient undergo thyroidectomy january december retrospectively review anteroposterior transversal ap tr diameter solid structure infiltrative margin hypoechoic appearance microcalcifications common malignant nodule benign nodule p ultrasonographic feature independent risk factor malignancy p determine logistic regression analysis base multivariate analysis characteristic also present large nodule diameter mm however small nodule diameter mm ap tr infiltrative margin independent risk factor malignancy p ultrasonography high diagnostic value malignant thyroid nodule may help improve differential diagnosis small large nodule distinct ultrasonographic feature thyroid cancer incidence among people live area contaminate radiation chernobyl accident result chernobyl nuclear power plant accident massive amount radioactive material release environment large number individual live belarus russia ukraine expose radioactive iodine primarily iodine concentrate thyroid gland resident contaminate area child adolescent particularly affect decade accident substantial increase thyroid cancer incidence observe among expose child three affect country compel evidence association pediatric thyroid cancer incidence radiation exposure thyroid gland accumulate datum currently available suggest magnitude pattern thyroid cancer risk generally consistent report follow external exposure base datum certain peculiarity clinical picture cancer thyroid gland childhood adolescence background objective thyroid hemiagenesis rare embryological condition predominantly female leave lobe absent associate disease remain thyroid lobe include benign adenoma multinodular goiter hyperthyroidism chronic thyroiditis rarely carcinoma common pathology involve thyroid hemiagenesis hyperthyroidism presence carcinoma patient hemiagenesis quite rare case report world literature method report year old female present leave thyroid mass gradually increase size period month patient pre operative workup include thyroid scan reveal cold nodule leave lobe absent right lobe fine needle aspiration biopsy suspicious papillary thyroid carcinoma patient undergo thyroid exploration leave thyroid lobectomy result operative finding confirm hemiagenesis right lobe papillary carcinoma leave lobe four parathyroids normal position conclusion purpose presentation discuss review literature thyroid hemiagenesis present rare case absent right thyroid lobe carcinoma remain leave thyroid lobe pediatric differentiate thyroid carcinoma trend practice outcome year single tertiary care institution background study aim analyze change characteristic practice outcome pediatric differentiate thyroid cancer dtc tertiary care institution method patient year age diagnose identify clinicopathological datum treatment outcome obtain retrospective review result thirteen male female divide group n diagnose july group b n diagnose july group b likely undergo neck ultrasound us vs p concurrent medullary papillary carcinoma thyroid simultaneous occurrence papillary thyroid carcinoma ptc medullary thyroid carcinoma mtc thyroid gland rare condition tumor derive different cell ptc originate follicular cell whereas mtc originate parafollicular cell treatment tumor also differ article describe two rare case simultaneous occurrence mtc ptc thyroid gland gene expression profile radiation induce thyroid cancer question whether radiation induce thyroid cancer differ molecular biology sporadic disease still remain study tissue patient develope thyroid cancer chernobyl accident provide unique opportunity look biological consequence low dose irradiation compare gene expression profile sporadic papillary thyroid cancer ptc whose aetiology unknown ptc induce internal radiation far four transcriptomic study compare radiation induce sporadic thyroid cancer report however no final conclusion draw regard presence radiation signature either no difference note report difference not sufficiently convince due low numb case analyse presence confound factor list putative biological clinical factor may influence ptc gene expression profile long sufficient datum report literature link expression profile differ pathological variant ptc comparison expression profile tumour sample allow search radiation signature whereas comparison expression profile normal contralateral tissue offer substantial opportunity assess existence susceptibility radiation can responsible tumour development undertake analysis part european union fund project genrisk gene expression profile investigate tumour arise population expose fallout chernobyl e bear april compare profile tumour similar pathology arise age match population reside geographical area ethnicity bear january rna sample tumour contralateral normal tissue obtain chernobyl tissue bank several line evidence suggest predisposition develope cancer radiation exposure variable general population may measurable gene expression comparable outcome patient pt pt b differentiate thyroid cancer need change ajcc classification system introduction current american joint committee cancer tnm classification differentiate thyroid cancer dtc separate status b base cm cutoff maximal tumor dimension american thyroid association recommend total thyroidectomy tumor cm contrast possibility lobectomy tumor cm aim investigate prognostic significance cm tumor cutoff method institutional database patient dtc patient tumor without neck disease distant metastasis identify patient tumor treatment characteristic compare disease specific survival dss recurrence free survival rfs outcome analyze result total thyroidectomy rate similar patient b tumor p median follow month range no disease specific death b group total patient experience recurrence five year rfs comparable patient b tumor vs p conclusion b tumor similar prognosis term dss rfs seem distinction tumor cm no prognostic benefit cancer thyroid advance age background surgical strategy patient thyroid cancer tc infiltrate aerodigestive system controversial study undertake examine meta analysis clinical significance thyroidectomy combine central neck dissection differentiate thyroid carcinoma \\ufeff1 treatment objective compare difference recurrence rate surgical complication thyroidectomy alone thyroidectomy combine central neck dissection initial treatment differentiate thyroid cancer evaluate clinic significance central neck dissection patient method literature publish search wanfang database chongqing vip database chinese biomedical literature database china national knowledge infrastructure pubmed medline beijing kangjian foreign medical journal full text service accord inclusion deletion criterium article include article involve complication hypocalcemia recurrent laryngeal nerve palsy two major complication involve article article respectively article involve recurrence rate revman software package use perform meta analysis result total complication rate experimental group plus central neck dissection high control group thyroidectomy odd ratio confidence interval ci z value p hypocalcemia experimental group high control group value ci z p rate recurrent laryngeal nerve paralysis low experimental group control group value ci z p recurrence rate experimental group low control group value ci z p conclusion central compartment dissection initial treatment differentiate thyroid cancer may reduce risk recurrence increase incidence total complication hypocalcemia no significant effect rate recurrent laryngeal nerve paralysis predictive value serum thyroglobulin diagnostic image post surgical follow differentiate thyroid cancer important detect metastasis differentiate thyroid cancer total thyroidectomy major site metastasis neck lymphnodes lung bone purpose diagnostic whole body scan wbs serum thyroglobulin tg important tool wbs perform month surgery show metastasis treatment high dose therapeutic utility patient metastasis patient wbs tg pet ct may useful detect metastasis patient wbs tg follow periodically neck ultrasonography serum tg measurement ectopic thyroid cancer diagnose endobronchial ultrasound guide transbronchial needle aspiration report case papillary carcinoma mediastinal ectopic thyroid diagnose endobronchial ultrasound guide transbronchial needle aspiration ebus tbna case tumor adjacent central airway therefore attempt perform ebus tbna obtain specimen diagnosis papillary thyroid carcinoma surgical resection conduct histological evaluation resect specimen confirm ectopic papillary thyroid carcinoma consistent histology ebus tbna specimen safe minimally invasive procedure reconsideration tumor size threshold total thyroidectomy differentiate thyroid cancer background optimal extent surgery differentiate thyroid cancer may not good recognize initially identification intermediate risk feature surgical pathology may prompt need completion thyroidectomy lobectomy perform study examine factor relation need completion thyroidectomy method study consecutive patient undergo thyroidectomy differentiate thyroid cancer total thyroidectomy indicate tumor size cm clinical extrathyroidal extension clinical lymph node metastasis distant metastasis present need completion thyroidectomy define presence aggressive histology extrathyroidal extension lymphovascular invasion non low risk nodal metastasis result among patient definitely indicate total thyroidectomy need completion thyroidectomy identify patient initially eligible lobectomy proportion patient require completion thyroidectomy microcarcinomas tumor cm respectively receiver operate characteristic curve analysis indicate tumor size cm high accuracy prediction multivariate logistic regression reveal tumor size braf v e mutation independent factor predict risk require completion thyroidectomy conclusion substantial portion patient differentiate thyroid cancer preoperatively eligible lobectomy would find intermediate risk pathologic feature incorporate share decision make surgery sorafenib metastatic thyroid cancer although thyroid cancer usually excellent prognosis therapeutic option available refractory set base recent result phase ii study tyrosine kinase inhibitor design retrospective analysis patient metastatic thyroid cancer treat sorafenib seven spanish referral center consecutive patient progressive metastatic thyroid cancer papillary follicular medullary anaplastic not suitable curative surgery radioactive iodine therapy radiotherapy treat sorafenib mg twice day primary end point objective response rate rr secondary end point include toxicity median progression free survival mpfs median overall survival mos correlation tumor marker level thyroglobulin calcitonin carcinoembryonic antigen efficacy june january patient include study sixteen patient present differentiate thyroid carcinoma dtc seven papillary nine follicular medullary mtc three anaplastic atc eleven patient achieve partial response stable disease beyond month regard histological subtype rrs seven mtc three dtc one three atc median follow month mpfs month dtc mtc atc respectively tumor marker evaluate patient statistically significant association observe rr decrease tumor marker level p retrospective trial sorafenib show antitumor efficacy histological subtype thyroid cancer warrant development set occupational exposure pesticide biocide risk thyroid cancer objective assess association occupational exposure biocide pesticide risk thyroid cancer method use datum population base downregulated long noncoding rna linc inhibit epithelial mesenchymal transition invasion migration thyroid cancer cell inhibit methylation alx thyroid cancer represent one prevalent endocrine cancer relatively high incidence rate around world accompany unchanged fatality rate probe specific role linc mediation cellular process thyroid cancer include proliferation migration invasion methylation aristaless like homeobox alx thyroid cancer relate long noncoding rnas lncrnas gene analyze microarray base analysis antitumor effect linc examine gain loss function experiment addition bind linc promoter region alx interaction linc methylation relate protein detect late xenograft tumor nude mouse induce expect dig modulatory function linc tumor growth thyroid carcinoma microarray base analysis manifest linc overexpress whereas alx downregulated thyroid cancer result also verify thyroid cancer tissue besides result demonstrate linc bind alx promoter region linc recruit dnmt dnmt b protein promote methylation alx promoter region thus suppress alx expression finally downregulation linc upregulation alx repress akt mtor signal axis thus inhibit proliferative migratory invasive ability good epithelial mesenchymal transition emt thyroid cancer cell collectively downregulated linc suppress cell proliferation migration good invasion thyroid cancer inhibit methylation alx increase expression inactivation akt mtor signal pathway extent surgery low risk differentiate thyroid cancer although incidence thyroid cancer increase survival remain unchanged due concern overtreatment surgical management thyroid cancer evolve papillary thyroid microcarcinoma measure cm small consider low risk manage either thyroid lobectomy active surveillance total thyroidectomy no long recommend cancer unless evidence metastasis local invasion aggressive disease recommendation low risk differentiate thyroid cancer measure cm cm remain controversial article explore controversy extent surgery patient low risk low risk differentiate thyroid cancer anti thyroglobulin antibody risk find iodine avid metastasis metastasis submandibular gland extremely rare literature search retune three previously report case thyroid gland primary site herein report two case metastatic thyroid carcinoma submandibular gland year old woman ptc year old woman medullary thyroid carcinoma mtc metastasis identify ct pet ct one case ct case diagnose ultrasound guide fine needle aspiration case highlight rare ptc mtc metastasize submandibular gland minimal thyroid cancer clinical consequence previous epidemiological study report persistent organic pollutant pop nonpersistent pesticide risk thyroid cancer aim study assess association exposure pop pesticide thyroid cancer carry meta analysis literature search perform use pubmed embase reference list relevant article summary risk estimate thyroid cancer calculate use fix effect random effect model addition several subgroup sensitivity analysis carry fifteen study review eight study include meta analysis pesticide exposure show positive statistically significant association thyroid cancer odd ratio confidence interval ci pheterogenetiy subgroup analysis herbicide exposure ci agricultural exposure pesticide ci associate increase risk thyroid cancer sensitivity analysis show result robust exposure pesticide associate increase risk thyroid cancer meta analysis future study investigate exposure pop pesticide control potential confounder use biological sample importance lymph node metastasis follicular thyroid cancer many concept risk prognostic factor analysis differentiate thyroid cancer prognostic role lymph node metastasis follicular thyroid cancer ftc however still controversial perform retrospective trial patient ftc woman man mean follow year question whether lymph node metastasis radical thyroid surgery neck dissection contribute prognosis ftc univariate analysis demonstrate lymph node metastasesp tumor size p tumor stage p distant metastasis p gender p significant prognostic factor recurrence kaplan meier tumor size p lymph node metastasis p distant metastasis p influence mortality age extent surgery not significant recurrence gender mortality multivariate analysis cox regression test characterize tumor size p lymph node metastasis p prognostic factor recurrence ftc no significant difference detect patient treat thyroidectomy compare patient treat thyroidectomy plus neck dissection relation recurrence datum demonstrate lymph node metastasis significant prognostic factor recurrence ftc patient survival advocate thyroidectomy plus central lymph node dissection basic surgical strategy tumor unilateral modify neck dissection optional procedure whether radical surgery thyroidectomy plus neck dissection impact survival remain questionable investigation thyroid carcinoma year use database ion chiricuta institute oncology cluj napoca purpose purpose retrospective study analyse incidence trend thyroid cancer tc treat ion chiricuta institute oncology iocn romania method patient institute diagnose tc treat follow analyse epidemiological datum distribution age group sex histopathological diagnosis treatment year overall survival rate result tc increase fold last decade patient mean age standard deviation sd year although woman represent man patient man year overall survival rate low not significantly woman p patient age year old low year overall survival rate respectively conclusion aggressive histology old age male gender significantly influence survival rate high incidence tc underline necessity national regional tc registry improve epidemiological datum role functional image neoplasm thyroid iodine iodine suitable physical property enable use functional image thyroid iodine use routine test hyperthyroidism thyroid nodule whereas long sonographic diagnosis thyroid cancer support have aim differentiate thyroid carcinoma dtc favourable outlook overall cornerstone treatment total thyroidectomy tt follow need radiometabolic therapy lesion however show definite tendency recur case generally \\ufeff1 decade follow patient recurrence local surgical resection curative treatment option local recurrence good differentiate thyroid cancer intraoperative ultrasonography us significant help facilitate localization complete resection lesion aim study review author experience use diagnostic method clinical set thyroid neoplasm recurrence method january march patient dtc recurrence undergo intraoperative us exploration recurrence easily identify resect patient postoperative tireoglobuline tg undetectable result patient preoperative us confirm presence lesion patient digital exploration surgical field not yield definitively positive find whereas lesion easily palpable intraoperative us reveal presence pathologic tissue case examination time range minute median minute case surgical resection complete pathologic confirmation sample no necessity extend ablation conclusion intraoperative us significant help identification dtc recurrence particular lesion dimension small mm diameter facilitate radical excision tumor surgical field anatomical landmark alter previous surgery radiometabolic therapy response dullaart effect short term hypothyroidism lipid transfer high density lipoprotein parameter relate lipoprotein metabolism patient submit thyroidectomy thyroid cancer context repeat neck exploration difficult task patient recurrent metastatic cervical lymph node papillary thyroid carcinoma ptc objective aim retrospective study assess efficacy ultrasound us guide percutaneous ethanol injection pei treatment metastatic cervical lymph node ptc material method sixty nine patient previously undergo thyroidectomy ptc select inclusion however three patient late exclude due lack follow lymph node status determine us guide fine needle aspiration biopsy raise level thyroglobulin washout cytological needle guide us ml ethanol inject metastatic lymph node result three patient eight metastatic lymph node total reassign surgery due progression multiple new metastasis leave patient neck lymph node include mean observation time month range total metastatic lymph node respond pei treatment completely nine incompletely two not respond four progress two lymph node previously consider successfully treat show evidence malignancy follow no significant side effect report conclusion us guide pei treatment metastatic lymph node seem excellent alternative surgery patient limit numb neck metastasis ptc procedure replace berry pick surgery study group thyroid cancer mexico catimex collaborative study case understand prognostic factor risk group crucial management good differentiate thyroid cancer important prognostic factor age grade tumor extrathyroidal extension size tumor distant metastasis base prognostic factor patient divide low intermediate high risk group treatment decision base risk group analysis extent thyroidectomy adjuvant therapy base risk group analysis histopathologic study important distinguish good differentiate tall cell insular poorly differentiate thyroid cancer letter needle aspiration biopsy thyroid cancer diagnostic operative management thyroid cancer controversial nature disease heterogeneous growth rate pattern spread histological type therefore surgery must extensive enough minimize chance recurrence death period thyroid cancer observe accord histological type total thyroidectomy hemithyroidectomies isthmusectomy subtotal thyroidectomy perform cervical lymph node dissection perform patient year postoperative survival rate lymphadenectomy without lymphadenectomy iodine uptake focal bronchiectasis mimick metastatic thyroid cancer january september examine subject receive therapeutic irradiation primarily infection inflammatory disease upper respiratory tract institution tonsillar nasopharyngeal region treatment site examine palpable nodular thyroid disease find nonpalpable lesion detect tc pertechnetate thyroid image additional prevalence nodular disease operation nodular disease reveal thyroid cancer preliminary analysis potential risk factor suggest correlation radiation exposure presence thyroid nodule p little finding indicate nodular thyroid disease benign malignant continue major health problem little year expose subject nomogram predict contralateral central neck lymph node metastasis papillary thyroid carcinoma background objective central compartment neck dissection ccnd recommend patient papillary thyroid carcinoma ptc however whether perform contralateral ccnd remain unclear individualize estimation contralateral central neck metastasis cnm risk would assist tailor treatment ptc patient method consecutive patient undergo bilateral ccnd unilateral ptc tertiary center identify clinicopathological datum patient analyze retrospectively variable clinical significance final multivariate logistic regression model build nomogram assess risk metastasis contralateral central compartment model internally validate use bootstrap resample result nomogram demonstrate good calibration discrimination concordance index bootstrap correct variable great influence risk contralateral cnm model include tumor size numb positive lymph node extranodal extension ipsilateral central neck conclusion nomogram integrate three variable estimate individualize risk contralateral cnm unilateral ptc patient model may assist individual decision make regard contralateral ccnd help avoid treatment ptc j surg oncol wiley periodical inc randomize control trial use thymus honey decrease salivary gland damage follow radioiodine therapy thyroid cancer research protocol aim test effectiveness thymus honey complementary intervention decrease salivary gland damage due radioiodine therapy background radioiodine treatment choice people diagnose thyroid cancer follow total thyroidectomy although value acknowledge eradicate remnant thyroid tissue treat residual disease patient visible inoperable iodine avid metastasis associate various salivary gland side effect design randomize control trial mix within subject design method total participant postsurgical differentiate thyroid cancer refer centre therapy ablate remnant thyroid tissue treat metastatic tumour prospectively study vary regimen lemon candy standard treatment thymus honey mouthwash experimental intervention patient randomize four equally number group base assumption hypothesis study recruit process inform predefine inclusion exclusion criterium mix statistical model adopt take consideration within subject effect repeat measure discussion recommend intervention protocol expect improve comprehensive management salivary gland relate side effect induce radioiodine treatment people diagnose thyroid cancer methodological approach choose ideal intervention protocol term time initiate intervention frequency intervention acquire optimal result minimize salivary gland damage test identification unsuspected thyroid carcinoma use immunoperoxidase thyroglobulin two patient poorly differentiate metastatic cancer show metastatic thyroid carcinoma patient poorly differentiate cancer remain thyroid tissue neck diagnosis secure use immunoperoxidase technique antibody thyroglobulin proper evaluation patient carcinoma unknown primary involve specific tissue identification use special technique pathology implication suspicious afirma test result thyroid fine needle aspiration cytology institutional experience background fine needle aspiration fna biopsy frequently use method thyroid nodule evaluation however case consider indeterminate surgery typically recommend case two third indeterminate case find benign afirma test use preoperative classification thyroid nodule indeterminate cytology study review author institutional experience afirma method cohort case thyroid fna afirma test select study file relevant information record analyze study institution afirma mainly perform atypia undetermined significance aus follicular lesion undetermined significance flus case diagnose repeat fna result cohort include female male patient cytology diagnosis aus flus case follicular neoplasm fn case fn oncocytic feature fnof case fnof case suspicious afirma finding malignant benign fn case suspicious afirma finding malignant benign aus flus case suspicious afirma finding malignant benign conclusion afirma classifier useful tool aid distinction cytologically indeterminate nodule perform afirma case diagnose aus flus repeat fna would increase positive predictive value thereby minimize numb benign case refer surgery result afirma test can limit case diagnose fnof ultrasound thyroid elastography use carotid artery pulsation preliminary study objective purpose study evaluate feasibility ultrasound thyroid elastography use carotid artery pulsation compression source potential differential diagnosis thyroid nodule method baseband sonographic datum acquire thyroid nodule patient natural pulsation carotid artery use compression source thyroid strain estimate offline quantitative assessment thyroid tissue stiffness new metric call thyroid stiffness index tsi compute ratio strain near carotid artery high strain region stiff region low strain region inside thyroid nodule stiffness information elastography correlate histopathologic finding result tsi papillary carcinoma n high tsi benign nodular goiter n indicate papillary carcinoma stiff benign nodular goiter p patient able distinguish papillary carcinoma nodule benign nodular goiter locate thyroid lobe base stiffness information obtain elastography suggest elastography can use guide fine needle aspiration biopsy thyroid nodule high probability cancer conclusion result preliminary study indicate feasibility pulsation induce thyroid elastography ultrasound thyroid elastography use carotid artery pulsation appear potential noninvasively differentiate papillary carcinoma benign nodular goiter future study need evaluate efficacy elastography detect thyroid cancer guide thyroid biopsy knockdown trim inhibit proliferation invasion papillary thyroid cancer cell suppress wnt catenin signal pathway tripartite motif trim member trim family function critical regulator several type malignancy however role trim thyroid cancer never reveal thus study explore role ptc detect expression pattern human papillary thyroid cancer ptc tissue cell line investigate effect cell proliferation invasion result demonstrate trim highly express human ptc tissue cell line addition silence trim significantly suppress proliferation migration invasion epithelial mesenchymal transition emt process ptc cell furthermore silence trim dramatically regulate expression case rapidly grow recurrent thyroid carcinoma perform tracheobronchial expandable metallic stent ems therapy case year old female undergo operation right lobectomy thyroid resection neck enlarge cystic lymph node pathological result adenomatous goiter metastatic lymph node papillary thyroid carcinoma primary lesion thyroid carcinoma not find four year operation local recurrence anaplastic formation tumor occur tracheobronchial expandable metallic stent ems therapy perform tracheal stenosis die rapidly enlargement anaplastic thyroid carcinoma two month stent therapy necessary observe case severely \\ufeff1 operation primary lesion thyroid carcinoma not resect tracheobronchial ems therapy effective respiratory failure short term cause tracheal stenosis thyroid anaplastic carcinoma novel target therapy immunotherapy advance thyroid cancer thyroid cancer frequently encounter endocrine malignancy despite favorable prognosis disease differentiate thyroid cancer dtc case anaplastic type remain resistant standard treatment option include radioactive iodine rai addition around medullary thyroid cancer mtc case show resistance surgery evolve understand disease specific molecular therapeutic target lead approval two target therapy sorafenib lenvatinib rai refractory dtc another two drug vandetanib cabozantinib mtc advance therapy exert effect block mapk pathway widely correlate different type thyroid cancer drug remain reserve thyroid cancer patient fail treatment option ability improve patient overall survival remain hinder low efficacy molecular factor among factor tumor ability activate parallel proliferative signal pathway cascade block drug along overexpression tyrosine kinase receptor tkr fact urge search novel different treatment strategy advance thyroid case beyond drug furthermore grow knowledge dynamic immune system interaction tumor microenvironment revolutionize cancer immune therapy field review aim discuss molecular escape mechanism thyroid tumor drug also highlight novel therapeutic option target pathway mapk include pi k pathway alk translocation receptor clinical impact also aim discuss usage target therapy restore thyroid tumor sensitivity rai finally turn extensively discuss role immunotherapy potential alternative treatment option advance thyroid disease extracorporeal oxygenation support curative surgery patient papillary thyroid carcinoma invade trachea objective local extension thyroid carcinoma result massive invasion trachea cause severe airway compromise pre peri operative management airway compromise difficult critical report use extracorporeal oxygenation support alternative peri operative airway management option situation approach facilitate curative surgery patient papillary thyroid carcinoma invade trachea method present case report regard extracorporeal oxygenation support patient locally advance thyroid carcinoma result patient year old woman aggressive thyroid papillary carcinoma invade trachea airway almost totally obstruct tracheal resection end end anastomosis plan venovenous bypass catheter place cardiopulmonary bypass use bilateral femoral vein curative surgery reconstruction perform successfully general anaesthesia assist cardiopulmonary bypass oxygenation conclusion cardiopulmonary bypass oxygenation safe effective alternative airway management option patient locally aggressive thyroid cancer comparative characteristic thyroid cancer morbidity base clinical datum comparative assessment incidence thyroid cancer patient operate different thyroid disease case group case group carry increase incidence thyroid cancer group patient note good incidence cancer development among hyperplastic disease thyroid gland autoimmune thyroiditis particular result obtain indicative necessity correction tactic treatment prophylactic follow patient different form goiter identification metastatic papillary thyroid carcinoma fna specimen use thyroid peroxidase immunohistochemistry introduction evaluate immunohistochemical stain thyroid peroxidase tpo glycoprotein find apical plasma membrane thyroid follicular cell marker metastatic ptc fna sample compare result thyroglobulin tg thyroid transcription factor ttf stain method cell block section prepare fna specimen stain rabbit monoclonal antibody tpo ep fnas include metastatic malignancy non thyroid primary site include lung case thyroid tumour ptc six case medullary thyroid carcinoma one thyroid anaplastic carcinoma thyroid tumour stain ttf tg addition tpo case metastatic lung carcinoma also ttf stain result result tpo stain negative non thyroid malignancy ninety percent ptc positive positive case show strong cytoplasmic stain although show positivity little half cell comparison tg stain tpc case present ttf addition show high sensitivity interpretation stain result tpo generally easy tg metastatic lung adenocarcinoma positive ttf tpo negative six medullary cancer show positivity tpo tg ttf respectively conclusion tpo mab ep may useful addition immunohistochemical panel fna specimen metastatic ptc consideration particularly case metastatic lung carcinoma feature differential diagnosis clinicopathologic characteristic familial versus sporadic papillary thyroid carcinoma objective investigate clinicopathologic feature familial papillary thyroid carcinoma ptc compare sporadic ptc method january august patient undergo surgery liaoning cancer hospital institute diagnose familial ptc compare clinicopathologic characteristic familial ptc sporadic ptc result prevalence familial ptc median age patient diagnosis year female male thirty percent familial ptc case exhibit parent offspring relationship exhibit sibling relationship significant difference familial ptc sporadic ptc term concomitant chronic thyroiditis p nodular goiter p tumor multicentricity p bilaterality p histological subtype p central lymph node metastasis p familial ptc patient classify base parent child sibling relationship significant difference preoperative tsh level p concomitant chronic thyroiditis p two category conclusion significant difference clinicopathologic feature familial ptc sporadic ptc familial ptc parent child sibling relationship familial ptc appear aggressive sporadic carcinoma optimal treatment familial ptc not yet establish improve awareness screen permit early detection timely intervention improve outcome patient family thyroid cancer delay effect head neck irradiation child neovascularization carcinogenesis tumor progression good establish molecular mediator implicate different mode vascular remodel expansion e g sprout angiogenesis sa vasculogenesis vascular mimicry evaluate prognostic biomarker therapeutic target different malignant tumor significant progress make understand complex interplay thyroid cancer tc cell tumor microenvironment thus unravel role angiogenic mediator area cover review summarize current research neovascularization tc current knowledge vascular remodel context carcinogenesis present preclinical clinical datum tc study also discuss expert opinion remarkable effort pharmacologically target several key molecule vessel form cascade despite encourage preclinical result clinical outcome tc not optimal possibly reflect knowledge gap pathophysiology neovascularization thyroid tissue increase amount datum support possibility redundancy pathway regulate vascular network remodel allow tumor adapt different condition hypothesize alternative form neovascularization upregulate sa pharmacologically block target two different pathway neovascularization can promise future strategy research require explore molecular mechanism neovascularization tc rapid control thyrotoxicosis patient metastatic follicular thyroid cancer treat lenvatinib background radioactive iodine rai remnant ablation use eliminate normal thyroid tissue may also facilitate monitor persistent recurrent thyroid carcinoma use rai low risk patient define age stage disease age stage ii disease base american joint committee cancer ajcc th edition low risk metastasis age completeness resection invasion size macis stage system value controversial extensive literature review seek analyze evidence use rai treatment improve mortality survival reduce recurrence patient various stage disease risk particularly patient low risk recurrence death thyroid cancer method medline search conduct study publish january april compare effectiveness administer versus not administer rai treatment differentiate thyroid cancer dtc study group base methodological rigor well wrong analysis focus group study perform determine whether treatment rai dtc result decrease recurrence improve survival rate result majority study not find statistically significant improvement mortality disease specific survival low risk patient treat rai whereas improve survival confirm high risk ajcc stage iii iv patient evidence rai decrease recurrence mix half study show significant relationship half show no relationship conclusion propose management guideline base patient risk low low moderate high clinician use delineate patient undergo rai treatment initial postoperative management dtc majority low risk low risk patient good select case patient moderate risk not demonstrate survival disease free survival benefit postoperative rai treatment therefore recommend postoperative rai case thoracic uptake previous pneumonectomy patient treat differentiate thyroid cancer patient treat differentiate thyroid cancer radioiodine abnormal uptake post therapeutic whole body scan may lead repeat administration uptake not link thyroid cancer condition recognize patient not overtreated describe case unilateral thoracic uptake patient previously treat pneumonectomy lung cancer without evidence persistent lung cancer new subgrouping small thyroid carcinoma clinicopathologic finding small thyroid carcinoma measure mm little diameter analyze thyroidectomied case author divide small thyroid tumor two subgroup accord diameter little equal mm classify minute carcinoma little little equal mm classify tiny carcinoma characteristic include sex age histologic type extrathyroid invasion lymph node metastasis examine subgroup patient minute carcinoma incidence extrathyroid invasion lymph node metastasis find however involvement especially lymph node metastasis find frequently patient tiny carcinoma incidence cervical lymph node metastasis minute carcinoma tiny carcinoma p little finding suggest need careful observation treatment tiny carcinoma especially respect lymph node metastasis accordance world health organization classification histologic type thyroid carcinoma classify papillary follicular carcinoma papillary carcinoma follicular carcinoma ratio compare two subgroup discovery rate follicular carcinoma significantly high minute carcinoma tiny carcinoma p little suggest papillary carcinoma follicular carcinoma ratio p f increase size carcinoma increase follicular carcinoma seed initial form thyroid cancer female male ratio small thyroid cancer suggest no sex difference carcinogenesis probability cancer development thyroid woman improve detection not fully explain rise incidence background increase incidence thyroid cancer may artifact increase diagnostic scrutiny permit detection small subclinical thyroid cancer objective examine trend incidence good differentiate thyroid cancer large size adverse pathological feature method detail population base analysis incidence trend good differentiate thyroid carcinoma surveillance epidemiology end result seer cancer registry use weight little square joinpoint regression model result incidence good differentiate thyroid cancer wdtc unite state triple since p incidence trend differ significantly geographic region racial group large wdtcs include cm cm double incidence p cancer extrathyroidal extension cervical metastasis also double incidence p conclusion model improve screen explain increase diagnosis small thyroid cancer significant rise incidence large cancer cancer clinically significant pathological adverse feature hard explain alternative hypothesis include true increase cancer incidence would seem merit exploration aggressive variant papillary thyroid carcinoma wrong clinical outcome classic papillary thyroid carcinoma objective evidence unfavorable outcome type aggressive variant papillary thyroid carcinoma av ptc not clear previous study focus tall cell variant tcv not control major confound factor contribute clinical outcome design retrospective cohort study method study include patient classical ptc cptc av ptc include tcv columnar cell variant ccv hobnail variant disease free survival dfs dynamic risk stratification drs compare two one propensity score match age sex tumor size lymph node metastasis extrathyroidal extension result av ptc group significantly low dfs rate match cptc group hr ci p tcv ccv evaluate separately no significant difference dfs drs patient tcv n match cptc however ccv group n significantly poor dfs match cptc group hr ci p drs significantly patient structural incomplete response ccv group compare match cptc group p ccv independent risk factor structural persistent recurrent disease multivariate analysis hr ci synchronous primary triple cancer include lung stomach thyroid case report year old man synchronous multiple primary cancer involve lung stomach thyroid admit initially patient chest x ray show abnormal shadow right middle lobe indicate lung cancer preoperative examination gastric cancer antrum angle detect excisional biopsy lymph node neck chest surgery reveal thyroid cancer middle lobectomy mediastinal lymph node dissection perform lung cancer histological diagnosis moderately differentiate adenocarcinoma pt n stage iiib gastric cancer treat endoscopic mucosal resection consider relatively well prognosis papillary thyroid cancer conclude no treatment thyroid lesion necessary japan accord autopsy report triple primary cancer gradually increase period incidence triple cancer autopsy case report difference latin american american association thyroid cancer guideline objective study aim investigate difference metabolomic profile patient receive different surgery papillary thyroid carcinoma ptc method two surgical method e unilateral total thyroidectomy employ accord different disease condition serum patient treat levothyroxine sodium tablet surgery analyze bruker hz nuclear magnetic resonance nmr spectrometer datum analyze via principal component analysis pca partial little square discriminate analysis pl da simca p software metabolite obtain compare \\ufeff1 2 principal component select pca pl da orthogonal partial little square discriminate analysis opls da p value little consider statistically significant result significant difference serum metabolomics surgery compare unilateral thyroidectomy total thyroidectomy reverse highly increase metabolite level e g taurine betaine significant variation abnormal metabolite note total thyroidectomy unilateral thyroidectomy e g alanine choline hippurate formic acid conclusion choice surgical method ptc patient base not tumor condition also potential consequence metabolic variation total thyroidectomy reverse increase metabolite level lead accumulation metabolite due loss thyroid function thus metabolic disturbance cause thyroid hormone deficiency prevent advance obstructive endotracheal lesion thyroid cancer airway invasion life threaten complication thyroid cancer important issue deserve well attention differentiation clinical feature tracheal wall invasion versus obstructive endotracheal lesion present information clinical course diagnostic modality utilize management institute along prognosis follow datum group patient present obstructive endotracheal lesion thyroid cancer two thousand four hundred eighty nine thyroid cancer patient see institution december may thirteen patient present symptom respiratory distress relate obstructive endotracheal lesion presentation patient undergo endoscopic examination image study consist whole body scan wbs compute tomography magnetic resonance image ct mri neck chest whole body positron emission tomography use fluoro deoxy glucose fdg pet do also determination tumour marker serum thyroglobulin tg calcitonin patient follow one month initial presentation intraluminal tracheal obstruction severe eight patient five near total occlusion paralysis vocal fold present five evidence metastatic disease present patient dissociation iodine uptake tg synthesis evident five patient follow four patient die cancer nine live patient cancer persist six recur two patient remit one study identify obstructive endotracheal lesion thyroid cancer distinct entity apart tracheal wall disease datum provide evidence intraluminal tracheal invasion thyroid cancer ominous sign frequent cause morbidity iodine deficiency belarusian child possible factor stimulate irradiation thyroid gland chernobyl catastrophe ten year chernobyl nuclear plant catastrophe child belarus suffer thyroid cancer major cause high incidence thyroid cancer child year age appear contamination result catastrophe mainly isotope radioactive iodine another important factor may iodine deficiency environment countrywide program investigation goiter prevalence iodine deficiency establish republic belarus assistance european world health organization office program oversee examination child adolescent year age school urban rural area result obtain group child adolescent pilot phase typical significant iodine deficiency moderate goiter endemism clear present situation not completely reflect situation exist time chernobyl catastrophe however datum epidemiologic study conduct many year accident show high goiter prevalence contaminate area indicate prevalence iodine deficiency time catastrophe similar present one even great assumption can lead well understand thyroid pathology observe unusual muscular metastasis papillary thyroid carcinoma detect fluorine fluorodeoxyglucose pet mri single multiple thyroid metastasis extra thyroid primary tumor report rare malignancy metastasize thyroid include cancer originate lung breast kidney report experience case thyroid metastasis detect year curative kidney surgery renal cell carcinoma year patient note sudden appearance lump neck ultrasonography show presence multinodular goiter nodule cold scintiscan total thyroidectomy perform histology nodule reveal metastatic thyroid cancer renal cell carcinoma patient still alive good health month thyroidectomy history patient thyroid nodule include inquire extra thyroid malignancy especially renal cell carcinoma may diagnose even many year early corollary follow patient include periodic thyroid exploration little physical examination thyroid cancer grave disease background lymph nodal involvement common differentiate thyroid cancer addition cervical lymph node micrometastases observe papillary thyroid cancer last decade role routine central lymph node dissection rcld treatment papillary thyroid cancer ptc object research still controversial nevertheless many scientific society referral author definitely state even expert hand rcld not associate high morbidity indicate select case main body order well analyze current role prophylactic neck dissection surgical treatment papillary thyroid cancer analysis recent literature datum perform prophylactic therapeutic lymph node dissection selective lateral central lymph node dissection modify radical neck dissection papillary thyroid cancer use author keyword perform pubmed database research literature review ptcs large clinical series recent guideline different referral endocrine society inhere neck dissection papillary thyroid cancer also specifically evaluate high ptc incidence nowadays report differentiate thyroid cancer dtc clinical series addition ultrasound guide fine needle aspiration citology allow precocious diagnosis early phasis disease role prophylactic neck dissection papillary thyroid cancer management remain controversial especially regard indication approach surgical extension even morbidity rate seem similar report total thyroidectomy alone rcld impact local recurrence long term survival still matt research nevertheless selective use high risk case support scientific datum conclusion last year high papillary thyroid cancer incidence precocious diagnosis worldwide report among endocrine neck surgeon agreement indication prophylactic treatment node negative high risk patient recent trend toward rcld avoid radioactive treatment still debate nevertheless prophylactic dissection low risk case avoid prospective randomize trial need evaluate benefit different approach allow draw definitive conclusion papillary thyroid microcarcinoma struma ovarii oleanolic acid oa naturally occur triterpenoid possess antitumor activity several tumor cell line however potential mechanism underlie oa induce thyroid carcinoma cell death poorly understand investigate biological function oa perform migration invasion colony formation apoptosis assay sw cell forkhead box foxa expression use predict poor prognosis patient thyroid carcinoma among tcga sample ualcan gene expression profile interactive analysis database western blot use detect protein expression level result reveal oa inhibit migration colony formation invasion thyroid carcinoma cell dose dependent manner investigation verify oa treatment induce significant apoptosis thyroid carcinoma cell moreover high foxa expression predict poor prognosis patient thyroid cancer proliferation migration invasion thyroid carcinoma cell significantly decrease foxa silence oa significantly increase akt phosphorylation reduce foxa expression sw cell pi k akt inhibitor ly attenuate oa induce foxa downregulation furthermore akt overexpression suppress foxa expression sw cell addition molecular dock assay reveal oa possess high affinity toward foxa low bind energy oa may potential chemotherapeutic agent thyroid carcinoma cell cancer relate worry canadian thyroid cancer survivor context little know cancer relate worry thyroid cancer survivor objective quantify cancer relate worry canadian thyroid cancer survivor explore associate factor design set participant perform cross sectional self administer write survey thyroid cancer survivor member thyroid cancer canada support group independent factor associate cancer relate worry identify use multivariable linear regression analysis main outcome measure use assessment survivor concern asc questionnaire include question worry diagnostic test 2 primary malignancy recurrence dye health child health result response rate eligible member respondent woman age year participant thyroid cancer diagnose within year participant mean overall asc score sd scale little worry worry factor associate increase asc score include young age p current suspect prove recurrent persistent disease ie current prove active disease abnormal diagnostic test p partner marital status p child p year since thyroid cancer diagnosis p conclusion population canadian thyroid cancer survivor cancer relate worry great young survivor either confirm suspect disease activity family status time since thyroid cancer diagnosis also associate increase worry research need confirm finding develop effective preventative supportive strategy risk surgical treatment reconstruction thyroid carcinoma invade cervical esophagus trachea full thickness objective summary clinical therapy experience thyroid carcinoma invade cervical esophagus trachea full thickness reconstruction improve survival rate quality life patient method patient thyroid carcinoma inviding cervical esophagus trachea patient operate total thyroid resection patient operate one lobectomy side subtotal thyroid resection patient operate partial lobectomy trachea local recection intubation perform patient partial laryngectomy pyriform sinus resection trachea local recection intubation perform patient case operate tracheal sleeve resection end end anastomos result patient primary heal without tracheal anastomosis fistula tracheal wall necrosis esophageal fistula pharyngeal fistula one case hypoparathyroidism operation take favorable turn month late seven case dead year year year survival rate thyroid papillary carcinoma inviding cervical esophagus trachea year year year survival rate thyroid carcinoma inviding cervical esophagus trachea conclusion thyroid carcinoma invade cervical esophagus trachea population base study evaluate predict probability death result thyroid cancer cause among patient thyroid cancer purpose purpose study evaluate probability death patient thyroid cancer construct comprehensive nomogram base compete risk model predict cumulative incidence death result thyroid cancer cancer non cancer relate cause patient method patient diagnose thyroid cancer select study surveillance epidemiology end result program estimate probability death result thyroid cancer cancer noncancer cause analyze association patient tumor characteristic probability death nomogram predict probability death build use proportional subdistribution hazard compete risk model result entire cohort comprise patient malignant thyroid cancer median duration follow censor death month range month five year probability death result thyroid cancer cancer noncancer cause respectively increase age tumor size male sex poorly differentiate carcinoma lymph node involvement regional metastatic disease associate increase cumulative incidence death result thyroid cancer conclusion nomogram base compete risk model develope predict probability death patient thyroid cancer performance model excellent nomogram may useful patient clinician prediction need thyrotropin thyroid cancer diagnosis systematic review dose response context tsh major growth factor thyrocytes may causative role thyroid cancer objective objective study systematically assess association serum tsh thyroid cancer datum source medline embase database search use synonym tsh thyroid cancer supplement reference list search author contact study selection prospective cohort case control cross sectional study identify tsh exposure thyroid cancer outcome datum extraction three reviewer independently extract datum study report odd ratio tsh level thyroid cancer analyze via meta analysis generalize little square trend estimation dose response relationship datum synthesis datum extract study include total subject thyroid cancer case dose response spline analysis reveal nonlinear relationship p tsh level little mu liter thyroid cancer per milliunits per liter however relationship change tsh level mu liter great thereafter per milliunits per liter study control autoimmunity report low tsh mu liter per milliunits per liter tsh mu liter great per milliunits per liter six group assess serum tsh relation marker poor thyroid cancer prognosis three show significant positive relationship conclusion high serum tsh concentration associate increase risk thyroid cancer thyroid autoimmunity may partially explain association epidemiological assessment require future clinical research investigate validity include serum tsh diagnostic nomograms prognostic importance potential therapeutic tsh suppression thyroid cancer prevention not numb location lymph node matter recurrence rate disease free survival patient differentiate thyroid cancer background several japanese study focus identify prognostic factor patient positive lymph node predict recurrence rate disease free survival dfs however different treatment protocol follow japan compare european american approach study design investigate whether numb location lymph node predict prognosis patient dtc treat total thyroidectomy lymph node dissection postoperative radioactive iodine ablation method patient treat department nuclear medicine dtc review patient treat near total thyroidectomy lymph node dissection indication postoperative ablation median follow range month outcome measure recurrence rate disease free survival mean time recurrence result ninety seven patient prove lymph node metastasis recurrence rate significantly high patient positive lymph node lateral compartment vs patient lymph node metastasis central compartment vs p disease free survival mean time recurrence also significantly short vs month p vs month p respectively numb lymph node extranodal growth not significantly associate outcome measure use conclusion location positive lymph node significantly correlate risk recurrence short dfs hence tnm criterium useful subdivide patient base risk recurrence dfs use baseline recombinant human tsh stimulate tg measurement manage thyroid cancer without diagnostic scan early diagnosis thyroid cancer ultrasonography us us guide induction ttf pax expression proliferation tumorigenicity thyroid carcinoma ttf pax responsible thyroid organogenesis maintenance differentiation thyrocytes thus hypothesize induction two transcription factor can affect proliferation tumorigenicity moreover ability various pharmacological agent modulate expression ttf pax effect apoptosis also analyse purpose cell line derive papillary tpc bhp anaplastic aro thyroid carcinoma stably transfect expression vector contain ttf pax gene subsequently effect expression gene protein level good cell growth cell cycle migration vivo tumorigenicity study result show ttf reciprocally induce pax expression ii basal state ttf pax influence proliferation migration tumorigenicity iii induction ttf act cell proliferation pax mainly affect tumorigenicity iv ttf find sensitive epigenetic modulator pax therefore postulate ttf pax co express anti proliferative anti tumorigenic property threshold expression level beyond able induce pro tumorigenic effect hence future quite interest systematically take account basal state expression ttf pax also important study two thyroid transcription factor part duo can open long term new therapeutic perspective thyroid carcinoma elevate level tsh may predictive differentiate thyroid cancer suppression therapy thyreostimulin tsh use thyroid hormone improve survival subject operate differentiate thyroid cancer tsh level may different depend type nodule objective study compare retrospectively tsh level two group subject undergo total thyroidectomy nodule match sex ethnicity age biological method tsh measurement one whose final histology benign one malignant no significant difference two group term age sex family history thyroid disease thyroid autoimmunity subject whose final histology malignant mean tsh level significantly high subject benign disease mu l versus mu l p cancer risk great tsh upper tertile normal range no correlation risk thyroid cancer age sex family history thyroid disease menopausal status relative risk thyroid carcinoma high margin nodule blur presence microcalcifications datum confirm trend toward baseline value tsh high subject thyroid differentiate cancer however can not define preoperative threshold would reliably determine malignant benign nature nodule polymorphism select dna repair gene cell cycle regulate gene involve risk papillary thyroid carcinoma background papillary thyroid carcinoma ptc common type thyroid cancer addition causal somatic mutation braf gene ret ptc rearrangement contribution single nucleotide polymorphism snps low penetrance gene development ptc propose method four snps xrcc arg gln arg arg trp c one snp three gene participate dna repair pathway cell cycle regulation atm asp asn tp arg pro cdkn b val gly select allelic genotypic distribution variant good haplotype xrcc examine individual comprise good characterize cohort ptc patient healthy volunteer correlation polymorphism clinical pathological datum mutation status perform result xrcc c polymorphism affect genetic susceptibility ptc development man specific combination xrcc haplotype correlate ret ptc incidence cdkn b val gly significantly influence risk develope ptc regardless gender ptc case select genotype tp arg pro atm asp asn significantly associate monitor tumour characteristic conclusion seem snps study regulate gene contribute development ptc modify tumour behaviour characteristic long intergenic non code rna predictive poor prognosis papillary thyroid cancer numb long non code rnas lncrnas find play critical role oncogenesis tumor progression aim investigate whether lncrnas can act prognostic biomarker papillary thyroid cancer ptc may assist us evaluate disease status prognosis patient find lncrnas expression alteration annotate lncrnas approve hugo gene nomenclature committee cancer genome atla tcga dataset fam c ctbp linc har linc associate recurrence adjust classical clinicopathogical factor braf v e mutation linc find independent risk factor extrathyroidal extension lymph node metastasis advance tumor stage iii iv recurrence multivariate analysis additionally linc expression significantly downregulated ptcs versus adjacent normal tissue p gene set enrichment analysis gsea reveal gene associate cell adhesion molecule cell cycle p signal pathway jak stat signal pathway remarkably enrich low linc versus high linc tumor conclusion linc identify possible suppressor gene ptc study may serve potential predictor poor prognosis ptc detection residual lesion metastasis medullary thyroid cancer persistent hypercalcitoninemia represent frequent situation particularly case inadequate surgery medullary throid carcinoma mtc event conduct surgical exploration exclude presence distant metastasis adequate initial surgical treatment localisation residual recurrent tumor tissue often difficult conventional image technique immunoscintigraphy selective venous sample calcitonin measurement good diagnostic sensitivity cervical mediastinal localisation also distant metastasis however complete remission not rule cervical mediastinal reintervention propose patient free distant metastasis underline necessity early diagnosis mtc adequate \\ufeff1 neck operation new perspective regard anaplastic thyroid carcinoma approach improvement background objective anaplastic thyroid carcinoma rare represent deadly type thyroid cancer characterise rapid course diagnosis usually make late stage half patient distant metastasis main purpose review current information anaplastic thyroid aetiology risk factor may contribute early diagnosis good give new perspective regard recent treatment option future direction result treatment option mainly palliative lack efficacy particular multikinase inhibitor braf inhibitor direct agent aim stabilize tumour growth may enable radical surgery curative intent conclusion mutational landscape investigation discovery new target new direct treatment try consider current tendency conservative regard multinodular goiter approach differentiate thyroid carcinoma treatment vital understand may evolve anaplastic cancer thyroid cancer pediatric age sicily influence volcanic environment background aim pediatric thyroid cancer tc rare incidence increase analyze incidence characteristic pediatric tc sicily comparatively evaluate datum volcanic non volcanic area material method incident pediatric year tcs sicily analyze area residence compare datum adult result total differentiate tcs dtc nine medullary tcs diagnose sicily child dtc age standardize rate world population asrw female male high incidence volcanic area asrw female male vs rest sicily asrw female male pediatric tcs large size frequently extrathyroid extension lymph node involvement comparison tcs adult conclusion volcanic environment sicily tc incidence markedly increase child suggest short term effect unidentified carcinogen volcanic origin pregnancy outcome thyroid cancer background thyroid cancer one common cancer woman reproductive age purpose evaluate association thyroid cancer maternal neonatal outcome pregnancy method conduct retrospective cohort study use healthcare cost utilization project nationwide inpatient sample hcup nis database us cohort consist woman deliver create multivariate logistic regression control baseline maternal characteristic use compare pregnancy complication neonatal outcome pregnant woman thyroid cancer international classification disease 9 edition icd code diagnose pregnancy obstetric population without thyroid cancer result study include pregnant woman woman diagnosis thyroid cancer observation period upward trend prevalence thyroid cancer among pregnant woman though not statistically significant p woman thyroid cancer likely caucasian belong high income quartile private insurance discharge urban teach hospital pre gestational hypertension woman thyroid cancer great chance deliver vaginally require transfusion blood develope venous thromboembolism vte neonate mother thyroid cancer not find increase risk adverse neonatal outcome examine specifically congenital malformation intrauterine growth restriction fetal death preterm labor conclusion pregnancy complicate thyroid cancer high incidence vte need transfusion comparable overall newborn outcome ring fire thyroid cancer several study reveal increase incidence thyroid cancer volcanic area around world hawaii philippines rim pacific ocean great numb volcano locate convergent plate boundary among region high incidence thyroid carcinoma worldwide iceland another region also rich volcano high incidence thyroid cancer europe find common denominator region numerous volcano fact several constituent volcanic lava postulate involve pathogenesis thyroid cancer article aim present pertinent datum can link volcanic environment thyroid cancer long term progression non invasive follicular thyroid neoplasm papillary like nuclear feature single center retrospective study french marne ardennes thyroid cancer registry context non invasive form encapsulate follicular variant papillary thyroid carcinoma efvptc reclassify non invasive follicular thyroid neoplasm papillary like nuclear feature niftp order reduce overtreatment study show neck lymphadenopathy diagnosis even distant metastasis patient niftp objective aim report frequency clinical feature long term progression histologically confirm niftp use datum french marne ardennes thyroid cancer registry compare finding fvptc method retrospective study datum follicular variant ptc fvptc diagnose obtain specialize marne ardennes thyroid cancer registry pathology report use select appropriate case large series fvptc specimen review endocrine pathologist strict diagnostic criterium use reclassification niftp result total case review histologically case fvptc sixty five meet criterium niftp consequently reclassify incidence niftp case fvptc fifty patient woman median age year mean niftp size cm no significant difference age gender tumor size niftp fvptc fifty patient undergo total thyroidectomy lobectomy no lymph node metastasis diagnosis none patient n undergo central lateral neck dissection positive finding microscopic examination patient receive radioiodine rai patient follow year median year initial treatment patient remain complete remission follow conclusion consistently previous study result show indolent course niftp risk recurrence complete resection low zero cohort even size cm absence adjuvant rai treatment prospective study need confirm result central lymph node dissection secondary procedure papillary thyroid cancer add morbidity background routine central lymph node dissection clnd papillary thyroid cancer ptc time initial thyroidectomy advocate demonstrate decrease post ablation serum thyroglobulin compare total thyroidectomy alone patient present central compartment metastatic disease initial thyroid cancer surgery diagnosis ptc diagnostic lobectomy require completion thyroidectomy undissected central compartment aim compare clinical outcome patient ptc undergo clnd secondary event initial clnd method retrospective cohort study patient undergo clnd ptc june november undertake datum gather include patient demographics numb lymph node excise lymph node involvement incidence postoperative complication result one hundred seventy f patient grp clnd part primary surgical procedure f patient grp b undergo clnd secondary procedure therapeutic prophylactic procedure mean numb lymph node sample involve group b vs vs respectively similarly incidence temporary hypocalcemia vs permanent hypoparathyroidism vs temporary recurrent laryngeal nerve rln paresis vs permanent rln paresis vs wind infection vs comparable group b conclusion study demonstrate no additional morbidity clnd perform secondary procedure patient ptc secondary clnd perform patient prove central compartment metastatic disease previous thyroidectomy offer safely prophylactic procedure patient high risk central lymph node metastasis clnd not perform initial primary operation ptc medullary cancer thyroid paper deal study case medullary carcinoma account form thyroid cancer female male ratio mean age year medullary carcinoma occur sporadically case familial endocrine syndrome case sipple syndrome report medullar carcinoma hormonally active tumor produce calcitonin latter serve tumor marker carcinoma medullary carcinoma characterize bilateral involvement thyroid frequent case familial disease high rate incidence regional metastasis apart clinical diagnostic mean disease chiefly identify cytologically calcitonin assay blood plasma mainly treat surgery year survival rate respectively connexin expression associate aggressive phenotype human papillary follicular thyroid cancer connexin cx component gap junction recently believe tumor suppressor gene show play important role lymphatic invasion good lymph node distant metastasis squamous lung cancer breast cancer study present investigate cx expression human papillary thyroid cancer ptc follicular thyroid cancer ftc relationship various clinicopathological parameter ptcs positive cx five ftcs follicular thyroid adenoma n normal thyroid tissue n negative cx statistically significant association observe cx expression large tumor size p ptc lymph node metastasis p marginally significant ptc p ftc presence intra glandular dissemination tumor cell significantly p frequent cx positive cx negative ptcs lymphatic vessel invasion frequent neoplastic transformation cyst thyroglossal tract apropos case cancer thyroglossal tract rare seventy four patient cyst thyroglossal tract operate hospital papillary carcinoma discover histological examination one case cancer treat sistrunk operation patient no sign recurrence one five year operation paper present case report unusual cancer few similar case report literature regulation mir promote thyroid cancer cell invasion target zeb zeb thyroid cancer common endocrine malignancy incidence increase rapidly worldwide molecular mechanism underlie thyroid cancer tumorigenesis still need investigate micrornas mirnas short rna molecule approximately nucleotide length play crucial role tumorigenesis present study find expression mir significantly regulate thyroid cancer compare normal thyroid tissue suggest mir may involve thyroid cancer tumorigenesis moreover result show restoration mir k wro thyroid cancer cell can suppress invasion migration capability cell also demonstrate mir suppress expression zeb zeb two e cadherin suppressor directly bind untranslated region furthermore restoration zeb zeb partially rescue mir induce inhibition cell invasion datum suggest mir function tumor suppressor thyroid cancer procedure guideline radioiodine therapy iodine whole body scintigraphy paediatric patient differentiate thyroid cancer procedure guideline radioiodine therapy whole body scintigraphy differentiate thyroid cancer paediatric patient counterpart procedure guideline version adult patient specify interdisciplinary guideline thyroid cancer deutsche krebsgesellschaft concern nuclear medicine part characteristic thyroid cancer child high aggressiveness papillary thyroid cancer high frequency extrathyroidal extension disseminate pulmonary metastasis good high risk local recurrence radioiodine therapy generally recommend child activity depend child body weight radioiodine ablation child small papillary cancer cm consider tsh stimulation reach two week child three week adolescent withdrawal thyroid hormone anti emetic drug highly recommend ct chest examination pulmonary function clearly indicate suspicion metastasis month ablation whole body scintigraphy highly recommend lymph node metastasis frequently detect paediatric patient follow care arrange short interval adult test compliance adapt dosage thyroid hormone child body weight reference value ft high child adult evidence insufficient describe constellation tsh may keep within low normal level therefore tsh suppression generally recommend f fdg pet ct show thyroid incidentaloma patient thyroid cancer objective postoperative radioiodine remnant ablation rra represent adjunctive therapeutic modality patient differentiate thyroid cancer dtc impact late vs early rra outcome dtc currently unclear aim study evaluate outcome patient dtc accord rra time design retrospective study patient total tnm stage dtc patient divide two group group n rra administer little month median range group b n month median thyroidectomy remission achieve stimulate serum tg level undetectable absence local recurrence cervical lymph node metastasis neck ultrasound result patient undergo three gene panel distinguish benign malignant thyroid nodule reliable preoperative diagnosis malignant thyroid tumor remain challenge inconclusive cytological examination fine needle aspiration biopsy although numerous study successfully demonstrate use dna microarray mirna analysis reinforce classification follicular thyroid tumor context focus mitochondrial function thyroid tumorigenesis use integrative approach identify relevant biomarker borderline thyroid lesion design use cdna microrna mirna microarray quantitative rt pcr analysis qpcr explore sample various type thyroid tumor include benign follicular adenoma represent macrofollicular variant thyroid adenoma oncocytic variant follicular thyroid tumor papillary thyroid carcinoma tumor uncertain malignant potential together normal thyroid tissue sample result transcriptomic analysis highlight discrepancy control tumor tissue good various tumor type lead identification gene allow discrimination thyroid adenoma oncocytic variant follicular thyroid tumor papillary thyroid carcinoma whereas tumor uncertain malignant potential find overlap class five gene tp hoxa runx myd cite differential expression confirm qpcr analysis implicate tumorigenesis mitochondrial metabolism mrpl mrps mrps cox thyroid metabolic pathway camkiinalpha tpo global mirna analysis reveal differential mirnas expression level confirm qpcr differential expression mirnas accordance modulation gene expression ontology reveal transcriptomic analysis conclusion finding reinforce classification follicular thyroid tumor establish world health organization technique offer novel molecular approach refine classification thyroid tumor uncertain malignant potential case thyroid cancer context metabolic reprogramme common feature tumorigenesis remain unknown concern expression pattern metabolism associate gene dedifferentiated thyroid cancer ddtc objective study aim identify useful signature indicate dedifferentiation papillary thyroid cancer ptc design set use one discovery two validation cohort screen aberrant metabolic gene ddtc use cancer genome atla tcga cohort search independent risk factor low differentiate phenotype ptc signature dedifferentiation prediction signature ddtc validate tcga cohort combine gene expression omnibus cohort also analyze correlation signature risk score clinicopathological feature ptc gene set enrichment analysis perform tcga cohort result significant enrichment metabolic pathway correlate differentiation status ptc signature metabolic gene include lpcat acot hsd b pde b st gal discover validate across three cohort signature not predictive ddtc also significantly associate brafv e mutation p stage p extrathyroidal extension p lymph node metastasis p tumor lymph node metastasis iii iv stage p ptc downregulations lpcat expression p st gal expression p increase risk decrease disease free survival patient furthermore signature implicate numb oncogenic biological pathway conclusion finding suggest metabolic deregulation mediate dedifferentiation ptc metabolic gene signature use biomarker ddtc cytometric estimation lymphoid cell population needle biopsy sample patient thyroid cancer fine needle aspiration cytological examination establish small lymphocyte fraction total population lymphoid cell thyroid cancer patient dysphagia present symptom thyroid cancer year old man present progressive dysphagia poorly differentiate thyroid carcinoma occlude esophagus diagnose trachea initially unaffected mode presentation thyroid carcinoma uncommon incidence cancer rate false negative cytology thyroid nodule great equal cm size background high false negative rate fine needle aspiration biopsy fnab thyroid nodule great cm prompt recommendation diagnostic lobectomy consider presence great cm nodule independent indication thyroidectomy regardless fnab result method review clinical datum patient thyroid nodule great equal cm operate july november unifocal micropapillary cancer consider clinically insignificant result clinically significant thyroid cancer frequent occur patient subgroup analysis show patient carcinoma within mass patient significant carcinoma elsewhere resect thyroid multifocal micropapillary cancer find additional patient preoperative fnab read incorrectly benign patient cancer include multifocal micropapillary carcinoma benign fnab result fail identify follicular lesion include cancer patient preoperative fnab result categorize indeterminate lesion patient carcinoma mass final pathology conclusion thyroid nodule great equal cm incidence carcinoma high high false negative rate preoperative benign cytology thyroid nodule great equal cm consider diagnostic lobectomy regardless fnab result time radioactive iodine therapy not impact overall survival high risk papillary thyroid carcinoma objective postthyroidectomy radioiodine rai therapy indicate papillary thyroid carcinoma ptc high risk feature variability time rai therapy no consensus analyze impact time initial rai therapy overall survival os ptc method national cancer datum base ncdb query patient ptc undergo near subtotal total thyroidectomy rai therapy high risk patient tumor cm size lymph node involvement grossly positive margin early rai month whereas delay month thyroidectomy kaplan meier km cox survival analysis perform adjust patient tumor relate variable propensity match set high risk patient eliminate bias rai time also analyze result patient high risk group median survival month km analysis show survival benefit early rai high risk patient p however difference disappear hazard ratio hr confidence interval ci change structure surgically treat goiter base goiter material treat surgically compare incidence various type goiter thyroid carcinoma year primary thyroid lymphoma arise hashimotos thyroiditis diagnose fine needle aspiration cytology background objective emit positron image positron emission tomography pet scanner objective study compare ability diagnostic pet image versus planar whole body image detect residual thyroid tissue metastatic good differentiate thyroid cancer wdtc method patient recruit prospectively study wdtc ii suspect metastatic wdtc iii refer whole body dosimetry prescribe activity mci mbq mci mbq respectively image one blind reader v n categorize every focus radioiodine uptake definite physiological uptake artifact likely physiological uptake artifact indeterminate residual thyroid tissue metastasis neck bed likely metastasis definite metastasis focus categorize consider positive available focus categorize correlate diagnostic study result patient patient positive focus image patient date metastasis confirm one additional positive focus demonstrate numb focus patient no positive focus two positive five positive focus one patient one additional positive focus not see not yet confirm metastasis total positive focus identify either identify positive focus not see identify one positive focus not see conclusion relative planar whole body image pet identify many focus radioiodine uptake suggestive additional residual thyroid tissue metastasis many patient wdtc silicone prosthesis cover large tracheal defect patient undergo surgery locally recurrent aggressive thyroid cancer follow usual sleeve window resection trachea reconstruction trachea carry without difficulty patient aggressive thyroid cancer cancer recur locally patient reoperation often yield large tracheal defect commercially available tracheostomy cannula silicone tube not fit use technique maxillofacial prosthetic field become possible make new type prosthesis comfortable acceptable patient large tracheal defect new type silicone rubber prosthesis make individually mold patient several appointment require adjustment chair side must tightly obstruct tracheostomy stoma patient easily breathe speak take oral fluid patient easily remove replace device care prosthesis easy practical use type prosthesis three patient report herein false positive diagnosis iodine whole body scintigraphy differentiate thyroid cancer iodine use ablate residual thyroid tissue metastatic disease obtain whole body diagnostic image total thyroidectomy differentiate thyroid cancer dtc even though whole body scan highly accurate show thyroid residue good metastasis dtc false positive result find possibly lead diagnostic error unnecessary treatment paper review physiological pathological process involve good strategy recognize rule false positive radioiodine image quality indicator thyroid cancer surgery current perspective introduction disease specific mortality differentiate thyroid cancer remain low current treatment incidence steadily rise past several decade cancer relate recurrence morbidity remain significant problem quality indicator currently employ relevant surgical intervention not necessarily reflect oncological outcome therefore thyroid cancer specific surgical quality indicator offer insight risk cancer relate morbidity mortality need area cover review aim discuss role measure quality thyroid surgical oncology carry comprehensive review potential quality indicator thyroid cancer operation three quality indicator review postoperative radioactive iodine update remnant thyroid tissue proportion resect lymph node evidence metastasis post operative serum thyroglobulin level expert commentary together quality indicator may utilize guide improvement quality surgical care unique patient population critical future step establish role quality indicator thyroid cancer surgery determination cutoff value indicator evidence base manner relationship genetic alteration clinicopathological characteristic papillary thyroid carcinoma papillary thyroid carcinoma ptc characterize proliferation follicular cell distinctive nuclear feature grind glass appearance nuclear groove pseudoinclusion proliferation pattern ptc divide several histological subtype conventional histology classify papillary type also follicular solid variant ptc heterogeneous genetic alteration ptc braf mutation present histology conventional ptc follow aggressive clinical course case ptc ras mutation show follicular variant prognosis favorable ret ptc observe sporadically young case prognosis favorable ret ptc associate radiation exposure solid variant frequent etv ntrk may associate radiation exposure clinical course aggressive mutation telomerase reverse transcriptase promoter observe ptc case involve elderly male patient tumor size large associate distant metastasis advance stage mutation find concomitantly braf mutation clinical course aggressive genetic alteration form subset ptc distinct clinicopathological feature careful assessment clinicopathological feature consider useful predict clinical course plan treatment thyroidectomy block dissection neck carcinoma thyroid gland objective tsh suppression therapy patient differentiate thyroid cancer dtc associate adverse effect areal bone mineral density abmd postmenopausal woman purpose study examine effect tsh suppression therapy skeletal integrity use peripheral quantitative compute tomography pqct radius tibia pre postmenopausal woman dtc control study design patient subject include woman dtc pre postmenopausal respectively control pqct perform radius tibia dual energy x ray absorptiometry dxa hip lumbar spine sample take calciotropic hormone bone marker result no difference observe concern abmd dxa premenopausal woman no significant difference concern vbmd cortical thickness high radius patient dtc p compare control postmenopausal woman dtc trabecular bone mineral content bmc area vbmd low radius p tibia trabecular bmc vbmd low mix transition zone distal end p compare control cortical thickness low radius p postmenopausal patient compare control serum ctx high postmenopausal woman dct p premenopausal patient parathyroid hormone pth low p compare control conclusion tsh suppression therapy associate high bone resorption postmenopausal woman adversely affect trabecular cortical bone property especially nonweight bear site radius confuse lesion thyroid papillary carcinoma thyroid cancer consider one deadly cancer differentiation benign malignant structure difficult patient thyroid cancer work devote problem early clinical diagnosis thyroid cancer case primary thyroid cancer study pathomorphologic analysis thyroid cancer carry problem early detection thyroid cancer review conclude thyroid nodule fine needle aspirate biopsy intraoperative freeze section examination not allow accurate differentiation benign tumour malignant neoplasm novel diagnostic method early detection thyroid cancer need hashimoto disease complicate thyroid cancer case objective investigate clinical characteristic surgical treatment hashimoto disease complicate thyroid cancer method clinical datum patient hashimoto disease complicate thyroid cancer retrospectively analyze include clinical characteristic surgical treatment short term effect result rate hashimoto disease complicate thyroid cancer patient hashimoto disease patient surgical treatment proper thyroid region take euthyrox operation month year followup one patient local recurrence lymph node metastasis neck patient 2 operation thyroid gland no death occur conclusion hashimoto disease complicate thyroid cancer no typical symptom combine examination brafv e immunohistochemistry papillary thyroid carcinoma relationship clinical morphological parameter objective investigate association brafv e mutation papillary thyroid carcinoma use clinical morphological prognostic parameter also intend assess utility brafv e immunohistochemistry compare braf polymerase chain reaction rt pcr material method apply brafv e immunohistochemistry cohort papillary carcinoma adenoma normal thyroid tissue choose retrospectively statistical analysis base semiquantitative immunohistochemistry finding also apply braf rt pcr subgroup papillary carcinoma metastatic lymph node adenoma choose randomly result regard comparison brafv e immunohistochemistry braf rt pcr nuclear cytoplasmic immunoexpression consider positive brafv e mutation frequently observe classic variant case no mutation detect follicular variant case mutational status primary tumour lymph node metastasis consistent significant relationship brafv e mutation find prognostic factor high pt stage classic variant lymphatic invasion perineural invasion low mitotic index lack tumour capsule intrathyroidal spread extrathyroidal extension conclusion immunohistochemistry use clone reliable technique detection brafv e mutation result immunohistochemistry consistent previous effort study despite correlation pathological prognostic parameter brafv e mutation poor prognosis find irrelevant overall morphological parameter seem keen brafv e mutation nevertheless different series display different result possibly due environmental factor consider prove success target therapy brafv e mutation thorough assessment would important thyroid cancer associate adenomatous goiter analysis incidence clinical factor evaluate incidence thyroid cancer patient adenomatous goiter investigate clinical factor distinguish patient occult thyroid cancer define tumor size small equal mm clinical thyroid cancer define tumor size large mm patient histologically confirm adenomatous goiter also thyroid cancer occult patient clinical patient no correlation maximum size thyroid cancer tumor age patient percentage patient thyroid cancer group not influence age no significant difference age sex serum concentration free triiodothyronine free thyroxine thyrotropin thyroglobulin urinary iodine creatinine ratio frequency calcify lesion detect ultrasonography us neck x ray patient clinical thyroid cancer significantly great occult cancer vs respectively p study disclose high prevalence thyroid cancer associate adenomatous goiter result suggest considerable numb associate carcinoma remain occult detection calcification thyroid gland one surgical indication patient adenomatous goiter thyroid cancer iceland retrospective study carry incidence thyroid cancer iceland year period case thyroid cancer register incidence female male per per year little twice high nordic country among high incidence figure report anywhere considerable increase report incidence thyroid cancer note around mean size cancer nodule diagnosis decrease time survival rate patient improve incidence decrease last year study period mortality rate remain similar year period survival rate correct intercurrent death similar papillary follicular carcinoma patient anaplastic carcinoma die within one year diagnosis cox regression analysis multiple covariate reveal age diagnosis anaplastic medullary history type compare papillary type pathological evaluation tumour extent calendar period diagnosis significant prognostic power sex follicular vs papillary histology type not significant prognostic factor overexpression wild type c ret zero prevalence ret ptc rearrangement associate papillary thyroid cancer ptc kuwait background papillary thyroid carcinoma ptc common kuwait activation ret oncogene dna rearrangement ret ptc know important role ptc carcinogenesis however real frequency ret ptc expression ptc variable different study study seek determine prevalence ret ptc analyze ret oncogene expression associate ptc kuwait method ret expression dna rearrangement ret ptc ret ptc ret ptc study rt pcr different thyroid disease result confirm southern blot immunohistochemistry quantitative real time pcr use determine level ret mrna expression ptcs result wild type nonrearranged c ret oncogene overexpress ptc case absent follicular thyroid carcinoma ftc anaplastic thyroid carcinoma atc follicular adenoma fa normal thyroid no ret ptc rearrangement detect sample c ret expression hashimoto thyroiditis multinodular goiter limit follicular cell ptc like nuclear change conclusion overexpression wild type c ret characteristic molecular event ptcs kuwait prevalence ret ptc zero among low record world thyroid cancer molecular study make difference translational research encompass activity apply basic scientific research finding clinical practice although take almost year since \\ufeff1 scientific discovery approval new drug herceptin avastin represent successful example also successful translation science clinic field otolaryngology last decade see major development molecular biology genetic two notable achievement completion human genome project parallel advance high throughput molecular genomic proteomic technology link event enormous accumulation new datum offer promise important future clinical application review aim discuss major scientific development demonstrate success thyroid translational research summarise recent research finding thyroid disease provide hope development future clinical tool coexistence papillary thyroid cancer hashimoto thyroiditis child report case report document pediatric papillary thyroid carcinoma case associate hashimoto thyroiditis case hypoechoic nodule accompany multiple echogenic spot note sonography thyroid hashimoto thyroiditis suspect basis positive thyroid autoantibody test result pathologic examination thyroidectomy specimen reveal chronic thyroiditis lymphocytic infiltration background papillary thyroid carcinoma development potential papillary carcinoma development warrant close follow meticulous sonographic examination must perform child hashimoto thyroiditis current treatment strategy metastasize differentiate thyroid cancer successful completion activity one able judge prognosis patient harbor metastasize differentiate thyroid cancer dtc identify suitable treatment regimen take account characteristic tumor patient general condition know basic radioiodine treatment tyrosine kinase treatment redifferentiation treatment metastasize dtc medullary thyroid cancer wisconsin kindred sipple syndrome use provoke calcitonin test background objective evaluate feasibility use optical coherence tomography oct identify microscopic extrathyroidal extension mete ex vivo thyroidectomy specimen patient undergo thyroidectomy treatment papillary thyroid carcinoma ptc method total ex vivo oct image tumor acquire completion thyroidectomy patient oct image patient separately evaluate two blind investigator outcome compare histopathology report result sensitivity specificity mete identification oct image respectively \\ufeff1 investigator respectively 2 investigator substantial agreement investigator verify cohen cohen conclusion preliminary study limit series ex vivo thyroidectomy specimen verify feasibility oct method identify mete patient ptc long non code rna uca promote papillary thyroid cancer cell proliferation via mir mediate brd activation long non code rna lncrna urothelial carcinoma associate uca use tumor development progression many type cancer however function mechanism underlie action uca papillary thyroid cancer ptc remain unclear therefore topic investigate present study vitro vivo experiment demonstrate expression level uca significantly upregulated ptc cell line tissue compare immortal human thyroid follicular cell line adjacent normal tissue respectively uca knockdown significantly inhibit ptc cell viability colony formation bromodomain contain brd expression level vitro retard ptc tumor growth vivo previous study microrna mir inhibit thyroid cancer progression regulate uca type cancer addition conduct dual luciferase reporter assay confirm mir directly bind uca untranslated region brd furthermore uca compete brd mir bind mir knockdown enhance brd expression partially restore short hairpin uca result present study illustrate uca promote ptc progression act compete endogenous rna sponge mir conclusion uca may regard oncogenic lncrna promote ptc cell proliferation potential target human ptc treatment prognostic importance solid variant papillary thyroid carcinoma systematic review meta analysis background solid variant papillary thyroid carcinoma svptc rare variant papillary thyroid cancer ptc prognostic value still unclear purpose systematic clinical review meta analysis investigate prognostic value svptc comparison classical ptc cptc method four electronic database include pubmed scopus web science virtual health library search june extract datum pool odd ratio hazard ratio hr correspond confidence interval ci use random effect model result article finally include study svptcs meta analysis overall svptc manifest significantly high risk vascular invasion tumor recurrence cancer mortality compare cptc genetic profile svptc also distinct cptc conclusion case svptc regard aggressive variant ptc high risk tumor recurrence mortality iodine contamination thyroid cancer patient high dose radioactive iodine therapy use treatment choice patient thyroid cancer follow thyroidectomy large amount activity excrete hospitalization contamination hazard excretion via perspiration saliva breath urine may arise eight patient treat dose range gbq mci activity level measure room air room surface toilet patient exhale breath skin saliva toothbrush glove use medical staff thyroid bioassay also perform medical staff personnel care patient two day administration treatment dose removable activity skin positively correlate treatment dose reach maximum hr post therapy removable activity room surface exceed level contamination require clean restrict area patient hospitalization thyroid bioassay medical staff show no significant uptake day treatment relatively high activity present saliva urine skin patient emphasize need individual come contact patient make aware contamination hazard present histopathologic reproducibility thyroid disease epidemiologic study investigation long term effect childhood scalp irradiation demonstrate significantly increase risk thyroid tumor irradiate population complexity thyroid cancer diagnosis histopathologic slide review patient irradiate nonirradiated thyroid disease undertake review reveal agreement kappa p little original review diagnosis four case previously diagnose malignant reclassify benign yield cancer misdiagnosis rate four misdiagnose cancer follicular mix papillary follicular type result histologic review ratio malignant benign tumor decrease since disagreement diagnosis similar irradiate nonirradiated group relative risk radiation associate neoplasm not change substantially histopathologic review show although problem diagnostic reproducibility not statistically significant not alter previous conclusion regard radiation exposure however reduction numb malignancy may affect epidemiologic study external comparison good geographic temporal comparison radiation dose matt thyroid cancer pattern local regional failure recurrent metastatic good differentiate thyroid cancer treat introduction due complex multimodal treatment lengthy natural history disease impact radiation therapy good differentiate thyroid cancer wdtc challenge evaluate analyse effect dose escalation enable intensity modulate radiation therapy imrt prevent local regional failure lrf microscopic macroscopic wdtc method perform retrospective review wdtc patient treat imrt diagnostic image demonstrate \\ufeff1 lrf register simulation ct contain treat radiation isodose volume area disease progression contour relationship lrfs isodose volume record result thirty patient median follow month range seventeen gross residual five microscopic residual eight clear margin time imrt nine patient develope lrf median time month range six radiate gross disease one microscopic residual seven analysable case one lrf occur within gy isodose volume marginal lrfs four outside gy one outside gy one outside gy one recurrence occur perioesophageal region conclusion local regional failure see patient gross disease time imrt almost always occur outside gy volume frequently area oesophageal spare meticulous surgical dissection especially perioesophageal region prioritise prevent long term lrf thyroid nodule ultrasonic examination thyroid essential diagnostic process thyroid help meet challenge identify malignant among thousand benign nodule besides tumour infiltration surround tissue lymph node metastasis may prove thyroid cancer good establish criterium suggest malignancy safe distinction benign malignant nodule however not possible ultrasound alone hormone produce adenoma discriminate inactive nodule scintigraphy helpful identify autonomous adenoma no use assess risk malignancy thyroid nodule ultrasound guide thyroid fine needle aspiration fna safe method prove malignancy select case ultrasound guide therapy like percutaneous ethanol instillation pei effective treatment autonomous thyroid ademona approach thyroid cancer patient extracervical metastasis patient distant extracervical metastasis differentiate thyroid cancer require multimodality diagnostic therapeutic monitor approach whereas cure initial goal especially small radioiodine avid pulmonary metastasis improve survival management symptom become primary objective many patient persistent disease especially bone metastasis levothyroxine therapy suppression serum tsh primary therapy patient advance differentiate thyroid cancer therapy show improve overall survival slow disease progression radioiodine also important systemic therapy patient radioiodine avid disease respond target therapy review compare standard fix dose radioiodine therapy vs dosimetric approach direct therapy external beam radiotherapy surgery embolization generally consider large painful lesion careful collaboration multiple specialty tumor board mechanism help optimize complex management decision patient advance thyroid cancer multimodality monitor focus organ interest pulmonary compute tomography ct bone magnetic resonance image ct bone scan brain ct magnetic resonance image metastasis good general metastatic surveillance bone scan f fluorodeoxyglucose positron emission tomography aid decision make careful monitor vs direct systemic therapy f fluorodeoxyglucose positron emission tomography image additional role patient prognosis guide direct therapy fluorodeoxyglucose avid lesion patient asymptomatic stable radioiodine resistant metastasis may carefully monitor disease progression patient symptomatic disease receive direct therapy goal symptom relief patient progressive metastatic disease consider clinical trial target systemic therapy sorafenib sunitinib although agent not food drug administration fda approve patient thyroid cancer goal therapy patient extracervical metastasis improve survival relieve symptom decrease morbidity disease progression limit morbidity associate therapy knockdown kdm suppress tumour migration invasion epigenetically regulate timp mmp pathway papillary thyroid cancer epigenetic dysregulation play important role cancer histone demethylation good know mechanism epigenetic regulation promote inhibit tumourigenesis various malignant tumour however pathogenic role histone demethylation modifier papillary thyroid cancer ptc high incidence early lymphatic metastasis largely unknown detect expression common histone demethylation modifier find histone h lysine h k h lysine h k demethylase kdm lysine demethylase frequently overexpress ptc tissue cell line high kdm expression correlate positively age year lymph node metastasis patient ptc moreover kdm require ptc cell migration invasion kdm knockdown inhibit migration invasive ability ptc cell vitro vivo also identify tissue inhibitor metalloproteinase timp key kdm target gene kdm activate matrix metalloproteinase mmp epigenetic repression timp expression demethylating h k timp promoter region rescue experiment clarify finding altogether uncover new mechanism kdm repression timp ptc suggest kdm may promise therapeutic target ptc increase incidence thyroid cancer due increase pathologic detection background mark increase incidence thyroid cancer worldwide recent decade patient retrosternal goiter rsg not pick generally common surveillance technique ultrasound aim project study incidence thyroid cancer patient rsg method retrospective cohort study document patient demographics good size type number thyroid cancer numb routine histologic block examine multinodular goiter different time period also examine result within cohort thyroidectomy perform year patient undergo surgery rsg percentage patient rsg contain thyroid cancer increase p however papillary microcarcinomas pmc mm exclude no increase cancer incidence p increase numb pmc diagnose associate increase routine numb block sample year time period p conclusion study confirm increase incidence thyroid cancer decade however increase appear due increase diagnosis pmc associate increase sample resect specimen pathologist raise possibility current epidemic thyroid cancer may largely manmade coexistence grave disease papillary thyroid carcinoma unilateral benign struma ovarii case report review literature background struma ovarii rare cause hyperthyroidism coexistence grave disease scarcely report patient finding report patient grave disease unilateral benign function struma ovarii accompany ascites pleural effusion elevate cancer antigen ca level subsequent thyroidectomy incidental papillary thyroid carcinoma also identify functionality struma ovarii tissue patient support immunohistochemical identification tsh receptor tshr may stimulate growth thyroid hormone production presence circulate tshr stimulate antibody tshr ab review literature systematic review report case coexistent grave disease struma ovarii perform conclusion diagnosis struma ovarii may mask grave disease therefore delay several year furthermore ascites pleural effusion increase ca may result benign struma ovarii presence tshr struma ovarii tissue along absence surround ovarian tissue indirectly suggest struma ovarii functional unclear whether tshr ab play role development thyroid carcinoma patient surgical treatment advance thyroid carcinoma aero digestive invasion objective study surgical management advance thyroid carcinoma prognostic value f fluorodeoxyglucose positron emission tomographic scan patient thyroid cancer poorly differentiate thyroid cancer lesion often lose ability concentrate radioactive iodine rai exhibit increase metabolic activity evidence enhance glucose uptake incorporate f fluorodeoxyglucose fdg positron emission tomography pet scan routine follow cohort thyroid cancer patient undergo annual evaluation one hundred twenty five patient previous thyroidectomy include diagnostic rai whole body scan serum thyroglobulin measurement additional image study clinically indicate month follow patient die univariate analysis demonstrate survival reduce age yr distant metastasis pet positivity high rate fdg uptake high volume fdg avid disease ml survival not correlate gender rai uptake initial histology grade multivariate analysis demonstrate single strong predictor survival volume fdg avid disease yr survival probability patient fdg volume ml little confidence interval compare confidence interval patient fdg volume great ml death leukemia occur pet negative group n patient distant metastasis negative pet scan alive good patient yr distant metastasis concentrate fdg high risk distant metastasis discover patient differentiate thyroid carcinoma fdg pet identify high low risk subset subject fdg volume great ml significantly reduce short term survival follicular h rthle cell carcinoma predict outcome direct therapy background follicular thyroid cancer heterogeneous disease include follicular h rthle cell tumor without vascular major capsular invasion analysis prognosis risk group criticize not take difference account method retrospective analysis do patient treat result ninety two patient without vascular major capsular invasion follow median year no recurrence death remain patient h rthle cell follicular cell carcinoma patient h rthle cell carcinoma significantly old vs year p lymphatic metastasis not influence outcome patient high risk age sex metastasis extent size year survival rate follicular h rthle cell carcinoma patient low risk year survival rate respectively no significant difference follicular h rthle cell carcinoma recurrence treat successfully patient follicular carcinoma never cure patient h rthle cell carcinoma bilateral versus unilateral operation radioiodine ablation not alter outcome conclusion follicular h rthle cell carcinoma minimal capsular invasion behave benignly age sex metastasis extent size risk criterium differentiate strongly patient high risk low risk follicular h rthle cell carcinoma control risk factor h rthle cell follicular cell carcinoma similar prognosis thyroid cytology article cover comprehensive way thyroid cytopathology bethesda system report thyroid cytology review emphasis atypical indeterminate diagnostic category immunohistochemistry stain molecular test panel applicable cytology specimen describe type b multiple endocrine adenomatosis case report present demonstrate typical diagnostic therapeutic problem young patient multiple endocrine adenomatosis type b patient exhibit complete syndrome endocrine non endocrine organ manifestation medullary thyroid cancer bilateral pheochromocytoma mucosal neuroma marfanoid habitus pes equinus diverticulosis \\ufeff1 present symptom diverticulitis lead emergency surgical intervention perforation sigmoid colon perioperatively blood pressure increase note follow diagnostic measure lead adrenalectomy thyroidectomy surgery local metastasis thyroid cancer family screen demonstrate far possible sporadic form disease unusual adverse event vandetanib metastatic medullary thyroid cancer background despite low mortality associate micropapillary thyroid cancer locoregional recurrence common controversy exist regard optimal surgical treatment role adjunctive radioiodine method national thyroid cancer treatment cooperative study group registry analyze recurrence patient unifocal versus multifocal micropapillary cancer without nodal disease depend upon extent surgery use adjunctive radioiodine six hundred eleven patient consider disease free initial therapy follow person year result thirty patient recurrence detect mean year primary treatment recurrence not differ patient unifocal multifocal disease overall however among patient receive little near total thyroidectomy ntt multifocal disease recurrence unifocal disease vs p patient multifocal disease total ntt trend toward few recurrence undergo little ntt vs p patient not receive radioiodine therapy recurrence common patient multifocal disease versus unifocal disease vs p however radioiodine not reduce recurrence patient multifocal disease patient positive node patient positive node recurrence node negative patient regardless surgical extent use radioiodine conclusion patient micropapillary multifocal disease reduce risk recurrence ntt compare little surgery randomize control trial necessary feasible determine radioiodine ablation thyroid remnant advantageous patient intrathyroidal micropapillary cancer differentiate thyroid cancer present distant metastasis population analysis two decade background differentiate thyroid cancer dtc distant metastasis presentation uncommon prognosis patient condition favorable cancer demographic clinical pathologic characteristic describe population level factor associate reliability fine needle aspiration ultrasound base characteristic thyroid nodule diagnose malignancy iranian patient background sonography fine needle aspiration biopsy fna b approve method choice diagnosis malignant thyroid nodule unnecessary fna b not invasive costly also result 2 biopsy unnecessary surgery aim determine specificity sensitivity sonography fna b without sonography guidance diagnosis malignant benign thyroid nodule method patient thyroid nodule refer baqiyatallah hospital pregnancy predispose factor thyroid neoplasia thirty patient assess thyroid neoplasia arise pregnancy predominantly 3 trimester manifest preeminently solitary nodule despite appropriate thyroid treatment patient show mark increase nodular growth pregnancy needle aspiration biopsy specimen obtain patient disclose cancer relevant patient although cellularity reveal remain patient twenty six operation perform two 2 trimester post partum incidence cancer incidence adenoma total neoplasia rate surgery no major morbidity complication one woman receive thyroid feed throughout pregnancy deliver stillborn child thyroid neoplasia associate pregnancy appear high incidence cancer course may aggravate pregnancy needle biopsy clinical assessment permit appropriate selection patient thyroid cancer surgery do safely either 2 trimester pregnancy post partum hyperthyroidism often present patient thyroid differentiate carcinoma coexistence thyroid cancer hyperthyroidism confirm many author appear frequency disease great result lack proper penetrate biopsy diagnosis qualification surgery treatment patient hyperfunctional goiter grave disease especially coexist node aim study estimation occurrence hyperthyroidism patient thyroid differentiate cancer examine group patient diagnose thyroid differentiate cancer patient early hyperthyroidism diagnose hyperfunctional nodular goiter diagnose three grave disease confirm presence anti tsh receptor antibody trak thyroidectomy ultrasonography show nodular goiter patient hypoechogenic goiter nodule patient thyroidectomy hyperthyroid patient papillary thyroid cancer follicular thyroid cancer diagnose frequency coexistence cancer hyperthyroidism material amount result observation not diverge fact give world literature point need precise analysis patient hyperthyroidism proper qualification surgery treatment change suspect malignant process morphogenetic aspect thyroid cancer multiple growth focus complex morphologic study resect material patient primary tumor carry multiple focus malignant growth find case three type tumor focus identify primary tumor early stage multicentral growth metastasis organ morpho histochemical criterium diagnosis morphogenetically different focus malignant growth discuss image thyroidology medullary thyroid cancer thyroid carcinoma commonly diagnose endocrine malignancy incidence currently rise worldwide discovery genetic mutation associate development thyroid cancer braf ret lead development new drug target pathway influence despite recent advance prognosis anaplastic thyroid carcinoma still unfavourable review look emerge novel therapy treatment association braf v e mutation pathological feature ptc braf v e mutation common genetic alteration papillary thyroid carcinoma ptc associate pathological feature association widely report result inconclusive study rare thyroid malignancy overview oncologist anaplastic thyroid cancer medullary thyroid cancer primary thyroid lymphoma primary thyroid sarcoma rare thyroid cancer comprise thyroid malignancy unlike good differentiate thyroid cancer malignancy treatment option carry wrong prognosis literature surround pathology limit remain area active research despite rarity condition remain important part differential diagnosis thyroid nodule awareness presentation work management critical oncologist head neck surgeon purpose article provide broad overview malignancy emphasis emerge clinical research therapy current role radionuclide image differentiate thyroid cancer nuclear medicine play integral role management differentiate thyroid cancer editorial aim provide summary current role radionuclide image include whole body iodine scan fluorodeoxyglucose fdg positron emission tomography pet diagnostic work follow patient thyroid cancer interaction vascular endothelial growth factor p mir thyroid carcinoma possible therapeutic target aggressive thyroid cancer background clinical pathological feature good cellular mechanism mir not investigate thyroid carcinoma objective aim study identify interaction vascular endothelial growth factor vegf p mir thyroid carcinoma clinical pathological feature mir also investigate method expression level mir identify primary thyroid carcinoma lymph node metastatic papillary thyroid carcinoma seven non neoplastic thyroid tissue control good two thyroid carcinoma cell line b cpap metastasize human papillary thyroid carcinoma mb anaplastic thyroid carcinoma real time polymerase chain reaction use western blot immunofluorescence effect exogenous mir vegf p protein expression level examine cell cycle apoptosis assay perform evaluate role mir cell cycle progression apoptosis result expression mir downregulated majority papillary thyroid carcinoma tissue good cell introduction exogenous mir result downregulation vegf upregulation p protein expression upregulation mir thyroid carcinoma cell result cell cycle arrest moreover demonstrate mir inhibit cell cycle progression induction apoptosis thyroid carcinoma cell conclusion finding show \\ufeff1 time mir act tumour suppressor regulate cell cycle progression apoptosis target vegf p thyroid carcinoma current study exhibit mir may represent potential therapeutic target patient thyroid carcinoma aggressive clinical behaviour follicular thyroid cancer present radiculopathy ten year follow lenvatinib tyrosine kinase inhibitor tki antiproliferative antiangiogenic effect indicate treatment progressive locally advance metastatic progressive thyroid carcinoma refractory radioactive iodine therapy antiangiogenic therapy induce ischemic necrosis tumor tissue increase risk hemorrhagic complication management hemorrhagic risk base precautionary measure surgical procedure advise interrupt treatment order avoid complication flare tumor activity may follow tki interruption however not know continue tkis minimally invasive intervention safe report \\ufeff1 case embolization metastasis perform without interrupt lenvatinib treatment procedure successful free complication cm tumor size not associate distant metastasis mortality small thyroid cancer population base study guideline diagnosis management thyroid nodule suggest diagnostic value fdg pet ct image patient differentiate thyroid cancer dtc relatively good overall prognosis develop local recurrence distant metastasis relatively high mortality current prognostic system lack ability predict outcome patient discover harbor metastasis year late introduction f fluoro deoxyglucose fdg positron emission tomography pet pet compute tomography ct evaluate patient dtc add new information disease review summarize datum publish far use fdg dtc appropriate indication fdg pet ct evaluate patient high thyroglobulin level follow mainly radioiodine whole body scan negative set high accuracy report lead change management patient clear relationship demonstrate fdg pet ct accuracy thyroglobulin level well result obtain thyroid stimulate hormone tsh stimulate condition moreover fdg image provide potentially relevant information tumour biology scan result may enable prognostically stratify dtc patient local distant recurrence base literature datum fdg pet ct not routine clinical indication initial stage dtc patient good evaluate cytologically indeterminated thyroid nodule factor relate lymph node recurrence patient n b papillary thyroid carcinoma unilateral therapeutic modify radical neck dissection background papillary thyroid carcinoma clinically node positive lateral neck n b ptc likely recur modify radical neck dissection mrnd present study investigate risk factor recurrence n b ptc patient unilateral therapeutic mrnd method literature publish january december factor relate lymph node recurrence mrnd retrieve search national international online database meta analysis perform datum extraction process result thirty five potentially relevant article find lymph node recurrence patient n b papillary thyroid carcinoma careful review full text article seven study include no association recurrence age patient ci p male patient ci p tumor size cm ci p multifocal tumor ci p extracapsular invasion ci p lymphovascular invasion ci p associate significantly high incidence recurrence conclusion patient tumor size cm multifocality extrathyroidal extension lymphovascular invasion likely tumor recurrence total thyroidectomy therapeutic mrnd approach treatment thyroid disorder elderly thyroid gland dysfunction prevalent old adult may associate significant morbidity misdiagnose leave untreated decrease numb symptom presentation increase susceptibility adverse event not treat great likelihood harm treatment diagnosis management thyroid disorder old adult challenge review focus epidemiology clinical presentation risk complication management thyroid disorder old adult include hyperthyroidism hypothyroidism thyroid nodule thyroid cancer association p ins pro haplotype decrease risk differentiate thyroid carcinoma iranian azeri patient association p polymorphism increase risk various cancer investigate numerous study however result conflict no polymorphism determine definite risk factor likely study p combine genotype haplotype may useful individual polymorphism thus study analyze association intron ins bp exon arg pro polymorphism good combine genotype haplotype risk differentiate thyroid carcinoma iranian azeri patient case control study perform iranian azeri patient differentiate thyroid carcinoma healthy subject intron genotype determine use pcr product analysis polyacrylamide gel pcr use genotype arg pro polymorphism javastat online statistic package software shesis program apply datum analysis no significant difference genotype frequency two polymorphism case control however ins ins arg pro genotype combination noticeable not significant association decrease risk thyroid cancer development ci p also frequency ins pro haplotype significantly high control rather patient ci p study association ins pro haplotype decrease risk differentiate thyroid carcinoma development iranian azeri patient identify risk factor recurrence clinically node negative papillary thyroid carcinoma pathologic n background whether not perform prophylactic central lymph node dissection clnd case clinically node negative papillary thyroid cancer ptc controversial purpose study investigate risk factor recurrence clinically node negative ptc patient undergo total thyroidectomy plus bilateral central neck dissection verify pathologic n method retrospectively review medical record ptc patient undergo total thyroidectomy prophylactic bilateral clnd january december use cox proportional hazard regression analysis order explore potential predictive factor recurrence result median follow range month recurrence occur patient main tumor size cm gross extrathyroidal extension ete positive lymph node ln ln ratio significantly associate recurrence accord univariate analysis model multivariate analysis tumor size gross ete ln ratio ln ratio hazard ratio hr confidence interval ci p find predictive recurrence gross ete hr ci p positive ln hr ci p predictor recurrence model ii multivariate analysis tumor size gross ete numb positive ln conclusion recommend surgeon try focus completely perform prophylactic clnd patient suspicious gross ete preoperative evaluation close monitor thorough management need clinically change landscape papillary thyroid cancer epidemiology management implication patient incidence thyroid cancer triple past decade vast majority increase note among small indolent papillary thyroid carcinoma substantial overdiagnosis potential overtreatment lead shift clinical practice toward little aggressive approach focus improve risk stratification shift practice may associate recent evidence suggest increase incidence thyroid cancer slow patient often young diagnose thyroid cancer excellent long term disease specific survival ever grow population survivor thyroid cancer unite state accumulate substantial associate health care cost undergo surveillance remedial treatment survivor thyroid cancer experience significant detriment quality life endure financial hardship future research focus appropriateness treatment good financial quality life effect thyroid cancer survivorship cancer american cancer society unique treatment policy thyoid cancer japan country treatment policy patient good differentiate thyroid cancer vary among institution although surgery mainstay treatment cancer no consensus concern optimal extent thyroid resection extent lymph node dissection furthermore controversy remain regard indication radiation therapy hormonal therapy surgical nonsurgical case thyroid resection extensive country japan although extent lymph node dissection limit former papillary carcinoma total thyroidectomy treatment \\ufeff1 choice overseas respondent japan despite lymph node dissection extensive japan country japan high dose therapy available institution limit indication reflect discrepancy frequency total thyroidectomy prerequisite postoperative high dose therapy japan country cutaneous implantation papillary thyroid carcinoma secondary percutaneous ethanol injection nodal metastasis previous study suggest thyroid nodule find patient grave disease gd high likelihood malignant thyroid cancer behave aggressively associate gd although assertion remain controversial purpose study assess frequency cold scintiscan sc defect patient gd determine prevalence thyroid cancer patient secondary objective determine risk factor develope cold defect compare clinical characteristic gd patient cold sc defect age gender match gd patient without cold defect include analysis patient confirm diagnosis gd sc result adequate follow information available clinic record available patient gd patient meet eligibility criterium cold defect find patient among refer surgery gd patient gd patient cold nodule gd patient palpable nodule undergo surgery papillary thyroid cancer ptc location correspond sc defect ptc patient no palpable abnormality correspond cold defect find contain cancer surgery one ptc patient find metastatic disease bone additional ptc patient require multiple therapy radioiodine compare age gender match control patient gd without cold sc defect no difference radioactive iodine uptake raiu goiter size duration disease degree elevation microsomal antibody titer thyroid stimulate immunoglobulin tsi conclude thyroid scintigraphy important preliminary test evaluation patient gd prevalence thyroid cancer location correspond focal cold sc defect provide justification diagnostic evaluation surgical management thyroid cancer invasion neck structure epidemiology evaluation stage management purpose review review address issue direct extra capsular invasion thyroid cancer may occur several way vary degree evidence regard prognostic treatment implication extra thyroidal spread examine phenomenon common papillary carcinoma thyroid focus review little common aggressive tumour medullary anaplastic carcinoma not consider recent finding overall around thyroid cancer exhibit extra thyroid spread rate much high specific subgroup presence invasive disease affect stage tumour implication surgery substantial complete tumour extirpation achieve no particular examination completely accurate detect extra thyroid spread preoperatively invasion posteriorly carry great morbidity mortality anterior spread presence extra thyroid spread usually warrant adjuvant radiotherapy radioiodine external beam summary histologic assessment gold standard detect invasive thyroid cancer thyroidectomy effectively stage procedure presence extent invasive disease establish subsequent management determine extra thyroidal spread influence morbidity mortality synchronous parathyroid carcinoma papillary thyroid carcinoma patient papillary microcarcinomas specific subgroup papillary thyroid cancer histological feature papillary thyroid cancer cm little diameter tumour common incidental find autopsy thyroid gland excise pathology tumour metastasize regional lymph node ability cause significant morbidity mortality question papillary microcarcinomas represent per cent papillary cancer see thyroid surgeon practice important group aim review article outline natural history papillary microcarcinoma offer therapeutic management strategy genetic predisposition papillary thyroid cancer approximately differentiate thyroid cancer hereditary hereditary non medullary thyroid cancer may occur minor component familial cancer syndrome e g familial adenomatous polyposis primary feature familial non medullary thyroid cancer fnmtc among fnmtc ptc common although hereditary predisposition non medullary thyroid cancer good establish susceptibility gene poorly know linkage analysis use microsatellite marker several putative locus describe q q p p q however validation study unsuccessful present review discuss result linkage analysis recent result genome wide association study gwas high resolution snp single nucleotide polymorphism array mechanism endocrinology microrna diagnostics therapy thyroid cancer micrornas short non code regulator gene expression subject numerous investigation assess potential use diagnostics management human disease review focus study analyze utility micrornas novel diagnostic therapeutic tool follicular modification eight edition tumor node metastasis stage system n b papillary thyroid carcinoma multi institutional cohort study objective base tumor node metastasis stage system 8 edition radioactive iodine refractory differentiate thyroid cancer uncommon challenge situation radioiodine rai refractory thyroid cancer uncommon entity occur estimate incidence case year million people rai refractoriness frequent old patient large metastasis poorly differentiate thyroid cancer tumor high fluordeoxyglucose uptake pet ct patient year survival rate little recent year new therapeutic agent molecular target become available multikinase inhibitor mkis investigate drug two compound sorafenib lenvatinib show significant objective response rate significantly improve progression free survival two large publish prospective trial mki use however no overall survival benefit achieve yet probably relate crossover occur patient progress placebo treatment open treatment study consequence challenge correctly identify patient benefit treatment also crucial understand appropriate time initiate mki treatment stop purpose article define rai refractoriness summarize therapy available condition review select patient suitable cytologic diagnostic approach poorly differentiate thyroid carcinoma single institution study background fine needle aspiration cytology fnac good establish technique preoperative evaluation thyroid nodule minimally invasive symptom serum calcium level affect result surgical treatment primary hyperparathyroidism introduction purpose study investigate difference surgical outcome symptomatic asymptomatic patient primary hyperparathyroidism phpt patient high serum calcium normal blood calcium good explore epidemiological trend phpt northern china method clinicopathologic datum patient man woman phpt undergo surgery \\ufeff1 affiliate hospital harbin medical university analyze change clinicopathology compare among different subgroup patient patient categorize subgroup base serum calcium level whether not present symptom admission time result total patient hypercalcemic primary hyperparathyroidism hcphpt normocalcemic primary hyperparathyroidism ncphpt symptomatic primary hyperparathyroidism sphpt asymptomatic primary hyperparathyroidism asphpt seventy seven case phpt involve thyroid nodule confirm papillary thyroid carcinoma confirm nodular goiter no significant difference success rate surgery postoperative recurrence rate symptom temporary hypocalcemia hcphpt ncphpt group sphpt asphpt group incidence phpt increase threefold since conclusion symptom serum calcium level not affect result surgical treatment phpt incidence phpt northern china increase moreover phpt manifestation shift symptomatic asymptomatic form thyroid surgery perform phpt patient thyroid nodule chernobyl thyroid cancer toll thyroid disease common endocrine disorder general population case consistent benign condition may asymptomatic affect people variable extent since often represent chronic condition prevalence increase age reach elderly high rate thyroid nodule common clinical find subject thyroid nodule no symptom thyroid nodule commonly non function however elderly toxic multinodular goiter frequent cause spontaneous hyperthyroidism often emerge insidiously nontoxic multinodular goiter although autoimmune thyroiditis common cause hypothyroidism elderly subject cause drug neck radiotherapy thyroidectomy radioiodine therapy frequently observe among subject small subset medication include dopamine agonist glucocorticoid somatostatin analog affect thyroid function suppression tsh medication may affect tsh level metformin antiepileptic medication lithium carbonate iodine contain medication drug alter absorption transport serum metabolism proton pump inhibitor antacid estrogen mitotane fluorouracil phenobarbital rifampin amiodarone administration associate thyrotoxicosis hypothyroidism thyroid cancer similar characteristic elderly general population however rate aggressive form anaplastic histotype high old young subject diagnosis thyroid disease include comprehensive medical history physical examination appropriate laboratory test correct diagnosis thyroid disease elderly crucial proper treatment consist removal medication may alter thyroid function use levo thyroxine case hypothyroidism prevalence thyroid cancer hot nodule prevalence thyroid cancer not nodule low estimate adult order accurately estimate prevalence recommend optimal treatment hot nodule operate review subject euthyroid suffer clinical hyperthyroidism present subclinical hyperthyroidism patient operate hot nodule cm diameter two group patient consider basis histological examination group consist patient f mean age year multinodular goitre undergo total thyroidectomy group ii compose patient f mean age year solitary hot nodule patient undergo unilateral lobectomy microscopic carcinoma diameter little tha cm w discover patient group patient group correspond total prevalence microscopic carcinoma locate nodule capsule four case away nodule ipsilateral lobe three case every case incidental find no clinical feature distinguish patient without microscopic carcinoma study suggest probability discover microscopic carcinoma associate hot nodule considerable however microscopic carcinoma incidental discovery numb subject undergo thyroidectomy present autopsied thyroid surgical treatment devoid risk appear indicate particularly nodule exceed cm diameter radioiodine ablation necessary patient low risk papillary thyroid carcinoma tumor cm perithyroidal ipsilateral cervical lymphatic system not commonly involve thyroid cancer also common site recurrence modify radical neck dissection preservation sternocleidomastoid muscle spinal accessory nerve treatment choice patient clinically evident lymph node metastasis due differentiate thyroid cancer also recommend us patient year age primary thyroid tumor great cm size whether not node clinically palpable little per cent patient metastasis discernment operation unreliable aggressive surgery recurrence free survival rate improve substantially without cosmetic deformity postoperative dysfunction comment high versus low radioiodine activity patient differentiate thyroid cancer meta analysis background papillary thyroid carcinoma ptc recurrence long term follow r ltfu occur even appear excellent prognosis initial thyroid surgery usually radioactive iodine e primary treatment initial study predict r ltfu not good define value serum thyroglobulin tg measurement serum thyrotropin tsh u ml result either recombinant tsh l thyroxine withdrawal refer stimulate tg stg previously evaluate aim current study determine parameter associate r ltfu patient ptc categorize low risk disease month primary treatment method retrospective study patient ptc mean follow year study patient no uptake \\ufeff1 postablative diagnostic iodine whole body scan wbs perform month primary treatment normal cervical ultrasonography c us stg ng ml test antithyroglobulin antibody anti tg negative \\ufeff1 two criterium require patient positive anti tg test nominal serum tg concentration not analyze result twelve patient develope recurrence cervical region great tumor size high stg positive anti tg test initial evaluation associate great r ltfu recurrence rate respectively patient negative positive anti tg test initial evaluation recurrence free survival low patient initial lymph node metastasis positive reliability fine needle aspiration biopsy term malignancy patient hashimoto thyroiditis aim study analyze presence malignancy patient hashimoto thyroiditis investigate reliability preoperative thyroid carcinoma molecular pathway therapeutic target thyroid cancer common malignant tumor endocrine system frequent type thyroid malignancy papillary carcinoma tumor frequently genetic alteration lead activation mitogen activate protein kinase mapk signal pathway common mutation papillary carcinoma point mutation braf ras gene ret ptc rearrangement genetic alteration find papillary carcinoma rarely overlap tumor frequent alteration follicular carcinoma 2 common type thyroid malignancy include ras mutation pax ppargamma rearrangement ret point mutation crucial development medullary thyroid carcinoma many mutation particularly lead activation mapk pathway actively explore therapeutic target thyroid cancer numb compound study show antitumor effect preclinical study test ongoing clinical trial primary squamous cell carcinoma thyroid associate papillary thyroid carcinoma hashimoto thyroiditis introduction report \\ufeff1 case squamous cell carcinoma scc thyroid gland coexist papillary thyroid carcinoma ptc hashimoto thyroiditis discuss various theory concern histogenesis scc thyroid gland optimal treatment strategy case report year old woman present anterior neck mass measure cm clinical examination image show suspicious thyroid nodule invade trachea total thyroidectomy bilateral central lymph node resection perform histological examination reveal tall cell variant papillary thyroid carcinoma associate scc right lobe thyroid hashimoto thyroiditis immunohistochemistry scc show positive stain p ki negative stain thyroglobulin patient undergo adjuvant radioactive iodine therapy radiotherapy postoperative follow month patient good health discussion conclusion probable origin scc case malignant transformation hashimoto thyroiditis follow phase metaplasia immunohistological profile associate well prognosis optimal treatment consist extensive surgical resection tumour tissuefollowed radiotherapy generalize xanthomatosis female diabetes mellitus patient operate thyroid cancer objective aim study investigate effect aromatherapy decrease salivary gland damage patient undergo radioactive iodine rai therapy differentiate thyroid cancer dtc material method subject patient dtc divide aromatherapy group group n control group group b n blend ml lemon ml ginger essential oil patient inhalation aromatherapy group inhale blend oil control group inhale distill water placebo min admission statistically compare salivary gland function treatment group b result comparison group b rate change accumulation rate significantly high parotid gland submandibular gland group p comparison group b significant increase rate secretion change treatment note bilateral parotid gland group p conclusion amelioration salivary gland function observe present study result suggest efficacy aromatherapy prevention treatment relate salivary gland disorder trial register umin clinical trial registry umin atypical familial thyroid cancer sister localize ovary follow extirpation benign goiter brother disclose osteolytic lesion rationale malignant struma ovarii extremely rare clinic diagnosis modality treatment still controversial describe case extensive peritoneal implant metastasis originate malignant struma ovarii discover year ovariectomy chemotherapy patient concern year old female admit clinic due hematochezia past history leave malignant struma ovarii enhance compute tomography ct examination suggest multiple metastasis nodule abdomen pelvic cavity diagnosis laparoscopy biopsy result intraperitoneal nodule show metastasis papillary thyroid carcinoma pathological examination total thyroidectomy show no definite malignant tumor component thyroid tissue finally combine patient past history malignant struma ovarii peritoneal implantation metastasis derive malignant struma ovarii diagnose intervention patient treat total thyroidectomy iodine therapy post therapy iodine scan single photon emission compute tomography compute tomography spect ct fusion image show iodine uptake distal descend colon sigmoid colon rectal lesion large lesion live outcome treatment although thyroid globulin remain high level month treatment patient hematochezia relieve lesson therefore thyroidectomy follow adjuvant treatment recommend patient malignant struma ovarii metastatic risk difficult predict base histopathologic examination guideline radioiodine therapy rit differentiate thyroid cancer objective paper report large series use radio probe guide surgery rgs nonradioiodine avid good differentiate thyroid cancer dtc design thirty seven patient locoregional recurrent nonradioiodine avid dtc study tc sestamibi direct rgs use handheld gamma probe intraoperative detector outcome twenty three woman man follow rgs month range papillary one tall cell variant follicular h rthle cell cancer patient thyroid cancer recur neck cervical lymph node metastasis find patient one patient papillary cancer thyroid bed cervical lymph node sixty six discrete nodule range mm mean tumor diameter mm identify high resolution ultrasound tc sestamibi probe guide rgs rgs tg thyroglobulin fall patient mean target nontarget sestamibi uptake ratio decrease patient p conclusion datum confirm early observation tc sestamibi intraoperative gamma probe use identify guide resection recurrent tumor involve lymph node locoregional metastasis nonradioiodine avid thyroid cancer guideline thyroid cancer include diagnostics nodule thyroid cancer comparatively rare thyroid nodule hand frequently diagnose result increase use diagnostic image cytological investigation small nodule find chance often reveal micropapillary carcinoma probably not clinically relevant new guideline thyroid cancer advise cytological investigation non palpable incidentally discover thyroid nodule perform indication standard treatment patient papillary follicular thyroid cancer consist thyroidectomy follow indicate lymph node dissection ablation therapy radioactive iodine tsh suppression extent treatment determine basis know prognostic factor result initial treatment target systemic therapy available patient metastatic progressive disease focus effect short study oncogene tumor suppressor gene human thyroid carcinoma clinical implication introduction discussion molecular genetic investigation relate thyroid cancer start gain clinical importance discovery tumor specific oncogene ptc papillary thyroid cancer syndrome specific mutation ret protooncogene man man b familial mtc patient furthermore thyroid specific sodium iodine symporter cause iodine accumulation thyroid tissue clone offer study enhance iodine radioiodine uptake thyroid cancer can soon prove clinically applicable inhibition nuclear factor kappa b differentially affect thyroid cancer cell growth apoptosis invasion background nuclear factor kappab nf kappab constitutively activate many cancer play key role promote cell proliferation survival invasion understand nf kappab signal thyroid cancer however limit study investigate role nf kappab signal thyroid cancer cell proliferation invasion apoptosis use selective genetic inhibition nf kappab advance thyroid cancer cell line result three pharmacologic inhibitor nf kappab differentially inhibit growth panel advance thyroid cancer cell line suggest nf kappab inhibitor may target effect therefore use selective genetic approach inhibit nf kappab signal overexpression dominant negative ikappabalpha mikappabalpha study reveal decrease cell growth one five thyroid cancer cell line c occur block g transition resistance tnfalpha induce apoptosis observe cell line likely nf kappab dependent mechanism inhibition nf kappab mikappabalpha sensitize subset cell line tnfalpha induce apoptosis sensitive cell line display sustain activation stress activate protein kinase c jun nh terminal kinase sapk jnk pathway define potential mechanism response finally nf kappab inhibition mikappabalpha expression differentially reduce thyroid cancer cell invasion thyroid cancer cell line sensitive cell line demonstrate approximately two fold decrease invasion associate differential expression mmp mmp reduce mikappabalpha expression cell line test conclusion datum indicate selective inhibition nf kappab represent attractive therapeutic target treatment advance thyroid however apparent global regulation thyroid cancer cell growth invasion not achieve nf kappab signal alone instead finding suggest important molecular process play critical role define extent nf kappab function within cancer cell prognostic significance numb metastatic lymph node stratify risk recurrence background prophylactic dissection facilitate identification central lymph node ln metastasis patient papillary thyroid cancer ptc stage system not stratify risk numb ln metastasis postoperative treatment vary among different institution therefore investigate significance numb ln metastasis risk stratification recurrence ptc material method retrospective review perform patient undergo thyroidectomy ajou university hospital total patient undergo total thyroidectomy another undergo central ln dissection lateral cervical ln dissection perform patient result patient recurrence recurrence free rate year year univariate analysis prognostic factor recurrence extent thyroidectomy tumor size capsular invasion stage n stage numb ln metastasis tnm stage radioactive iodine rai therapy multivariate analysis numb ln metastasis n stage significant prognostic factor recurrence recurrence free rate significantly different patient ln ln conclusion numb metastatic ln significant prognostic factor addition n stage therefore numb metastatic ln must consider postoperative stage system tailor treatment follow recommendation addition patient metastatic ln may benefit total thyroidectomy rai therapy postoperative follow serum thyroglobulin papillary thyroid cancer dual energy spectral ct quantitative parameter preoperative diagnosis metastasis cervical lymph node purpose evaluate use dual energy spectral compute tomographic ct quantitative parameter compare use conventional ct image feature preoperative diagnosis metastasis cervical lymph node patient papillary thyroid cancer material method study approve ethic committee patient provide write inform consent analysis quantitative gemstone spectral image datum qualitative conventional ct image feature independently perform different group radiologist excise lymph node locate label surgery accord location preoperative ct image evaluate histopathologically single combine parameter fit simple multiple logistic regression model respectively mean generalize estimate equation method sensitivity specificity analysis perform use receiver operate characteristic curve compare datum qualitative analysis result slope spectral hounsfield unit curve hu slope spectral hounsfield unit curve normalize iodine concentration normalize effective atomic numb measure arterial venous phasis significantly high metastatic benign lymph node well single parameter detection metastatic lymph node venous phase hu sensitivity specificity accuracy positive predictive value negative predictive value respectively well combination parameter venous phase hu slope spectral hounsfield unit curve arterial phase normalize iodine concentration value respectively compare qualitative analysis venous phase hu slope spectral hounsfield unit curve show high specificity vs p similar sensitivity vs p combine venous phase hu slope spectral hounsfield unit curve arterial phase normalize iodine concentration show high sensitivity vs p specificity vs p conclusion quantitative assessment gemstone spectral image quantitative parameter show high accuracy qualitative assessment conventional ct image feature preoperative diagnosis metastatic cervical lymph node patient papillary thyroid cancer study autophagy relate protein light chain lc ii expression level thyroid disease thyroid cancer common malignant tumor endocrine system survival promote role autophagy tumor cell receive universally study aim explore autophagy relate protein light chain lc ii expression level thyroid disease include papillary thyroid cancer total thyroid sample include sample papillary thyroid cancer sample nodular goiter sample hashimoto thyroiditis sample normal thyroid tissue resect surgery select divide pathological group use light microscope level autophagy relate protein lc ii four different type thyroid tissue test western blot spss software utilize analyze research datum statistically lc ii protein level papillary thyroid cancer tissue low normal thyroid tissue significantly p compare normal thyroid tissue expression level lc ii protein high sample hashimoto thyroiditis nodular goiter p multi factor analysis variance show no significant correlation lc ii protein level patient gender thyroid cancer significant variation patient without lymph node metastasis compare patient thyroid cancer without lymph node metastasis level lc ii protein low patient thyroid cancer lymph node metastasis p detection lc ii protein expression level thyroid disease may contribute clinical diagnosis provide theoretic basis therapy toxic adenoma cancer objective investigate expression significance role transform growth factor activate kinase tak human thyroid cancer tissue method datum patient thyroid cancer undergo surgical treatment hospital june march collect patient diagnose thyroid cancer post operative pathological examination immunohistochemistry stain perform detect expression tak protein thyroid cancer tissue adjacent tissue correlation analysis perform explore relationship tak expression level clinical pathological feature patient prognosis addition thyroid cancer cell bcpap culture vitro investigate role tak proliferation invasion apoptosis thyroid cancer cell possible mechanism action result tak expression rate human thyroid cancer tissue significantly high adjacent normal tissue p tak expression level unrelated patient age gender histological type p closely relate clinical stage lymph node metastasis p moreover five year survival rate patient tak expression significantly low without tak expression p vitro z oxozeaenol selective tak inhibitor significantly inhibit proliferation invasion promote apoptosis thyroid cancer cell possibly due inhibition activation nuclear factor b nf b signal pathway conclusion tak may important factor involve pathogenesis thyroid cancer target prognostic factor recurrence papillary thyroid carcinoma lymph node lung bone analysis patient average year follow background papillary thyroid carcinoma ptc frequently recur lymph node may not fatal immediately stressor physician patient recurrence distant organ although little frequent often life threaten lung bone organ ptc likely recur present study investigate factor predict recurrence ptc lymph node lung bone large numb patient undergo long term follow method total ptc patient male female without distant metastasis diagnosis undergo initial surgery kuma hospital enroll study postoperative follow range month month year average result date node lung bone recurrence detect patient respectively patient die ptc examine prognostic significance tumor size extrathyroid extension ex age year old age male gender gender clinical node metastasis n extranodal tumor extension ln ex outcome multivariate analysis age gender cm n ex independent predictor lymph node recurrence age ex cm n independent prognostic factor lung recurrence ex cm n independently predict bone recurrence n cm strong prognostic value lymph node lung bone recurrence contrast age strong predictor carcinoma death ln ex also prognostic value carcinoma death although not predictor carcinoma recurrence ex n cm cm also prognostic impact carcinoma death conclusion large lymph node metastasis show strong prognostic impact carcinoma recurrence not lymph node also lung bone carcinoma death extrathyroid extension also independently predict recurrence carcinoma death although hazard ratio low large node metastasis age year old contrast strong predictor carcinoma death extranodal tumor extension not independently affect recurrence prognostic significance carcinoma death finding suggest recur ptc lesion old patient extranodal tumor extension difficult control progressive use fine needle aspiration biopsy ultrasound guidance assess risk malignancy patient multinodular goiter purpose fine needle aspiration biopsy fnab commonly perform procedure use evaluation solitary thyroid nodule risk malignancy approximately patient recently use ultrasound us guidance fnab show enhance diagnostic efficacy procedure however risk malignancy thyroid nodule occur within multinodular goiter mng not completely clarify optimal mean investigate nodule use fnab subject method perform retrospective study patient see year period mng one nodule undergo fnab us guidance result history physical examination thyroid function antibody test radionuclide study thyroid sonogram cytology aspirate nodule surgical pathology record analyze result total nodule aspirate patient mng adequate material obtain aspirate \\ufeff1 attempt sixty seven aspirate patient yield benign cytology aspirate patient yield suspicious cytology patient suspicious cytology undergo thyroid surgery thyroid cancer find nodule include case papillary cancer case h rthle cell cancer additional patient occult papillary cancer discover overall malignancy rate thyroid nodule among patient mng approximately conclusion fnab us guidance useful diagnostic modality evaluation thyroid nodule select patient mng risk thyroid malignancy nodule comparable exist solitary thyroid nodule possibility thyroid malignancy consider patient mng insular type component follicular thyroid carcinoma year old girl case report insular type carcinoma thyroid rare form undifferentiated thyroid cancer manifestation disease occur mainly adult extremely rare child prognosis type thyroid carcinoma unfavorable childhood rarity not yet clear whether tumor carry risk progression therapy choice total thyroidectomy combine cervical lymph node dissection child surgery associate high risk recurrent nerve palsy loss parathyroid gland adult therefore identification protection recurrent laryngeal nerve use electrical neuromonitoring good exact preparation parathyroid gland may reduce risk history year old girl insular type thyroid carcinoma present surgical consideration total thyroidectomy vs prevalence thyroid cancer medical screen center pathological feature screen detect thyroid carcinoma purpose assess incidence thyroid malignancy adult population screen high resolution ultrasonography medical screen center compare clinical pathological feature screen detect thyroid carcinoma symptomatic overt thyroid carcinoma material method calculate prevalence screen detect thyroid cancer medical screen center use differentiate thyroid gland carcinoma child adolescent differentiate thyroid cancer rare disease childhood adolescence frequently thyroid cancer child belong papillary variant whereas follicular histological pattern much little frequently encounter dedifferentiated anaplastic cancer rare age especially indolent cervical lymph node enlargement suspicious thyroid cancer even occur together solitary rapidly grow indurated thyroid nodule every nodule thyroid child adolescent not unequivocally cystic suspicious malignancy contrast adult multifocal tumor manifestation frequently find child adolescent often spread beyond capsule thyroid time diagnosis regional lymph node involve distant metastasis present case despite much advance stage usually find adult prognosis child well advance age since tumor highly differentiate even case distant metastasis curative approach still possible therapy surgery radioiodine follow follow principle establish old patient p bcl ki diagnosis insular thyroid gland cancer case report review literature report cover \\ufeff1 case insular thyroid cancer record croatian medical literature year old female patient present hospital symptom inspiratory stridor clinical examination disclose expansive tumor mass us guide fna indicate anaplastic cancer total thyroidectomy accordingly indicate pathohistological analysis h e biopsy disclose tumor mass characteristic insular growth pattern monomorphic tumor cell immunohistochemical analysis confirm diagnosis diffuse positive reaction thyreoglobulin focally ttf scant cytokeratin calcitonin fviii cd lca clearly negative p bcl express tumor cell respectively proliferation index ki accord survey suggest panel immunohistochemistry diagnose insular cancer even partly present insular cancer mention pathohistological description prognostic mean medullary thyroid cancer introduction objective purpose study evaluate feasibility ultrasound thyroid elastography use carotid artery pulsation compression source potential differential diagnosis thyroid nodule method baseband sonographic datum acquire thyroid nodule patient natural pulsation carotid artery use compression source thyroid strain estimate offline quantitative assessment thyroid tissue stiffness new metric call thyroid stiffness index tsi compute ratio strain near carotid artery high strain region stiff region low strain region inside thyroid nodule stiffness information elastography correlate histopathologic finding result tsi papillary carcinoma n high tsi benign nodular goiter n indicate papillary carcinoma stiff benign nodular goiter p patient able distinguish papillary carcinoma nodule benign nodular goiter locate thyroid lobe base stiffness information obtain elastography suggest elastography can use guide fine needle aspiration biopsy thyroid nodule high probability cancer conclusion result preliminary study indicate feasibility pulsation induce thyroid elastography ultrasound thyroid elastography use carotid artery pulsation appear potential noninvasively differentiate papillary carcinoma benign nodular goiter future study need evaluate efficacy elastography detect thyroid cancer guide thyroid biopsy incidental thyroid cancer detect f fdg pet different clinicopathological feature objective prevalence risk malignancy thyroid incidentalomas investigate previous study however study not look characteristic incidental thyroid cancer itc detect fluorine fluorodeoxyglucose pet therefore aim assess clinicopathologic feature itc method march december total patient undergo total thyroidectomy papillary thyroid cancer among patient belong itc group define focal thyroid uptake report incidental find pet image evaluation reveal presence malignancy addition two control group non pet incidental thyroid cancer nitc select nitc patient n undergo total thyroidectomy march nitc b patient n undergo total thyroidectomy papillary thyroid cancer match confound effect age sex result no significant difference clinicopathologic feature except age tumour node metastasis tnm stage itc nitc patient itc nitc patient age year old although n stage not different itc nitc itc patient stage iii iv tumour match age sex none clinicopathologic feature show significant difference itc nitc b patient conclusion no significant difference observe itc nitc patient except age tnm stage itc patient advance tnm stage likely due patient age nabothian cyst associate high false positive incidence iodine uptake whole body scan treatment differentiate thyroid cancer objective study aim analyze focal uptake iodine upper pelvis superior urinary bladder whole body image patient undergo treatment thyroidectomy differentiate thyroid cancer method june march patient man woman average age year undergo radioactive treatment thyroid cancer surgery analyze retrospectively pathological finding confirm papillary thyroid carcinoma whole body scan acquire day mci sodium iodide administer orally patient single photon emission compute tomography compute tomography spect ct scan carry locate lesion show abnormal intense activity upper pelvis superior urinary bladder evaluate ultrasonography result use spect scan five female patient show abnormal focal radioactivity low abdomen subsequent spect ct examination show radioactivity locate cervix four five patient sigmoid colon one patient transvaginal ultrasonography perform former four patient reveal several echo free region cervix finding consistent diagnosis nabothian cyst three patient administer 2 course radioiodine therapy radioactive uptake still visible site whole body image conclusion nabothian cyst consider case abnormal uptake upper pelvis superior urinary bladder detect whole body scan differentiate thyroid cancer resection epidermal growth factor receptor expression upregulated undifferentiated thyroid carcinoma human background epidermal growth factor receptor egfr signal involve human cancer cell progression responsible aggressive biological behavior poor clinical outcome several human malignancy activation egfr pathway propose among other involve progression thyroid cancer toward thyroid stimulate hormone tsh independent phenotype previously observe undifferentiated thyroid carcinoma cell hyper sensitive egf signal downstream intracellular pathway correlate loss tsh dependency increase egf dependent proliferation migration thus hypothesize upregulation egfr protein expression may enhance parallel transition toward poorly differentiate phenotype human thyroid carcinoma method expression egfr evaluate immunohistochemistry series human thyroid carcinoma different degree tumor differentiation result expression egfr protein significantly upregulated poorly differentiate anaplastic thyroid carcinoma whereas absent faint normal thyroid gland tissue differentiate thyroid papillary carcinoma note select thyroid tumor characterize mix population differentiate undifferentiated tumor cell likely progress good poorly differentiate anaplastic phenotype exhibit egfr negative differentiate field together egfr positive poorly differentiate anaplastic area conclusion upregulation egfr expression may molecular marker dedifferentiation thyroid epithelial carcinoma likely responsible activation egf signal observe tumor cell favor progression toward angiogenic poorly differentiate tsh independent phenotype current management medullary thyroid cancer medullary thyroid cancer account thyroid cancer majority medullary thyroid cancer sporadic case result germline mutation ret proto oncogene hereditary medullary thyroid cancer see part multiple endocrine neoplasia syndrome type b part familial medullary thyroid cancer article discuss current method available diagnosis evaluation patient suspect medullary thyroid cancer management medullary thyroid cancer predominantly surgical excision consist total thyroidectomy lymph node dissection extent time surgical excision discuss systemic therapeutic option limit medullary thyroid cancer several therapeutic target show promise development new therapy future anaplastic transformation medullary thyroid cancer paper present detail microscopic study case medullary thyroid carcinoma loss amyloid production argyrophilic cellular granule combine prevalence giant multinucleated cell part primary tumor namely metastatic deposit change believe give evidence anaplastic dedifferentiation similar case report review conclusion not differentiate thyroid cancer medullary thyroid cancer good capable anaplastic transformation however rare medullary thyroid cancer diagnose radically treat prevent fatal anaplastic transformation occult papillary thyroid cancer present cystic metastasis lateral neck case report rationale papillary thyroid cancer account case thyroid carcinoma disease entity notorious metastatic invasion adjacent lymph node include cervical lymph node potentially present grow lateral neck mass however lesion tend recognize diagnose soon due palpable mass patient concern report describe rare case huge slow grow neck metastasis base mm papillary thyroid microcarcinoma patient present painless continuously grow right lateral neck mass aside no specific complaint mention diagnosis underlie cause patient neck mass turn occult papillary thyroid microcarcinoma mm metastatic invasion subsequent cystic degeneration cervical lymph node accurate diagnosis make surgical intervention histopathological analysis intervention patient undergo complete resection cervical mass conjunction total thyroidectomy right cervical neck dissection follow adjuvant iodine chemotherapy outcome margin free surgical resection without postoperative complication can achieve patient receive iodine supplementation remain free recurrence regular clinical follow up year therapy curative lesson case report emphasize importance thorough diagnostic work include preoperative tissue sample cervical neck mass since benign appearance image not exclude malignant process differential expression galectin advance thyroid cancer cell clue toward understand tumour progression metastasis introduction galectin member beta galactoside bind protein family play important role cell cell adhesion cell matrix interaction cellular expression galectin correlate cancer aggressiveness metastasis method examine differential expression galectin collection case thyroid lesion include case papillary thyroid carcinoma ptc case follicular carcinoma fca immunohistochemical method apply semiquantitative score perform stain intensity positive tissue score do cell central portion tumour focus cell periphery adjacent neighbour normal thyroid tissue matrix result significantly high expression p galectin observe advance peripheral thyroid cancer cell compare centrally locate cell not close contact neighbour stromal tissue case ptc compare fca conclusion find support role galectin high dose rai therapy justify pathological n disease reveal prophylactic central neck dissection cn papillary thyroid cancer patient superior low dose rai therapy objective one presume advantage prophylactic central neck dissection pcnd offer stage basis aggressive radioactive iodine rai therapy postulate necessity high dose treatment efficacy present study aim compare effectiveness low dose high dose rai select cohort cn papillary thyroid cancer ptc patient pathological n pn disease reveal pcnd term ablation rate response therapy frequency short term adverse effect two group also compare patient method january april cn ptc patient pn disease reveal pcnd hospital retrospectively review patient indication high dose rai presence extrathyroidal extension vascular invasion suspicion distant metastasis exclude include patient high dose mbq administer january august low dose mbq august april ablation assessment perform month rai therapy response evaluation rai therapy perform month high dose group month low dose group patient also evaluate short term adverse effect hour rai administration result total patient enroll among high dose group low dose group no significant difference ablation rate p response rai therapy p two group twenty four hour rai administration neck pain swell vs p gastrointestinal discomfort vs p significantly frequent high dose group conclusion high dose rai therapy high frequency short term adverse effect appear not superior low dose rai therapy cn ptc patient pn disease reveal pcnd achieve well response therapy randomize study large series patient long follow duration especially low dose group need validate result thyroid cancer article review common type thyroid cancer focus old male worldwide thyroid carcinoma common endocrine malignancy include tumour type range localise papillary carcinoma lethal anaplastic disease among elderly population male gender seem highly correlate risk aggressiveness thyroid cancer early diagnosis urgent aggressive treatment important age patient article include numerous study evaluate prevalence morbidity mortality thyroid cancer old male pediatric thyroid cancer postoperative classification response initial therapy prognostic factor context prognostic factor pediatric differentiate thyroid cancer dtc not good establish objective objective study retrospectively compare postoperative risk stratification system american thyroid association ata risk category schneider child medical center israel scmci score response initial therapy predictor disease outcome patient method fifty four dtc patient median age diagnosis year range follow median year range stratify prepubertal n pubertal n postpubertal n group patient undergo total near total thyroidectomy receive radioiodine therapy extent dtc evaluate apply ata risk category novel scmci score postoperative risk stratification low intermediate high determine use histopathological laboratory image finding response initial therapy complete acceptable incomplete base stimulate thyroglobulin image result \\ufeff1 year follow result risk recurrent persistent disease assess postoperative ata differentiate thyroid carcinoma girl resistance thyroid hormone management triiodothyroacetic acid thyroid hormone resistance syndrome characterize reduce target tissue response action thyroid hormone lead high level free thyroxine free triiodothyronine non suppress level thyrotropin tsh recently three case papillary thyroid carcinoma associate thyroid hormone resistance syndrome publish main challenge situation difficulty maintain suppression tsh level without produce symptom hyperthyroidism present another case association thyroid hormone resistance syndrome papillary thyroid carcinoma share experience triiodothyroacetic acid make possible easy management carcinoma surgery maintain tsh level suppress despite resistance thyroid hormone cytologically indeterminate follicular thyroid nodule fine needle aspiration cytology indication total thyroidectomy magnitude case management indeterminate thyroid nodule difficult controversial addition recent evidence incidence follicular lesion may increase prove follicular cancer prospective observational study do department surgery bangabandhu sheikh mujib medical university dhaka bangladesh february january investigate rate malignancy inability demographical clinical sonographic datum predict malignancy indeterminate nodule unreliability intraoperative freeze section biopsy scope determine need total thyroidectomy patient study population consist case present indeterminate nodule thy female male mean age year patient undergo total thyroidectomy malignancy diagnose patient mean nodule size mm malignant lesion malignant nodule cm size malignant case irregular border malignant lesion hard consistency datum statistically significant correlate malignancy rate malignancy cytologically indeterminate lesion high present study sample compare report study thus consider fact demographical clinical sonographic feature find inaccurate predictor malignancy opinion total thyroidectomy always recommend patient analysis prognostic factor patient multiple recurrence papillary thyroid carcinoma purpose numerous study past mention various factor influence recurrence papillary thyroid carcinoma include age tumor size advance stage extrathyroidal extension distant metastasis attempt make classify disease low risk high risk group base clinicopathological factor however relatively scarce study patient multiple recurrent papillary thyroid carcinoma study analyze risk factor associate case material method study investigate various clinicopathological factor patient diagnose papillary thyroid carcinoma receive primary surgery yonsei university wonju college medicine department surgery january december follow october investigation factor associate patient show multiple recurrence make result patient divide group group no recurrence n group recurrence n group multiple recurrence n univariate analysis risk factor reveal tumor size great cm multifocality clinical apparent lymph node metastasis risk factor associate multiple recurrence papillary thyroid carcinoma multivariate analysis perform variable select univariate analysis demonstrate no significant risk factor year disease specific survival different patient group group respectively patient clinically advance group demonstrate poor prognosis p year overall survival rate patient group respectively clinically advance group tend show poor overall survival rate good p discussion aggressive extensive surgery good close follow require operate patient tumor size great cm multifocality clinical apparent lymph node metastasis use image modality ultrasonography pet ct scan may desirable monitor patient giant cell carcinoma thyroid p protein member p family like p induce cell cycle arrest apoptosis response dna damage loss p function responsible progression good differentiate thyroid cancer aggressive phenotype hypothesize p may also involve thyroid carcinogenesis find normal thyrocites not express p whereas thyroid malignancy positive p expression however p protein thyroid cancer cell unresponsive dna damage agent fail elicit block cell cycle apoptotic response notably overexpression transcriptionally active p thyroid cancer line arrest cell cycle still unable induce cell death loss p biological activity neoplastic thyroid cell partly explain interaction transcriptionally inactive variant p deltanp mutant p finding suggest functional impairment p can involve development thyroid malignancy define p potential therapeutic target thyroid cancer add benefit dedicate neck f fdg pet ct image protocol patient suspect recurrent differentiate thyroid carcinoma purpose retrospectively analyze whether add delay high resolution dedicate neck f fdg positron emission tomography computerize tomographic immune cell infiltrate associate dysregulation dna repair machinery may predispose papillary thyroid carcinogenesis background alter immune microenvironment may contribute papillary thyroid cancer development immune infiltrate identify postoperatively many papillary thyroid cancer case without diagnose thyroiditis oxygen radical endogenous inflammation induce generate dna damage cause mutation repair incorrectly hypothesize infiltrate immune cell may promote aberrant dna repair predispose thyrocytes papillary thyroid cancer method quantitative reverse transcriptase polymerase chain reaction assay measure gene expression fresh freeze sample n rna seq datum obtain papillary thyroid cancer normal thyroid sample cancer genome atla n hashimoto affect normal thyroid genotype tissue expression project n immune cell marker expression level compare histological estimate select dna repair gene immunohistochemistry localize gene expression specific cell type result dna polymerase theta expression quantitative reverse transcriptase polymerase chain reaction high papillary thyroid cancer papillary thyroid cancer adjacent sample benign normal thyroid p immune marker include cd correlate dna polymerase theta expression r not dna repair gene examine benign tissue hashimoto exhibit increase dna polymerase theta p cd e p expression dna polymerase theta localize thyrocytes not lymphocyte conclusion identify strong correlation immune cell infiltrate dysregulated thyrocyte dna repair gene likely reflect pathway papillary thyroid cancer development restrict ultrasound thyroid fine needle aspiration biopsy nodule size tumor miss population base study clinician use nodule size determine thyroid nodule receive cytological evaluation american thyroid association ata recommend cytological evaluation nodule cm unknown however nodule size accurately discriminate lesion represent tumor favorable versus unfavorable prognosis also characteristic thyroid cancer would not diagnose strict cm size cut use threshold biopsy intrathyroidal nodule not good establish use rochester epidemiology project population base cohort identify thyroid nodule olmsted county resident assess presence favorable unfavorable feature nodule size cutoff patient find thyroid cancer risk stratify use ata risk score predict risk recurrence persistent disease thyroid cancer case biopsy do factor thyroid nodule size suspicious ultrasound feature exclude identify thyroid nodule harbor thyroid cancer thyroid cancer ata low risk intermediate ata high risk score frequency thyroid cancer distribution ata risk score similar across tumor size thyroid nodule cm benign malignant ata low risk ata intermediate risk without extrathyroid extension aggressive histology distant metastasis thyroid cancer patient no case persistent disease find median follow year population base study show high risk thyroid cancer rare indeed highly select cohort patient ata recommendation avoid cytologic evaluation thyroid nodule little cm would not miss thyroid cancer high risk feature however thyroid nodule size presentation not accurately discriminate tumor favorable versus unfavorable clinicopathologic feature thus discrimination desire example avoid overdiagnosis feature size presentation need evaluate thyroid cancer associate multinodular goiter child purpose review incidence differentiate thyroid cancer dtc especially among small tumor increase worldwide despite fact mortality rate thyroid cancer remain stable total thyroidectomy without radioiodine therapy actually standard treatment last decade several study show lobectomy can alternative total thyroidectomy low risk dtc without compromise overall survival aim article assess role conservative surgery hemithyroidectomy dtc review literature datum recent finding recent advance diagnostic technique allow treatment tailor patient need late consensus guideline suggest patient high risk tumor undergo total thyroidectomy whereas patient small low risk node negative dtc may candidate conservative surgery careful risk evaluation stratification make possible individualize treatment avoid overtreatment guarantee good long term prognosis low recurrence risk excellent prognosis dtc would require large sample size long term follow prospective trial compare outcome total thyroidectomy vs lobectomy however several remarkable retrospective study summary base current clinical datum conservative surgery may appropriate patient low risk dtc risk thyroid cancer diagnostic dose radioiodine papillary thyroid carcinoma ptc desmoid type fibromatosis dtf characterize genetic alteration fibroblast ptc dtf extremely rare report case sporadic immunohistochemical stain use antibody beta catenin useful diagnose variant report aim describe clinical pathological immunohistochemical finding case ptc dtf clarify diagnostic significance variant patient include woman man mean age year ptcs focal dtf component extensive dtf component include case no significant difference note term age gender serum thyroglobulin level extensive focal dtf case aspiration cytology case report suspicious malignancy malignant schwannoma fibroma suggest case dtf component histologically classify type namely central case peripheral case mix case diffuse type case stromal component consistent dtf immunohistochemically fibroblast dtf component show nuclear cytoplasmic expression beta catenin case feature observe even case stromal component focally exist neither carcinoma cell fibroblast ki label index find case agree ptc nodular fasciitis like stroma rename ptc dtf solitary thyroid nodule diagnosis management thyroid nodule common benign lesion since clinically important thyroid carcinoma relatively rare disease sensitive specific test diagnosis thyroid cancer fine needle aspiration biopsy diagnostic accuracy depend upon whether not one excise suspicious nodule thus include correctly diagnose nevertheless fine needle aspiration biopsy sensitive specific cost effective test thyroid cancer therapy depend upon cause thyroid nodule 2 malignancy thyroid cancer patient population base survey case norway population base survey thyroid cancer patient diagnose norway total case 2 malignancy observe person year mean follow year male patient significantly increase incidence urogenital cancer standardise incidence ratio sir confidence interval ci include cancer testis sir ci urinary bladder sir ci occurrence malignant melanoma also increase among male sir ci apparent association urogenital cancer among male present time not explain although increase surveillance good specific aetiological factor consider risk factor nodal metastasis recurrence among patient papillary thyroid microcarcinoma difference clinical relevance nonincidental incidental tumor background papillary microcarcinoma pmc subgroup papillary thyroid carcinoma ptc measure cm little diameter herein focus search risk factor predict nodal metastasis recurrence pmcs analyze difference presentation treatment prognosis nonincidental incidental tumor method january may patient diagnosis pmc department cross sectional study patient nonincidental patient incidental pmc carry demographic datum diagnostic result tumor characteristic risk assessment surgical treatment postoperative follow result evaluate result cytology detect thyroid cancer nodal involvement nonincidental pmc mean tumor size significantly large nonincidental pmc vs mm commonly find within normal thyroid gland hashimoto thyroiditis incidental pmc associate multinodular goiter tnm stage system show high cancer stage iva nonincidental multivariate analysis capsular invasion nonincidental diagnosis two independent factor significantly affect nodal metastasis patient nonincidental pmc undergo iodine ablation therapy surgery compare patient incidental nodal metastasis diagnosis factor influence recurrence find three nonincidental case two lateral one central neck compartment conclusion several pmcs present risk free clinical course nonincidental tumor aggressive behavior tendency recurrence case early detection aggressive treatment mandatory conventional ptc accord risk stratification cancer stage papillary thyroid carcinoma adolescent girl grave disease background mix connective tissue disease mctd connective tissue disorder characterize high titer distinct antibody u ribonucleoprotein clinical feature see systemic lupus erythematosus sle rheumatoid arthritis ra dermatomyositis dm polymyositis scleroderma association sle dm various cancer thyroid report literature however no report associate mctd thyroid cancer case report present year old woman diagnose mctd co morbid interstitial lung disease remain stable year develope papillary thyroid carcinoma ptc year initial diagnosis conclusion theorize mctd may primary diagnosis complicate ptc mctd may initial presentation paraneoplastic syndrome silent ptc symptom mctd significantly improve total thyroidectomy well knowledge \\ufeff1 case report associate mctd ptc highlight importance maintain high index suspicion thyroid malignancy mctd patient metastatic cervical carcinoma present primary thyroid cancer case report secondary neoplasm thyroid mimick primary thyroid lesion rare find case squamous anaplastic cell carcinoma uterine cervix metastatic thyroid describe diagnostic lobectomy unilateral follicular nodule thyroid gland describe technique diagnostic lobectomy dl rationale base define dl minimally invasive procedure consist total lobectomy isthmusectomy preservation omolateral recurrent laryngeal nerve parathyroid gland without digital exploration contralateral lobe fact entry previously explore field complete thyroidectomy increase risk complication must take consideration subject consecutive patient undergo surgery unilobar follicular neoplasm thyroid gland january december follicular adenoma carcinoma patient thyroid cancer total thyroidectomy perform within week \\ufeff1 operation sterile environment normal anatomical cleavage plain avoid risk injury laryngeal nerve parathyroid gland conclude dl safe suitable surgical procedure patient follicular structure lesion thyroid gland thyroid cancer thyroid gland vulnerable organ ionize radiation indeed epidemiological study reveal increase incidence thyroid cancer among atomic bomb survivor hiroshima nagasaki radiation casualty chernobyl carcinogenic risk thyroid dependent radiation dose high young people recent advance molecular biology contribute clarify mechanism thyroid carcinogenesis genetic molecular level radiation induce thyroid carcinogenesis review epidemiological datum basic research treatment sorafenib advance thyroid cancer papillary thyroid cancer ptc usually good prognosis treatment include total thyroidectomy complementary radioiodine rai therapy give complete remission patient however subject metastatic disease prognosis poor group patient disease progression no uptake search new therapeutic modality tyrosine kinase inhibitor antiangiogenic agent necessary study present case year old male advance ptc pt mnxmo diagnose primary treatment total thyroidectomy ablation lead complete remission local good lymph node recurrence diagnose successively treat surgery increase serum thyroglobulin level note single lung metastasis diagnose operate new focus cns vertebral column no uptake state progression bone cns pterygoid muscle confirm pet ct patient undergo neurosurgical metastasectomy twice palliative cns vertebra radiotherapy live metastasis diagnose treatment increase dose thalidomide mg administer month good tolerance however therapy withdraw due cancer progression next sorafenib mg give week radiological examination perform week confirm stable disease whereas month late sorafenib withdrawal due lack treatment possibility progression observe metronomic chemotherapy adriamycin institute give disease stabilization month patient die advance disseminate disease due pulmonary embolism present case document no adverse effect therapy sorafenib patient brain dtc metastasis sorafenib therapy short term no progression occur time non scintigraphy treatment follow thyroid cancer single photon emitter fdg pet respect therapeutic option whole body scintigraphy wbs important functional image technique treatment follow differentiate thyroid cancer many patient thyroid cancer tissue not concentrate therefore not localize use wbs addition morphologic technique low specificity many case method necessary localize tumor tissue patient besides tl use initially tumor seek agent sestamibi tetrofosmin f dg pet image evaluate differentiate thyroid carcinoma paper summarize clinical impact functional image tracer besides direct comparison f dg pet high sensitivity exceed case negative wbs available method consider patient suffer differentiate thyroid cancer suspect recurrence metastasis particularly case elevate thyroglobulin value negative wbs also mtc label tracer use detect tumor tissue sufficient sensitivity medullary thyroid cancer present frequently diagnostic difficulty octreotide mtc v dmsa mibg reply difference impact age mortality good differentiate thyroid cancer actin cytoskeleton important cell structure motility disorder actin architecture correlate high metastatic potential melanoma fibrosarcoma colon cancer model thyrotropin know induce growth differentiation culture thyroid cell whereas carcinogenic phorbol ester papillary type carcinoma thyroglossal duct cyst case conservative management objective thyroglossal duct cyst tgdc common congenital neck mass present population tgdc carcinoma much little common occur roughly patient diagnose tgdc vast majority tumor papillary type thyroid cancer give rarity wide variation management recommendation disease extent surgical management need adjuvant therapy include radioactive iodine ablation rai particularly debate author argue aggressive therapy include rai patient undergo concurrent thyroidectomy sistrunk procedure tgdc carcinoma present series patient treat tgdc carcinoma institution discuss management algorithm method retrospective chart review patient tgdc treat separate institution factor review include patient age sex preoperative diagnosis preoperative work extent therapy use adjuvant therapy result six patient treat tgdc carcinoma institution identify one patient exclude patient treat outside facility prior referral patient papillary type thyroid cancer one patient undergo sistrunk procedure alone remain undergo sistrunk procedure plus total thyroidectomy two patient note malignancy thyroid two patient undergo thyroidectomy additionally receive adjuvant rai conclusion thyroglossal duct cyst carcinoma uncommon management controversial low risk patient single tumor focus negative margin normal preoperative neck thyroid image no extension tgdc carcinoma beyond cyst wall sistrunk procedure alone observation thyroid may sufficient patient population rai unlikely substantial benefit measurement variation estimation quality life effect patient undergo treatment papillary thyroid carcinoma background thyroid cancer incidence increase effect diagnosis treatment health relate quality life hrqol essential variable absence change life spin majority patient hrqol instrument datum useful disease comparison increasingly use health policy outcome evaluation variation exit among instrument base impact specific disease assess four good validate preference base survey detect change health clinical intervention patient diagnose papillary thyroid cancer ptc method four commonly use hrqol questionnaire short form v sf euroqol eq health utility index mark hui hui administer patient diagnosis ptc three perioperative time point \\ufeff1 year treatment clinicopathological treatment course datum assess hrqol impact include complication surgery operation persistence early recurrence adjuvant radioactive iodine treatment compare standard metric include ceil effect intraclass correlation coefficient effect size quality adjust life year four instrument result patient preoperative diagnosis anxiety depression regional lymph node metastasis three distant metastasis undergo adjuvant radioactive iodine treatment ceil effect e proportion perfect score great eq little sf index score range sf eq score decline two week postoperatively return pretreatment level six month sf instrument exceed conventional minimally important difference three time point quality adjust life year follow sf eq hui hui conclusion result reflect general good health ptc patient effect quality life primarily relate emotional social impact treatment result support measurement similar underlie construct although variation detect change health exist instrument instrument assess sf responsive treatment effect utilize future economic analysis patient population lymphadenectomy differentiate thyroid carcinoma background study author analyze indication type surgical procedure perform neck lymph node case differentiate thyroid carcinoma method study carry retrospective way differentiate thyroid cancer observe woman man mean age year range patient divide three group \\ufeff1 include patient undergo thyroidectomy total thyroidectomy lobectomy 2 group include patient undergo total thyroidectomy lymphadenectomy central compartment 3 group include patient undergo total thyroidectomy functional neck dissection median follow month result postoperative complication similar three group follow show similar survival recurrence group conclusion elective lymphadenectomy central can solution routine treatment differentiate thyroid cancer without lymph node involvement presence cervico lateral node metastasis impose functional neck dissection adjuvant therapy long term management differentiate thyroid carcinoma therapy differentiate thyroid carcinoma little consensus optimal use postoperative adjuvant therapy long term follow strategy however increase body datum indicate patient benefit postoperative radioiodine ablation follow thyroid hormone suppression therapy approach long term monitor therapy provide include use strategy dependent upon extent patient initial disease occult thyroid cancer recent publication bring attention histopathological immunohistochemical molecular aspect rare breast tumor resemble tall cell variant papillary thyroid carcinoma brtc nine archive case entity retrieve review compare randomly select tall cell variant papillary thyroid carcinoma thtc seven brtc case good case solid papillary carcinoma breast analyze oncomine endocrinology time covid management thyroid nodule cancer patient thyroid nodule thyroid cancer tc refer diagnostic low expression long noncoding rna casc indicate poor prognosis promote tumorigenesis thyroid carcinoma recently long noncoding rnas lncrnas show link regulate different biological process cell growth differentiation tumorigenesis lncrnas identify promise clinical biomarker various tumor long noncoding rnas cancer susceptibility candidate casc recently demonstrate correlate tumorigenesis renal cell carcinoma lung carcinoma glioma gastric carcinoma nevertheless research biological function clinical significance casc thyroid carcinoma still unclear research focus relationship casc expression clinicopathological factor thyroid cancer find low expression casc correlate multifocality advance tumor node metastasis tnm stage kaplan meier survival analysis multivariate analysis show casc expression may independent prognostic factor human thyroid carcinoma moreover area receiver operate characteristic roc curve casc indicate diagnostic value thyroid carcinoma additionally overexpression casc significantly inhibit proliferation thyroid carcinoma cell arrest cell cycle g g stage thyroid cancer cell finding show casc may potential prognostic marker therapeutic target anaplastic thyroid cancer cytogenetic pattern comparative genomic hybridization study chromosomal abnormality comparative genomic hybridization cgh flow cytometry anaplastic thyroid cancer atc present coexist previous differentiate thyroid cancer dtc overall freeze tissue patient atc cell line atc dtcs analyze find chromosomal abnormality atc tissue abnormality gain loss among atcs associate prior concurrent dtc chromosomal abnormality find atc associate follicular thyroid cancer ftc associate ptc median number respectively p no associate differentiate thyroid cancer gain q relatively common atcs flow cytometry find aneuploidy atc tissue diploidy concordance dna aneuploidy presence chromosomal abnormality cgh atcs p also find chromosomal abnormality atc cell line ftc cell line ptc cell line conclusion chromosomal abnormality frequent atcs associate ftc uncommon associate ptc atcs no associate differentiate thyroid cancer finding support concept ptc ftc different genetic background even transformation atc may retain cytogenetic characteristic five year survival similar thyroid cancer patient distant metastasis prepare radioactive iodine therapy either thyroid hormone withdrawal recombinant human tsh context elevate level tsh markedly enhance effectiveness radioiodine rai therapy metastatic thyroid cancer objective objective study compare short term overall survival thyroid cancer patient rai avid distant metastasis prepare rai therapy either traditional thyroid hormone withdrawal thw recombinant human tsh rhtsh stimulation design retrospective chart review set study conduct tertiary care comprehensive cancer center patient patient include patient rai avid metastatic disease lung bone intervention patient rai treatment remnant ablation therapy metastatic disease do rhtsh stimulation patient rai treatment do thw patient thw use initial rai treatment subsequent administer activity give rhtsh stimulation main outcome measure overall survival measure result median follow yr no significant difference overall survival patient prepare rai therapy rhtsh alone thw alone thw follow rhtsh kaplan meier analysis p multivariate analysis include clinicopathological feature method preparation rhtsh twh age diagnosis independent predictor overall survival conclusion preparation rai therapy use either thw rhtsh stimulation associate similar yr overall survival rate patient rai avid thyroid cancer metastasis lung bone value thyroglobulin determination follow treatment patient thyroid cancer tg measurement perform regularly thyroid carcinoma order evaluate metastasis local recurrencies elevate tg level detect patient operate local recurrencies lymph node metastasis patient need reoperation elevate tg level follow period no patient need reoperation elevate tg level metastasis detect diagnostic procedure summarise result find tg level measurement valuable follow patient differentiate thyroid cancer tg level measurement supplement sometimes replace j thyroid scan overexpression forkhead box q correlate poor prognosis papillary thyroid carcinoma objective forkhead box q foxq member forkhead transcription factor family play important part cell cycle apoptosis metabolism immunology tumour genesis expression associate poor clinical prognosis various tumour however clinical significance foxq papillary thyroid carcinoma ptc not fully study purpose study investigate whether foxq correlate poor prognosis ptc design method perform retrospective study ptcs immunohistochemistry ihc use examine expression foxq ptcs nodular goitre specimen expression profile long noncoding rnas human papillary thyroid carcinoma long non code rnas lncrnas strongly associate cancer biology objective study investigate expression profile lncrnas human papillary thyroid carcinoma ptc understand biological role lncrnas involvement ptc oncogenesis lncrnas messenger rnas mrnas expression human ptc pair adjacent non cancerous thyroid nct tissue study micro array quantitative real time polymerase chain reaction complete blood count frequently abnormal year dosimetry guide radioactive iodine therapy metastatic thyroid cancer objective radioactive iodine rai associate hematologic abnormality previous research show even single dose rai cause change peripheral complete blood count cbc unclear use dosimetry guidance would prevent effect high dose rai bone marrow suppression method cbc baseline compare cbc obtain year last rai treatment thyroid cancer patient receive mci rai course disease cumulative dose numb treatment patient age use external beam radiation therapy ebrt consider analysis result observe small statistically significant decrease hemoglobin hb hematocrit hct platelet plt count year patient receive mci rai not find significant change white blood cell count wbc approximately patient develope anemia concomitant wbc plt abnormality rai dose numb treatment age diagnosis not confer high risk bone marrow suppression conclusion high cumulative activity rai administer dosimetric guidance associate small statistically significant decrease hb hct plt count clinical implication change unclear benefit obtain high dose rai indicate likely outweigh minimal hematologic risk observe present study xrcc gene polymorphism risk differentiate thyroid carcinoma dtc background previous study investigate association x ray repair cross complement group xrcc polymorphism thyroid cancer risk yield inconsistent result meta analysis perform derive precise estimation relationship three xrcc polymorphism thyroid cancer risk method principal finding pubmed embase database systematically search identify relevant study publication select meta analysis include study arg gln polymorphism case control study arg trp polymorphism case control study arg polymorphism case control result total population not show significant association three polymorphism risk dtc genetic model however stratify ethnicity result show arg polymorphism associate increase risk dtc among caucasians arg vs arg arg ci dominant model ci additive model ci whereas individual carry arg genotype significantly reduce risk dtc among asians arg vs arg arg ci also detect gln variant allele carrier may present overall decrease risk dtc mix population furthermore subgroup analysis histological subtype reveal arg trp polymorphism significantly associate reduce risk papillary thyroid carcinoma ptc dominant model ci conclusion meta analysis suggest arg polymorphism may contribute susceptibility dtc among caucasians whereas may provide protective effect asians risk dtc additionally result support protective role arg trp polymorphism develope ptc show evidence association arg gln polymorphism decrease risk dtc mix population value mass screen thyroid cancer study aim clarify presently uncertain value mass screen thyroid cancer perform physical examination along mass screen breast cancer zentsuji japan since among subject individual thyroid cancer find detection rate initial screen subsequent periodic screen thyroid cancer confirm histologically good differentiate carcinoma tumor size mass screen group mm significantly small patient present outpatient clinic period mm p incidence nodal metastasis mass screen group significantly low outpatient group p thus mass screen seem find thyroid cancer relatively early stage mass screen thyroid cancer economic instance perform together screen cancer breast cancer thyroid cancer screen require little one additional minute per subject ultimate aim mass screen reduce mortality no improvement prognosis enforce mass screen thyroid cancer detect study not demonstrate sufficient value mass screen thyroid cancer perform independently despite early cancer detection unilateral papillary thyroid carcinoma treat contralateral central lymph node dissection nomogram aid decision make central lymph node neck common site papillary thyroid carcinoma ptc not easily diagnose preoperatively prophylactic central lymph node dissection clnd especially contralateral clnd not recommend various guideline due high risk aim study establish objective point score base preoperative intraoperative datum guide selection patient contralateral clnd retrospectively evaluate consecutive patient ptc treat thyroidectomy inclusion study train cohort variable contralateral central lymph node macro metastasis clnmm investigate use univariate multivariate analysis subsequently nomograms develope validate independent cohort patient n validation cohort univariate multivariate analysis indicate preoperative fine needle aspiration prove ipsilateral lateral lymph node metastasis lnm odd ratio confidence interval ci p case freeze section pretracheal lnm ci p delphian lnm ci p risk factor contralateral clnmm receiver operate characteristic curve indicate cutoff value freeze section pretracheal lnm numb delphian lnm numb predictor contralateral central lymph node metastasis clnm nomogram generate accord risk factor good validate external cohort intraoperative freeze section result highly consistent postoperative pathological result propose nomogram base factor show good prediction contralateral clnmm ptc follicular cancer thyroid atypical presentation follicular thyroid carcinoma usually present thyroid nodule rare case show metastatic disease diagnosis present patient follicular thyroid carcinoma diagnose large pelvic metastatic mass biochemical profile subclinical hyperthyroidism treat local field radiotherapy since surgical resection not possible radioiodine therapy would little benefit due large volume currently continuous remission two year diagnosis evaluation urine activity external dose rate patient receive radioiodine therapy thyroid cancer aim study determine external dose rate iodine retention function time body thyroid cancer patient isolation period hospital urine sample collect th th th th h nd rd th th patient oral administration count external dose rate also simultaneously determine time point express retain radioiodine body activity versus dose rate effective half life calculate urine sample measurement find h within \\ufeff1 h h h accord result external dose rate sv h patient can discharge achieve h mbq h mbq treatment expression sodium iodide symporter thyroglobulin gene reduce papillary thyroid cancer alter expression gene encode sodium iodine symporter nis may important factor lead reduce iodine accumulation characteristic benign malignant thyroid nodule regulation nis gene expression report thyroid cancer use several different method goal present study accurately identify alteration nis gene expression benign malignant thyroid nodule use accurate real time quantitative rt pcr assay system total rna prepare benign thyroid nodule papillary thyroid cancer normal thyroid sample subject quantitative rt pcr use measure nis thyroglobulin tg mrna expression normal thyroid tissue nodular tissue sample papillary thyroid cancer sample significantly low nis mrna expression picogram equivalent pg eq benign nodule pg eq normal tissue pg eq p important pair sample nis gene expression decrease papillary thyroid cancer compare normal tissue median decrease range p eleven benign nodule also demonstrate low nis gene expression normal tissue decrease range p analysis pair sample demonstrate tg mrna expression significantly low thyroid cancer sample correspond normal tissue pg eq vs pg eq p demonstrate significant decrement nis gene expression papillary thyroid cancer benign nodule examine compare adjacent normal thyroid tissue use highly accurate quantitative rt pcr technique similarly thyroid cancer demonstrate significantly low tg mrna expression correspond normal thyroid reduce nis expression may important factor impairment iodine concentrate ability neoplastic thyroid tissue r polymorphism common risk marker associate papillary thyroid cancer papillary thyroid cancer ptc common type thyroid cancer rapid development genome wide association study gwas many genome variant associate susceptibility ptc identify include single nucleotide polymorphism r q near foxe evaluate association r ptc different ethnicity country conduct tsh thyroid cancer purpose diagnosis relate group drg base hospital reimbursement system become mandatory germany aim study provide nationwide datum surgery thyroid cancer analyze drg statistic year method unit analysis hospital admission diagnosis thyroid cancer assess influence age sex region relative frequency thyroid cancer relate hospitalisation surgery thyroid measure association hospitalisation rate incidence rate thyroid cancer among federal state germany result period thyroid cancer associate hospitalisation include surgical treatment thyroid age standardise drg base hospitalisation rate correspond cancer registry base incidence thyroid cancer positively associate overall hospitalisation thyroid surgery include total thyroidectomy percentage surgery thyroid total thyroidectomy nearly identical among man woman decrease among man age vary considerably region minimum saarland maximum saxony anhalt conclusion analysis drg statistic provide \\ufeff1 time representative population base datum surgical management thyroid cancer patient germany despite identical health care system germany exist guideline surgical treatment thyroid cancer observe considerable regional variation proportion total thyroidectomy perform germany 2 radioiodine treatment limit benefit differentiate thyroid cancer locoregional persistent disease objective radioactive iodine rai treatment often indicate total thyroidectomy differentiate thyroid cancer dtc however role biochemical locoregional persistent dtc unclear aim investigate effect 2 rai treatment patient incomplete response initial treatment no evidence distant metastasis method patient undergo little two rai treatment year period tertiary hospital identify thyroglobulin level neck image compare year rai retreatment evaluate last visit result cohort include patient female mean age year patient retreat without prior reoperation structural disease year rai retreatment patient sufficient datum structural progression resolution shrinkage stable disease stimulate thyroglobulin sttg measure ng ml ng ml retreatment p ns patient biochemical persistence sttg level decrease ng ml p patient undergo neck reoperation rai retreatment show no substantial change sttg still image finding year late final follow despite additional treatment patient no evidence disease conclusion comprehensive study show limit benefit 2 rai treatment dtc patient biochemical locoregional structural persistent disease prospective study need distinguish patient repeat rai may indicate avoid unnecessary exposure value f fdg pet negativity tg suppressibility marker prognosis patient elevate tg negative differentiate thyroid carcinoma tenis syndrome aim aim study investigate prognostic value fluorine fluorodeoxyglucose f fdg pet negativity thyroglobulin tg suppressibility differentiate thyroid carcinoma patient elevate tg negative radioiodine scan material method study population select thyroid cancer patient register large tertiary cancer care center management consist patient metastatic thyroid cancer elevate tg follow negative whole body scan negative f fdg pet compute tomography ct study patient thyroid carcinoma subject thyroid stimulate hormone stimulate assessment basis whole body scan serum tg level whole body f fdg pet ct scan evaluation metastatic disease burden patient subject follow evaluation serum tg whole body f fdg pet ct scan thyroid stimulate hormone suppression thyroxine sodium comparison also make finding f fdg pet ct patient demonstrate suppressible tg result total male female patient include study patient negative whole body f fdg pet ct study stimulate tg ng dl range ng ml indicate presence disease patient demonstrate variable tg suppressibility classify basis extent tg suppressibility tg suppressibility patient tg suppressibility patient tg suppressibility five patient no suppressibility two patient f fdg pet normal patient stimulation suppression patient asymptomatic period no definite correlation can establish status metastasis histopathology suppressibility tg average follow datum available year patient two patient no tg suppressibility group year patient little year four patient time analysis study patient asymptomatic aforementioned follow period base upon follow datum available conclusion study observe elevate tg normal f fdg pet exist definitive entity differentiate thyroid carcinoma basis study follow negative f fdg pet set elevate tg level can regard favorable prognostic indicator predict symptom free status follow period group patient suppressibility tg observe significant fraction patient appear independent status metastasis histopathology also patient show no tg suppressibility negative f fdg pet ct scan still well prognosis indicate disease free interval patient indicate study whether exist relation extent suppressibility long term outcome require examine future prospective study evolve paradigm successful molecular image medullary thyroid carcinoma background efficacy prepare thyroid fine needle aspiration fnas differentiate thyroid cancer complete rational approach controversy continue regard optimal management patient differentiate thyroid cancer no prospective randomize study evaluate merit extent thyroidectomy postoperative radioactive iodine ablation thyroid stimulate hormone tsh suppressive therapy exist patient low risk differentiate thyroid cancer enjoy relatively good prognosis mortality rate recurrence rate despite excellent prognosis patient consider low risk total near total thyroidectomy patient differentiate thyroid cancer advantage postoperative radioactive iodine use detect treat residual normal thyroid tissue local distant metastasis follow serum thyroglobulin level sensitive marker persistent recurrent disease thyroid tissue remove total near total thyroidectomy postoperative ablation tsh suppressive therapy associate well survival low recurrence rate patient occult papillary thyroid cancer minimally invasive follicular thyroid cancer treat thyroid lobectomy near normal life expectancy virtually patient differentiate thyroid cancer appear benefit extensive initial treatment value radial probe endobronchial ultrasound guide transbronchial needle aspiration diagnosis mediastinal lymph node metastasis primary papillary thyroid cancer health effect result accident chernobyl nuclear power plant occur consider paper wrong prognosis health effect respect mortality morbidity among population expose low radiation dose show prove increase thyroid cancer case among people child age time accident show linear relationship thyroid cancer case dose thyroid range gy consider additional absolute risk thyroid cancer child vary range case per person year gy fifteen year follow accident no case acute chronic radiation sickness reveal population live contaminate area receive low radiation dose also exposure low radiation dose not result excess malignant tumor among population case outcome acute radiation sickness follow radiation damage skin cancer cataract development oncopathology rise trend papillary thyroid carcinoma true increase diagnosis no abstract available understand natural history papillary thyroid cancer case series background papillary thyroid cancer ptc incidence continue rise describe natural history untreated ptc patient method retrospective case series untreated ptc patient result identify untreated patient kaiser permanente cancer registry ptc patient categorize low risk n high risk n low risk medically contraindicate surgery n diagnosis high risk group cervical lymph node metastasis distant metastasis compare none low risk group among latter three patient develope tumor growth mm one develope regional lymph node metastasis without distant metastasis year overall survival low risk paratracheal lymph node metastasis papillary thyroid carcinoma present middle mediastinal cyst report case majority middle mediastinal cyst benign disease however case middle mediastinal cyst reveal malignant tumor herein report case middle mediastinal cyst prove right paratracheal lymph node metastasis thyroid papillary carcinoma patient year old lady undergo thyroidectomy regional lymph node dissection papillary thyroid carcinoma year follow compute tomography reveal grow cyst right side intrathoracic trachea metastasis thyroid cancer suspect history right upper mediastinal lymphadenectomy thoracoscopy perform pathologically cyst diagnose metastasis thyroid cancer show cystic change geographic pattern trend incidence thyroid cancer norway norway special geographic distribution thyroid cancer high incidence rate northern part average scandinavian level south incidence begin decline increase long time decline affect female male mainly see old age group mid north norway decline papillary carcinoma stage occur primary trade community other cohort analysis demonstrate secular trend female continuous risk shift old young age group cohort become young explain current bimodular age specific incidence curve etiologic aspect discuss high fdg low flt uptake thyroid papillary carcinoma incidentally discover fdg pet ct report year old man whose incidentally discover papillary thyroid carcinoma leave lobe show high fdg low flt uptake pet ct suvmax fdg flt ki label index tumor thus low flt uptake may attribute low proliferative activity cancer good differentiate thyroid cancer last year move towards aggressive therapy retrospective analysis tgf expression patient thyroidectomy objective investigate relationship expression transform growth factor tgf thyroid lesion retrospective analysis patient thyroidectomy method immunohistochemical analysis tgf perform archive formalin fix paraffin embed thyroid resection tissue sample include case thyroid cancer papillary thyroid carcinoma follicular thyroid carcinoma case nodular goiter ng case thyroid adenoma case grave disease case hashimoto thyroiditis result pathological analysis resection thyroid show high coincidence diagnose preoperative fine needle aspiration biopsy fnab coincidence rate result show expression tgf thyroid cancer significantly high benign thyroid lesion normal thyroid tissue p moreover high expression tgf find closely relate occurrence thyroid cancer no significant difference tgf expression different thyroid cancer conclusion overexpression tgf associate occurrence thyroid cancer use candidate diagnosis prognosis thyroid cancer spinal metastasis thyroid cancer background thyroid carcinoma generally respond good treatment spinal metastasis uncommon feature many study look management spinal metastasis propose treatment plan algorithm range rise incidence thyroid cancer singapore not solely due micropapillary subtype introduction annual incidence thyroid cancer know vary geographic area age gender increase incidence thyroid cancer attribute increase detection micropapillary subtype among factor aim study investigate time trend incidence thyroid cancer singapore iodine sufficient area material method datum retrieve singapore national cancer registry thyroid cancer diagnose review study time trend thyroid cancer base gender race pathology treatment modality available result age standardise incidence rate thyroid cancer increase thyroid cancer appear common woman high incidence chinese malays compare indians papillary carcinoma common subtype percentage papillary microcarcinoma remain relatively stable around papillary cancer although incidence thyroid cancer increase since mortality rate remain stable conclusion trend increase incidence thyroid cancer singapore compare publish series however rise see not solely due micropapillary type thyroid cancer also common chinese malays compare indians reason need study papillary thyroid cancer thalassaemia thyroid cancer frequent endocrine neoplasm general population incidence per year annual death rate man woman thalassaemia patient frequency disease unknown paper describe five case papillary thyroid cancer thalassaemia patient follow day hospital thalassaemia haemoglobinopathy ferrara italy consider possible key role iron carcinogenic agent also discuss practical implication clinical observation diagnosis incidental thyroid nodule f fluorodeoxyglucose positron emission tomography image significant objective determine prevalence thyroid malignancy \\ufeff1 uk case series patient incidentally detect thyroid lesion f fluorodeoxyglucose positron emission tomography image method total patient evaluate f fluorodeoxyglucose positron emission tomography image incidental focal uptake thyroid gland identify nine patient per cent retrospective review case note conduct result rate malignancy per cent mean standard deviation maximum standardise uptake value patient malignancy nodule identify positive positron emission tomography value patient without malignancy nodule identify positive positron emission tomography p palpable thyroid nodule likely malignant lesion p conclusion prevalence incidental thyroid lesion find f fluorodeoxyglucose positron emission tomography patient primary malignancy low incidence malignancy patient high patient palpable thyroid nodule focal uptake f fluorodeoxyglucose positron emission tomography increase maximum standardise uptake value require investigation thyroid cancer risk smoke status meta analysis purpose previous researcher report inverse association cigarette smoke thyroid cancer risk summarize role smoke relation thyroid cancer occurrence conduct meta analysis method perform application nano carbon lymph node dissection thyroid cancer protection parathyroid gland background aim study explore new method identify protect parathyroid gland neck lymph node dissection patient thyroid cancer material method one hundred patient thyroid cancer undergo total thyroidectomy combine central neck lymph node dissection operation patient receive nano carbon suspension include experiment group patient without nano carbon suspension include control group compare change parathyroid hormone level surgery h surgery group serum ca level within h surgery good postoperative parathyroid pathological lymph node dissection result result eight parathyroid gland detect pathologically control experimental group respectively decrease parathyroid hormone level h occur patient control group patient experimental group hypocalcemia find h surgery patient control group patient experimental group conclusion nano carbon suspension cause development thyroid gland central lymph node negative development parathyroid gland careful identification removal black stain lymphatic tissue process total thyroidectomy neck lymph node dissection ensure complete lymph node dissection prevent parathyroid damage thus effectively reduce incidence hypoparathyroidism prevalence thyroid cancer benign thyroid disease patient familial adenomatous polyposis may high previously recognize purpose patient familial adenomatous polyposis fap increase risk colorectal cancer extracolonic neoplasm prevalence thyroid cancer tc benign thyroid disease patient population unclear guideline screen tc patient not good establish purpose study report prevalence tc benign thyroid disease patient fap method prospectively maintain hereditary colorectal cancer family registry memorial sloan kettering cancer center query identify patient fap tc benign thyroid disease result sixty six patient fap identify man woman median age year four patient history tc woman mean age tc diagnosis year three tcs papillary thyroid cancer two patient tc present palpable nodule additional patient fap history benign thyroid disease include nodule hypothyroidism cyst goiter thyroiditis three patient tc patient benign thyroid disease extracolonic manifestation associate fap conclusion prevalence tc benign thyroid disease increase patient fap high note previous report periodic thyroid ultrasound screen consider patient fap elucidate prevalence possible early detection tc benign thyroid disease population value quantitative dna analysis evaluate prognosis differentiate thyroid cancer study analyze dna ploidy potential prognostic parameter differentiate thyroid carcinoma case papillary cancer depth tumor infiltration micro macroinvasive tumor growth invasion vessel ploidy influence prognosis case follicular cancer depth tumor infiltration presence distant metastasis grade uni multifocal tumor growth ploidie influence prognosis case papillary cancer multivariate analysis ploidy show strong independent influence prognosis even compare tumor stage eortc score age score ploidy allow additional prognostic differentiation follicular carcinoma multivariate analysis not possible due strong association prognostic parameter emergency urgent operation treatment patient thyroid cancer report analysis clinical manifestation preoperative preparatory procedure variant result urgent emergency surgical procedure carry case advance thyroid cancer syndrome grave lung heart failure prove major clinical sign disease can compensate intensive care special ward include cervical cervico transsternal access use surgery perform extent determine pattern extension tumor thirteen patient die within day operation late stage among immediate cause death lung artery embolism obstructive tracheobronchitis tumor progression development emergency avoid many case carry timely examination treatment detection serum deoxyribonucleic acid methylation marker novel diagnostic tool thyroid cancer context serum dna methylation marker may potentially useful diagnose thyroid cancer monitor recurrence objective objective study assess utility serum dna methylation diagnostic test patient thyroid nodule monitor test detect thyroid cancer recurrence previously treat patient design set subject use real time quantitative methylation specific pcr analyze methylation status five gene calca cdh timp dapk rarbeta bisulfite treat serum dna sample isolate preoperatively either solid thyroid nodule patient patient follow history treat thyroid cancer main outcome measure diagnostic sensitivity specificity accuracy serum dna methylation marker thyroid cancer measure result patient thyroid nodule positive result define serum methylation level appropriately choose cutoff value one five gene preoperative diagnostic sensitivity thyroid cancer specificity overall preoperative diagnostic accuracy positive negative predictive value respectively subset patient cytologically indeterminate thyroid nodule serum dna methylation test can correctly diagnose eight cancer four four benign tumor diagnostic accuracy also analyze serum dna methylation marker previously treat thyroid cancer patient among patient prove recurrent disease conventional measure seven positive methylation test among patient no corroboration residual recurrent disease conventional study six positive serum dna methylation marker conclusion demonstrate potential usefulness serum dna methylation marker novel tool differential diagnosis solid thyroid nodule thyroid cancer recurrence monitor post crisis effort towards recovery resilience fukushima daiichi nuclear power plant accident one good know radiation associate late onset cancer childhood thyroid cancer demonstrate around chernobyl apparently therefore immediately fukushima daiichi nuclear power plant accident march iodine thyroid block consider regardless successful implementation not indicate time place one radiation protection measurement addition evacuation indoor shelter short live radioactive iodine massively release environment may crucially affect thyroid gland inhalation unrestricted consumption contaminate food milk however fortunately increasingly believe exposure dose thyroid good whole body low detect radiation associate cancer risk fukushima although risk radiation associate health consequence resident fukushima quite different chernobyl considerably low base estimate radiation dose receive accident individual large numb people receive psychosocial mental stress aggravate radiation fear anxiety remain indeterminate uncertain situation evacuate not relocate therefore critically important well activity practice relate recovery resilience encourage support implement local regional level since psychosocial postoperative nomogram predict disease specific death recurrence papillary thyroid carcinoma background nomogram can provide individualize prognostic papillary thyroid carcinoma ptc purpose study develop validate new nomogram method consecutive patient ptc different institution analyze divide development n validation n set former use formulate nomogram predict disease specific death recurrence whereas latter validation area curve auc result nomogram excellent discrimination predict year disease specific death recurrence respectively score mean patient survive year die within year score score mean almost patient disease free within year conclusion use compete risk model nomogram create excellent discriminatory ability accuracy predict year disease specific death recurrence ptc result imply potential wide use population wiley periodical inc head neck e e cancer undetermined significance incidental thyroid carcinoma introduction incidence thyroid cancer increase attribute part improve ultrasonography us method increase detection incidental thyroid carcinoma itc aim compare itc nonincidental thyroid carcinoma nitc study method retrospective analysis individual patient operate benign malignant thyroid disease final histopathological diagnosis thyroid carcinoma enroll study preoperative us examination fine needle aspiration fna biopsy result evaluate tumor focus thyroidectomy specimen not represent preoperative us fna report classify itc tumor focus match lesion define us fna result classify nitc result final histology reveal itc patient nitc patient mean age itc group nitc group p nitc group patient operate suspicious cytology patient itc group operate indication p cancer focus histopathology specimen among cancer focus detect incidentally detect non incidentally nonincidental cancer focus papillary cancer ptc incidental cancer focus ptc mean size mm nitc group mm itc group differ significantly group p tumor size cm patient nitc patient itc tumor cm occurrence multinodularity high itc nitc group p median tsh level high patient nitc itc reference range vs iu ml p frequency thyroiditis detect us thyroid peroxidase antibody thyroglobulin antibody positivity similar patient itc nitc p p p respectively frequency capsular invasion vs extrathyroidal extension vs multifocality vs non complete resection vs lymph node metastasis vs significantly high nitc group p persistent recurrent disease patient nitc frequent patient itc p outcome similar cancer measure cm p conclusion itc often encounter old patient frequently determine early stage favorable histopathological feature well prognosis malignancy rate operate patient hyperthyroidism area endemic goiter aim evaluate incidence thyroid cancer turkish patient hyperthyroidism undergo thyroid surgery datum patient operate hyperthyroidism center evaluate retrospectively sixty five subject single toxic adenoma toxic multinodular goiter grave disease patient papillary carcinoma diagnose form thyroid carcinoma not observe rate carcinoma find patient toxic multinodular goiter patient single toxic adenoma patient grave disease occult papillary carcinoma find malignancy diagnosis primary aim surgical treatment hyperthyroidism abolish hyperthyroid state however probability malignancy especially occult carcinoma always consider classification stage thyroid cancer order establish concept early carcinoma thyroid operative method patient cancer thyroid measure little cm maximum diameter study among patient thyroid cancer treat 2 department surgery shinshu university school medicine exclude occult carcinoma minimal carcinoma measure little cm almost never show metastasis lymph node distant site therefore equip condition require early cancer since detection minimal carcinoma measure little cm difficult however problem arise clinical application prognosis minimal carcinoma measure little cm hand show no remarkable difference carcinoma measure little cm present consequently minimal carcinoma measure little cm exclusion occult carcinoma may classify early carcinoma no removal regional lymph node require carcinoma measure little cm operative procedure minimal carcinoma measure cm necessary perform modify neck dissection strict follow observation necessary cancer histopathological diagnosis encapsulate type invasive type infiltrative type surgical treatment thyroid cancer inherit sporadic medullary thyroid cancer mtc rare carcinoma sporadic mtcs represent case diagnosis currently make routine use serum calcitonin ct measurement screen patient nodular thyroid disease surgery curative treatment mtc since cervical lymph node metastasis frequent occur early stage standardize lymph node dissection associate total thyroidectomy however extent lymphadenectomy remain debate prognosis mtc relate stage disease extent initial surgery tumor remnant persist surgery therapeutic alternative generally limit curative value microrna promote invasion metastasis papillary thyroid cancer target protein phosphatase regulatory subunit b alpha expression background increase evidence indicate microrna dysfunction involve pathogenesis progression cancer microrna mir upregulated papillary thyroid carcinoma ptc however role mir invasion metastasis ptc remain unknown study investigate function mir underlie mechanism progression ptc method expression mir detect quantitative reverse transcription polymerase chain reaction correlation various clinical characteristic analyze role mir ptc cell migration ability assess transwell assay wind heal assay tpc k cell use bioinformatics analysis dual luciferase utr reporter assay study identify direct target mir downstream pathway ptc study confirm role mir promote ptc distant metastasis vivo inject tpc cell nude mouse result study confirm mir upregulated ptc tissue compare adjacent thyroid tissue correlate aggressive cancer phenotype result indicate ectopic mir enhance cell migration invasion thyroid cancer cell vitro distant pulmonary metastasis vivo protein phosphatase regulatory subunit b alpha ppp r tumor suppressor identify direct target mir utr ppp r restore ppp r expression lead attenuation migration invasion mir overexpress thyroid cancer cell moreover find mir promote invasion metastasis partly akt signal pathway conclusion take together result suggest mir promote tumor invasion metastasis thyroid cancer target ppp r thus mir can serve potential diagnostic biomarker good attractive therapeutic tool thyroid cancer radiation exposure thyroid cancer abundant experimental clinical datum associate radiation exposure thyroid cancer incidence thyroid cancer increase increase dose thyroidal radiation rad rad high dose tend destroy gland associate hypothyroidism rather cancer peak occurrence thyroid tumor five year exposure person may develop thyroid tumor long year irradiation multiple thyroidal lesion disorder include adenoma thyroditis hypothyroidism good malignant neoplasm occur radiation exposure imperative therefore study carefully patient history radiation exposure gland observe carefully life suggestion make management thyroid disease patient value pet ct stage patient differentiate thyroid cancer aim study evaluate clinical significance positron emission tomography pet use combine pet ct tomograph patient differentiate thyroid carcinoma compare pet ct result whole body scintigraphy wbs dedicate pet ct alone twelve thyroid cancer patient refer diagnostic workup enter complete clinical evaluation include histology cytology thyroglobulin level ultrasonography fluorine fluorodeoxyglucose fdg pet fdg pet ct ct lesion base evaluation show lesion delectability ct pet combine pet ct image respectively lesion delectability wbs conclude pet ct image promise technique improve treatment plan thyroid cancer particularly valuable patient suffer advance differentiate thyroid cancer prior radio iodine therapy patient suspect recurrence potential metastatic disease serum thyrotropin level iu ml inadequate preablative thyroglobulin serve prognostic marker differentiate thyroid cancer purpose preablative stimulate thyroglobulin ps tg manifest potential predict prognosis patient differentiate thyroid carcinoma dtc level affect thyrotropin tsh objective study evaluate utility ps tg predict individual response radioactive iodine rai therapy explore appropriate tsh level ps tg serve prognostic marker dtc without initial distant metastasis dm method total consecutive non dm dtc patient serial ps tg tsh thyroid cancer south africa indicator regional iodine deficiency objective follicular thyroid cancer predominate iodine deficient papillary cancer predominate iodine replete population analyse national regional former transvaal incidence cancer type surrogate measure population iodine nutritional status south africa design statistical analysis race sex differentiate thyroid cancer report south african national cancer registry computerise histology record department anatomical pathology saimr january june transvaal datum main outcome measure relative frequency two cancer type nationally geographically transvaal region main result thyroid cancer underdiagnosed population white nationally follicular histology account differentiate primary thyroid cancer predominate especially black woman follicular morphology predominate black resident rural region former transvaal papillary histology predominate urban area present day gauteng irrespective race p conclusion national predominance follicular thyroid cancer indicate significant iodine deficiency exist country whole observe urban rural difference prevalence follicular papillary cancer type suggest regional difference severity iodine deficiency need formal survey population iodine nutritional status south africa association tuberculosis thyroid cancer value exploratory cervicotomy background role routine central lymph node dissection clnd papillary thyroid cancer ptc remain controversial aim study evaluate impact routine clnd total thyroidectomy ttx management patient ptc clinically node negative presentation emphasis stimulate thyroglobulin tg level reoperation rate method retrospective multicenter cohort study use pool datum international endocrine surgery unit australia unite state england study participant ptc cm without preoperative evidence lymph node disease cn group patient ttx alone group b ttx addition clnd result patient include study group patient group b patient stimulate tg value low group b initial radioiodine ablation vs ng ml p trend toward low tg final follow group b vs ng ml p rate reoperation central compartment low group b vs p numb clnd procedure require prevent central compartment reoperation calculate conclusion addition routine clnd cn papillary thyroid carcinoma associate low postoperative tg level reduce need reoperation central compartment pet pet ct thyroid cancer background percentage thyroid cancer case attributable specific risk factor calculate focus preventive strategy per cent population attributable risk par thyroid cancer estimate relation history benign thyroid disease history radiotherapy residence endemic goitre area select indicator poor diet use datum case control study conduct northern italy method case histologically confirm incident thyroid cancer control patient admit hospital wide range acute non neoplastic non hormone relate disease par compute basis multivariate odd ratio distribution risk exposure among case assume representative general population case result history benign thyroid disease account case radiotherapy residence year endemic goitre area case combination thyroid cancer case select indicator poor diet account thyroid cancer case population combination factor consider explain thyroid cancer case sex estimate thyroid relate condition high woman man whereas opposite true dietary indicator overall par somewhat high people age year young subject follicular rather papillary cancer conclusion exposure simply identify potentially modifiable risk factor indicator benign thyroid disease residence endemic goitre area poor diet explain thyroid cancer case italian population indicate theoretical scope prevention metformin revert secretion cxcl induce tnf primary culture human thyroid cell additional indirect anti tumor effect drug context metformin display direct indirect anti tumor effect cxcl crucial downstream mediator nuclear factor b signal relate growth progression thyroid cancer target cxcl result prolong survival reduce metastatic spread vivo animal model thyroid tumor objective study aim evaluate whether metformin inhibit secretion cxcl induce tumor necrosis factor tnf primary culture normal tumor human thyroid cell good thyroid cancer cell line method normal human thyrocytes papillary thyroid cancer cell thyroid cancer cell line tpc bcpap stimulate tnf ng ml alone combination metformin mm cxcl level measure cell supernatants hour result metformin significantly dose dependently inhibit tnf induce cxcl secretion normal thyrocytes anova f p papillary thyroid cancer cell anova f p not tpc bcpap cell line conclusion metformin inhibit tnf induce cxcl secretion primary culture normal thyroid cell differentiate thyroid cancer cell little frequent poorly aggressive phenotype recruitment neutrophil within thyroid gland crucial metastasis promote factor depend amount cxcl produce tumor cell abundant normal thyroid cell expose tnf thus report inhibit effect metformin tnf induce cxcl secretion can consider indirect anticancer property drug lncrna unc b promote proliferation migration invasion papillary thyroid cancer cell line incidence thyroid cancer detection continually improve worldwide spread diagnostic image surveillance although make great progress still unknown mechanism papillary thyroid cancer find unc b potential oncogene thyroid cancer therefore study aim investigate biological function lncrna unc b papillary thyroid cancer result rna seq datum primary papillary thyroid cancer ptc tcga database obtain rt qpcr perform evaluate expression level thyroid tissue analyse expression level unc b association clinicopathologic characteristic tcga database downregulated unc b use small interfere rna carry assay cell proliferation colony formation migration invasion explore function unc b ptc cell line tpc bcpap result suggest lncrna unc b significantly upregulated tcga cohort tissue cohort upregulated unc b correlate lymph node metastasis p tumor size p histological type p also achieve area roc curve auc validate cohort consistent auc tcga cohort differentiate ptc tissue normal tissue downregulating unc b expression rna level significantly inhibit cell proliferation colony formation migration invasion ptc cell line tpc bcpap study demonstrate lncrna unc b play important role tumourigenesis metastasis ptc may potential therapeutic target ptc adequate operative treatment thyroid cancer background thyroid nodule common principal method diagnosis high dose hydroxytyrosol induce apoptosis papillary follicular thyroid cancer cell purpose recent evidence indicate hydroxytyrosol one main olive oil phenol possess antitumor effect pro oxidant property capacity inhibit proliferation promote apoptosis several tumor cell line although result obtain breast digestive system cancer method study evaluate activity hydroxytyrosol papillary tpc fb follicular wro thyroid cancer cell line result cellular viability reveal high dose hydroxytyrosol reduce cancer cell viability concomitantly reduction cyclin expression regulation cell cycle key modulator p level experimental condition annexin v pi stain dna ladder reveal hydroxytyrosol exert proapoptotic effect papillary follicular cancer cell furthermore western blot analysis observe hydroxytyrosol treatment reduce thyroid cancer cell viability promote apoptotic cell death via intrinsic pathway conclusion collectively result demonstrate \\ufeff1 time thyroid cancer cell hydroxytyrosol promote apoptosis high dose respect cancer cell line therefore study reveal mechanism thyroid cancer cell resistant proapoptotic effect exert hydroxytyrosol good potential application novel target therapeutic thyroid cancer change face paediatric adolescent thyroid cancer objective aim study review royal child hospital cohort child thyroidectomy thyroid nodule last year report change pattern thyroid cancer see institution time method undertake retrospective case note review patient undergo thyroid surgery result patient identify pathological diagnosis benign tumour thyroid cancer four case multiple endocrine neoplasia type treat prophylactic thyroidectomy sixteen patient history childhood cancer cancer treatment include direct scatter radiation patient receive irradiation four follicular adenoma six develope thyroid cancer six patient euthyroid one patient present palpable nodule five detect surveillance ultrasound conclusion result confirm high detection malignancy thyroid nodule childhood compare early study institution numb thyroid malignancy appear increase surveillance royal child hospital change increase long term cancer survival prospective yearly evaluation past history radiation exposure result early detection benign malignant thyroid lesion nodular change usually not clinically apparent many year lifelong surveillance necessary cancer detection group retrospective analysis thyroid nodule thyroid cancer risk factor suzhou china background thyroid nodule common frequently discover clinical practice incidence increase recent decade clinically important primarily due malignant potential malignant correct identification malignancy thyroid nodule diagnostic challenge lead potentially unnecessary surgery patient final histology benign no accurate preoperative detection important predict risk malignancy patient nodular thyroid disease method medical record patient undergo surgery nodular thyroid disease retrospectively review clinical parameter preoperative serum marker compare benign thyroid nodular disease thyroid cancer group result young year ci p preoperative tsh level equal high miu l ci p tgab positivity ci p nodule little equal cm ci p associate increase risk thyroid cancer patient thyroid nodule conclusion retrospective analysis suggest young patient nodular thyroid disease not ignore small size nodule especially high tsh level tgab positivity autophagy thyroid disease autophagy dynamic process regulate variety factor may play different role different thyroid disease different stage thyroid disease autophagy mediate inflammatory response immunity closely relate pathogenesis thyroid autoimmune disease therefore still necessary understand relationship autophagy autoimmune thyroid disease hypothyroidism study relationship autophagy thyroid cancer relationship two become complicate perspective current study still worth ponder whether inhibition activation autophagy valuable target therapy thyroid cancer research effort still need pulmonary miliaria reveal thyroid cancer year old girl report immunohistochemical diagnosis include ttf thyroid transcription factor ki rare mix thyroid neoplasm compose minimally invasive good differentiate follicular area highly aggressive undifferentiated anaplastic area old female present clinic rapidly grow neck mass consider dynamic disease multiple challenge present patient advance age tumor size history longstanding goiter decide transfer department surgery intraoperative finding enlarge right lobe tracheal surround tissue infiltration total thyroidectomy radical neck lymph node dissection tracheostomy perform histopathological immunohistochemical examination reveal coexistent anaplastic follicular thyroid carcinoma proliferation index ki cell proliferation marker find significantly high anaplastic area comparison follicular area evaluation thyroid transcription factor ttf expression reveal correlation tumor cell aggressiveness accordingly cancer area radical surgery external adjuvant radiation apply patient alive five year diagnosis present increase serum thyroglobulin level suggest probably recurrence follicular form cancer accord survey suggest thyroid cancer ttf ki can provide useful information differentiation activity thyroid tumor cell may helpful distinguish good differentiate undifferentiated area mix thyroid cancer low postoperative nonstimulated serum thyroglobulin level not exclude presence radioactive iodine avid metastatic focus intermediate risk differentiate thyroid cancer patient background postsurgical thyrotropin tsh stimulate serum thyroglobulin tg level use predict likelihood find radioactive iodine rai avid metastatic focus postablation scan however little datum regard predictive value nonstimulated postoperative tg obtain levothyroxine therapy patient consider recombinant human tsh rhtsh assist remnant ablation method study include intermediate risk differentiate thyroid cancer dtc patient postsurgical nonstimulated tg ng ml prior rhtsh assist remnant ablation patient stratify four group base postsurgical nonstimulated tg value tg ng ml n tg ng ml n tg ng ml n tg ng ml n rai avid metastatic focus identify use post therapy scan spect ct single photon emission compute tomography result rai avid metastasis identify patient include tg ng ml tg ng ml tg ng ml tg ng ml p rai avid focus locate neck lung uptake see one patient tg ng ml one patient tg ng ml patient tg ng ml patient conclusion postoperative nonstimulated tg ng ml not exclude identification rai avid metastatic focus postablation spect ct scan intermediate risk dtc patient therefore patient selection rai ablation intermediate risk group must base integration multiple risk factor rather single clinicopathologic risk factor excisional range tracheal infiltration thyroid cancer study histopathologically infiltrative mode case tracheal infiltration thyroid cancer study excisional range macroscopically morphology region trachea divide type type ii note case type iii note case infiltrative mode trachea divide localize infiltrative type localize type note case type infiltrative type note case type ii type note case case type iii respectively infiltrative region tracheal mucous membrane case type iii localize range infiltrative region extratracheal mucous membrane infiltrative region tracheal mucous membrane wide case type ii compare extratracheal mucous membrane consider radical treatment type iii obtain excisional range infiltration extratracheal mucous membrane operative diagnosis necessary wide range infiltration cancer observe tracheal mucous membrane type ii extracellular vesicle thyroid carcinoma new frontier liquid biopsy diagnostic approach thyroid cancer one challenge issue oncology endocrine system high incidence new cancer case us difficulty distinguish benign malignant non functional thyroid nodule establish cervical lymph node involvement stage routine diagnosis thyroid nodule usually rely fine needle aspirate biopsy invasive often inaccurate therefore urgent need identify novel accurate non invasive diagnostic procedure liquid biopsy non invasive approach detection diagnostic biomarker early tumor diagnosis prognosis disease monitor may particular benefit context extracellular vesicle ev consistent source tumor derive rna due prevalence circulate bodily fluid comparison survival rate papillary follicular thyroid carcinoma among patient objective seek determine impact histologic subtype disease specific survival dss case differentiate thyroid carcinoma method adult patient papillary thyroid carcinoma ptc follicular thyroid carcinoma ftc identify surveillance epidemiology end result seer database year patient group accord tumor type ptc ftc age gender tumor size extension nodal distant metastasis record kaplan meier method use compare dss rate basis histologic subtype result identify patient female male ptc diagnose patient ftc remain patient ptc young likely female small tumor high rate regional metastasis few distant metastasis ftc patient p case stratify stage ftc patient wrong dss ptc patient stage except stage iii iva ivc among patient year age conclusion follicular thyroid carcinoma portend wrong dss ptc even case control stage consideration give individual stage subtype differentiate thyroid carcinoma thyroid cancer detect ultrasound guide fine needle aspiration biopsy great percentage thyroid cancer detect ultrasound guide survival aggressive variant papillary thyroid carcinoma patient year old seer population base retrospective analysis background patient young year age papillary thyroid carcinoma ptc excellent survival diffuse sclerosing variant dsv tall cell variant tcv ptc associate aggressiveness survival patient year age variant still unclear aim investigate clinicopathological feature survival variant age group year method adult patient year old dsv tcv conventional ptc cptc come surveillance epidemiology end result program kaplan meier method log rank test use analyze survival prognostic factor associate survival analyze cox multivariate regression result dsv tcv cptc age group year dsv tcv associate multifocality extrathyroidal extension lymph node distant metastasis p year disease specific survival dss tcv wrong cptc vs p no significant difference dsv cptc vs p cox multivariate regression show tcv independent predictor dss hr p conclusion age group year dsv tcv likely exhibit aggressive characteristic cptc patient year age dsv excellent survival likewise patient year age tcv carry wrong survival investigation recurrence risk patient year variant would contribute optimal clinical management make multitargeted kinase inhibition metastatic differentiate radioiodine refractory thyroid cancer look new therapeutic option rare disease background metastatic differentiate thyroid cancer dtc rare disease \\ufeff1 line treat iodine radioisotope therapy recently option limit case progressive radioactive iodine rai refractory disease base new study result tyrosine kinase inhibitor tkis attract attention tki sorafenib demonstrate significantly improve progression free survival pf phase iii trial recent datum another phase iii trial show tki lenvatinib achieve high response rate large improvement pf metastatic rai refractory dtc patient \\ufeff1 line set prior line tki however little know response lenvatinib patient pretreated multiple line tkis case report present case year old man metastatic rai refractory dtc progress multiple prior treatment tkis chemotherapy good long last response lenvatinib observe careful prospective monitor good management side effect include dose adaptation necessary ensure success treatment conclusion review different novel treatment option patient metastatic rai refractory dtc clinical management outcome papillary follicular medullary thyroid cancer surgery clinical characteristic pathological subtype patient survival patient thyroid carcinoma march march evaluate study include female seven male female male ratio median age patient range papillary carcinoma common pathological subtype patient follow follicular carcinoma patient medullary carcinoma case total thryoidectomy perform lobectomy six subtotal multifocal thryoidectomy two patient median time follow year range year i have year patient alive six dead overall year actuarial survival papillary carcinoma follicular carcinoma medullary carcinoma result suggest total thryoidectomy well outcome comparison surgery neovascularization attractive tricky target thyroid cancer neovascularization carcinogenesis tumor progression good establish molecular mediator implicate different mode vascular remodel expansion e g sprout angiogenesis sa vasculogenesis vascular mimicry evaluate prognostic biomarker therapeutic target different malignant tumor significant progress make understand complex interplay thyroid cancer tc cell tumor microenvironment thus unravel role angiogenic mediator area cover review summarize current research neovascularization tc current knowledge vascular remodel context carcinogenesis present preclinical clinical datum tc study also discuss expert opinion remarkable effort pharmacologically target several key molecule vessel form cascade despite encourage preclinical result clinical outcome tc not optimal possibly reflect knowledge gap pathophysiology neovascularization thyroid tissue increase amount datum support possibility redundancy pathway regulate vascular network remodel allow tumor adapt different condition hypothesize alternative form neovascularization upregulate sa pharmacologically block target two different pathway neovascularization can promise future strategy research require explore molecular mechanism neovascularization tc thyroid cancer adolescent young adult despite increase thyroid cancer incidence among adolescent young adult ayas group receive limit attention review epidemiology challenge thyroid cancer care among ayas propose research agendum improve care thyroid cancer common cancer american adult year age ayas thyroid cancer face challenge include overdiagnosis reduce healthcare access inconsistent care successful treatment patient result additional challenge due ongoing side effect treatment good last impact quality life challenge fuel collaborative research agendum aim improve quality care ayas thyroid cancer across spectrum diagnosis treatment survivorship severe hyponatremia association therapy patient metastatic thyroid cancer hyponatremia common clinical problem result various cause hypothyroidism know one cause disorder report case metastatic thyroid cancer present severe hyponatremia association hypothyroidism induce pretreatment therapy low iodine diet withdrawal thyroid hormone serum arginine vasopressin avp elevate urine osmolality high serum saline infusion thyroid hormone replacement normalize serum sodium avp inappropriate secretion avp hypothyroid state think one cause hyponatremia pediatric papillary thyroid carcinoma outcome survival predictor surgical patient objective evaluate outcome predictor survival pediatric thyroid carcinoma specifically papillary thyroid carcinoma method seer search surgical pediatric case year old papillary thyroid carcinoma diagnose demographics clinical characteristic survival outcome analyze use standard statistical method papillary type include follicular variant include result total case identify overall incidence person per year significant annual percent change apc occurrence baseline p mean age diagnosis year high incidence find white female patient age patient tumor size cm likely receive lobectomy isthmusectomies versus subtotal total thyroidectomy p patient tumor cm lymph node positive status p likely undergo subtotal total thyroidectomy compare lobectomy isthmusectomy tumor cm likely lymph node positive p mortality not differ procedure mean survival year high regional disease disease specific year survival range regardless tumor size procedure lymph node sample not affect survival conclusion incidence pediatric papillary thyroid cancer increase female high incidence similar survival male tumor cm likely lymph node positive although tumor cm likely resect subtotal total thyroidectomy survival high not differ base procedure malignant metastasis thyroid gland medullary thyroid carcinoma rare tumour thyroid cancer numb factor influence prognosis suggest relative significance not clear retrospective study perform consecutive patient treat aim study identify prognostic factor assess result treatment associate complication mean age year patient stage stage ii stage iii stage iv total thyroidectomy perform case also undergo neck dissection no postoperative complication observe patient overall survival year year univariate analysis factor significant predictor survival stage iii iv metastasis presentation cervical lymph node dissection postoperative external beam radiotherapy elevate postoperative calcitonin multivariate analysis stage iv metastasis presentation persistent postoperative elevate calcitonin significant predictor survival predictive factor skip metastasis lateral neck compartment leap central neck compartment papillary thyroid carcinoma skip metastasis refer leap metastasis lateral neck without associate lymphadenopathy central compartment level vi occur patient papillary thyroid carcinoma ptc however study predictive value ptc patient review medical record patient undergo simultaneous central lateral neck lymph node dissection primary treatment lymph node metastasis lateral neck ptc patient no patient suspect metastasis central compartment preoperative image study frequency skip metastasis lateral neck compartment without central neck metastasis numb metastatic lymph node dissect lateral neck patient without skip metastasis respectively p skip metastasis closely associate significantly few lymphovascular invasion p extracapsular spread p skip metastasis occur significantly frequently ptc patient presence lymphovascular invasion extracapsular spread numb positive lymph node dissect inversely correlate skip metastasis dose response relationship radiation induce thyroid cancer thyroid nodule evidence prolong effect radiation thyroid risk develope thyroid cancer thyroid neoplasm radiation exposure good know specific modifier dose response relationship not identify subject receive treatment 16 birthday orthovoltage radiation benign condition head neck area individual thyroid dose estimate calculate subject subject find develope thyroid nodule type develope thyroid cancer radiation dose response relationship consistent linear excess relative risk model thyroid cancer thyroid nodule within range observe dose woman develope thyroid cancer thyroid nodule high rate slope dose response curve man woman age radiation exposure significant factor risk low age exposure associate high risk determine effect wide publicity screen program begin compare dose response relationship case diagnose overall rate increase dramatically estimate slope dose response curve not statistically different slope indication basic principle surgical treatment thyroid disease surgical treatment indicate patient nodular goiter malignancy seem possible mechanical reason request patient patient goiter hyperthyroidism surgery radioiodine alternative contrast thyroid autonomy always require surgery treatment patient suffer differentiate thyroid cancer include thyroidectomy radioiodine anaplastic thyroid cancer external radiation surgery perform apart classic indication surgical procedure recent year selective resection multinodular goiter conservative surgery small papillary thyroid cancer surgical treatment iodine induce thyrotoxicosis become establish retrosternal metastatic papillary thyroid cancer cause superior vena cavum syndrome rare presentation thyroid cancer cause superior vena cavum svc syndrome rare clinical entity case report worldwide metastatic thyroid cancer cause svc syndrome several year follow resection primary tumor extremely rare case report one papillary variety report 2 case worldwide metastatic papillary thyroid cancer cause svc syndrome year total thyroidectomy original tumor year old indian female pilgrim unfortunately patient die 3 day intensive care unit admission severity clinical condition addition late presentation result catastrophic outcome make possible resuscitative effort difficult conservative management good differentiate thyroid cancer background controversy exist optimal surgical treatment thyroid cancer occur late consequence head neck irradiation evaluation patient january september examine subject receive therapeutic irradiation primarily infection inflammatory disease upper respiratory tract institution tonsillar nasopharyngeal region treatment site examine palpable nodular thyroid disease find nonpalpable lesion detect tc pertechnetate thyroid image additional prevalence nodular disease operation nodular disease reveal thyroid cancer preliminary analysis potential risk factor suggest correlation radiation exposure presence thyroid nodule p little finding indicate nodular thyroid disease benign malignant continue major health problem little year expose subject value mirna diagnose thyroid cancer systematic review thyroid cancer common endocrine neoplasm account approximately total cancer diagnosis gold standard evaluation thyroid nodule cytology fine needle aspiration biopsy no conclusive diagnosis patient undergo diagnostic hemithyroidectomy somatic mutation occur frequently thyroid cancer value test fna biopsy different mutation analyze improve accuracy sensitivity low another class molecule potential diagnostic value mirnas mirna mir mirnas function gene regulator thereby control many cellular process include cell growth differentiation proliferation apoptosis several study analyze expression mirnas thyroid cancer either perform microarray analysis validate set mirnas recent report focus diagnostic value mirnas indeterminate fna biopsy systematic review provide overview mirnas find downregulated different type thyroid carcinoma give overview value validate set micrornas single micrornas distinguish malignant benign lesion conclude clinical view future study strategy b h expression associate cancer progression predict patient survival human thyroid cancer objective study aim investigate expression b h human thyroid cancer determine association patient clinicopathological parameter survival method b h expression clinical thyroid cancer specimen assess immunohistochemistry moreover b h mrna expression fresh resect specimen evaluate reverse transcription polymerase chain reaction rt pcr immunohistochemical stain cd perform assess numb tumor infiltrate lymphocyte tils thyroid cancer result positive b h immunohistochemical stain observe specimen thyroid cancer tissue significantly b h mrna copy find thyroid cancer tissue adjacent normal tissue moreover b h expression human thyroid cancer tissue significantly correlate patient tnm stage extrathyroidal extension p inversely correlate numb tils p overall survival rate patient high b h expression significantly wrong patient low b h expression conclusion present study suggest high b h expression associate cancer progression reduce tumor immunosurveillance wrong patient outcome human thyroid cancer association multinodular goiter thyroid cancer many part world especially current former iodine deficiency multinodular goiter still endemic disease brief review several clinically relevant issue complex association nodular goiter differentiate thyroid cancer highlight intrigue link etiology multinodular goiter thyroid cancer can also influence incidence thyroid cancer multinodular goiter however multinodular goiter cause extra difficulty diagnosis differentiate thyroid cancer difficulty also cause additional issue thyroid cancer treatment multinodular goiter patient last not little discuss whether possibility impede development thyroid cancer multinodular goiter molecular test thyroid nodule review current state thyroid nodule affect nearly two third world population fine needle biopsy cytologic evaluation remain diagnostic test choice distinguish benign malignant thyroid nodule yet fail discriminate benign malignant one 3 case review discuss limitation current cytopathologic evaluation development thyroid molecular test strength limitation commercially available test initial cytomolecular test seek identify specific gene mutation associate thyroid cancer although presence mutation strongly associate cancer likelihood identify mutation low therefore test low sensitivity subsequent test develope seek improve accuracy cytomolecular test thyroid fine needle aspiration reassure patient provider malignancy may absent confirm malignancy present development cytomolecular test thyroid nodule inform improve current understand thyroid nodule formation progression use appropriately clear understand advantage disadvantage cytomolecular test potential improve patient care set indeterminate thyroid nodule help guide need extent thyroid surgery cancer american cancer society multiparametric pet image thyroid malignancy characterize tumour heterogeneity somatostatin receptor glucose metabolism purpose radiolabelled somatostatin sst analogue prove useful diagnose tumour positive sst receptor sstr different subtype sstr express tumour cell surface choice appropriate therapeutic sst analogue crucial evaluate sstr status thyroid cancer patient sign progressive disease compare different sstr ligand pet image evaluate possible therapeutic option method pet ga radiolabelled sstr ligand dota lanreotide dota lan dota tyr octreotide dota toc f fdg perform patient thyroid cancer tc patient comprise radioiodine non avid differentiate tc dtc include papillary tc ptc follicular tc ftc oxyphilic tc oxytc anaplastic tc atc medullary tc mtc pet result compare region base evaluation result patient undergo pet study ga dota lan patient ga dota toc patient f fdg lack sstr expression find patient negative result sstr tracer patient ambiguous result sstr tracer observe one patient high tracer uptake sstr pet image see seven dtc patient two ptc three ftc two oxytc four atc patient six mtc patient lesion show aerobic glycolysis f fdg pet find patient correspond positive result ga dota lan ga dota toc conclusion heterogeneous sstr profile tc tumour lesion need evaluate use different sstr pet tracer characterize closely sstr subtype affinity patient progressive tc order stratify therapy sstr therapeutics correlation contrast enhance ultrasonographic feature microvessel density papillary thyroid carcinoma background purpose study investigate correlation contrast enhance ultrasonographic ceus feature microvessel density mvd papillary thyroid carcinoma ptcs material method contrast enhance ultrasonography ceus perform patient man woman ptc tomtec software apply analyze time intensity curve ceus immunohistochemistry perform evaluate level mvd papillary thyroid carcinoma relationship quantitative feature level mvd analyze use spss software result mean peak intensity ptc tissue low peripheral thyroid parenchyma vs p mvds cd cd antibody stain respectively ptc sample significantly positive correlation observe peak intensity mvd ptc tissue pcd rcd pcd rcd conclusion peak intensity ceus can reflect mvd ptc tissue therefore quantification ceus seem helpful assessment mvd ptc tissue evaluation survivin expression prognostic value papillary thyroid carcinoma overexpression survivin inhibitor apoptosis protein find variety human cancer associate tumor aggressiveness study analyze expression survivin papillary thyroid carcinoma ptc evaluate clinical significance predict aggressive course disease time diagnosis survivin expression determine immunohistochemistry tissue specimen ptc confirm western blot correlate clinicopathological parameter tumor examine show high cytoplasmic survivin expression no association high survivin expression age gender tumor size hand closely correlate presence lymph node metastasis p tendency correlation extrathyroidal invasion p high risk ptc group tnm stage iii iv associate high level survivin p result indicate survivin unfavorable molecule ptc prognosis high expression may indicate subset ptc patient aggressive disease course evaluation expression fine needle aspiration sample can useful tool identification ptc patient require extensive surgery careful follow therapeutic strategy conservative surgical approach thyroid lymph node involvement papillary thyroid carcinoma childhood adolescence background prior papillary thyroid carcinoma ptcs childhood adolescence undergo standard therapeutic approach total thyroidectomy plus elective neck dissection follow radioactive iodine rai ablation overall survival aim study outline possibility conservative approach hemithyroidectomy plus selective neck dissection clinically involve node follow tsh suppressive therapy select group patient procedure pediatric ptc patient treat institution absence distant metastasis tumor clinically limit one lobe present case undergo radical case conservative case surgical approach thyroid level cervical node level patient undergo radical conservative surgical approach clinicopathologic feature onset type therapy radical vs conservative post operative complication outcome till may record impact type surgery outcome evaluate result overall progression free survival pf curve find independent type therapy radical vs conservative subgroup patient match extent disease onset post operative complication occur radical surgical approach conclusion childhood adolescence ptcs show high rate spread excellent outcome independent type therapy radical vs conservative take account mark responsiveness tsh suppression complication radical therapy select case conservative approach consider reserve aggressive therapy case metastasis relapse radiation induce thyroid cancer background thyroid cancer common endocrine neoplasia represent approximately cancer diagnose annually worldwide iodine refractory differentiate thyroid carcinoma rr dtc advance metastatic medullary thyroid carcinoma relatively uncommon yet prognostically significant thyroid cancer gene rearrangement result aberrant activity tyrosine kinase identify driver oncogenesis variety cancer include thyroid cancer many multi kinase inhibitor mkis fda ema approve thyroid cancer show clinical benefit patient advance cancer treatment relate toxicity occur frequently drug severe life threaten objective review summarize role target therapy mkis management rrdtc advance metastatic mtc patient focus side effect profile drug presentation several recent patent publish field method review scientific literature advance thyroid cancer analyze international pharmacovigilance database faers eudravigilance vigibase adverse drug reaction result systematic analysis highlight difference safety profile recent drug use treatment advance thyroid cancer recent discovery diagnosis treatment thyroid cancer conclusion essential investigate safety profile recent anticancer drug advance thyroid cancer allow health professional make well choice patient conduct risk benefit assessment thioredoxin biomarker papillary thyroid carcinoma lymph node metastasis identify maldi image papillary thyroid carcinoma ptc metastasis feature aggressive tumor phenotype identify protein biomarker distinguish patient aggressive tumor behavior proteomic signature metastatic non metastatic tumor investigate comparatively particular matrix assist laser desorption ionization maldi image mass spectrometry ims use analyze primary tumor sample investigate tumor cohort ptc n match age tumor stage gender proteomic screen maldi ims perform discovery set n protein relate discriminate mass peak identify gel electrophoresis follow mass spectrometry candidate protein subsequently validate immunohistochemistry ihc use tissue microarray independent ptc validation set n study find mass charge ratio z species specifically distinguish metastatic non metastatic tumor among z identify thioredoxin z z furthermore use ihc validation set show overexpression three protein highly associate lymph node metastasis ptc p functional analysis metastasis specific protein perform ingenuity pathway analysis discover strong relationship candidate tgf dependent emt pathway result demonstrate potential application maldi ims proteomic approach identify protein marker metastasis ptc novel protein marker identify study may use risk stratification regard metastatic potential ptc identification treatment aggressive thyroid cancer part risk assessment treatment thyroid cancer slow grow easily treatable tumor excellent prognosis surgical resection target medical therapy unfortunately thyroid cancer exhibit aggressive behavior not follow indolent course approximately one 3 patient differentiate thyroid cancer tumor recurrence distant metastasis present patient recurrent cancer approximately half patient distant metastasis die within year loss ability concentrate radio iodine produce thyroglobulin sign dedifferentiation occur patient persistent recurrent thyroid cancer dedifferentiation associate poor response conventional therapy difficulty monitor tumor burden clinician must identify tumor aggressive biology treat accordingly aggressive regimen part two part article appear march describe detail distinct type thyroid cancer good risk factor outcome treatment prognostic factor focus thyroid cancer follicular cell origin part cover risk assessment stage finding suggest presence aggressive tumor recurrent metastatic disease treatment chemotherapy external beam radiotherapy experimental treatment utilize molecular target redifferentiation agent gene therapy cover briefly good surgical therapy thyroid cancer controversial view discussion surgical treatment thyroid cancer retrospective study cover period conduct author analyse resective approach thyroid cancer operation perform papillary carcinoma follicular carcinoma case overall five year survival rate differentiate thyroid cancer record stage n microcarcinoma accord publication hence much little radical procedure like hemithyroidectomy fully support author microcarcinoma total thyroidectomy apply differentiate thyroid cancer advance stage medullary anaplastic carcinoma extent surgery affect papillary thyroid cancer population base study demonstrate increase numb incidental thyroid nodule identify correspond increase thyroid base diagnostic procedure fine needle aspiration biopsy part lead increase diagnosis thyroid cancer thyroid surgery perform small papillary thyroid cancer account increase diagnosis cancer consider low risk excellent patient outcome year disease specific survival result controversy remain regard optimal management newly diagnose differentiate thyroid cancer complication relate thyroidectomy primarily recurrent laryngeal nerve injury hypoparathyroidism considerable effect patient quality life review highlight current debate include undertake active surveillance versus thyroid surgery papillary thyroid microcarcinoma extent thyroid surgery lymphadenectomy low risk differentiate thyroid cancer use molecular test guide decision make whether surgery require extent initial operation review include discussion current consensus guideline recommendation regard topic patient differentiate thyroid cancer additionally innovative thyroidectomy technique include robotic transoral approach discuss emphasis patient preference around decision make outcome follow thyroidectomy low risk papillary thyroid cancer thyroid cancer one fast grow diagnosis case thyroid cancer find every year leukemia cancer live pancreas stomach incident case papillary origin small localize patient small localize papillary thyroid cancer survival rate year view excellent prognosis tumor denote low risk incidence low risk thyroid cancer grow probably use image technology capable expose large reservoir subclinical disease despite excellent prognosis subclinical low risk cancer often treat aggressively although surgery traditionally view cornerstone treatment tumor little agreement extent surgery lobectomy v near total thyroidectomy whether prophylactic central neck dissection removal lymph node need many tumor treat radioactive iodine ablation thyrotropin suppressive therapy although effective aggressive form thyroid cancer not show benefit management lesion review offer evidence base approach manage low risk papillary thyroid cancer also look future promise alternative surgical technique non surgical minimally localize invasive therapy ethanol ablation laser ablation active surveillance form part individualize treatment approach low risk papillary thyroid tumor sleep disturbance incidence thyroid cancer postmenopausal woman woman health initiative purpose recent evidence indicate hydroxytyrosol one main olive oil phenol possess antitumor effect pro oxidant property capacity inhibit proliferation promote apoptosis several tumor cell line although result obtain breast digestive system cancer method study evaluate activity hydroxytyrosol papillary tpc fb follicular wro thyroid cancer cell line result cellular viability reveal high dose hydroxytyrosol reduce cancer cell viability concomitantly reduction cyclin expression regulation cell cycle key modulator p level experimental condition annexin v pi stain dna ladder reveal hydroxytyrosol exert proapoptotic effect papillary follicular cancer cell furthermore western blot analysis observe hydroxytyrosol treatment reduce thyroid cancer cell viability promote apoptotic cell death via intrinsic pathway conclusion collectively result demonstrate \\ufeff1 time thyroid cancer cell hydroxytyrosol promote apoptosis high dose respect cancer cell line therefore study reveal mechanism thyroid cancer cell resistant proapoptotic effect exert hydroxytyrosol good potential application novel target therapeutic thyroid cancer significance incidentally detect thyroid tissue lymph node neck dissection patient head neck carcinoma background incidental discovery thyroid tissue lymph node neck dissection perform separate primary head neck cancer unusual clinical entity careful screen large numb lymph node neck dissection specimen pathologist critical pick case controversy regard clinical significance incidentally detect thyroid tissue cervical node whether represent benign inclusion whether represent metastatic focus underlie thyroid cancer appropriate clinical approach case little clear occur context another malignancy usually squamous cell carcinoma aggressive potential material method review record neck dissection do patient head neck cancer year study identify patient incidentally detect thyroid tissue feature malignancy cervical lymph node subsequent thyroidectomy do case show primary thyroid cancer conclusion study result emphasize need clinician accurate reevaluation follow patient incidental occult metastasis detection primary thyroid tumor thorough sample screen lymph node neck dissection specimen pathologist also essential incidentally discover thyroid tissue cervical lymph node need not always benign inclusion aggressive therapy however may not need case thyroid cancer childhood thyroid cancer tc good know endocrine neoplasia good common malignant tumor head neck study design assess prognostic meaningful tnfrsf expression tc dependent datum acquire tcga increase knowledge biological pathway involve tc pathogenesis relate tnfrsf information gene expression compare clinical datum identify download tcga gene set enrichment analysis gsea create arrange list gene indicate connection tnfrsf expression study cohort include female male patient scatter plot pair plot show difference tnfrsf expression normal tumor sample p univariate analysis suggest tnfrsf low associate essentially age hr ci identification two distinct molecular subtype non invasive follicular neoplasm papillary like nuclear feature digital rna count background follicular variant fv papillary thyroid cancer ptc one common variant ptc clinically non infiltrative fvptc consider low risk variant ptc non invasive encapsulate form fvptc represent group thyroid tumor particularly good prognosis consequently neoplasm recently reclassify non invasive follicular neoplasm papillary like nuclear feature niftp molecular standpoint niftp appear similar follicular neoplasm however limit datum currently available regard gene expression profile method aim study identify specific molecular signature niftps compare follicular adenoma fas infiltrative fvptcs ifvptcs nanostring custom assay use perform mrna expression analysis case also genotype braf n h k ras mutation sample group basis gene expression profile pearson correlation non negative matrix factorization cluster analysis finally uncorrelated shrink centroid machine learn algorithm use classify sample result result reveal distinct expression profile fas ifvptcs niftp sample exhibit different expression profile similar fas fa like ifvptcs ifvptc like different expression profile largely depend presence different mutation ras braf conclusion conclusion although validation model require use large group prospective case datum reinforce hypothesis ifvptc like niftps may represent precursor ifvptc parvovirus b infection hashimoto thyroiditis papillary thyroid carcinoma anaplastic thyroid carcinoma background human pathogenic parvovirus b b recently detect papillary thyroid carcinoma ptc hashimoto thyroiditis ht tissue high frequency two study chinese cohort want extend datum include another cohort expand thyroid tumor tissue type assess particular interest find whether b also infect anaplastic thyroid carcinoma atc one aggressive human cancer method commercially available thyroid tumor tissue array use detect b capsid protein immunohistochemistry various type thyroid tumor disorder array representative four main type thyroid tumor good thyroid autoimmune disorder ht grave disease adenoma goiters lymphoma normal thyroid tissue total little different type thyroid condition good normal tissue represent many multiple subject result twenty one ptc tumor atc undifferentiated tumor ht tissue sample positive b capsid protein immunohistochemistry localization protein differ base pathological disease type nuclear cytoplasmic shift see unaffected tumor tissue conclusion extend datum available b detection thyroid show high correlation virus another cohort ptc ht protein level also show \\ufeff1 time b infection much highly aggressive atc undifferentiated tumor nuclear cytoplasmic shift b protein cancer tissue suggest possible link b thyroid cancer pathogenesis progression microrna inhibit thyroid cancer tumor growth invasion suppress bdnf mir reportedly play critical role tumor development progression many type cancer therefore investigate function underlie mechanism mir thyroid cancer find mir downregulated thyroid cancer tissue mir level negative correlate advance clinical stage lymph node metastasis overexpress mir suppress thyroid cancer cell proliferation colony formation migration invasion vitro inhibit tumorigenesis vivo moreover brain derive neurotrophic factor bdnf know oncogene confirm direct target mir thyroid cancer cell mir overexpression suppress bdnf expression downstream pathway pi k akt vitro vivo bdnf level upregulated inversely correlate mir level human thyroid cancer specimen rescue experiment show force overexpression bdnf effectively reverse tumor suppressive function mir result show mir thyroid cancer tumor suppressor act repress bdnf nonhsat aid ultrasonography predict lymph node metastasis promote migration invasion papillary thyroid cancer cell lymph node metastasis lnm primary challenge papillary thyroid cancer ptc recurrent cancerous lymph node require repeat surgery increase risk surgical complication thus evaluation lnm surgery important ultrasonography convenient way examine cervical lnm sensitivity ultrasonography identification lnm case ptc extremely low series lncrnas long noncoding rnas report candidate biomarker variety tumor study detect lncrna nonhsat ptc analyze correlation nonhsat clinicopathological ultrasonographic characteristic patient ptc value nonhsat auxiliary diagnostic biomarker use along ultrasonography differentiation lnm ptc assess additionally biological function nonhsat ptc cell demonstrate study indicate nonhsat promote migration invasiveness ptc serve valuable auxiliary biomarker use along ultrasonography prediction cervical lnm medical image clinical significance medical image thyroid cancer supplementary diagnose method thyroid cancer discuss particular reference medical image although palpation course essential examination nodule also use soft x ray scintigraphy good tl scintigraphy ultrasonography aspiration biopsy addition various diagnose method employ determine degree invasion advance cancer patient ct scan observe invasion surround tissue naso tracheoscopy invasion trachea flow meter vascular tract tumor size cm use soft x ray ultrasonography sometimes try additional aspiration biopsy tumor small aspiration biopsy employ ultrasonography tumor large cm use ultrasonographic feature associate malignancy cytologically indeterminate thyroid nodule context thyroid nodule indeterminate cytology usually treat surgery benign neck ultrasonography vary result predict malignancy objective evaluate predictive value ultrasonography frequency malignancy patient indeterminate thyroid nodule design retrospective study set university hospital patient patient thyroid nodule diagnose cytology fine needle aspiration follicular lesion atypia undetermined significant follicular neoplasm ultrasonography available patient intervention main outcome measure diagnostic fine needle aspiration cytology ultrasonography surgical pathology thyroid nodule result fine needle aspiration indeterminate patient follicular lesion patient follicular neoplasm patient ultrasonography show micro calcification patient irregular border patient size cm patient hypoechogenicity patient surgical pathology show nodule benign patient malignant patient malignancy significantly associate male sex relative risk solid nodule structure relative risk irregular border relative risk compare ultrasonographic characteristic irregular border high specificity positive predictive value accuracy malignancy conclusion frequency malignancy high indeterminate thyroid nodule base limit accuracy predictive value ultrasonographic risk factor surgery treatment choice indeterminate thyroid nodule review f fdg pet diagnosis follow thyroid malignancy diagnosis carcinoma thyroid usually make process investigate thyroid nodule clinical examination technetium scan ultrasonography fine needle aspiration fna cytology follow mainly base iodine iodine scan serum thyroglogulin measurement aim present review establish role f fdg pet differential diagnosis doubtful thyroid nodule follow patient increase serum thyroglobulin level negative iodine scan remain define metabolic image pet can useful routine procedure management thyroid tumour since majority good differentiate therefore little avidity f fdg present work collect specific literature derive medline last year clarify potential clinical value f fdg pet thyroid malignancy emerge role f fdg pet assessment incidental find thyroid nodule show high fdg uptake regard possible malignancy need assessment another good document role f fdg pet investigation case establish good differentiate thyroid carcinoma present high thyroglobulin negative iodine image increase f fdg uptake tumour indicate shift towards lesser differentiation aggression poor prognosis may benefit alternative management f fdg pet consider routine functional image method detect iodine negative recurrent disease thyroid cancer patient elevate serum thyroglobulin level follow f fdg pet seem useful also differential diagnosis suspect thyroid nodule especially use alteration gut microbiota metabolite profile thyroid carcinoma patient aim study investigate relationship among gut microbiota community metabolite profile thyroid carcinoma tc \\ufeff1 tc patient healthy control hcs fecal sample apply characterize gut microbial community use rrna gene sequence differential microbiota composition observe significant enrichment depletion genus tc sample compare hcs q value genus correlate various clinical parameter lipoprotein apolipoprotein b furthermore different genus distinguish tc patient hcs auc picrust analysis show remarkably different metabolic pathway q value subsequently systematically analyze gut microbiota metabolite tc patient n hcs n characteristic gut microbiota community mostly consistent result tc patient hcs liquid chromatography mass spectrometry analysis perform characterize metabolite profile total different genus q value significantly change metabolite vip p observe correlate eight metabolite combine genus effective distinguish tc patient hcs auc conclusion study present comprehensive landscape gut microbiota metabolite tc patient provide research direction mechanism interaction gut microbiota alteration tc pathogenesis prognostic factor determine survival differentiate thyroid cancer background differentiate thyroid cancer dtc among curable cancer evaluate prognosis patient dtc iodine deficient area material method four hundred twenty two patient thyroid cancer undergo surgery ankara oncology hospital evaluate three hundred eighty two patient dtc include gender age histopathological type tumor size capsular invasion vascular invasion distant metastasis tnm ames macis score analyze result year disease free survival rate overall survival rate age year presentation follicular thyroid cancer tumor extension beyond thyroid capsule vascular invasion distant metastasis increase tumor size stage high macis ames score find statistically significant adverse prognostic factor univariate analysis dfs oas multivariate analysis dfs oas confirm distant metastasis follicular thyroid cancer tumor extension beyond thyroid capsule vascular invasion primary tumor size tnm stage high macis score independent prognostic factor conclusion dtc patient addition traditional risk factor prognostic factor vascular invasion capsular invasion need evaluate not achieve adequate therapeutic approach also avoid overtreatment low risk patient feature trend thyroid cancer patient thyroidectomy beijing china retrospective study objective study aim summarise feature trend thyroid carcinoma past two decade china design set participant clinical datum obtain patient treat thyroidectomy department general surgery people liberation army general hospital beijing china retrospectively analyse outcome measure incidence histopathological feature thyroid cancer compare risk factor local lymph node metastasis analyse result datum indicate significant increase detection thyroid cancer p among thyroid cancer case papillary thyroid carcinoma ptc common histotype account malignancy year period among ptcs micro ptcs mptc large diameter mm gradually become dominant form percentage ptcs increase biennial period furthermore size tumour decrease significantly cm cm large diameter p average age diagnosis female dominance remain unchanged period logistic regression show tumour nodule cm male gender main risk factor local lymph node metastasis lnm whereas patient year low risk conclusion year period increase detection thyroid cancer particularly mptc find occurrence lnm decrease result suggest current preoperative diagnosis risk stratification adequate support publish guideline diagnosis thyroid cancer persistent elevation thyroglobulin patient treat differentiate thyroid cancer ten year review differentiate thyroid cancer dtc increase prevalence due well diagnostic tool excellent long term survival study understand outcome twenty six patient dtc period year initial treatment surgery radioiodine therapy study analysis show no death indicate old man likely persistent disease study need focus cost effective long term management dtc current status lymph node dissection treatment papillary thyroid cancer literature review aim cervical lymph node micrometastases observe papillary thyroid cancer ptc show lymph nodal involvement common nevertheless last year role lymph node dissection treatment ptc controversial present well indication routine therapeutic neck dissection remain subject research order well analyze current role lymph node dissection surgical treatment ptc analysis recent literature datum perform study design use keyword lymph node dissection selective lateral central lymph node dissection modify radical neck dissection prophylactic therapeutic lymph node dissection papillary thyroid cancer pub med datum base research carry recent guideline different referral endocrine society inhere neck dissection ptc also evaluate result role neck dissection ptc management remain controversial regard routine therapeutic indication surgical extension impact local recurrence long term survival due inhomogeneous literature datum current status node dissection still subject research conclusion agreement endocrine neck surgeon extension therapeutic lymph node dissection n ptc patient also prophylactic treatment n high risk patient consider recent trend toward routine central lymphadenectomy avoid radioactive treatment prospective randomize trial need evaluate benefit different approach medullary thyroid cancer undetectable serum calcitonin context calcitonin sensitive biomarker use diagnosis follow medullary thyroid cancer mtc patient tumor cm uncommon preoperative serum calcitonin normal laboratory reference range patient mtc even unusual serum calcitonin undetectable case year old woman find leave thyroid nodule magnetic resonance image do neck pain ultrasound fine needle aspiration biopsy perform cytopathology positive malignant cell cell also feature suggestive neuroendocrine tumor specimen immune stain calcitonin positive immunoreactivity calcitonin isolate cell cytospin highly favor diagnosis mtc serum calcitonin pg ml pg ml serum carcinoembryonic antigen ng ml ng ml give low calcitonin level procalcitonin also test elevate ng ml ng ml patient subsequently undergo total thyroidectomy central ipsilateral lateral lymph node dissection histopathology confirm cm mtc strong diffuse immunostaining calcitonin postoperatively serum calcitonin remain undetectable carcinoembryonic antigen remain within reference range procalcitonin become undetectable conclusion present rare case patient mtc undetectable preoperative serum calcitonin whose tumor demonstrate strong diffuse immunohistochemical stain calcitonin discuss possible pathogenesis calcitonin negative mtc challenge follow patient condition alcohol drink tobacco smoke anthropometric characteristic risk factor thyroid cancer countrywide case control study new caledonia exceptionally high incidence rate thyroid cancer observe new caledonia particularly melanesian woman investigate etiology thyroid cancer clarify reason elevate incidence author conduct countrywide population base case control study multiethnic population study include case histologically verify papillary follicular carcinoma woman man diagnose population control woman man frequency match gender year age group thyroid cancer negative associate tobacco smoke alcohol drink no inverse dose response relation observe height positively associate thyroid cancer particularly man strong positive association weight body mass index observe melanesian woman age year odd ratio confidence interval body mass index kg great compare normal weight woman clear late result surgical therapy thyroid cancer purpose although incidence thyroid cancer korea rapidly increase past decade study investigate risk factor study examine risk factor thyroid cancer korean adult material method study design hospital base case control study august december total thyroid cancer case patient screen cancer screenee cohort national cancer center south korea include analysis total control case select cohort match individually age year area residence control group additionally sex control group result multivariate conditional logistic regression analysis use control group show female family history thyroid cancer increase risk thyroid cancer whereas ever smoker high monthly household income decrease risk thyroid cancer hand analysis use control group show family history cancer alcohol consumption associate decrease risk thyroid cancer whereas high body mass index bmi family history thyroid cancer associate increase risk thyroid cancer conclusion finding suggest female family history thyroid cancer high bmi non smoker non drinker low monthly household income increase risk develope thyroid cancer thyroid cancer diagnosis management article provide overview classification thyroid carcinoma primary clear cell thyroid carcinoma squamous feature clear cell neoplasm thyroid indistinguishable light microscopic feature similar tinctorial reaction lipid glycogen clear cell renal carcinoma describe however electron microscopic examination disclose cytoplasmic tonofibrils keratohyaline granule good suggestive transition tumor cell acinar epithelium former appear represent helpful marker distinction type thyroid cancer parathyroid metastatic renal clear cell tumor evidence not clear cell thyroid neoplasm possess squamous feature nevertheless apparent electron microscopy may necessary pathological discrimination primary secondary clear cell neoplasm thyroid situation analogous clear cell tumor site lung noninvasive follicular thyroid neoplasm papillary like nuclear feature niftp shape way interpret thyroid cytology objective determine whether previous radiation exposure head neck relate little favorable pathologic clinical outcome patient surgical management thyroid cancer design retrospective chart review set academic teach hospital referral center patient patient diagnose thyroid cancer expose radiation surgical treatment retrospectively identify thyroid cancer database institution one hundred twenty five patient woman man include inclusion criterium include surgical treatment thyroid cancer history exposure radiation little year diagnosis disease main outcome measure pathologic feature datum relate disease recurrence distant metastasis survival result mean range age \\ufeff1 exposure radiation year mean lag time diagnosis disease year patient treat surgically either total near total thyroidectomy partial subtotal thyroidectomy pathologic diagnosis include papillary carcinoma sixty three percent patient multifocal disease lymphovascular tumor invasion direct extrathyroid extension disease twenty five percent patient metastasis cervical lymph node distant metastasis sixteen percent patient experience local recurrence disease last follow patient alive free disease alive disease die thyroid cancer die unrelated cause compare patient thyroid cancer radiation expose cohort likely undergo total thyroidectomy multiple operative procedure external radiotherapy high percentage multifocal disease extrathyroid extension stage iv disease distant metastasis follow few patient free disease patient die thyroid disease conclusion patient expose radiation aggressive disease wrong clinical outcome patient thyroid cancer routine preoperative octreotide scintigraphy patient medullary thyroid cancer background surgery potential cure patient medullary thyroid carcinoma mtc preoperative ultrasound compute tomography magnetic resonance image not sensitive enough detection microscopic disease aim study investigate routine preoperative label dtpa phe octreotide scintigraphy sr can use stage procedure plan primary surgery patient mtc method study include patient primary sporadic clinically overt mtc diagnose patient undergo conventional image neck thorax sr prior standardise surgery finding sr correlate finding conventional image histopathology postoperative biochemical result survival result total patient sporadic mtc enroll median follow month sr visualise primary tumour patient fifteen patient locoregional lymph node metastasis sr detect metastatic lesion patient three patient distant spread sr fail detect metastatic lesion two late follow six patient die nine patient alive elevate tumour marker four patient consider complete biochemical remission conclusion study provide evidence sr compare conventional image fairly sensitive detection primary mtc not metastatic disease although preoperative sr may prognostic value no indication routine use stage procedure plan primary surgery hashimoto thyroid disease thyroid cancer background anaplastic thyroid cancer atc fatal endocrine malignancy current therapy fail significantly improve survival recent insight thyroid tumorigenesis post malignant dedifferentiation mode metastatic activity offer new therapeutic strategy method extensive literature search medline pubmed conduct include publish report atc secondary article identify key paper reference listing conclusion significant progress last year make outline thyroid tumorigenesis progression anaplasia continue identification development drug therapy require counter specific molecular target responsible post malignant dedifferentiation process ultimately fatal neoplastic phenotype carcinoma thyroid carcinoma testicle occur patient differentiate thyroid cancer include papillary follicular carcinoma originate follicular epithelium treatment choice usually total near total thyroidectomy follow ablative radioiodine treatment growth factor receptor genesis treatment thyroid cancer aim study evaluation early diagnosis thyroid cancer impact management patient hospital base study primary thyroid cancer case diagnose evaluate report study reveal crucial importance accurate information subtype thyroid tumor management patient prognosis thyroid cancer need reproducible biomarker correlate directly presence progression thyroid cancer update status clinical trial kinase inhibitor thyroid cancer context thyroid cancer usually cure timely thyroidectomy however treatment patient advance disease challenge tumor mostly unresponsive conventional therapy recently malignancy attract much interest two reason dramatic increase incidence last three decade discovery genetic mutation chromosomal rearrangement cause histological type thyroid cancer objective update review molecular genetic thyroid cancer clinical trial evaluate kinase inhibitor kis patient locally advance metastatic disease update also review study malignancy identify mechanism efficacy also resistance specific kis information critical development effective 2 generation drug design combinatorial therapeutic regimen finally update address major challenge face clinician seek develop effective therapy patient thyroid cancer result pubmed search january november use follow term thyroid cancer treatment thyroid cancer clinical trial thyroid cancer small molecule therapeutics kinase inhibitor next generation sequence conclusion new era cancer therapy emerge base introduction kis treatment patient liquid solid organ malignancy patient thyroid cancer benefit advance continue development drug great specificity implementation clinical trial combine therapeutics overcome drug resistance pregnancy thyroid cancer ultrasound study foetal thyroid thyroid cancer common endocrine malignancy frequently diagnose young woman childbearing age approximately thyroid cancer diagnose pregnancy early post partum period thyroid cancer young people generally excellent prognosis survival among woman thyroid cancer diagnose pregnancy may not differ age match non pregnant woman similar cancer pregnancy treatment thyroid carcinoma require maternal foetal control utmost importance ensure adequate maintenance maternal level levothyroxine need foetal central nervous system normal maturation mother avoid possible recurrence spread disease present investigation confirm normal foetal growth foetal thyroid development ultrasound study foetal thyroid perform full term pregnancy woman receive levothyroxine treatment previously treat thyroid cancer patient undergo either suppressive substitutive levothyroxine treatment foetal thyroid growth note normal case newborn thyroid status always normal incidence maternal morbidity not influence present study group pregnancy not appear compromise mother disease free interval compromise thyroid cancer treatment result present study confirm regular adjustment levothyroxine treatment utmost importance maternal foetal good foetal thyroid ultrasound study may add useful reassure datum child good cribriform morular variant papillary thyroid carcinoma year old girl case report immunohistochemical molecular test description histological feature immunohistochemical molecular analysis case cribriform morular variant papillary thyroid carcinoma year old girl family history adenomatous polyposis present neoplasm multifocal bilateral mix pattern solid trabecular morular area neoplasm show angioinvasive behavior extracapsular infiltration extension perythyroidal muscle lymph node metastasis tumor cell positive cam cytokeratins ttf papillary thyroid cancer prognosis prognostic factor papillary thyroid carcinoma operate retrospectively analyse median follow year range year primary operation patient may classify tumor free lethality rate thyroid cancer cumulative survival rate year respectively thus survival not significantly different one follicular carcinoma whole material characterize thoroughly clinical morphological parameter simultaneous examination variable prognostic relevance perform mean log logistic regression model survival datum age extension primary tumor vascular invasion presence colloid determine prognosis histopathological practice differentiation vascular lymphatic invasion demand rankl opg trail kras c fos expression relation central lymph node metastasis papillary thyroid carcinoma purpose rankl opg trail long pursue cancer mutate kras protein c fos overexpression good recognize oncogenic event conceive coordinator rankl opg trail pathway consider paucity relevant literature purpose present study investigate whether expression molecule configure distinct papillary thyroid carcinoma ptc subgroup adverse clinicopathological characteristic method rankl opg trail kras c fos immunohistochemical expression relation clinicopathological characteristic ptc assess retrospectively paraffin embed ptc specimen patient undergo total thyroidectomy simultaneous central lymph node dissection clnd result expression rankl opg trail kras c fos reveal ptc respectively predominant kras express ptc histotype emerge classical ptc cptc comprise ptc significant correlation demonstrate rankl opg trail expression central lymph node metastasis clnm p p p respectively concern especially cptc regard rankl p opg p cptc p follicular variant ptc fvptc p regard trail opg expression associate significantly multifocality p multivariable adjust logistic regression model characterize trail independent predictor clnm ci clnm correlate significantly six pair coexpressions trail kras p trail c fos p opg c fos p rankl trail p rankl opg p trail opg p conclusion present study suggest \\ufeff1 time opg rankl trail expression either alone concert involve c fos kras expression relate clnm research warrant elucidate whether examine molecule endorse indicator aggressive ptc behavior guide personalize therapeutic intervention not always puncture thyroid nodule incidence thyroid cancer increase especially papillary subtype increase mainly attribute detection small mostly indolent papillary thyroid cancer consequence high sensitivity diagnostic technique frequent use diagnostic application two patient describe non palpable thyroid nodule illustrate risk overdiagnostics overtreatment thyroid incidentaloma detect ultrasound ct mri not require diagnostic procedure standard pro con diagnostic procedure must discuss multidisciplinary team anaplastic thyroid cancer hyperfractionated accelerate radiotherapy hart without surgery anaplastic carcinoma thyroid gland atc one aggressive cancer human insufficient treatment disease often lead death suffocation treatment strategy hyperfractionated accelerate radiotherapy hart high dose gy neck follow surgery week late feasible aim gain control neck pathology review patient diagnose atc period south east norway thirty one receive hart present study patient death suffocation primary endpoint survival 2 no patient treat hart die suffocation six tracheostomy course disease four dependent tracheal cannula die well median survival month obtain patient radiotherapy surgery possible primary treatment surgery come prognostic factor survival multivariate analysis patient survive year characterise surgery r resection no small residual focus atc specimen stage c patient survive month microrna expression profile thyroid nodule fine needle aspiration cytology confirmatory series introduction mirnas small endogenous non code rnas implicate gene expression regulation change mirna level report thyroid cancer thyroid cancer patient hepatitis c infection background investigate differentiate thyroid cancer risk factor native french polynesia interest high incidence cancer archipelago material method assess role various potential risk factor thyroid cancer native french polynesia perform thyroid cancer overview objective review current literature hyalinizing trabecular tumor htt relationship sinister neoplasm thyroid include papillary thyroid carcinoma ptc apply information clinical practice thus elucidate well approach regard management patient thyroid tumour method thorough literature search perform article publish htt thus far article review epidemiology discussion categorization possible area differentiation thyroid tumor type hospital record review possible case htt result many attempt make find objective way categorize htt thyroid tumor article find highlight difficulty understand classification molecular genetic pathology htt especially regard differentiation ptc institution find one case confirm htt conclusion ability differentiate htt ptc remain imperfect currently permanent histologic section well mean obtain diagnosis relationship elucidate treatment approach tailor patient possibly avoid total thyroidectomy radioactive iodine ablation currently indicate ptc thyroglobulin metastatic thyroid cancer culprit red herring study aim evaluate association potential functional tag single nucleotide polymorphism tagsnps braf tshr papillary thyroid cancer ptc two tagsnps r r braf six tagsnps r r r r r r tshr genotype case ptc healthy control no difference genotype frequency braf tshr ptc patient control subject suggest no contribution braf tshr polymorphism susceptibility ptc observe tagsnp locate untranslated region tshr r can affect incidence lymph node metastasis lnm variant tc tc cc genotype confer increase risk lnm tc vs tt odd ratio confidence interval ci p tc cc vs tt ci p moreover subject carry variant genotype high tsh level low thyroxine anti tg level compare subject carry common genotype finding show ptc patient carry tshr r tc cc variant associate high tsh level low anti tg level prone develope lnm confirm result additional study functional experiment especially ethnic population need coordinate expression galectin caveolin thyroid cancer galectin gal single accurate marker diagnosis differentiate thyroid cancer dtc gal override tumour suppressor activity caveolin cav function concert cav promote focal adhesion turnover tumour cell migration invasion study coordinate role progression human cancer investigate expression gal cav specimen human benign thyroid lesion dtc anaplastic thyroid cancer atc gal cav expression significantly associate dtc atc not benign nodule essentially cav positive dtc cancer express gal support synergistic activity two protein dtc progression similarly coordinate elevate gal cav expression observe three dtc derive cell line papillary tcp ktc follicular ftc one act five atc derive cell line use sirna knockdown gal cav show require rhoa gtpase activation stabilization focal adhesion kinase fak measure focal adhesion signal turnover increase migration dtc cell line study not atc cell line include act express elevate level gal cav co expression gal cav anaplastic cell line stabilize fak gfp focal adhesion gal cav therefore function synergistically promote focal adhesion signal migration progression dtc thyroid neoplasm dog clinicopathologic study fifty seven case incidence papillary thyroid carcinoma grow rapidly especially young patient patient high demand well cosmetic effect little psychological trauma application laparoscope technique papillary thyroid carcinoma surgery meet need patient development needle assist technique make easy access neck potential fascial space provide basic instrument laparoscope modify neck dissection application needle assist technique mainly include suture suspension v type needle retractor minilap mm laparoscopic apparatus indication procedure important necessary make full use critical point mark line fascia layer precise position operation furthermore level dissection must determine base pattern cervical lymph node metastasis differentiate thyroid carcinoma make surgical procedure safety identification carcinoembryonic antigen c cell normal thyroid carcinoembryonic antigen cea activity confirm c cell normal thyroid immunohistochemical technique suggest cea production medullary carcinoma thyroid not initiate carcinogenesis reflect function normal c cell not yet clear whether cea production c cell may influence carcinogenesis c cell \\ufeff1 apud cell confirm cea activity case resistance thyroid hormone diagnose total thyroidectomy thyroid cancer case woman diagnose resistance thyroid hormone total thyroidectomy thyroid cancer preoperative laboratory examination reveal syndrome inappropriate secretion tsh however patient no thyrotoxic symptom no family history base result ultrasonography fine needle aspiration diagnose papillary thyroid carcinoma undergo total thyroidectomy surgery receive l therapy tsh level remain elevate mri perform brain no lesion find pituitary gland therefore test tr gene previously define mutation p detect ultimately diagnose rth treat l case dose l need increase suppress tsh level normal range little prevent stimulate malignant cell currently dose l increase tsh level still low normal however no thyrotoxic symptom recurrence metastasis thyroid cancer patient currently careful observation regard circulatory physiological status addition result treatment still need monitor evaluate role fluorine fluorodeoxyglucose positron emission tomography image medullary thyroid cancer thyroid cancer represent one prevalent endocrine cancer relatively high incidence rate around world accompany unchanged fatality rate probe specific role linc mediation cellular process thyroid cancer include proliferation migration invasion methylation aristaless like homeobox alx thyroid cancer relate long noncoding rnas lncrnas gene analyze microarray base analysis antitumor effect linc examine gain loss function experiment addition bind linc promoter region alx interaction linc methylation relate protein detect late xenograft tumor nude mouse induce expect dig modulatory function linc tumor growth thyroid carcinoma microarray base analysis manifest linc overexpress whereas alx downregulated thyroid cancer result also verify thyroid cancer tissue besides result demonstrate linc bind alx promoter region linc recruit dnmt dnmt b protein promote methylation alx promoter region thus suppress alx expression finally downregulation linc upregulation alx repress akt mtor signal axis thus inhibit proliferative migratory invasive ability good epithelial mesenchymal transition emt thyroid cancer cell collectively downregulated linc suppress cell proliferation migration good invasion thyroid cancer inhibit methylation alx increase expression inactivation akt mtor signal pathway indication clinical evaluation radical semiradical neck dissection basis operation period radical semiradical neck dissection perform en bloc method use patient cancer larynx thyroid cancer patient analysis patient material reveal operative mortality year survival observe patient incidence local recurrence amount prophylactic lymph node dissection papillary thyroid carcinoma place lateral neck dissection background cervical lymph node ln metastasis common patient papillary thyroid carcinoma ptc negative impact recurrence management preoperatively node negative n ptc still controversial aim study describe result prophylactic bilateral lymph node dissection lnd investigate impact recurrence method analyze consecutive preoperatively n ptc patient patient review demographics datum tumor characteristic pattern risk factor ln metastasis outcome result lymph node metastasis find patient central compartment lateral compartment include lateral compartment opposite side tumor multivariate analysis show hyperthyroidism extrathyroidal invasion tumor significantly associate ln metastasis analysis show localization tumor upper 3 thyroid lobe metastatic ln central compartment independent risk factor lateral ln metastasis year follow recurrence observe include central compartment recurrence rate n group n patient n b patient p conclusion preoperatively n ptc patient ln metastasis frequent central ipsilateral lateral compartment prophylactic lnd central ipsilateral lateral compartment therefore recommend presence ptc identify high risk patient risk benefit ratio tsh thyroid cancer set differentiate thyroid cancer dtc management mu l tsh suppression prove beneficial patient likely microscopic macroscopic disease tsh direct trophic effect thyroid cancer cell however optimal degree tsh reduction remain unclear category dtc patient well prognosis excessive thyroid hormone replacement lead atrial fibrillation osteoporosis therefore levothyroxine dose carefully adjust respect underlie individual health status dynamically reassess risk relapse medical monitor future guideline give priority tailor approach tsh suppression therapy dtc patient increase iodine uptake nabothian cyst year old female patient papillary thyroid cancer status post total thyroidectomy radioablation undergo posttherapy whole body scan spect reveal increase iodine activity cervix subsequent ultrasound examination demonstrate site elevate iodine activity cause cervical nabothian cyst incidence clinical characteristic thyroid carcinoma iodine prophylaxis endemic goiter country iodized salt prophylaxis perform austria since approach mean urinary iodine excretion normalize microg g creatinine per day thus tyrol no long endemic goiter area analyze impact iodized salt prophylaxis thyroid cancer tc compare datum early correspond period iodine supply normalize study include patient tyrol southern tyrol incidence tc tyrol rise past decade cr year observe rise percentage differentiate adenocarcinoma predominance papillary tc along decrease anaplastic tc addition histological feature shift little advance tnm stage eg n obvious increase whereas advance tumor ie n b decrease change significantly improve prognosis current year survival rate compare rate value year survival respectively mark effect age tumor stage histology prognosis confirm kaplan meier method conclude together normalization iodine supply endemic goiter region epidemiological profile tc change even though incidence tc rise prognosis significantly improve due shift towards differentiate form tc diagnose early stage multifocal versus solitary papillary thyroid carcinoma introduction incidence thyroid cancer increase worldwide peru report describe national regional epidemiology thyroid cancer objective incidence thyroid cancer increase worldwide peru report describe national regional epidemiology thyroid cancer method descriptive study trend conduct secondary datum obtain public information source peru icd c code record evaluate age group year region age standardize prevalence period mortality period calculate region year study result period case thyroid cancer record age group high frequency year prevalence increase case per inhabitant period lncrna linc induce proliferation metastasis epithelial mesenchymal transition thyroid carcinoma via kruppel like factor incidence thyroid cancer increase past decade however underlie molecular mechanism thyroid cancer tumorigenesis remain unknown use sequence technology long intergenic non protein code rna linc identify upregulated several tumor tissue however biological role linc thyroid carcinoma yet determine study match pair thyroid tumor tissue normal tissue select study use reverse transcription quantitative polymerase chain reaction rt qpcr validate previous finding clinicopathologic feature tissue analyze proliferation colony formation migration invasion assay perform epithelial mesenchymal transition emt associate phenotype investigate follow transfection small interfere rna determine specific role linc thyroid carcinoma cell line tpc ktc bcpap study reveal long non code rna linc significantly upregulated thyroid cancer tissue compare pair adjacent non tumor tissue use rt qpcr high expression linc associate large tumor size lymph node metastasis validate cohort knockdown linc inhibit cell proliferation metastasis whereas linc overexpression opposite effect result show linc may influence emt expression kruppel like factor klf notably klf consider tumor suppressor gene variety tumor finally knock klf enhance thyroid carcinoma cell proliferation invasion migration study function linc promote proliferation metastasis thyroid carcinoma cell line identify linc may act novel therapeutic target treat thyroid carcinoma thyroid parathyroid cancer epidemiology etiology pathology management thyroid parathyroid carcinoma discuss emphasis place clinical difference management treatment various histologic subtype thyroid cancer biologic prognostic difference among various histologic type thyroid cancer relationship age stress finding scintigram thyroid cancer include among controversy involve thyroid cancer risk factor treatment decision patient nodal metastasis review select clinical pathologic therapeutic parameter patient present cervical node metastasis relate parameter disease outcome patient woman man mean age year univariate analysis show significantly increase risk recurrence associate presence primary tumor invasion vascular lymphatic nerve muscle age sex patient presence mediastinal node adjuvant treatment iodine presence tumor invasion age sex patient presence mediastinal node significantly associate high rate recurrence test multivariate analysis year disease free survival rate respectively mean follow month comparison recurrence survival rate thyroid cancer patient either node positive node negative year period patient show no statistically significant difference however node positive patient risk factor tumor invasion age year positive mediastinal node aggressive disease although thyroid cancer patient nodal metastasis generally good prognosis high risk subgroup identify may benefit aggressive therapeutic follow approach cost effectiveness gene expression classifier test indeterminate thyroid nodule utilize real cohort comparator objective predict cost effectiveness implement routine gene expression classifier test thyroid nodule indeterminate fine needle aspiration cytology utilize real cohort patient comparator study design quantitative performance evaluation pet mri lesion dosimetry differentiate thyroid cancer aim investigate quantitative performance pet mri pre therapy lesion dosimetry differentiate thyroid cancer dtc phantom measurement perform pet mri system biograph mmr siemens healthcare use f pet calibration factor influence radiofrequency coil attenuation determine use cylindrical phantom homogeneously fill radioactivity calibration factor f near radiofrequency surface coil underestimation little radioactivity concentration observe ccl ccr promote invasion migration thyroid cancer cell via nf kappa b signal induce mmp production ccl important member cc chemokine family ligand activate ccr level ccl ccr elevate many human cancer ccl ccr interaction participate development progression cancer present study find ccr overexpress thyroid cancer cell activation ccr ccl promote invasion migration human thyroid cancer sw cell knockdown ccr repress effect ccl furthermore ccl ccr interaction induce activation nf b stimulate expression secretion mmp addition bay special inhibitor nf b suppress expression secretion mmp stimulate ccl ccr together result suggest ccl ccr enhance thyroid cancer cell invasion migration possible molecular mechanism involve nf b activation nf b dependent mmp upregulation thus molecular therapy aim ccl ccr may offer promise intervention strategy thyroid cancer familial vs sporadic papillary thyroid carcinoma match case comparative study show similar clinical prognostic behaviour objective familial non medullary thyroid cancer propose aggressive clinical entity aim study investigate potential distinguish feature good biological clinical aggressiveness familial vs sporadic papillary thyroid carcinoma ptc assess clinicopathological characteristic outcome measure dna ploidy design match case comparative study method series patient familial ptc n two subgroup one three affect element n another include index case n compare patient sporadic ptc n match age gender ptnm disease extension approximate follow duration histological variant extrathyroidal extension vascular invasion tumour multifocality bilateral growth evaluate ploidy pattern analyse available sample dna flow cytometry probability disease free survival dfs overall survival os estimate accord kaplan meier k method result no patient familial ptc die disease follow median month contrarily five patient p sporadic ptc median month significantly high tumour multifocality familial ptc index case subgroup vs sporadic ptc p trend familial ptc cohort three affect element show extrathyroidal extension p frequently no difference observe dna ploidy status k analysis show no significant difference entity relation dfs os conclusion apart multifocality familial ptc appear similar clinical prognostic behaviour compare sporadic form disease screen thyroid cancer survivor childhood young adult cancer treat neck radiation background optimal method screen thyroid cancer survivor childhood young adult cancer expose neck radiation remain controversial outcome datum physical exam base screen approach lack method conduct retrospective review adult survivor childhood young adult cancer history neck radiation follow adult long term follow clinic memorial sloan kettering november august eligible patient undergo physical exam thyroid follow little year afterwards ineligible patient prior diagnosis benign malignant thyroid nodule result median follow year range year ultrasound physical exam perform among patient forty survivor abnormal thyroid physical exam median year radiotherapy abnormal exam survivor hodgkin lymphoma radiation age female ultimately undergo fine needle aspiration fna surgery reveal papillary carcinoma seven survivor six currently free disease one active disease undergo watchful wait among one annual visit represent person year follow no case thyroid cancer diagnose within year normal physical exam conclusion finding support application annual physical exam without routine ultrasound thyroid cancer screen among survivor history neck radiation implication cancer survivor survivor history neck radiation may not require routine thyroid ultrasound thyroid cancer screen among adult survivor childhood young adult cancer history radiation therapy neck annual physical exam acceptable thyroid cancer screen strategy molecular genetic thyroid cancer pathogenesis development progression thyroid cancer tc far clear present accumulate evidence suggest complex polygenic disorder genetic factor play important role disease aetiology review literature report genetic variation alteration describe aetiology tc functional effect mutation single nucleotide polymorphism tc validate establish role sequence variation cancer however large prospective study still require evaluate diagnostic prognostic value genetic determinant clinical practice thyroid nodule child current profile change disease pediatric thyroid disease change since decline widespread cervical irradiation analysis recently resect childhood thyroid nodule show incidence malignancy decrease though incidence nodule stable risk factor development thyroid disease include female sex age around puberty family history thyroid disease previous coexist thyroid disease history medical condition may steroid endocrine relate age sex location size nodule duration symptom family patient history thyroid disease not distinguish malignant benign disease preoperatively seven child thyroid cancer six unrelated concurrent medical condition compare benign disease adenoma fine needle biopsy provide correct preoperative diagnosis case pediatric thyroid malignancy become rare high risk nodule become well define criterium surgical versus nonsurgical mode diagnosis treatment become distinct association preoperative us feature recurrence patient classic papillary thyroid carcinoma purpose investigate whether ultrasonographic us feature thyroid nodule associate tumor recurrence classic papillary thyroid carcinoma ptc material method retrospective study approve institutional review board need obtain inform consent waive total patient mean age year standard deviation range year undergo total thyroidectomy central lymph node dissection classic ptc great mm january february follow month long include malignant appear ptcs define show little one suspicious us feature among mark hypoechogenicity irregular microlobulated margin microcalcifications tall wide shape benign appear ptcs define without suspicious us feature kaplan meier cumulative event curve recurrence compare use log rank test multivariate cox proportional hazard regression analysis use estimate hazard ratio hr malignant appear us feature recurrence preoperative postoperative combine model result fifty six patient recurrence malignant appear ptcs low year disease free survival rate compare benign appear ptcs p preoperative model malignant appear us feature hr confidence interval ci large nodule size hr ci independently associate recurrence combine model male sex hr ci malignant appear us feature hr ci large nodule size hr ci extrathyroidal extension hr ci lymph node metastasis hr ci independently associate recurrence conclusion presence malignant appear us feature independently associate recurrence patient classic ptc outcome incidentally discover thyroid nodule refer high volume head neck surgeon background incidental thyroid nodule commonly find radiological study do indication yearly incidence thyroid cancer increase part detection nonpalpable nodule image perform unrelated issue method new patient refer high volume thyroid surgeon thyroid nodule review february january datum regard patient demographics risk factor refer physician radiologic finding nuclear power plant emergency thyroid cancer risk new jersey physician need know event severe nuclear power plant emergency result release radioactive iodine potassium iodide relatively safe effective salt may use prophylaxis article present history thyroid cancer due radiation exposure risk benefit potassium iodide prophylaxis heterogenous nature gene expression pattern braf like papillary thyroid carcinoma braf v e purpose papillary thyroid cancer ptcs common type thyroid cancer braf v e prevalent driver mutation know braf v e positive ptcs clinically molecularly heterogenous term aggressiveness prognosis molecular mechanism heterogeneity evaluate method publicly available rna seq datum classical c follicular variant fv ptcs braf v e mutation braf like expression signature braf v e ras score brs respective normal adjacent tissue download analyze differentially express gene deg deg analyze gene ontology annotation kegg pathway dataset result find four line evidence heterogeneity cptcs \\ufeff1 cluster dendrogram principle component analysis can not completely distinguish cancer tissue normal tissue 2 deg identify sample highly diverse one another 3 although deg enrich many term contain word extracellular extracellular region extracellular space analyze group degree enrichment variable analyze individually 4 intersection underexpressed gene annotate term contain word extracellular among sample examine essentially result obtain braf like fvptcs braf v e nevertheless frequently level v therapeutic neck dissection papillary thyroid carcinoma neck dissection papillary thyroid carcinoma ptc standard care patient clinical evidence regional metastasis however extent neck dissection debatable purpose current study develop evidence base recommendation include level v sublevels among patient ptc undergo neck dissection literature review study evaluate occurrence metastasis level v patient regional metastasis ptc undergo neck dissection perform occurrence metastasis level v low series although wide range notice case metastasis find level v occur almost exclusively sublevel vb sublevel va rarely ever involve metastatic lymph node however recently investigator begin specify sublevels level v risk therapeutic dissection level v indicate clinical evidence disease involve zone elective dissection sublevel vb indicate involvement level iv possibly multiple node level ii iii circumstance dissection sublevel vb indicate sublevel va may spare hypometabolic lateral rectus due bilateral cranial nerve vi palsy thyroid cancer tc good know endocrine neoplasia good common malignant tumor head neck study design assess prognostic meaningful tnfrsf expression tc dependent datum acquire tcga increase knowledge biological pathway involve tc pathogenesis relate tnfrsf information gene expression compare clinical datum identify download tcga gene set enrichment analysis gsea create arrange list gene indicate connection tnfrsf expression study cohort include female male patient scatter plot pair plot show difference tnfrsf expression normal tumor sample p univariate analysis suggest tnfrsf low associate essentially age hr ci sentinel lymph node biopsy papillary thyroid cancer commentary efficacy lateral neck sentinel lymph node biopsy papillary thyroid carcinoma se kyung lee et al background serum thyroglobulin use screen disease persistence recurrence papillary thyroid carcinoma ptc seek assess utility early postoperative unstimulated thyroglobulin level utg decision make tool guide use radioactive iodine rai ptc patient method perform retrospective analysis prospectively maintain database patient surgically treat ptc analyze utg approximately week postoperatively patient undergo total thyroidectomy completion thyroidectomy include study patient analyze accord postoperative utg receipt rai result total patient analyze patient meet inclusion criterium median postoperative utg ng ml overall patient achieve target utg ng ml mean time week postoperatively patient achieve utg ng ml postoperatively not receive rai utg ng ml maintain month patient include patient receive rai patient not receive rai p not receive rai none demonstrate structural disease recurrence month ultrasound patient early postoperative utg ng ml show benefit rai patient utg ng ml not achieve target utg level regardless receipt rai conclusion postoperative utg may use guide use rai achieve near undetectable utg within week postoperatively can aid provider assess disease burden minimize rai use patient low risk disease recurrence continue follow necessary accurately determine long term outcome surgical treatment differentiate thyroid cancer institute gustave roussy background growth spread many tumor trigger change cell membrane metabolism lead systemic alteration level phospholipid seek determine whether plasma level several phospholipid can differentiate healthy remnant thyroid tissue residual tumor tissue metastasis patient thyroid carcinoma method measure plasma phospholipid level phosphorus magnetic resonance spectroscopy p mrs blood sample patient thyroid cancer render hypothyroid preparation diagnostic therapeutic administration iodine patient undergo total thyroidectomy iodine whole body scintigraphy measurement thyroglobulin value year follow use distinguish patient remission healthy thyroid remnant tumor tissue metastasis result mean sd level sphingomyelin mmol l vs mmol l p phosphatidylcholine mmol l vs mmol l p significantly low patient metastatic thyroid cancer n patient n remission patient remnant thyroid tissue n also significantly low phospholipid level patient remission significantly great level patient tumor tissue metastasis conclusion preliminary result suggest p mrs may useful help differentiate presence tumor tissue remnant thyroid tissue not require treatment remission patient thyroid cancer gene therapy thyroid cancer current status future prospect despite multimodality treatment thyroid cancer include surgical resection radioiodine therapy thyrotropin tsh suppressive thyroxine treatment chemotherapy radiotherapy survival rate not improve last decade therefore development evaluation novel treatment strategy include gene therapy urgently need variety gene therapy approach evaluate treatment follicular cell derive medullary thyroid cancer include corrective gene therapy p restoration expression dominant negative ret mutant cytoreductive gene therapy suicide gene prodrug strategy herpes simplex virus thymidine kinase hsv tk ganciclovir antiangiogenic therapy endostatin immunomodulatory gene therapy expression interleukin il il furthermore clone sodium iodide symporter nis gene pave way development novel cytoreductive gene therapy strategy base nis gene transfer follow application radioiodine therapy nis gene delivery medullary follicular cell derive thyroid cancer cell show capable establish restore radioiodine accumulation may therefore represent effective therapy medullary dedifferentiated thyroid tumor lack iodide accumulate activity datum summarize review article clearly demonstrate currently available strategy represent potentially curative novel therapeutic approach future gene therapy thyroid cancer combination different therapeutic gene demonstrate useful enhance therapeutic efficacy seem promise role little part multimodality approach advance thyroid cancer diagnostic ability core needle biopsy nodular thyroid disease introduction non diagnostic result fine needle aspiration biopsy fnab remain important limitation technqiue aim study evaluate result core needle biopsy cnb thyroid nodule effectiveness non diagnostic fnab case method cnbs perform patient male female mean age year range year spring load g needle initially fnabs insufficient evaluation cnb report review patient suspicious malignant cnb result undergo total thyroidectomy result consider cnbs non diagnostic rate however \\ufeff1 case eliminate learn curve reduce case initial fnabs non diagnostic also non diagnostic cnb twelve patient undergo surgery malignant cnb report case confirm malignant postoperative pathology specimen result accuracy no major complication although three thyroid carcinoma child adolescent clinical characteristic follow two center aim study aim study analyze clinical feature outcome thyroid carcinoma tc child adolescent population treat institution material method gather tc patient year age initial diagnose two hospital patient clinical characteristic laboratory test outcome collect analyze result incidence tc high woman vs papillary carcinoma account major type significant difference tumor numb extra thyroidal invasion distant metastasis compare child group p high proportion patient lymph node metastasis lnm radioiodine therapy adolescent patient thyroid peroxidase antibody thyroglobulin thyroglobulin antibody urine iodine high level compare normal reference range moreover ft urine iodine show statistical significance adolescent group p papillary carcinoma medullary tc likely lnm extrathyroidal invasion no significant difference see recurrence rate survival rate pulmonary metastasis common way cancer metastasis conclusion initial workup crucial determine benign malignant lesion surgery effective therapy even associate complication child extremely good prognosis pediatric tc even distant metastasis happen iodine intake thyroid carcinoma potential risk factor role enhance thyroid stimulate hormone tsh secretion aetiology thyroid cancer not totally consistent circumstance condition cause e g iodine deficiency suboptimal intake water food indicate e g goitre increase tsh secretion associate increase risk thyroid cancer notably follicular anaplastic carcinoma elevate incidence mortality rate thyroid cancer however also find area iodine intake high hawaii iceland little country switzerland favourable impact introduction iodized salt mortality thyroid cancer report elsewhere correction iodine deficiency coincide elevation diagnostic standard e g spread thyroid scintigraphy ultrasound fine needle biopsy correspond increase incidence papillary carcinoma often clinically silent thus hamper distinction two phenomenon upward trend papillary carcinoma incidence however see affluent country irrespective iodine status population anaplastic thyroid cancer therapy dream reality objective purpose article discuss recent medium report suggest link mammography increase incidence thyroid cancer woman report cause many request thyroid shield use mammography conclusion basis previously publish study investigate organ dose mammography cancer risk estimate use 7 biologic effect ionize radiation report contend thyroid shield mammography unnecessary may increase retake rather afford radiation protection thyroid good cancer wdtc study cytological specimen conventional papillary thyroid carcinoma ptc follicular variant papillary thyroid carcinoma fvptc noninvasive follicular thyroid tumor papillary like nuclear feature niftp formerly noninvasive fvptc identify useful cytological parameter differentiation cytological finding invasive fvptc niftp similar differ conventional ptc intranuclear cytoplasmic inclusion true papillary cell cluster monolayered cell sheet ropy colloid multinucleate giant cell psammoma body cystic background observe characteristic feature conventional ptc microfollicular cell cluster dense globule colloid characteristic feature invasive fvptc niftp score eight parameter intranuclear cytoplasmic inclusion nuclear groove powdery chromatin true papillary cell cluster ropy colloid multinucleate giant cell psammoma body cystic background readily distinguish niftp conventional ptc can not distinguish niftp invasive fvptc average total score niftp invasive fvptc conventional ptc respectively difference conventional ptc niftp invasive fvptc statistically significant p student test individual three identify parameter likely harbor conventional ptc rather niftp way conventional ptcs can differentiate niftp definitively diagnose malignant cytology virtual touch tissue quantification vtq diagnosis thyroid nodule coexistent chronic autoimmune hashimoto thyroiditis preliminary study objective study aim detect whether virtual touch tissue quantification vtq can apply differentiate benign malignant thyroid nodule chronic autoimmune hashimoto thyroiditis ht method convenient ultrasound virtual touch tissue quantification perform patient thyroid nodule histology result ht group consist patient nodule non ht group consist patient nodule result stiffness extra nodular thyroid tissue can significantly affect severity chronic autoimmune thyroiditis shear wave velocity thyroid benign nodule malignant nodule not significantly differ ht group compare non ht group benign nodule vs p malignant nodule vs p two group shear wave velocity malignant nodule significantly high benign nodule ht group vs non ht group vs p well cutoff point shear wave velocity malignant benign thyroid nodule conclusion virtual touch tissue quantification technology can perform differential diagnosis malignant thyroid nodule benign thyroid nodule independently coexistence chronic autoimmune thyroiditis helicase like transcription factor new marker good differentiate thyroid cancer background preoperative characterization thyroid nodule challenge clinician fine needle aspiration fna commonly use pre operative technique diagnosis malignant thyroid tumor however many benign lesion indeterminate diagnosis follow fna refer surgery urgent need identify biomarker can use fna distinguish benign thyroid nodule malignant tumor purpose study examine level expression helicase like transcription factor hltf relation neoplastic progression thyroid carcinoma method presence hltf investigate use quantitative semi quantitative immunohistochemistry series thyroid lesion specimen \\ufeff1 clinical series compose patient include patient present thyroid adenoma patient present thyroid papillary carcinoma patient present thyroid follicular carcinoma patient present anaplastic carcinoma specimen assess quantitatively use computer assist microscopy initial result validate 2 clinical series compose benign thyroid lesion malignant thyroid lesion use semi quantitative approach finally hltf protein expression investigate western blot four thyroid cancer cell line result decrease hltf stain statistically significant thyroid tumor progression term percentage mean optical density mod correspond mean stain intensity kruskall wallis p label index li correspond percentage immunopositive cell kruskall wallis p adenoma present pronounce nuclear hltf immunostaining whereas papillary carcinoma exhibit hltf cytoplasm numb hltf positive nucleus clearly high adenoma group papillary carcinoma group kda full size hltf protein immunodetected four study thyroid cancer cell line moreover three truncate hltf form kda kda kda also find tumor cell conclusion study reveal association hltf expression level thyroid neoplastic progression nuclear hltf immunostaining can use fna attempt well distinguish benign thyroid nodule malignant tumor evaluation ultrasound report thyroid cancer diagnosis surveillance background despite importance ultrasound image thyroid disease care ultrasound report vary greatly feature describe essential ultrasound report contain present component necessary clinical decision reader friendly format method one hundred ninety thyroid neck ultrasound report score use universal ultrasound report template develope su et al along american thyroid association ata american association clinical endocrinologist associazione medici endocrinologi european thyroid association aace ame eta guideline ultrasound perform patient see august november single surgeon l u originate variety physician institution result average su et al criterium satisfactorily include report similar result reach ata aace ame eta guideline apply score template conclusion result reveal wide variation ultrasound report standardization ultrasound report would help improve physician ability properly diagnose manage patient thyroid disease seminar controversy management pediatric thyroid malignancy thyroid cancer child rare malignancy unusual biological behavior often present advance stage yet behave benign manner compare adult counterpart surgeon debate risk benefit aggressive surgical procedure decade consensus treatment plan childhood thyroid cancer not achieve however radical surgical procedure general fall favor well operative adjuvant strategy child determine well understand tumor cell biology genetic cancer know review discuss current controversy management differentiate childhood thyroid malignancy variation clinicopathologic characteristic thyroid cancer among racial ethnic group analysis large public city hospital seer database background clinicopathologic variable influence treatment prognosis patient thyroid cancer method retrospective analysis public hospital thyroid cancer database surveillance epidemiology end result database conduct demographic clinical pathologic datum compare across ethnic group result within public hospital database hispanics versus non hispanic white young lymph node involvement vs p median tumor size not statistically different across ethnic group similar finding demonstrate within surveillance epidemiology end result database african americans age year large tumor little likely lymph node involvement asians stage iv disease despite no difference tumor size lymph node involvement capsular invasion conclusion considerable variability clinical presentation thyroid cancer across ethnic group disparity persist within equal access health care system finding suggest factor beyond socioeconomics may contribute difference consideration anatomo clinical phenomenon thyroid cancer treatment prognosis personal experience operate case author present retrospective study histologically confirm case thyroid cancer encounter along period year activity case find among patient operate thyroid disorder case differentiate carcinoma follicular papillary trabecular type nondifferentiated carcinoma medullary carcinoma treatment form cancer complex one depend clinical stage anatomo pathologic form author advocate total quasi total thyroidectomy form differentiate cancer follow administration radioactive iodine hormone condition prognosis extremely favourable nondifferentiated medullary cancer author propose wide resection follow application x ray cobalt hormonal substitution therapy prognosis case poor poorly differentiate undifferentiated thyroid carcinoma thyroid cancer common endocrine malignancy incidence go increase worldwide majority thyroid tumour comprise good differentiate papillary follicular thyroid carcinoma usually carry excellent prognosis minority progress poorly differentiate carcinoma pdtc ultimately highly aggressive lethal undifferentiated carcinoma utc recently major advance make histologic imunohistochemical identification good molecular characterization pdtc utc review summarize recent immunohistochemical molecular finding pdtc utc give particular emphasis diagnostic prognostic mean genetic alteration complex vivo vitro radiodiagnosis thyroid cancer background thyroid cancer child adolescent rarely report taiwan purpose study realize characteristic thyroid cancer child adolescent method total patient cancer thyroid treat veteran general hospital taipei age follow year average year result one patient thyroid cancer history previous radiation therapy head neck tumor neck mass common mode presentation associate cervical adenopathy histologically papillary cancer find patient follicular cancer medullary cancer no undifferentiated cancer twenty three patient lymph node metastasis eight patient develope distant metastasis especially lung male recurrence initial surgical treatment find patient without significant association surgical procedure major operative complication hypoparathyroidism disease relate mortality occur one case conclusion good differentiate carcinoma thyroid child young adult rare taiwan mostly papillary carcinoma not relate previous neck irradiation age puberty boy predominant series rate distant metastasis high male prognosis surgical treatment excellent indication status surgical strategy cold struma nodule scintigraphy sonography fine needle cytology well accuracy evaluation cold nodular goitre investigation nodular goitre can find incidence prophylactic operation histological diagnosis decrease half hand precise diagnosis surgeon able perform thyroidectomy thyroid cancer \\ufeff1 operation thus complication thyroidectomy paralysis recurrent laryngeal nerve tetany residual thyroid tissue can reduce molecular image management thyroid cancer thyroid cancer common endocrine malignancy adult disease classify papillary follicular medullary anaplastic type characteristic histology pattern biological behavior diagnosis thyroid cancer usually make needle aspiration suspicious thyroid nodule disease management good differentiate thyroid cancer rely upon characteristic accumulation radioisotope iodine continue play central role detection treatment disease recombinant human thyrotropin rhtsh use alternative thyroid hormone withdrawal provide tsh stimulation necessary diagnostic radioiodine scintigraphy preparation thyroid remnant ablation cancer therapy hybrid spect ct camera combine functional scintigraphic information ct anatomy replace stand alone gamma camera device show outperform traditional planar spect image technique similarly clinical application novel radioisotope like iodine pet ct thyroid cancer image provide improve lesion resolution direct tumor dosimetry alternative tracer f fluorodeoxyglucose fdg use evaluate good differentiate thyroid cancer no long express na symporter role stage h rthle cell poorly differentiate anaplastic thyroid cancer medullary thyroid cancer recurrence often difficult detect use conventional image traditional radionuclide study whereas f fdg f fluorodihydroxyphenylalanine dopa pet pet ct show promise localize often elusive source elevate calcitonin patient association nf b polymorphism clinical outcome non medullary thyroid carcinoma nf b inflammatory pathway play major role cancer development clinical progression activation nf b signal promote nfkb inhibit nfkbia present study aim determine relevance nfkb r nfkbia r genetic variant non medullary thyroid cancer nmtc susceptibility progression clinical outcome case control cohort study consist romanian discovery cohort patient control dutch validation cohort patient control addition patient cohort analyze association genetic variant clinical parameter functional study perform human peripheral blood mononuclear cell no association observe study genetic variant tc susceptibility although no statistically significant association clinical parameter observe nfkb r heterozygous genotype nfkbia r correlate decrease radioactive iodide sensitivity require high cumulative dosage achieve clinical response finding discover romanian cohort p confirm dutch cohort p functional study reveal nfkbia r genotype associate elevate tlr mediate il production conclusion genetic variation nfkbia inhibitor nf b signal associate clinical response rai therapy increase production pro inflammatory cytokine il provide potential mechanism observe clinical association datum suggest nf b signal involve nmtc pathogenesis inflammatory tumor microenvironment can contribute rai resistance expression clinical significance connective tissue growth factor thyroid carcinoma objective examine expression connective tissue growth factor ctgf gene human thyroid cancer establish whether correlation exist presence ctgf protein clinicopathological parameter disease method ctgf protein expression investigate retrospectively immunohistochemical analysis ctgf protein level thyroid tumour tissue association immunohistochemical score several clinicopathological parameter examine result total thyroid tissue specimen include high level ctgf protein observe papillary thyroid carcinoma tissue benign thyroid tumour tissue score negative ctgf protein papillary thyroid carcinoma significant relationship high ctgf protein level union international cancer control disease stage iii iv presence lymph node metastasis papillary thyroid carcinoma ctgf protein level not significantly associate sex age conclusion finding suggest ctgf protein level increase papillary thyroid carcinoma cell compare benign thyroid tumour ctgf expression may play role development malignant tumour thyroid use ultrasensitive thyroglobulin assay reduce not abolish need tsh stimulation patient differentiate thyroid carcinoma measurement serum tg use ultrasensitive assay propose replace tsh stimulate tg measurement follow differentiate thyroid cancer dtc aim study verify possibility use two ultrasensitive tg assay select dtc patient undetectable ng ml basal serum tg time recombinant human tsh rhtsh stimulation accord standard criterium patient consider free disease document disease no evidence disease detectable serum rhtsh stimulate tg biochemical disease serum patient assay two commercial ultrasensitive assay result compare clinical datum basal access e iason tg assay able distinguish patient persistent disease free disease sensitivity specificity positive predictive value ppv negative predictive value npv respectively assay addition neck ultrasound basal tg increase sensitivity npv decrease false negative rate patient detectable basal tg without evidence disease serum tg convert detectable undetectable case yr follow study indicate combination neck ultrasound basal ultrasensitive tg allow identify patient free disease decrease need rhtsh stimulation nearly patient case myasthenia gravis associate thymoma thyroid cancer purpose thyroid cancer frequently occur endocrine malignancy however preoperative diagnosis lesion particular follicular histology difficult consistent numb not otherwise specify follicular nodule surgically resect diagnosis therapeutic purpose study investigate whether lectin relate molecule cd v galectin expression alter deregulate cell growth malignant transformation can potential marker improve diagnostic accuracy conventional cytology material method comparative immuno chemical molecular analysis perform thyroid specimen representative normal benign malignant tissue cytologic sample obtain preoperatively fine needle aspiration biopsy nonselected patient palpable thyroid nodule result normal thyrocytes not express galectin cd v although expression cd v isnegligible thyroiditis molecule variably detect benign malignant proliferative lesion interestingly galectin never express benign lesion invariably detect cancer comparative evaluation cd v galectin expression thyroid malignancy demonstrate molecule coexpressed messenger rna protein level almost lesion conclusion finding suggest cd v galectin can potential marker preoperatively identify malignant transform thyrocytes immunodetection molecule cytologic specimen obtain fine needle aspiration biopsy accurate improve method select molecular basis nodular lesion thyroid gland need surgically resect mortality relate factor radioiodine treat patient background report risk factor death relate good differentiate thyroid cancer vary possibly depend method geographical site datum collection method evaluate variable relate death good differentiate thyroid cancer wdtc population southern thailand retrospectively review medical record treat radioactive iodine division nuclear medicine find subject variable examine include present status subject transfer lose die cause death relate not relate wdtc duration follow since surgery large size tumor available gender histology follicular papillary mix include papillary age surgery site spread treat survival wdtc death utilize kaplan meier cox regression analysis result median follow year year elapse surgery die not know status subject despite attempt contact survival not affect age gender maximum size tumor age surgery significant group old year year survival spread disease affect survival localize aerodigestive tract year survival metastasis associate bone fracture year survival metastasis include asymptomatic bone metastasis exhibit year survival neither lymph node spread elevate tg maximum stimulation predict survival conclusion well predict survival wdtc site spread degree spread specific thyroid cancer iv tsh receptor resum round table discussion thyroid cancer tc good know endocrine neoplasia good common malignant tumor head neck study design assess prognostic meaningful tnfrsf expression tc dependent datum acquire tcga increase knowledge biological pathway involve tc pathogenesis relate tnfrsf information gene expression compare clinical datum identify download tcga gene set enrichment analysis gsea create arrange list gene indicate connection tnfrsf expression study cohort include female male patient scatter plot pair plot show difference tnfrsf expression normal tumor sample p univariate analysis suggest tnfrsf low associate essentially age hr ci uncommon presentation common cancer papillary thyroid cancer paediatric population carcinoma thyroid gland rare paediatric age group age year year old girl present swell midline neck no exposure radiation past ultrasonography fine needle aspiration cytology finding suggestive papillary carcinoma thyroid case report account rarity target therapy thyroid cancer use immunohistochemistry fas apo protein expression investigate thyroid cancer patient thyroid biopsy twenty eight patient benign thyroid disease also examine patient thyroid cancer manifest variable histology cancer include patient follicular carcinoma papillary carcinoma patient medullary carcinoma benign thyroid disease involve nodular goitre patient follicular adenoma patient study aim examine immunohistochemical expression fas protein order determine whether level expression correlate histological diagnosis individual patient fas expression prevalent thyroid carcinoma compare benign tumor p mark increase fas expression find papillary carcinoma compare follicular medullary carcinoma p conclusion fas significantly frequently overexpress thyroid cancer indicate role thyroid tumorigenesis diagnostic performance ata bta tirads sonographic pattern prediction malignancy histologically prove thyroid nodule introduction aim compare malignancy risk stratification histologically prove thyroid nodule use american thyroid association ata management guideline british thyroid association bta guideline management thyroid cancer thyroid image report datum system tirads method thyroid nodule measure cm resect year retrospectively study demographic information good cytology histopathology result collect static ultrasonography us image radiologist report resect nodule review classify base risk classification system result total thyroid nodule patient examine malignant nodule solid vs p hypoechoic vs p irregular margin vs p tall wide morphology vs p microcalcifications vs p disrupt rim calcification vs p associate abnormal cervical lymphadenopathy vs p compare benign nodule guideline diagnostic performance ata sensitivity specificity positive predictive value ppv negative predictive value npv bta sensitivity specificity ppv npv tirads sensitivity specificity ppv npv conclusion sonographic pattern outline three guideline display high sensitivity npv although isolate suspicious us feature not predict malignancy risk consider risk stratify nodule not fit particular sonographic pattern base current guideline thyroid cancer patient sensitive ionise radiation purpose determine ionise radiation sensitivity peripheral blood lymphocyte group differentiate thyroid cancer dtc patient material method total thyroid cancer patient woman man donor woman man include study cytokinesis block micronucleus assay cbmn g peripheral blood lymphocyte carry use cytochalasin b technique four culture establish per donor two irradiate gy c g ray two remain untreated result no significant difference observe frequency binucleated cell micronucleus bnmn patient control spontaneous irradiation frequency nevertheless positive significant correlation find frequency spontaneous irradiation dna damage control patient group conclusion find dtc patient not present particular sensitivity ionise radiation vitro treatment perform g stage cell cycle result not discard hypothesis increase sensitivity stage cell cycle dtc patient occupation risk factor thyroid cancer canadian cancer registry epidemiology research group canadian case control study explore etiology thyroid cancer include occupational exposure analysis job history thyroid cancer patient control reveal statistically significant risk among follow occupation wood process pulp papermaking odd ratio confidence interval ci sale service ci screen benign malignant thyroid nodule physical examination population objective investigate distribution characteristic thyroid nodule thyroid cancer physical examination population tianjin report outcome ultrasonography detection thyroid nodule method enroll physical examination population hospital jan dec study subject thyroid gland lesion screen ultrasound diagnostic technique risk assessment benign malignant thyroid nodule assess ultrasonography thyroid image report datum system ti rad individual follow year result among case patient thyroid nodule case thyroid nodule male female subject low female male case p case thyroid cancer patient detect thyroid cancer rate male female respectively p thyroid nodule increase age thyroid cancer patient mainly concentrate year old group year old group thyroid cancer patient undergo surgical treatment well differentiation thyroid papillary carcinoma case major early stage cancer micro cancer possess relatively low risk recurrence sensitivity specificity accuracy ultrasonography ti rad diagnosis thyroid cancer conclusion detection rate thyroid nodule population close difference sex age ultrasonography ti rad association efficient method detect nodule thyroid change cancer diagnosis case follicular variant papillary thyroid cancer primum non nocere niftp biology thyroid cancer represent spectrum behavior range braf v co test technically feasible conventional thyroid fine needle aspiration fna cytology smear reduce need completion thyroidectomy introduction fine needle aspiration cytology fnac mainstay diagnosis thyroid nodule molecular marker thyroid cancer recently show value improve diagnosis reduce rate unnecessary surgery method technical method present assessment braf v gene mutation thyroid cancer use simple adaptation commercially available kit standard preparation report conventionally stain alcohol fix papanicolaou air dry giemsa stain slide coverslip remove one slide dna extract submit pcr analysis result assessment braf v mutational status feasible small quantity dna require great ng per case single pre stain fna slide use method case examine thus far one thy bethesda class v case suspicious malignancy identify braf v mutation patient multidisciplinary discussion receive total thyroidectomy conclusion base methodology publish result braf mutation believe feasible cost effective uk nhs braf co test thy bethesda class v thyroid fnas additional cost braf test still much little cost submit thy bethesda class v patient partial late completion thyroidectomy evaluation management thyroid nodule child purpose review review focus new information presentation management thyroid nodule child adolescent recent finding palpable thyroid nodule uncommon child many child nodule detect radiologic image evaluate suspect thyroid cancer well follow apparently benign nodule become area great interest american thyroid association recently publish treatment guideline child thyroid nodule cancer much learn since publication summary personal family history ultrasound feature fine needle aspiration cytology use determine risk cancer thyroid nodule manage accord cancer risk serum thyroglobulin management thyroid cancer purpose review article focus role ultrasound fine needle aspiration management benign nodule extent thyroid resection management regional lymph node disease risk stratification stage good differentiate thyroid cancer dtc child recent finding recent guideline american thyroid association focus specifically management thyroid nodule dtc child adolescent mark change previous version extrapolate adult guideline pediatric population dtc child distinct presentation clinical behavior compare adult disease overall excellent outcome pediatric patient lead risk stratification approach management low intermediate high risk disease grouping aim minimize potential morbidity treatment summary review focus pediatric thyroid disease include recent study debate regard management thyroid nodule dtc optimize treatment child adolescent papillary thyroid carcinoma post chernobyl expose region role lymph node dissection central lateral neck compartment lack datum predict lymph node metastasis pediatric thyroid cancer aim study factor affect lymph node metastasis child adolescence papillary thyroid carcinoma region expose radiation evaluate predictive significance factor lateral compartment lymphadenectomy five hundred nine patient papillary thyroid carcinoma undergo total thyroidectomy lymph node resection central lateral compartment neck surgery period belarus recruit factor relate lymph node metastasis study patient patient papillary thyroid carcinoma increase numb cancer positive lymph node central neck compartment associate risk develop lateral nodal disease good bilateral nodal disease futhermore positive lateral compartment nodal metastasis associate age gender patient tumour size minimal extra thyroidal extension solid architectonic extensive desmoplasia carcinoma presence psammoma body extensive involvement thyroid metastatic ratio index reveal examination central cervical chain lymph node presence nodal disease degree lymph node involvement distribution lymph node metastasis significantly increase recurrence rate patient papillary thyroid carcinoma conclude lymph node metastasis young patient papillary thyroid carcinoma post chernobyl expose region common pattern can predict many clinical pathological factor evidence base review treatment follow pediatric patient differentiate thyroid carcinoma childhood onset differentiate thyroid cancer dtc distinct adult onset disease aggressive time initial evaluation high risk category disease recurrence however ultimately little lethal international group outline consensus statement detail follow management guideline adult dtc since disease progression marker significantly different childhood dtc compare adult management protocol may differ unfortunately no consensus regard mean follow time management strategy regard pediatric dtc perform evidence base review dtc child target address follow question appropriate initial treatment goal thyroid hormone replacement management approach follow childhood dtc tumor recurrence persistence assess treat conduct literature search use pubmed cochrane database guideline various international group study pertain pediatric dtc management outcome order answer question suggest pre set algorithm approach management child dtc accord review researcher delve thyroid cancer disparity race age incidence disease continue grow slow rate group nine patient good differentiate thyroid cancer age year treat thyroidectomy subsequent irradiation radioactive iodine dose apply mci no metastasis mci regional distant metastasis group child compare group adult age year observation time year patient alive without recurrence metastasis no complication one patient neck dissection external irradiation local complaint difficulty hormone substitution actin architecture culture human thyroid cancer cell predictor differentiation actin cytoskeleton important cell structure motility disorder actin architecture correlate high metastatic potential melanoma fibrosarcoma colon cancer model thyrotropin know induce growth differentiation culture thyroid cell whereas carcinogenic phorbol ester anaplastic thyroid carcinoma epidemiologic histologic immunohistochemical molecular single institution study anaplastic thyroid carcinoma atc highly aggressive form thyroid cancer single institution thyroid cancer cohort atc identify within last year institution retrospective analysis reveal frequency atc thyroid carcinoma average age diagnosis atc year female male ratio atc present rapidly enlarge neck mass involve predominantly leave thyroid lobe cervical adenopathy present case fifty five percent patient distant metastasis time diagnosis histologically atc closely simulate large variety soft tissue sarcoma osteoclast like giant cell rich tumor squamous cell spindle cell small cell carcinoma anaplastic large cell lymphoma four tumor show heterologous element include rhabdoid chondroid differentiation immunohistochemical study show atcs lose ttf thyroglobulin expression whereas pax expression identify tumor intense extensive nuclear stain p high ki proliferative rate see atcs medullary cancer thyroid gland fluid nodule report case diagnosis medullary thyroid carcinoma often delay rarity ultrasound examination usually show solid nodule rarely cystic nodule four case procalcitonin new biomarker medullary thyroid cancer systematic review medullary thyroid cancer mtc rare aggressive thyroid malignancy body mass index evaluation thyroid cancer risk background obesity link numerous disease include thyroid cancer exact nature relationship especially respect patient thyroid nodule remain unclear objective study evaluate impact body mass index bmi thyroid cancer risk population patient indeterminate cytology fine needle aspiration biopsy fnab method total consecutive patient indeterminate thyroid nodule fnabs undergo total thyroidectomy tertiary care teach hospital review height weight report anesthesia summary record patient malignancy rate calculate underweight normal overweight obese group stratify accord bmi subanalyses accord age sex also perform result risk malignancy tend low obese patient compare patient bmis underweight normal overweight range vs p man bmi classify obese associate significantly low rate malignancy vs p woman old year subgroup high malignancy rate associate obesity vs p conversely man age year woman year bmi obesity range link low incidence malignancy vs p vs p respectively old woman exclude population study rate malignancy obese patient versus nonobese patient p associate reduction risk malignancy per increase unit bmi conclusion patient fnab result indeterminate significance high bmi correlate low rate thyroid malignancy patient except woman age year management hereditary thyroid cancer child hereditary thyroid cancer childhood occur set multiple endocrine neoplasia type b familial medullary thyroid carcinoma fmtc prophylactic thyroidectomy childhood recommend patient find inherit mutation ret protooncogene prevent development medullary thyroid carcinoma report present clinical genetic aspect hereditary thyroid cancer child good surgical recommendation medium term outcome result ultrasound guide laser ablation incidental papillary thyroid microcarcinoma potential therapeutic approach patient surgical risk background incidental papillary thyroid microcarcinoma ptmc frequent clinical problem usually associate favorable outcome long term follow minority case show aggressive behavior either lymph node distant metastasis recently opportunity evaluate efficacy nonsurgical ultrasound us guide percutaneous laser ablation pla local treatment ptmc otherwise inoperable patient patient method neck us examination reveal incidental solitary mm hypoechoic nodule microcalcifications right thyroid lobe patient suffer decompensated live cirrhosis renal failure recent surgery follow external beam radiation therapy breast cancer cytologic diagnosis show papillary thyroid carcinoma patient decline surgery high risk thyroid surgery local anesthesia xylocaine pla perform accord previously report procedure nd yag laser summary procedure good tolerate without side effect patient require no analgesic us guide fine needle aspiration biopsy core needle biopsy perform month pla demonstrate necrotic material inflammatory cell no viable neoplastic cell month us follow examination area necrosis decrease demonstrate mm hypoechoic zone small hyperechoic area due fibrotic change fine needle aspiration biopsy confirm absence malignant cell conclusion laser induce thermal ablation safe effective ablative treatment patient ptmc confine thyroid gland high surgical risk approach consider elderly patient comorbidity may expose patient undue high surgical risk evaluation neck us compute tomography magnetic resonance image positron emission tomography compute tomography rule lymph node involvement metastatic disease thyroid cancer incidence discovery hide iceberg background initial surgical treatment differentiate thyroid cancer dtc residual lymph node metastasis often find time radioactive iodine therapy recurrence dtc due persistent disease not remove initial surgery also not respond treatment study aim determine location reason residual nodal metastasis detect scan single photon emission compute tomography spect ct obtain prior radioiodine therapy follow surgical treatment dtc method retrospective study patient intermediate high risk dtc treat therapy university michigan patient undergo total thyroidectomy without lymph node dissection follow radioiodine therapy pre ablation diagnostic scan spect ct use postoperatively localize nodal metastasis compare cervical lymph node basin dissect time surgery determine reason residual nodal metastasis incomplete nodal dissection versus preoperative unrecognized nodal metastasis result patient study residual nodal metastasis detect scan spect ct follow initial surgery prior therapy among patient residual disease total distinct nodal metastasis relative primary tumor n metastasis ipsilateral n contralateral n non side central neck level vi vii cervical lymph node level vi iii ii great frequency residual metastasis respectively residual metastasis occur incomplete nodal dissection lack preoperative identification combination conclusion residual nodal metastasis follow initial surgical treatment regionally advance differentiate thyroid cancer rather common highly sensitive scan spect ct due unrecognized nodal involvement preoperatively incomplete removal metastatic lymph node compartment orientate nodal dissection surgical management high risk dtc include preoperative image evaluate nodal metastasis central lateral neck compartment orientate nodal dissection involve compartment attention give complete dissection level vi iii ii particularly dissect compartment ipsilateral primary tumor survival patient anaplastic thyroid cancer follow intensity modulate radiotherapy sunitinib case report background anaplastic thyroid cancer poor prognosis especially patient gross residual disease follow resection case report present case patient anaplastic thyroid cancer significant gross residual disease treat intensity modulate radiotherapy concurrent chemotherapy sunitinib complete response remain without evidence disease month diagnosis conclusion chemoradiotherapy important role adjuvant treatment anaplastic thyroid cancer select patient consider gross residual disease present follow resection combine use radiotherapy target biological agent sunitinib may warrant investigation trend incidence mortality thyroid cancer china objective analyze trend incidence mortality thyroid cancer china method datum cancer registry site china collect jionpoint model use obtain crude age specify incidence mortality chinese national world age standardize rate incidence mortality trend result crude incidence thyroid cancer chinese national world age standardize rate respectively crude mortality thyroid cancer chinese national world age standardize rate country thyroid cancer account chinese national world age standardize proportion total cancer incidence mortality thyroid cancer high female male time high urban area rural area incidence thyroid cancer show annually increase mortality increase conclusion incidence mortality thyroid cancer increase rapidly china call control effort disease thyroid nodule indeterminate cytology utility american thyroid association sonographic pattern cancer risk stratification background american thyroid association ata guideline recommend use classification base sonographic pattern set size threshold biopsy pattern associate distinct estimate rate malignancy hypothesize stratify risk malignancy cytologically indeterminate thyroid nodule itns method ultrasound image itns atypia follicular lesion undetermined significance follicular neoplasm histological follow consecutively evaluate october june author academic cancer center independently evaluate three observer classify one five sonographic pattern propose ata nodule sonographic pattern not define classification group non ata pattern category difference clinical histological finding sonographic pattern assess prevalence malignancy odd ratio malignancy calculate sonographic pattern low intermediate pattern collapse analysis result distribution size cytological diagnosis significantly different sonographic pattern p overall rate malignancy rate malignancy low low intermediate high non ata pattern respectively significantly different compare low intermediate suspicion pattern odd ratio malignancy non ata high suspicion pattern p odd ratio non ata pattern high suspicion pattern p result similar cytological category observer separately sonographic pattern associate distinct histopathological profile p conclusion ata sonographic pattern associate distinct clinical feature pathological outcome effectively stratify cancer risk itns thus ata sonographic pattern use not set size threshold biopsy also personalize management biopsy sodium iodide symporter nis molecular physiology preclinical clinical application active iodide transport thyroid extrathyroidal tissue mediate na symporter nis thyroid nis mediate uptake play pivotal role thyroid hormone th biosynthesis ths key embryonic postembryonic development critical cell metabolism stage life molecular characterization nis use radioactive isotope lead significant advance diagnosis treatment thyroid cancer provide molecular basis study aim extend use radioiodide treatment extrathyroidal malignancy review focus recent finding homeostasis transport deficiency cause nis mutation good current knowledge structure function property nis nis regulatory mechanism also discuss employ nis reporter gene use viral vector stem cell image diagnostic therapeutic procedure circular rna circbach play role papillary thyroid carcinoma sponge mir p regulate lmo expression circular rnas circrnas class non code rnas broadly express various biological cell function regulate gene expression structurally stable tissue specific however function human circrnas role circrnas papillary thyroid carcinoma ptc remain determine herein function circrna circbach investigate human ptc cell \\ufeff1 detect expression circbach ptc tissue ptc cell line rt pcr fish use confirm subcellular localization circbach luciferase reporter assay ago rip use confirm relationship circbach mir p ptc cell stably transfect sirna circbach cell proliferation migration invasion detect evaluate effect circbach ptc tumorigenesis assay nude mouse find circbach highly express ptc tissue ptc cell line mechanistically confirm circbach can directly bind mir p relieve suppression target lmo functionally find inhibit circbach expression decrease cell proliferation migration invasion finally impact marital status diagnosis cancer survival patient differentiate thyroid cancer previous study reveal marital status influence prognosis patient various type cancer evaluate influence marriage survival outcome differentiate thyroid cancer dtc surveillance epidemiology end result seer database use compare cancer specific mortality different marital status sex age stage stratification multivariate cox regression model total eligible patient identify widowed group high proportion woman elderly patient year advance stage iii iv tumor p total thyroidectomy tt perform radioisotope therapy rate low marry group marry patient well cancer specific survival css unmarried p analysis show widowed patient always present low css compare group widowed patient significant increase risk css compare marry patient male hazard ratio hr confidence interval ci p female hr ci p young patient hr ci p elderly patient hr ci ci treatment thyroid cancer objective aim evaluate impact minimal extrathyroidal extension mete alone risk recurrence papillary thyroid carcinoma ptc impact factor include multifocality age tumor size stimulate thyroglobulin stg value also assess subject method retrospectively analyze ptc patient medical institution present tumor cm without adverse characteristic mete patient classify accord response initial treatment month surgery propose american thyroid association ata guideline statistical analysis perform use multivariate logistic regression receiver operate characteristic roc curve result multivariate logistic regression analysis mete not impact response initial treatment p similar multifocality age tumor size initial tg value variable associate poor response p odd ratio confidence interval roc analysis reveal tg significant area curve cutoff value stg predictor poor response ng ml sensitivity specificity conclusion low risk ptc present mete aggressive feature initial stg value essential identify patient may poor response initial treatment benefit treatment arch endocrinol metab increase thyroid cancer incidence clinically may difficult differentiate benign branchial cleave cyst bcc malignant bcc papillary carcinoma preoperatively radiological feature review retrospectively benign bcc malignant bcc papillary carcinoma use compute tomography ct magnetic resonance mr image patient mass right upper lateral neck without lesion thyroid gland two patient mass upper medial part bcc ct image one patient show good circumscribe mass upper portion bcc mr image two patient receive bcc removal one patient undergo total thyroidectomy include removal bcc result case papillary carcinoma bcc detect incidentally surgical resection bcc however differentiate benign bcc malignant bcc primary papillary carcinoma carefully review radiologic image surgery methylation status tshr good differentiate thyroid cancer use cytologic material background role methylation status thyroid stimulate hormone receptor gene tshr discrimination benign malignant thyroid nodule already study use paraffin block cell line cytological sample play important role assessment thyroidal nodule investigate potential clinical use tshr methylation status fine needle aspiration specimen report accord bethesda system method sixty nine patient cytological pathological diagnosis nodule select four group compose accord cytological pathological diagnosis benign b papillary thyroid carcinoma ptc atypia unknown significance aus follicular neoplasia fn latter group sub classify benign aus b fn b malignant aus fn accord final pathological diagnosis dnas isolate fine needle aspiration cytology specimen methylation status tshr promotor region investigate use methylation specific polymerase chain reaction result overall tshr methylation present case malignant benign nodule ptc group show high tshr methylation rate follow aus b fn p tshr methylation rate significantly high ptc group compare b p fn b p group not fn p aus p group case papillary thyroid carcinoma lymph node metastasis show tshr methylation positive predictive value negative predictive value sensitivity specificity tshr methylation determination malignancy calculate respectively conclusion eminent ratio tshr methylation initial surgical management thyroid cancer rapid increase rate papillary thyroid cancer likely cause improve surveillance significant trend toward total thyroidectomy low risk differentiate thyroid cancer present unite state paradigm shift treatment macroscopic disease treatment macroscopic microscopic disease increasingly sensitive test compel argument thyroid lobectomy total thyroidectomy low risk thyroid cancer remain relatively small numb death thyroid cancer small numb clinical thyroid cancer huge numb incidental thyroid cancer indicative little understand biology disease clinical medicine await biologic marker refine treatment recommendation solitary brain metastasis thyroid carcinoma study case aim background although systemic metastasis thyroid cancer relatively frequent rarely affect nervous system exceptionally originate good differentiate carcinoma method author describe case solitary brain metastasis thyroid carcinoma good differentiate case anaplastic case result four patient female male f ratio average age yr range average interval diagnosis thyroid tumor appearance metastasis year range year short anaplastic form versus year average survival month range month particular average survival long patient good differentiate carcinoma vs month also not present metastatic site vs month death due systemic progression disease case brain relapse case conclusion surgery radioactive iodine uptake demonstrable radiotherapy main therapy available metastasis thyroid carcinoma however survival patient appear modify type treatment perform obesity thyroid cancer clinical update background last decade significant contribution make knowledge connection thyroid adipose tissue modern society face climb rate obesity metabolic syndrome accumulate evidence association obesity increase cancer risk aim review summarize clinical datum association thyroid cancer tc obesity briefly present plausible hypothesis explain interplay summary perform search pubmed database study publish english march use term thyroid cancer obesity body mass index although inconsistency among clinical study seem overweight obesity relate modestly increase tc risk various factor sex ethnicity body change certain life period example adolescence may influence association obesity tc risk preliminary datum link obesity little favorable clinicopathologic profile tc however validation large multicenter study need precise underlie mechanism not yet elucidate insulin igf axis adipokines leptin adiponectin may implicate link excess weight tc conclusion give rise prevalence tc development obesity epidemic important clarify connection tc good mediate pathway however unless association confirm causation prove screen tc overweight obese subject rapidly increase body general population not seem justify study call thyroid cancer test review study call review thyroid cancer follow practice follow concern unnecessary image test carry primary treatment thyroid nodule detection thyroid cancer although thyroid nodule common cause concern possible malignancy relatively thyroid cancer relatively thyroid cancer lethal consideration justify selective approach recommend surgical excision nodule selection patient base assessment cancer risk factor history physical examination importantly fine needle aspiration biopsy thyroid cytologic examination test case limit serum thyroid stimulate hormone antithyroid antibody thyroid sonogram result evaluation recommendation make either immediate surgery observation approach reduce numb operation benign thyroid nodule avoid excessive diagnostic test epidemiology thyroid carcinoma world thyroid cancer tc incidence france world dramatically increase last two decade temporal geographical incidence trend france world analyse increase incidence tc actual mainly due increase papillary microcarcinomas spread ultrasonographic cytological procedure extensiveness thyroidectomy lead diagnostic advance well preoperative selection patient discovery occult microcarcinomas nevertheless impact risk factor thyroid cancer increase incidence not exclude risk factor analyse especially environmental chemical agent disrupt thyroid function follow differentiate thyroid cancer value fdg sestamibi diagnostic algorithm aim fdg pet mibi scintigraphy spect compare whole body scintigraphy wbs morphologic image follow differentiate thyroid cancer influence therapy plan analyse method consecutive patient papillary follicular variant follicular carcinoma primary status pt fdg pet neck chest familial nonmedullary thyroid cancer review genetic objective thyroid cancer common endocrine malignancy continue increase incidence new case diagnose european union per year although nonmedullary thyroid cancer nmtc mostly sporadic evidence familial form not associate mendelian cancer syndrome e g familial adenomatous polyposis cowden syndrome good document think cause aggressive disease decade ago search genetic susceptibility locus familial nmtc fnmtc begin review detail genetic study conduct thus far search potential gene fnmtc design electronic pubmed search perform english literature genetic fnmtc genetic familial papillary thyroid carcinoma subdivision fnmtc reference select paper review identify study not find original search criterium main outcome six potential region harbor fnmtc gene identify mng q tco p fptc prn q nmtc q ften p p telomere telomerase complex important gene report exclude ret trk meet apc pten tshr conclusion genetic fnmtc excite field medical research potential permit individualize management thyroid cancer study thus far small family group use vary criterium diagnosis fnmtc result contradictory large scale genetic study utilize emerge molecular screen test warrant elucidate underlie genetic basis fnmtc age great year portend wrong prognosis patient papillary thyroid cancer three age category stage background age important prognostic factor papillary thyroid cancer ptc well survival observe patient year age regardless stage although impact increase age ptc relate survival good know previous study focus survival relative age year numb patient enter th decade life increase ptc relate survival demographic become increasingly important survival patient year specifically compare group not previously examine seek determine whether age year adverse prognostic factor disease specific survival recurrence patient ptc method california cancer registry database link inpatient ambulatory patient record office statewide health plan development year papillary thyroid carcinoma arise within follicular adenoma case report ultrasound feature consideration papillary thyroid carcinoma ptc arise within follicular adenoma exceptionally rare histopathological subtype show nuclear feature ptc within benign appear circumscribe follicular adenoma although clinically significant malignant nature ultrasonographic feature not describe previously year old man present heterogeneous isoechoic solid nodule mark hypoechoic solid focus low echoic peripheral rim right thyroid gland ultrasonography color doppler image markedly increase vascularity see hypoechoic solid component ultrasound guide gun biopsy suggest follicular neoplasm evaluation hemithyroidectomy specimen thyroid follicle thin fibrous capsule see favor follicular adenoma tumor cell focal area indicate papillary carcinoma report case ptc arise within follicular adenoma discuss possible consideration thyroid ultrasonographic examination diffuse sclerosing variant major subtype papillary thyroid carcinoma young background pediatric thyroid cancer differ adult thyroid cancer presentation outcome pediatric thyroid cancer high recurrence rate great percentage lymph node pulmonary metastasis clinicopathologic characteristic pediatric thyroid cancer accord histologic subtype not report however study determine histological subtype pediatric thyroid cancer analyze clinicopathologic characteristic method patient thyroid cancer admit severance hospital seoul south korea retrospectively review age year diagnosis see january august result sixty eight patient identify histologic type thyroid carcinoma papillary thyroid carcinoma ptc follicular carcinoma poorly differentiate carcinoma case diffuse sclerosing variant papillary carcinoma dsvpc conventional ptc follicular ptc cribriform morular ptc patient ptc high incidence bilateral thyroid involvement p extrathyroidal extension p lymph node involvement p low recurrence free survival p dsvpc non dsvpc univariate regression analysis reveal extrathyroidal extension p tumor size p positively associate short time recurrence conclusion dsvpc major subtype ptc young high grade thyroid cancer paper analyze datum available literature morphological prognostic feature relatively rare high grade thyroid cancer show difficulty unsolved problem morphological diagnosis possibility current method immunohistochemical molecular genetic study determine malignant potential tumor prognosis pediatric thyroid cancer case year old japanese woman develope thyroid cancer exhibit unusual cribriform structure follow familial adenomatous polyposis gardner syndrome report patient present osteomas pigmented retinal lesion adenoma duodenum papilla vater addition numerous adenomatous polyp colorectum ultrasonography thyroid cancer localise right lobe identify irregular internal echo tumour peripheral hypoechoic zone measure cm diameter histological examination resect tumour show concomitance papillary proliferation cribriform structure follicle vary size feature distinguish sporadic thyroid cancer undetectable rhtsh stimulate tg level month initial treatment thyroid cancer indicate remission objective routine monitor initial treatment differentiate thyroid cancer dtc include periodic cervical ultrasonography us measurement serum thyroglobulin tg thyrotrophin tsh suppression recombinant human tsh rhtsh stimulation aim study evaluate utility repeat rhtsh stimulate tg measurement patient dtc no evidence disease initial rhtsh stimulation test perform year treatment material method retrospective chart review patient dtc repeat rhtsh stimulation test initial undetectable rhtsh stimulate serum tg level result numb rhtsh stimulation test perform individual patient follow period year mean vary two seven biochemical cytological evidence potential persistent recurrent disease base detectable 2 3 rhtsh stimulate tg value us finding observe patient subsequent follow datum reveal five case result 2 stimulation false positive one case false negative combine negative neck us negative predictive value disease free survival \\ufeff1 undetectable rhtsh stimulate tg 2 one conclusion patient dtc intensity follow adjust new risk estimate evolve time \\ufeff1 rhtsh stimulate tg excellent predictor remission independent clinical stage presentation 2 negative rhtsh tg stimulation additionally reassure guide little aggressive follow measurement nonstimulated tg neck us every year papillary carcinoma thyroglossal duct cyst diagnosis fine needle aspiration cytology immunocytochemistry carcinoma associate thyroglossal duct cyst tdc extremely rare occur invariably papillary carcinoma year old man present midline swell upper part neck cystic lesion multiple septae ultrasonogram indicate thyroglossal duct cyst ct scan finding also corroborate ultrasound report fine needle aspiration fna smear show hemosiderin lade cyst macrophage occasional papillary cluster neoplastic cell central psammoma body rare intranuclear cytoplasmic inclusion neoplastic cell reveal positive reaction thyroglobulin galectin cd fna cytodiagnosis thyroglossal duct cyst cytologic feature suggestive papillary carcinoma histopathological diagnosis resect lesion however metastatic papillary thyroid carcinoma lymph node cystic change positive reaction thyroglobulin galectin hbme ck follow histopathology report thyroidectomy perform reveal lymphocytic thyroiditis no evidence papillary carcinoma review paraffin section upper midline neck mass show cavity bind thick fibrocollageneous wall line partly epithelium consistent papillary carcinoma cyst wall show dense lymphomononuclear cell infiltration germinal center formation focus papillary carcinoma cyst wall frequent nuclear groove cerebriform nucleus intranuclear cytoplasmic inclusion review histopathological diagnosis consistent papillary carcinoma thyroglossal duct cyst thus fna cytodiagnosis rare case papillary carcinoma thyroglossal duct cyst lead review change histopathological diagnosis achieve cyto histopathological correlation highly sensitive thyroglobulin assay superior diagnostic sensitivity recurrence differentiate thyroid cancer patient undergo tsh suppression background aim recommend treatment thyroid cancer mm single stage total thyroidectomy sst cancer diagnose diagnostic lobectomy may need completion surgery result two stage thyroidectomy tst notice significant variation number sst tst hospital within cancer network explore reason use prospective database contain case n therefore conduct survey thyroid cytology provision across network method central university hospital large caseload total choose benchmark remain hospital exclude analysis due low thyroid operation number remain compare benchmark use individual chi square test bonferroni correction explore variation expect observe number sst tst analysis variance anova use examine reason observe difference result significant variance sst tst see hospital p three hospital frequency sst statistically similar reference hospital report thyroid cytology case survey period remain low rate sst low perform hospital sst rate p p eight hospital report few cytology case share amongst pathologist per site difference unrelated patient age gender tumour histology stage anova reference hospital specialist cytopathologists conclusion variation thyroid cytology provision may increase tst rate thyroid cytology concentrate high volume centre specialist thyroid cytopathologists nevus ambient ultraviolet radiation thyroid cancer risk french prospective study background incidence rate increase considerably worldwide differentiate thyroid cancer cutaneous melanoma two way association neoplasm describe whether melanoma risk factor associate thyroid cancer risk remain unknown method use cox regression model prospectively analyze relationship self report pigmentary trait baseline residential ultraviolet uv exposure thyroid cancer risk woman e n cohort follow biennial questionnaire assess association pigmentary trait uv exposure personal history benign thyroid disease use logistic regression model statistical test two side result model adjust age thyroid cancer risk factor numb nevus positively associate thyroid cancer risk many vs none hazard ratio hr confidence interval ci ptrend independently residential uv exposure iodine intake risk inversely associate latitude positively associate mean daily uv level baseline hr 4 vs \\ufeff1 quartile latitude spring summer uvb level ci ptrend hr ci ptrend respectively association restrict woman dietary iodine median intake numb nevus uv level also associate personal history dysthyroidism goiter nodule although weakly conclusion result suggest numb nevus residential uv exposure associate risk thyroid cancer benign condition point novel pathway thyroid cancer melanoma etiology warrant replication low dose radioactive iodine ablation sufficient patient small papillary thyroid cancer minor extrathyroidal extension central lymph node metastasis n purpose aim study evaluate effectiveness low dose radioactive iodine rai ablation patient small papillary thyroid cancer ptc exhibit microscopic extrathyroidal extension mete central lymph node cln metastasis method among patient undergo rai ablation march february small ptcs cm good mete cln metastasis n enroll response ablation long term outcome assess compare accord administer rai dose factor associate unsuccessful ablation also determine result total patient include study eighty eight patient treat mbq low dose group mbq high dose group rai no significant difference response ablation p long term outcome p group among patient enroll not achieve successful ablation long term follow logistic regression find high ratio metastatic node significant factor predict unsuccessful ablation conclusion low dose rai ablation not produce significantly different response long term outcome patient small ptcs exhibit mete cln metastasis finding suggest low dose ablation may sufficient specific group intermediate risk patient although careful selection require patient high ratio metastatic node clinical pathologic feature sporadic papillary thyroid carcinoma register year child adolescent belarus background systematic analysis clinical pathologic pattern childhood sporadic thyroid carcinoma belarus absence chernobyl radioactive iodine factor never perform aim study establish essential feature sporadic papillary thyroid carcinoma ptc belarusian child adolescent relationship tumor pathology extrathyroidal extension ete lymph node metastasis method retrospective population base study assessment histological sample case thyroid cancer belarusian child adolescent year old register year sporadic ptc note child not expose chernobyl radiation release none case thyroid follicular thyroid cancer result incidence rate ptc per person median age diagnosis year fourfold predominance diagnosis female patient relapse detect case median follow year median tumor size mm three percent case ptc multifocal growth classical variant ptc register patient thyroid cancer follicular variant ptc note case percent rare type ptc tall cell diffuse sclerosing equal solid ptcs respectively adolescent pure papillary carcinoma often compare child represent tumor mix papillary follicular pattern frequently p two third patient ptc regional lymph node metastasis ete establish patient ete can assess morphology multivariate analysis show lymphatic invasion strong independent factor associate ete p lymph node metastasis p conclusion sporadic thyroid cancer child belarus represent high prevalence ptc absence follicular thyroid cancer sporadic case ptc belarus characterize small tumor size small numb case multifocal growth equal numb rare type solid ptcs relatively high prevalence pure papillary variant ptc adolescent low frequency early relapse high frequency ete lymph node metastasis detect strong morphologic factor associate lymphatic invasion expression clinical significance mechanism slit papillary thyroid cancer thyroid cancer common endocrine malignancy last decade see excite progress understand thyroid cancer molecular pathogenesis several major signal pathway relate molecular derangement elucidate represent novel diagnostic prognostic molecular marker thyroid cancer base molecular biology thyroid cancer series therapeutic target develope provide unprecedented opportunity thus histological characterization subgroup patient correct molecular characterization patient think key aspect future clinical management patient present study identify slit prognostic marker thyroid cancer oncogenesis recurrence mechanistically slit regulate warburg effect thyroid cancer cell regulation hif hif transcriptional activity take together present datum uncover slit novel predictive marker thyroid cancer mechanism study indicate slit regulate warburg effect additional study function slit thyroid cancer require provide new insight potential mechanism oncogenesis recurrence potential thyroid cancer simultaneous hodgkin lymphoma brafv e positive papillary thyroid carcinoma case report rationale papillary thyroid carcinoma ptc common endocrine malignancy however simultaneous occurrence ptc hodgkin lymphoma hl rarely report patient concern present case simultaneous cancer stem cell hypothesis thyroid cancer increase evidence many type cancer contain stem cell cancer stem cell characterize self renew capacity differentiation ability cancer can regard abnormal organ initiate cancer stem cell cancer stem cell may play decisive role tumor initiation progression dysregulation stem cell self renewal likely requirement development cancer stem cell seem likely transform target cell carcinogenesis cancer stem cell model great implication understand oncogenesis treatment cancer abundant evidence suggest parallel solid tumor cancer stem cell also exist thyroid cancer although characteristic largely unknown date present review discuss potential trait cancer stem cell thyroid cancer transformation target stem cell thyroid gland relate factor skip metastasis neck lymph node papillary thyroid carcinoma objective investigate correlation skip metastasis neck lymph node clinicopathological feature papillary thyroid carcinoma method totally papillary thyroid carcinoma patient lateral lymph node metastasis receive surgical procedure department thyroid surgery \\ufeff1 hospital jilin university january june analyze retrospectively male female patient age year mean age year patient skip metastasis correlation skip metastasis neck lymph node clinicopathological feature analyze test multivariate logistic regression test result rate skip metastasis patient summarize distribution lateral lymph node patient skip metastasis case metastasize single level meanwhile two level three level strong correlation age tumor location skip metastasis find use test value respectively p value age year ci p microcarcinoma ci p tumor locate upper thyroid ci p risk factor skip metastasis multivariable logistic regression analysis conclusion age year old microcarcinoma tumor locate upper part thyroid gland likely present skip metastasis skip metastasis often involve lateral multi level therefore confront patient one risk factor occurrence skip metastasis awared lateral lymph node large abnormally accordingly may appropriate extend indication fine needle aspiration lateral lymph node order prevent miss diagnosis problem associate general anesthesia patient thyroid cancer group patient thyroid cancer operate institute oncology gliwice describe risk anaesthesia intraoperative complication result obtain depend preoperative preparation especially adequate treatment endocrine disorder thyroid parathyroid adrenal gland necessary estimate presence multiendocrine disorder medullary thyroid carcinoma especially pheochromocytoma high mortality non alfa blocker prepare patient thyroid cancer year material background papillary thyroid cancer ptc incidence increase dramatically child chernobyl accident provide unique opportunity investigate molecular feature radiation induce thyroid cancer contrast previous study include age relate confound factor investigate mrna expression ptc normal contralateral tissue patient expose non expose chernobyl fallout use age ethnicity match non irradiate cohort method forty five patient analyse full genome mrna microarray twenty two patient expose chernobyl fallout other age match resident region ukraine bear march not expose result gene expression signature probe correspond gene permit differentiation normal tissue patient expose not expose radiation identify difference confirm quantitative rt pcr many deregulate pathway expose normal tissue relate cell proliferation conclusion result suggest high proliferation rate normal thyroid can relate radiation induce cancer either predisposition consequence radiation signature allow identification radiation induce thyroid cancer iodine refractory differentiate thyroid cancer ominous diagnosis potential bright future child thyroid carcinoma present regional lymph node metastasis lead symptom cold nodule typical scintigraphic find thyroid cancer infant papillary carcinoma predominate histologic type good prognosis radical removal thyroid lobe primary lesion subtotal resection opposite lobe combine selective neck dissection necessary seem improve result postoperative scintigraphic examination detect remnant malignant tissue require iodine treatment finally tsh suppressive hormone administer case survival rate child blockade programme death ligand pd l potential therapy anaplastic thyroid cancer purpose anaplastic thyroid carcinoma atc rare highly aggressive form thyroid cancer tc characterize aggressive behavior poor prognosis result patient death within year standard treatment chemo radiotherapy good tyrosine kinase inhibitor ineffective atc treatment cancer immunotherapy one promise research area oncology pd pd l axis particular interest light promise datum show restoration host immunity tumor prospect information physician irradiation relate thyroid cancer national cancer institute report present experience thyroid cancer patient year age old patient age compare series describe thyroid cancer patient age find thyroid carcinoma age group present advance clinical stage behave aggressively high death rate finding attribute mainly high incidence undifferentiated carcinoma aggressive course differentiate type carcinoma old age group suspect thyroid nodule manage initial radical treatment carcinoma diagnose early patient survive long clinical importance bilateral disease patient papillary thyroid cancer cancer relate factor not include papillary thyroid cancer ptc prognostic score system bilaterality may seem bilaterality consider management ptc clinical importance debate controversy exist extent surgery ptc not find affect survival low risk individual despite potential ptc bilaterality seek determine ptc bilaterality cancer prognosticator base upon association know clinical pathological ptc prognosticators macis score article discuss finding potential clinical implication cytologic diagnosis thyroid cancer purpose review purpose review present overview regard rename encapsulate follicular variant papillary thyroid cancer noninvasive follicular thyroid neoplasm papillary like nuclear feature recent finding recent retrospective study show excellent clinical outcome noninvasive encapsulate follicular variant papillary thyroid cancer diagnosis base thorough examination tumor tissue capsule exclude vascular capsular invasion give extremely low malignant potential entity term cancer eliminate name tumor require little aggressive follow treatment summary low risk tumor previously treat conservatively prior rename however elimination term cancer name may decrease psychological social consequence diagnosis evaluation circulate thyroid specific transcript marker thyroid cancer relapse circulate thyroid specific transcript suggest potential molecular marker residual recurrent thyroid cancer assess accuracy recombinant human tsh assist radioactive iodine remnant ablation achieve short term clinical recurrence rate similar traditional thyroid hormone withdrawal recent study confirm radioactive iodine therapy recombinant human tsh rhtsh stimulation effectively ablate normal thyroid remnant however no publish study determine effectiveness rhtsh preparation important endpoint disease recurrence method disease recurrence retrospectively assess median radioiodine remnant ablation rra consecutive thyroid cancer patient papillary female old mean sd median dose mbq mci result similar rate clinically evident disease recurrence rhtsh vs thyroid hormone withdrawal thw p not statistically significant residual thyroid bed uptake without evidence persistent disease rhtsh vs thw p not statistically significant see patient undergo rhtsh assist rra patient prepare rra thw definition no clinical evidence disease include suppress thyroglobulin level little ng ml stimulate thyroglobulin level little ng ml rhtsh assist rra associate significantly high rate no clinical evidence disease rhtsh vs thw p significantly low rate persistent disease rhtsh vs thw p rra thw patient select rhtsh assist rra old vs p receive slightly high administer activity median mbq mci vs mbq mci p not differ respect sex histology disease stage mean time recurrence mo rhtsh vs mo thw conclusion rhtsh assist rra associate rate clinically evident disease recurrence persistent uptake thyroid bed similar traditional thw perspective amp activate kinase ampk signal pathway thyroid cancer approximately non medullary thyroid malignancy originate follicular cell classify papillary follicular good differentiate thyroid carcinoma show overall favourable prognosis however recurrence persistence disease occur case associate presence utility quantitative contrast enhance ultrasound prediction extracapsular extension papillary thyroid carcinoma aim study find accurate method detection extracapsular extension ece papillary thyroid carcinoma ptc total patient ptc nodule retrospectively enroll contrast enhance ultrasound ceus characteristic evaluate diagnostic efficacy quantitative ceus tumor size analyze qualitative ceus feature not differ significantly ece non ece group p quantitative ceus parameter exception peak intensity tumor size find differ significantly ece non ece group p multivariate stepwise logistic regression analysis demonstrate time peak one half tph tumor size wash slope wis significantly different parameter ece non ece group p p p respectively sensitivity specificity diagnosis ece tph respectively wis respectively tumor size respectively quantitative ceus analysis tumor size essential prediction ece ptc particular tph good diagnostic value detect ece study provide important insight prediction ece ptc increase prevalence chronic lymphocytic thyroiditis papillary microcarcinoma although incidence malignancy decrease recent year not case papillary thyroid microcarcinoma ptmc whose incidence increase worldwide ptmc find incidentally histological examination specimen surgery benign thyroid disease hashimoto thyroiditis whose incidence also increase coexist one three ptmc patient three different mechanism propose clarify association chronic lymphocytic thyroiditis ptmc namely tumor development growth tsh stimulation ii expression certain proto oncogene iii chemokine molecule produce lymphocytic infiltrate whether hashimoto thyroiditis protect lymph node metastasis debate overall autommune thyroiditis seem contribute favorable prognosis ptmc major limitation study far perform include retrospective design ii limit statistical power iii high risk selection bias iv predominant asian ethnicity patient full genetic profile disease identification environmental factor capable trigger good good power prospective study different ethnical group may help understand causal association frequency continue raise thyroid mass addition history give case consultant ask information regard family history thyroid cancer exposure irradiation fna order time dr fredrickson no history irradiation dr clark repeatedly mass cystic dr harvey concur thyroid suppression fna thyroid scan support benign diagnosis fna report follicular neoplasm consultant state pathologist narrow histology couple cold nodule thyroid scan lobectomy order would proceed lobectomy rely freeze section go mass malignant freeze section completion total thyroidectomy order freeze section report papillary follicular carcinoma agree total thyroidectomy order management lymph node vary removal ipsilateral lymph node dr clark bilateral paratracheal lymph node dissection dr fredrickson sample adjacent lymph node include mediastinum dr harvey neck dissection order lymph node positive tumor two expert drs clark harvey never comfortable lose parathyroid gland one find autotransplanted sternocleidomastoid muscle dr clark brachioradialis dr harvey every attempt make identify preserve parathyroid gland another expert believe one parathyroid gland probably enough sustain normal hormone level dr fredrickson abstract truncate word mix medullary papillary thyroid carcinoma stepwise diagnosis breast thyroid cancer two malignancy high incidence woman cancer often occur metachronously woman thyroid cancer increase risk subsequent breast cancer woman breast cancer increase incidence late development thyroid cancer suggest common etiology bidirectional relationship report worldwide however underlie reason co occurrence unknown review summarize current epidemiologic evidence putative mechanism metachronous synchronous cancer key potential causative factor chemotherapy radiotherapy primary tumor genetic variant link two disease hormonal signal thyroid gland estrogen lifestyle environmental factor critical need additional epidemiologic study focus gender regional incidence together molecular investigation common tumorigenic pathway endocrine cancer understand putative mechanism aid diagnosis clinical management disease long term recurrence small papillary thyroid cancer risk factor korean multicenter study context small papillary thyroid cancer ptc generally excellent prognosis however long term recurrence not uncommon sometimes lead morbidity mortality objective identify high risk factor long term recurrence patient small ptc stratify pathologic characteristic design set patient conduct nationwide retrospective multicenter study patient ptc size cm high volume hospital korea main outcome measure maximally select method use find well cutoff point tumor size numb metastatic lymph node lns ratio metastatic examine lns lnr predict recurrence kaplan meier analysis cox proportional hazard regression model use analyze recurrence risk factor result optimal tumor size cutoff cm year recurrence rate tumor size cm cm vs respectively metastatic lns provide optimal estimate recurrence year recurrence rate vs respectively lnr optimal cutoff point predict risk recurrence year recurrence rate lnrs vs respectively ln metastasis lobectomy tumor size cm bilateral tumor independent risk factor recurrence conclusion long term recurrence increase patient undergo lobectomy tumor size cm metastatic lns bilateral tumor patient high risk feature total thyroidectomy can consider avoid reoperation primary hyperparathyroidism nonmedullary thyroid cancer patient surgically prove primary hyperparathyroidism mayo clinic percent associate nonmedullary thyroid carcinoma history radiation exposure head neck obtain patient question thyroid disease consist grade papillary adenocarcinoma case pure follicular adenocarcinoma case parathyroid disease include single adenoma case parathyroid hyperplasia patient adenoma follow none patient evidence metastatic thyroid carcinoma ten patient receive calcium vitamin supplementation protracted hypocalcemia presumably due increase insult parathyroids combine bilateral thyroidectomy parathyroidectomy consecutive thyroidectomy along parathyroid autotransplantation indicate provide definitive treatment thyroid cancer time minimize risk postoperative hypoparathyroidism noninvasive follicular thyroid neoplasm papillary like nuclear feature review pathologist rise incidence papillary thyroid carcinoma link part inclusion noninvasive follicular variant papillary thyroid carcinoma despite designation carcinoma noninvasive follicular variant papillary thyroid carcinoma appear exceptionally indolent often treat current treatment practice additionally criterium diagnosis historically subjective challenge recently international multidisciplinary collaborative group perform clinicopathologic survey case extend follow conclude base outcome datum revision nomenclature warrant propose noninvasive follicular thyroid neoplasm papillary like nuclear feature niftp monograph synopsis guide pathologist niftp focus histologic feature include inclusion exclusion criterium use define niftp good gross guideline report practice potential diagnostic limitation subdivision correlate risk recurrence papillary thyroid cancer background base ajcc 7 tnm classification intraglandular tumor subdivide mm b mm difference prognosis remain controversial present study aim determine clinicopathological feature outcome b patient method retrospective study patient include b patient undergo surgery ptc conduct patient preoperative operative diagnosis ptc total thyroidectomy tt prophylactic macroscopically n therapeutic evident n lymph node dissection lnd perform patient tt partial thyroidectomy without lnd mean follow time year median year range year result tt perform patient include lnd patient n single lobectomy isthmectomy multifocality bilaterality numb tumor sum large size focus vascular invasion patient lnd ln metastasis significantly frequent b patient patient lnd ln metastasis n include b patient p ln metastasis diagnose prophylactic lnd b patient p recurrence frequent b n patient n p multivariate analysis independent prognostic factor recurrence group numb tumor sum large size focus patient lnd ln metastasis extranodal extension n x patient recurrence rate significantly high b group vs respectively p although rate similar n patient b patient p year disease free survival rate b patient respectively p conclusion ptc patient b poor clinicopathological feature increase risk recurrence serum thyroglobulin concentration whole body radioiodine scan follow differentiate thyroid cancer thyroid ablation measurement serum thyroglobulin tg concentration whole body radioiodine scan perform simultaneously follow patient differentiate thyroid cancer undergo thyroid ablation operation radioiodine almost patient serum tg undetectable normal scan concentration exceed ng ml invariably associate residual metastatic tumour uptake scan observation detectable value ng ml patient whose scan show subclinical sub radiological tumour uptake seven patient normal scan sensitivity serum tg tumour marker compare favourably whole body scan scan unnecessary serum tg undetectable patient detectable serum tg concentration particularly ng ml scan important assess localise tumour uptake iodine advise treatmet iodine association cancer tumor like disease thyroid gland inhabitant kiev kiev region clinico morphological aspect background papillary thyroid cancer ptc excellent prognosis current treatment method however rate locoregional recurrence initial surgical management remain significant study evaluate effect reoperative neck dissection locoregional recurrence ptc initial total thyroidectomy radioiodine therapy incidence cervical recurrence postoperative serum thyroglobulin tg level method retrospective cohort study conduct single academic medical center patient recurrent persistent ptc isolate neck previous total thyroidectomy without lymph node dissection adjuvant therapy treat reoperative lymph node dissection outcome include operative complication pathologic finding effect surgery tg level rate recurrent disease analyze result total patient reoperative neck dissection recurrent cervical ptc complication rate seventy two percent patient clinically free detectable disease patient recurrent persistent newly metastatic disease detect follow period patient significant decrease tg level median reduction preoperative level however patient undetectable stimulate tg ng ml follow period month conclusion reoperative treatment recurrent persistent ptc perform low complication rate tg level greatly decrease patient however achieve undetectable stimulate tg papillary carcinoma thyroglossal duct cyst report two case aim present two case papillary carcinoma thyroglossal duct cyst tdc report management patient method two patient year old woman year old man operate department digestive metabolic surgery jean verdier hospital result diagnosis papillary carcinoma establish pathological examination carry thyroglossal duct cyst complete surgical excision total thyroidectomy follow treatment radioactive iodine substitutive hormonal therapy carry 2 time one two patient patient total thyroidectomy follow substitute hormonal therapy achieve evolution favorable follow four year \\ufeff1 patient two year 2 one discussion total thyroidectomy complete excision cyst currently recommend treatment papillary carcinoma tdc show latent thyroid cancer can develop even year initial excision thyroglossal cyst treatment curative case conclusion current treatment papillary carcinoma thyroglossal duct cyst good codify allow excellent prognostic influence calcitonin assay definition biochemical cure patient medullary thyroid carcinoma aim calcitonin hct important diagnostic parameter medullary thyroid carcinoma mtc determine variability reference range several currently available immunometric assay biochemically cure mtc patient patient method compare six assay nichols icma biomerica iema immulite siemens calcitonin irma magnum medipan selco irma medipan calcitonin irma medgenix subgroup patient differentiate thyroid cancer dtc total thyroidectomy model curatively treat mtc patient addition hct measure pentagastrin stimulation dtc patient patient mtc result basal hct concentration detection limit respective assay thyroidectomized dtc patient nichols icma n immulite n biomerica iema n irma magnum n however basal hct mostly within reference range selco irma n medgenix irma n dtc patient mtc patient pentagastrin stimulate hct detection limit nichols icma immulite four mtc patient elevate stimulate hct develope recurrence follow conclusion assay high monomer specificity nichols icma biomerica iema immulite lesser degree irma magnum biochemical cure define basal stimulate calcitonin level detection limit assay low monomer specificity selco irma irma medgenix calcitonin level reference range patient without thyroid disease consistent biochemical cure spect image body outline use convenient lightweight source order make body outline clearly spect image devise simple line source holder objective lightweight line source reduce radiation exposure staff make system readily available technique apply evaluate localize lesion patient radioiodine treatment thyroid cancer spect image body outline find effective percent case compare planar image clinically result significantly help discrimination cervical lymph node metastasis thyroid bed mediastinal lymph node metastasis bone metastasis case multiple lung metastasis demonstrate diffuse accumulation lung field spect image body outline not provide increase sensitivity compare planar image method easy perform consider useful localization abnormal accumulation relative body outline anthropometric factor physical activity risk thyroid cancer postmenopausal woman purpose investigate association anthropometric factor physical activity risk thyroid cancer large prospective study method examine association risk incident thyroid cancer cohort postmenopausal woman enroll woman health initiative cox proportional hazard model use estimate hazard ratio hr confidence interval ci factor interest risk thyroid cancer n two major subtype papillary n follicular thyroid cancer n result adjustment covariate measure height baseline positively associate thyroid cancer overall hr high vs low quartile ci p trend papillary carcinoma hr ci p trend respectively molecular genetic thyroid cancer implication diagnosis treatment prognosis thyroid cancer common malignant tumor endocrine system account approximately newly diagnose cancer case frequent type thyroid malignancy papillary carcinoma constitute approximately case papillary carcinoma frequently genetic alteration lead activation mapk signal pathway include ret ptc rearrangement point mutation braf ras gene mutation gene find papillary carcinoma rarely overlap tumor frequent genetic alteration follicular carcinoma 2 common type thyroid malignancy include ras mutation pax ppar gamma rearrangement ret point mutation crucial development medullary thyroid carcinoma many mutation particularly lead activation mapk pathway actively explore therapeutic target thyroid cancer detection genetic alteration use molecular technique important preoperative ultrasound thyroid parathyroid gland controversy diagnosis thyroid cancer purpose determine role adjuvant external beam radiotherapy ebrt management patient good differentiate thyroid cancer invade trachea method material thyroid cancer patient find tracheal invasion receive shave excision tracheal cartilage among patient no postoperative residuum patient microscopic residuum patient macroscopic residuum patient divide two group accord treatment modality without ebrt control group n ebrt group n result locoregional recurrence rate ebrt patient much low control patient control group vs ebrt group p year local progression free survival rate ebrt group significantly well control group ebrt group vs control group log rank p use adjuvant ebrt conservative surgery independent prognostic factor univariate multivariate analysis conclusion external beam radiotherapy find effective particularly patient thyroid cancer invade trachea microscopic gross residuum conservative surgery image guide radiation therapy use surgical clip localization colonic metastasis thyroid cancer year old man history papillary thyroid cancer ptc present metastatic disease leave colon form x cm bleed ulcerate mass radiopaque surgical clip use fiducial marker localize gross tumor volume gtv good correspond clinical target volume ctv plan target volume ptv daily cone beam compute tomography cbct image guidance utilize verify tumor position inter intrafraction movement tumor mass assess gastrointestinal bleed control use palliative image guide radiation therapy igrt elective central node dissection comparison open minimally invasive video assist approach objective hypothesis compare outcome concomitant primary thyroidectomy elective central neck dissection cnd standard open versus minimally invasive video assist miva approach study design case series chart review single institution tertiary referral center method current procedural terminology code use identify patient undergo cnd february june therapeutic cnd revision case exclude miva approach perform patient low risk thyroid carcinoma ct cn primary outcome include nodal yield complication secondary outcome include recurrence result eligible patient open miva miva group likely female vs p group similar age vs mean year p percentage unilateral dissection vs p miva group often pt vs p pathological node positivity overall not significantly different group vs p nodal yield similar group vs p transient recurrent laryngeal nerve paralysis rate similar vs p transient hypoparathyroidism postanesthesia care unit parathyroid hormone pg ml low miva group not statistically significant vs p no patient experience permanent hypoparathyroidism develope clinically detectable structural recurrence rate biochemical response similar thyroglobulin ng dl vs p conclusion concomitant miva thyroidectomy elective cnd appear safe effective alternative open approach low risk thyroid carcinoma similar nodal yield complication recurrence level evidence laryngoscope noninvasive encapsulate follicular variant papillary thyroid cancer not time name change introduction thyroid cancer unusually common iceland histological classification tnm stage alter somewhat last decade aim study investigate epidemiology thyroid cancer iceland half century identify factor affect survival material method information thyroid cancer diagnose iceland obtain icelandic cancer registry tumour diagnose post mortem exclude date diagnosis sex age diagnosis register histopathology material evaluate reclassify tumour tnm stage determine effect register parameter prognosis determine uni multivariate analysis result thyroid cancer case study woman mean age year woman year man oscillation incidence mark study period although not increase last decade study overall proportion papillary carcinoma around proportion tumour neither numb change significantly last year study overall disease specific year survival increase significantly study period multivariate analysis patient age year diagnosis tumour type tnm stage independent significant prognostic variable conclusion thyroid cancer incidence iceland no long different many neighbour country sex not independent prognostic parameter year diagnosis independent prognostic factor may indicate efficient treatment late year postoperative unstimulated thyroglobulin decision use radioactive iodine patient low intermediate risk papillary thyroid carcinoma radioiodine uptake thyroid remnant metastasis postthyroidectomy thyroid cancer increase withdraw thyroid hormone raise tsh level minimal withdrawal time maximal uptake unknown therefore perform study patient week week withdrawal examine cervical pulmonary uptake whole body scan h whole body retention h radioiodine study physiological nonthyroidal activity see scan cervical uptake low study remain study thyroid activity scan high cervical uptake week decrease week little week value trend see whole body retention study uptake increase week compare week change small reflect whole body retention subject study include metastatic disease individual uptake whole body retention similar week mean uptake retention also not differ despite significantly high p little tsh value week definite area localization radioactivity see scan week see week therefore radioiodine uptake scan therapy perform week withdrawal patient minimally hypothyroid serum tsh also measure identify rare individual not respond brief withdrawal choice substantiation optimal strategy surgical treatment thyroid cancer patient female eight male thyroid cancer develope age register observe radium center finsen institute papillary adenocarcinoma diagnose case mix papillary follicular adenocarcinoma six case three patient medullary carcinoma no patient previously receive cervical irradiation admission lung metastasis evident two case patient undergo surgical treatment case consist total thyroidectomy nine also lymph node dissection external irradiation give patient radioiodine treatment perform five patient local distant relapse thyroid carcinoma occur five case three patient medullary carcinoma two papillary mix adenocarcinoma three patient medullary carcinoma die disease two recurrence recover surgery external irradiation radioiodine treatment currently patient alive without evidence disease period follow range year role lateral neck ultrasound detect single multiple lymph node papillary thyroid cancer background lateral neck dissection lnd papillary thyroid cancer ptc transition isolate lymphadenectomy berry pick base clinical examination multicompartment lymphadenectomy aim assess ultrasound us predictor solitary sln multiple lymph node mln metastasis method demographics us finding extent lnd pathology collect patient ptc undergo lnd us sensitivity specificity calculate accuracy correlate us finding patient characteristic result total patient undergo lnds us show sln patient mlns patient sensitivity positive predictive value accuracy us detect sln us detect mlns us accuracy mlns increase node size increase mm mm mm p conclusion us limit accuracy detection sln metastasis lateral neck care take consider focus compartment dissection pediatric thyroid cancer update seer database objective update medical literature regard incidence disease specific survival treatment modality utilize pediatric patient diagnose thyroid carcinoma study design cross sectional analysis national database study set seer database method national cancer institute surveillance epidemiology end result seer database query case pediatric thyroid cancer year patient age group histological subtype demographic datum overall incidence rate disease specific survival surgery surgery radiation therapy fifteen year disease specific survival curve generate treatment modality compare assess statistical difference yearly interval result total pediatric patient identify average age adjust rate malignancy determine per patient incidence pediatric thyroid cancer approximately compare female male respectively papillary subtype common n follow follicular variant subtype n follicular subtype n medullary subtype n pediatric patient reach fifteen nineteen year age incidence papillary follicular variant subtype increase analysis medullary thyroid cancer datum reveal incidence high zero four age group decline late year pediatric patient present metastatic medullary thyroid carcinoma maintain significantly poor fifteen year disease specific survival compare histologic subtype p intervention surgery radiation therapy provide significant benefit across histologic subtype evaluate disease specific survival fifteen year past initial diagnosis p conclusion pediatric thyroid carcinoma remain uncommon diagnosis despite annual increase incidence approximately one percent since development seer database overall pediatric thyroid carcinoma demonstrate excellent prognosis identify early appropriate management available caucasian female patient high incidence carcinoma diagnosis compare male medullary histologic subtype especially metastatic initial diagnosis demonstrate statistically poor outcome compare subtype homogeneity parameter contrast enhance ultrasound image improve classification abnormal cervical lymph node thyroidectomy patient papillary thyroid carcinoma objective explore conventional contrast enhance ultrasound ceus feature cervical lymph node metastasis clnm papillary thyroid carcinoma ptc patient postoperatively analyze pathological basis material method conventional ceus perform abnormal cervical lymph node aclns ptc patient receive thyroidectomy fine needle aspiration fna take confirm pathological result multivariate analysis perform correlate sonographic feature clnm equation clnm establish result fifty four lymph node confirm metastasis ptc fna intensity peak time homogeneity color flow pattern cystic change microcalcification echogenicity significantly associate clnm multivariate analysis show three strong feature homogeneity intensity peak cystic change calcification significantly associate evidence clnm equation establish follow significant predictive factor p exp cystic calcification cdfi pattern homogeneity intensity peak time conclusion depiction heterogeneous hyperenhancement cervical lymph node within ceus study cystic change microcalcification conventional ultrasound identify predictive metastatic lymph node invasion equation accurate predict clnm compare single b mode ultrasound ceus feature chemotherapy thyroid cancer risk report childhood cancer survivor study background although ionize radiation establish environmental risk factor thyroid cancer effect chemotherapy drug thyroid cancer risk remain unclear evaluate chemotherapy relate risk thyroid cancer childhood cancer survivor possible joint effect chemotherapy radiotherapy method study include five year survivor childhood cancer diagnose chemotherapy radiotherapy information obtain medical record radiation dose estimate thyroid gland cumulative incidence relative risk calculate life table method poisson regression chemotherapy relate risk evaluate separately category radiation dose result histologically confirm thyroid cancer occur patient thirty year \\ufeff1 childhood cancer treatment cumulative incidence thyroid cancer ci female male among patient thyroid radiation dose gy little treatment alkylating agent associate significant fold increase risk thyroid cancer ci p chemotherapy risk decrease radiation dose increase significant decrease patient treat alkylating agent p trend no chemotherapy relate risk evident thyroid radiation dose gy conclusion treatment alkylating agent increase thyroid cancer risk radiation dose range little gy cell spare likely predominate cell kill impact study add evidence chemotherapy agent specific increase risk thyroid cancer date mainly think relate prior radiotherapy radioiodine treatment metastatic thyroid cancer recent technologic advance engender alternative innovative approach thyroid surgery aim reduce cosmetic sequela minimally invasive technique via small anterior cervical incision hide natural skin crease remote access approach eliminate anterior neck incision entirely emerge viable option patient regard cosmesis priority safe application technique benign malignant thyroid disease evaluate clinical relevance psammoma body hashimoto thyroiditis papillary thyroid carcinoma large case control study study aim investigate impact psammoma body pb papillary thyroid carcinoma ptc evaluate association among pb hashimoto thyroiditis ht clinicopathologic characteristic ptc patient conduct retrospective case control study involve ptc patient undergo total thyroidectomy lobectomy lymph node dissection psammoma body observe ptc patient ultrasonographic us calcification p multifocality tumor p lymph node metastasis lnm p ht p primary tumor regional lymph node n distant metastasis stage p significantly relate presence pb presence pb significantly associate us microcalcification p subgroup ht compare patient without pb patient pb exhibit high frequency central lnm vs p us microcalcification vs p good small tumor vs cm p subgroup without ht patient pb display high incidence lateral lnm vs p us microcalcification vs p extrathyroidal extension vs p good large tumor vs cm p without pb moreover subgroup pb ptc patient ht show high lnm vs p low frequency extrathyroidal extension vs p without ht psammoma body useful predictor aggressive tumor behavior ptc patient ht pb show aggressive behavior non ht pb ptc patient molecular biology thyroid cancer initiation thyroid cancer stand among solid tumour many tumour initiate genetic event identify mutation lead constitutive activation map kinase effector tyrosine receptor kinase ret intracellular signal effector ras braf essential pathogenesis papillary thyroid carcinoma ptc similarly increase evidence demonstrate mutation lead activation phosphatidylinositol kinase pi k akt effector pten pi kca essential pathogenesis follicular thyroid carcinoma ftc besides strong relationship histological phenotype pathway predominantly activate nature genetic event seem determine biological behaviour tumour ultimate clinical outcome patient review summarise discuss main genetic event relate thyroid cancer initiation contribution genomics convenience use new molecular classification thyroid cancer complementary clinicopathological classification may help us predict faithfully clinical outcome patient thyroid cancer select appropriately candidate target therapy role differentially express gene long non code rnas papillary thyroid carcinoma diagnosis progression prognosis currently combination ultrasonography fine needle aspiration biopsy fnab not discriminate benign malignant tumor thyroid case main issue assess patient thyroid nodule distinguish thyroid cancer benign nodule reduce diagnostic surgery identify potential molecular biomarker patient indeterminate fnab explore differentially express gene deg differentially express long non code rnas delncrnas tcga database papillary thyroid carcinoma ptc tissue normal thyroid gland tissue deseq r furthermore deg verify gene expression profile gse ten top deg delncrnas identify candidate biomarker diagnosis lasso little absolute shrinkage selection operator logistic regression analysis perform improve diagnostic accuracy besides partial molecular biomarker top deg delncrnas closely relate tumor stage lymph node metastasis n metastasis pathological stage ptc can reflect behavior tumor progression accord multivariate cox analysis combination two deg mettl b kctd two delncrnas linc linc can predict outcome exact way conclusion top deg delncrnas can raise diagnosis ptc indeterminate fnab specimen can function molecule biomarker tumor progression prognosis thyrotropic thyroid hormone thyroid cancer patient non radical surgery background thyroid nodule common among adult accurate diagnosis critical management decision ultrasound fine needle aspiration cytology common method evaluate nodule not practical screen large number patient cost time consideration objective aim study isolate autoantibody tumour antigen wd repeat domain wdr evaluate diagnostic sensitivity specificity thyroid neoplasm patient method investigate serological biomarker patient thyroid carcinoma poor prognosis use serological analysis recombinant cdna expression clone serex strategy isolate wdr specific autoantibody serum patient undifferentiated thyroid carcinoma utc examine use indirect elisa titre anti wdr antibody awa study patient utc papillary thyroid carcinoma ptc benign thyroid nodule btn autoimmune thyroid disease aitd good control n result wdr ubiquitously express various type thyroid tissue however titre awa utc ptc significantly high btn aitd n p no significant correlation observe thyroid function serum thyroglobulin tumour diameter cut value estimate use roc differentiate malignancy other sensitivity specificity auc p conclusion anti wdr antibody can novel approach serological screen ptc utc can efficient inexpensive biomarker radioactive iodine thyroid cancer ii therapeutic importance apropos case treat examine feasibility sentinel lymph node biopsy papillary thyroid cancer dye injection method isosulfan blue dye inject around tumor patient intra operatively radioisotope ri colloid injection method mtc tin colloid inject patient day preoperatively lymph node map detection sentinel node perform thyroidectomy central modify lateral neck lymph node dissection dissect node examine postoperatively hematoxylineosin stain determine whether not metastasis present dye injection method sentinel lymph node identify patient lymph node metastasis find patient sentinel lymph node papillary cancer metastasis patient false negative case sensitivity accuracy sentinel lymph node biopsy ri method detection rate sensitivity accuracy sentinel lymph node biopsy respectively preliminary study indicate sentinel lymph node biopsy feasible patient thyroid cancer may helpful avoid unnecessary lymph node dissection improve quality life patient thyroid cancer report case thyroid cancer intratracheal growth patient operate upon tracheal tumor include case thyroid cancer intratracheal growth operative finding show case small intraluminal cancer mass large extraluminal cancer mass fix together intratracheal growth secondary extratracheal thyroid cancer evidence cancer aberrant intratracheal thyroid tissue not find differential diagnosis tracheal tumor thyroid cancer intratracheal growth difficult palliative resection post operative irradiation use two case generally poor condition patient multimetastatic medullary thyroid carcinoma breast pet ct mammographic us mr finding background invasive thyroid cancer rare extent surgery controversial purpose study present evaluate therapeutic prognostic factor method conduct retrospective single center study differentiate thyroid carcinoma invade larynx trachea esophagus treat surgically macroscopic complete resection result forty six patient average age year average follow year include free margin r obtain microscopic residual tumor present surgery r ten year actuarial local control r r p five year local control low recurrent tumor versus inaugurally invasive disease vs log rank p five year year actuarial disease specific survival dss correlate preoperative distant metastasis respectively vs p conclusion trend toward low local control observe r versus r morbidity surgery weigh prognosis metastasis present extensive lymph node metastasis find f fdg pet ct patient diffuse sclerosing variant papillary thyroid carcinoma background interference antithyroglobulin antibody tgab serum thyroglobulin tg occur even detectable tgab concentration reference limit borderline tgab thus borderline tgab consider tgab positivity patient thyroid cancer prospective study evaluate patient papillary thyroid carcinoma undetectable tg normal neck ultrasonography us total thyroidectomy ablation compare tumor persistence recurrence long term tg tgab behavior borderline versus undetectable tgab method total patient evaluate divide two group group undetectable tgab n group b borderline tgab n result group b similar term patient tumor characteristic time follow range month follow patient group group b develope recurrence p group recurrence occur patient continue undetectable tgab patient progress borderline tgab group b recurrence detect patient progress undetectable tgab still borderline tgab develope elevate tgab presence tg level ng ml recurrence detect patient undetectable tgab borderline tgab elevate tgab result post therapy whole body scan rxwbs patient tg ng ml normal us time ablation also analyze low risk patient none patient borderline tgab none undetectable tgab exhibit ectopic uptake rxwbs intermediate risk patient lymph node metastasis detect rxwbs borderline tgab undetectable tgab conclusion result suggest among low intermediate risk patient undetectable tg normal us thyroidectomy borderline tgab no great risk tumor persistence recurrence undetectable tgab undetectable tg level persist recurrence suspect case tgab elevation reference limit metastatic lymph node ratio stratify risk mortality medullary thyroid cancer patient population base analysis medullary thyroid cancer mtc propensity cervical lymph node metastasis lnm recent study show numb involve lymph node lns metastatic lymph node ratio mlnr confer prognostic information study determine predictive value mlnr cancer specific survival css seer surveillance epidemiology end result register mtc patient treat thyroidectomy lymphadenectomy investigate cutoff point mlnr stratify risk mortality provide evidence selection appropriate treatment strategy x tile program determine optimal cut value mlnr term css mtc patient accord multivariate cox regression analysis mlnr significant independent prognostic factor css hazard ratio confidence interval p mlnr great prognostic impact css female non hispanic white n b patient lymph node yield lny influence effect mlnr css lny result mlnr high hr css mlnr conclusion high mlnrs predict poor survival mtc patient eradication involve node ensure accurate stage maximize ability mlnr predict prognosis change thyroid cancer incidence post american thyroid association guideline background thyroid cancer incidence rate triple unite state since especially among woman small size tumor trend attribute increase detection due availability ultrasound prognostic factor patient good differentiate thyroid cancer present pulmonary metastasis purpose survival outcome patient present good differentiate thyroid cancer pulmonary metastasis variable aim study evaluate prognostic factor outcome patient population method prospective registry database search identify patient present pulmonary metastasis good differentiate thyroid cancer patient undergo total thyroidectomy postoperative therapy cox proportional hazard model perform evaluate prognostic factor survival outcome result forty patient identify good differentiate thyroid cancer involve thyroid metastatic cervical lymph node lung initial diagnosis median follow year alive last follow cox proportional hazard model evaluate age diagnosis gender primary tumor size vascular invasion cause specific progression free survival age diagnosis significant independent prognostic factor p year cause specific survival patient year compare year p correspond year progression free survival p conclusion patient year age present pulmonary metastasis good differentiate thyroid cancer excellent prognosis old patient poor survival outcome postoperative therapy recommend patient hyperthyroidism coexist thyroid cancer report case nowadays commonly occur differentiate thyroid cancer many country microcarcinoma patient old year incidentally find neck ultrasound view low morbidity mortality crucial point manage microcarcinomas recently publish european american guideline aim minimize diagnostic therapeutic procedure without affect diagnostic accuracy therapeutic effectiveness keep mind deal patient normal life expectancy guarantee excellent quality life present review summarize clinical pathological feature thyroid microcarcinoma include definition prevalence presentation pathology genetic clinical impact try derive rationale therapeutic diagnostic intervention radioactive iodine rai treatment near magic bullet always precede risk assessment especially pediatric patient radioactive iodine treatment frequently well approach optimize dosimetric risk consideration progress nuclear oncology radionuclide use cancer patient produce cyclotron nuclear reactor thyroid cancer patient lung bone metastasis successfully treat year diagnosis cancer patient mtc superior many mtc label compound develope diagnosis bone metastasis live kidney disease recently pet study use f label fdg widely perform excellent result report many cancer patient lung colorectal malignant lymphoma malignant melanoma radionuclide beta emitter suitable therapy various cancer label anti cd monoclonal antibody mibg use therapy lymphoma pheochromocytoma respectively palliation metastatic bone pain sr sm promise radionuclide administer outpatient basis image guide ablation patient thyroid tumor insulin stimulate proliferation thyroid cell culture presence insulin resistance ir associate large thyroid gland volume increase prevalence thyroid nodule aim study investigate presence possible association ir thyroid cancer forty one patient diffuse thyroid cancer group match age gender patient nodular goiter group group compare term frequency ir estimate homeostasis model assessment good parameter metabolic syndrome mets fourteen patient group mets twelve patient group ir compare group mean homa ir score group respectively thirty two patient group body mass index bmi compare patient group difference group regard homa ir frequency ir bmi parameter mets statistically insignificant p subgroup analysis base tumor size not reveal significant difference patient microcarcinoma mm macrocarcinoma mm term study parameter p neither mets ir significant risk factor thyroid cancer follow logistic regression analysis p ir not prevalent patient thyroid cancer pathologic mechanism may prominent thyroid carcinogenesis surgery thyroid cancer recommendation versus reality objective evaluate risk factor influence recurrence papillary thyroid carcinoma method meta analysis use medline pubmed embase cnki include cohort study report risk factor influence recurrence initial operation ptc february software revman use meta analysis result thirteen study total patient include meta analysis variable gender extrathyroid extension lnm tumor size distance metastasis thyroid surgery type give not significantly correlate recurrence overall recurrence similar group year year multifolicality solitary however stratify participant study location ie asian include china korea japan western country include america france italy australia statistically significant summary odd ratio age find western country none asian conclusion risk factor influence recurrence include male extrathyroid extension lnm tumor size cm distance metastasis subtotal thyroidectomy however selection operation mode base not recurrence comprehensive consideration clinical feature association screen thyroid cancer epidemic south korea evidence nationwide study objective investigate whether screen thyroid cancer lead current epidemic south korea design review medical record nationally representative sample patient diagnosis thyroid cancer set sample case randomly select south korea nationwide cancer registry use systematic sample method stratification region participant patient thyroid cancer include main outcome measure primary outcome age standardise incidence thyroid cancer change incidence accord method use detect tumour screen detection versus clinical detection versus unspecified result incidence thyroid cancer increase fold confidence interval fold fold confidence interval per population per population increase per population tumour little mm detect mainly screen total increase localise regional tumour accord surveillance epidemiology end result seer summary stage case clinically detect increase incidence per population period tumour little mm conclusion current epidemic thyroid cancer south korea due increase detection small tumour likely result overdetection concerted effort need national level reduce unnecessary thyroid ultrasound examination asymptomatic general population target therapy refractory thyroid cancer current achievement limitation thyroid cancer refractory conventional treatment lack effective treatment target therapy emerge therapeutic strategy cancer base preliminary promise result tyrosine kinase inhibitor target specific oncogenic pathway involve thyroid cancer progression aspecific mechanism neoangiogenesis generally good tolerate adverse event low moderate severity class drug test alone combination tyrosine kinase inhibitor far result limit aim article describe benefit limitation innovative drug currently investigation patient refractory thyroid cancer incidence rate thyroid cancer histological type japan metastasis differentiate thyroid cancer may show different uptake pattern fluorine fluorodeoxyglucose nai fdg positron emission tomography pet iodine whole body scintigraphy wbs magnetic resonance image perform unselected patient spiral compute tomography ct lung patient thirty eight patient present papillary carcinoma patient follicular carcinoma five patient variant follicular carcinoma primary tumour stage pt pt pt pt pt case detection metastasis fdg pet find sensitivity wbs sensitivity two method combine sensitivity fdg pet limit patient elevate thyroglobulin tg level negative wbs sensitivity algorithm patient lymph node metastasis seven present fdg uptake no iodine uptake four 2 fdg hot spot appear lymph node metastasis normal size five seven patient undergo surgery none eight patient pulmonary metastasis small cm exhibit fdg uptake five iodine uptake positive result spiral ct conclusion fdg pet not substitute wbs tg level elevate wbs negative fdg pet use detect lymph node metastasis complement anatomical image spiral ct lung useful exclude pulmonary metastasis plan dissection iodine negative lymph node metastasis management thyroid nodule thyroid nodule common several article suggest thyroid nodule detect ultrasonography us one six male one female japan thyroid cancer exist among nodule distinction benign malignant nodule not always easy japan thyroid association jta currently prepare guideline management thyroid nodule article describe treat thyroid nodule accord guideline progress ultrasonography fine needle aspiration cytology fna critical evaluate nodule every nodule examine us since safe relatively cheap japan provide lot information characteristic nodule several finding suggest benign malignancy know regard fna classification bethesda system report thyroid cytopathology publish year ago expect become prevail world currently classification 6 version use japan jta guideline adopt modify classification indeterminate divide two category indeterminate consider follicular tumor indeterminate b consider follicular tumor fna not recommend former subgroup fna possibility lead correct fna diagnosis latter subgroup article discuss several issue regard papillary thyroid cancer follicular thyroid cancer also brief metastasis thyroid cancer primary lung cancer present case year old woman whose thyroid cancer metastasize lesion primary lung cancer ten year total thyroidectomy thyroid cancer chest radiograph medical check demonstrate three nodular lesion bilateral lung field segmental resection leave partial resection right leave perform remove lesion histologically small nodule right diagnose metastatic tumor thyroid good differentiate adenocarcinoma respectively leave lesion cm diameter also diagnose good differentiate adenocarcinoma noguchi type c however small metastatic focus papillary adenocarcinoma identify within lesion reveal cancer cancer metastasis metastasis cancer another primary cancer rare event discuss interest phenomenon cancer cancer metastasis review literature role radiotherapy management elevate calcitonin surgery medullary thyroid cancer among patient medullary thyroid cancer mtc treat royal marsden hospital persistently elevate calcitonin level initial surgery absence clinically radiologically demonstrable residual disease treat radiotherapy advance local disease presentation result normalization calcitonin patient although remain free clinical recurrence surveillance alone use remain patient remain free overt disease local relapse rate significantly low radiotherapy vs no significant difference year survival two group vs view favorable long term survival patient elevate calcitonin observation not recommend routine use radiotherapy however appear role present advance disease reduce incidence loco regional relapse significance thyroglobulin antibody papillary thyroid cancer clt chronic lymphocytic thyroiditis ptc papillary thyroid cancer tgab thyroglobulin antibody genomic medicine thyroid cancer report case year old man follicular carcinoma thyroid complain worsen dyspnea successfully treat external radiation therapy total dose give gy fraction case suggest external radiation therapy effective management differentiate thyroid cancer critical stenosis trachea inoperable difficult treat radioiodine thyroid cancer reveal suppressive hot nodule report case year old woman euthyroidism present thyroid cancer locate within hot nodule nodule partially extinctive triiodothyronine test show incomplete suppression fine needle cytology show no malignant cell systematic lobectomy perform diagnosis cancer make pathology rare situation not mean non toxic hot nodule must remove surgery decide extemporaneous histological examination mandatory besides case provide additional argument favour surgery treatment toxic adenoma effect short term hypothyroidism lipid transfer high density lipoprotein parameter relate lipoprotein metabolism patient submit thyroidectomy thyroid cancer sigal et al thyroid background thyroid cancer common endocrine malignancy differentiate thyroid cancer dtc comprise thyroid cancer case dtc curable use surgery radioactive iodine rai ablation remain thyroid remnant prognosis dire treatment option limit dtc become rai refractory rai r standard cytotoxic chemotherapy limit efficacy make enrollment clinical trial novel target therapy prefer treatment approach thus conduct comprehensive systematic review clinical trial scientific literature focus efficacy safety economics identify potential treatment option currently evaluate treatment rai r dtc method embase com include medline medline process nonindexed citation cochrane library clinicaltrials gov relevant recent conference proceeding search use predefine search criterium important inclusion criterium include english language randomize control study interventional single arm study study drug therapy search result screen utilize discretion multiple researcher key datum abstract result forty five unique trial full text conference abstract clinicaltrials gov entry include clinical review no study meet criterium inclusion economic review identify among trial result available phase ii one randomize commonly study drug tyrosine kinase inhibitor tkis drug include celecoxib doxorubicin interferon alpha b rosiglitazone selumetinib azd thalidomide vegf trap vorinostat overall efficacy safety profile specific treatment regimen objective response rate orr range gefitinib rosiglitazone vegf trap vorinostat lenvatinib tki conclusion limit clinical research no economic research conduct rai r dtc certain treatment notably tkis show promise phase ii trial two phase iii randomize placebo control trial ongoing new research economic humanistic burden rai r dtc must pair clinical evidence currently development examine exist burden future promise treat patient rai r dtc diagnosis treatment thyroid cancer papillary thyroid carcinoma ptc common form thyroid cancer account great case surgical resection without postoperative radioiodine therapy remain standard care patient ptc prognosis generally excellent appropriate treatment despite significant number patient not respond maximal surgical medical therapy ultimately die disease mortality reflect incomplete understand oncogenic mechanism initiate drive promote ptc nonetheless significant insight pathologic subcellular event underlie ptc discover last decade remain area significant research interest chromosomal rearrangement result expression fusion protein involve rearrange transfection ret proto oncogene \\ufeff1 oncogenic event identify ptc member fusion protein family ret ptc family appear play oncogenic role approximately ptcs herein author review current understand clinicopathologic role ret ptc fusion protein ptc development progression molecular mechanism ret ptcs exert oncogenic effect thyroid epithelium role positron emission tomography scan patient radioactive iodine scan negative recurrent differentiate thyroid cancer elevate thyroglobulin tg level total thyroidectomy differentiate thyroid cancer often associate disease recurrence whole body scan wbs cross sectional image commonly use localize occult metastasis patient localize disease wbs negative cross section image equivocal remain challenge medical record patient thyroid cancer undergo positive positron emission tomography pet scan wbs negativetg elevation presence anti tg antibody identify chart review retrospective fashion treat total thyroidectomy ablation past compute tomography magnetic resonance image ultrasound study reveal suspicious lesion eight patient patient undergo resection pet positive lesion resection positive thyroid cancer region predict positive pet scan nine patient elevate preoperative tg level experience reduction tg level resection pet scan accurately predict presence recurrent thyroid cancer wbs negative pet scan consider follow wbs negative patient thyroid cancer suspect recurrent disease author reply prophylactic central neck dissection papillary thyroid cancer br j surg incidence good differentiate thyroid cancer rise follicular cancer represent lesion vast majority thyroid nodule follicular origin benign fine needle aspiration not provide cytologic evidence capsular vascular invasion therefore patient undergo surgical excision freeze section not recommend intraoperative evaluation follicular neoplasia patient deem follicular cancer require thyroid cancer incidence among chernobyl emergency worker follow period vast amount research article devote increase childhood thyroid cancer incidence contaminate radionuclide territory belarus russia ukraine affect chernobyl accident publish recent year however amount research study thyroid cancer incidence among chernobyl emergency worker liquidator quite scanty article result study thyroid cancer incidence cohort chernobyl liquidator person reside administrative region russia north west volgo vyatsky central chernozemny povolzhsky north caucasus urals describe discuss period eighty seven case thyroid cancer detect cohort statistically significant excess incidence among liquidator baseline incidence sir ci among man russia find high thyroid cancer incidence sir register among liquidator involve mitigation work april july time no statistically significant relationship incidence rate external radiation dose err ci detect management thyroid disorder pregnancy recommendation make simple review cover current american thyroid association recommendation diagnosis management thyroid disease pregnancy postpartum period list recommendation reader friendly way facilitate rational therapy thyroid disorder relation obstetric health primary care level clinical molecular feature papillary thyroid cancer adolescent young adult background age disparity thyroid cancer incidence outcome among adolescent young adult ayas thyroid cancer report study author compare molecular clinical feature papillary thyroid cancer ptc ayas feature among patient age group method one thousand eleven patient undergo initial treatment ptc university california san francisco patient subdivide age group age year aya group age year demographic clinical survival datum cohort also compare datum national cancer instsitute surveillance epidemiology end result seer program subset study cohort primary tumor analyze genome wide expression analysis genotype common somatic mutation pathway specific gene expression array age group result percentage woman lymph node metastasis rate significantly high aya group aya group rate distant metastasis low disease free survival median overall survival significantly high aya group well survival aya patient also apparent national seer datum unsupervised cluster analysis gene expression datum reveal no distinct cluster age ptc sample frequency type somatic mutation primary tumor not differ significantly age group aya group vs group age year six gene extracellular matrix protein ecm v erb erythroblastic leukemia viral oncogene homolog erbb urinary plasminogen activator upa phosphofructo kinase fructose biphosphatase pfkfb meis homeobox meis carbonic anhydrase ii ca significant differential expression age group conclusion extent disease presentation survival patient ptc differ ayas old patient current result indicate difference may cause several candidate gene gene express differentially may play important role tumor cell biology however no distinct gene expression profile exist patient ptc distinguish ayas patient age year body mass index incidence thyroid cancer korea korean cancer prevention study ii purpose prevalence thyroid cancer obesity increase worldwide however association remain controversial study perform asia study evaluate correlation incidence thyroid cancer body mass index bmi korea method multi center prospective cohort study korean cancer prevention study ii total individual include newly develope thyroid cancer patient enroll subject divide four group bmi person year incidence rate hazard ratio hr calculate use cox proportional hazard model result increase trend hr thyroid cancer man woman young year age observe bmi increase p trend group however woman old year age no association thyroid cancer incidence bmi conclusion finding suggest positive association thyroid cancer incidence high bmi man woman year old base result suggest obese man woman year old well consider high possibility thyroid cancer development effort need control weight gain ginsenoside improve papillary thyroid cancer cell malignancy partially upregulating connexin connexin cx consider suppressor many tumor ginsenoside rg traditional chinese herb widely acknowledge due anti tumor characteristic however limit study focus role rg papillary thyroid cancer ptc cell current study find expression cx thyroid cancer tissue thyroid cancer cell line significantly low normal thyroid epithelial tissue cell line overexpression cx reduce thyroid cancer cell proliferation migration invasion furthermore find rg significantly enhance expression cx moreover proliferation migration ihh bcpap cell significantly reduce rg treatment contrast silence cx enhance expression ki proliferate cell nuclear antigen pcna meanwhile treatment rg significantly decrease protein level ki pcna effect can abolish transfection si cx summary provide novel evidence expression cx decrease thyroid cancer cell rg treatment can significantly enhance expression cx thereby suppress thyroid cancer cell proliferation migration proteomics thyroid tumor research background recent year omics technology pave novel way broad scale identification molecular signature signal pathway specific tumorigenesis relate high hope discovery biomarker facilitate diagnosis prognosis cancer good option pathway target tumor treatment among different omics method potential proteomics begin emerge accord current literature proteome date feasible tool reflect tumor biology objective review discuss application proteomics field thyroid tumor research context \\ufeff1 provide overview different method protein expression profile discuss specific requirement challenge thyroid proteomics furthermore summarize result publish proteomics study human thyroid tumor finally explore perspective thyroid proteomics combine mrna expression profile traditional biochemical method increasingly contribute improve understand thyroid tumorigenesis may future open novel avenue thyroid cancer therapy diagnosis treatment primary ectopic thyroid carcinoma report case literature review objective discuss clinical feature primary ectopic thyroid carcinoma method clinical datum three case diagnose primary ectopic thyroid carcinoma department since analyze ret respectively relate literature review result three patient young female cervical lump surgery pathology result confirm diagnosis ectopic thyroid papillary carcinoma case follow till no relapse sign occur conclusion ectopic thyroid tissue result developmental defect early stage thyroid gland embryogenesis cancerization treatment ectopic thyroid carcinoma also controversial report case primary ectopic thyroid papillary carcinoma remove surgery take thyroxin orally surgery great prognosis metastasis papillary thyroid carcinoma thoracic spine introduction papillary thyroid carcinoma ptc common form follow result treatment thyroid cancer paper summarize experience application chromothyrolymphography patient thyroid cancer rationale indirect chromothyrolymphography technique procedure evaluate result discuss respect determine extent organ save surgery thyroid regional lymphatic good differentiate cancer procedure not sophisticate involve low incidence specific complication relapse good differentiate thyroid carcinoma concomitant hashimoto thyroiditis present little aggressive clinical stage low recurrence papillary thyroid carcinoma ptc follicular thyroid carcinoma ftc common differentiate thyroid cancer previous study report hashimoto thyroiditis ht concomitant ptc unusual improve prognosis compare classical ptc previous study address ftc concomitant ht study retrospectively analyze datum one institution compare clinical presentation result treatment ptc ftc without ht addition study compare presentation long term follow prognosis classical ptc ftc conduct total ptc patient ftc patient undergo thyroidectomy without lymph node dissection follow chang gung medical center linkou taiwan thyroid carcinoma pathologically classify accord world health organization criterium histological pattern ptc categorize classical ptc ptc ht follicular thyroid carcinoma patient categorize ftc ftc ht dataset contain total ptc case categorize classical ptc case ptc ht case ftc eight case ftc ht analysis classification malignant tumor tnm stage reveal high percentage classical ptc stage iv ht group vs mean tumor size classical ptc large ht group although ftc case present distant metastasis no case ftc ht present distant metastasis cancer specific mortality high classical ptc group ptc ht ftc without ht assign recurrent status six die thyroid cancer no cancer mortality recurrence ht ftc ptc ftc ht present well clinical stage well prognosis therapeutic modality conclusion ptc ftc ht little aggressive clinical presentation well prognosis cervical thyroid remnant consistent papillary carcinoma incidental find patient benign total thyroidectomy ten year prior background differential diagnosis cervical lesion correspond papillary thyroid carcinoma ptc benign total thyroidectomy real challenge method cervical thyroid remnant compatible papillary carcinoma incidentally find ten year total thyroidectomy non functional multinodular goitre histological analysis fine needle puncture aspiration fnpa highly suggestive ptc surgical excision cervical lesion perform specimen study demonstrate classic variant ptc contact peripheral margin apply ablative treatment radioactive iodine postoperatively result patient not present sign recurrence follow small thyroid remnant benign thyroidectomy often leave behind although risk malignancy exceptional conclusion important individualize therapeutic approach face rare entity decide treat patient remove lesion follow ablation therapy successful result ptc papillary thyroid carcinoma fnpa fine needle puncture aspiration total circulate cell free mirna plasma predictive biomarker thyroid disease background thyroid cancer common endocrine cancer great progress make resolve molecular mechanism recent year molecular change observe thyroid cancer use biomarker diagnostic prognostic therapeutic purpose micrornas mirnas important component biological metabolic pathway developmental stage signal transduction cell maintenance differentiation hence malfunction expose human malignancy mirna expression show dysregulated different tumor type like thyroid cancer may cause tumor initiation progression previous study cancer study mirna detect tissue study perform study focus thyroid disease bening nodule hashimoto disease may cause thyroid cancer carry mirna test blood sample take arm thyroid patient material method present study conduct blood sample thyroid patient patient study consist patient thyroiditis patient diagnose benign thyroid nodule patient thyroid cancer control group patient include plasma sample analyze total mirna level determine result find ccf mirna amount benign patient significantly low control similarly mirna amount control significantly high thyroiditis p malign group mirna p although present study low numb patient plasma sample can use source circulate mirnas addition total mirna thyroid disease can use biomarker different type thyroid disease can suggest future study specific mirnas bodily fluid may show specific property use biomarker thyroid disease molecular biology follicular thyroid carcinoma ii clinical application great advance molecular medicine last year give us attractive vision new possibility diagnosis therapeutics thyroid cancer help us understand biological behaviour clinical application grow understand gene alteration involve thyroidal oncogenesis become reality knowledge may contribute great diagnostic accuracy help us characterise malignant benign cell predict tumour outcome state origin likewise may useful know response conventional therapy future implication pharmacogenetics addition molecular medicine application ought consider determine prognosis spontaneous familiar carcinoma information significantly improve current clinical pathologic prognostic method value detection serum thyroglobin scintigraphy follow differentiate thyroid cancer objective objective work know sensitivity serum thyroglobulin scintigraphy detection thyroid remnant metastasis evaluate predictive value serum thyroglobulin follow differentiate thyroid cancer patient method carry retrospective study patient differentiate thyroid cancer detection serum thyroglobulin level scintigraphy clinical status hypothyroidism perform thyroidectomy six nine month late reject patient present high serum level thyroglobulin incomplete follow result result show good correlation parameter sensitivity tg scan respectively superior procedure diagnosis osseous lung metastasis sensitivity scan tg little detection thyroid remnant regional lymphatic node positive negative value tg respectively total false negative result conclusion consider study believe technique complementary low sensitivity serum tg detection thyroid remnant regional lymphatic involvement negative predictive value not permit accomplish follow differentiate thyroid cancer patient consider exclusively result tumoral marker screen early detection radiation associate thyroid cancer pilot study approximately israeli child receive scalp irradiation treatment tinea capitis ringworm scalp evaluate necessity feasibility early screen individual thyroid cancer small pilot program undertake examination consist thorough palpation thyroid gland surround area mtc thyroid scan thyroid function test perform individual palpation suggest nodular abnormality multidisciplinary committee make recommendation surgery total person screen nodular abnormality thyroid detect person nine display symptomatology report knowledge thyroid condition despite three not receive treatment leave subject new case previously untreated patient need follow care altogether nine person recommend surgery one refuse eight excise lesion benign four colloid nodule four adenoma screen program feasible fact no cancer detect suggest population expose low dose radiation thyroid screen may not justify large scale tumour thrombus follicular thyroid cancer detect f fdg pet ct background fine needle cytology fnc thyroid nodule not always diagnostic fncs undeterminated malignancy belong cytological class follicular neoplasm suspicious follicular neoplasm lesion fn group case malignant appropriate surgical management still controversial issue address reliable predictive criterium malignancy also evaluate method retrospectively evaluate patient surgically treat fn diagnosis tertiary care referral center patient affect bilateral thyroid disease cytological diagnosis fn high risk clinical feature familiarity thyroid cancer present total thyroidectomy tt perform conversely hemithyroidectomy ht prefer nodule single age year freeze section examination not use cancer diagnose definitive pathology ht specimen remnant thyroid lobe remove histological feature surgical complication long term outcome remnant lobe report clinical feature predictivity also evaluate result tt perform pt ht carry case overall malignancy rate mr pt respectively pt follow ht pt follow tt statistically significant difference similarly rate transient definitive hypoparathyroidism mean hospital stay follow tt high ht statistically significant age year female gender frequently associate malignancy rate complication follow 2 surgery comparable primary ht ht group incidence unexpected contralateral papillary thyroid cancer ptc month mean follow completion surgery benign pathology carry case conclusion datum show histology follow cytological fn diagnosis malignant low percentage case follow tt mr high ht observe even clinical feature cancer associate malignancy not reliably predict surgery thus solitary low risk lesion ht still standard care low complication rate make ht safe procedure case multiglandular disease tt may recommend investigation warrant achieve well preoperative diagnostic accuracy order reduce amount surgical operation diagnostic aim discussion thyroid cancer common endocrine malignancy increase progressively largely result increase incidence small papillary thyroid cancer majority little cm increase almost fold yr study time thyroid cancer find affect woman often man ratio almost moreover papillary thyroid cancer find common form differentiate thyroid cancer among woman childbearing age either pregnant early postpartum period thyroid cancer diagnose although prevalence thyroid cancer pregnant woman remain high \\ufeff1 identify delivery nonetheless management thyroid cancer pregnancy pose serious diagnostic therapeutic challenge patient fetus thyroid gland may secrete thyroid hormone usual early pregnancy may not cause problem also may responsible high rate differentiate thyroid cancer pregnancy concern therapy thyroid cancer period include time surgery use levothyroxine assessment follow gestation extent surgery affect survival papillary thyroid cancer background extent surgery papillary thyroid cancer ptc remain controversial consensus guideline recommend total thyroidectomy ptc cm however no study support recommendation base survival advantage objective study examine whether extent surgery affect outcome ptc determine whether size threshold can identify total thyroidectomy associate improve outcome method national cancer datum base patient undergo surgery ptc survival estimate kaplan meier method compare use log rank test cox proportional hazard model stratify tumor size use assess impact surgical extent outcome identify tumor size threshold total thyroidectomy associate improvement recurrence long term survival rate result patient undergo total thyroidectomy undergo lobectomy ptc cm extent surgery not impact recurrence survival p p tumor cm lobectomy result high risk recurrence death p p minimize influence large tumor cm lesion examine separately lobectomy result high risk recurrence death p p conclusion result study demonstrate total thyroidectomy result low recurrence rate improve survival ptc cm compare lobectomy \\ufeff1 study demonstrate total thyroidectomy ptc cm improve outcome combine effect glutathione transferase polymorphism thyroid cancer risk since exposure ionize radiation risk factor thyroid cancer may produce genotoxins potentially eliminate glutathione transferase conduct case control study evaluate role gstm gstt null genotype gstp polymorphism thyroid cancer frequency gstp ile ile gstm gstt null genotype increase cancer patient compare control population consider genotype represent thyroid cancer patient potential risk genotype carry odd ratio analysis consider presence none one two three risk genotype result obtain show presence three potentially risk allele gstm null gstt null gstp ile ile lead significant increase case irrespective type tumor papillary not follicular tumor presence gstp ile ile lead significant late age tumor onset compare gstp ile val val val p suggest possible association gstp ile ile age disease manifestation result suggest combine gst polymorphism lead moderate increase risk thyroid cancer especially papillary type gstp polymorphism may modulate age onset disease ultrasound feature medullary thyroid carcinoma correlate cancer aggressiveness retrospective multicenter study background poor prognosis medullary thyroid cancer mtc suspicious ultrasound us feature report aim study investigate association preoperative us presentation aggressiveness feature mtc also us feature mtc compare previously report method study group comprise mtc nine different center base us presentation nodule stratify risk malignancy mtc probably benign b mtc lesion result eighty nine mtc b mtc find metastatic lymph node p extrathyroid invasiveness p frequent mtc statistically significant correlation p advance tnm stage mtc odd ratio ci mean postsurgical calcitonin value pg ml mtc b mtc p conclusion study show sonographically suspicious mtc frequently associate feature aggressiveness suggest careful preoperative us mtc patient may well plan surgical approach acute effect tsh oxygenation state volume erythrocyte subject thyroidectomized differentiate thyroid carcinoma previously report presence membrane erythrocyte tsh receptor tshr g protein couple receptor respond tsh increase camp level since evidence role g protein receptor oxygen sensor implicate cell volume regulation hypothesize erythrocyte tshr tsh stimulation can modify erythrocyte volume oxygenation state erythrocyte determine effect tsh gas analysis thyroidectomized patient stage differentiate thyroid cancer enroll recombinant human thyroid stimulate hormone rhtsh test chronic treatment synthetic l thyroxine moreover explore influence tsh shape erythrocyte venous blood gas analysis tsh determine ph blood gas electrolyte co oxymeter subgroup subject n isolate red blood cell rbc analyze flow cytometry morphological change tsh stimulation find significant decrease pco p increase ph p increase hb p po p flow cytometry erythrocyte tsh show significant enrichment mean numb select region r correspond big volume p n finally contrast phase microscopy cell area measure mean increase volume observe erythrocyte tsh compare basal tsh p conclusion result indicate acute stimulation tsh rhtsh modify oxygenation state volume erythrocyte clinical morphological prognostic feature papillary thyroid carcinoma different braf mutational status assess immunohistochemistry somatic mutation braf braf v e datum prognostic role contradictory one common molecular genetic abnormality cell papillary thyroid carcinoma ptc objective investigate association immunoexpression mutant braf ptc different morphological characteristic long term treatment result patient material method information inpatient ptc obtain database pathology department f tsyb medical radiology research center branch national medical radiology research center ministry health russia paraffin embed block surgically remove primary metastatic recurrent ptc tissue cut stain hematoxylin eosin etiological pathogenic consideration case thyroid cancer plasma tsh level measure occasion patient treat differentiate thyroid cancer prior thyroid surgery plasma tsh level within range normal plasma tsh level increase slightly follow partial thyroid resection definitely total thyroid ablation patient removal normal thyroid induce hormonogenesis thyroid tumour plasma tsh level dependent hormonal secretion tumour show inverse relationship tsh pbi uptake increase radioiodide uptake follow stimulation exogenous bovine tsh inversely relate plasma thyrotropin level suppressibility enhance thyrotropin level complete individually adjust dose synthetic thyroid hormone exception patient suppressive treatment trh administration induce increase plasma tsh level finding discuss regard role play tsh induction hormonogenesis thyroid tumour practical value tsh estimation trh stimulation seem low measurement thyrotropin level may important estimation suppressive effect course follow withdrawal treatment thyroid hormone upregulated mir papillary thyroid carcinoma promote tumor growth target apc activate wnt catenin signal context micrornas mirnas strongly implicate many cancer include papillary thyroid carcinoma ptc common malignancy thyroid tissue recently mirna mir prove play substantial role liposarcoma breast cancer function context ptc remain unknown objective objective investigate potential involvement mir ptc design expression level mir assess via quantitative cancer statistic highlight progress challenge cancer death rate middle age black man drop half year thyroid cancer remain fast grow cancer diagnosis u among strike finding american cancer society annual report cancer statistic noninvasive follicular thyroid neoplasm papillary like nuclear feature niftp thyroid tumor classification objective circulate tumor dna ctdna subset cell free dna cfdna potential biomarker thyroid cancer determine performance ctdna panel detect thyroid malignancy patient thyroid nodule method sixty six patient thyroid nodule without prior history cancer enroll prospective year study blood draw ctdna analysis prior undergo fine needle aspiration biopsy fnab thyroid nodule ctdna panel consist mutation cancer driver gene primary outcome measure sensitivity specificity positive negative predictive value ppv npv ctdna panel diagnosis thyroid malignancy determine pathologic molecular tissue examination result result subject can not determine due inadequate volume technical issue final classification thyroid nodule malignant benign lesion kras g v mutation detect plasma patient stage iva papillary carcinoma whose tissue contain mutation two patient benign lesion also ctdna detect give sensitivity specificity ppv npv no significant difference benign malignant lesion cfdna level conclusion neither cfdna measurement panel ctdna mutation sensitive specific enough provide valuable information fnab expand panel inclusion proteomics may improve sensitivity specificity thyroid cancer detection abbreviation cfdna cell free dna ctdna circulate tumor dna fnab skeletal relate event due bone metastasis differentiate thyroid cancer background oncology clinical impact metastatic bone disease convey via composite end point term skeletal relate event sre encompass spinal cord compression pathological fracture need external beam radiation surgery bone hypercalcemia malignancy appreciation high incidence sre advance cancer involve bone lead approval potent antiresorptive agent delay time \\ufeff1 sre decrease incidence sre risk rate sre diagnosis bone metastasis not describe thyroid cancer antiresorptive agent not routinely use method retrospective review differentiate thyroid cancer patient bone metastasis identify part routine clinical care memorial sloan kettering cancer center occurrence sre record initial diagnosis bone metastasis final follow death result seventy eight percent patient either present develope little one sre diagnosis metastatic bone disease median time identification bone metastasis \\ufeff1 sre month exclude patient \\ufeff1 sre occur time bone metastasis diagnosis patient sustain initial sre go sustain 2 sre median month \\ufeff1 event sre frequently multiple sustain three discrete sre conclusion thyroid cancer bone metastasis identify part routine clinical follow frequently cause significant recurrent morbidity incidence sre median time \\ufeff1 sre metastatic thyroid cancer bone similar report solid tumor prospective clinical trial assess efficacy antiresorptive agent population need differentiate thyroid cancer people age old objective describe characteristic treatment pattern differentiate thyroid cancer old adult design retrospective cohort study set national cancer institute surveillance epidemiology end result database participant individual age old primary thyroid cancer diagnosis papillary follicular histology diagnose n measurement age sex histology extent disease tumor size treatment type surgery cause death length survival result tumor size extent disease significantly relate cause death p participant not surgery likely die thyroid cancer cause p whether participant surgery significantly relate age p participant surgery significantly long survival not p type surgery p add radioactive iodine surgery p not appear influence length survival conclusion although differentiate thyroid cancer typically consider relatively indolent disease not case old adult surgery appear reduce likelihood death thyroid cancer population confer survival benefit type surgery add radioactive iodine therapy not seem improve survival benefit surgical management role chemokine thyroid carcinoma global incidence thyroid cancer increase metastatic spread lymph node common papillary thyroid carcinoma metastatic course thyroid carcinoma intricate process involve invasion angiogenesis cell traffic extravasation organ specific home growth key aspect process involve multitude interaction chemokine receptor chemokine group small protein act elicit normal physiologic immune response principally recruitment specific cell population site infection malignancy thyroid cancer cell like tumor possess ability corrupt chemokine system advantage alter cell movement tumor microenvironment affect aspect thyroid cancer progression image endocrine pathology similar not order establish concept early carcinoma thyroid operative method patient cancer thyroid measure little cm maximum diameter study among patient thyroid cancer treat 2 department surgery shinshu university school medicine exclude occult carcinoma minimal carcinoma measure little cm almost never show metastasis lymph node distant site therefore equip condition require early cancer since detection minimal carcinoma measure little cm difficult however problem arise clinical application prognosis minimal carcinoma measure little cm hand show no remarkable difference carcinoma measure little cm present consequently minimal carcinoma measure little cm exclusion occult carcinoma may classify early carcinoma no removal regional lymph node require carcinoma measure little cm operative procedure minimal carcinoma measure cm necessary perform modify neck dissection strict follow observation necessary cancer histopathological diagnosis encapsulate type invasive type infiltrative type radioimmunoscintigraphy xenografted human thyroid carcinoma develope monoclonal antibody human thyroid cancer associate antigen fuse mouse myeloma cell mouse spleen cell immunize insoluble fraction homogenize thyroid papillary carcinoma cell one monoclonal antibody 2 primary malignancy follow thyroid cancer population base study taiwan objective study 2 primary malignancy spms primary thyroid cancer conduct usa europe discrepancy spms study can attribute geographical ethnic heterogeneity thus clear need another large scale epidemiological study particularly asian country define incidence risk spms thyroid cancer survivor design population base study conduct use nation wide database taiwan cancer registry method quantify standardize incidence ratio sir cumulative incidence spms among individual male female primary thyroid cancer result total case develope little spm person year follow risk subsequent spms significantly great general population sir ci great risk develope major salivary gland nasopharyngeal lung thymus breast female bladder brain cancer leukemia lymphoma observe risk high within \\ufeff1 year diagnosis thyroid cancer sir respectively young patient sir vs respectively median overall survival primary thyroid cancer patient year year develope spms conclusion thyroid cancer associate risk increment spms negative impact survival site spms asian population distinctive western population suggest genetic predisposition environmental factor may play role surgical treatment superior thyroid artery aneurysm concomitant thyroid cancer objective research investigate clinical value contrast enhance ultrasound ceus prediction cervical lymph node metastasis clnm papillary thyroid cancer ptc one hundred eighty six patient ptc confirm fine needle aspiration fna preoperatively perform ceus multivariate analysis perform predict clnm independent variable receiver operate characteristic roc curve analysis use evaluate diagnostic performance totally patient clnm confirm pathology multivariate analysis demonstrate intensity peak time capsule contact size ceus three strong independent predictor clnm roc analysis characteristic show area curve az sensitivity specificity intensity peak time capsule contact size respectively ceus pattern ptc relative not size ptc also possibility clnm thyroidectomy ceus seem tool predict clnm ptc patient south korea thyroid cancer epidemic turn tide background aim common thyroid malignancy papillary follicular thyroid carcinoma account approximately thyroid cancer recent study report relevance cyclooxygenase cox gene polymorphism human carcinogenesis aim study investigate relationship thyroid carcinoma cox gene polymorphism turkish population material method include total differentiate thyroid cancer patient mean age year male female healthy control subject mean age year male female frequency g c c g gene polymorphism cox promoter region investigate thyroid cancer patient control group use spurious lung metastasis radioiodine thyroid whole body image patient differentiate thyroid cancer radioiodine uptake area lung usually denote metastasis however can represent uptake unrelated pulmonary disease breast external contamination study focus simulate lung metastasis thyroid whole body scan prove not metastasis reimaging clean focus strongly suspect due external contamination feature image focus focus note anterior view chest focus focal two smear one lobar focus multiple scan unilateral scan associate artifact scan caution use interpret apparent pulmonary radioiodine uptake lung metastasis reimaging clean skin change garment obtain uptake confine anterior view chest pattern atypical impact lymph node ratio survival papillary thyroid cancer background papillary thyroid cancer role lymph node dissection remain controversial stage system consider metastatic lymph node binary entity purpose study determine threshold lymph node ratio lnr impact disease specific mortality dsm method utilize surveillance epidemiology end result seer database analyze adult patient undergo thyroidectomy lymph node dissection lnr metastatic lymph node total lymph node calculate eliminate patient little three node collect kaplan meier estimate dsm plot lnrs compare log rank test cox proportional hazard model use evaluate lnr know clinical pathologic determinant prognosis result total case contain datum lymph node median follow time month range month mean lnr compare kaplan meier survival estimate overall dsm rate find lnr well divide lymph node metastasis base dsm p lnr experience dsm rate lnr dsm rate p addition patient lnr experience high dsm rate compare metastatic lymph node whole consider know determinant prognosis find lnr strongly associate dsm hazard ratio confidence interval radioiodine therapy patient differentiate thyroid cancer thyroidectomy direct comparison network meta analysis background objective effective dose radioiodine ablation patient differentiate thyroid cancer dtc thyroidectomy unclear try find activity well use method direct comparison network meta analysis method direct comparison network thyroglobulin whole body scintigraphy risk factor follow differentiate thyroid cancer result whole body scan measurement thyroglobulin tg follow patient differentiate thyroid cancer analyse retrospective study patient assume tumor free therapy follow cancer recurrence observe patient scan perform suspect recurrence cancer localize routinely perform scan tg measurement hormone withdrawal new pathology observe two case one year last therapy tumor recurrence observe high risk group patient follicular histology stage iii iv uicc one recurrence occur low risk group patient papillary histology uicc stage ii late one year therapy no recurrence observe patient belong low risk group result indicate scan tg measurement endogenous tsh stimulation necessary case suspect recurrence probably routine basis one year last therapy patient event inconspicuous course diagnostic procedure restrict special high risk group use cut level ng ml compare ng ml numb false negative tg result suppressive therapy decrease clearly whereas false positive result increase little pronounce abstract truncate word brafv e mutation really orchestrate thyroid cancer brafv e constitutively active onco kinase common genetic alteration papillary thyroid carcinoma ptc anaplastic thyroid carcinoma good albeit low frequency brafv e mutation study significantly associate extra thyroidal extension metastasis recurrence mortality patient ptc recent genome wide expression profile approach gene set enrichment analysis gsea vitro vivo functional study reveal brafv e affect extracellular matrix composition e increase expression collagen laminin promote thyroid cancer migration invasion brafv e phospho mek phospho erk pathway may control network gene crucial integrate regulate extracellular intracellular signal thyroid cancer cell may fundamental trigger abnormal cell differentiation totipotency shape polarity contribute tumor aggressiveness mechanism e cell adhesion migration invasion increase knowledge brafv e modulate ecm gene target subset gene essential tumor aggressiveness help establish novel paradigm treatment thyroid cancer harbor brafv e furthermore identify downstream event brafv e erk pathway eventually identify novel biomarker use correlate disease outcome overall survival thyroid papillary carcinoma associate hashimoto thyroiditis controversy literature regard association papillary thyroid carcinoma ptc hashimoto thyroiditis ht would etiological relationship objective establish proportion case among patient th cpt correlate histomorphological aspect method retrospective study patient undergo partial total thyroidectomy ptc total case result regard association ht cpt find case female without statistical significance mean age year among patient coexistent th cpt whereas year without association average size tumor without th mm th mm p regard pathology stage ratio without th keep b no case coexistence ht ptc conclusion rate patient association th cpt without difference relation tumor size coexistence papillary thyroid cancer hashimoto thyroiditis aim conflict datum report regard hashimoto thyroiditis ht risk malignancy aim study evaluate coexistence papillary thyroid cancer ptc ht patient method retrospective cohort study ht diagnose f ratio median age year patient qualify thyroidectomy throughout year pathological report review identify prevalence ptc ht vs non ht patient result ptc diagnose ht patient vs non ht patient p metastasis level vi lymph node observe patient ptc ht vs patient ptc non ht disease p conclusion ht associate threefold increase ptc prevalence compare non ht thyroid disease spread ptc level vi lymph node four time frequent ht non ht patient peripheral thyroid nodule calcification sonography evaluation malignant potential objective purpose study assess association thyroid cancer sonographic feature peripheral calcification material method retrospectively review patient total thyroid nodule peripheral calcification undergo ultrasound guide fine needle aspiration three board certify radiologist evaluate nodule feature peripheral calcification percentage nodule involve peripheral calcification whether calcification continuous discontinuous visibility internal component nodule presence extrusion soft tissue beyond calcification correlation peripheral calcification parameter rate thyroid nodule malignancy evaluate addition interobserver agreement reader assess cohen kappa coefficient result nodule peripheral calcification n find malignant biopsy continuity peripheral calcification visibility internal component extrusion soft tissue beyond calcification rim show no significant association benign malignant nodule reader good agreement peripheral calcification continuity ci moderate agreement internal component visibility ci percentage nodule involve rim calcification ci fair agreement extranodular soft tissue extrusion ci conclusion peripheral rim calcification highly associate malignancy however specific peripheral rim calcification feature not aid distinguish benign malignant nodule may part cause high interobserver variability update diagnosis therapy distant metastasis differentiate thyroid carcinoma differentiate thyroid cancer adequately treat overall good prognosis however patient develop distant metastasis presence metastasis important prognostic factor negative affect survival avid distant metastasis therapy effective treatment modality induce complete remission 3 patient figure may even high case early diagnosis tumor burden still limit additional measure may include surgery external beam radiation therapy cytotoxic chemotherapy largely ineffective patient progressive poorly differentiate cancer patient candidate trial new molecularly target therapeutic agent paper review diagnostic modality prognostic factor therapeutic option patient distant metastasis propose particular prognostic value early discovery metastatic disease underline thyrotoxicosis thyroid cancer generally hold thyroid cancer uncommonly associate thyrotoxicosis report nine patient thyroid cancer amongst patient thyrotoxicosis three patient present feature malignancy together thyrotoxicosis group one triiodothyronine surgical treatment thyroid cancer singapore general hospital experience patient differentiate thyroid cancer generally good prognosis consider decide extent surgical resection radical surgery however may appropriate control locally advance disease audit case thyroid cancer treat department general surgery singapore general hospital october june present particular attention draw eight patient undergo radical surgery woman man median age year range year cancer papillary carcinoma follicular medullary anaplastic total near total thyroidectomy common procedure primary disease patient eight patient undergo radical surgery four laryngectomy one pharyngectomy three median sternotomy tumour clearance morbidity include wind complication hypocalcaemia transient permanent hoarseness voice prove recurrent laryngeal nerve palsy three patient anaplastic thyroid cancer die within month eight undergo radical surgery three alive disease free median follow month correctly select group patient locally invasive differentiate thyroid cancer aggressive surgery appropriate acceptable morbidity mortality thyroid disease pregnancy woman health series pregnancy state many hormonal change make interpretation thyroid function test difficult measure trimester specific reference value thyrotropin free thyroxine recommend overt maternal hypothyroidism negative affect fetus timely recognition treatment important woman take levothyroxine prepregnancy require dose increase pregnancy hyperthyroidism result excessive human chorionic gonadotropin grave disease radioactive scan avoid pregnancy antithyroidal drug therapy consist propylthiouracil \\ufeff1 trimester methimazole thereafter indicate beta blocker administer obstetrical supervision iodine deficiency know goitrogen stimulus thyroid nodular growth thyroid nodule may enlarge incidence thyroid cancer not increase pregnancy suspicious nodule biopsied necessary remove 2 trimester otherwise follow safely conduct postpartum thyroid stimulate hormone suppression preexist thyroid cancer suspicious nodule achieve free total upper normal range pregnancy postpartum thyroiditis occur frequently antithyroid peroxidase positive woman screen measure serum thyrotropin week gestation month postpartum surgical management recur metastatic thyroid cancer surgical oncologist sometimes confront patient surgically treat cancer thyroid gland recurrent disease instance additional surgical treatment indicate magnitude surgery primarily determine amount tissue remove original operation surgery recurrent disease may include completion total thyroidectomy dissection lymphatic tissue thyroid compartment neck dissection preferably modify several clinical situation outline discuss benign intranodal thyroid tissue mimick nodal metastasis patient papillary thyroid carcinoma case report background case benign intranodal thyroid tissue mimick nodal metastasis ultrasound ct patient papillary thyroid carcinoma not report method clinical image histopathological finding patient present year old woman undergo ultrasound guide diffuse sclerosing variant thyroid papillary carcinoma diagnostic challenge occur hashimoto thyroiditis diffuse sclerosing papillary thyroid carcinoma dsptc relatively rare variant papillary thyroid carcinoma distinct histological feature radiological characteristic biological aggressiveness compare conventional papillary thyroid carcinoma dsptc characterize scatter microscopic tumor island diffuse fibrosis calcification abundant lymphocytic aggregation preoperative diagnosis challenge absence nodule scanty fine needle aspiration cytology sample describe unique dsptc patient year old woman present neck mass grow slowly year palpable neck mass nontender good define firm unmovable laboratory study show normal thyroid function positive autoimmune marker antithyroglobulin antibody antimicrosomal antibody neck ultrasound show diffusely prominent microcalcifications one small vague nodule hashimoto thyroiditis accompany malignancy suspect base result intraoperative pathology report patient give total thyroidectomy lymph node dissection histological analysis reveal bilateral dsptc addition lymphocytic thyroiditis nonmalignant area thyroid clinical histological diagnostic challenge usually occur dsptc present diffuse thyroid enlargement disperse microscopic tumor island frequently without mass formation extensive fibrosis abundant lymphocytic infiltration mimick thyroiditis prognostic impact tumour multifocality thyroid papillary microcarcinoma base series case objective objective study evaluate prognostic impact tumour multifocality papillary thyroid microcarcinoma ptmc method patient undergo total thyroidectomy central neck dissection ptmc institution include retrospective study statistical correlation tumour multifocality various clinical pathological prognostic parameter assess univariate multivariate analysis result total patient woman man mean age year include study tumour multifocality demonstrate patient central neck metastatic lymph node involvement identify patient no statistical correlation demonstrate tumour multifocality follow factor age gender tumour size extension beyond thyroid metastatic central neck lymph node involvement risk recurrence tumour diameter great mm associate high risk recurrence p conclusion tumour multifocality not appear prognostic impact ptmc thyroid cancer seom clinical guideline thyroid cancer tc common type endocrine malignancy account nearly malignancy incidence tc spain woman man diagnosis tc usually follow identification thyroid nodule physical examination incidental find diagnostic image perform reason case prognosis excellent despite low mortality rate local recurrence occur distant metastasis occur approximately year well knowledge molecular biology tc allow development new target agent direct main pathway involve tc pathogenesis know new strategy help us face therapeutic management tc effectively'"
      ]
     },
     "execution_count": 86,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "key_cluster_5 = ''\n",
    "for word in df_cluster_5:\n",
    "    key_cluster_5 = key_cluster_5 + ' ' + word\n",
    "key_cluster_5"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {},
   "outputs": [],
   "source": [
    "wordcloud = WordCloud(width=800, height=800, background_color='white', min_font_size=14).generate(key_cluster_5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x864 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(12,12), facecolor = None)\n",
    "plt.imshow(wordcloud)\n",
    "plt.axis(\"off\")\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
